FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Jones, NB
   Ottesen, RA
   Niland, JC
   Breslin, TM
   Weeks, JC
   Hughes, ME
   Agnese, DM
   Edge, SB
AF Jones, Natalie Beckman
   Ottesen, Rebecca A.
   Niland, Joyce C.
   Breslin, Tara M.
   Weeks, Jane C.
   Hughes, Melissa E.
   Agnese, Doreen Marie
   Edge, Stephen B.
TI Overuse of sentinel lymph node biopsy with breast conserving surgery for
   clinical DCIS
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Ohio State Univ, Columbus, OH 43210 USA.
   Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1125
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800543
ER

PT J
AU Kacel, EL
   Maciejewski, PK
   Prigerson, HG
AF Kacel, Elizabeth L.
   Maciejewski, Paul K.
   Prigerson, Holly Gwen
TI Lifetime traumas and their influence on advanced cancer patients'
   illness understanding and likelihood of end-of-life discussions.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9146
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801159
ER

PT J
AU Kalinsky, K
   Lee, SJ
   Lawrence, DP
   Iafrate, AJ
   Borger, DR
   Averbook, BJ
   Tarhini, AA
   Kirkwood, JM
AF Kalinsky, Kevin
   Lee, Sandra J.
   Lawrence, Donald P.
   Iafrate, A. John
   Borger, Darrell R.
   Averbook, Bruce Jeffrey
   Tarhini, Ahmad A.
   Kirkwood, John M.
TI A phase II trial of dasatinib in patients with unresectable locally
   advanced or stage IV mucosal, acral, and solar melanomas: An Eastern
   Cooperative Oncology Group study (E2607)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Columbia Univ, Med Ctr, New York, NY USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Metrohlth Med Ctr, Cleveland, OH USA.
   Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8522
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800046
ER

PT J
AU Kanakry, JA
   Li, HL
   Gellert, LL
   Lemas, MV
   Hsieh, WS
   Tan, KL
   Gascoyne, RD
   Gordon, LI
   Horning, SJ
   Kahl, BS
   Ambinder, RF
AF Kanakry, Jennifer Ann
   Li, Hailun
   Gellert, Lan L.
   Lemas, M. Victor
   Hsieh, Wen Son
   Tan, King L.
   Gascoyne, Randy D.
   Gordon, Leo I.
   Horning, Sandra J.
   Kahl, Brad S.
   Ambinder, Richard F.
TI Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin
   lymphoma in a phase III study (E2496).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Johns Hopkins Sch Med, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   Canc Sci Inst Singapore, Singapore, Singapore.
   Univ British Columbia, British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 1M9, Canada.
   Northwestern Univ, Deparment Hematol Oncol, Chicago, IL 60611 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   Univ Wisconsin, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8003
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803745
ER

PT J
AU Kassam, A
   Habib, S
   Skiadaresis, J
   Alexander, S
   Wolfe, J
AF Kassam, Alisha
   Habib, Sharifa
   Skiadaresis, Julia
   Alexander, Sarah
   Wolfe, Joanne
TI Paucity of core palliative care elements available to children with
   cancer at end-of-life: Perspectives of bereaved parents and clinicians.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9076
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800248
ER

PT J
AU Kelly, WK
   Halabi, S
   Carducci, MA
   George, DJ
   Mahoney, JF
   Stadler, WM
   Morris, MJ
   Kantoff, PW
   Monk, JP
   Small, EJ
AF Kelly, William Kevin
   Halabi, Susan
   Carducci, Michael Anthony
   George, Daniel J.
   Mahoney, John Francis
   Stadler, Walter Michael
   Morris, Michael J.
   Kantoff, Philip W.
   Monk, J. P.
   Small, Eric Jay
CA Alliance Clinical Trials Oncology
TI Liver metastases (LM) to predict for short overall survival (OS) in
   metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   Duke Univ, Sch Med, Durham, NC USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Duke Canc Inst, Durham, NC USA.
   Carolinas Hematol Oncol Associates, Charlotte, NC USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Ohio State Univ, Columbus, OH 43210 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4655
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803265
ER

PT J
AU Keung, EZY
   Liu, XX
   Nuzhad, A
   Rabinowits, G
   Patel, V
AF Keung, Emily Zhi-Yun
   Liu, Xiaoxia
   Nuzhad, Afrin
   Rabinowits, Guilherme
   Patel, Vihas
TI In-hospital and long-term outcomes in patients with malignancy
   undergoing percutaneous endoscopic gastrostomy (PEG)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9086
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801081
ER

PT J
AU Khan, SA
   Callahan, M
   Postow, MA
   Chapman, PB
   Schwartz, GK
   Dickson, MA
   D'Angelo, SP
   Luke, JJ
   Bluth, MJ
   Roman, RA
   Montefusco, M
   Barker, CA
   Abramson, DH
   Wolchok, JD
   Carvajal, RD
AF Khan, Shaheer A.
   Callahan, Margaret
   Postow, Michael Andrew
   Chapman, Paul B.
   Schwartz, Gary K.
   Dickson, Mark Andrew
   D'Angelo, Sandra P.
   Luke, Jason John
   Bluth, Mark J.
   Roman, Ruth Ann
   Montefusco, Mary
   Barker, Christopher Andrew
   Abramson, David H.
   Wolchok, Jedd D.
   Carvajal, Richard D.
TI Ipilimumab in the treatment of uveal melanoma: The Memorial
   Sloan-Kettering Cancer Center experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8549
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800607
ER

PT J
AU Kim, B
   He, R
   Antonio, ALM
   Asch, SM
   Malin, J
AF Kim, Benjamin
   He, Ren
   Antonio, Anna Liza M.
   Asch, Steven M.
   Malin, Jennifer
TI Comparative effectiveness of erlotinib versus no treatment for advanced
   non-small cell lung cancer patients in the Veterans Administration.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 UCSF Sch Med, San Francisco, CA USA.
   VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
   Univ Calif Los Angeles, Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA.
   Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6105
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803168
ER

PT J
AU Kim, DW
   Ahn, MJ
   Shi, YK
   De Pas, TM
   Yang, PC
   Riely, GJ
   Crino, L
   Evans, TL
   Liu, XQ
   Han, JY
   Salgia, R
   Moro-Sibilot, D
   Ou, SHI
   Gettinger, SN
   Wu, YL
   Lanzalone, S
   Polli, A
   Iyer, S
   Shaw, AT
AF Kim, Dong-Wan
   Ahn, Myung-Ju
   Shi, Yuankai
   De Pas, Tommaso Martino
   Yang, Pan-Chyr
   Riely, Gregory J.
   Crino, Lucio
   Evans, Tracey L.
   Liu, Xiaoqing
   Han, Ji-Youn
   Salgia, Ravi
   Moro-Sibilot, Denis
   Ou, Sai-Hong Ignatius
   Gettinger, Scott N.
   Wu, Yi Long
   Lanzalone, Silvana
   Polli, Anna
   Iyer, Shrividya
   Shaw, Alice Tsang
TI Results of a global phase II study with crizotinib in advanced
   ALK-positive non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Seoul Natl Univ Hosp, Seoul 110744, South Korea.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing 100730, Peoples R China.
   Peking Union Med Coll, Beijing 100021, Peoples R China.
   European Inst Oncol, New Drugs Dev Div, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy.
   Natl Taiwan Univ Hosp, Coll Med, Taipei, Taiwan.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Azienda Osped Perugia, Perugia, Italy.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China.
   Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea.
   Univ Chicago, Chicago, IL 60637 USA.
   Hop Univ, Grenoble, France.
   Univ Calif Irvine, Irvine, CA USA.
   Yale Univ, Sch Med, New Haven, CT USA.
   Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China.
   Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China.
   Pfizer Italia Srl, Pfizer Oncol, Milan, Italy.
   Pfizer Oncol, Milan, Italy.
   Pfizer Inc, New York, NY USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI MORO-SIBILOT, denis/N-6493-2013
NR 0
TC 46
Z9 47
U1 2
U2 15
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7533
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804120
ER

PT J
AU Kim, SP
   Karnes, RJ
   Nguyen, PL
   Leibovich, BC
   Ziegenfuss, JY
   Thompson, RH
   Boorjian, SA
   Han, LC
   Costello, BA
   Tilburt, JC
AF Kim, Simon P.
   Karnes, R. Jeffrey
   Nguyen, Paul Linh
   Leibovich, Bradley C.
   Ziegenfuss, Jeanette Y.
   Thompson, R. Houston
   Boorjian, Stephen A.
   Han, Leona C.
   Costello, Brian Addis
   Tilburt, Jon C.
TI A national survey of radiation oncologists and urologists on active
   surveillance for low-risk prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mayo Clin, Rochester, MN USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4657
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803107
ER

PT J
AU Kirby, C
   Ambros, PF
   Billiter, D
   London, WB
   Mendonca, E
   Monclair, T
   Pearson, ADJ
   Cohn, SL
   Volchenboum, SL
AF Kirby, Chaim
   Ambros, Peter F.
   Billiter, David
   London, Wendy B.
   Mendonca, Eneida
   Monclair, Tom
   Pearson, Andrew D. J.
   Cohn, Susan Lerner
   Volchenboum, Samuel Louis
TI Development of an open-source, flexible framework for interinstitutional
   data sharing and collaboration.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Chicago, Chicago, IL 60637 USA.
   St Anna Childrens Hosp, Childrens Canc Res Inst, Vienna, Austria.
   Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc, Columbus, OH USA.
   Harvard Canc Care, Dana Farber Canc Inst, Boston, MA USA.
   Childrens Hosp, Boston, MA 02115 USA.
   Univ Wisconsin, Madison, WI USA.
   Aker Univ Hosp, Sect Paediat Surg, Div Surg, Rikshosp, Oslo, Norway.
   Inst Canc Res, Sutton, Surrey, England.
   Royal Marsden Hosp, Sutton, Surrey, England.
RI Mendonca, Eneida/J-8895-2016
OI Mendonca, Eneida/0000-0003-4297-9221
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9583
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800149
ER

PT J
AU Klepin, HD
   Pitcher, B
   Ballman, KV
   Kimmick, GG
   Kornblith, AB
   Cohen, HJ
   Hurria, A
   Winer, EP
   Hudis, C
   Muss, HB
AF Klepin, Heidi D.
   Pitcher, Brandy
   Ballman, Karla V.
   Kimmick, Gretchen Genevieve
   Kornblith, Alice B.
   Cohen, Harvey Jay
   Hurria, Arti
   Winer, Eric P.
   Hudis, Clifford
   Muss, Hyman Bernard
TI Comorbidity, chemotherapy toxicity, and outcomes among older women
   receiving adjuvant chemotherapy for breast cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Wake Forest Sch Med, Winston Salem, NC USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Mayo Clin, Rochester, MN USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6015
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800622
ER

PT J
AU Kodali, S
   Limaye, SA
   Shreenivas, AV
   Zhao, D
   Lorch, JH
   Tishler, RB
   Margalit, DN
   Posner, MR
   Haddad, RI
AF Kodali, Swati
   Limaye, Sewanti Atul
   Shreenivas, Aditya V.
   Zhao, Dave
   Lorch, Jochen H.
   Tishler, Roy B.
   Margalit, Danielle Nina
   Posner, Marshall R.
   Haddad, Robert I.
TI Retrospective review of patients treated with intensity modulated
   radiation therapy (IMRT) with or without concurrent chemotherapy for
   locally advanced thyroid cancer: The Dana-Farber experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
   Harvard Canc Consortium, Harvard Radiat Oncol Program, Boston, MA USA.
   Mt Sinai, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e16060
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802485
ER

PT J
AU Kollmannsberger, CK
   Hurwitz, H
   Cleary, JM
   Strickler, JH
   Drouin, MA
   Juretic, M
   Hunt, W
   Reid, GK
   Maroun, CR
   Bonfils, C
   Wang, J
   Karam, A
   Besterman, JM
   Mehran, M
   Shapiro, G
AF Kollmannsberger, Christian K.
   Hurwitz, Herbert
   Cleary, James M.
   Strickler, John H.
   Drouin, Michel A.
   Juretic, Manuela
   Hunt, Wendy
   Reid, Gregory K.
   Maroun, Christiane R.
   Bonfils, Claire
   Wang, James
   Karam, Andre
   Besterman, Jeffrey M.
   Mehran, Mariam
   Shapiro, Geoffrey
TI MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met
   and VEGFR: Dose-escalation phase I study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
   Duke Univ, Med Ctr, Durham, NC USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   MethylGene Inc, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3039
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802507
ER

PT J
AU Kong, Y
   Si, L
   Xu, XW
   Flaherty, KT
   Chi, ZH
   Cui, CL
   Sheng, XN
   Dai, J
   Liang, L
   Zhang, QN
   Guo, J
AF Kong, Yan
   Si, Lu
   Xu, Xiao Wei
   Flaherty, Keith T.
   Chi, Zhi Hong
   Cui, Chuan Liang
   Sheng, Xi Nan
   Dai, Jie
   Liang, Long
   Zhang, Qian Nan
   Guo, Jun
TI Association of the activation of the mTOR pathway with prognosis in
   Chinese melanoma patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8561
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803081
ER

PT J
AU Kopp, LM
   Bernstein, ML
   Schwartz, CL
   Ebb, D
   Krailo, MD
   Grier, HE
   Meyers, PA
   Wexler, LH
   Marina, N
   Womer, R
   Janeway, KA
   Gorlick, RG
   Lipshultz, SE
AF Kopp, Lisa M.
   Bernstein, Mark L.
   Schwartz, Cindy L.
   Ebb, David
   Krailo, Mark D.
   Grier, Holcombe E.
   Meyers, Paul A.
   Wexler, Leonard H.
   Marina, Neyssa
   Womer, Richard
   Janeway, Katherine A.
   Gorlick, Richard Greg
   Lipshultz, Steven E.
CA Childrens Oncology Grp
TI The effects of dexrazoxane on cardiac status and second malignant
   neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Arizona, Tucson, AZ USA.
   IWK Hlth Ctr, Halifax, NS, Canada.
   Brown Univ, Hasbro Childrens Hosp, Providence, RI 02912 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Childrens Oncol Grp, Arcadia, CA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
   Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   Childrens Hosp, Bronx, NY USA.
   Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9503
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800049
ER

PT J
AU Kris, MG
   Mok, T
   Ou, SHI
   Martins, R
   Kim, DW
   Goldberg, Z
   Zhang, H
   Taylor, I
   Letrent, SP
   Janne, PA
AF Kris, Mark G.
   Mok, Tony
   Ou, Sai-Hong Ignatius
   Martins, Renato
   Kim, Dong-Wan
   Goldberg, Zelanna
   Zhang, Hui
   Taylor, Ian
   Letrent, Stephen P.
   Janne, Pasi Antero
TI First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine
   kinase inhibitor, for patients with EGFR-mutant lung cancers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
   Chao Family Comprehens Canc Ctr, Orange, CA USA.
   Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
   Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   Pfizer Oncol, La Jolla, CA USA.
   Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China.
   Pfizer Oncol, Groton, CT USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7530
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804334
ER

PT J
AU Krishnan, MS
   Recht, A
   Bellon, JR
   Punglia, RS
AF Krishnan, Monica Shalini
   Recht, Abram
   Bellon, Jennifer Ruth
   Punglia, Rinaa S.
TI Trade-offs associated with axillary lymph node dissection: Implications
   of the eligibility versus enrollment in ACOSOG Z0011.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Radiat Oncol Program, Boston, MA USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6022
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803732
ER

PT J
AU Krop, IE
   Saura, C
   Ahnert, JR
   Becerra, C
   Britten, CD
   Isakoff, SJ
   Demanse, D
   Hackl, W
   Quadt, C
   Silva, AP
   Burris, HA
   Abu-Khalaf, MM
   Baselga, J
AF Krop, Ian E.
   Saura, Cristina
   Ahnert, Jordi Rodon
   Becerra, Carlos
   Britten, Carolyn D.
   Isakoff, Steven J.
   Demanse, David
   Hackl, Wolfgang
   Quadt, Cornelia
   Silva, Antonio P.
   Burris, Howard A.
   Abu-Khalaf, Maysa M.
   Baselga, Jose
TI A phase I/IB dose-escalation study of BEZ235 in combination with
   trastuzumab in patients with PI3-kinase or PTEN altered HER2+metastatic
   breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Vall dHebron Univ Hosp, Barcelona, Spain.
   Texas Oncol Sammons Canc Ctr Baylor, Dallas, TX USA.
   Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Novartis Pharma AG, Basel, Switzerland.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Yale Comprehens Canc Ctr, New Haven, CT USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 508
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800118
ER

PT J
AU Kurzrock, R
   Blay, JY
   Nguyen, BB
   Wagner, AJ
   Maki, RG
   Schwartz, GK
   Patnaik, A
   Gore, L
   Wu, L
   Vassilev, LT
   Ding, M
   Geho, D
   Zhi, JG
   Middleton, S
   Nichols, GL
AF Kurzrock, Razelle
   Blay, Jean-Yves
   Binh Bui Nguyen
   Wagner, Andrew J.
   Maki, Robert G.
   Schwartz, Gary K.
   Patnaik, Amita
   Gore, Lia
   Wu, Lin
   Vassilev, Lyubomir T.
   Ding, Michelle
   Geho, David
   Zhi, Jianguo
   Middleton, Steven
   Nichols, Gwen L.
TI A phase I study of MDM2 antagonist RG7112 in patients (pts) with
   relapsed/refractory solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
   Ctr Leon Berard, F-69373 Lyon, France.
   Inst Bergonie, Bordeaux, France.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Roche Mol Syst, Pleasanton, CA USA.
   Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e13600
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802223
ER

PT J
AU La Madrid, AEM
   Stricker, T
   Pytel, P
   Gosiengfiao, YC
   Shohet, J
   Shimada, H
   Furman, WL
   Zage, PE
   Park, JR
   Perlman, E
   Guerrero, L
   Salwen, H
   Chlenski, A
   London, WB
   Cohn, SL
AF La Madrid, Andres Eduardo Morales
   Stricker, Thomas
   Pytel, Peter
   Gosiengfiao, Yasmin C.
   Shohet, Jason
   Shimada, Hiroyuki
   Furman, Wayne Lee
   Zage, Peter E.
   Park, Julie R.
   Perlman, Elizabeth
   Guerrero, Lisa
   Salwen, Helen
   Chlenski, Alexandre
   London, Wendy B.
   Cohn, Susan Lerner
TI Genome-based outcome prediction in MYCN nonamplified high-risk
   neuroblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Chicago, Chicago, IL 60637 USA.
   Childrens Memor Hosp, Chicago, IL USA.
   Baylor Coll Med, Houston, TX 77030 USA.
   Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
   St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Seattle Childrens Hosp, Seattle, WA USA.
   Childrens Mem Hosp, Chicago, IL 60614 USA.
   Harvard Canc Care, Dana Farber Canc Inst, Boston, MA USA.
   Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9534
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802096
ER

PT J
AU Lamont, EB
   He, YL
   Lan, L
   Joffe, S
AF Lamont, Elizabeth B.
   He, Yulei
   Lan, Lan
   Joffe, Steven
TI Survival of elderly Medicare patients after standard chemotherapy for
   advanced lung and gastrointestinal cancers in the real world
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1605
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801119
ER

PT J
AU Lee, RJ
   Michaelson, MD
   Saylor, PJ
   Gurski, CA
   Rothenberg, SM
   Miyamoto, DT
   Maheswaran, S
   Haber, DA
   Goldin, JG
   Smith, MR
AF Lee, Richard J.
   Michaelson, M. Dror
   Saylor, Philip James
   Gurski, Carol Ann
   Rothenberg, Stephen M.
   Miyamoto, David Tomoaki
   Maheswaran, Shyamala
   Haber, Daniel A.
   Goldin, Jonathan G.
   Smith, Matthew Raymond
TI Investigator-sponsored trial of efficacy and tolerability of
   cabozantinib (cabo) at lower dose: A dose-finding study in men with
   castration-resistant prostate cancer (CRPC) and bone metastases
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Calif Los Angeles, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4566
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802683
ER

PT J
AU Lennes, IT
   Temel, JS
   Gallagher, ER
   Greer, JA
   Pirl, WF
AF Lennes, Inga Tolin
   Temel, Jennifer S.
   Gallagher, Emily R.
   Greer, Joseph A.
   Pirl, William F.
TI Patient-related predictors of poor-quality pain care in advanced lung
   cancer patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6062
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802030
ER

PT J
AU Lerner, SP
   Sternberg, CN
   Younes, M
   Calabro, F
   Cerbone, L
   Chandrashekar, A
   Mitchell, C
   Shen, SS
   Sonpavde, G
AF Lerner, Seth P.
   Sternberg, Cora N.
   Younes, Mamoun
   Calabro, Fabio
   Cerbone, Linda
   Chandrashekar, A.
   Mitchell, Carmen
   Shen, Steven S.
   Sonpavde, Guru
TI Phase II trial of tamoxifen for progressive advanced urothelial
   carcinoma following prior chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Baylor Coll Med, Houston, TX 77030 USA.
   San Camillo & Forlanini Hosp, Rome, Italy.
   Univ Texas Hlth Sci Ctr, Houston, TX USA.
   San Camillo Forlanini Hosp, Rome, Italy.
   Methodist Hosp, Houston, TX 77030 USA.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15003
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803021
ER

PT J
AU Levitt, JM
   Chan, KS
   Jian, WG
   Lerner, SP
   Sonpavde, G
AF Levitt, Jonathan M.
   Chan, Keith S.
   Jian, Weiguo
   Lerner, Seth P.
   Sonpavde, Guru
TI The preclinical activity of lenalidomide in urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Baylor Coll Med, Houston, TX 77030 USA.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15002
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803112
ER

PT J
AU Liedke, PER
   Chavarri-Guerra, Y
   Shepherd, LE
   Tu, DS
   Pritchard, KI
   Goss, PE
AF Liedke, Pedro Emanuel Rubini
   Chavarri-Guerra, Yanin
   Shepherd, Lois E.
   Tu, Dongsheng
   Pritchard, Kathleen I.
   Goss, Paul Edward
TI Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with
   outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG
   MA.17
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Avon Int Breast Canc Ctr, Boston, MA 02114 USA.
   Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada.
   NCIC Clin Trials Grp, Kingston, ON, Canada.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 524
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800323
ER

PT J
AU Ligibel, JA
   Giobbie-Hurder, A
   Shockro, L
   Campbell, N
   Partridge, AH
   Tolaney, SM
   Lin, NU
   Winer, EP
AF Ligibel, Jennifer A.
   Giobbie-Hurder, Anita
   Shockro, Laura
   Campbell, Nancy
   Partridge, Ann H.
   Tolaney, Sara M.
   Lin, Nancy U.
   Winer, Eric P.
TI Randomized trial of a physical activity intervention in patients with
   metastatic breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Ligibel, Jennifer A.; Giobbie-Hurder, Anita; Shockro, Laura; Campbell, Nancy; Partridge, Ann H.; Tolaney, Sara M.; Lin, Nancy U.; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9084
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802541
ER

PT J
AU Lim, E
   He, HSHS
   Chi, D
   Garber, JE
   Richardson, A
   Brown, M
AF Lim, Elgene
   He, Housheng Hansen
   Chi, David
   Garber, Judy Ellen
   Richardson, Andrea
   Brown, Myles
TI Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation
   associated, and ER-positive breast cancer (BC) mammary cells.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 576
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800130
ER

PT J
AU Limaye, SA
   Sonis, ST
   Cilli, F
   Colevas, AD
   Brennan, M
   Hu, K
   Haddad, RI
   Murphy, BA
AF Limaye, Sewanti Atul
   Sonis, Stephen T.
   Cilli, Fiona
   Colevas, A. Dimitrios
   Brennan, Michael
   Hu, Kenneth
   Haddad, Robert I.
   Murphy, Barbara A.
TI Phase Ib, multicenter, single-blinded, placebo-controlled, sequential
   dose-escalation study to assess the safety and tolerability of topically
   applied AG013 in subjects with locally advanced head and neck cancer
   (LAHNC) receiving induction chemotherapy (ICT).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Biomodels, Watertown, MA USA.
   ActoGeniX NV, Zwijnaarde, Belgium.
   Stanford Univ, Stanford, CA 94305 USA.
   Carolinas Med Ctr, Charlotte, NC 28203 USA.
   Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
   Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9024
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802371
ER

PT J
AU Lin, NU
   Danso, MA
   David, AK
   Muscato, JJ
   Rayson, D
   Houck, WA
   Ellis, CE
   DeSilvio, M
   Garofalo, A
   Nagarwala, YM
   Winer, E
AF Lin, Nancy U.
   Danso, Michael A.
   David, Alice K.
   Muscato, Joseph J.
   Rayson, Daniel
   Houck, William A.
   Ellis, Catherine Elizabeth
   DeSilvio, Michelle
   Garofalo, Amanda
   Nagarwala, Yasir M.
   Winer, Eric
TI HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab
   in HER2-positive metastatic breast cancer (LPT112515)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Virginia Oncol Associates, Norfolk, VA USA.
   Augusta Oncol Associates, Augusta, GA USA.
   Missouri Canc Associates, Columbia, MO USA.
   QEII Hlth Sci Ctr, Halifax, NS, Canada.
   Virginia Canc Specialists PC, Winchester, VA USA.
   GlaxoSmithKline Oncol, Collegeville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS658
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800508
ER

PT J
AU Lipshultz, SE
   Miller, TL
   Gerschenson, M
   Neuberg, DS
   Stevenson, K
   Franco, VI
   Anderson, L
   LiButti, D
   Silverman, LB
   Vrooman, LM
   Sallan, SE
AF Lipshultz, Steven E.
   Miller, Tracie L.
   Gerschenson, Mariana
   Neuberg, Donna S.
   Stevenson, Kristen
   Franco, Vivian I.
   Anderson, Lynn
   LiButti, Daniel
   Silverman, Lewis B.
   Vrooman, Lynda M.
   Sallan, Stephen E.
CA Dana-Farber Canc Inst Acute
TI Effect of dexraoxane on impaired mitochondrial structure and function in
   doxorubicin-treated childhood ALL survivors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   Univ Hawaii Manoa, Honolulu, HI 96822 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9530
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800529
ER

PT J
AU Llombart, A
   Lluch, A
   Villanueva, C
   Delaloge, S
   Morales, S
   Balmana, J
   Amillano, K
   Bonnefoi, HR
   Casas, AM
   Manso, L
   Roche, HH
   Gonzalez-Santiago, S
   Gavila, J
   Sanchez-Rovira, P
   Di Cosimo, S
   Charpentier, E
   Garcia-Ribas, I
   Penault-Llorca, FM
   Aura, C
   Baselga, J
AF Llombart, Antonio
   Lluch, Ana
   Villanueva, Cristian
   Delaloge, Suzette
   Morales, Serafin
   Balmana, Judith
   Amillano, Kepa
   Bonnefoi, Herve R.
   Casas, Ana Maria
   Manso, Luis
   Hubert Roche, Henri
   Gonzalez-Santiago, Santiago
   Gavila, Joaquin
   Sanchez-Rovira, Pedro
   Di Cosimo, Serena
   Charpentier, Eric
   Garcia-Ribas, Ignacio
   Penault-Llorca, Frederique Madeleine
   Aura, Claudia
   Baselga, Jose
CA SOLTI Grp
TI SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib
   plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients
   with triple-negative breast cancer (TNBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Solti Grp, Valencia, Spain.
   Hosp Clin Univ Valencia, Valencia, Spain.
   CHU Besancon, F-25030 Besancon, France.
   Inst Gustave Roussy, Villejuif, France.
   Hosp Arnau Vilanova, Lleida, Spain.
   Vall dHebron Univ Hosp, Breast Canc Dept, Barcelona, Spain.
   Hosp St Joan de Reus, Reus, Spain.
   Inst Bergonie Canc Ctr, Bordeaux, France.
   Hosp Virgen Del Rocio, Seville, Spain.
   Hosp Univ 12 Octubre ONCOSUR, Madrid, Spain.
   Inst Claudius Regaud, Toulouse, France.
   Complejo Hosp Caceres, Caceres, Spain.
   Inst Valenciano Oncol, Valencia, Spain.
   Complejo Hosp Jaen, Jaen, Spain.
   Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain.
   Sanofi Aventis, Malvern, PA USA.
   Sanofi Aventis, Madrid, Spain.
   Ctr Jean Perrin, Clermont Ferrand, France.
   Hosp Valle De Hebron, Barcelona, Spain.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Roche, Henri/O-9211-2014
OI Roche, Henri/0000-0001-7463-205X
NR 0
TC 1
Z9 1
U1 0
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1011
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800658
ER

PT J
AU Loggers, ET
   Lee, S
   Chilson, K
   Back, A
   Block, S
   Loberiza, FR
AF Loggers, Elizabeth T.
   Lee, Stephanie
   Chilson, Kate
   Back, Anthony
   Block, Susan
   Loberiza, Fausto R.
TI Advance care planning (ACP) among hematopoietic cell transplant (HCT)
   patients and bereaved caregivers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Seattle Canc Care Alliance, Seattle, WA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Nebraska Med Ctr, Omaha, NE USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9139
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802653
ER

PT J
AU Lonial, S
   Richardson, PGG
   Moreau, P
   Orlowski, RZ
   San-Miguel, JF
   Dimopoulos, MA
   Palumbo, AP
   Facon, T
   Vij, R
   White, D
   Reece, DE
   Singhal, A
   Kroog, GS
   Kopit, J
   Anderson, KC
AF Lonial, Sagar
   Richardson, Paul Gerard Guy
   Moreau, Philippe
   Orlowski, Robert Z.
   San-Miguel, Jesus F.
   Dimopoulos, Meletios A.
   Palumbo, Antonio Pierangelo
   Facon, Thierry
   Vij, Ravi
   White, Darrell
   Reece, Donna Ellen
   Singhal, Anil
   Kroog, Glenn Scott
   Kopit, Justin
   Anderson, Kenneth Carl
TI ELOQUENT-2: A phase III, randomized, open-label trial of
   lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in
   relapsed or refractory multiple myeloma (RR MM) (CA204-004).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Multiple Myeloma Res Consortium, Norwalk, CT USA.
   Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Hosp, Nantes, France.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Hosp Univ Salamanca, Salamanca, Spain.
   Hellen Cooperat Oncol Grp, Athens, Greece.
   Univ Turin, Turin, Italy.
   Hop Claude Huriez, Lille, France.
   Washington Univ, Sch Med, St Louis, MO USA.
   Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
   Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada.
   Abbott Biotherapeut, Redwood City, CA USA.
   Bristol Myers Squibb Co, Global Clin Res Oncol, Princeton, NJ USA.
   Bristol Myers Squibb Co, Princeton, NJ USA.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015
OI FACON, THIERRY/0000-0001-7705-8460; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS8112
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804079
ER

PT J
AU Lonial, S
   Baz, RC
   Wang, M
   Talpaz, M
   Liu, G
   Berg, D
   Gupta, N
   Di Bacco, A
   Hui, AM
   Richardson, PGG
AF Lonial, Sagar
   Baz, Rachid C.
   Wang, Michael
   Talpaz, Moshe
   Liu, Guohui
   Berg, Deborah
   Gupta, Neeraj
   Di Bacco, Alessandra
   Hui, Ai-Min
   Richardson, Paul Gerard Guy
TI Phase I study of twice-weekly dosing of the investigational oral
   proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or
   refractory multiple myeloma (MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Univ Michigan Comprehens Canc Ctr, Ann Arbor, MI USA.
   Millennium Pharmaceut Inc, Cambridge, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8017
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803758
ER

PT J
AU Lorch, JH
   Hanna, G
   Dai, W
   Thotakura, V
   Nair, V
   Jaffa, Z
   Posner, MR
   Limaye, SA
   Rabinowits, G
   Tishler, RB
   Sher, DJ
   Haddad, RI
AF Lorch, Jochen H.
   Hanna, Glenn
   Dai, Wei
   Thotakura, Vijaya
   Nair, Vidya
   Jaffa, Zachary
   Posner, Marshall R.
   Limaye, Sewanti Atul
   Rabinowits, Guilherme
   Tishler, Roy B.
   Sher, David J.
   Haddad, Robert I.
TI HPV and survival in patients with oropharyngeal squamous cell cancer of
   the head and neck (OPC) treated with induction chemotherapy followed by
   chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): The
   Dana-Farber experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mt Sinai, New York, NY USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5582
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802660
ER

PT J
AU LoRusso, P
   Shapiro, G
   Pandya, SS
   Kwak, EL
   Jones, C
   Belvin, M
   Musib, LC
   de Crespigny, A
   McKenzie, M
   Gates, MR
   Chan, ITC
   Bendell, JC
AF LoRusso, Patricia
   Shapiro, Geoffrey
   Pandya, Shuchi Sumant
   Kwak, Eunice Lee
   Jones, Cheryl
   Belvin, Marcia
   Musib, Luna C.
   de Crespigny, Alex
   McKenzie, Meghan
   Gates, Mary R.
   Chan, Iris Tan-Chi
   Bendell, Johanna C.
TI A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973,
   combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced
   solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Karmanos Canc Inst, Detroit, MI USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 10
Z9 10
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2566
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802034
ER

PT J
AU Lu-Emerson, C
   Snuderl, M
   Davidson, C
   Kirkpatrick, ND
   Huang, YH
   Duda, DG
   Ancukiewicz, M
   Stemmer-Rachamimov, A
   Batchelor, T
   Jain, RK
AF Lu-Emerson, Christine
   Snuderl, Matija
   Davidson, Christian
   Kirkpatrick, Nathaniel D.
   Huang, Yuhui
   Duda, Dan G.
   Ancukiewicz, Marek
   Stemmer-Rachamimov, Anat
   Batchelor, Tracy
   Jain, Rakesh K.
TI Effect of antiangiogenic therapy on tumor-associated macrophages in
   recurrent glioblastoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Lu-Emerson, Christine; Snuderl, Matija; Davidson, Christian; Kirkpatrick, Nathaniel D.; Huang, Yuhui; Duda, Dan G.; Ancukiewicz, Marek; Stemmer-Rachamimov, Anat; Batchelor, Tracy; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2010
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801505
ER

PT J
AU Luis, IMVD
   Ottesen, RA
   Hughes, ME
   Marcom, PK
   Moy, B
   Rugo, HS
   Theriault, RL
   Wilson, J
   Niland, JC
   Weeks, JC
   Lin, NU
AF Luis, Ines Maria Vaz Duarte
   Ottesen, Rebecca A.
   Hughes, Melissa E.
   Marcom, P. Kelly
   Moy, Beverly
   Rugo, Hope S.
   Theriault, Richard L.
   Wilson, John
   Niland, Joyce C.
   Weeks, Jane C.
   Lin, Nancy U.
TI Impact of hormone receptor (HR) status on clinicopathological features,
   patterns of recurrence, and clinical outcomes among patients (pts) with
   human epidermal growth factor receptor-2 positive (HER2) breast cancer
   (BC) in the National Comprehensive Cancer Network (NCCN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Dana Farber Canc Inst, Lexington, MA USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Ohio State Univ, Columbus, OH 43210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 599
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800012
ER

PT J
AU Luke, JJ
   Rubinstein, L
   Smith, GL
   Ivy, SP
   Harris, PJ
AF Luke, Jason John
   Rubinstein, Larry
   Smith, Gary L.
   Ivy, S. Percy
   Harris, Pamela Jo
TI The role of phase I clinical trials in advanced malignant melanoma:
   Retrospective analysis of CTEP-sponsored trials 1995-2011.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Div Canc Treatment & Diag, Bethesda, MD USA.
   NCI, Rockville, MD USA.
   NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2606
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802153
ER

PT J
AU Lypas, G
   Root, EJ
   George, S
   Wagner, AJ
   Butrynski, JE
   Morgan, JA
   Demetri, GD
   DiGianni, L
   Masciari, S
   Rath, MG
   Garber, JE
   Raut, CP
AF Lypas, Georgios
   Root, Elizabeth J.
   George, Suzanne
   Wagner, Andrew J.
   Butrynski, James E.
   Morgan, Jeffrey A.
   Demetri, George D.
   DiGianni, Lisa
   Masciari, Serena
   Rath, Michelle Genevieve
   Garber, Judy Ellen
   Raut, Chandrajit P.
TI Features of familiality in a cohort of patients (pts) with sarcoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1547
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801348
ER

PT J
AU Machiels, JPH
   Licitra, LF
   Haddad, RI
   Tahara, M
   Svensson, L
   Cong, XJ
   Ehrnrooth, E
   Cohen, EEW
AF Machiels, Jean-Pascal H.
   Licitra, Lisa F.
   Haddad, Robert I.
   Tahara, Makoto
   Svensson, Liz
   Cong, Xiuyu Julie
   Ehrnrooth, Eva
   Cohen, Ezra E. W.
CA Lux-H&N1 Study Grp
TI LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate
   (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck
   squamous cell carcinoma (HNSCC) who progressed after platinum-based
   therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Clin Univ St Luc, B-1200 Brussels, Belgium.
   Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
   Danmark AS, Boehringer Ingelheim, Copenhagen, Denmark.
   Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA.
   Boehringer Ingelheim GmbH & Co KG, Copenhagen, Denmark.
   Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS5598
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802706
ER

PT J
AU Maeda, LS
   Geiger, JL
   Savage, KJ
   Rose, J
   Pinter-Brown, LC
   Lunning, MA
   Abramson, JS
   Bartlett, N
   Vose, J
   Drape, J
   Muffly, LS
   McMillan, A
   Evens, AM
   Smith, SM
   Horwitz, SM
   Ansell, SM
   Advani, R
AF Maeda, Lauren Shizue
   Geiger, Jessica L.
   Savage, Kerry J.
   Rose, Jim
   Pinter-Brown, Lauren C.
   Lunning, Matthew Alexander
   Abramson, Jeremy S.
   Bartlett, Nancy
   Vose, Julie
   Drape, Jacqueline
   Muffly, Lori S.
   McMillan, Alex
   Evens, Andrew M.
   Smith, Sonali M.
   Horwitz, Steven M.
   Ansell, Stephen Maxted
   Advani, Ranjana
TI Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A
   North American (NA) multi-institutional experience.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Stanford Univ Med Ctr, Stanford, CA USA.
   Mayo Clin, Div Hematol, Rochester, MN USA.
   British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Washington Univ, Ctr Canc, St Louis, MO USA.
   Univ Nebraska Med Ctr, Omaha, NE USA.
   Univ Massachusetts Med Sch, Worcester, MA USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Stanford Univ, Stanford, CA 94305 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8060
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803765
ER

PT J
AU Mahadevan, D
   Rensvold, DM
   Kurtin, SE
   Cleary, JM
   Gandhi, L
   Lyons, JF
   Lock, V
   Lewis, S
   Shapiro, G
AF Mahadevan, Daruka
   Rensvold, Diane M.
   Kurtin, Sandra E.
   Cleary, James M.
   Gandhi, Leena
   Lyons, John F.
   Lock, Victoria
   Lewis, Samantha
   Shapiro, Geoffrey
TI First-in-human phase I study: Results of a second-generation
   non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in
   refractory solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Arizona Canc Ctr, Tucson, AZ USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Astex Pharmaceut, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3028
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802491
ER

PT J
AU Mahadevan, D
   Rensvold, DM
   Kurtin, SE
   Cleary, JM
   Gandhi, L
   Lyons, JF
   Lock, V
   Lewis, S
   Shapiro, G
AF Mahadevan, Daruka
   Rensvold, Diane M.
   Kurtin, Sandra E.
   Cleary, James M.
   Gandhi, Leena
   Lyons, John F.
   Lock, Victoria
   Lewis, Samantha
   Shapiro, Geoffrey
TI First-in-human phase I study: Results of a second-generation
   non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in
   refractory solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Astex Pharmaceut, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3028
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802471
ER

PT J
AU Manola, J
   Zhao, FM
   Miller, AH
   Pirl, WF
   Wagner, LI
   Fisch, M
AF Manola, Judith
   Zhao, Fengmin
   Miller, Andrew H.
   Pirl, William F.
   Wagner, Lynne I.
   Fisch, Michael
TI Patterns of antidepressant use in cancer patients (pts): An analysis
   from SOAPP (ECOG E2Z02: Symptom Outcomes and Practice Patterns)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Emory Univ, Sch Med, Atlanta, GA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Northwestern Univ, Chicago, IL 60611 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9016
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800048
ER

PT J
AU Marreaud, S
   Van der Graaf, WTA
   Blay, JY
   Chawla, SP
   Lee, J
   Nguyen, BB
   Casali, PG
   Aglietta, M
   Staddon, AP
   Beppu, Y
   Le Cesne, A
   Gelderblom, H
   Judson, IR
   Araki, N
   Ouali, M
   Dewji, M
   Powell, A
   Demetri, GD
   Hohenberger, P
AF Marreaud, Sandrine
   Van der Graaf, Winette T. A.
   Blay, Jean-Yves
   Chawla, Sant P.
   Lee, Jeeyun
   Binh Bui Nguyen
   Casali, Paolo Giovanni
   Aglietta, Massimo
   Staddon, Arthur P.
   Beppu, Yasuo
   Le Cesne, Axel
   Gelderblom, Hans
   Judson, Ian Robert
   Araki, Nobuhito
   Ouali, Monia
   Dewji, Mohamedraza
   Powell, Alex
   Demetri, George D.
   Hohenberger, Peter
TI Global differences in chemotherapeutic regimens of soft tissue sarcoma
   (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network
   phase III trial of pazopanib versus placebo
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 EORTC Headquarters, Brussels, Belgium.
   Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   Ctr Leon Berard, F-69373 Lyon, France.
   Sarcoma Oncol Ctr, Santa Monica, CA USA.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea.
   Inst Bergonie, Bordeaux, France.
   Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   Inst Canc Res & Treatment, Candiolo, Italy.
   Univ Penn, Philadelphia, PA 19104 USA.
   Natl Canc Ctr, Tokyo, Japan.
   Inst Gustave Roussy, Villejuif, France.
   Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
   Royal Marsden Hosp NHS Fdn Trust, Sarcoma Unit, London, England.
   Osaka Med Ctr, Osaka, Japan.
   European Org Res & Treatment Canc Headquarters, Brussels, Belgium.
   GlaxoSmithKline R&D, Greenford, Middx, England.
   Hollywood Med Ctr, Nedlands, WA, Australia.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Mannheim, Med Ctr, Dept Surg, D-68131 Mannheim, Germany.
RI van der Graaf, Winette/A-5006-2014; Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10067
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802395
ER

PT J
AU Marur, S
   Lee, JW
   Cmelak, A
   Zhao, WQ
   Westra, WH
   Chung, CH
   Gillison, ML
   Gilbert, J
   Bauman, JE
   Wagner, LI
   Ferris, RL
   Trevarthen, DR
   Colevas, AD
   Jahagirdar, BN
   Burtness, B
AF Marur, Shanthi
   Lee, Ju-Whei
   Cmelak, Anthony
   Zhao, Weiqiang
   Westra, William H.
   Chung, Christine H.
   Gillison, Maura L.
   Gilbert, Jill
   Bauman, Julie E.
   Wagner, Lynne I.
   Ferris, Robert L.
   Trevarthen, David R.
   Colevas, A. Dimitrios
   Jahagirdar, Balkrishna N.
   Burtness, Barbara
CA Eastern Cooperative Oncology Grp
TI ECOG 1308: A phase II trial of induction chemotherapy followed by
   cetuximab with low dose versus standard dose IMRT in patients with
   HPV-associated resectable squamous cell carcinoma of the oropharynx
   (OP).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   Arthur G James Canc Hosp, Columbus, OH USA.
   Solove Res Inst, Columbus, OH USA.
   Johns Hopkins Sch Med, Baltimore, MD USA.
   Johns Hopkins Univ, Baltimore, MD USA.
   Ohio State Univ, Columbus, OH 43210 USA.
   Vanderbilt Univ, Nashville, TN USA.
   Univ New Mexico, Albuquerque, NM 87131 USA.
   Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   Univ Pittsburgh, Pittsburgh, PA USA.
   Colorado Canc Res Program, Denver, CO USA.
   Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   HealthPartners & Reg Canc Care Ctr, St Paul, MN USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5566
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800120
ER

PT J
AU Maughan, B
   Boucher, KM
   Agarwal, N
   Choueiri, TK
   Qu, AQ
   Vogelzang, NJ
   Fougeray, R
   Niegisch, G
   Albers, P
   Wong, YN
   Ko, YJ
   Sridhar, SS
   Galsky, MD
   Petrylak, DP
   Vaishampayan, UN
   Beer, TM
   Sternberg, CN
   Rosenberg, JE
   Molins, JB
   Sonpavde, G
AF Maughan, Benjamin
   Boucher, Kenneth M.
   Agarwal, Neeraj
   Choueiri, Toni K.
   Qu, Angela Q.
   Vogelzang, Nicholas J.
   Fougeray, Ronan
   Niegisch, Guenter
   Albers, Peter
   Wong, Yu-Ning
   Ko, Yoo-Joung
   Sridhar, Srikala S.
   Galsky, Matt D.
   Petrylak, Daniel Peter
   Vaishampayan, Ulka N.
   Beer, Tomasz M.
   Sternberg, Cora N.
   Rosenberg, Jonathan E.
   Molins, Joaquim Bellmunt
   Sonpavde, Guru
TI Correlation of progression-free survival at 6 months (PFS6) with overall
   survival at 12 months (OS12) in an analysis of 10 trials of second-line
   therapy for advanced urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Utah, Salt Lake City, UT USA.
   Huntsman Canc Inst, Salt Lake City, UT USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   US Oncol Res, Las Vegas, NV USA.
   Inst Rech Pierre Fabre, Boulogne, France.
   Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany.
   Univ Dusseldorf, D-40225 Dusseldorf, Germany.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.
   Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
   Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
   Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
   Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
   San Camillo Hosp, Rome, Italy.
   Forlanini Hosp, Rome, Italy.
   Univ Hosp del Mar IMIM, Barcelona, Spain.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4525
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803328
ER

PT J
AU May, KF
   Franz, B
   Harvey, C
   Hodi, FS
   Dranoff, G
   Wucherpfennig, K
AF May, Kenneth F.
   Franz, Bettina
   Harvey, Christopher
   Hodi, F. Stephen
   Dranoff, Glenn
   Wucherpfennig, Kai
TI Isolation of human anti-MICA antibody from cancer patients responding to
   immunotherapies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [May, Kenneth F.; Franz, Bettina; Harvey, Christopher; Hodi, F. Stephen; Dranoff, Glenn; Wucherpfennig, Kai] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2502
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801788
ER

PT J
AU Mayer, IA
   Abramson, VG
   Balko, JM
   Isakoff, SJ
   Kuba, MG
   Sanders, M
   Forero-Torres, A
   Yap, JT
   Van Den Abbeele, AD
   Li, YS
   Arteaga, CL
   Winer, EP
AF Mayer, Ingrid A.
   Abramson, Vandana Gupta
   Balko, Justin M.
   Isakoff, Steven J.
   Kuba, Maria Gabriela
   Sanders, Melinda
   Forero-Torres, Andres
   Yap, Jeffrey T.
   Van Den Abbeele, Annick D.
   Li, Yisheng
   Arteaga, Carlos L.
   Winer, Eric P.
CA Stand Canc PI3K Women's Canc
TI SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in
   ER+/HER2-metastatic breast cancer (MBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   Vanderbilt Univ, Nashville, TN USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Alabama Birmingham, Birmingham, AL USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 510
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800055
ER

PT J
AU McBride, SM
   Busse, PM
   Clark, JR
   Parambi, RJ
   Wirth, LJ
   Chan, AW
AF McBride, Sean M.
   Busse, Paul M.
   Clark, John Ross
   Parambi, Ron J.
   Wirth, Lori J.
   Chan, Annie W.
TI Long-term survival after distant metastasis in oropharyngeal carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Radiat Oncol Program, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5594
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802858
ER

PT J
AU McCauley, D
   Landesman, Y
   Senapedis, W
   Kashyap, T
   Saint-Martin, JR
   Plamondon, L
   Sandanayaka, V
   Shechter, S
   Froim, D
   Nir, R
   Williams, J
   Chin, L
   Benes, C
   Mirza, MR
   Kauffman, M
   Shacham, S
AF McCauley, Dilara
   Landesman, Yosef
   Senapedis, William
   Kashyap, Trinayan
   Saint-Martin, Jean-Richard
   Plamondon, Louis
   Sandanayaka, Vincent
   Shechter, Sharon
   Froim, Doriana
   Nir, Raphael
   Williams, Jennifer
   Chin, Lynda
   Benes, Cyril
   Mirza, Mansoor Raza
   Kauffman, Michael
   Shacham, Sharon
TI Preclinical evaluation of selective inhibitors of nuclear export (SINE)
   in basal-like breast cancer (BLBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Karyopharm Therapeut, Boston, MA USA.
   Karyopharm Therapeut, Natick, MA USA.
   Karyopharm, Natick, MA USA.
   Karyopharm Therapeut, Newton, MA USA.
   SBH Sci, Natick, MA USA.
   Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   NSGO Nord Soc Gynaecol Oncol, Copenhagen, Denmark.
NR 0
TC 0
Z9 0
U1 4
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1055
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800737
ER

PT J
AU McCleary, NJ
   Wigler, D
   Berry, DL
   Sato, K
   Hurria, A
   Ng, K
   Abrams, TA
   Chan, JA
   Enzinger, PC
   Fuchs, CS
   Wolpin, BM
   Schrag, D
   Meyerhardt, JA
AF McCleary, Nadine Jackson
   Wigler, Devin
   Berry, Donna Lynn
   Sato, Kaori
   Hurria, Arti
   Ng, Kimmie
   Abrams, Thomas Adam
   Chan, Jennifer A.
   Enzinger, Peter C.
   Fuchs, Charles S.
   Wolpin, Brian M.
   Schrag, Deborah
   Meyerhardt, Jeffrey A.
TI Feasibility of computer-based self-administered cancer-specific
   geriatric assessment (SA-CSGA) in older pts with gastrointestinal
   malignancy (GIM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e19586
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804236
ER

PT J
AU McDermott, DF
   Drake, CG
   Sznol, M
   Choueiri, TK
   Powderly, J
   Smith, DC
   Wigginton, J
   McDonald, D
   Kollia, G
   Gupta, AK
   Atkins, MB
AF McDermott, David F.
   Drake, Charles G.
   Sznol, Mario
   Choueiri, Toni K.
   Powderly, John
   Smith, David C.
   Wigginton, Jon
   McDonald, Dan
   Kollia, Georgia
   Gupta, Ashok Kumar
   Atkins, Michael B.
TI Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in
   patients with previously treated metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Yale Canc Ctr, New Haven, CT USA.
   Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
   Carolina Biooncol Inst, Huntersville, NC USA.
   Univ Michigan, Ann Arbor, MI 48109 USA.
   Bristol Myers Squibb Co, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4505
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803325
ER

PT J
AU Meany, HJ
   Attiyeh, EF
   Naranjo, A
   Twist, C
   London, WB
   Villablanca, J
   Schmidt, ML
   Baker, D
   Strother, DR
   Shimada, H
   Matthay, KK
   Cohn, SL
   Maris, JM
   Park, JR
AF Meany, Holly Jane
   Attiyeh, Edward F.
   Naranjo, Arlene
   Twist, Clare
   London, Wendy B.
   Villablanca, Judith
   Schmidt, Mary Lou
   Baker, Dave
   Strother, Douglas R.
   Shimada, Hiroyuki
   Matthay, Katherine K.
   Cohn, Susan Lerner
   Maris, John M.
   Park, Julie R.
TI Outcome analysis of non-high-risk neuroblastoma patients enrolled on
   Children's Oncology Group trials P9641 and A3961
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Childrens Natl Med Ctr, Washington, DC 20010 USA.
   Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   Childrens Oncol Grp, Gainesville, FL USA.
   Stanford Univ, Palo Alto, CA 94304 USA.
   Harvard Canc Care & Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA.
   Childrens Hosp, Los Angeles, CA 90027 USA.
   Univ Illinois, Chicago, IL USA.
   Princess Margaret Hosp Children, Perth, WA, Australia.
   Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
   Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
   Univ Calif San Francisco, San Francisco Childrens Hosp, San Francisco, CA 94143 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   Seattle Childrens Hosp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9533
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800569
ER

PT J
AU Mega, AE
   Petrylak, DP
   Kantoff, P
   Stephenson, J
   Vogelzang, NJ
   Dreicer, R
   Shore, ND
   Stambler, N
   Carpenito, J
   D'Ambrosio, P
   Israel, RJ
AF Mega, Anthony E.
   Petrylak, Daniel Peter
   Kantoff, Philip
   Stephenson, Joe
   Vogelzang, Nicholas J.
   Dreicer, Robert
   Shore, Neal D.
   Stambler, Nancy
   Carpenito, Jennifer
   D'Ambrosio, Paul
   Israel, Robert Joseph
TI Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A
   phase I trial in metastatic castration-resistant prostate cancer (mCRPC)
   previously treated with a taxane.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Brown Univ, Oncol Grp, Providence, RI 02912 USA.
   Columbia Univ, Med Ctr, New York, NY USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Canc Ctr Carolinas, Greenville, SC USA.
   Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   US Oncol Res, Las Vegas, NV USA.
   Cleveland Clin, Cleveland, OH 44106 USA.
   Carolina Urol Res Ctr, Myrtle Beach, SC USA.
   Progen Pharmaceut Inc, Tarrytown, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4662
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803270
ER

PT J
AU Mehra, R
   Camidge, DR
   Sharma, S
   Felip, E
   Tan, DSW
   Vansteenkiste, JF
   De Pas, TM
   Kim, DW
   Santoro, A
   Liu, G
   Goldwasser, M
   Dai, D
   Radona, M
   Boral, A
   Shaw, AT
AF Mehra, Ranee
   Camidge, D. Ross
   Sharma, Sunil
   Felip, Enriqueta
   Tan, Daniel Shao-Weng
   Vansteenkiste, Johan F.
   De Pas, Tommaso Martino
   Kim, Dong-Wan
   Santoro, Armando
   Liu, Geoffrey
   Goldwasser, Meredith
   Dai, David
   Radona, Marietta
   Boral, Anthony
   Shaw, Alice Tsang
TI First-in-human phase I study of the ALK inhibitor LDK378 in advanced
   solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Huntsman Canc Inst, Salt Lake City, UT USA.
   Vall dHebron Univ Hosp, Barcelona, Spain.
   Natl Canc Ctr, Singapore, Singapore.
   Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
   European Inst Oncol, Milan, Italy.
   Seoul Natl Univ Hosp, Seoul 110744, South Korea.
   Humanitas Canc Ctr, Rozzano, Italy.
   Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
   Novartis Inst BioMed Res Inc, Cambridge, MA USA.
   Novartis Pharmaceut, E Hanover, NJ USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI Vansteenkiste, Johan/B-8191-2014
OI Vansteenkiste, Johan/0000-0002-6721-2775
NR 0
TC 5
Z9 6
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3007
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802462
ER

PT J
AU Meier, FE
   Forschner, A
   Klumpp, B
   Flaherty, KT
   Honegger, JB
   Witte, M
   Bornemann, A
   Dummer, R
   Bauer, J
   Tabatabai, G
   Weide, B
   Eigentler, TK
   Schadendorf, D
   Quintanilla-Fend, L
   Niessner, H
   Garbe, C
AF Meier, Friedegund Elke
   Forschner, Andrea
   Klumpp, Bernhard
   Flaherty, Keith T.
   Honegger, Juergen Bernd
   Witte, Maria
   Bornemann, Antje
   Dummer, Reinhard
   Bauer, Juergen
   Tabatabai, Ghazaleh
   Weide, Benjamin
   Eigentler, Thomas K.
   Schadendorf, Dirk
   Quintanilla-Fend, Leticia
   Niessner, Heike
   Garbe, Claus
TI Targeting hyperactivation of the AKT survival pathway to overcome
   therapy resistance of melanoma brain metastases.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Tubingen, Tubingen, Germany.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland.
   Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.
   Univ Tubingen, Dept Dermatol, Tubingen, Germany.
   Univ Hosp Essen, Essen, Germany.
   Univ Tubingen, Dept Dermatol & Oncol, Tubingen, Germany.
RI Eigentler, Thomas/K-8570-2015
OI Eigentler, Thomas/0000-0003-0019-2770
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8526
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800067
ER

PT J
AU Mendoza, TR
   Zhao, FM
   Cleeland, CS
   Wagner, LI
   Patrick-Miller, LJ
   Fisch, M
AF Mendoza, Tito R.
   Zhao, Fengmin
   Cleeland, Charles S.
   Wagner, Lynne I.
   Patrick-Miller, Linda J.
   Fisch, Michael
TI Understanding the symptom experience of breast cancer outpatients: The
   validity and utility of the MD Anderson Symptom Inventory (MDASI)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Northwestern Univ, Chicago, IL 60611 USA.
   Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9106
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802578
ER

PT J
AU Merchant, MS
   Baird, K
   Wexler, LH
   Rodriguez-Galindo, C
   Mackall, C
AF Merchant, Melinda S.
   Baird, Kristin
   Wexler, Leonard H.
   Rodriguez-Galindo, Carlos
   Mackall, Crystal
TI Ipilimumab: First results of a phase I trial in pediatric patients with
   advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 NCI, Bethesda, MD 20892 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9545
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801660
ER

PT J
AU Metzger, M
   Billett, A
   Friedmann, AM
   Krasin, MJ
   Howard, SC
   Weinstein, HJ
   Larsen, E
   Marcus, KC
   Billups, C
   Wu, JR
   Donaldson, SS
   Link, MP
   Hudson, MM
AF Metzger, Monika
   Billett, Amy
   Friedmann, Alison M.
   Krasin, Matthew J.
   Howard, Scott C.
   Weinstein, Howard J.
   Larsen, Eric
   Marcus, Karen Chayt
   Billups, Catherine
   Wu, Jianrong
   Donaldson, Sarah S.
   Link, Michael Paul
   Hudson, Melissa M.
TI Stanford V chemotherapy and involved field radiotherapy for children and
   adolescents with unfavorable risk Hodgkin lymphoma: Results of a
   multi-institutional prospective clinical trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Boston, MA 02114 USA.
   Maine Childrens Canc Program, Scarborough, ME USA.
   Childrens Hosp, Boston, MA 02115 USA.
   Stanford Canc Ctr, Stanford, CA USA.
   Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9502
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801580
ER

PT J
AU Metzger, O
   Michiels, S
   Singhal, SK
   Bertucci, F
   Desmedt, C
   Fumagalli, D
   Salgado, R
   Galant, C
   Veys, I
   Saini, KVS
   Larsimont, D
   Winer, EP
   Piccart-Gebhart, MJ
   Sotiriou, C
AF Metzger, Otto
   Michiels, Stefan
   Singhal, Sandeep K.
   Bertucci, Francois
   Desmedt, Christine
   Fumagalli, Debora
   Salgado, Roberto
   Galant, Christine
   Veys, Isabelle
   Saini, Kamal V. S.
   Larsimont, Denis
   Winer, Eric P.
   Piccart-Gebhart, Martine J.
   Sotiriou, Christos
TI Urokinase-type plasminogen activator gene (PLAU) to predict clinical
   outcome in invasive lobular carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Libre Brussels, Dana Farber Canc Inst, Inst Jules Bordet, Boston, MA USA.
   Inst Jules Bordet, B-1000 Brussels, Belgium.
   Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
   Inst J Paoli I Calmettes, F-13009 Marseille, France.
   Clin Univ St Luc, B-1200 Brussels, Belgium.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Michiels, Stefan/L-1516-2013
OI Michiels, Stefan/0000-0002-6963-2968
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e21010
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802198
ER

PT J
AU Michaelson, MD
   Rini, BI
   Escudier, BJ
   Clark, J
   Redman, B
   Tarazi, JC
   Rosbrook, B
   Kim, S
   Motzer, RJ
AF Michaelson, M. Dror
   Rini, Brian I.
   Escudier, Bernard J.
   Clark, Joseph
   Redman, Bruce
   Tarazi, Jamal Christo
   Rosbrook, Brad
   Kim, Sinil
   Motzer, Robert John
TI Phase III AXIS trial of axitinib versus sorafenib in metastatic renal
   cell carcinoma: Updated results among cytokine-treated patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
   Inst Gustave Roussy, Villejuif, France.
   Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Maywood, IL USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Pfizer Oncol, San Diego, CA USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4546
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803341
ER

PT J
AU Miles, D
   Swain, SM
   Im, YH
   Knott, A
   Ross, G
   Clark, E
   Benyunes, M
   Baselga, J
AF Miles, David
   Swain, Sandra M.
   Im, Young-Hyuck
   Knott, Adam
   Ross, Graham
   Clark, Emma
   Benyunes, Mark
   Baselga, Jose
TI Concordance between independently and investigator-assessed
   progression-free survival in CLEOPATRA
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Vernon Hosp, Northwood HA6 2RN, Middx, England.
   MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea.
   Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England.
   Genentech Inc, San Francisco, CA USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e11055
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800276
ER

PT J
AU Millar, EKA
   Coates, AS
   O'Toole, S
   Selinger, C
   Musgrove, EA
   Yan, M
   Viale, G
   Regan, MM
   Price, KN
   Sun, ZX
   Castiglione, MM
   Colleoni, M
   Gelber, RD
   Goldhirsch, A
   Sutherland, RL
AF Millar, Ewan K. A.
   Coates, Alan Stuart
   O'Toole, Sandra
   Selinger, Cristina
   Musgrove, Elizabeth A.
   Yan, Max
   Viale, Giuseppe
   Regan, Meredith M.
   Price, Karen N.
   Sun, Zhuoxin
   Castiglione, Monica M.
   Colleoni, Marco
   Gelber, Richard D.
   Goldhirsch, Aron
   Sutherland, Robert L.
CA Int Breast Canc Study Grp
TI Intrinsic subtype and its clinical significance in early node-negative
   breast cancer: Results from two randomized trials of adjuvant
   chemoendocrine therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Kinghorn Canc Ctr, Sydney, NSW, Australia.
   Garvan Inst, Sydney, NSW, Australia.
   IBCSG, Sydney, NSW, Australia.
   St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia.
   Garvan Inst Med Res, Sydney, NSW, Australia.
   European Inst Oncol, Div Pathol, Milan, Italy.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   IBCSG Stat Ctr, Boston, MA USA.
   Int Breast Canc Study Grp, Bern, Switzerland.
   European Inst Oncol, Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 504
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800179
ER

PT J
AU Modi, S
   Elias, AD
   LoRusso, P
   Samant, M
   Guardino, E
   Althaus, B
   Krop, IE
AF Modi, Shanu
   Elias, Anthony D.
   LoRusso, Patricia
   Samant, Meghna
   Guardino, Ellie
   Althaus, Betsy
   Krop, Ian E.
TI Results from a phase Ib study of trastuzumab emtansine (T-DM1),
   paclitaxel (T), and pertuzumab (P) in patients with HER2-positive
   metastatic breast cancer (MBC) previously treated with trastuzumab.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Karmanos Canc Inst, Detroit, MI USA.
   F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
   Genentech Inc, San Francisco, CA 94080 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 528
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800063
ER

PT J
AU Moinpour, C
   Berry, DL
   Ely, B
   Tangen, CM
   Higano, CS
   Picus, J
   Schellhammer, PF
   Skinner, EC
   Cher, ML
   Thompson, IM
   Hussain, M
AF Moinpour, Carol
   Berry, Donna Lynn
   Ely, Benjamin
   Tangen, Catherine M.
   Higano, Celestia S.
   Picus, Joel
   Schellhammer, Paul F.
   Skinner, Eila C.
   Cher, Michael L.
   Thompson, Ian Murchie
   Hussain, Maha
TI Preliminary quality-of-life outcomes for SWOG-9346: Intermittent
   androgen deprivation in patients with hormone-sensitive metastatic
   prostate cancer (HSM1PC)-Phase III.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   SWOG Stat Ctr, Seattle, WA USA.
   Univ Washington, Puget Sound Oncol Consortium, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
   Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
   Eastern Virginia Med Sch, Urol Virginia, Norfolk, VA 23501 USA.
   Univ So Calif, USC Inst Urol, Los Angeles, CA USA.
   Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
   Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4571
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803174
ER

PT J
AU Molina, AM
   Motzer, RJ
   Hutson, TE
   Larkin, JMG
   Gold, A
   Andresen, C
   Wood, K
   Michaelson, MD
AF Molina, Ana M.
   Motzer, Robert John
   Hutson, Thomas E.
   Larkin, James M. G.
   Gold, Anne
   Andresen, Corina
   Wood, Karen
   Michaelson, M. Dror
TI Treatment of refractory metastatic renal cell carcinoma (RCC) with
   lenvatinib (E7080) and everolimus
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
   Royal Marsden Hosp, London SW3 6JJ, England.
   Eisai, Woodcliff Lake, NJ USA.
   Eisai, Hatfield, Herts, England.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4682
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802870
ER

PT J
AU Molins, JB
   Werner, L
   Guix, M
   Guancial, EA
   Schutz, FAB
   O'Brien, R
   Stack, EC
   Loda, MF
   Berman, DM
   Hirsch, MS
   Signoretti, S
   Gallardo, E
   Rojo, F
   Ross, RW
   Kantoff, P
   Choueiri, TK
   Rosenberg, JE
AF Molins, Joaquim Bellmunt
   Werner, Lillian
   Guix, Marta
   Guancial, Elizabeth Ann
   Schutz, Fabio Augusto Barros
   O'Brien, Robert
   Stack, Edward C.
   Loda, Massimo F.
   Berman, David M.
   Hirsch, Michelle S.
   Signoretti, Sabina
   Gallardo, Enrique
   Rojo, Federico
   Ross, Robert W.
   Kantoff, Philip
   Choueiri, Toni K.
   Rosenberg, Jonathan E.
TI PI3KCA mutations in advanced urothelial carcinoma: A potential
   therapeutic target?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Hosp Mar IMIM, Barcelona, Spain.
   Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Pathol, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Kings Coll London, Boston, MA USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Corp Sanitaria, Sabadell, Spain.
   Univ Parc Tauli, Sabadell, Spain.
   Fdn Jimenez Diaz, Canc Res Unit, E-28040 Madrid, Spain.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
RI Rojo, Federico/S-6551-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4582
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802684
ER

PT J
AU Montgomery, RB
   Joshua, A
   Hannah, AL
   Peterson, AC
   Lopez, C
   Gleave, ME
   Taplin, ME
AF Montgomery, Robert B.
   Joshua, Anthony
   Hannah, Alison L.
   Peterson, Amy C.
   Lopez, Christian
   Gleave, Martin Edwin
   Taplin, Mary-Ellen
TI A randomized, open-label, phase II study of MDV3100 alone or in
   combination with leuprolide and dutasteride as neoadjuvant therapy to
   prostatectomy in intermediate and high-risk prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Washington Sch Med, Seattle, WA USA.
   Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   Medivation Inc, San Francisco, CA USA.
   Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4695
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803238
ER

PT J
AU Montgomery, RB
   Eisenberger, MA
   Rettig, M
   Chu, F
   Pili, R
   Stephenson, J
   Vogelzang, NJ
   Morrison, J
   Taplin, ME
AF Montgomery, Robert B.
   Eisenberger, Mario A.
   Rettig, Matthew
   Chu, Franklin
   Pili, Roberto
   Stephenson, Joe
   Vogelzang, Nicholas J.
   Morrison, Jodie
   Taplin, Mary-Ellen
TI Phase I clinical trial of galeterone (TOK-001), a multifunctional
   antiandrogen and CYP17 inhibitor in castration resistant prostate cancer
   (CRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Washington, Seattle, WA 98195 USA.
   Johns Hopkins Univ, James Buchanan Brady Urol Inst, Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
   San Bernadino Urol Associates, San Bernardino, CA USA.
   Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   Canc Ctr Carolinas, Greenville, SC USA.
   Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   US Oncol Res, Las Vegas, NV USA.
   Tokai Pharmaceut, Boston, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4665
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802806
ER

PT J
AU Moreau, P
   Richardson, PGG
   Jakubowiak, AJ
   Jagannath, S
   Raab, M
   Facon, T
   Vij, R
   Reece, DE
   White, D
   Benboubker, L
   Zonder, JA
   Rossi, JF
   Tsao, C
   Parli, T
   Kroog, GS
   Singhal, A
   Lonial, S
AF Moreau, Philippe
   Richardson, Paul Gerard Guy
   Jakubowiak, Andrzej J.
   Jagannath, Sundar
   Raab, Marc
   Facon, Thierry
   Vij, Ravi
   Reece, Donna Ellen
   White, Darrell
   Benboubker, Lotfi
   Zonder, Jeffrey A.
   Rossi, Jean-Francois
   Tsao, Claire
   Parli, Teresa
   Kroog, Glenn Scott
   Singhal, Anil
   Lonial, Sagar
TI A randomized phase II study of elotuzumab with lenalidomide and low-dose
   dexamethasone in patients with relapsed/refractory multiple myeloma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Hosp, Dept Hematol, Nantes, France.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
   Mt Sinai Med Ctr, New York, NY 10029 USA.
   Univ Klinikum Heidelberg, Heidelberg, Germany.
   Hop Claude Huriez, Lille, France.
   Multiple Myeloma Res Consortium, Norwalk, CT USA.
   Washington Univ, Sch Med, St Louis, MO USA.
   Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada.
   Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
   Hop Bretonneau, CHU Tours, Tours, France.
   Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
   CHU Lapeyronie, Montpellier, France.
   Abbott Biotherapeut, Redwood City, CA USA.
   Bristol Myers Squibb Global Clin Research Oncol, Princeton, NJ USA.
   Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015
OI FACON, THIERRY/0000-0001-7705-8460; 
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8020
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803838
ER

PT J
AU Morgans, AK
   Smith, MR
   O'Malley, AJ
   Keating, NL
AF Morgans, Alicia Katherine
   Smith, Matthew Raymond
   O'Malley, A. James
   Keating, Nancy Lynn
TI Osteoporosis screening among prostate cancer survivors treated with
   androgen deprivation therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6045
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803058
ER

PT J
AU Morris, MJ
   Hammers, HJ
   Sweeney, C
   Bloma, M
   Aksnes, AK
   O'Bryan-Tear, CG
   Carrasquillo, JA
AF Morris, Michael J.
   Hammers, Hans J.
   Sweeney, Christopher
   Bloma, Marianne
   Aksnes, Anne-Kirsti
   O'Bryan-Tear, C. Gillies
   Carrasquillo, Jorge A.
TI A phase I/IIa study of the safety and efficacy of radium-223 chloride
   (Ra-223) with docetaxel (D) for castration-resistant prostate cancer
   (CRPC) patients with bone metastases.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Johns Hopkins Univ, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Algeta ASA, Oslo, Norway.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4694
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803155
ER

PT J
AU Moskowitz, CS
   Chou, JF
   Wolden, SL
   Bernstein, JL
   Malhotra, J
   Friedman, DN
   Mubdi, NZ
   Henderson, TO
   Leisenring, WM
   Stovall, M
   Hammond, S
   Boice, JD
   Hudson, MM
   Diller, L
   Bhatia, S
   Neglia, JP
   Begg, CB
   Robison, LL
   Oeffinger, KC
AF Moskowitz, Chaya S.
   Chou, Joanne F.
   Wolden, Suzanne L.
   Bernstein, Jonine L.
   Malhotra, Jyoti
   Friedman, Danielle Novetsky
   Mubdi, Nidha Z.
   Henderson, Tara O.
   Leisenring, Wendy M.
   Stovall, Marilyn
   Hammond, Sue
   Boice, John D.
   Hudson, Melissa M.
   Diller, Lisa
   Bhatia, Smita
   Neglia, Joseph Philip
   Begg, Colin B.
   Robison, Leslie L.
   Oeffinger, Kevin C.
CA WECARE Study Collaborative
TI New insights into the risk of breast cancer in childhood cancer
   survivors treated with chest radiation: A report from the Childhood
   Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and
   Radiation Epidemiology (WECARE) Study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Nationwide Childrens Hosp, Columbus, OH USA.
   Vanderbilt Ingram Canc Ctr, Rockville, MD USA.
   Int Epidemiol Inst, Rockville, MD USA.
   St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 3
Z9 3
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA CRA9513
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800191
ER

PT J
AU Mostaghel, EA
   Nelson, P
   Lange, PH
   Lin, DW
   Taplin, ME
   Balk, SP
   Ellis, WJ
   Penning, T
   Marck, B
   True, LD
   Vessella, R
   Montgomery, RB
AF Mostaghel, Elahe A.
   Nelson, Peter
   Lange, Paul H.
   Lin, Daniel W.
   Taplin, Mary-Ellen
   Balk, Steven P.
   Ellis, William J.
   Penning, Trevor
   Marck, Brett
   True, Lawrence D.
   Vessella, Robert
   Montgomery, Robert B.
TI Neoadjuvant androgen pathway suppression prior to prostatectomy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Univ Washington, Seattle, WA 98195 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Univ Penn, Philadelphia, PA 19104 USA.
   Univ Washington, Dept Urol, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4520
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802579
ER

PT J
AU Moy, B
   Bradbury, AR
   Helft, PR
   Sheikh-Salah, M
   Egleston, B
   Sands, CB
   Storm, CD
   Peppercorn, JM
AF Moy, Beverly
   Bradbury, Angela R.
   Helft, Paul R.
   Sheikh-Salah, Moktar
   Egleston, Brian
   Sands, Colleen B.
   Storm, Courtney D.
   Peppercorn, Jeffrey M.
TI Association between financial relationships with commercial interests
   and research merit at the ASCO Annual Meeting (AM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
   ASCO, Alexandria, VA USA.
   Duke Univ, Med Ctr, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6095
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800799
ER

PT J
AU Munster, PN
   Miller, K
   Krop, IE
   Dhindsa, N
   Reynolds, J
   Geretti, E
   Niyikiza, C
   Nielsen, U
   Hendriks, B
   Wickham, TJ
   Moyo, VM
   LoRusso, P
AF Munster, Pamela N.
   Miller, Kathy
   Krop, Ian E.
   Dhindsa, Navreet
   Reynolds, Joe
   Geretti, Elena
   Niyikiza, Clet
   Nielsen, Ulrik
   Hendriks, Bart
   Wickham, Thomas J.
   Moyo, Victor M.
   LoRusso, Patricia
TI A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in
   patients with advanced, HER2-positive (HER2+) breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Merrimack Pharmaceut, Cambridge, MA USA.
   Karmanos Canc Inst, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS663
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800515
ER

PT J
AU Murphy, JE
   Liebman, HM
   Zhou, Q
   Bote, JT
   Daskalova, A
   Hooshmand, SM
   Ryan, DP
   Kulke, M
   Christiani, DC
AF Murphy, Janet E.
   Liebman, Hannah M.
   Zhou, Qian
   Bote, Josiah T.
   Daskalova, Anastassia
   Hooshmand, Susanne M.
   Ryan, David P.
   Kulke, Matthew
   Christiani, David C.
TI Functional SNPs in vascular endothelial growth factor (VEGF-A) and
   overall survival (OS) in bevacizumab-treated patients with metastatic
   colorectal cancer (mCRC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3594
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803881
ER

PT J
AU Musuuza, JS
   Sherman, ME
   Knudsen, KJ
   Sweeney, H
   Tyler, CV
   Koroukian, SM
AF Musuuza, Jackson S.
   Sherman, Marion E.
   Knudsen, Kraig J.
   Sweeney, HelenAnne
   Tyler, Carl V.
   Koroukian, Siran M.
TI Analyzing excess mortality from cancer among individuals with mental
   illness.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA.
   US Dept Vet Affairs, Joint Ambulatory Care Ctr, Pensacola, FL USA.
   Ohio Dept Mental Hlth, Columbus, OH USA.
   Cleveland Clin Hosp, Fairview Hosp, Cleveland, OH USA.
   Case Western Reserve Univ, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1598
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801312
ER

PT J
AU Navarro, A
   Oliveira, M
   De Mattos-Arruda, L
   Sanchez-Olle, G
   Bellet, M
   Balmana, J
   Gomez-Pardo, P
   Perez-Garcia, JM
   Munoz-Couselo, E
   Vidal, M
   Ortega, V
   Dienstmann, R
   Aura, C
   Hernandez-Losa, J
   Rodon, J
   Cajal, SRY
   Baselga, J
   Tabernero, J
   Cortes, J
   Saura, C
AF Navarro, Alejandro
   Oliveira, Mafalda
   De Mattos-Arruda, Leticia
   Sanchez-Olle, Gessam
   Bellet, Meritxell
   Balmana, Judith
   Gomez-Pardo, Patricia
   Manuel Perez-Garcia, Jose
   Munoz-Couselo, Eva
   Vidal, Maria
   Ortega, Vanesa
   Dienstmann, Rodrigo
   Aura, Claudia
   Hernandez-Losa, Javier
   Rodon, Jordi
   Ramon y Cajal, Santiago
   Baselga, Jose
   Tabernero, Josep
   Cortes, Javier
   Saura, Cristina
TI Prognostic significance of PI3K pathway (PI3Kp) dysregulation in
   metastatic breast cancer (MBC) patients (pts)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
   Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain.
   Vall dHebron Univ Hosp, Breast Canc Dept, Barcelona, Spain.
   Vall dHebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain.
   Vall dHebron Univ Hosp, Mol Pathol Lab, Barcelona, Spain.
   Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain.
   Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain.
RI Javier, Hernandez Losa/C-1173-2008
OI Javier, Hernandez Losa/0000-0003-1526-3201
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 566
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800379
ER

PT J
AU Neal, JW
   Pennell, NA
   Govindan, R
   Lanuti, M
   Rosovsky, RPG
   Heist, RS
   Shaw, AT
   Temel, JS
   Muzikansky, A
   Janne, PA
   Lynch, TJ
   Azzoli, CG
   Sequist, LV
AF Neal, Joel W.
   Pennell, Nathan A.
   Govindan, Ramaswamy
   Lanuti, Michael
   Rosovsky, Rachel Pam Greenerger
   Heist, Rebecca Suk
   Shaw, Alice Tsang
   Temel, Jennifer S.
   Muzikansky, Alona
   Janne, Pasi A.
   Lynch, Thomas James
   Azzoli, Christopher G.
   Sequist, Lecia V.
TI The SELECT study: A multicenter phase II trial of adjuvant erlotinib in
   resected epidermal growth factor receptor (EGFR) mutation-positive
   non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Stanford Univ, Palo Alto, CA 94304 USA.
   Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA.
   Washington Univ, St Louis, MO USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Yale Canc Ctr, New Haven, CT USA.
   Smilow Canc Hosp, New Haven, CT USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7010
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801374
ER

PT J
AU Ng, CS
   Lee, TY
   Coleman, RL
   Zhang, Z
   Dunning, B
   L'Heureux, D
   Mannel, RS
   Lee, S
AF Ng, Chaan S.
   Lee, Ting Yim
   Coleman, Robert L.
   Zhang, Zheng
   Dunning, Bernadine
   L'Heureux, Darryl
   Mannel, Robert S.
   Lee, Susanna
TI ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian
   cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Robarts Res Inst, London, ON N6A 5C1, Canada.
   Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA.
   Brown Univ, Providence, RI 02912 USA.
   Amer Coll Radiol, Philadelphia, PA USA.
   Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS5114
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803600
ER

PT J
AU Nishino, M
   Heon, S
   Dahlberg, SE
   Jackman, DM
   Ramaiya, NH
   Hatabu, H
   Rabin, MS
   Janne, PA
   Johnson, BE
AF Nishino, Mizuki
   Heon, Stephanie
   Dahlberg, Suzanne Eleanor
   Jackman, David Michael
   Ramaiya, Nikhil H.
   Hatabu, Hiroto
   Rabin, Michael S.
   Janne, Pasi Antero
   Johnson, Bruce E.
TI Radiographic assessment and therapeutic decisions at RECIST progression
   in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7553
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804382
ER

PT J
AU Noguchi, S
   Masuda, N
   Ito, Y
   Iwata, H
   Mukai, H
   Horiguchi, J
   Tokuda, Y
   Kuroi, K
   Iwase, H
   Inaji, H
   Ohsumi, S
   Piccart-Gebhart, MJ
   Hortobagyi, GN
   Rugo, HS
   Gnant, M
   Campone, M
   Sahmoud, T
   Pritchard, KI
   Burris, HA
   Baselga, J
AF Noguchi, Shinzaburo
   Masuda, Norikazu
   Ito, Yoshinori
   Iwata, Hiroji
   Mukai, Hirofumi
   Horiguchi, Jun
   Tokuda, Yutaka
   Kuroi, Katsumasa
   Iwase, Hirotaka
   Inaji, Hideo
   Ohsumi, Shozo
   Piccart-Gebhart, Martine J.
   Hortobagyi, Gabriel N.
   Rugo, Hope S.
   Gnant, Michael
   Campone, Mario
   Sahmoud, Tarek
   Pritchard, Kathleen I.
   Burris, Howard A.
   Baselga, Jose
TI BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian
   patients with HER2-negative, hormone receptor-positive breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan.
   Osaka Natl Hosp, Osaka, Japan.
   Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Breast Oncol Ctr, Tokyo, Japan.
   Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan.
   East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan.
   Gunma Univ Hosp, Maebashi, Gumma, Japan.
   Tokai Univ Hosp, Isehara, Kanagawa, Japan.
   Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo, Japan.
   Kumamoto Univ, Dept Breast & Endocrine Surg, Kumamoto, Japan.
   Med Ctr Canc & Cardiovasc Dis, Osaka, Japan.
   NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan.
   Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium.
   Univ Texas Houston, Houston, TX USA.
   Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria.
   Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, St Herblain, France.
   Novartis Pharmaceut, E Hanover, NJ USA.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 540
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800065
ER

PT J
AU Nutt, S
   Rechis, R
   Shulman, LN
   Hayes-Lattin, BM
AF Nutt, Stephanie
   Rechis, Ruth
   Shulman, Lawrence N.
   Hayes-Lattin, Brandon M.
TI Cancer survivors' perspectives on the US generic drug shortage
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 LIVESTRONG, Austin, TX USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e19503
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800510
ER

PT J
AU O'Brien, SM
   Barrientos, JC
   Flinn, IW
   Barr, PM
   Burger, JA
   Navarro, T
   James, DF
   Hedrick, E
   Friedberg, JW
   Brown, JR
AF O'Brien, Susan Mary
   Barrientos, Jacqueline Claudia
   Flinn, Ian W.
   Barr, Paul M.
   Burger, Jan Andreas
   Navarro, Tasheda
   James, Danelle Frances
   Hedrick, Eric
   Friedberg, Jonathan W.
   Brown, Jennifer R.
TI Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765
   with bendamustine (B)/rituximab (R) (BR) in patients (pts) with
   relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim
   results of a phase Ib/II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Long Isl Jewish Med Ctr, Hyde Pk, NY USA.
   PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
   Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   Pharmacyclics, Sunnyvale, CA USA.
   Pharmacyclics, Summit, NJ USA.
   Univ Rochester, James P Wilmot Canc Ctr, Hematol Oncol Div, Rochester, NY USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6515
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802779
ER

PT J
AU O'Dorisio, TM
   Phan, AT
   Langdon, RM
   Marek, BJ
   Ikhlaque, N
   Bergsland, EK
   Freiman, J
   Law, L
   Banks, PL
   Frazier, K
   Jackson, J
   Zambrowicz, B
   Kulke, M
AF O'Dorisio, Thomas M.
   Phan, Alexandria T.
   Langdon, Robert M.
   Marek, Billie J.
   Ikhlaque, Nadeem
   Bergsland, Emily K.
   Freiman, Joel
   Law, Linda
   Banks, Phillip Lee
   Frazier, Kenneth
   Jackson, Jessica
   Zambrowicz, Brian
   Kulke, Matthew
TI Relief of bowel-related symptoms with telotristat etiprate in octreotide
   refractory carcinoid syndrome: Preliminary results of a double-blind,
   placebo-controlled multicenter study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Nebraska Methodist Hosp, Omaha, NE USA.
   Texas Oncol PA, Mcallen, TX USA.
   St Francis Hosp & Hlth Ctr, Beech Grove, IN USA.
   Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Lexicon Pharmaceut Inc, The Woodlands, TX USA.
   Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4085
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800498
ER

PT J
AU Oh, WK
   Kantoff, P
   Scher, HI
   Magidson, J
   Wassmann, K
   Lee, GSM
   Katz, LM
   Subudhi, SK
   Anand, A
   Fleisher, M
   Galsky, MD
   Ross, RW
AF Oh, William K.
   Kantoff, Philip
   Scher, Howard I.
   Magidson, Jay
   Wassmann, Karl
   Lee, Gwo-Shu Mary
   Katz, Leah M.
   Subudhi, Sumit Kumar
   Anand, Aseem
   Fleisher, Martin
   Galsky, Matt D.
   Ross, Robert W.
TI A validated whole-blood RNA transcript-based prognostic model that
   predicts survival in men with castration-resistant prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
   Stat Innovat Inc, Belmont, MA USA.
   Source MDx, Boulder, CO USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RI Oh, William/B-9163-2012; Anand, Aseem/P-1214-2014
OI Oh, William/0000-0001-5113-8147; Anand, Aseem/0000-0002-3606-540X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4516
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802766
ER

PT J
AU Ohashi, K
   Sequist, LV
   Sos, M
   Chen, X
   Rudin, CM
   Moran, T
   Arcila, ME
   Lovly, CM
   Vnencak-Jones, CL
   Sasaki, H
   Dias-Santagata, D
   Dubinett, SM
   Riely, GJ
   Ladanyi, M
   Franklin, WA
   Kris, MG
   Camidge, DR
   Bunn, PA
   Pao, W
AF Ohashi, Kadoaki
   Sequist, Lecia V.
   Sos, Martin
   Chen, Xi
   Rudin, Charles M.
   Moran, Teresa
   Arcila, Maria E.
   Lovly, Christine Marie
   Vnencak-Jones, Cindy L.
   Sasaki, Hidefumi
   Dias-Santagata, Dora
   Dubinett, Steven M.
   Riely, Gregory J.
   Ladanyi, Marc
   Franklin, Wilbur A.
   Kris, Mark G.
   Camidge, D. Ross
   Bunn, Paul A.
   Pao, William
TI Characteristics of NSCLCs harboring NRAS mutations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vanderbilt Univ, Nashville, TN USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Hosp Cologne, Ctr Integrated Oncol, Lung Canc Grp Cologne, Cologne, Germany.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   Nagoya City Univ, Grad Sch Med, Nagoya, Aichi, Japan.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   Univ Colorado, Denver, CO 80202 USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7532
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804214
ER

PT J
AU Oliveira, M
   Navarro, A
   De Mattos-Arruda, L
   Sanchez-Olle, G
   Bellet, M
   Balmana, J
   Gomez-Pardo, P
   Perez-Garcia, JM
   Munoz-Couselo, E
   Vidal, M
   Ortega, V
   Dienstmann, R
   Aura, C
   Prudkin, L
   Vivancos, A
   Ahnert, JR
   Baselga, J
   Tabernero, J
   Cortes, J
   Saura, C
AF Oliveira, Mafalda
   Navarro, Alejandro
   De Mattos-Arruda, Leticia
   Sanchez-Olle, Gessami
   Bellet, Meritxell
   Balmana, Judith
   Gomez-Pardo, Patricia
   Manuel Perez-Garcia, Jose
   Munoz-Couselo, Eva
   Vidal, Maria
   Ortega, Vanessa
   Dienstmann, Rodrigo
   Aura, Claudia
   Prudkin, Ludmilla
   Vivancos, Ana
   Rodon Ahnert, Jordi
   Baselga, Jose
   Tabernero, Josep
   Cortes, Javier
   Saura, Cristina
TI PI3K pathway (PI3Kp) dysregulation and response to
   pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic
   breast cancer (MBC) patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain.
   Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
   Vall dHebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain.
   Vall dHebron Univ Hosp, Mol Pathol Lab, Barcelona, Spain.
   Vall dHebron Inst Oncol, Canc Genom Grp, Barcelona, Spain.
   Vall dHebron Univ Hosp, Expt Therapeut Grp, Barcelona, Spain.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 509
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800242
ER

PT J
AU Otterson, GA
   Riely, GJ
   Shaw, AT
   Crino, L
   Kim, DW
   Martins, R
   Salgia, R
   Zhou, CC
   Solomon, BJ
   Wilner, KD
   Polli, A
   Tang, YY
   Bartlett, CH
   Ou, SHI
AF Otterson, Gregory Alan
   Riely, Gregory J.
   Shaw, Alice Tsang
   Crino, Lucio
   Kim, Dong-Wan
   Martins, Renato
   Salgia, Ravi
   Zhou, Caicun
   Solomon, Benjamin J.
   Wilner, Keith D.
   Polli, Anna
   Tang, Yiyun
   Bartlett, Cynthia Huang
   Ou, Sai-Hong Ignatius
TI Clinical characteristics of ALK plus NSCLC patients (pts) treated with
   crizotinib beyond disease progression (PD): Potential implications for
   management.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   S Maria della Misericordia Hosp, Div Med Oncol, Perugia, Italy.
   Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Shanghai Pulm Hosp, Shanghai, Peoples R China.
   Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
   Pfizer Oncol, La Jolla, CA USA.
   Pfizer Oncol, Milan, Italy.
   Pfizer Oncol, New York, NY USA.
   Univ Calif Irvine, Irvine, CA USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7600
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804095
ER

PT J
AU Oxnard, GR
   Lo, P
   Jackman, DM
   Butaney, M
   Heon, S
   Johnson, BE
   Sequist, LV
   Janne, PA
AF Oxnard, Geoffrey R.
   Lo, Peter
   Jackman, David Michael
   Butaney, Mohit
   Heon, Stephanie
   Johnson, Bruce E.
   Sequist, Lecia V.
   Janne, Pasi A.
TI Delay of chemotherapy through use of post-progression erlotinib in
   patients with EGFR-mutant lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 16
Z9 16
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7547
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804380
ER

PT J
AU Park, RS
   Werner, L
   Greulich, H
   de Muga, S
   Salido, M
   Stack, EC
   Lis, R
   Schutz, FAB
   Trull, JL
   Gallardo, E
   Rojo, F
   Berman, DM
   Molins, JB
   Rosenberg, JE
AF Park, Rachel S.
   Werner, Lillian
   Greulich, Heidi
   de Muga, Silvia
   Salido, Marta
   Stack, Edward C.
   Lis, Rosina
   Schutz, Fabio A. B.
   Trull, Josep Lloreta
   Gallardo, Enrique
   Rojo, Federico
   Berman, David M.
   Molins, Joaquim Bellmunt
   Rosenberg, Jonathan E.
TI Multidimensional investigation of HER2 in advanced urothelial carcinoma
   (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Autonoma Barcelona, Dept Pathol, Hosp del Mar Parc Salut Mar IMIM, E-08193 Barcelona, Spain.
   Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain.
   Univ Hosp del Mar GRETNHE IMIM, Dept Pathol, Mol Cytogenet Lab, Barcelona, Spain.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
   Hosp del Mar Parc Salut Mar IMIM, Dept Pathol, Barcelona, Spain.
   Corp Sanitaria, Sabadell, Spain.
   Univ Parc Tauli, Sabadell, Spain.
   Fdn Jimenez Diaz, Canc Res Unit, E-28040 Madrid, Spain.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Univ Hosp del Mar IMIM, Barcelona, Spain.
RI Rojo, Federico/S-6551-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4580
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803349
ER

PT J
AU Partridge, AH
   Sepucha, K
   O'Neill, AM
   Miller, K
   Motley, C
   Swaby, RF
   Schneider, BP
   Dang, CT
   Northfelt, DW
   Sledge, GW
AF Partridge, Ann H.
   Sepucha, Karen
   O'Neill, Anne M.
   Miller, Kathy
   Motley, Christine
   Swaby, Ramona F.
   Schneider, Bryan P.
   Dang, Chau T.
   Northfelt, Donald W.
   Sledge, George W.
CA Eastern Cooperative Oncology Grp
TI Does unblinding of treatment assignment impact participant perceptions
   in clinical trials?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Indiana Univ Simon Canc Ctr, Indianapolis, IN USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Indiana Univ Sch Med, Indianapolis, IN USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Mayo Clin, Scottsdale, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6025
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803420
ER

PT J
AU Patel, MR
   Bendell, JC
   Mayer, RJ
   Benedetti, FM
   Rosen, LS
AF Patel, Manish R.
   Bendell, Johanna C.
   Mayer, Robert J.
   Benedetti, Fabio M.
   Rosen, Lee S.
TI A phase I dose-escalation study of TAS-102 in patients (pts) with
   refractory metastatic colorectal cancer (mCRC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Taiho Pharma, Princeton, NJ USA.
   Univ Calif Los Angeles, Sch Med, Santa Monica, CA USA.
NR 0
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3631
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804078
ER

PT J
AU Patrick-Miller, LJ
   Zhao, FM
   Cleeland, CS
   Wagner, LI
   Fisch, M
   Mendoza, TR
AF Patrick-Miller, Linda J.
   Zhao, Fengmin
   Cleeland, Charles S.
   Wagner, Lynne I.
   Fisch, Michael
   Mendoza, Tito R.
TI Validity and utility of the University of Texas M. D. Anderson Symptom
   Inventory (MDASI) among prostate cancer patients: Data from E2Z02:
   Symptom Outcomes and Practice Patterns (SOAPP).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Northwestern Univ, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15173
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803144
ER

PT J
AU Penel, N
   Demetri, GD
   Blay, JY
   Cousin, S
   Maki, RG
   Chawla, SP
   Judson, IR
   von Mehren, M
   Schoffski, P
   Verweij, J
   Casali, PG
   Rodenhuis, S
   Gomez, J
   Nieto, A
   Zintl, P
   Valero, MJP
   Cassar, A
   Le Cesne, A
AF Penel, Nicolas
   Demetri, George D.
   Blay, Jean-Yves
   Cousin, Sophie
   Maki, Robert G.
   Chawla, Sant P.
   Judson, Ian Robert
   von Mehren, Margaret
   Schoffski, Patrick
   Verweij, Jaap
   Casali, Paolo Giovanni
   Rodenhuis, Sjoerd
   Gomez, Javier
   Nieto, Antonio
   Zintl, Patrik
   Valero, Maria Jose Pontes
   Cassar, Alexia
   Le Cesne, Axel
TI Growth modulation index (GMI) as a metric of clinical benefit assessment
   among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin
   as salvage therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Ctr Oscar Lambret, F-59020 Lille, France.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France.
   Mt Sinai Sch Med, New York, NY USA.
   Sarcoma Oncol Ctr, Santa Monica, CA USA.
   Royal Marsden NHS Fdn Trust, London, England.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Catholic Univ Louvain, Leuven Canc Inst, Dept Gen Med Oncol, B-3000 Louvain, Belgium.
   Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
   Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
   PharmaMar, Madrid, Spain.
   Quintiles, Levallois Perret, France.
   Inst Gustave Roussy, Villejuif, France.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10013
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800614
ER

PT J
AU Penson, RT
   Moore, KN
   Fleming, GF
   Braly, PS
   Schimp, VL
   Nguyen, H
   Matulonis, U
   Banerjee, SN
   Haluska, P
   Gore, ME
   Bodurka, DC
   Morozov, A
   Xu, YH
   Rutstein, MD
   Schwartz, JD
   McGuire, WP
AF Penson, Richard T.
   Moore, Kathleen N.
   Fleming, Gini F.
   Braly, Patricia S.
   Schimp, Veronica L.
   Hoa Nguyen
   Matulonis, Ursula
   Banerjee, Susana N.
   Haluska, Paul
   Gore, Martin Eric
   Bodurka, Diane C.
   Morozov, Alexei
   Xu, Yihuan
   Rutstein, Mark D.
   Schwartz, Jonathan D.
   McGuire, William P.
TI A phase II, open-label, multicenter study of IMC-1121B (ramucirumab;
   RAM) monotherapy in the treatment of persistent or recurrent epithelial
   ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC)
   carcinoma (CP12-0711/NCT00721162).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
   Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
   Hem Onc Spclsts, Marrero, LA USA.
   Univ Texas MD Anderson Canc Ctr, Orlando, FL USA.
   Gynecol Oncol Associates, Hollywood, FL USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Royal Marsden Hosp, Surrey, England.
   Mayo Clin, Rochester, MN USA.
   Royal Marsden Hosp, London SW3 6JJ, England.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   ImClone Syst, Bridgewater, NJ USA.
   Franklin Sq Hosp, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5012
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803521
ER

PT J
AU Phelps, AC
   Zhang, BH
   Prigerson, HG
AF Phelps, Andrea Catherine
   Zhang, Baohui
   Prigerson, Holly Gwen
TI Clinical trial participation as part of end-of-life (EOL) cancer care:
   Associations with medical care near death and bereaved caregivers'
   mental health
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Phelps, Andrea Catherine; Zhang, Baohui; Prigerson, Holly Gwen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9102
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804531
ER

PT J
AU Phillips, KA
   Ribi, K
   Aldridge, J
   Thompson, AM
   Harvey, VJ
   Thurlimann, BJK
   Cardoso, F
   Pagani, O
   Coates, AS
   Goldhirsch, A
   Price, KN
   Gelber, RD
   Bernhard, J
AF Phillips, Kelly-Anne
   Ribi, Karin
   Aldridge, Julie
   Thompson, Alastair Mark
   Harvey, Vernon J.
   Thurlimann, Beat J. K.
   Cardoso, Fatima
   Pagani, Olivia
   Coates, Alan Stuart
   Goldhirsch, Aron
   Price, Karen N.
   Gelber, Richard D.
   Bernhard, Juerg
CA Big 1-98 Collaborative Grp
   Int Breast Canc Study Grp
TI Subjective cognitive complaints one year after ceasing adjuvant
   endocrine therapy for early-stage breast cancer: Findings from the
   Breast International Group (BIG) 1-98 trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   Int Breast Canc Study Grp, Bern, Switzerland.
   Dana Farber Canc Inst, Int Breast Canc Study Grp, Ctr Stat, Boston, MA 02115 USA.
   Univ Dundee, Dundee, Scotland.
   Auckland Hosp, Auckland, New Zealand.
   Kantonsspital St Gallen, St Gallen, Switzerland.
   Inst Jules Bordet, B-1000 Brussels, Belgium.
   Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland.
   Univ Sydney, Sydney, NSW 2006, Australia.
   European Inst Oncol, Milan, Italy.
   IBCSG Stat Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9022
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802350
ER

PT J
AU Piccart-Gebhart, MJ
   Noguchi, S
   Pritchard, KI
   Burris, HA
   Rugo, HS
   Gnant, M
   Hortobagyi, GN
   Melichar, B
   Petrakova, K
   Arena, FP
   Xu, C
   Cahana, A
   Taran, T
   Sahmoud, T
   Lebwohl, DE
   Campone, M
   Baselga, J
AF Piccart-Gebhart, Martine J.
   Noguchi, Shinzaburo
   Pritchard, Kathleen I.
   Burris, Howard A.
   Rugo, Hope S.
   Gnant, Michael
   Hortobagyi, Gabriel N.
   Melichar, Bohuslav
   Petrakova, Katarina
   Arena, Francis P.
   Xu, Cindy
   Cahana, Ayelet
   Taran, Tanya
   Sahmoud, Tarek
   Lebwohl, David Edward
   Campone, Mario
   Baselga, Jose
TI Everolimus for postmenopausal women with advanced breast cancer: Updated
   results of the BOLERO-2 phase III trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
   Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Palacki Univ, Sch Med, Olomuc, Czech Republic.
   Teaching Hosp, Olomuc, Czech Republic.
   Masaryk Mem Canc Inst, Brno, Czech Republic.
   Arena Oncol Associates, Lake Success, NY USA.
   Novartis Pharmaceut, E Hanover, NJ USA.
   Novartis Pharmaceut, Florham Pk, NJ USA.
   Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, St Herblain, France.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 559
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800074
ER

PT J
AU Pinho, MC
   Polaskova, P
   Jennings, D
   Wen, PY
   Jain, RK
   Sorensen, AG
   Gerstner, ER
   Batchelor, T
AF Pinho, Marco C.
   Polaskova, Pavlina
   Jennings, Dominique
   Wen, Patrick Y.
   Jain, Rakesh K.
   Sorensen, A. Gregory
   Gerstner, Elizabeth Robins
   Batchelor, Tracy
TI Impact of adjuvant anti-VEGF therapy on treatment-related
   pseudoprogression in patients with newly diagnosed glioblastoma
   receiving chemoradiation with or without anti-VEGF therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Simemens Healthcare USA, Malvern, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2025
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801568
ER

PT J
AU Pinto, NR
   Gamazon, ER
   Konkashbaev, A
   Im, HK
   Diskin, S
   London, WB
   Maris, JM
   Dolan, ME
   Cox, NJ
   Cohn, SL
AF Pinto, Navin R.
   Gamazon, Eric R.
   Konkashbaev, Anuar
   Im, Hae Kyung
   Diskin, Sharon
   London, Wendy B.
   Maris, John M.
   Dolan, M. Eileen
   Cox, Nancy J.
   Cohn, Susan Lerner
TI Relationship of divergent ancestral genetic variation on chromosome 6p22
   and racial disparities in survival in neuroblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Chicago, Chicago, IL 60637 USA.
   Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   Harvard Canc Care & Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9516
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801625
ER

PT J
AU Pirl, WF
   Greer, JA
   Gallagher, ER
   Temel, JS
   Traeger, L
   Lennes, IT
AF Pirl, William F.
   Greer, Joseph A.
   Gallagher, Emily R.
   Temel, Jennifer S.
   Traeger, Lara
   Lennes, Inga Tolin
TI Association of screening for psychosocial distress in patients with
   newly diagnosed stage IV NSCLC and survival.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9030
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800108
ER

PT J
AU Plesner, T
   Lokhorst, HM
   Gimsing, P
   Nahi, H
   Lisby, S
   Richardson, PGG
AF Plesner, Torben
   Lokhorst, Henk M.
   Gimsing, Peter
   Nahi, Hareth
   Lisby, Steen
   Richardson, Paul Gerard Guy
TI Daratumumab, a CD38 mab, for the treatment of relapsed/refractory
   multiple myeloma patients: Preliminary efficacy data from a multicenter
   phase I/II study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vejle Hosp, Vejle, Denmark.
   UMC Utrecht, Utrecht, Netherlands.
   Copenhagen Univ Hosp, Copenhagen, Denmark.
   Karolinska Univ Sjukhuset Huddinge, Huddinge, Sweden.
   Genmab AS, Copenhagen, Denmark.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8019
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803759
ER

PT J
AU Plotkin, SR
   Merker, VL
   Bredella, MA
   Cai, WL
   Kassarjian, A
   Harris, GJ
   Muzikansky, A
   Askenazi, M
   Nguyen, R
   Wenzel, R
   Mautner, VF
AF Plotkin, Scott Randall
   Merker, Vanessa L.
   Bredella, Miriam A.
   Cai, Wenli
   Kassarjian, Ara
   Harris, Gordon J.
   Muzikansky, Alona
   Askenazi, Manor
   Rosa Nguyen
   Wenzel, Ralph
   Mautner, Victor-Felix
TI Relationship between whole-body tumor burden and quality of life in
   patients with neurofibromatosis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Corades SL, Majadahonda, Spain.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Hamburg Hosp, Hamburg, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6136
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800402
ER

PT J
AU Polaskova, P
   Pinho, MC
   Kalpathy-Cramer, J
   Guimaraes, AR
   Wen, PY
   Sorensen, AG
   Jain, RK
   Batchelor, T
   Gerstner, ER
AF Polaskova, Pavlina
   Pinho, Marco C.
   Kalpathy-Cramer, Jayashree
   Guimaraes, Alexander R.
   Wen, Patrick Y.
   Sorensen, A. Gregory
   Jain, Rakesh K.
   Batchelor, Tracy
   Gerstner, Elizabeth Robins
TI Effects of cediranib (VEGF signaling inhibitor) on edema in newly
   diagnosed glioblastoma patients during initial chemoradiation
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA.
   Martinos Ctr Biomed Imaging, Charlestown, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Siemens Healthcare North Amer, Malvern, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 2012
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801565
ER

PT J
AU Pomerantz, MM
   Gray, KP
   Augusto, F
   Schutz, B
   Percy, A
   Lampron, M
   Signoretti, S
   Hirsch, MS
   Rosenberg, JE
   Lee, GSM
   McDermott, DF
   Atkins, MB
   Kantoff, PW
   Freedman, ML
   Choueiri, TK
AF Pomerantz, Mark M.
   Gray, Kathryn P.
   Augusto, Fabio
   Schutz, Barros
   Percy, Andrew
   Lampron, Megan
   Signoretti, Sabina
   Hirsch, Michelle S.
   Rosenberg, Jonathan E.
   Lee, Gwo-Shu Mary
   McDermott, David F.
   Atkins, Michael B.
   Kantoff, Philip W.
   Freedman, Matthew L.
   Choueiri, Toni K.
TI Association of inherited genetic variation with clinical outcome in
   patients with advanced renal cell carcinoma treated with mTOR
   inhibition.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Lank Ctr Genitourinary Onco, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Broad Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4543
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803165
ER

PT J
AU Pond, GR
   Sonpavde, G
   Choueiri, TK
   Qu, AQ
   Vaughn, DJ
   Fougeray, R
   Niegisch, G
   Albers, P
   Wong, YN
   Ko, YJ
   Sridhar, SS
   Galsky, MD
   Petrylak, DP
   Beer, TM
   Stadler, WM
   O'Donnell, PH
   Sternberg, CN
   Rosenberg, JE
   Molins, JB
AF Pond, Gregory Russell
   Sonpavde, Guru
   Choueiri, Toni K.
   Qu, Angela Q.
   Vaughn, David J.
   Fougeray, Ronan
   Niegisch, Guenter
   Albers, Peter
   Wong, Yu-Ning
   Ko, Yoo-Joung
   Sridhar, Srikala S.
   Galsky, Matt D.
   Petrylak, Daniel Peter
   Beer, Tomasz M.
   Stadler, Walter Michael
   O'Donnell, Peter H.
   Sternberg, Cora N.
   Rosenberg, Jonathan E.
   Molins, Joaquim Bellmunt
TI Time from prior chemotherapy (TFPC) as a prognostic factor in advanced
   urothelial carcinoma (UC) receiving second-line systemic therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 McMaster Univ, Hamilton, ON, Canada.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
   Harvard Univ, Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst,Med Sch, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Inst Rech Pierre Fabre, Boulogne, France.
   Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany.
   Univ Dusseldorf, D-40225 Dusseldorf, Germany.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.
   Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA.
   Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
   Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   San Camillo Hosp, Rome, Italy.
   Forlanini Hosp, Rome, Italy.
   Univ Hosp del Mar IMIM, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4522
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803076
ER

PT J
AU Pritchard, KI
   Burris, HA
   Rugo, HS
   Gnant, M
   Baselga, J
   Piccart-Gebhart, MJ
   Noguchi, S
   Dakhil, SR
   Srimuninnimit, V
   Puttawibul, P
   Osborne, K
   Mukhopadhyay, P
   Taran, T
   Sahmoud, T
   Campone, M
   Hortobagyi, GN
AF Pritchard, Kathleen I.
   Burris, Howard A.
   Rugo, Hope S.
   Gnant, Michael
   Baselga, Jose
   Piccart-Gebhart, Martine J.
   Noguchi, Shinzaburo
   Dakhil, Shaker R.
   Srimuninnimit, Vichien
   Puttawibul, Puttisak
   Osborne, Karen
   Mukhopadhyay, Pabak
   Taran, Tanya
   Sahmoud, Tarek
   Campone, Mario
   Hortobagyi, Gabriel N.
TI Safety of everolimus for women over 65 years of age with advanced breast
   cancer (BC): 12.5-mo follow-up of BOLERO-2.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Inst Jules Bordet, B-1000 Brussels, Belgium.
   Osaka Univ, Osaka, Japan.
   Canc Ctr Kansas, Wichita, KS USA.
   Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand.
   Prince Songkla Univ, Fac Med, Dept Surg, Hat Yai, Thailand.
   Novartis Pharma AG, Basel, Switzerland.
   Novartis Pharmaceut, E Hanover, NJ USA.
   Novartis Pharmaceut, Florham Pk, NJ USA.
   Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, St Herblain, France.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 551
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800186
ER

PT J
AU Psyrri, A
   Lee, JW
   Pectasides, E
   Vassilakopoulou, M
   Burtness, B
   Rimm, D
   Wanebo, HJ
   Forastiere, AA
AF Psyrri, Amanda
   Lee, Ju-Whei
   Pectasides, Eirini
   Vassilakopoulou, Maria
   Burtness, Barbara
   Rimm, David
   Wanebo, Harold J.
   Forastiere, Arlene A.
TI Predictors for response to cetuximab in a prospective clinical trial
   (E2303) of patients with head and neck squamous cell carcinoma (HNSCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Athens, Athens, Greece.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Albert Einstein, New York, NY USA.
   Yale Univ, New Haven, CT USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
   Landmark Med Ctr, Woonsocket, RI USA.
   Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5576
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801193
ER

PT J
AU Pujade-Lauraine, E
   Vergote, IB
   Allard, A
   Rey, AA
   Sessa, C
   Birrer, MJ
AF Pujade-Lauraine, Eric
   Vergote, Ignace B.
   Allard, Aurore
   Rey, Augustin A.
   Sessa, Cristiana
   Birrer, Michael J.
TI OPSALIN: A phase II placebo-controlled randomized study of ombrabulin in
   patients with platinum-sensitive recurrent ovarian cancer treated with
   carboplatin (Cb) and paclitaxel (P).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Paris 05, Hop Univ Paris Ctr, AP HP, Paris, France.
   Univ Hosp, Louvain, Belgium.
   Sanofi, Chilly Mazarin, France.
   Sanofi, Vitry Sur Seine, France.
   Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS5112
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803450
ER

PT J
AU Quinn, DI
   Tangen, CM
   Hussain, M
   Lara, P
   Goldkorn, A
   Garzotto, M
   Mack, PC
   Carducci, MA
   Monk, JP
   Twardowski, P
   Van Veldhuizen, PJ
   Agarwal, N
   Higano, CS
   Vogelzang, NJ
   Thompson, IM
AF Quinn, David I.
   Tangen, Catherine M.
   Hussain, Maha
   Lara, Primo
   Goldkorn, Amir
   Garzotto, Mark
   Mack, Philip C.
   Carducci, Michael Anthony
   Monk, J. P.
   Twardowski, Przemyslaw
   Van Veldhuizen, Peter J.
   Agarwal, Neeraj
   Higano, Celestia S.
   Vogelzang, Nicholas J.
   Thompson, Ian Murchie
TI SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus
   docetaxel and placebo (P) for men with advanced castrate resistant
   prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
   SWOG Stat Ctr, Seattle, WA USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Univ Calif Davis, Sacramento, CA 95817 USA.
   Portland VA Med Ctr, Portland, OR USA.
   Johns Hopkins Univ, Baltimore ECOG, Baltimore, MD USA.
   Ohio State Univ, CALGB, Columbus, OH 43210 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Univ Kansas, Ctr Canc, Westwood, KS USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
   Comprehens Canc Ctr NV, US Oncol Res, Las Vegas, NV USA.
   Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4511
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803074
ER

PT J
AU Radhakrishnan, K
   Ricci, AM
   Geyer, MB
   Harrison, L
   Duffy, D
   Ozkaynak, MF
   Satwani, P
   Cheerva, AC
   Talano, J
   Moore, T
   Gillio, AP
   Wada, RK
   Baxter-Lowe, LA
   Cairo, MS
AF Radhakrishnan, Kavita
   Ricci, Angela M.
   Geyer, Mark B.
   Harrison, Lauren
   Duffy, Deirdre
   Ozkaynak, Mehmet Fevzi
   Satwani, Prakash
   Cheerva, Alexandra C.
   Talano, Julie
   Moore, Theodore
   Gillio, Alfred P.
   Wada, Randal K.
   Baxter-Lowe, Lee Ann
   Cairo, Mitchell S.
TI Low day 100 transplant-related mortality (TRM) and relapse rate
   following clofarabine (CLO) in combination with cytarabine, total body
   irradiation (TBI), and allogeneic stem cell transplantation (AlloSCT) in
   children, adolescents, and young adults (CAYA) with poor-risk acute
   leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 New York Med Coll, Valhalla, NY 10595 USA.
   Columbia Univ, New York, NY USA.
   Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   Univ Louisville, Louisville, KY 40292 USA.
   Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
   Hackensack Univ, Med Ctr, Hackensack, NJ USA.
   Univ Hawaii, Honolulu, HI 96822 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6537
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802608
ER

PT J
AU Reardon, DA
   Vredenburgh, JJ
   Desjardins, A
   Steis, RG
   Dunbar, EM
   Chandramouli, NB
   Rixe, O
   Green, JA
   Davis, TA
   Sampson, JH
AF Reardon, David A.
   Vredenburgh, James J.
   Desjardins, Annick
   Steis, Ronald G.
   Dunbar, Erin M.
   Chandramouli, Nitin B.
   Rixe, Olivier
   Green, Jennifer A.
   Davis, Thomas A.
   Sampson, John Howard
CA ReACT Study Grp
TI REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV)
   in relapsed glioblastoma (GB)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Atlanta Canc Care, Alpharetta, GA USA.
   Univ Florida, Gainesville, FL USA.
   Utah Canc Specialists, Salt Lake City, UT USA.
   Univ Cincinnati, Inst Canc, Cincinnati, OH USA.
   Celldex Therapeut Inc, Needham, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS2103
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801606
ER

PT J
AU Rhondali, W
   Perez-Cruz, PE
   Hui, D
   Chisholm, GB
   Dalal, S
   Baile, WF
   Chittenden, E
   Filbet, M
   Bruera, E
AF Rhondali, Wadih
   Perez-Cruz, Pedro Emilio
   Hui, David
   Chisholm, Gary B.
   Dalal, Shalini
   Baile, Walter F.
   Chittenden, Eva
   Filbet, Marilene
   Bruera, Eduardo
TI Patient-physician communication about code status preferences: A
   randomized controlled trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Biostat Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Hosp Civils Lyon, Lyon, France.
RI Rhondali, Wadih/K-2348-2013
OI Rhondali, Wadih/0000-0001-7740-1476
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9049
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804520
ER

PT J
AU Ribas, A
   Hodi, FS
   Kurland, JF
   Shahabi, V
   Francis, S
   Konto, C
   Joe, AK
   Lainas, I
   Wolchok, JD
AF Ribas, Antoni
   Hodi, F. Stephen
   Kurland, John F.
   Shahabi, Vafa
   Francis, Stephen
   Konto, Cyril
   Joe, Andrew K.
   Lainas, Ioannis
   Wolchok, Jedd D.
TI CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients
   with BRAF V600 mutation-positive metastatic melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Bristol Myers Squibb Co, Princeton, NJ USA.
   Bristol Myers Squibb Co, Braine Lalleud, Belgium.
   Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
   Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS8603
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801483
ER

PT J
AU Richardson, PGG
   Berdeja, JG
   Niesvizky, R
   Lonial, S
   Roy, V
   Hari, P
   Berg, D
   Liu, GH
   Gupta, N
   Di Bacco, A
   Hui, AM
   Kumar, S
AF Richardson, Paul Gerard Guy
   Berdeja, Jesus G.
   Niesvizky, Ruben
   Lonial, Sagar
   Roy, Vivek
   Hari, Parameswaran
   Berg, Deborah
   Liu, Guohui
   Gupta, Neeraj
   Di Bacco, Alessandra
   Hui, Ai-Min
   Kumar, Shaji
TI Oral weekly MLN9708, an investigational proteasome inhibitor, in
   combination with lenalidomide and dexamethasone in patients (pts) with
   previously untreated multiple myeloma (MM): A phase I/II study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Ctr Excellence Lymphoma & Myeloma, New York, NY 10021 USA.
   Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   Mayo Clin, Jacksonville, FL 32224 USA.
   Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA.
   Millennium Pharmaceut Inc, Cambridge, MA USA.
   Mayo Clin, Div Hematol, Rochester, MN USA.
RI Kumar, Shaji/A-9853-2008
OI Kumar, Shaji/0000-0001-5392-9284
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8033
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803842
ER

PT J
AU Riester, M
   Werner, L
   Molins, JB
   Selvarajah, S
   Weir, B
   Stack, EC
   Park, RS
   O'Brien, R
   Schutz, FAB
   Choueiri, TK
   Signoretti, S
   Gallardo, E
   Rojo, F
   Trull, JL
   Marchionni, L
   Hahn, WC
   Berman, DM
   Kantoff, PW
   Michor, F
   Rosenberg, JE
AF Riester, Markus
   Werner, Lillian
   Molins, Joaquim Bellmunt
   Selvarajah, Shamini
   Weir, Barbara
   Stack, Edward C.
   Park, Rachel S.
   O'Brien, Robert
   Schutz, Fabio Augusto Barros
   Choueiri, Toni K.
   Signoretti, Sabina
   Gallardo, Enrique
   Rojo, Federico
   Trull, Josep Lloreta
   Marchionni, Luigi
   Hahn, William C.
   Berman, David Monty
   Kantoff, Philip W.
   Michor, Franziska
   Rosenberg, Jonathan E.
TI External validation of somatic copy number alteration (SCNA) at
   chromosome 1q23.3 in advanced urothelial carcinoma (UC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   Univ Hosp del Mar IMIM, Barcelona, Spain.
   Brigham & Womens Hosp, Ctr Adv Mol Diag, Boston, MA 02115 USA.
   Broad Inst MIT & Harvard, Cambridge, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Corp Sanitaria, Sabadell, Spain.
   Univ Parc Tauli, Sabadell, Spain.
   Fdn Jimenez Diaz, Canc Res Unit, E-28040 Madrid, Spain.
   Hosp del Mar, Dept Pathol, Barcelona, Spain.
   Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA.
   Johns Hopkins Univ, Baltimore, MD USA.
RI Rojo, Federico/S-6551-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4585
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803252
ER

PT J
AU Ritchie, C
   Manola, J
   Kvale, E
   Snyder, CF
   Fisch, M
AF Ritchie, Christine
   Manola, Judith
   Kvale, Elizabeth
   Snyder, Claire Frances
   Fisch, Michael
TI The relationship between symptom burden and perceived comorbidity in
   outpatients with common solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Unviers Calif San Francisco, San Francisco, CA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Alabama Birmingham, Birmingham, AL USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6080
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802091
ER

PT J
AU Robert, C
   Flaherty, KT
   Hersey, P
   Nathan, PD
   Garbe, C
   Milhem, MM
   Demidov, LV
   Hassel, JC
   Rutkowski, P
   Mohr, P
   Dummer, R
   Trefzer, U
   Larkin, JMG
   Utikal, J
   Casey, M
   Sherman, LJ
   Crist, WA
   Wu, FS
   Patel, K
   Schadendorf, D
AF Robert, Caroline
   Flaherty, Keith T.
   Hersey, Peter
   Nathan, Paul D.
   Garbe, Claus
   Milhem, Mohammed M.
   Demidov, Lev V.
   Hassel, Jessica C.
   Rutkowski, Piotr
   Mohr, Peter
   Dummer, Reinhard
   Trefzer, Uwe
   Larkin, James M. G.
   Utikal, Jochen
   Casey, Michelle
   Sherman, Laurie Jill
   Crist, Wendy A.
   Wu, Frank S.
   Patel, Kiran
   Schadendorf, Dirk
TI METRIC phase III study: Efficacy of trametinib (T), a potent and
   selective MEK inhibitor (MEKi), in progression-free survival (PFS) and
   overall survival (OS) compared with chemotherapy (C) in patients (pts)
   with BRAF(V600/k) mutant advanced or metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Gustave Roussy, Villejuif, France.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Melanoma Inst Australia, Sydney, NSW, Australia.
   Univ Sydney, Sydney, NSW 2006, Australia.
   Mt Vernon Canc Ctr, Middlesex, England.
   Univ Hosp Tuebingen, Tubingen, Germany.
   Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA.
   Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia.
   Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Dermatol, Heidelberg, Germany.
   Maria Sklodowska Curie Mem Canc Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
   Inst Oncol, Warsaw, Poland.
   Elbeklinikum Buxtehude, Buxtehude, Germany.
   Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland.
   Charite, D-13353 Berlin, Germany.
   Royal Marsden Hosp, London SW3 6JJ, England.
   German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany.
   Heidelberg Univ, Dept Dermatol Venereol & Allergol, Univ Med Ctr Mannheim, Mannheim, Germany.
   GlaxoSmithKline, Collegeville, PA USA.
   Univ Hosp Essen, Dept Dermatol, Essen, Germany.
NR 0
TC 3
Z9 3
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA LBA8509
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801044
ER

PT J
AU Rose, BS
   Zakeri, K
   Gulaya, S
   D'Amico, AV
   Mell, LK
AF Rose, Brent Shane
   Zakeri, Kaveh
   Gulaya, Sachin
   D'Amico, Anthony Victor
   Mell, Loren K.
TI Competing event risk stratification may improve the design and
   efficiency of clinical trials: Secondary analysis of SWOG 8794.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Boston, MA 02115 USA.
   Univ Calif San Diego, La Jolla, CA 92093 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
   Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6121
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802169
ER

PT J
AU Rose, S
   Cheng, JD
   Viscusi, J
   Iannone, R
   Schellens, JHM
   Leijen, S
   Shapiro, G
   Pavlick, AC
   Oza, AM
   Rosen, LS
   Tosolini, A
   Lam, R
   Demuth, T
AF Rose, Shelonitda
   Cheng, Jonathan D.
   Viscusi, Johnny
   Iannone, Robert
   Schellens, Jan H. M.
   Leijen, Suzanne
   Shapiro, Geoffrey
   Pavlick, Anna C.
   Oza, Amit M.
   Rosen, Lee S.
   Tosolini, Alessandra
   Lam, Raymond
   Demuth, Tim
TI Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker
   to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Merck Res Labs, Kenilworth, NJ USA.
   Merck & Co Inc, N Wales, PA USA.
   Merck Res Labs, N Wales, PA USA.
   Merck, N Wales, PA USA.
   Netherlands Canc Inst, Amsterdam, Netherlands.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   NYU, Sch Med, New York, NY USA.
   Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Santa Monica, CA USA.
   Merck & Co Inc, N Wales, PA USA.
   Italfarmaco SpA, Cinisello Balsamo, Italy.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e13598
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802281
ER

PT J
AU Rosenberg, JE
   Werner, L
   Bamias, A
   Choueiri, TK
   Schutz, FAB
   Park, RS
   O'Brien, R
   Guancial, EA
   Ross, RW
   Berman, DM
   Riester, M
   Lis, R
   Loda, MF
   Stack, EC
   Michor, F
   Chehab, N
   Molins, JB
AF Rosenberg, Jonathan E.
   Werner, Lillian
   Bamias, Aristotelis
   Choueiri, Toni K.
   Schutz, Fabio A. B.
   Park, Rachel S.
   O'Brien, Robert
   Guancial, Elizabeth Ann
   Ross, Robert W.
   Berman, David M.
   Riester, Markus
   Lis, Rosina
   Loda, Massimo F.
   Stack, Edward C.
   Michor, Franziska
   Chehab, Nabil
   Molins, Joaquim Bellmunt
TI FGFR3 protein expression and gene mutation in primary and metastatic
   urothelial carcinoma (UC) tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   HECOG, Athens, Greece.
   Univ Athens, Athens, Greece.
   Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   ImClone Syst, New York, NY USA.
   Univ Hosp Mar IMIM, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4577
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802783
ER

PT J
AU Rosenberg, S
   Tamimi, RM
   Gelber, SI
   Ruddy, KJ
   Kereakoglow, S
   Borges, VF
   Come, SE
   Schapira, L
   Winer, E
   Partridge, AH
AF Rosenberg, Shoshana
   Tamimi, Rulla M.
   Gelber, Shari I.
   Ruddy, Kathryn Jean
   Kereakoglow, Sandra
   Borges, Virginia F.
   Come, Steven E.
   Schapira, Lidia
   Winer, Eric
   Partridge, Ann H.
TI Sexual functioning in young women with breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Colorado Denver, Aurora, CO USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9100
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800306
ER

PT J
AU Ruddy, KJ
   Gelber, S
   Tamimi, RM
   Ginsburg, ES
   Schapira, L
   Come, SE
   Meyer, ME
   Winer, E
   Partridge, AH
AF Ruddy, Kathryn Jean
   Gelber, Shari
   Tamimi, Rulla M.
   Ginsburg, Elizabeth S.
   Schapira, Lidia
   Come, Steven E.
   Meyer, Meghan E.
   Winer, Eric
   Partridge, Ann H.
TI Biomarkers of amenorrhea and ovarian function in breast cancer survivors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9071
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803337
ER

PT J
AU Rudman, SM
   Gray, KP
   Kasperzyk, J
   Giovannucci, E
   Pitt, M
   Loda, MF
   Mucci, L
   Sweeney, C
AF Rudman, Sarah Maria
   Gray, Kathryn P.
   Kasperzyk, Julie
   Giovannucci, Edward
   Pitt, Michael
   Loda, Massimo F.
   Mucci, Lorelei
   Sweeney, Christopher
TI Association of metabolic syndrome with poorer prostate cancer and
   overall survival in men receiving androgen deprivation therapy (ADT) for
   biochemical relapse.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Kings Coll London, Guys Hosp, Div Canc Studies, London WC2R 2LS, England.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Pathol, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Kings Coll London, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4555
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803169
ER

PT J
AU Rugo, HS
   Barry, WT
   Moreno-Aspitia, A
   Lyss, AP
   Cirrincione, C
   Mayer, EL
   Naughton, M
   Layman, RM
   Carey, LA
   Somer, RA
   Perez, EA
   Hudis, C
   Winer, EP
AF Rugo, Hope S.
   Barry, William Thomas
   Moreno-Aspitia, Alvaro
   Lyss, Alan P.
   Cirrincione, Constance
   Mayer, Erica L.
   Naughton, Michael
   Layman, Rachel M.
   Carey, Lisa A.
   Somer, Robert A.
   Perez, Edith A.
   Hudis, Clifford
   Winer, Eric P.
TI CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel
   (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or
   ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy
   for locally recurrent or metastatic breast cancer (MBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Duke Univ, Alliance Stat Ctr, Durham, NC USA.
   Mayo Clin Jacksonville, Jacksonville, FL 32224 USA.
   Heartland Canc Res CCOP, Missouri Baptist Canc Ctr, St Louis, MO USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Washington Univ, Sch Med, St Louis, MO USA.
   Ohio State Univ, Columbus, OH 43210 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   Cooper Canc Inst, Voorhees, NJ USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RI Layman, Rachel/E-3475-2011
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA CRA1002
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800885
ER

PT J
AU Ruiz-Garcia, A
   Janne, PA
   Park, K
   Yamamoto, N
   Giri, N
   Bello, C
   O'Connell, JP
AF Ruiz-Garcia, Ana
   Janne, Pasi A.
   Park, Keunchil
   Yamamoto, Nobuyuki
   Giri, Nagdeep
   Bello, Carlo
   O'Connell, Joseph P.
TI EGFR status and daily dose: Effect on tumor growth inhibition in cancer
   patients treated with dacomitinib (PF-00299804).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Pfizer Oncol, La Jolla, CA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan.
   Pfizer Inc, New York, NY USA.
   Pfizer Oncol, Groton, CT USA.
RI Ruiz-Garcia, Ana/O-8252-2014
OI Ruiz-Garcia, Ana/0000-0002-5462-3110
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e18093
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804154
ER

PT J
AU Ryan, CJ
   Smith, MR
   De Bono, JS
   Molina, A
   Logothetis, C
   De Souza, PL
   Fizazi, K
   Mainwaring, PN
   Rodriguez, JMP
   Ng, S
   Carles, J
   Mulders, P
   San Kheoh, T
   Griffin, TW
   Small, EJ
   Scher, HI
   Rathkopf, DE
AF Ryan, Charles J.
   Smith, Matthew Raymond
   De Bono, Johann Sebastian
   Molina, Arturo
   Logothetis, Christopher
   De Souza, Paul L.
   Fizazi, Karim
   Mainwaring, Paul N.
   Piulats Rodriguez, Jose Maria
   Ng, Siobhan
   Carles, Joan
   Mulders, Peter
   San Kheoh, Thian
   Griffin, Thomas W.
   Small, Eric Jay
   Scher, Howard I.
   Rathkopf, Dana E.
CA COU-AA-302 Investigators
TI Interim analysis (IA) results of COU-AA-302, a randomized, phase III
   study of abiraterone acetate in chemotherapy-naive patients (pts) with
   metastatic castration-resistant prostate cancer (mCRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Royal Marsden Hosp, Sutton, Surrey, England.
   Inst Canc Res, Sutton, Surrey, England.
   Janssen Res & Dev, Los Angeles, CA USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   St George Hosp, Kogarah, NSW, Australia.
   Inst Gustave Roussy, Villejuif, France.
   Haematol & Oncol Clin Australasia, Brisbane, Qld, Australia.
   Inst Catala Oncol Hosp, Barcelona, Spain.
   St John God Hosp, Subiaco, WA, Australia.
   Hosp Univ Vall dHebron, Barcelona, Spain.
   Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RI Mulders, Peter/H-8076-2014
NR 0
TC 7
Z9 7
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA LBA4518
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803310
ER

PT J
AU Saad, F
   Smith, MR
   Shore, ND
   Oudard, S
   Miller, K
   Tombal, B
   Sieber, P
   Fizazi, K
   Van Veldhuizen, P
   Damiao, R
   Marx, GM
   Morote, J
   Ye, ZS
   Dansey, RD
   Goessl, CD
AF Saad, Fred
   Smith, Matthew Raymond
   Shore, Neal D.
   Oudard, Stephane
   Miller, Kurt
   Tombal, Bertrand
   Sieber, Paul
   Fizazi, Karim
   Van Veldhuizen, Peter
   Damiao, Ronaldo
   Marx, Gavin M.
   Morote, Juan
   Ye, Zhishen
   Dansey, Roger D.
   Goessl, Carsten Dietrich
TI Effect of denosumab on prolonging bone-metastasis free survival (BMFS)
   in men with nonmetastatic castrate-resistant prostate cancer (CRPC)
   presenting with aggressive PSA kinetics
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Carolina Urol Res Ctr, Myrtle Beach, SC USA.
   Georges Pompidou European Hosp, Paris, France.
   Charite, D-13353 Berlin, Germany.
   Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
   Urol Associates Lancaster Ltd, Lancaster, PA USA.
   Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
   Kansas City VA Med Ctr, Kansas City, MO USA.
   Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil.
   Sydney Haematol Oncol Clin, Sydney, NSW, Australia.
   Vall dHebron Univ Hosp, Dept Urol, Barcelona, Spain.
   Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4510
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803327
ER

PT J
AU Sadrzadeh, H
   Brunner, AM
   Drapkin, BJ
   Babirak, L
   Werner, L
   Ballen, KK
   Amrein, PC
   Attar, EC
   Chen, YB
   Spitzer, TR
   McAfee, SL
   Neuberg, DS
   Fathi, AT
AF Sadrzadeh, Hossein
   Brunner, Andrew Mark
   Drapkin, Benjamin Jacob
   Babirak, Loren
   Werner, Lillian
   Ballen, Karen K.
   Amrein, Philip C.
   Attar, Eyal C.
   Chen, Yi-Bin Albert
   Spitzer, Thomas R.
   McAfee, Steven L.
   Neuberg, Donna S.
   Fathi, Amir Tahmasb
TI The prognostic role of serum albumin in patients receiving induction
   chemotherapy for acute myeloid leukemia (AML)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6618
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800682
ER

PT J
AU Sales, E
   Penson, RT
   Sullivan, LA
   Borger, DR
   Krasner, CN
   Goodman, A
   del Carmen, MG
   Growdon, WB
   Schorge, JO
   Boruta, DM
   Birrer, MJ
AF Sales, Elizabeth
   Penson, Richard T.
   Sullivan, Laura A.
   Borger, Darrell R.
   Krasner, Carolyn N.
   Goodman, Annekathryn
   del Carmen, Marcela G.
   Growdon, Whitfield Board
   Schorge, John O.
   Boruta, David M.
   Birrer, Michael J.
TI A snapshot of potentially personalized care: Molecular diagnostics in
   gynecologic cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5029
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803483
ER

PT J
AU Salgia, R
   Solomon, BJ
   Shaw, AT
   Camidge, DR
   Evans, TL
   Kim, DW
   Shi, YK
   Han, JY
   De Pas, TM
   Ou, SHI
   Bartlett, CH
   Wilner, KD
   Reisman, A
   Iyer, S
AF Salgia, Ravi
   Solomon, Benjamin J.
   Shaw, Alice Tsang
   Camidge, D. Ross
   Evans, Tracey L.
   Kim, Dong-Wan
   Shi, Yuankai
   Han, Ji-Youn
   De Pas, Tommaso Martino
   Ou, Sai-Hong Ignatius
   Bartlett, Cynthia Huang
   Wilner, Keith D.
   Reisman, Arlene
   Iyer, Shrividya
TI Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced
   non-small cell lung cancer (NSCLC) patients treated with crizotinib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Chicago, Chicago, IL 60637 USA.
   Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing 100730, Peoples R China.
   Peking Union Med Coll, Beijing 100021, Peoples R China.
   Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea.
   European Inst Oncol, New Drugs Dev Div, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy.
   Univ Calif Irvine, Irvine, CA USA.
   Pfizer Oncol, New York, NY USA.
   Pfizer Oncol, La Jolla, CA USA.
   Pfizer Inc, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7596
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804183
ER

PT J
AU Sallman, DA
   Macklin, E
   Ali, S
   Michaelson, J
   Barnes, JA
   Abramson, JS
   Banerji, A
   Hochberg, EP
AF Sallman, David A.
   Macklin, Eric
   Ali, Shihab
   Michaelson, James
   Barnes, Jeffrey A.
   Abramson, Jeremy S.
   Banerji, Aleena
   Hochberg, Ephraim P.
TI Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and
   severe reactions based on severity of reaction, NHL histologic subtype,
   and burden of disease.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e18520
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803789
ER

PT J
AU Sallman, DA
   Macklin, E
   Ali, S
   Michaelson, J
   Barnes, JA
   Abramson, JS
   Banerji, A
   Hochberg, EP
AF Sallman, David A.
   Macklin, Eric
   Ali, Shihab
   Michaelson, James
   Barnes, Jeffrey A.
   Abramson, Jeremy S.
   Banerji, Aleena
   Hochberg, Ephraim P.
TI Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and
   severe reactions based on severity of reaction, NHL histologic subtype,
   and burden of disease.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e18520
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803775
ER

PT J
AU Sanft, TB
   Alvarez-Reeves, M
   Irwin, M
AF Sanft, Tara Beth
   Alvarez-Reeves, Marty
   Irwin, Melinda
TI Post diagnosis weight gain and the role of exercise in breast cancer
   survivors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Yale Univ, New Haven, CT USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9007
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801518
ER

PT J
AU Saura, C
   Jones, S
   Mateo, J
   Hollebecque, A
   Cleary, JM
   Perez, DR
   Zhu, J
   Musib, LC
   Patel, PH
   Cervantes-Ruiperez, A
   Isakoff, SJ
   Soria, JC
   Molife, LR
   Tabernero, J
   Bendell, JC
AF Saura, Cristina
   Jones, Suzanne
   Mateo, Joaquin
   Hollebecque, Antoine
   Cleary, James M.
   Perez, Desamparados Roda
   Zhu, Jin
   Musib, Luna C.
   Patel, Premal H.
   Cervantes-Ruiperez, Andres
   Isakoff, Steven J.
   Soria, Jean-Charles
   Molife, L. Rhoda
   Tabernero, Josep
   Bendell, Johanna C.
TI A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or
   mFOLFOX-6 (F) in patients (pts) with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Royal Marsden Hosp, Surrey, England.
   Inst Canc Res, Surrey, England.
   Inst Gustave Roussy, Villejuif, France.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Hosp Clin, Dept Med Oncol, Colorectal Unit, Dept Surg, Valencia, Spain.
   Genentech Inc, San Francisco, CA 94080 USA.
   Univ Valencia, Dept Hematol & Med Oncol, INCLIVA, Valencia, Spain.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA.
RI Hollebecque, Antoine/M-2695-2013
OI Hollebecque, Antoine/0000-0003-2869-7551
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3021
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802501
ER

PT J
AU Scagliotti, G
   Kim, DW
   Shaw, AT
   Ou, SHI
   Riely, GJ
   Gettinger, SN
   Besse, B
   Thomas, M
   Salgia, R
   Wilner, KD
   Bartlett, CH
   Polli, A
   Gandara, DR
AF Scagliotti, Giorgio
   Kim, Dong-Wan
   Shaw, Alice Tsang
   Ou, Sai-Hong Ignatius
   Riely, Gregory J.
   Gettinger, Scott N.
   Besse, Benjamin
   Thomas, Michael
   Salgia, Ravi
   Wilner, Keith D.
   Bartlett, Cynthia Huang
   Polli, Anna
   Gandara, David R.
TI A large retrospective analysis of the activity of pemetrexed (PEM) in
   patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer
   (NSCLC) prior to crizotinib (CRIZ)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Turin, Orbassano, Italy.
   Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Calif Irvine, Irvine, CA USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Yale Univ, Sch Med, New Haven, CT USA.
   Inst Gustave Roussy, Villejuif, France.
   Heidelberg Univ, Thoraxklin, Heidelberg, Germany.
   Univ Chicago, Chicago, IL 60637 USA.
   Pfizer Oncol, San Diego, CA USA.
   Pfizer Oncol, New York, NY USA.
   Pfizer Oncol, Milan, Italy.
   UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7599
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804388
ER

PT J
AU Schnabel, CA
   Kerr, SE
   Sullivan, PS
   Zhang, Y
   Singh, V
   Carey, B
   Erlander, MG
   Highsmith, WE
   Dry, SM
   Brachtel, EF
AF Schnabel, Catherine A.
   Kerr, Sarah E.
   Sullivan, Peggy S.
   Zhang, Yi
   Singh, Veena
   Carey, Brittany
   Erlander, Mark G.
   Highsmith, W. Edward
   Dry, Sarah M.
   Brachtel, Elena F.
TI Multisite validation of a 92-gene molecular classifier: Diagnostic
   accuracy and clinical utility in metastatic cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 bioTheranostics Inc, San Diego, CA USA.
   Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10588
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802023
ER

PT J
AU Schoffski, P
   Elisei, R
   Muller, S
   Brose, MS
   Shah, MH
   Licitra, LF
   Jarzab, B
   Medvedev, V
   Kreissl, M
   Niederle, B
   Cohen, EEW
   Wirth, LJ
   Ali, HY
   Hessel, C
   Yaron, Y
   Ball, DW
   Nelkin, B
   Sherman, SI
   Schlumberger, M
AF Schoffski, Patrick
   Elisei, Rossella
   Mueller, Stefan
   Brose, Marcia S.
   Shah, Manisha H.
   Licitra, Lisa F.
   Jarzab, Barbara
   Medvedev, Viktor
   Kreissl, Michael
   Niederle, Bruno
   Cohen, Ezra E. W.
   Wirth, Lori J.
   Ali, Haythem Y.
   Hessel, Colin
   Yaron, Yifah
   Ball, Douglas Wilmot
   Nelkin, Barry
   Sherman, Steven I.
   Schlumberger, Martin
CA EXAM Study Grp
TI An international, double-blind, randomized, placebo-controlled phase III
   trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma
   (MTC) patients (pts) with documented RECIST progression at baseline
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Katholieke Univ Leuven Hosp, Dept Gen Med Oncol, Louvain, Belgium.
   Univ Pisa, Pisa, Italy.
   Univ Klinikum Essen, Essen, Germany.
   Univ Penn, Philadelphia, PA 19104 USA.
   Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
   Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
   Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Gliwice, Poland.
   Med Radiol Res Ctr, Obninsk, Russia.
   Univ Wurzburg, Nukl Med Klin & Poliklin, D-97070 Wurzburg, Germany.
   Med Univ Wien, Univ Klin Chirurg, Vienna, Austria.
   Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
   Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA.
   Henry Ford Hosp, Detroit, MI 48202 USA.
   Exelixis, San Francisco, CA USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Inst Gustave Roussy, Villejuif, France.
NR 0
TC 27
Z9 28
U1 2
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5508
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800441
ER

PT J
AU Schuchter, LM
   Flaherty, LE
   Hamid, O
   Linette, GP
   Hallmeyer, S
   Gonzalez, R
   Cowey, CL
   Pavlick, AC
   Kudrik, FJ
   Lawson, DH
   Margolin, KA
   Ribas, A
   McDermott, DF
   Khatcheressian, JL
   Flaherty, KT
   Day, BM
   Linke, RG
   Hainsworth, JD
AF Schuchter, Lynn Mara
   Flaherty, Lawrence E.
   Hamid, Omid
   Linette, Gerald P.
   Hallmeyer, Sigrun
   Gonzalez, Rene
   Cowey, Charles Lance
   Pavlick, Anna C.
   Kudrik, Fred J.
   Lawson, David H.
   Margolin, Kim Allyson
   Ribas, Antoni
   McDermott, David F.
   Khatcheressian, James L.
   Flaherty, Keith T.
   Day, Bann-Mo
   Linke, Rolf Gerhard
   Hainsworth, John D.
TI A single-arm, open-label, US expanded access study of vemurafenib in
   patients with metastatic melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Penn, Philadelphia, PA 19104 USA.
   Karmanos Canc Ctr, Detroit, MI USA.
   Angeles Clin & Res Inst, Santa Monica, CA USA.
   Washington Univ, St Louis, MO USA.
   Oncol Specialists SC, Park Ridge, IL USA.
   Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
   Texas Oncol PA, Baylor Sammons Canc Ctr, Dallas, TX USA.
   NYU Med Ctr, New York, NY 10016 USA.
   South Carolina Oncol Associates, Columbia, SC USA.
   Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   Seattle Canc Care Alliance, Seattle, WA USA.
   Univ Calif Los Angeles, Los Angeles, CA USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Virginia Canc Inst, Richmond, VA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8567
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800247
ER

PT J
AU Schultes, BC
   Lolkema, MPJK
   Chu, CL
   Zhou, H
   Long, A
   Lockley, M
   Avery, W
   Kurtagic, E
   Galcheva-Gargova, Z
   Miller, P
   Duffner, J
   Maschek, BJ
   Jarlenski, D
   Tuveson, DA
   Roach, J
   Venkataraman, G
   Kishimoto, TK
   Flaherty, KT
AF Schultes, Birgit Corinna
   Lolkema, Martijn P. J. K.
   Chu, Chia Lin
   Zhou, He
   Long, Alison
   Lockley, Michelle
   Avery, William
   Kurtagic, Elma
   Galcheva-Gargova, Zoya
   Miller, Paul
   Duffner, Jay
   Maschek, Birgit J.
   Jarlenski, Donna
   Tuveson, David A.
   Roach, Jim
   Venkataraman, Ganesh
   Kishimoto, Takashi K.
   Flaherty, Keith T.
TI M402, a heparan sulfate mimetic and novel candidate for the treatment of
   pancreatic cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Momenta Pharmaceut, Cambridge, MA USA.
   Univ Med Ctr Utrecht, Utrecht, Netherlands.
   Univ London, CRUK Queen Mary, London, England.
   Adjuvantis LLC, Windham, NH USA.
   CRUK Cambridge, Cambridge, England.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4056
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804864
ER

PT J
AU Schutz, FAB
   Gray, KP
   Pomerantz, MM
   Atkins, MB
   Hirsch, MS
   McDermott, DF
   Lampron, M
   Percy, A
   Lee, GSM
   Rosenberg, JE
   Signoretti, S
   Kantoff, PW
   Freedman, M
   Choueiri, TK
AF Schutz, Fabio Augusto Barros
   Gray, Kathryn P.
   Pomerantz, Mark M.
   Atkins, Michael B.
   Hirsch, Michelle S.
   McDermott, David F.
   Lampron, Megan
   Percy, Andrew
   Lee, Gwo-Shu Mary
   Rosenberg, Jonathan E.
   Signoretti, Sabina
   Kantoff, Philip W.
   Freedman, Matthew
   Choueiri, Toni K.
TI Genetic polymorphisms' influence in outcome of metastatic renal cell
   cancer patients treated with VEGF-targeted agents.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4635
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803259
ER

PT J
AU Seah, DS
   Luis, IMVD
   Olson, EM
   Sohl, J
   Litsas, G
   Winer, E
   Lin, NU
   Burstein, HJ
AF Seah, Davinia Shien
   Luis, Ines Maria Vaz Duarte
   Olson, Erin Macrae
   Sohl, Jessica
   Litsas, Georgia
   Winer, Eric
   Lin, Nancy U.
   Burstein, Harold J.
TI Use and duration of chemotherapy (CT) in patients (pts) with metastatic
   breast cancer (MBC) according to tumor subtype (TS) and line of therapy
   (tx).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Seah, Davinia Shien; Luis, Ines Maria Vaz Duarte; Olson, Erin Macrae; Sohl, Jessica; Litsas, Georgia; Winer, Eric; Lin, Nancy U.; Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6089
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801491
ER

PT J
AU Seng, SM
   Liu, ZY
   Chiu, S
   Proverbs-Singh, T
   Sonpavde, G
   Choueiri, TK
   Tsao, CK
   Yu, MG
   Hahn, NM
   Oh, WK
   Galsky, MD
AF Seng, Sonia Maria
   Liu, Ziyue
   Chiu, Sophia
   Proverbs-Singh, Tracey
   Sonpavde, Guru
   Choueiri, Toni K.
   Tsao, Che-Kai
   Yu, Menggang
   Hahn, Noah M.
   Oh, William K.
   Galsky, Matt D.
TI Risk of venous thromboembolism in cancer patients treated with
   cisplatin: A systematic review and meta-analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Southcoast Ctr Canc Care, Fall River, MA USA.
   Indiana Univ, Div Biostat, Indianapolis, IN 46204 USA.
   Mt Sinai Sch Med, New York, NY USA.
   Baylor Coll Med, Div Med Oncol, Texas Oncol Deke Slayton Canc Ctr, Houston, TX 77030 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA.
   Indiana Univ Sch Med, Indianapolis, IN USA.
   IU Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA.
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e21016
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802218
ER

PT J
AU Sequist, LV
   Modiano, MR
   Rixe, O
   Jackman, DM
   Andreas, K
   Pearlberg, J
   Moyo, VM
   Harb, WA
AF Sequist, Lecia V.
   Modiano, Manuel R.
   Rixe, Olivier
   Jackman, David Michael
   Andreas, Karen
   Pearlberg, Joseph
   Moyo, Victor M.
   Harb, Wael A.
TI Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a
   phase I trial of MM-121 in combination with erlotinib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Arizona Clin Res Ctr, Tucson, AZ USA.
   Univ Cincinnati, Cincinnati, OH USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Merrimack Pharmaceut, Cambridge, MA USA.
   Sanofi Oncol, Cambridge, MB, Canada.
   Horizon Oncol Ctr, Lafayette, IN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7556
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804220
ER

PT J
AU Sgroi, D
   Goss, PE
   Chapman, JAW
   Richardson, E
   Binns, SN
   Zhang, Y
   Schnabel, CA
   Erlander, MG
   Pritchard, KI
   Han, L
   Shepherd, LE
   Pollak, MN
AF Sgroi, Dennis
   Goss, Paul Edward
   Chapman, Judy-Anne W.
   Richardson, E.
   Binns, Shemeica N.
   Zhang, Yi
   Schnabel, Catherine A.
   Erlander, Mark G.
   Pritchard, Kathleen I.
   Han, Lei
   Shepherd, Lois E.
   Pollak, Michael N.
TI Assessment of the prognostic and predictive utility of the breast cancer
   index (BCI): An NCIC CTG MA.14 study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Avon Fdn, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Avon Int Breast Canc Ctr, Boston, MA 02114 USA.
   Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   bioTheranostics Inc, San Diego, CA USA.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 561
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800075
ER

PT J
AU Shah, PD
   Garber, JE
   Stopfer, J
   Powers, J
   Nathanson, KL
   Domchek, SM
AF Shah, Payal D.
   Garber, Judy Ellen
   Stopfer, Jill
   Powers, Jacquelyn
   Nathanson, Katherine L.
   Domchek, Susan M.
TI Sensitivity of clinical BRCA1 testing compared with linkage analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Penn, Philadelphia, PA 19104 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1506
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801251
ER

PT J
AU Shapiro, G
   Kwak, EL
   Cleary, JM
   Tolaney, S
   Gandhi, L
   Clark, JW
   Wolanski, A
   Frame, S
   Rodig, SJ
   Chiao, JH
AF Shapiro, Geoffrey
   Kwak, Eunice Lee
   Cleary, James M.
   Tolaney, Sara
   Gandhi, Leena
   Clark, Jeffrey W.
   Wolanski, Andrew
   Frame, Sheelagh
   Rodig, Scott J.
   Chiao, Judy H.
TI Phase I study of sequential sapacitabine and seliciclib in patients with
   advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Cyclacel Ltd, Dundee, Scotland.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 3053
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802348
ER

PT J
AU Shaw, AT
   Camidge, DR
   Engelman, JA
   Solomon, BJ
   Kwak, EL
   Clark, JW
   Salgia, R
   Shapiro, G
   Bang, YJ
   Tan, WW
   Tye, L
   Wilner, KD
   Stephenson, P
   Varella-Garcia, M
   Bergethon, K
   Iafrate, AJ
   Ou, SHI
AF Shaw, Alice Tsang
   Camidge, D. Ross
   Engelman, Jeffrey A.
   Solomon, Benjamin J.
   Kwak, Eunice Lee
   Clark, Jeffrey W.
   Salgia, Ravi
   Shapiro, Geoffrey
   Bang, Yung-Jue
   Tan, Weiwei
   Tye, Lesley
   Wilner, Keith D.
   Stephenson, Patricia
   Varella-Garcia, Marileila
   Bergethon, Kristin
   Iafrate, A. John
   Ou, Sai-Hong Ignatius
TI Clinical activity of crizotinib in advanced non-small cell lung cancer
   (NSCLC) harboring ROS1 gene rearrangement.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Colorado, Ctr Canc, Anschutz Canc Pavill, Aurora, CO USA.
   Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
   Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   Pfizer Oncol, La Jolla, CA USA.
   Rho Inc, Chapel Hill, NC USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Chao Family Comprehens Canc Ctr, Orange, CA USA.
NR 0
TC 34
Z9 38
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7508
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804175
ER

PT J
AU Shepherd, FA
   Bourredjem, A
   Brambilla, E
   Domerg, C
   Douillard, JY
   Filipits, M
   Graziano, SL
   Hainaut, P
   Janne, PA
   Le Chevalier, T
   Le Teuff, G
   Pignon, JP
   Pirker, R
   Seymour, L
   Soria, JC
   Taron, M
   Tsao, MS
AF Shepherd, Frances A.
   Bourredjem, Abderrahmane
   Brambilla, Elisabeth
   Domerg, Caroline
   Douillard, Jean-Yves
   Filipits, Martin
   Graziano, Stephen L.
   Hainaut, Pierre
   Janne, Pasi Antero
   Le Chevalier, Thierry
   Le Teuff, Gwenael
   Pignon, Jean-Pierre
   Pirker, Robert
   Seymour, Lesley
   Soria, Jean-Charles
   Taron, Miquel
   Tsao, Ming Sound
CA LACE-Bio Collaborative Res Grp
TI Prognostic and predictive effects of KRAS mutation subtype in completely
   resected non-small cell lung cancer (NSCLC): A LACE-bio study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
   Inst Cancerol Gustave Roussy, Villejuif, France.
   CHU Grenoble, F-38043 Grenoble, France.
   ICO Ctr Rene Gauducheau, St Herblain, France.
   Med Univ Vienna, Vienna, Austria.
   SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
   Int Ctr Res & Training, Sao Paulo, Brazil.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Inst Gustave Roussy, Villejuif, France.
   Queens Univ, Kingston, ON, Canada.
   Hosp Badalona Germans Trias & Pujol, Badalona, Spain.
RI Brambilla, Elisabeth/L-8796-2013; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7007
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803189
ER

PT J
AU Shepherd, LE
   Chapman, JAW
   Ali, SM
   Zhu, LT
   Leitzel, K
   Goss, PE
   Lipton, A
AF Shepherd, Lois E.
   Chapman, Judy-Anne W.
   Ali, Suhail M.
   Zhu, Liting
   Leitzel, Kim
   Goss, Paul Edward
   Lipton, Allan
TI Effect of osteoporosis in postmenopausal breast cancer patients
   randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada.
   Penn State Hershey Med Ctr, Hershey, PA USA.
   NCIC Clin Trials Grp, Kingston, ON, Canada.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 501
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800054
ER

PT J
AU Sherman, SL
   Crawford, B
   Giammicchio, K
   Kimbro, L
   Masny, A
   Shannon, KM
AF Sherman, Stephen L.
   Crawford, Beth
   Giammicchio, Karen
   Kimbro, Lisa
   Masny, Agnes
   Shannon, Kristen Mahoney
TI The 2010 National Comprehensive Cancer Network (NCCN) risk assessment
   and genetic counseling (RA/GC) study: Operational aspects of RA/GC
   programs at academic medical centers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Natl Comprehens Canc Network, Ft Washington, PA USA.
   UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
   Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   Massachusetts Gen Hosp, Canc Ctr Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e16510
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802235
ER

PT J
AU Si, L
   Xu, XW
   Kong, Y
   Flaherty, KT
   Chi, ZH
   Cui, CL
   Sheng, XN
   Li, SM
   Tang, BX
   Guo, J
AF Si, Lu
   Xu, Xiao Wei
   Kong, Yan
   Flaherty, Keith T.
   Chi, Zhi Hong
   Cui, Chuan Liang
   Sheng, Xi Nan
   Li, Si Ming
   Tang, Bi Xia
   Guo, Jun
TI mTOR pathway activation in KIT-mutated melanoma with acquired imatinib
   resistance.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8562
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800206
ER

PT J
AU Small, AC
   Tsao, CK
   Moshier, EL
   Gartrell, BA
   Wisnivesky, JP
   Godbold, JH
   Smith, CB
   Sonpavde, G
   Oh, WK
   Galsky, MD
AF Small, Alexander C.
   Tsao, Che-Kai
   Moshier, Erin L.
   Gartrell, Benjamin Adam
   Wisnivesky, Juan P.
   Godbold, James H.
   Smith, Cardinale B.
   Sonpavde, Guru
   Oh, William K.
   Galsky, Matt D.
TI Prevalence and characteristics of patients with stage IV solid tumors
   who receive no anticancer therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
   Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
   Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6065
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802050
ER

PT J
AU Small, EJ
   Halabi, S
   Carducci, MA
   Ryan, CJ
   George, DJ
   Mahoney, JF
   Stadler, WM
   Morris, MJ
   Kantoff, P
   Monk, JP
   Kelly, WK
AF Small, Eric Jay
   Halabi, Susan
   Carducci, Michael Anthony
   Ryan, Charles J.
   George, Daniel J.
   Mahoney, John Francis
   Stadler, Walter Michael
   Morris, Michael J.
   Kantoff, Philip
   Monk, J. P.
   Kelly, William Kevin
TI The impact of prior therapy with ketoconazole (keto) on clinical
   outcomes after subsequent docetaxel treatment in metastatic
   castration-resistant prostate cancer (mCRPC) patients: Results from a
   randomized phase III trial (CALGB 90401)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Duke Univ, Sch Med, Durham, NC USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
   Duke Canc Inst, Durham, NC USA.
   Carolinas Hematol Oncol Associates, Charlotte, NC USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Ohio State Univ, CALGB, Columbus, OH 43210 USA.
   Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4667
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802618
ER

PT J
AU Smith, IE
   Finkelstein, DM
   O'Shaughnessy, J
   Moy, B
   Ejlertsen, B
   Kaufmann, M
   Buzdar, A
   Fumoleau, P
   Gradishar, WJ
   Martin, M
   Boyle, F
   Piccart-Gebhart, MJ
   Pritchard, KI
   Lindquist, D
   Rappold, E
   Williams, LS
   Liedke, PER
   Chavarri-Guerra, Y
   Goss, PE
AF Smith, Ian Edward
   Finkelstein, Dianne M.
   O'Shaughnessy, Joyce
   Moy, Beverly
   Ejlertsen, Bent
   Kaufmann, Manfred
   Buzdar, Aman
   Fumoleau, Pierre
   Gradishar, William John
   Martin, Miguel
   Boyle, Frances
   Piccart-Gebhart, Martine J.
   Pritchard, Kathleen I.
   Lindquist, Deborah
   Rappold, Erica
   Williams, Lisa Simone
   Liedke, Pedro E. R.
   Chavarri-Guerra, Yanin
   Goss, Paul Edward
TI Adjuvant lapatinib in women with early-stage HER2-positive breast cancer
   (HER2+BC): Analysis of the hormone receptor-negative subgroup of the
   intent-to-treat (ITT) population of the TEACH trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Royal Marsden Hosp, London SW3 6JJ, England.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Baylor Sammons Canc Ctr, Dallas, TX USA.
   US Oncol, Dallas, TX USA.
   Rigshosp, DK-2100 Copenhagen, Denmark.
   Goethe Univ Frankfurt, D-60054 Frankfurt, Germany.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Ctr Georges Francois Leclerc, Dijon, France.
   Northwestern Univ, Chicago, IL 60611 USA.
   Hosp Univ Gregorio Maranon, Madrid, Spain.
   Mater Hosp, Sydney, NSW, Australia.
   Inst Jules Bordet, B-1000 Brussels, Belgium.
   Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Arizona Oncol, Sedona, AZ USA.
   US Oncol, Sedona, AZ USA.
   GlaxoSmithKline, Collegeville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 596
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800203
ER

PT J
AU Smith, MR
   Sweeney, C
   Rathkopf, DE
   Scher, HI
   Logothetis, C
   George, DJ
   Higano, CS
   Yu, EY
   Harzstark, AL
   Small, EJ
   Sartor, AO
   Gordon, MS
   Vogelzang, NJ
   Smith, DC
   Hussain, M
   De Bono, JS
   Haas, NB
   Scheffold, C
   Lee, Y
   Corn, PG
AF Smith, Matthew Raymond
   Sweeney, Christopher
   Rathkopf, Dana E.
   Scher, Howard I.
   Logothetis, Christopher
   George, Daniel J.
   Higano, Celestia S.
   Yu, Evan Y.
   Harzstark, Andrea Lynne
   Small, Eric Jay
   Sartor, A. Oliver
   Gordon, Michael S.
   Vogelzang, Nicholas J.
   Smith, David C.
   Hussain, Maha
   De Bono, Johann Sebastian
   Haas, Naomi B.
   Scheffold, Christian
   Lee, Yihua
   Corn, Paul G.
TI Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration
   resistant prostate cancer (mCRPC): Results from a phase II nonrandomized
   expansion cohort (NRE)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Tulane Canc Ctr, New Orleans, LA USA.
   Pinnacle Oncol Hematol, Scottsdale, AZ USA.
   US Oncol Res Comprehens Canc Ctr NV, Las Vegas, NV USA.
   Univ Michigan, Ann Arbor, MI 48109 USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Royal Marsden Hosp, Sutton, Surrey, England.
   Inst Canc Res, Sutton, Surrey, England.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Exelixis, San Francisco, CA USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4513
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802576
ER

PT J
AU Sonpavde, G
   Amiel, G
   Margulis, V
   Link, RE
   Lerner, SP
   Raj, G
   Mayer, WA
   Palapattu, GS
   Lotan, Y
   Sagalowsky, AI
   Higgins, LC
   Tello, SA
   Pavia-Jimenez, A
   VonMerveldt, D
   Brugarolas, J
AF Sonpavde, Guru
   Amiel, Gilad
   Margulis, Vitaly
   Link, Richard E.
   Lerner, Seth P.
   Raj, Ganesh
   Mayer, Wesley A.
   Palapattu, Ganesh S.
   Lotan, Yair
   Sagalowsky, Arthur I.
   Higgins, Linda C.
   Tello, Sebrina A.
   Pavia-Jimenez, Andrea
   VonMerveldt, Dendra
   Brugarolas, James
TI Neoadjuvant therapy preceding cytoreductive nephrectomy to develop
   individualized first-line therapy with everolimus for advanced renal
   cell carcinoma (RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Houston, TX 77030 USA.
   Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   Methodist Hosp, Houston, TX 77030 USA.
   Weill Cornell Med Coll, Houston, TX USA.
   Univ Texas Southwestern, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4678
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802866
ER

PT J
AU Sonpavde, G
   Pond, GR
   Clarke, SJ
   Vardy, JL
   Wang, SL
   Paolini, J
   Lechuga, M
   Michaelson, MD
   Smith, MR
   Chen, I
   Maneval, EC
AF Sonpavde, Guru
   Pond, Gregory Russell
   Clarke, Stephen John
   Vardy, Janette L.
   Wang, S. L.
   Paolini, Jolanda
   Lechuga, Mariajose
   Michaelson, M. Dror
   Smith, Matthew Raymond
   Chen, Isan
   Maneval, Edna Chow
TI Prognostic stratification of post-docetaxel metastatic castration
   resistant prostate cancer (mCRPC) from a phase III randomized trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA.
   McMaster Univ, Hamilton, ON, Canada.
   Royal N Shore Hosp, St Leonards, NSW 2065, Australia.
   Univ Sydney, Sydney Canc Ctr, Sydney, NSW 2006, Australia.
   Pfizer Oncol, La Jolla, CA USA.
   Pfizer Inc, Milan, Italy.
   Pfizer Italia Srl, Pfizer Oncol, Milan, Italy.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Aragon Pharmaceut, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4644
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802800
ER

PT J
AU Sosman, JA
   Pavlick, AC
   Schuchter, LM
   Lewis, KD
   McArthur, GA
   Cowey, CL
   Moschos, SJ
   Flaherty, KT
   Kim, KB
   Weber, J
   Hersey, P
   Long, GV
   Lawrence, DP
   Kockx, M
   Spleiss, O
   Koehler, A
   Bollag, G
   Joe, AK
   Trunzer, K
   Ribas, A
AF Sosman, Jeffrey Alan
   Pavlick, Anna C.
   Schuchter, Lynn Mara
   Lewis, Karl D.
   McArthur, Grant A.
   Cowey, Charles Lance
   Moschos, Stergios J.
   Flaherty, Keith T.
   Kim, Kevin B.
   Weber, Jeffrey
   Hersey, Peter
   Long, Georgina V.
   Lawrence, Donald P.
   Kockx, Mark
   Spleiss, Olivia
   Koehler, Astrid
   Bollag, Gideon
   Joe, Andrew K.
   Trunzer, Kerstin
   Ribas, Antoni
TI Analysis of molecular mechanisms of response and resistance to
   vemurafenib (vem) in BRAF(V600E) melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   NYU, Sch Med, New York, NY USA.
   Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia.
   Baylor Sammons Canc Ctr, Dallas, TX USA.
   Univ Pittsburgh, Melanoma Program, UPCI, Pittsburgh, PA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   Univ Newcastle, Newcastle, NSW 2300, Australia.
   Melanoma Inst Australia, Sydney, NSW, Australia.
   Melanoma Inst Australia, Westmead, NSW, Australia.
   Royal Prince Alfred Hosp, Sydney, NSW, Australia.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   HistoGeneX, Antwerp, Belgium.
   F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
   Roche Diagnost GmbH, Penzberg, Germany.
   Plexxikon Inc, Berkeley, CA USA.
   Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
   Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 8
Z9 8
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8503
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802827
ER

PT J
AU Sparano, JA
   O'Neill, A
   Gray, RJ
   Perez, EA
   Shulman, LN
   Martino, S
   Badve, SS
   Baehner, FL
   Childs, BH
   Yoshizawa, CN
   Rowley, S
   Davidson, NE
   Shak, S
   Goldstein, LJ
AF Sparano, Joseph A.
   O'Neill, Anne
   Gray, Robert James
   Perez, Edith A.
   Shulman, Lawrence N.
   Martino, Silvana
   Badve, Sunil S.
   Baehner, Frederick L.
   Childs, Barrett H.
   Yoshizawa, Carl N.
   Rowley, Steve
   Davidson, Nancy E.
   Shak, Steven
   Goldstein, Lori J.
TI 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus
   doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN plus and
   high-risk LN-breast cancer and the comparison of the prognostic utility
   of the 21-gene recurrence score (RS) with clinicopathologic features
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Albert Einstein Coll Med, Bronx, NY 10467 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mayo Clin, Jacksonville, FL 32224 USA.
   Angeles Clin & Res Inst, Santa Monica, CA USA.
   Indiana Univ Sch Med, Indianapolis, IN USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Sanofi, Bridgewater, NJ USA.
   Genom Hlth, Redwood City, CA USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1021
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800616
ER

PT J
AU Sullivan, RJ
   Lawrence, DP
   Flaherty, KT
   McDermott, DF
   Aldridge, J
   Cho, DC
   Simonson, R
   Seery, VJ
   Hodi, FS
   Atkins, MB
   Mier, JW
   Panka, DJ
AF Sullivan, Ryan J.
   Lawrence, Donald P.
   Flaherty, Keith T.
   McDermott, David F.
   Aldridge, Julie
   Cho, Daniel C.
   Simonson, Rachel
   Seery, Virginia Jean
   Hodi, F. Stephen
   Atkins, Michael B.
   Mier, James Walter
   Panka, David J.
TI Predicting early relapse in patients with BRAF(V600E) melanoma with a
   highly sensitive blood BRAF assay
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Dana Farber Canc Inst, Int Beast Canc Study Grp, Ctr Stat, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8516
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802388
ER

PT J
AU Suri, A
   Horowitz, NS
   Carter, EB
   Denslow, S
   Gehrig, PA
AF Suri, Anuj
   Horowitz, Neil S.
   Carter, Ebony B.
   Denslow, Sheri
   Gehrig, Paola A.
TI Factors associated with an increased risk of recurrence in women with
   ovarian granulosa cell tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ North Carolina Hosp, Div Gynecol Oncol, Chapel Hill, NC USA.
   Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Chestnut Hill, MA USA.
   Hlth Res Grp, Asheville, NC USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5063
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803460
ER

PT J
AU Taplin, ME
   Montgomery, RB
   Logothetis, C
   Bubley, GJ
   Richie, JP
   Dalkin, BL
   Sanda, MG
   Loda, MF
   True, LD
   Troncoso, P
   Genega, EM
   Balk, SP
   Nelson, P
   Xie, WL
   Haqq, CM
   Tran, N
   Liu, CS
   Kheoh, TS
   Molina, A
   Kantoff, P
AF Taplin, Mary-Ellen
   Montgomery, Robert B.
   Logothetis, Christopher
   Bubley, Glenn J.
   Richie, Jerome P.
   Dalkin, Bruce L.
   Sanda, Martin G.
   Loda, Massimo F.
   True, Lawrence D.
   Troncoso, Patricia
   Genega, Elizabeth M.
   Balk, Steven P.
   Nelson, Peter
   Xie, Wanling
   Haqq, Christopher M.
   Tran, Namphuong
   Liu, Cameron S.
   Kheoh, Thian San
   Molina, Arturo
   Kantoff, Philip
TI Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate
   (LHRHa) on PSA, pathological complete response (pCR), and near pCR in
   localized high-risk prostate cancer (LHRPC): Results of a randomized
   phase II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Washington, Seattle, WA 98195 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Genom Syst, San Francisco, CA USA.
   Janssen Res & Dev, Los Angeles, CA USA.
RI Sanda, Martin/B-2023-2015
NR 0
TC 18
Z9 18
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4521
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802874
ER

PT J
AU Temel, JS
   Greer, JA
   Gallagher, ER
   Jackson, VA
   Lennes, IT
   Park, ER
   Pirl, WF
AF Temel, Jennifer S.
   Greer, Joseph A.
   Gallagher, Emily R.
   Jackson, Vicki A.
   Lennes, Inga Tolin
   Park, Elyse R.
   Pirl, William F.
TI Electronic prompt to improve outpatient code status documentation for
   advanced lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6048
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800720
ER

PT J
AU Tishler, RB
   Lorch, JH
   Sher, DJ
   Clark, JR
   Chan, AW
   Suda, M
   Balboni, TA
   Busse, PM
   Haddad, RI
   Wirth, LJ
AF Tishler, Roy B.
   Lorch, Jochen H.
   Sher, David J.
   Clark, John Ross
   Chan, Annie W.
   Suda, Margaret
   Balboni, Tracy A.
   Busse, Paul M.
   Haddad, Robert I.
   Wirth, Lori J.
TI A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT
   for locally advanced squamous cancer of the head and neck (LASCCHN).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5579
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802642
ER

PT J
AU Tolaney, SM
   Duda, DG
   Boucher, Y
   Goel, S
   Martin, J
   Ancukiewicz, M
   Potler, H
   Incio, J
   Ligibel, JA
   Isakoff, SJ
   Fukumura, D
   Winer, EP
   Krop, IE
   Jain, RK
AF Tolaney, Sara M.
   Duda, Dan G.
   Boucher, Yves
   Goel, Shom
   Martin, John
   Ancukiewicz, Marek
   Potler, Hannah
   Incio, Jaoa
   Ligibel, Jennifer A.
   Isakoff, Steven J.
   Fukumura, Dai
   Winer, Eric P.
   Krop, Ian E.
   Jain, Rakesh K.
TI A phase II study of preoperative (preop) bevacizumab (bev) followed by
   dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in
   combination with bev in HER2-negative operable breast cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1026
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800667
ER

PT J
AU Topalian, SL
   Brahmer, JR
   Hodi, FS
   McDermott, DF
   Smith, DC
   Gettinger, SN
   Taube, JM
   Drake, CG
   Pardoll, DM
   Antonia, S
   Spigel, DR
   Atkins, MB
   Lawrence, DP
   McDonald, D
   Jure-Kunkel, M
   Korman, A
   Kollia, G
   Gupta, AK
   Wigginton, J
   Sznol, M
AF Topalian, Suzanne Louise
   Brahmer, Julie R.
   Hodi, F. Stephen
   McDermott, David F.
   Smith, David C.
   Gettinger, Scott N.
   Taube, Janis M.
   Drake, Charles G.
   Pardoll, Drew M.
   Antonia, Scott
   Spigel, David R.
   Atkins, Michael B.
   Lawrence, Donald P.
   McDonald, Dan
   Jure-Kunkel, Maria
   Korman, Alan
   Kollia, Georgia
   Gupta, Ashok Kumar
   Wigginton, Jon
   Sznol, Mario
TI Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors:
   Clinical activity, safety, and a potential biomarker for response
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Univ Michigan, Ann Arbor, MI 48109 USA.
   Yale Univ, Sch Med, New Haven, CT USA.
   Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   SCRI Tennessee Oncol PLLC, Nashville, TN USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Bristol Myers Squibb Co, Princeton, NJ USA.
   Bristol Myers Squibb, Milpitas, CA USA.
   Yale Canc Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA CRA2509
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801667
ER

PT J
AU Trevino, KM
   Fasciano, K
   Prigerson, HG
AF Trevino, Kelly Marie
   Fasciano, Karen
   Prigerson, Holly Gwen
TI Rates and risks of suicidality in young adults (YAs) with advanced
   cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Trevino, Kelly Marie; Fasciano, Karen; Prigerson, Holly Gwen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9015
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802331
ER

PT J
AU Tripsas, C
   Ioakimidis, LI
   Hunter, ZR
   Patterson, CJ
   Manning, RJ
   Sheehy, PS
   Turnbull, B
   Treon, SP
AF Tripsas, Christina
   Ioakimidis, Leukothea I.
   Hunter, Zachary R.
   Patterson, Christopher J.
   Manning, Robert J.
   Sheehy, Patricia S.
   Turnbull, Barry
   Treon, Steven P.
TI Comparative response assessment by total serum IgM and IgM M-component
   in Waldenstrom's macroglobulinemia.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Biobridges, Needham, MA USA.
RI Hunter, Zachary/H-3018-2013
OI Hunter, Zachary/0000-0002-1689-1691
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e18575
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804031
ER

PT J
AU Tsao, CK
   Small, AC
   Kates, M
   Gartrell, BA
   Wisnivesky, JP
   Sonpavde, G
   Palese, M
   Hall, S
   Oh, WK
   Galsky, MD
AF Tsao, Che-Kai
   Small, Alexander C.
   Kates, Max
   Gartrell, Benjamin Adam
   Wisnivesky, Juan P.
   Sonpavde, Guru
   Palese, Michael
   Hall, Simon
   Oh, William K.
   Galsky, Matt D.
TI Trends in the use of cytoreductive nephrectomy for metastatic renal cell
   carcinoma in the VEGFR tyrosine kinase inhibitor era
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
   Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
   Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA.
   Texas Oncol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
   Mt Sinai Sch Med, Dept Urol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4623
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802603
ER

PT J
AU Tucker-Seeley, RD
   Abel, GA
   Prigerson, HG
AF Tucker-Seeley, Reginald D.
   Abel, Gregory Alan
   Prigerson, Holly Gwen
TI Racial differences in the impact of financial hardship on the intensity
   of end-of-life cancer care.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 [Tucker-Seeley, Reginald D.; Abel, Gregory Alan; Prigerson, Holly Gwen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6012
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800061
ER

PT J
AU Van Allen, EM
   Wagle, N
   Kryukov, G
   Ramos, A
   Getz, G
   Garraway, LA
AF Van Allen, Eliezer Mendel
   Wagle, Nikhil
   Kryukov, Gregory
   Ramos, Alexis
   Getz, Gad
   Garraway, Levi A.
TI A heuristic platform for clinical interpretation of cancer genome
   sequencing data
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Broad Inst MIT & Harvard, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10502
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803342
ER

PT J
AU Varella-Garcia, M
   Berry, LD
   Su, PF
   Franklin, WA
   Iafrate, AJ
   Ladanyi, M
   Camidge, DR
   Garon, EB
   Haura, EB
   Horn, L
   Khuri, FR
   Pao, W
   Rudin, CM
   Shaw, AT
   Schiller, JH
   Kris, MG
   Johnson, BE
   Minna, JD
   Kwiatkowski, DJ
   Bunn, PA
AF Varella-Garcia, Marileila
   Berry, Lynne D.
   Su, Pei-Fang
   Franklin, Wilbur A.
   Iafrate, A. John
   Ladanyi, Marc
   Camidge, D. Ross
   Garon, Edward B.
   Haura, Eric B.
   Horn, Leora
   Khuri, Fadlo Raja
   Pao, William
   Rudin, Charles M.
   Shaw, Alice Tsang
   Schiller, Joan H.
   Kris, Mark G.
   Johnson, Bruce E.
   Minna, John D.
   Kwiatkowski, David J.
   Bunn, Paul A.
TI ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer
   Mutation Consortium experience.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Colorado, Ctr Canc, Dept Med Med Oncol, Aurora, CO USA.
   Vanderbilt Univ, Nashville, TN USA.
   Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   Univ Colorado, Denver, CO 80202 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Univ Calif Los Angeles, Translat Oncol Res Int Network, Los Angeles, CA USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 7589
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804224
ER

PT J
AU Vergamini, LB
   Frazier, AL
   Abrantes, FL
   Ribeiro, KB
   Rodriguez-Galindo, C
AF Vergamini, Lucas B.
   Frazier, A. Lindsay
   Abrantes, Fernanda L.
   Ribeiro, Karina Braga
   Rodriguez-Galindo, Carlos
TI Increase in the incidence of differentiated thyroid carcinoma in
   children, adolescents, and young adults (AYA): A population-based study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9523
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802016
ER

PT J
AU Vij, R
   Richardson, PGG
   Jagannath, S
   Siegel, DSD
   Baz, RC
   Srinivasan, S
   Larkins, G
   Zaki, MH
   Hussein, MA
   Anderson, KC
AF Vij, Ravi
   Richardson, Paul Gerard Guy
   Jagannath, Sundar
   Siegel, David Samuel DiCapua
   Baz, Rachid C.
   Srinivasan, Shankar
   Larkins, Gail
   Zaki, Mohamed H.
   Hussein, Mohamad A.
   Anderson, Kenneth Carl
TI Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in
   patients (pts) with relapsed/refractory multiple myeloma (RRMM):
   Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib
   (BORT).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Washington Univ, Sch Med, St Louis, MO USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Mt Sinai Med Ctr, New York, NY 10029 USA.
   John Theurer Canc Ctr, Hackensack, NJ USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   Celgene Corp, Summit, NJ USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8016
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804036
ER

PT J
AU Vogelzang, NJ
   Ely, B
   Fink, LM
   Goldkorn, A
   Tangen, CM
   Twardowski, P
   Van Veldhuizen, PJ
   Agarwal, N
   Carducci, MA
   Monk, JP
   Datar, RH
   Garzotto, M
   Mack, PC
   Lara, P
   Higano, CS
   Hussain, M
   Quinn, DI
   Cote, RJ
   Thompson, IM
AF Vogelzang, Nicholas J.
   Ely, Benjamin
   Fink, Louis M.
   Goldkorn, Amir
   Tangen, Catherine M.
   Twardowski, Przemyslaw
   Van Veldhuizen, Peter J.
   Agarwal, Neeraj
   Carducci, Michael Anthony
   Monk, J. P.
   Datar, Ram H.
   Garzotto, Mark
   Mack, Philip C.
   Lara, Primo
   Higano, Celestia S.
   Hussain, Maha
   Quinn, David I.
   Cote, Richard J.
   Thompson, Ian Murchie
TI Circulating tumor cell counts (CTC) as prognostic of overall survival
   (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic
   castration resistant prostate cancer (mCRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   US Oncol Res, Las Vegas, NV USA.
   SWOG Stat Ctr, Seattle, WA USA.
   Nevada Canc Inst, Las Vegas, NV USA.
   Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Univ Kansas, Ctr Canc, Westwood, KS USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   Johns Hopkins Univ, Baltimore ECOG, Baltimore, MD USA.
   Ohio State Univ, CALGB, Columbus, OH 43210 USA.
   Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   Portland VA Med Ctr, Portland, OR USA.
   Univ Calif Davis, Sacramento, CA 95817 USA.
   Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800014
ER

PT J
AU Vogl, SE
   Altwairgi, AK
   Chapman, JAW
   Zhu, LT
   Shepherd, LE
   Goss, PE
AF Vogl, Steven E.
   Altwairgi, Abdullah Khalaf
   Chapman, Judy-Anne W.
   Zhu, Liting
   Shepherd, Lois E.
   Goss, Paul Edward
CA NCIC Clinical Trials Grp
TI Characterization of patients who received further adjuvant endocrine
   therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada.
   Massachusetts Gen Hosp, Avon Int Breast Canc Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e11005
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800401
ER

PT J
AU Volandes, AE
   Paasche-Orlow, M
   El-Jawahri, A
   Mitchell, SL
   Kemeny, M
   Hartshorn, KL
   Jackson, VA
   Barry, MJ
   Davis, AD
   Lopez, L
   Walker-Corkery, E
   Chang, YC
   Epstein, AS
   Bulone, L
   Misra, S
   Peachey, M
   Noy, A
   Levin, T
   Eichler, AF
   Temel, JS
AF Volandes, Angelo E.
   Paasche-Orlow, Michael
   El-Jawahri, Areej
   Mitchell, Susan L.
   Kemeny, Margaret
   Hartshorn, Kevan L.
   Jackson, Vicki A.
   Barry, Michael J.
   Davis, Aretha Delight
   Lopez, Lenny
   Walker-Corkery, Elizabeth
   Chang, Yuchiao
   Epstein, Andrew S.
   Bulone, Linda
   Misra, Sumathi
   Peachey, Matt
   Noy, Ariela
   Levin, Tomer
   Eichler, April F.
   Temel, Jennifer S.
TI A video decision support tool for CPR in advanced cancer: A randomized
   controlled trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Boston Med Ctr, Boston, MA USA.
   Hebrew Senior Life, Boston, MA USA.
   Queens Hosp, Queens Canc Ctr, Jamaica, NY USA.
   Boston Univ, Sch Med, Boston, MA 02118 USA.
   Mt Auburn Hosp, Cambridge, MA USA.
   Mt Sinai, New York, NY USA.
   Vanderbilt Univ, Nashville, TN USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9004
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803143
ER

PT J
AU Wagner, AJ
   Remillard, SP
   Zhang, YX
   Hornick, JL
AF Wagner, Andrew J.
   Remillard, Stephen P.
   Zhang, Yixiang
   Hornick, Jason L.
TI Immunohistochemical identification of SDHA-mutant gastrointestinal
   stromal tumors (GISTs).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10029
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802319
ER

PT J
AU Wagner, M
   Amodu, L
   Duh, MS
   Korves, C
   Solleza, F
   Mykletun, A
   Manson, S
   Diaz, J
   Neery, MP
   Demetri, GD
AF Wagner, Michael
   Amodu, Leo
   Duh, Mei Sheng
   Korves, Caroline
   Solleza, Franco
   Mykletun, Andrew
   Manson, Stephanie
   Diaz, Jose
   Neery, Maureen P.
   Demetri, George D.
TI Drug treatment (tx) patterns and survival among patients (pts) with
   metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at
   least one prior therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Anal Grp Inc, Boston, MA USA.
   GlaxoSmithKline, Uxbridge, Middx, England.
   GlaxoSmithKline, Collegeville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10061
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800492
ER

PT J
AU Wang, XS
   Zhao, FM
   Fisch, M
   Mendoza, TR
   O'Mara, AM
   Cella, D
   Cleeland, CS
AF Wang, Xin Shelley
   Zhao, Fengmin
   Fisch, Michael
   Mendoza, Tito R.
   O'Mara, Ann M.
   Cella, David
   Cleeland, Charles S.
TI Defining mild, moderate, and severe fatigue in cancer patients and
   survivors: E2Z02, a trial of the Eastern Cooperative Oncology Group.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   NCI, Bethesda, MD 20892 USA.
   Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9099
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804274
ER

PT J
AU Wang, XS
   Zhao, FM
   Fisch, M
   Mendoza, TR
   O'Mara, AM
   Cella, D
   Cleeland, CS
AF Wang, Xin Shelley
   Zhao, Fengmin
   Fisch, Michael
   Mendoza, Tito R.
   O'Mara, Ann M.
   Cella, David
   Cleeland, Charles S.
TI Defining mild, moderate, and severe fatigue in cancer patients and
   survivors: E2Z02, a trial of the Eastern Cooperative Oncology Group.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   NCI, Bethesda, MD 20892 USA.
   Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9099
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804071
ER

PT J
AU Weber, JS
   Flaherty, KT
   Infante, JR
   Falchook, GS
   Kefford, R
   Daud, A
   Hamid, O
   Gonzalez, R
   Kudchadkar, RR
   Lawrence, DP
   Burris, HA
   Long, GV
   Algazi, AP
   Lewis, KD
   Kim, KB
   Puzanov, I
   Sun, P
   Little, SM
   Patel, K
   Sosman, JA
AF Weber, Jeffrey S.
   Flaherty, Keith T.
   Infante, Jeffrey R.
   Falchook, Gerald Steven
   Kefford, Richard
   Daud, Adil
   Hamid, Omid
   Gonzalez, Rene
   Kudchadkar, Ragini Reiney
   Lawrence, Donald P.
   Burris, Howard A.
   Long, Georgina V.
   Algazi, Alain Patrick
   Lewis, Karl D.
   Kim, Kevin B.
   Puzanov, Igor
   Sun, Peng
   Little, Shonda M.
   Patel, Kiran
   Sosman, Jeffrey Alan
TI Updated safety and efficacy results from a phase I/II study of the oral
   BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2
   inhibitor trametinib (GSK1120212) in patients with BRAFi-naive
   metastatic melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33682 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
   Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
   Univ Sydney, Westmead Inst Canc Res, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
   Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Angeles Clin & Res Inst, Dept Med Oncol, Los Angeles, CA USA.
   Univ Colorado, Dept Med, Aurora, CO USA.
   Univ Colorado, Ctr Canc, Dept Med, Aurora, CO USA.
   Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.
   Vanderbilt Univ, Med Ctr, Dept Hematol & Oncol, Nashville, TN USA.
   GlaxoSmithKline, Collegeville, PA USA.
NR 0
TC 11
Z9 11
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8510
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802864
ER

PT J
AU Willis, S
   Miller, K
   Young, BF
   Perou, CM
   Hu, ZY
   Sparano, J
   Gray, RJ
   Sledge, GW
   Davidson, NE
   Leyland-Jones, B
AF Willis, Scooter
   Miller, Kathy
   Young, Brandon F.
   Perou, Charles M.
   Hu, Zhiyuan
   Sparano, Joseph
   Gray, Robert James
   Sledge, George W.
   Davidson, Nancy E.
   Leyland-Jones, Brian
TI Association of a compact 13-gene VEGF signature with OS in E2100
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Scripps Res Inst, Jupiter, FL USA.
   Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
   Univ N Carolina, Chapel Hill, NC USA.
   Dept Genet, Chapel Hill, NC USA.
   Montefiore Med Ctr Weiler Div, Bronx, NY USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   Emory Univ, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1027
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800818
ER

PT J
AU Winer, EP
   Tolaney, S
   Nechushtan, H
   Berger, R
   Kurzrock, R
   Ron, IG
   Schoffski, P
   Awada, A
   Yasenchak, CA
   Burris, HA
   Ramies, DA
   Rafferty, T
   Shen, XD
AF Winer, Eric P.
   Tolaney, Sara
   Nechushtan, Hovav
   Berger, Raanan
   Kurzrock, Razelle
   Ron, Ilan-Gil
   Schoffski, Patrick
   Awada, Ahmad
   Yasenchak, Christopher A.
   Burris, Howard A.
   Ramies, David A.
   Rafferty, Teresa
   Shen, Xiaodong
TI Activity of cabozantinib (XL184) in metastatic breast cancer (MBC):
   Results from a phase II randomized discontinuation trial (RDT)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Hadassah Ein Kerem Med Ctr, Jerusalem, Israel.
   Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
   Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program I, Houston, TX 77030 USA.
   Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
   Catholic Univ Louvain, Dept Gen Med Oncol, Leuven Canc Inst, B-3000 Louvain, Belgium.
   Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
   Northwest Canc Specialists, Tualatin, OR USA.
   Sarah Cannon Res Inst, Nashville, TN USA.
   Exelixis, San Francisco, CA USA.
NR 0
TC 1
Z9 1
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 535
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800333
ER

PT J
AU Wood, M
   Kadlubek, P
   Lu, KH
   Wollins, D
   Weitzel, JN
   Neuss, MN
   Hughes, KS
AF Wood, Marie
   Kadlubek, Pamela
   Lu, Karen H.
   Wollins, Dana
   Weitzel, Jeffrey N.
   Neuss, Michael N.
   Hughes, Kevin S.
TI Quality of cancer family history and referral for genetic counseling and
   testing among oncology practices: A pilot test of quality measures as
   part of the ASCO Quality Oncology Practice Initiative (QOPI)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Vermont, Burlington, VT USA.
   Amer Soc Clin Oncol, Alexandria, VA USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   City Hope Natl Med Ctr, Duarte, CA USA.
   Oncol Hematol Care Inc, Cincinnati, OH USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA CRA1505
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801209
ER

PT J
AU Wright, AA
   Hirsch, MS
   Wagle, N
   Howitt, BE
   Palescandolo, E
   MacConaill, LE
   Van Hummelen, P
   Shoni, M
   Hahn, WC
   Matulonis, UA
AF Wright, Alexi A.
   Hirsch, Michelle S.
   Wagle, Nikhil
   Howitt, Brooke E.
   Palescandolo, Emanuele
   MacConaill, Laura E.
   Van Hummelen, Paul
   Shoni, Melina
   Hahn, William C.
   Matulonis, Ursula A.
TI KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell
   carcinomas of the cervix.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 5011
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803520
ER

PT J
AU Xie, WL
   Choueiri, TK
   Lee, JL
   Harshman, LC
   Bjarnason, GA
   Knox, JJ
   MacKenzie, MJ
   Wood, L
   Vaishampayan, UN
   Yuasa, T
   Tan, MH
   Rha, SY
   Donskov, F
   Agarwal, N
   Kollmannsberger, CK
   North, SA
   Rini, BI
   Heng, DYC
AF Xie, Wanling
   Choueiri, Toni K.
   Lee, Jae-Lyun
   Harshman, Lauren Christine
   Bjarnason, Georg A.
   Knox, Jennifer J.
   MacKenzie, Mary J.
   Wood, Lori
   Vaishampayan, Ulka N.
   Yuasa, Takeshi
   Tan, Min-Han
   Rha, Sun Young
   Donskov, Frede
   Agarwal, Neeraj
   Kollmannsberger, Christian K.
   North, Scott A.
   Rini, Brian I.
   Heng, Daniel Yick Chin
TI Characteristics of long-term and short-term survivors of metastatic
   renal cell carcinoma (mRCC) treated with targeted therapy: Results from
   the International mRCC Database Consortium
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
   Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
   Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   London Reg Canc Program, London, ON, Canada.
   Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
   Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
   JFCR, Canc Inst Hosp, Tokyo, Japan.
   Natl Canc Ctr, Singapore, Singapore.
   Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea.
   Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
   Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
   Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
   Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
NR 0
TC 0
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4538
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803335
ER

PT J
AU Xu, L
   Hunter, ZR
   Yang, G
   Cao, Y
   Liu, X
   Zhou, YS
   Patterson, CJ
   Manning, RJ
   Tripsas, C
   Sheehy, PS
   Lindeman, NI
   Treon, SP
AF Xu, Lian
   Hunter, Zachary R.
   Yang, Guang
   Cao, Yang
   Liu, Xia
   Zhou, Yangsheng
   Patterson, Christopher J.
   Manning, Robert J.
   Tripsas, Christina
   Sheehy, Patricia S.
   Lindeman, Neal Ian
   Treon, Steven P.
TI Detection of the MYD88 L265P mutation in Waldenstrom's macroglobulinemia
   using a highly sensitive allele-specific PCR assay.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RI Hunter, Zachary/H-3018-2013
OI Hunter, Zachary/0000-0002-1689-1691
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 8042
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804039
ER

PT J
AU Yang, JCH
   Schuler, MH
   Yamamoto, N
   O'Byrne, KJ
   Hirsh, V
   Mok, T
   Geater, SL
   Orlov, SV
   Tsai, CM
   Boyer, MJ
   Su, WC
   Bennouna, J
   Kato, T
   Gorbunova, V
   Lee, KH
   Shah, RNH
   Massey, D
   Lorence, RM
   Shahidi, M
   Sequist, LV
AF Yang, James Chih-Hsin
   Schuler, Martin H.
   Yamamoto, Nobuyuki
   O'Byrne, Kenneth John
   Hirsh, Vera
   Mok, Tony
   Geater, Sarayut Lucien
   Orlov, Sergey V.
   Tsai, Chun-Ming
   Boyer, Michael J.
   Su, Wu-Chou
   Bennouna, Jaafar
   Kato, Terufumi
   Gorbunova, Vera
   Lee, Ki Hyeong
   Shah, Riyaz N. H.
   Massey, Dan
   Lorence, Robert M.
   Shahidi, Mehdi
   Sequist, Lecia V.
TI LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus
   pemetrexed and cisplatin as first-line treatment for patients with
   advanced adenocarcinoma of the lung harboring EGFR-activating mutations
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Natl Taiwan Univ Hosp, Taipei, Taiwan.
   West German Canc Ctr, Dept Med Oncol, Essen, Germany.
   Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan.
   St James Hosp, Dublin, Ireland.
   McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada.
   Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   Songklanagarind Hosp, Songkhla, Thailand.
   St Petersburg Pavlov State Med Univ, St Petersburg, Russia.
   Taipei Vet Gen Hosp, Taipei, Taiwan.
   Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
   Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan.
   Ctr Rene Gauducheau, Nantes, France.
   Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan.
   GU Russian Oncol Res Ctr, Moscow, Russia.
   Chungbuk Natl Univ Hosp, Taejon, South Korea.
   Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England.
   Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England.
   Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI bennouna, jaafar/K-9350-2015
NR 0
TC 9
Z9 9
U1 3
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA LBA7500
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804413
ER

PT J
AU Yock, TI
   Szymonifka, J
   Friedmann, AM
   Mahajan, A
   Yeap, BY
   MacDonald, SM
   Kasper, HB
   Grosshans, D
   Marcus, KC
   Tarbell, N
AF Yock, Torunn I.
   Szymonifka, Jackie
   Friedmann, Alison M.
   Mahajan, Anita
   Yeap, Beow Yong
   MacDonald, Shannon M.
   Kasper, Hallie Bieber
   Grosshans, David
   Marcus, Karen Chayt
   Tarbell, Nancy
TI Proton radiotherapy for rhabomyosarcoma: Preliminary results from a
   multicenter prospective study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Childrens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9585
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800348
ER

PT J
AU Yoong, J
   Park, ER
   Greer, JA
   Jackson, VA
   Gallagher, ER
   Pirl, WF
   Back, A
   Temel, JS
AF Yoong, Jaclyn
   Park, Elyse R.
   Greer, Joseph A.
   Jackson, Vicki A.
   Gallagher, Emily R.
   Pirl, William F.
   Back, Anthony
   Temel, Jennifer S.
TI Early outpatient palliative care in patients with metastatic NSCLC: A
   qualitative study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Seattle Canc Care Alliance, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 9101
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800326
ER

PT J
AU Zhao, FM
   Wagner, LI
   Pirl, WF
   Miller, AH
   Fisch, M
AF Zhao, Fengmin
   Wagner, Lynne I.
   Pirl, William F.
   Miller, Andrew H.
   Fisch, Michael
TI Racial disparities in depressive symptom prevalence and selective
   serotonin reuptake inhibitor (SSRI) utilization in cancer patients: An
   analysis from ECOG E2Z02: Symptom Outcomes and Practice Patterns (SOAPP)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
   Northwestern Univ, Chicago, IL 60611 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Emory Univ, Sch Med, Atlanta, GA USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6076
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803490
ER

PT J
AU Zhu, AX
   Chau, I
   Blanc, JF
   Okusaka, T
   Rojas, M
   Yang, L
   Von Broen, I
AF Zhu, Andrew X.
   Chau, Ian
   Blanc, Jean-Frederic
   Okusaka, Takuji
   Rojas, Maria
   Yang, Ling
   Von Broen, Ingo
TI A multicenter, randomized, double-blind, phase III study of ramucirumab
   (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and
   BSC as second-line treatment in patients (pts) with hepatocellular
   carcinoma (HCC) following first-line therapy with sorafenib (SOR)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
   Royal Marsden Hosp, London SW3 6JJ, England.
   Hop St Andre, Bordeaux, France.
   Natl Canc Ctr, Tokyo, Japan.
   ImClone Syst Int GmbH, Heidelberg, Germany.
   ImClone Syst, Bridgewater, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4146
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804539
ER

PT J
AU Zhu, AX
   Ancukiewicz, M
   Supko, JG
   Blaszkowsky, LS
   Meyerhardt, JA
   Abrams, TA
   McCleary, NJ
   Bhargava, P
   Fuchs, CS
   Ryan, DP
   Jain, RK
   Duda, DG
AF Zhu, Andrew X.
   Ancukiewicz, Marek
   Supko, Jeffrey G.
   Blaszkowsky, Lawrence Scott
   Meyerhardt, Jeffrey A.
   Abrams, Thomas Adam
   McCleary, Nadine Jackson
   Bhargava, Pankaj
   Fuchs, Charles S.
   Ryan, David P.
   Jain, Rakesh K.
   Duda, Dan G.
TI Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of
   cediranib in advanced hepatocellular carcinoma (HCC): A phase II study
   (CTEP 7147).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4112
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804242
ER

PT J
AU Zhu, AX
   Chau, I
   Blanc, JF
   Okusaka, T
   Rojas, M
   Yang, L
   Von Broen, I
AF Zhu, Andrew X.
   Chau, Ian
   Blanc, Jean-Frederic
   Okusaka, Takuji
   Rojas, Maria
   Yang, Ling
   Von Broen, Ingo
TI A multicenter, randomized, double-blind, phase III study of ramucirumab
   (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and
   BSC as second-line treatment in patients (pts) with hepatocellular
   carcinoma (HCC) following first-line therapy with sorafenib (SOR)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
   Royal Marsden Hosp, London SW3 6JJ, England.
   Hop St Andre, Bordeaux, France.
   Natl Canc Ctr, Tokyo, Japan.
   ImClone Syst Int GmbH, Heidelberg, Germany.
   ImClone Syst, Bridgewater, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4146
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801783
ER

PT J
AU Zornosa, CC
   Choti, MA
   Bobiak, S
   Kulke, M
   Yao, JC
   Bergsland, EK
   Nakakura, EK
   Bloomston, M
   Benson, AB
   Shah, MH
   Strosberg, JR
AF Zornosa, Carrie C.
   Choti, Michael A.
   Bobiak, Sarah
   Kulke, Matthew
   Yao, James C.
   Bergsland, Emily K.
   Nakakura, Eric K.
   Bloomston, Mark
   Benson, Al B.
   Shah, Manisha H.
   Strosberg, Jonathan R.
TI Baseline demographics of neuroendocrine tumor patients presenting to
   seven National Comprehensive Cancer Network (NCCN) institutions:
   Development of a multi-institutional outcomes database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Natl Comprehens Canc Network, Ft Washington, PA USA.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
   Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
   Solove Res Inst, Columbus, OH USA.
   Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
RI Bloomston, Mark/E-2767-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e14551
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009804892
ER

PT J
AU van der Graaf, WTA
   Blay, JY
   Chawla, SP
   Kim, DW
   Binh, BN
   Casali, PG
   Schoffski, P
   Aglietta, M
   Staddon, AP
   Beppu, Y
   Le Cesne, A
   Gelderblom, H
   Judson, IR
   Araki, N
   Ouali, M
   Marreaud, S
   Hodge, R
   Dewji, MR
   Coens, C
   Demetri, GD
   Fletcher, CD
   Tos, APD
   Hohenberger, P
AF van der Graaf, Winette T. A.
   Blay, Jean-Yves
   Chawla, Sant P.
   Kim, Dong-Wan
   Binh Bui-Nguyen
   Casali, Paolo G.
   Schoffski, Patrick
   Aglietta, Massimo
   Staddon, Arthur P.
   Beppu, Yasuo
   Le Cesne, Axel
   Gelderblom, Hans
   Judson, Ian R.
   Araki, Nobuhito
   Ouali, Monia
   Marreaud, Sandrine
   Hodge, Rachel
   Dewji, Mohammed R.
   Coens, Corneel
   Demetri, George D.
   Fletcher, Christopher D.
   Tos, Angelo Paolo Dei
   Hohenberger, Peter
CA EORTC Soft Tissue & Bone Sarcoma G
TI Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised,
   double-blind, placebo-controlled phase 3 trial
SO LANCET
LA English
DT Article
ID EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; II TRIAL; CANCER; ANGIOGENESIS;
   GEMCITABINE; SUNITINIB; CARDIOTOXICITY; INHIBITOR; DOCETAXEL
AB Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
   Methods This phase 3 study was done in 72 institutions, across 13 countries. Patients with angiogenesis inhibitor-naive, metastatic soft-tissue sarcoma, progressing despite previous standard chemotherapy, were randomly assigned by an interactive voice randomisation system in a 2:1 ratio in permuted blocks (with block sizes of six) to receive either pazopanib 800 mg once daily or placebo, with no subsequent cross-over. Patients, investigators who gave the treatment, those assessing outcomes, and those who did the analysis were masked to the allocation. The primary endpoint was progression-free survival. Efficacy analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00753688.
   Findings 372 patients were registered and 369 were randomly assigned to receive pazopanib (n = 246) or placebo (n = 123). Median progression-free survival was 4.6 months (95% CI 3.7-4.8) for pazopanib compared with 1.6 months (0.9-1.8) for placebo (hazard ratio [HR] 0.31, 95% CI 0.24-0.40; p < 0.0001). Overall survival was 12.5 months (10.6-14.8) with pazopanib versus 10.7 months (8.7-12.8) with placebo (HR 0.86, 0.67-1.11; p = 0.25). The most common adverse events were fatigue (60 in the placebo group [49%] vs 155 in the pazopanib group [65%]), diarrhoea (20 [16%] vs 138 [58%]), nausea (34 [28%] vs 129 [54%]), weight loss (25 [20%] vs 115 [48%]), and hypertension (8 [7%] vs 99 [41%]). The median relative dose intensity was 100% for placebo and 96% for pazopanib.
   Interpretation Pazopanib is a new treatment option for patients with metastatic non-adipocytic soft-tissue sarcoma after previous chemotherapy.
C1 [van der Graaf, Winette T. A.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 GA Nijmegen, Netherlands.
   [Blay, Jean-Yves] Ctr Leon Berard, F-69373 Lyon, France.
   [Chawla, Sant P.] Sarcoma Oncol Ctr, Santa Monica Oncol Ctr, Santa Monica, CA USA.
   [Kim, Dong-Wan] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
   [Binh Bui-Nguyen] Inst Bergonie, Bordeaux, France.
   [Casali, Paolo G.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   [Schoffski, Patrick] Katholieke Univ Leuven, Dept Gen Med Oncol, Louvain, Belgium.
   [Schoffski, Patrick] Katholieke Univ Leuven, Expt Oncol Lab, Univ Hosp Leuven, Leuven Canc Inst, Louvain, Belgium.
   [Aglietta, Massimo] Univ Torino, Inst Canc Res & Treatment, Candiolo, Italy.
   [Staddon, Arthur P.] Univ Penn, Philadelphia, PA 19104 USA.
   [Beppu, Yasuo] Natl Canc Ctr, Tokyo, Japan.
   [Le Cesne, Axel] Inst Gustave Roussy, Villejuif, France.
   [Gelderblom, Hans] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
   [Judson, Ian R.] Royal Marsden NHS Fdn Trust, London, England.
   [Araki, Nobuhito] Osaka Med Ctr, Osaka, Japan.
   [Ouali, Monia; Marreaud, Sandrine] European Org Res & Treatment Canc Headquarters, Brussels, Belgium.
   [Hodge, Rachel; Dewji, Mohammed R.] GlaxoSmithKline Oncol, Uxbridge, Middx, England.
   [Demetri, George D.] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA.
   [Demetri, George D.] Harvard Univ, Sch Med, Boston, MA USA.
   [Fletcher, Christopher D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Tos, Angelo Paolo Dei] Gen Hosp Treviso, Dept Oncol Anat Pathol, Treviso, Italy.
   [Hohenberger, Peter] Univ Klinikum Mannheim, Mannheim, Germany.
RP van der Graaf, WTA (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol 452, Geert Grooteplein Zuid 8, NL-6525 GA Nijmegen, Netherlands.
EM w.vandergraaf@onco.umcn.nl
RI Kim, Dong-Wan/J-5391-2012; van der Graaf, Winette/A-5006-2014; IBIS,
   BIOMARCADORES/P-3515-2015; Blay, Jean-Yves/N-3966-2016; casali, Paolo
   Giovanni/D-1524-2017; 
OI Blay, Jean-Yves/0000-0001-7190-120X; casali, Paolo
   Giovanni/0000-0003-4056-8023; DEI TOS, ANGELO/0000-0002-1228-8940
FU GlaxoSmithKline; Novartis; Roche; PharmaMar; Merck; Sharp; Dohme;
   Pfizer; Sanofi; Ariad; Johnson and Johnson; Daiichi-Sankyo; Amgen; Bayer
FX Funding GlaxoSmithKline.; J-YB has received research support and
   honoraria from GlaxoSmithKline, Novartis, Roche, PharmaMar, and Merck,
   Sharp, and Dohme. IRJ has received research support and honoraria from
   GlaxoSmithKline and has been on an advisory board for GlaxoSmithKline.
   GDD has received consultant and research support from GlaxoSmithKline,
   Pfizer, Novartis, Sanofi, Ariad, Merck, Johnson and Johnson, PharmaMar,
   Daiichi-Sankyo, and Amgen; and has been a consultant for ZioPharm. D-WK
   has been a consultant for GlaxoSmithKline. PS has received research
   funding from GlaxoSmithKline, and has been a consultant for and received
   honoraria from GlaxoSmithKline. ALC has received honoraria from
   Novartis, Pfizer, and PharmaMar. RH and MRD are employees of
   GlaxoSmithKline and hold shares in GlaxoSmithKline. HG has received
   research grants from GlaxoSmithKline, Novartis, and Pfizer. APS has
   received research support from GlaxoSmithKline. SPC has been a
   consultant for GlaxoSmithKline. PGC has received honoraria and travel
   grants from and is on advisory boards for Bayer, GlaxoSmithKline, Merck,
   Novartis, Pfizer, and PharmaMar. MA, WTAvdG, SM, NA, APDT, CDF, PH,
   BB-N, MO, CC, and YB declare that they have no conflicts of interest.
NR 31
TC 442
Z9 454
U1 3
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 19
PY 2012
VL 379
IS 9829
BP 1879
EP 1886
DI 10.1016/S0140-6736(12)60651-5
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 944IW
UT WOS:000304194200029
PM 22595799
ER

PT J
AU Li, XY
   Valencia, A
   McClory, H
   Sapp, E
   Kegel, KB
   DiFiglia, M
AF Li, Xueyi
   Valencia, Antonio
   McClory, Hollis
   Sapp, Ellen
   Kegel, Kimberly B.
   DiFiglia, Marian
TI Deficient Rab11 activity underlies glucose hypometabolism in primary
   neurons of Huntington's disease mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Neurodegenerative disorders; Huntington's disease; Primary neurons;
   Glucose uptake; Rab11
ID METABOLISM; REPEAT; SCAN; PET; HD
AB Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. Positron emission tomography studies have revealed a decline in glucose metabolism in the brain of patients with HD by a mechanism that has not been established. We examined glucose utilization in embryonic primary cortical neurons of wild-type (WT) and HD knock-in mice, which have 140 CAG repeats inserted in the endogenous mouse huntingtin gene (HD140Q/(140Q)). Primary HD140Q/(140Q) cortical neurons took up significantly less glucose than did WT neurons. Expression of permanently inactive and permanently active forms of Rab11 correspondingly altered glucose uptake in WT neurons, suggesting that normal activity of Rab11 is needed for neuronal uptake of glucose. It is known that Rab11 activity is diminished in HD140Q/(140Q) neurons. Expression of dominant active Rab11 to enhance the activity of Rab11 normalized glucose uptake in HD140Q/(140Q) neurons. These results suggest that deficient activity of Rab11 is a novel mechanism for glucose hypometabolism in HD. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Xueyi] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
   Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Li, XY (reprint author), Massachusetts Gen Hosp, Dept Neurol, 114,16th St,Room 2002, Charlestown, MA 02129 USA.
EM xli12@partners.org; difiglia@helix.mgh.harvard.edu
FU Hereditary Disease Foundation; CHDI Foundation; NINDS [NS074381]
FX This work was supported by the Hereditary Disease Foundation and the
   CHDI Foundation to XL and by NINDS (NS074381) to MD.
NR 27
TC 8
Z9 9
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 18
PY 2012
VL 421
IS 4
BP 727
EP 730
DI 10.1016/j.bbrc.2012.04.070
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 957NB
UT WOS:000305168600016
PM 22542623
ER

PT J
AU Bick, AG
   Calvo, SE
   Mootha, VK
AF Bick, Alexander G.
   Calvo, Sarah E.
   Mootha, Vamsi K.
TI Evolutionary Diversity of the Mitochondrial Calcium Uniporter
SO SCIENCE
LA English
DT Article
ID RAT KIDNEY MITOCHONDRIA; PROTEIN
C1 [Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   Broad Inst, Cambridge, MA 02142 USA.
RP Mootha, VK (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM vamsi@hms.harvard.edu
OI Bick, Alexander/0000-0001-5824-9595
FU NIH [R01GM077465, R01GM097136, T32GM007753-33]
FX We thank A. Pringle, K. Zimmerman, E. Koonin, and E. Lander for critical
   reading of the manuscript. Protein sequences were obtained from the KEGG
   Organisms Database, Release 58, or the Origins of Multicellularity
   Sequencing Project at the Broad Institute. This work was supported by
   NIH funds (R01GM077465 and R01GM097136 to V.K.M. and T32GM007753-33 to
   A.G.B.). Alignments and tree available at TreeBASE (accession S12416).
NR 7
TC 53
Z9 56
U1 0
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 18
PY 2012
VL 336
IS 6083
BP 886
EP 886
DI 10.1126/science.1214977
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 943SN
UT WOS:000304145600056
PM 22605770
ER

PT J
AU Jim, B
   Ghanta, M
   Qipo, A
   Fan, Y
   Chuang, PY
   Cohen, HW
   Abadi, M
   Thomas, DB
   He, JC
AF Jim, Belinda
   Ghanta, Mythili
   Qipo, Andi
   Fan, Ying
   Chuang, Peter Y.
   Cohen, Hillel W.
   Abadi, Maria
   Thomas, David B.
   He, John Cijiang
TI Dysregulated Nephrin in Diabetic Nephropathy of Type 2 Diabetes: A Cross
   Sectional Study
SO PLOS ONE
LA English
DT Article
ID SLIT-DIAPHRAGM PROTEIN; GLOMERULAR PROTEIN; NEPHROTIC SYNDROME; PODOCYTE
   NUMBER; KIDNEY-DISEASE; EXPRESSION; RAT; MICROALBUMINURIA; INHIBITION;
   EXCRETION
AB Background: Podocyte specific proteins are dysregulated in diabetic nephropathy, though the extent of their expression loss is not identical and may be subject to different regulatory factors. Quantifying the degree of loss may help identify the most useful protein to use as an early biomarker of diabetic nephropathy.
   Methodology/Principal Findings: Protein expression of synaptopodin, podocin and nephrin were quantified in 15 Type 2 diabetic renal biopsies and 12 control patients. We found statistically significant downregulation of synaptopodin (P < 0.0001), podocin (P = 0.0002), and nephrin (P < 0.0001) in kidney biopsies of diabetic nephropathy as compared with controls. Urinary nephrin levels (nephrinuria) were then measured in 66 patients with Type 2 diabetes and 10 healthy controls by an enzyme-linked immunosorbent assay (Exocell, Philadelphia, PA). When divided into groups according to normo-, micro-, and macroalbuminuria, nephrinuria was found to be present in 100% of diabetic patients with micro-and macroalbuminuria, as well as 54% of patients with normoalbuminuria. Nephrinuria also correlated significantly with albuminuria (rho = 0.89, P < 0.001), systolic blood pressure (rho = 0.32, p = 0.007), and correlated negatively with serum albumin (rho = 20.48, P < 0.0001) and eGFR (rho = 20.33, p = 0.005).
   Conclusions/Significance: These data suggest that key podocyte-specific protein expressions are significantly and differentially downregulated in diabetic nephropathy. The finding that nephrinuria is observed in a majority of these normoalbuminuric patients demonstrates that it may precede microalbuminuria. If further research confirms nephrinuria to be a biomarker of pre-clinical diabetic nephropathy, it would shed light on podocyte metabolism in disease, and raise the possibility of new and earlier therapeutic targets.
C1 [Jim, Belinda; Ghanta, Mythili; Qipo, Andi] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Div Nephrol, Bronx, NY 10467 USA.
   [Fan, Ying] Shanghai Jiao Tong Univ, Dept Nephrol, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China.
   [Chuang, Peter Y.; He, John Cijiang] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY USA.
   [Cohen, Hillel W.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Abadi, Maria] Albert Einstein Coll Med, Dept Pathol, Jacobi Med Ctr, Bronx, NY 10467 USA.
   [Thomas, David B.] Nephrocor, Uniondale, NY USA.
   [He, John Cijiang] James J Peters VA Med Ctr, Dept Med Bronx, Div Nephrol, New York, NY USA.
RP Jim, B (reprint author), Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Div Nephrol, Bronx, NY 10467 USA.
EM bun.jim@nbhn.net
OI Cohen, Hillel/0000-0002-4524-0898
FU VA Merit Award; NIH [1R01 DK078897]; National Center for Research
   Resources (NCRR), a component of the National Institutes of Health (NIH)
   [UL1 RR025750, KL2 RR025749, TL1 RR025748]; NIH roadmap for Medical
   Research
FX Dr. JC He is funded by the VA Merit Award and NIH 1R01 DK078897. This
   publication was supported in part by the Clinical Translational Science
   Award (CTSA) Grant UL1 RR025750, KL2 RR025749 and TL1 RR025748 from the
   National Center for Research Resources (NCRR), a component of the
   National Institutes of Health (NIH), and NIH roadmap for Medical
   Research. Its contents are solely the responsibility of the authors and
   do not necessary represent the official view of the NCRR or NIH. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 36
TC 40
Z9 49
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2012
VL 7
IS 5
AR e36041
DI 10.1371/journal.pone.0036041
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UQ
UT WOS:000305341200005
PM 22615747
ER

PT J
AU Leonard, JP
   LaCasce, AS
   Smith, MR
   Noy, A
   Chirieac, LR
   Rodig, SJ
   Yu, JQ
   Vallabhajosula, S
   Schoder, H
   English, P
   Neuberg, DS
   Martin, P
   Millenson, MM
   Ely, SA
   Courtney, R
   Shaik, N
   Wilner, KD
   Randolph, S
   Van den Abbeele, AD
   Chen-Kiang, SY
   Yap, JT
   Shapiro, GI
AF Leonard, John P.
   LaCasce, Ann S.
   Smith, Mitchell R.
   Noy, Ariela
   Chirieac, Lucian R.
   Rodig, Scott J.
   Yu, Jian Q.
   Vallabhajosula, Shankar
   Schoder, Heiko
   English, Patricia
   Neuberg, Donna S.
   Martin, Peter
   Millenson, Michael M.
   Ely, Scott A.
   Courtney, Rachel
   Shaik, Naveed
   Wilner, Keith D.
   Randolph, Sophia
   Van den Abbeele, Annick D.
   Chen-Kiang, Selina Y.
   Yap, Jeffrey T.
   Shapiro, Geoffrey I.
TI Selective CDK4/6 inhibition with tumor responses by PD0332991 in
   patients with mantle cell lymphoma
SO BLOOD
LA English
DT Article
ID DEPENDENT KINASE INHIBITOR; CYCLIN D1; PD 0332991; CENTROCYTIC LYMPHOMA;
   PHASE-II; IN-VITRO; CANCER; PROLIFERATION; OVEREXPRESSION; PATHOGENESIS
AB Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1-dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) and 3-deoxy-3[F-18]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUVmax), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of > 1 year (range, 14.9-30.1 + months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated > 70%,> 90%, and >= 87.5% reductions in summed FLT SUVmax and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056. (Blood. 2012; 119(20): 4597-4607)
C1 [Van den Abbeele, Annick D.; Yap, Jeffrey T.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA.
   [Leonard, John P.; Martin, Peter] Weill Cornell Med Coll, Div Hematol Oncol, Dept Med, New York, NY USA.
   [LaCasce, Ann S.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA.
   [LaCasce, Ann S.; Shapiro, Geoffrey I.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [LaCasce, Ann S.; Chirieac, Lucian R.; Rodig, Scott J.; Yap, Jeffrey T.; Shapiro, Geoffrey I.] Harvard Univ, Sch Med, Boston, MA USA.
   [Smith, Mitchell R.; Millenson, Michael M.] Fox Chase Canc Ctr, Dept Med Oncol, Lymphoma Serv, Philadelphia, PA 19111 USA.
   [Noy, Ariela] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA.
   [Chirieac, Lucian R.; Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Yu, Jian Q.] Fox Chase Canc Ctr, Dept Diagnost Imaging, Nucl Med Serv, Philadelphia, PA 19111 USA.
   [Vallabhajosula, Shankar] Weill Cornell Med Coll, Dept Radiol Radiochem & Radiopharm, New York, NY USA.
   [Schoder, Heiko] Mem Sloan Kettering Canc Ctr, Dept Radiol, Nucl Med Serv, New York, NY 10021 USA.
   [English, Patricia; Courtney, Rachel; Shaik, Naveed; Wilner, Keith D.; Randolph, Sophia] Pfizer Inc, Pfizer Global Res & Dev, La Jolla, CA USA.
   [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
   [Neuberg, Donna S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Ely, Scott A.; Chen-Kiang, Selina Y.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
   [Yap, Jeffrey T.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
   [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Dept Med Oncol, Early Drug Dev Ctr, Boston, MA 02215 USA.
RP Yap, JT (reprint author), Dana Farber Canc Inst, Dept Imaging, Dana L101,450 Brookline Ave, Boston, MA 02215 USA.
EM jeffrey_yap@dfci.harvard.edu; geoffrey_shapiro@dfci.harvard.edu
OI Noy, Ariela/0000-0002-3001-4898; Smith, Mitchell/0000-0003-1428-8765
FU Pfizer Clinical Development and Medical Affairs; Lymphoma Research
   Foundation Mantle Cell Lymphoma Correlative Science grant [MCLC-07-015];
   Mantle Cell Lymphoma Research Initiative grant [MCLI-03-011]; Pfizer
FX The authors thank Isan Chen and Deborah Womble of Pfizer for
   collaborative efforts during the inception of the study and protocol
   management; Anna Kreshock, Tyler Caron, and Donna Skinner of the
   Dana-Farber/Harvard Cancer Center Pathology Core for technical
   assistance; Christine Arris, PhD, of ACUMED (Tytherington, United
   Kingdom) for manuscript editing and preparation funded by Pfizer; all
   participating patients and their families; and the network of
   investigators, research nurses, study coordinators, and operations staff
   at the participating institutions.; This work was sponsored and funded
   by Pfizer Clinical Development and Medical Affairs, a Lymphoma Research
   Foundation Mantle Cell Lymphoma Correlative Science grant (MCLC-07-015
   to G.I.S.), and a Mantle Cell Lymphoma Research Initiative grant
   (MCLI-03-011 to G.I.S.).
NR 50
TC 132
Z9 139
U1 3
U2 17
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 17
PY 2012
VL 119
IS 20
BP 4597
EP 4607
DI 10.1182/blood-2011-10-388298
PG 11
WC Hematology
SC Hematology
GA 959CM
UT WOS:000305288400007
PM 22383795
ER

PT J
AU Golzio, C
   Willer, J
   Talkowski, ME
   Oh, EC
   Taniguchi, Y
   Jacquemont, S
   Reymond, A
   Sun, M
   Sawa, A
   Gusella, JF
   Kamiya, A
   Beckmann, JS
   Katsanis, N
AF Golzio, Christelle
   Willer, Jason
   Talkowski, Michael E.
   Oh, Edwin C.
   Taniguchi, Yu
   Jacquemont, Sebastien
   Reymond, Alexandre
   Sun, Mei
   Sawa, Akira
   Gusella, James F.
   Kamiya, Atsushi
   Beckmann, Jacques S.
   Katsanis, Nicholas
TI KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the
   16p11.2 copy number variant
SO NATURE
LA English
DT Article
ID TOOTH DISEASE TYPE-1A; MICRODELETION SYNDROME; CHROMOSOME 16P11.2;
   SYNDROME REGION; AUTISM; GENE; SCHIZOPHRENIA; DUPLICATIONS; ASSOCIATION;
   DELETIONS
AB Copy number variants (CNVs) are major contributors to genetic disorders(1). We have dissected a region of the 16p11.2 chromosome-which encompasses 29 genes-that confers susceptibility to neurocognitive defects when deleted or duplicated(2,3). Overexpression of each human transcript in zebrafish embryos identified KCTD13 as the sole message capable of inducing the microcephaly phenotype associated with the 16p11.2 duplication(2-5), whereas suppression of the same locus yielded the macrocephalic phenotype associated with the 16p11.2 deletion(5,6), capturing the mirror phenotypes of humans. Analyses of zebrafish and mouse embryos suggest that microcephaly is caused by decreased proliferation of neuronal progenitors with concomitant increase in apoptosis in the developing brain, whereas macrocephaly arises by increased proliferation and no changes in apoptosis. A role for KCTD13 dosage changes is consistent with autism in both a recently reported family with a reduced 16p11.2 deletion and a subject reported here with a complex 16p11.2 rearrangement involving de novo structural alteration of KCTD13. Our data suggest that KCTD13 is a major driver for the neurodevelopmental phenotypes associated with the 16p11.2 CNV, reinforce the idea that one or a small number of transcripts within a CNV can underpin clinical phenotypes, and offer an efficient route to identifying dosage-sensitive loci.
C1 [Golzio, Christelle; Willer, Jason; Oh, Edwin C.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC 27710 USA.
   [Golzio, Christelle; Willer, Jason; Oh, Edwin C.; Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
   [Talkowski, Michael E.; Sun, Mei; Gusella, James F.] Massachusetts Gen Hosp, Ctr Human Genet Res, Mol Neurogenet Unit, Boston, MA 02114 USA.
   [Talkowski, Michael E.; Gusella, James F.] Harvard Univ, Sch Med, Dept Neurol & Genet, Boston, MA 02115 USA.
   [Taniguchi, Yu; Sawa, Akira; Kamiya, Atsushi] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA.
   [Jacquemont, Sebastien; Beckmann, Jacques S.] CHU Vaudois, Serv Med Genet, CH-1011 Lausanne, Switzerland.
   [Reymond, Alexandre] Univ Lausanne, Ctr Integrat Gen, CH-1015 Lausanne, Switzerland.
   [Beckmann, Jacques S.] Univ Lausanne, Dept Med Genet, CH-1005 Lausanne, Switzerland.
   [Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27710 USA.
RP Katsanis, N (reprint author), Duke Univ, Ctr Human Dis Modeling, Durham, NC 27710 USA.
EM katsanis@cellbio.duke.edu
RI Katsanis, Nicholas/E-1837-2012; Beckmann, Jacques S /A-9772-2008;
   kamiya, atsushi/L-8550-2016; 
OI Beckmann, Jacques S /0000-0002-9741-1900; Golzio,
   Christelle/0000-0002-4420-3921; Katsanis, Nicholas/0000-0002-2480-0171
FU Silvo O. Conte center from the National Institute of Mental Health
   (NIMH), National Institutes of Health [MH-094268, MH-084018, MH-091230,
   HD06286]; Simon's Foundation; Autism Consortium of Boston; Leenaards
   Foundation; Swiss National Science Foundation; Swiss National Science
   Foundation Sinergia; NIMH National Research Service [F32MH087123];
   bourse de releve academique de la Faculte de Biologie et Medecine de
   l'Universite de Lausanne
FX We thank C. Hanscom for technical assistance. We also thank J. Black, J.
   Whetstine, K. Brown and C. Lee for assistance with the initial and
   confirmatory array CGH experiments, S. Santagelo for analysis of
   clinical phenotype data, and M. State, M. Daley and R. Gibbs for sharing
   unpublished exome sequencing data. This work was supported by a Silvo O.
   Conte center grant (MH-094268) from the National Institute of Mental
   Health (NIMH), National Institutes of Health grant MH-084018 (A. S., A.
   K. and N.K.), grant MH-091230 (A. K.), grant HD06286 (J. F. G.), the
   Simon's Foundation, the Autism Consortium of Boston (J. F. G.), the
   Leenaards Foundation Prize (S. J. and A. R.), the Swiss National Science
   Foundation (A. R. and J. S. B.), a Swiss National Science Foundation
   Sinergia grant (S. J., J. S. B. and A. R.). M. E. T. was supported by an
   NIMH National Research Service Award (F32MH087123). S. J. is a recipient
   of a bourse de releve academique de la Faculte de Biologie et Medecine
   de l'Universite de Lausanne. N.K. is a Distinguished Brumley Professor.
NR 31
TC 125
Z9 127
U1 1
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 17
PY 2012
VL 485
IS 7398
BP 363
EP U111
DI 10.1038/nature11091
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 943CW
UT WOS:000304099100041
PM 22596160
ER

PT J
AU Hochberg, LR
   Bacher, D
   Jarosiewicz, B
   Masse, NY
   Simeral, JD
   Vogel, J
   Haddadin, S
   Liu, J
   Cash, SS
   van der Smagt, P
   Donoghue, JP
AF Hochberg, Leigh R.
   Bacher, Daniel
   Jarosiewicz, Beata
   Masse, Nicolas Y.
   Simeral, John D.
   Vogel, Joern
   Haddadin, Sami
   Liu, Jie
   Cash, Sydney S.
   van der Smagt, Patrick
   Donoghue, John P.
TI Reach and grasp by people with tetraplegia using a neurally controlled
   robotic arm
SO NATURE
LA English
DT Article
ID BRAIN-COMPUTER INTERFACE; LOCAL-FIELD POTENTIALS; PRIMARY MOTOR CORTEX;
   CORTICAL CONTROL; SPIKING ACTIVITY; PROSTHETIC ARM; RESTORATION;
   MOVEMENTS; MUSCLES; SIGNALS
AB Paralysis following spinal cord injury, brainstem stroke, amyotrophic lateral sclerosis and other disorders can disconnect the brain from the body, eliminating the ability to perform volitional movements. A neural interface system(1-5) could restore mobility and independence for people with paralysis by translating neuronal activity directly into control signals for assistive devices. We have previously shown that people with long-standing tetraplegia can use a neural interface system to move and click a computer cursor and to control physical devices(6-8). Able-bodied monkeys have used a neural interface system to control a robotic arm(9), but it is unknown whether people with profound upper extremity paralysis or limb loss could use cortical neuronal ensemble signals to direct useful arm actions. Here we demonstrate the ability of two people with long-standing tetraplegia to use neural interface system-based control of a robotic arm to perform three-dimensional reach and grasp movements. Participants controlled the arm and hand over a broad space without explicit training, using signals decoded from a small, local population of motor cortex (MI) neurons recorded from a 96-channel microelectrode array. One of the study participants, implanted with the sensor 5 years earlier, also used a robotic arm to drink coffee from a bottle. Although robotic reach and grasp actions were not as fast or accurate as those of an able-bodied person, our results demonstrate the feasibility for people with tetraplegia, years after injury to the central nervous system, to recreate useful multidimensional control of complex devices directly from a small sample of neural signals.
C1 [Hochberg, Leigh R.; Jarosiewicz, Beata; Simeral, John D.; Liu, Jie; Donoghue, John P.] Rehabil Res & Dev Serv, Dept Vet Affairs, Providence, RI 02908 USA.
   [Hochberg, Leigh R.; Bacher, Daniel; Simeral, John D.; Liu, Jie; Donoghue, John P.] Brown Univ, Sch Engn, Providence, RI 02912 USA.
   [Hochberg, Leigh R.; Bacher, Daniel; Jarosiewicz, Beata; Masse, Nicolas Y.; Simeral, John D.; Liu, Jie; Donoghue, John P.] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.
   [Hochberg, Leigh R.; Simeral, John D.; Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Hochberg, Leigh R.; Cash, Sydney S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Jarosiewicz, Beata; Masse, Nicolas Y.; Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA.
   [Vogel, Joern; Haddadin, Sami; van der Smagt, Patrick] German Aerosp Ctr, Inst Robot & Mechatron DLR Oberpfaffenhofen, D-82230 Oberpfaffenhofen, Germany.
RP Donoghue, JP (reprint author), Rehabil Res & Dev Serv, Dept Vet Affairs, Providence, RI 02908 USA.
EM leigh@brown.edu; john_donoghue@brown.edu
OI Vogel, Jorn/0000-0002-1987-0028; Hochberg, Leigh/0000-0003-0261-2273;
   van der Smagt, Patrick/0000-0003-4418-4916
FU Rehabilitation Research and Development Service, Office of Research and
   Development, Department of Veterans Affairs [B6453R, A6779I, B6310N];
   National Institutes of Health: NINDS/NICHD [RC1HD063931]; NIDCD
   [R01DC009899]; NICHD-NCMRR [N01HD53403, N01HD10018]; NIBIB
   [R01EB007401]; NINDS-Javits [NS25074]; Defense Advanced Research
   Projects Agency (DARPA); Department of Veterans Affairs; Doris Duke
   Charitable Foundation; MGH-Deane Institute for Integrated Research on
   Atrial Fibrillation and Stroke; Katie Samson Foundation; Craig H.
   Neilsen Foundation; European Commission [248587]; Cyberkinetics
   Neurotechnology Systems (CKI)
FX We thank participants S3 and T2 for their dedication to this research.
   We thank M. Black for initial guidance in the BrainGate-DLR research. We
   thank E. Gallivan, E. Berhanu, D. Rosler, L. Barefoot, K. Centrella and
   B. King for their contributions to this research. We thank G. Friehs and
   E. Eskandar for their surgical contributions. We thank K. Knoper for
   assistance with illustrations. We thank D. Van Der Merwe and DEKA
   Research and Development for their technical support. The contents do
   not represent the views of the Department of Veterans Affairs or the
   United States Government. The research was supported by the
   Rehabilitation Research and Development Service, Office of Research and
   Development, Department of Veterans Affairs (Merit Review Awards B6453R
   and A6779I; Career Development Transition Award B6310N). Support was
   also provided by the National Institutes of Health: NINDS/NICHD
   (RC1HD063931), NIDCD (R01DC009899), NICHD-NCMRR (N01HD53403 and
   N01HD10018), NIBIB (R01EB007401), NINDS-Javits (NS25074); a Memorandum
   of Agreement between the Defense Advanced Research Projects Agency
   (DARPA) and the Department of Veterans Affairs; the Doris Duke
   Charitable Foundation; the MGH-Deane Institute for Integrated Research
   on Atrial Fibrillation and Stroke; Katie Samson Foundation; Craig H.
   Neilsen Foundation; the European Commission's Seventh Framework
   Programme through the project The Hand Embodied (grant 248587). The
   pilot clinical trial into which participant S3 was recruited was
   sponsored in part by Cyberkinetics Neurotechnology Systems (CKI).
NR 38
TC 572
Z9 587
U1 40
U2 308
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 17
PY 2012
VL 485
IS 7398
BP 372
EP U121
DI 10.1038/nature11076
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 943CW
UT WOS:000304099100043
PM 22596161
ER

PT J
AU Homma, S
   Thompson, JLP
   Pullicino, PM
   Levin, B
   Freudenberger, RS
   Teerlink, JR
   Ammon, SE
   Graham, S
   Sacco, RL
   Mann, DL
   Mohr, JP
   Massie, BM
   Labovitz, AJ
   Anker, SD
   Lok, DJ
   Ponikowski, P
   Estol, CJ
   Lip, GYH
   Di Tullio, MR
   Sanford, AR
   Mejia, V
   Gabriel, AP
   del Valle, ML
   Buchsbaum, R
AF Homma, Shunichi
   Thompson, John L. P.
   Pullicino, Patrick M.
   Levin, Bruce
   Freudenberger, Ronald S.
   Teerlink, John R.
   Ammon, Susan E.
   Graham, Susan
   Sacco, Ralph L.
   Mann, Douglas L.
   Mohr, J. P.
   Massie, Barry M.
   Labovitz, Arthur J.
   Anker, Stefan D.
   Lok, Dirk J.
   Ponikowski, Piotr
   Estol, Conrado J.
   Lip, Gregory Y. H.
   Di Tullio, Marco R.
   Sanford, Alexandra R.
   Mejia, Vilma
   Gabriel, Andre P.
   del Valle, Mirna L.
   Buchsbaum, Richard
CA WARCEF Investigators
TI Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ATRIAL-FIBRILLATION; VENTRICULAR DYSFUNCTION; ANTITHROMBOTIC THERAPY;
   MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; DOUBLE-BLIND; ANTICOAGULATION;
   STROKE; PREVENTION; ENALAPRIL
AB BACKGROUND
   It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm.
   METHODS
   We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [+/- SD], 3.5 +/- 1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause.
   RESULTS
   The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P=0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P=0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P=0.82).
   CONCLUSIONS
   Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized.
C1 [Homma, Shunichi; Thompson, John L. P.; Levin, Bruce; Mohr, J. P.; Di Tullio, Marco R.; Sanford, Alexandra R.; Mejia, Vilma; Gabriel, Andre P.; del Valle, Mirna L.; Buchsbaum, Richard] Columbia Univ, Med Ctr, New York, NY 10032 USA.
   [Pullicino, Patrick M.] Univ Kent, Canterbury, Kent, England.
   [Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
   [Freudenberger, Ronald S.] Lehigh Valley Hosp, Allentown, PA USA.
   [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Teerlink, John R.; Ammon, Susan E.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Graham, Susan] SUNY Buffalo, Buffalo, NY 14260 USA.
   [Sacco, Ralph L.] Univ Miami, Miami, FL USA.
   [Mann, Douglas L.] Washington Univ, St Louis, MO 63130 USA.
   [Labovitz, Arthur J.] Univ S Florida, Tampa, FL USA.
   [Anker, Stefan D.] Charite, D-13353 Berlin, Germany.
   [Anker, Stefan D.] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy.
   [Lok, Dirk J.] Hosp Deventer, Deventer, Netherlands.
   [Ponikowski, Piotr] Mil Hosp, Wroclaw, Poland.
   [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina.
RP Homma, S (reprint author), Columbia Univ, Med Ctr, PH 3-342,622 W 168th St, New York, NY 10032 USA.
RI Ponikowski, Piotr/O-6454-2015; 
OI Ponikowski, Piotr/0000-0002-3391-7064; Mann, Douglas
   /0000-0002-2516-0145; Kohsaka, Shun/0000-0003-3779-2972
FU National Institute of Neurological Disorders and Stroke [U01-NS-043975,
   U01-NS-039143]; St. Jude Medical; Boehringer Ingelheim; United
   Healthcare; Amgen; Cytokinetics; Novartis; NovaCardia/Merck; American
   College of Cardiology; Bosch Healthcare; GlaxoSmithKline; Helsinn;
   LoneStar Heart; Professional Dietetics; PsiOxus; Relypsa; SHL
   Telemedicine; Thermo Fisher; Vifor Pharma; Bayer; Coridea; Corthera;
   Johnson Johnson; Pfizer; Respicardia; Abbott; Merck Serono;
   Sanofi-Aventis; Servier; Astellas; AstraZeneca; Biotronik; Bristol-Myers
   Squibb; Merck; Portola; National Institute of Neurological Disorders and
   Stroke; WARCEF [NCT00041938]
FX Funded by the National Institute of Neurological Disorders and Stroke;
   WARCEF ClinicalTrials.gov number, NCT00041938.; Supported by grants
   (U01-NS-043975 [to Dr. Homma] and U01-NS-039143 [to Dr. Thompson]) from
   the National Institute of Neurological Disorders and Stroke.; Dr. Homma
   reports receiving payment from AGA Medical (now St. Jude Medical) for
   his work as a member of a data and safety monitoring board and
   consulting fees from Boehringer Ingelheim; Dr. Levin, receiving
   consulting fees from United Healthcare; Dr. Teerlink, receiving
   consulting fees from Amgen and grant support from Amgen, Cytokinetics,
   and Novartis on behalf of himself and from NovaCardia/Merck on behalf of
   himself and his institution; Dr. Graham, owning stock in March
   Pharmaceuticals, Medtronic, and Pfizer; Dr. Labovitz, receiving grant
   support from Boehringer Ingelheim on behalf of his institution, lecture
   fees from Boehringer Ingelheim, and fees for the development of
   educational presentations from the American College of Cardiology; Dr.
   Anker, receiving consulting fees from Amgen, Bosch Healthcare,
   GlaxoSmithKline, Helsinn, LoneStar Heart, Novartis, Professional
   Dietetics, PsiOxus, Relypsa, SHL Telemedicine, and Thermo Fisher, grant
   support from Vifor Pharma, and lecture fees from Novartis, holding
   patents with Brahms AG and Charite Berlin, and receiving royalties from
   Imperial College; Dr. Ponikowski, receiving consulting fees from Bayer,
   Boehringer Ingelheim, Coridea, Corthera, Johnson & Johnson, Pfizer,
   Respicardia, and Vifor Pharma, grant support from Vifor Pharma on behalf
   of himself and his institution, and lecture fees from Abbott, Boehringer
   Ingelheim, Merck Serono, Pfizer, Respicardia, Sanofi-Aventis, Servier,
   and Vifor Pharma; and Dr. Lip, receiving consulting fees from Astellas,
   AstraZeneca, Bayer, Biotronik, Boehringer Inhelheim, Bristol-Myers
   Squibb, Pfizer, Merck, Portola, and Sanofi-Aventis, speakers bureau fees
   from Bayer, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and
   Sanofi-Aventis, and payment for the development of educational
   presentations from Bayer, Boehringer Ingelheim, and Merck. No other
   potential conflict of interest relevant to this article was reported.
NR 28
TC 171
Z9 175
U1 0
U2 28
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 17
PY 2012
VL 366
IS 20
BP 1859
EP 1869
DI 10.1056/NEJMoa1202299
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 942WU
UT WOS:000304083000005
PM 22551105
ER

PT J
AU Venna, N
   Coyle, CM
   Gonzalez, RG
   Hedley-Whyte, ET
AF Venna, Nagagopal
   Coyle, Christina M.
   Gonzalez, R. Gilberto
   Hedley-Whyte, E. Tessa
TI Case 15-2012: A 48-Year-Old Woman with Diplopia, Headaches, and
   Papilledema
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID EXTRAPARENCHYMAL NEUROCYSTICERCOSIS; ENDOSCOPIC MANAGEMENT;
   INTRAVENTRICULAR NEUROCYSTICERCOSIS; HYDROCEPHALUS SECONDARY;
   CEREBROSPINAL-FLUID; TAENIA-SOLIUM; CYSTICERCOSIS; DIAGNOSIS; ANTIGEN;
   UPDATE
C1 [Venna, Nagagopal] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Hedley-Whyte, E. Tessa] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Coyle, Christina M.] Jacobi Med Ctr, Div Infect Dis, Dept Med, New York, NY USA.
   [Coyle, Christina M.] Albert Einstein Coll Med, Dept Med, New York, NY USA.
   [Venna, Nagagopal] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
   [Hedley-Whyte, E. Tessa] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Venna, N (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 32
TC 1
Z9 1
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 17
PY 2012
VL 366
IS 20
BP 1924
EP 1934
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 942WU
UT WOS:000304083000012
PM 22591299
ER

PT J
AU Bayliss, G
   Roshan, B
   Ventrapragada, S
   Weinrauch, LA
   Gleason, RE
   D'Elia, JA
AF Bayliss, G.
   Roshan, B.
   Ventrapragada, S.
   Weinrauch, L. A.
   Gleason, R. E.
   D'Elia, J. A.
TI The impact of a prior history of cardiovascular events on outcomes in
   patients on renal replacement therapy
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Diabetes; Renal replacement therapy; Cardiovascular events
ID PATIENTS INITIATING HEMODIALYSIS; RISK-FACTORS; DIABETIC-PATIENTS;
   CARDIAC EVENTS; DISEASE
C1 [Bayliss, G.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Joslin Diabet Ctr,Renal Unit,Dept Med, Boston, MA 02215 USA.
   Brown Univ, Rhode Isl Hosp, Dept Med, Alpert Sch Med, Providence, RI 02903 USA.
RP Bayliss, G (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Joslin Diabet Ctr,Renal Unit,Dept Med, Boston, MA 02215 USA.
EM gbayliss@lifespan.org
OI Weinrauch, Larry/0000-0003-1357-9528
NR 9
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAY 17
PY 2012
VL 157
IS 1
BP 146
EP 148
DI 10.1016/j.ijcard.2012.03.026
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 931HK
UT WOS:000303206800047
PM 22464248
ER

PT J
AU Rodriguez, DA
   Zamorano, S
   Lisbona, F
   Rojas-Rivera, D
   Urra, H
   Cubillos-Ruiz, JR
   Armisen, R
   Henriquez, DR
   Cheng, EH
   Letek, M
   Vaisar, T
   Irrazabal, T
   Gonzalez-Billault, C
   Letai, A
   Pimentel-Muinos, FX
   Kroemer, G
   Hetz, C
AF Rodriguez, Diego A.
   Zamorano, Sebastian
   Lisbona, Fernanda
   Rojas-Rivera, Diego
   Urra, Hery
   Cubillos-Ruiz, Juan R.
   Armisen, Ricardo
   Henriquez, Daniel R.
   Cheng, Emily H.
   Letek, Michal
   Vaisar, Tomas
   Irrazabal, Thergiory
   Gonzalez-Billault, Christian
   Letai, Anthony
   Pimentel-Muinos, Felipe X.
   Kroemer, Guido
   Hetz, Claudio
TI BH3-only proteins are part of a regulatory network that control the
   sustained signalling of the unfolded protein response sensor IRE1 alpha
SO EMBO JOURNAL
LA English
DT Article
DE BH3-only proteins; BIM; ER stress; IRE1 alpha modulation; PUMA
ID ENDOPLASMIC-RETICULUM STRESS; PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION
   FACTOR XBP-1; DNA-DAMAGE RESPONSE; BCL-X-L; ER STRESS; MITOCHONDRIAL
   APOPTOSIS; MESSENGER-RNA; BAX INHIBITOR-1; ACTIVATION
AB Adaptation to endoplasmic reticulum (ER) stress depends on the activation of the unfolded protein response (UPR) stress sensor inositol-requiring enzyme 1 alpha (IRE1 alpha), which functions as an endoribonuclease that splices the mRNA of the transcription factor XBP-1 (X-box-binding protein-1). Through a global proteomic approach we identified the BCL-2 family member PUMA as a novel IRE1 alpha interactor. Immunoprecipitation experiments confirmed this interaction and further detected the association of IRE1 alpha with BIM, another BH3-only protein. BIM and PUMA double-knockout cells failed to maintain sustained XBP-1 mRNA splicing after prolonged ER stress, resulting in early inactivation. Mutation in the BH3 domain of BIM abrogated the physical interaction with IRE1 alpha, inhibiting its effects on XBP-1 mRNA splicing. Unexpectedly, this regulation required BCL-2 and was antagonized by BAD or the BH3 domain mimetic ABT-737. The modulation of IRE1 alpha RNAse activity by BH3-only proteins was recapitulated in a cell-free system suggesting a direct regulation. Moreover, BH3-only proteins controlled XBP-1 mRNA splicing in vivo and affected the ER stress-regulated secretion of antibodies by primary B cells. We conclude that a subset of BCL-2 family members participates in a new UPR-regulatory network, thus assuming apoptosis-unrelated functions. The EMBO Journal (2012) 31, 2322-2335. doi: 10.1038/emboj.2012.84; Published online 17 April 2012
C1 [Rodriguez, Diego A.; Zamorano, Sebastian; Lisbona, Fernanda; Rojas-Rivera, Diego; Urra, Hery; Armisen, Ricardo; Irrazabal, Thergiory; Hetz, Claudio] Univ Chile, Ctr Mol Studies Cell, Inst Biomed Sci, Santiago 70086, Chile.
   [Rodriguez, Diego A.; Zamorano, Sebastian; Lisbona, Fernanda; Rojas-Rivera, Diego; Urra, Hery; Irrazabal, Thergiory; Hetz, Claudio] Univ Chile, Fac Med, Biomed Neurosci Inst, Santiago 70086, Chile.
   [Cubillos-Ruiz, Juan R.; Hetz, Claudio] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Henriquez, Daniel R.; Gonzalez-Billault, Christian] Univ Chile, Inst Cell Dynam & Biotechnol, Dept Biol, Santiago 70086, Chile.
   [Cheng, Emily H.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Letek, Michal; Pimentel-Muinos, Felipe X.] Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc CSIC, E-37008 Salamanca, Spain.
   [Vaisar, Tomas] Univ Washington, Dept Med, Seattle, WA USA.
   [Letai, Anthony] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, Villejuif, France.
   [Kroemer, Guido] Ctr Rech Cordeliers, Paris, France.
   [Kroemer, Guido] Hop Europe Georges Pompidou, Paris, France.
   [Kroemer, Guido] Univ Paris 05, Paris, France.
   [Hetz, Claudio] Neurounion Biomed Fdn, Santiago, Chile.
RP Hetz, C (reprint author), Univ Chile, Ctr Mol Studies Cell, Inst Biomed Sci, Independencia 1027, Santiago 70086, Chile.
EM chetz@med.uchile.cl
RI Armisen, Ricardo/A-7409-2012; Kroemer, Guido/B-4263-2013; Letek,
   Michal/C-6345-2008; Hetz, Claudio/I-1900-2013; Pimentel-Muinos,
   Felipe/K-4557-2014; Rojas Rivera, Diego/N-1870-2016
OI Armisen, Ricardo/0000-0003-2567-0521; Letek, Michal/0000-0002-9509-5174;
   Hetz, Claudio/0000-0001-7724-1767; Pimentel-Muinos,
   Felipe/0000-0002-0258-2855; Rojas Rivera, Diego/0000-0002-8773-9830
FU FONDECYT [1100176, 3100033, 1095089]; FONDAP [15010006]; Millennium
   Institute [P09-015-F]; Muscular Dystrophy Association; Michael J Fox
   Foundation; Alzheimer's Association; ALS Therapy Allianze; North
   American Spine Society; Ligue nationale contre le cancer; Agence
   Nationale pour la Recherche; National Institute of Health [R01CA125562];
   American Caner Society [RSG-10-030-01-CCG]; Nutrition and Obesity
   Research Center; Ministerio de Ciencia e Innovacion [SAF2008-00350];
   CSIC [200720I026]; ICM [P05-001-F]; Ministerio de Ciencia e Innovacion
   (Spanish Government) [SAF2008-00350]; European Social Fund; CONICYT
FX We thank David Ron for providing IRE1 alpha<SUP>-/-</SUP> cells. We
   thank Dr Ann-Hwee Lee for providing and generating IRE1 alpha
   KO-reconstituted cells. We also thank the Mass spectrometry resource
   (Department of Medicine, University of Washington) and the Mass
   spectrometry core of Diabetes and Endocrinology Research Center
   (University of Washington). We thank Dr Andres Stutzin (CEMC, University
   of Chile) for giving feedback and access to all equipment's for calcium
   measurements. This work was supported by the FONDECYT no. 1100176,
   FONDAP grant no. 15010006, Millennium Institute no. P09-015-F, Muscular
   Dystrophy Association, Michael J Fox Foundation, Alzheimer's
   Association, ALS Therapy Allianze and North American Spine Society (to
   CH); FONDECYT no. 3100033 (to DRG); Ligue nationale contre le cancer,
   and Agence Nationale pour la Recherche (to GK), National Institute of
   Health no. R01CA125562 and American Caner Society no. RSG-10-030-01-CCG
   (to EC); P&F award from Nutrition and Obesity Research Center (to TV);
   Grant SAF2008-00350 from Ministerio de Ciencia e Innovacion, and Grant
   200720I026 from CSIC (to FPM), Fondecyt 1095089 and ICM P05-001-F (to
   CG). Grant SAF2008-00350 from Ministerio de Ciencia e Innovacion
   (Spanish Government). ML is the holder of a JAE-Doc postdoctoral
   fellowship (Spain) co-funded by the European Social Fund. DRR, HU and FL
   are funded by a CONICYT PhD fellowship.
NR 65
TC 45
Z9 45
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD MAY 16
PY 2012
VL 31
IS 10
BP 2322
EP 2335
DI 10.1038/emboj.2012.84
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 945AN
UT WOS:000304245300012
PM 22510886
ER

PT J
AU Lee, DH
   Goodarzi, AA
   Adelmant, GO
   Pan, YF
   Jeggo, PA
   Marto, JA
   Chowdhury, D
AF Lee, Dong-Hyun
   Goodarzi, Aaron A.
   Adelmant, Guillaume O.
   Pan, Yunfeng
   Jeggo, Penelope A.
   Marto, Jarrod A.
   Chowdhury, Dipanjan
TI Phosphoproteomic analysis reveals that PP4 dephosphorylates KAP-1
   impacting the DNA damage response
SO EMBO JOURNAL
LA English
DT Article
ID STRAND BREAK REPAIR; PROTEIN PHOSPHATASE 6; ZINC-FINGER PROTEINS;
   IONIZING-RADIATION; CATALYTIC SUBUNIT; CHECKPOINT KINASE;
   PHOSPHORYLATION; COMPLEX; GAMMA-H2AX; HETEROCHROMATIN
AB Protein phosphatase PP4C has been implicated in the DNA damage response (DDR), but its substrates in DDR remain largely unknown. We devised a novel proteomic strategy for systematic identification of proteins dephosphorylated by PP4C and identified KRAB-domain-associated protein 1 (KAP-1) as a substrate. Ionizing radiation leads to phosphorylation of KAP-1 at S824 (via ATM) and at S473 (via CHK2). A PP4C/R3 beta complex interacts with KAP-1 and silencing this complex leads to persistence of phospho-S824 and phospho-S473. We identify a new role for KAP-1 in DDR by showing that phosphorylation of S473 impacts the G2/M checkpoint. Depletion of PP4R3 beta or expression of the phosphomimetic KAP-1 S473 mutant (S473D) leads to a prolonged G2/M checkpoint. Phosphorylation of S824 is necessary for repair of heterochromatic DNA lesions and similar to cells expressing phosphomimetic KAP-1 S824 mutant (S824D), or PP4R3 beta-silenced cells, display prolonged relaxation of chromatin with release of chromatin remodelling protein CHD3. Our results define a new role for PP4-mediated dephosphorylation in the DDR, including the regulation of a previously undescribed function of KAP-1 in checkpoint response. The EMBO Journal (2012) 31, 2403-2415. doi: 10.1038/emboj.2012.86; Published online 10 April 2012
C1 [Lee, Dong-Hyun; Pan, Yunfeng; Chowdhury, Dipanjan] Harvard Univ, Dept Radiat Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
   [Goodarzi, Aaron A.; Jeggo, Penelope A.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RH, E Sussex, England.
   [Adelmant, Guillaume O.; Marto, Jarrod A.] Harvard Univ, Dept Canc Biol, Sch Med, Boston, MA 02115 USA.
   [Adelmant, Guillaume O.; Marto, Jarrod A.] Harvard Univ, Blais Prote Ctr, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol,Med Sch, Boston, MA 02115 USA.
RP Chowdhury, D (reprint author), Harvard Univ, Dept Radiat Oncol, Dana Farber Canc Inst, Sch Med, 450 Brookline Ave,JF517, Boston, MA 02115 USA.
EM dipanjan_chowdhury@dfci.harvard.edu
FU NCI [R01CA142698]; JCRT; ACS [RSG-12-079-01]; NIH [CA 009078-34];
   Association for International Cancer Research; Medical Research Council
FX DC is supported by R01CA142698 (NCI), JCRT and RSG-12-079-01 (ACS). D-HL
   was supported by NIH-training grant (CA 009078-34). AAG was supported by
   a grant from the Association for International Cancer Research to the
   PAJ laboratory. The PAJ laboratory is additionally supported by a grant
   from the Medical Research Council.
NR 54
TC 44
Z9 46
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD MAY 16
PY 2012
VL 31
IS 10
BP 2403
EP 2415
DI 10.1038/emboj.2012.86
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 945AN
UT WOS:000304245300018
PM 22491012
ER

PT J
AU Gandy, S
   DeKosky, ST
AF Gandy, Sam
   DeKosky, Steven T.
TI APOE epsilon 4 Status and Traumatic Brain Injury on the Gridiron or the
   Battlefield
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID ENCEPHALOPATHY; FOOTBALL
C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
   [Gandy, Sam] Ctr Cognit Hlth, New York, NY 10029 USA.
   [Gandy, Sam] NFL Neurol Program, New York, NY 10029 USA.
   [Gandy, Sam] Alzheimers Dis Res Ctr, New York, NY 10029 USA.
   [Gandy, Sam] Mt Sinai Sch Med, New York, NY 10029 USA.
   [Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10029 USA.
RP Gandy, S (reprint author), Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
EM samuel.gandy@mssm.edu; dekosky@virginia.edu
FU NIA NIH HHS [P50 AG005138]; RRD VA [I01 RX000684]
NR 5
TC 7
Z9 7
U1 0
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 16
PY 2012
VL 4
IS 134
AR 134ed4
DI 10.1126/scitranslmed.3004274
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 943KY
UT WOS:000304121500001
PM 22593171
ER

PT J
AU Goldstein, LE
   Fisher, AM
   Tagge, CA
   Zhang, XL
   Velisek, L
   Sullivan, JA
   Upreti, C
   Kracht, JM
   Ericsson, M
   Wojnarowicz, MW
   Goletiani, CJ
   Maglakelidze, GM
   Casey, N
   Moncaster, JA
   Minaeva, O
   Moir, RD
   Nowinski, CJ
   Stern, RA
   Cantu, RC
   Geiling, J
   Blusztajn, JK
   Wolozin, BL
   Ikezu, T
   Stein, TD
   Budson, AE
   Kowall, NW
   Chargin, D
   Sharon, A
   Saman, S
   Hall, GF
   Moss, WC
   Cleveland, RO
   Tanzi, RE
   Stanton, PK
   McKee, AC
AF Goldstein, Lee E.
   Fisher, Andrew M.
   Tagge, Chad A.
   Zhang, Xiao-Lei
   Velisek, Libor
   Sullivan, John A.
   Upreti, Chirag
   Kracht, Jonathan M.
   Ericsson, Maria
   Wojnarowicz, Mark W.
   Goletiani, Cezar J.
   Maglakelidze, Giorgi M.
   Casey, Noel
   Moncaster, Juliet A.
   Minaeva, Olga
   Moir, Robert D.
   Nowinski, Christopher J.
   Stern, Robert A.
   Cantu, Robert C.
   Geiling, James
   Blusztajn, Jan K.
   Wolozin, Benjamin L.
   Ikezu, Tsuneya
   Stein, Thor D.
   Budson, Andrew E.
   Kowall, Neil W.
   Chargin, David
   Sharon, Andre
   Saman, Sudad
   Hall, Garth F.
   Moss, William C.
   Cleveland, Robin O.
   Tanzi, Rudolph E.
   Stanton, Patric K.
   McKee, Ann C.
TI Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and
   a Blast Neurotrauma Mouse Model
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; LOCAL PROTEIN-SYNTHESIS; DIFFUSE AXONAL
   INJURY; BRAIN-INJURY; HEAD-INJURY; EXPLOSIVE BLAST; SHOCK-WAVE;
   RAT-BRAIN; IRAQ-WAR; FOOTBALL
AB Blast exposure is associated with traumatic brain injury (TBI), neuropsychiatric symptoms, and long-term cognitive disability. We examined a case series of postmortem brains from U. S. military veterans exposed to blast and/or concussive injury. We found evidence of chronic traumatic encephalopathy (CTE), a tau protein-linked neuro-degenerative disease, that was similar to the CTE neuropathology observed in young amateur American football players and a professional wrestler with histories of concussive injuries. We developed a blast neurotrauma mouse model that recapitulated CTE-linked neuropathology in wild-type C57BL/6 mice 2 weeks after exposure to a single blast. Blast-exposed mice demonstrated phosphorylated tauopathy, myelinated axonopathy, microvasculopathy, chronic neuroinflammation, and neurodegeneration in the absence of macroscopic tissue damage or hemorrhage. Blast exposure induced persistent hippocampal-dependent learning and memory deficits that persisted for at least 1 month and correlated with impaired axonal conduction and defective activity-dependent long-term potentiation of synaptic transmission. Intracerebral pressure recordings demonstrated that shock waves traversed the mouse brain with minimal change and without thoracic contributions. Kinematic analysis revealed blast-induced head oscillation at accelerations sufficient to cause brain injury. Head immobilization during blast exposure prevented blast-induced learning and memory deficits. The contribution of blast wind to injurious head acceleration may be a primary injury mechanism leading to blast-related TBI and CTE. These results identify common pathogenic determinants leading to CTE in blast-exposed military veterans and head-injured athletes and additionally provide mechanistic evidence linking blast exposure to persistent impairments in neurophysiological function, learning, and memory.
C1 [Goldstein, Lee E.; Fisher, Andrew M.; Tagge, Chad A.; Wojnarowicz, Mark W.; Casey, Noel; Moncaster, Juliet A.; Minaeva, Olga] Boston Univ, Sch Med, Mol Aging & Dev Lab, Boston, MA 02118 USA.
   [Goldstein, Lee E.; Stern, Robert A.; Blusztajn, Jan K.; Wolozin, Benjamin L.; Ikezu, Tsuneya; Stein, Thor D.; Budson, Andrew E.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02118 USA.
   [Goldstein, Lee E.; Casey, Noel; Moncaster, Juliet A.; Minaeva, Olga] Boston Univ, Photon Ctr, Boston, MA 02215 USA.
   [Goldstein, Lee E.; Fisher, Andrew M.; Tagge, Chad A.; Kracht, Jonathan M.; Minaeva, Olga; Sharon, Andre] Boston Univ, Coll Engn, Boston, MA 02215 USA.
   [Zhang, Xiao-Lei; Velisek, Libor; Sullivan, John A.; Upreti, Chirag; Goletiani, Cezar J.; Maglakelidze, Giorgi M.; Stanton, Patric K.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
   [Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscope Facil, Boston, MA 02115 USA.
   [Moir, Robert D.; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
   [Nowinski, Christopher J.; Stern, Robert A.; Cantu, Robert C.; McKee, Ann C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA.
   [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA.
   [Geiling, James] Vet Affairs Med Ctr, Dept Med, White River Jct, VT 05009 USA.
   [Stein, Thor D.; Budson, Andrew E.; Kowall, Neil W.; McKee, Ann C.] Vet Affairs Boston Healthcare Syst, Neurol Serv, Boston, MA 02130 USA.
   [Chargin, David; Sharon, Andre] Boston Univ, Fraunhofer Ctr Mfg Innovat, Brookline, MA 02446 USA.
   [Saman, Sudad; Hall, Garth F.] Univ Massachusetts, Dept Biol Sci, Lowell, MA 01854 USA.
   [Cleveland, Robin O.] Univ Oxford, Dept Engn Sci, Inst Biomed Engn, Oxford OX3 7DQ, England.
   [Moss, William C.] Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.
RP Goldstein, LE (reprint author), Boston Univ, Sch Med, Mol Aging & Dev Lab, Boston, MA 02118 USA.
EM lgold@bu.edu; amckee@bu.edu
RI Kowall, Neil/G-6364-2012; Cleveland, Robin/G-9468-2013; 
OI Kowall, Neil/0000-0002-6624-0213; Ikezu, Tsuneya/0000-0002-3979-8596;
   Stern, Robert/0000-0002-5008-077X; Stein, Thor/0000-0001-6954-4477;
   Moncaster, Juliet/0000-0002-7849-4325; Goldstein,
   Lee/0000-0001-8419-9800
FU National Institute of General Medical Sciences [GM75986]; National
   Center for Research Resources [S10RR026599]; NSF [0901760, 0821304];
   Cure Alzheimer's Fund; Office of the Dean, Boston University School of
   Medicine; Office of the Provost, Boston University; Boston University
   Photonics Center Neurophotonics; U.S. Army and Boston University
   Photonics Center [W911NG-06-2-0040]; Department of Veterans Affairs
   [W911NG-06-2-0040]; Translational Research Center for TBI and Stress
   Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic
   Brain Injury Center of Excellence [B6796-C]; National Institute of Aging
   Center [P30AG13846, 0572063345-5]; NIH/National Institute of Biomedical
   Imaging and Bioengineering [5T32EB006359]; NIH/National Institute of
   Neurological Disorders and Stroke [F31NS077796]; National Institute of
   Diabetes and Digestive and Kidney Diseases [P01DK043881]; National
   Institute of Neurological Diseases and Stroke [NS044421, NS072966,
   R01NS078337]; Department of Defense [W81XWH]; Migraine Research
   Foundation; March of Dimes Foundation [6FY08591]; National Operating
   Committee on Standards for Athletic Equipment; Department of Energy
   [DE-AC52-07NA27344]; agency of the U.S. government
FX Supported by National Institute of General Medical Sciences grant
   GM75986 (L.E.G.); National Center for Research Resources grant
   S10RR026599 (L.E.G.); NSF grants 0901760 and 0821304 (L.E.G.); Cure
   Alzheimer's Fund (L.E.G., R.D.M., and R.E.T.), Office of the Dean,
   Boston University School of Medicine; Office of the Provost, Boston
   University (L.E.G.); Boston University Photonics Center Neurophotonics
   Pilot Project Grant (L.E.G.); Cooperative Agreement W911NG-06-2-0040
   between the U.S. Army and Boston University Photonics Center (L.E.G.);
   Department of Veterans Affairs (A.C.M.); Translational Research Center
   for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and
   Development Traumatic Brain Injury Center of Excellence (B6796-C;
   A.C.M., L.E.G.); National Institute of Aging Center grant P30AG13846
   (N.W.K.), Supplement 0572063345-5 (N.W.K.), and Pilot Project Grant
   (N.C.); NIH/National Institute of Biomedical Imaging and Bioengineering
   T32 Training Grant Award 5T32EB006359 and NIH/National Institute of
   Neurological Disorders and Stroke Pre-Doctoral Fellowship Research grant
   F31NS077796 (C.A.T.); National Institute of Diabetes and Digestive and
   Kidney Diseases grant P01DK043881 (R.O. C.); National Institute of
   Neurological Diseases and Stroke grants NS044421 (P.K.S.), NS072966
   (L.V.), and R01NS078337 (R.A.S.); Department of Defense grant W81XWH
   (P.K.S.); Migraine Research Foundation (P.K.S.); March of Dimes
   Foundation grant 6FY08591 (L.V.); National Operating Committee on
   Standards for Athletic Equipment (A.C.M.); an unrestricted gift from the
   National Football League (A.C.M.); and Department of Energy Contract
   DE-AC52-07NA27344 to the Lawrence Livermore National Laboratory
   (W.C.M.).; F.H. is a Science Advisory Board member of Immunotrex
   Biologics Inc. The other authors declare that they have no competing
   interests. The views expressed in this article are those of authors
   J.G., A. E. B., N.W.K., and A.C.M. and should not to be construed as
   official positions of the Department of Veterans Affairs or the U.S.
   government. Portions of this document were prepared, in part, as an
   account of work by W.C.M. sponsored by an agency of the U.S. government.
   Neither the U.S. government nor Lawrence Livermore National Security,
   LLC, nor any of their employees makes any warranty, expressed or
   implied, or assumes any legal liability or responsibility for the
   accuracy, completeness, or usefulness of any information, apparatus,
   product, or process disclosed, or represents that its use would not
   infringe privately owned rights. Reference herein to any specific
   commercial product, process, or service by trade name, trademark,
   manufacturer, or otherwise does not necessarily constitute or imply its
   endorsement, recommendation, or favoring by the U.S. government or
   Lawrence Livermore National Security, LLC. The views and opinions of
   author W.C.M. expressed herein do not necessarily state or reflect those
   of the U.S. government or Lawrence Livermore National Security, LLC, and
   shall not be used for advertising or product endorsement purposes.
NR 87
TC 146
Z9 149
U1 11
U2 77
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 16
PY 2012
VL 4
IS 134
AR 134ra60
DI 10.1126/scitranslmed.3003716
PG 16
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 943KY
UT WOS:000304121500003
PM 22593173
ER

PT J
AU Hofmann, FT
   Szostak, JW
   Seebeck, FP
AF Hofmann, Frank T.
   Szostak, Jack W.
   Seebeck, Florian P.
TI In Vitro Selection of Functional Lantipeptides
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID DEHYDROALANINE-CONTAINING PEPTIDES; STAPHYLOCOCCUS-AUREUS SORTASE;
   LACTICIN-481 SYNTHETASE; SUBSTRATE-SPECIFICITY; RIBOSOMAL SYNTHESIS;
   LANTIBIOTIC NISIN; AMINO-ACIDS; CELL-WALL; PROTEIN; TRANSPEPTIDASE
AB In this report we present a method to identify functional artificial lantipeptides. In vitro translation coupled with an enzyme-free protocol for posttranslational modification allows preparation of more than 10(11) different lanthionine containing peptides. This diversity can be searched for functional molecules using mRNA-lantipeptide display. We validated this approach by isolating binders toward Sortase A, a transamidase which is required for virulence of Staphylococcus aureus. The interaction of selected lantipeptides with Sortase A is highly dependent on the presence of a (2S,6R)-lanthionine in the peptide and an active conformation of the protein.
C1 [Hofmann, Frank T.; Seebeck, Florian P.] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany.
   [Szostak, Jack W.] Massachusetts Gen Hosp, Simches Res Ctr, Howard Hughes Med Inst, Boston, MA 02114 USA.
   [Szostak, Jack W.] Massachusetts Gen Hosp, Simches Res Ctr, Dept Mol Biol, Boston, MA 02114 USA.
   [Szostak, Jack W.] Massachusetts Gen Hosp, Simches Res Ctr, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
   [Seebeck, Florian P.] Univ Basel, Dept Chem, CH-4056 Basel, Switzerland.
RP Seebeck, FP (reprint author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.
EM florian.seebeck@unibas.ch
FU International Max Planck Research School in Chemical Biology; Professur
   fur Molecular Bionic
FX We thank M. C. T. Hartman, B. Seelig for insightful advice, and S. Gentz
   for technical assistance. F.T.H. was partly supported by the
   International Max Planck Research School in Chemical Biology; J.W.S. is
   an Investigator of the Howard Hughes Medical Institute; F.P.S. is
   supported by the "Professur fur Molecular Bionic". F.T.H. and F.P.S.
   thank R. S. Goody for financial support.
NR 40
TC 30
Z9 30
U1 2
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 16
PY 2012
VL 134
IS 19
BP 8038
EP 8041
DI 10.1021/ja302082d
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 942FC
UT WOS:000304027100010
PM 22545861
ER

PT J
AU Kelley, KW
   McBane, S
   Thomas, T
   Karr, S
AF Kelley, Kristi W.
   McBane, Sarah
   Thomas, Tyan
   Karr, Samantha
TI Serving as a preceptor to pharmacy students: Tips on maintaining the
   desire to inspire
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
C1 [Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
   [Kelley, Kristi W.] Baptist Hlth Syst Inc, Continu Clin, Trinity Med Ctr, Birmingham, AL 35213 USA.
   [McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
   [Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA.
   [Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Karr, Samantha] Midwestern Univ, Coll Pharm Glendale, Glendale, AZ USA.
RP Kelley, KW (reprint author), Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
EM watsokm@auburn.edu
NR 3
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 15
PY 2012
VL 69
IS 10
BP 826
EP +
DI 10.2146/ajhp110292
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VC
UT WOS:000313770200005
PM 22555078
ER

PT J
AU Childs, L
   Alexander, E
   Duong, MT
AF Childs, Lindsey
   Alexander, Earnest
   Minh-Tri Duong
TI Risk evaluation and mitigation strategies: Assessment of a medical
   center's policies and procedures
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE Administration; Compliance; Computers; Education; Food and Drug
   Administration (US); Hospitals; Quality assurance; Risk management;
   Storage; Toxicity
AB Purpose. The results of a hospital's initiative to evaluate and improve compliance with federally mandated risk evaluation and mitigation strategies (REMS) are presented.
   Summary. Food and Drug Administration approved REMS plans are required for more than 145 drugs, but clear guidance on strategies for achieving REMS compliance is lacking. As a first step toward determining the extent of REMS compliance at a large medical center, a systematic assessment was conducted to ascertain existing policies and procedures for the use of drugs subject to REMS requirements applicable in the inpatient setting. About 123 drugs with such "inpatient-applicable" REMS requirements were identified; of those, 10 had been ordered by hospital providers during a specified 18-month time frame and were included in the assessment of policies and procedures. The assessment revealed that the hospital lacked a formal REMS policy and had no REMS-compliant procedures in place for 7 evaluated drugs (ambrisentan, buprenorphine naloxone, darbepoetin alfa, epoetin alfa, oxycodone controlled-release tablets, prasugrel, and pregabalin). Pursuant to the compliance assessment, new procedures to help ensure the safe use of those 7 drugs were developed, and REMS-focused educational programs, order-entry system enhancements, and drug storage modifications were implemented.
   Conclusion. Quality-improvement initiatives including staff education, incorporation of REMS requirements into existing policy, development of an electronic resource, and creation of a separate storage section for drugs subject to REMS were implemented at a large academic medical center to help ensure compliance with inpatient-applicable REMS requirements.
C1 [Childs, Lindsey] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Childs, Lindsey; Alexander, Earnest; Minh-Tri Duong] Tampa Gen Hosp, Serv Pharm, Tampa, FL 33606 USA.
   [Alexander, Earnest] Tampa Gen Hosp, Clin Pharm Serv, Tampa, FL 33606 USA.
   [Minh-Tri Duong] Tampa Gen Hosp, Residency Programs, Tampa, FL 33606 USA.
RP Childs, L (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter St, San Antonio, TX 78229 USA.
EM lmchilds000410@gmail.com
NR 6
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 15
PY 2012
VL 69
IS 10
BP 885
EP 889
DI 10.2146/ajhp110356
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VC
UT WOS:000313770200012
PM 22555085
ER

PT J
AU Schiros, CG
   Dell'Italia, LJ
   Gladden, JD
   Clark, D
   Aban, I
   Gupta, H
   Lloyd, SG
   McGiffin, DC
   Perry, G
   Denney, TS
   Ahmed, MI
AF Schiros, Chun G.
   Dell'Italia, Louis J.
   Gladden, James D.
   Clark, Donald, III
   Aban, Inmaculada
   Gupta, Himanshu
   Lloyd, Steven G.
   McGiffin, David C.
   Perry, Gilbert
   Denney, Thomas S., Jr.
   Ahmed, Mustafa I.
TI Magnetic Resonance Imaging With 3-Dimensional Analysis of Left
   Ventricular Remodeling in Isolated Mitral Regurgitation Implications
   Beyond Dimensions
SO CIRCULATION
LA English
DT Article
DE magnetic resonance imaging; surgery; ventricular dysfunction left;
   ventricular remodeling
ID VALVE-REPLACEMENT; PERFORMANCE; SURGERY; ECHOCARDIOGRAPHY;
   RECONSTRUCTION; DETERMINANTS; DYSFUNCTION; PREDICTION; GEOMETRY;
   SURVIVAL
AB Background-Although surgery is indicated in patients with mitral regurgitation (MR) when left ventricular (LV) end-systolic (LVES) dimension is >40 mm, LV ejection fraction may decrease after mitral valve surgery. We hypothesize that significant LV remodeling before surgery is not reflected by standard echocardiographic parameters measured at the base of the heart.
   Methods and Results-Ninety-four patients (age, 54 +/- 11 years; 38% female) with degenerative isolated MR underwent cine magnetic resonance imaging with tissue tagging and 3-dimensional analysis. In 51 control subjects (age, 44 +/- 14 years; 53% female), the relation between LVES volume (LVESV) and LVES dimension was quadratic, whereas in 94 MR patients, this relation was cubic, indicating a greater increase in LVESV per LVES dimension among MR patients. Moreover, magnetic resonance imaging LVESV from summated serial short-axis slices was significantly greater than LVESV assessed with the Bullet formula in MR patients, attributed to a more spherical remodeling distal to the tips of the papillary muscles (P<0.001). Thirty-five patients underwent mitral valve repair per current guideline recommendations. LV ejection fraction decreased from 61 +/- 7% to 54 +/- 8% (P<0.0001) and maximum shortening decreased significantly below normal at 1 year postoperatively (P<0.0001). Despite normalization of LV stroke volume and LV end-diastolic volume/mass ratio, there was a persistent significant increase in distal LVES 3-dimensional radius/wall thickness ratio and LVESV index after surgery.
   Conclusions-Despite apparently preserved LVES dimension, MR patients demonstrate significant spherical mid to apical LVES remodeling that contributes to higher LVESV than predicted by standard geometry-based calculations. Decreased LV strain after surgery suggests that a volumetric analysis of LV remodeling and function may be preferred to evaluate disease progression in isolated MR.
C1 [Schiros, Chun G.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA.
   [Dell'Italia, Louis J.; Gupta, Himanshu; Lloyd, Steven G.; Perry, Gilbert] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Dell'Italia, Louis J.; Gladden, James D.; Clark, Donald, III; Gupta, Himanshu; Lloyd, Steven G.; McGiffin, David C.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
   [Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
RP Ahmed, MI (reprint author), Univ Alabama Birmingham, Dept Med, UAB Ctr Heart Failure Res, Div Cardiol, 434 BMR2,901 19th St S, Birmingham, AL 35294 USA.
EM mahmed@uab.edu
FU National Institutes of Health Specialized Center of Clinically Oriented
   Research in Cardiac Dysfunction [P50-HL077100]
FX This work was supported by National Institutes of Health Specialized
   Center of Clinically Oriented Research in Cardiac Dysfunction
   P50-HL077100.
NR 36
TC 24
Z9 25
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 15
PY 2012
VL 125
IS 19
BP 2334
EP +
DI 10.1161/CIRCULATIONAHA.111.073239
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981YQ
UT WOS:000307009202013
PM 22496130
ER

PT J
AU Maurovich-Horvat, P
   Kriegel, M
   Schlett, CL
   Alkadhi, H
   Nakano, M
   Tanaka, A
   Maehara, A
   Tearney, G
   Virmani, R
   Hoffmann, U
AF Maurovich-Horvat, Pal
   Kriegel, Matthias
   Schlett, Christopher L.
   Alkadhi, Hatem
   Nakano, Masataka
   Tanaka, Atsushi
   Maehara, Akiko
   Tearney, Guillermo
   Virmani, Renu
   Hoffmann, Udo
TI Coronary atherosclerotic plaque characterization with multimodality
   imaging in ex vivo human hearts
SO CIRCULATION
LA English
DT Meeting Abstract
CT World Congress of Cardiology Scientific Sessions
CY APR 18-21, 2012
CL Dubai, U ARAB EMIRATES
SP World Heart Federat
C1 [Maurovich-Horvat, Pal] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary.
   [Maurovich-Horvat, Pal; Kriegel, Matthias; Schlett, Christopher L.; Alkadhi, Hatem; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   [Maurovich-Horvat, Pal; Kriegel, Matthias; Schlett, Christopher L.; Alkadhi, Hatem; Tanaka, Atsushi; Tearney, Guillermo; Hoffmann, Udo] Harvard Univ, Sch Med, Boston, MA USA.
   [Nakano, Masataka; Virmani, Renu] CV Path Inst Inc, Gaithersburg, MD USA.
   [Tanaka, Atsushi; Tearney, Guillermo] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Maehara, Akiko] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 15
PY 2012
VL 125
IS 19
MA A0102
BP E684
EP E684
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981YQ
UT WOS:000307009200094
ER

PT J
AU Esterberg, M
   Compton, M
AF Esterberg, Michelle
   Compton, Michael
TI Family history of psychosis negatively impacts age at onset, negative
   symptoms, and duration of untreated illness and psychosis in
   first-episode psychosis patients
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Age at onset; Duration of untreated psychosis (DUP); Family history;
   First-episode psychosis; Schizophrenia
ID SCHIZOPHRENIA SPECTRUM DISORDERS; GENDER-DIFFERENCES; SPORADIC
   SCHIZOPHRENIA; SEX-DIFFERENCES; EPISODE; RISK; PSYCHOPATHOLOGY;
   DETERMINANTS; TRANSMISSION; FAMILIALITY
AB Family history (FH) of psychosis has been a focus of investigations attempting to explain the heterogeneity in schizophrenia. Previous studies have demonstrated that FH is associated with earlier age at onset, severity of positive and negative symptoms, and the duration of untreated illness (DUI). The current study examined the impact of FH on the clinical presentation and help-seeking behaviors of a well-characterized, first-episode sample. The present study utilized the Symptom Onset in Schizophrenia (SOS) Inventory, the Positive and Negative Syndrome Scale (PANSS), and structured interviews on FH to examine these relationships in a large (n = 152) sample of predominantly African American patients. Results showed that patients with a first-degree FH of psychosis had a younger age at onset of both the prodrome and psychosis, but did not differ in duration of prodromal period. Furthermore, FH and sex interacted to influence severity of negative, but not positive symptoms. Finally, FH interacted with sex to influence both the DUI and DUP in that only males with FH had longer DUI and DUP. The findings have implications for understanding the impact of specific family-related mechanisms on both clinical and help-seeking factors, as well as for informing future family-based intervention efforts. Published by Elsevier Ireland Ltd.
C1 [Esterberg, Michelle] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Mental Hlth Serv, Seattle, WA 98108 USA.
   [Compton, Michael] George Washington Univ, Sch Med & Hlth Sci, Dept Psychiat & Behav Sci, Washington, DC 20037 USA.
RP Esterberg, M (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Mental Hlth Serv, Mail Stop S-116,1660 S Columbian Way, Seattle, WA 98108 USA.
EM michelle.esterberg@va.gov; mcompton@mfa.gwu.edu
FU National Institute of Mental Health [K23 MH067589, R01 MH081011]
FX This work was supported by grants K23 MH067589 and R01 MH081011 from the
   National Institute of Mental Health to the second author (MTC).
NR 61
TC 16
Z9 16
U1 3
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAY 15
PY 2012
VL 197
IS 1-2
BP 23
EP 28
DI 10.1016/j.psychres.2012.03.001
PG 6
WC Psychiatry
SC Psychiatry
GA 975WE
UT WOS:000306541400005
PM 22503358
ER

PT J
AU Huang, G
   Wang, D
   Khan, UI
   Zeb, I
   Manson, JE
   Miller, V
   Hodis, HN
   Budoff, MJ
   Merriam, GR
   Harman, MS
   Brinton, EA
   Cedars, MI
   Su, YL
   Lobo, RA
   Naftolin, F
   Santoro, N
   Taylor, HS
   Wildman, RP
AF Huang, Gary
   Wang, Dan
   Khan, Unab I.
   Zeb, Irfan
   Manson, Joann E.
   Miller, Virginia
   Hodis, Howard N.
   Budoff, Matthew J.
   Merriam, George R.
   Harman, Mitchell S.
   Brinton, Eliot A.
   Cedars, Marcelle I.
   Su, Yali
   Lobo, Rogerio A.
   Naftolin, Frederick
   Santoro, Nanette
   Taylor, Hugh S.
   Wildman, Rachel P.
TI Associations between retinol-binding protein 4 and cardiometabolic risk
   factors and subclinical atherosclerosis in recently postmenopausal
   women: cross-sectional analyses from the KEEPS study
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE Retinol-binding protein 4; Subclinical atherosclerosis; Risk factors;
   Women
ID CORONARY-ARTERY CALCIUM; INTIMA-MEDIA THICKNESS; INSULIN-RESISTANCE;
   CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; SERUM
   RETINOL-BINDING-PROTEIN-4; GLUCOSE-TOLERANCE; NONOBESE SUBJECTS;
   OBESITY; OVERWEIGHT
AB Background: The published literature regarding the relationships between retinol-binding protein 4 (RBP4) and cardiometabolic risk factors and subclinical atherosclerosis is conflicting, likely due, in part, to limitations of frequently used RBP4 assays. Prior large studies have not utilized the gold-standard western blot analysis of RBP4 levels.
   Methods: Full-length serum RBP4 levels were measured by western blot in 709 postmenopausal women screened for the Kronos Early Estrogen Prevention Study. Cross-sectional analyses related RBP4 levels to cardiometabolic risk factors, carotid artery intima-media thickness (CIMT), and coronary artery calcification (CAC).
   Results: The mean age of women was 52.9 (+/- 2.6) years, and the median RBP4 level was 49.0 (interquartile range 36.9-61.5) mu g/mL. Higher RBP4 levels were weakly associated with higher triglycerides (age, race, and smoking-adjusted partial Spearman correlation coefficient = 0.10; P = 0.01), but were unrelated to blood pressure, cholesterol, C-reactive protein, glucose, insulin, and CIMT levels (all partial Spearman correlation coefficients <= 0.06, P > 0.05). Results suggested a curvilinear association between RBP4 levels and CAC, with women in the bottom and upper quartiles of RBP4 having higher odds of CAC (odds ratio [95% confidence interval] 2.10 [1.07-4.09], 2.00 [1.02-3.92], 1.64 [0.82-3.27] for the 1st, 3rd, and 4th RBP4 quartiles vs. the 2nd quartile). However, a squared RBP4 term in regression modeling was non-significant (P = 0.10).
   Conclusions: In these healthy, recently postmenopausal women, higher RBP4 levels were weakly associated with elevations in triglycerides and with CAC, but not with other risk factors or CIMT. These data using the gold standard of RBP4 methodology only weakly support the possibility that perturbations in RBP4 homeostasis may be an additional risk factor for subclinical coronary atherosclerosis.
C1 [Huang, Gary; Wang, Dan; Wildman, Rachel P.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Wildman, Rachel P.] Albert Einstein Coll Med, Bronx, NY 10461 USA.
   [Khan, Unab I.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
   [Zeb, Irfan; Budoff, Matthew J.] Harbor UCLA, Los Angeles Biomed Res Inst, Div Cardiol, Torrance, CA USA.
   [Manson, Joann E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Miller, Virginia] Mayo Clin, Dept Surg, Rochester, MN USA.
   [Miller, Virginia] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA.
   [Hodis, Howard N.] Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA.
   [Merriam, George R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   [Harman, Mitchell S.] Kronos Longev Res Inst, Phoenix, AZ USA.
   [Brinton, Eliot A.] Univ Utah, Sch Med, Dept Cardiovasc Genet, Salt Lake City, UT USA.
   [Cedars, Marcelle I.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.
   [Su, Yali] SliverCreek Technol, Gilbert, AZ USA.
   [Lobo, Rogerio A.] Columbia Univ, Coll Med, Dept Obstet & Gynecol, New York, NY USA.
   [Naftolin, Frederick] NYU, Dept Obstet & Gynecol, Sch Med, New York, NY 10016 USA.
   [Santoro, Nanette] Univ Colorado Denver, Sch Med, Dept Obstet & Gynecol & Womens Hlth, Aurora, CO USA.
   [Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
RP Wildman, RP (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
EM Rachel.wildman@einstein.yu.edu
FU Aurora Foundation; National Institutes of Health (NIH) [HL90639, 1 UL1
   RR024150, Mayo CTSA 1 UL1 RR024150]; Mayo Foundation [CTSA UL1
   RR024139]; National Center for Research Resources (NCRR) [UL1 RR024131];
   NIH [HL094581]
FX KEEPS is funded by grants from the Aurora Foundation to the Kronos
   Longevity Research Institute, National Institutes of Health (NIH)
   HL90639 to VMM, 1 UL1 RR024150, Mayo CTSA 1 UL1 RR024150, the Mayo
   Foundation, CTSA UL1 RR024139 and UL1 RR024131 from the National Center
   for Research Resources (NCRR), a component of at NIH and NIH Roadmap for
   Medical Research. The manuscript's contents are solely the
   responsibility of the authors and do not necessarily represent the
   official view of NCRR or NIH. Information on NCRR is available at
   http://www.ncrr.nih.gov. Study medications were supplied in part by
   Bayer Health Care and by Abbott Pharmaceuticals. RBP4, insulin, and CRP
   assays were funded by NIH grant HL094581 to Dr. Wildman.
NR 40
TC 10
Z9 11
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD MAY 15
PY 2012
VL 11
AR 52
DI 10.1186/1475-2840-11-52
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA 973MA
UT WOS:000306363000001
PM 22587616
ER

PT J
AU Barkley, LR
   Palle, K
   Durando, M
   Day, TA
   Gurkar, A
   Kakusho, N
   Li, JY
   Masai, H
   Vaziri, C
AF Barkley, Laura R.
   Palle, Komaraiah
   Durando, Michael
   Day, Tovah A.
   Gurkar, Aditi
   Kakusho, Naoko
   Li, Jianying
   Masai, Hisao
   Vaziri, Cyrus
TI c-Jun N-terminal kinase-mediated Rad18 phosphorylation facilitates Pol
   eta recruitment to stalled replication forks
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID DNA-POLYMERASE-ETA; S-PHASE CHECKPOINT; STRAND BREAK REPAIR;
   XERODERMA-PIGMENTOSUM; SIGNAL-TRANSDUCTION; PROTEIN-A; PCNA
   MONOUBIQUITINATION; TRANSLESION SYNTHESIS; ULTRAVIOLET-LIGHT; DAMAGE
   BYPASS
AB The E3 ubiquitin ligase Rad18 chaperones DNA polymerase eta (Pol eta) to sites of UV-induced DNA damage and monoubiquitinates proliferating cell nuclear antigen (PCNA), facilitating engagement of Pol eta with stalled replication forks and promoting translesion synthesis (TLS). It is unclear how Rad18 activities are coordinated with other elements of the DNA damage response. We show here that Ser-409 residing in the Pol eta-binding motif of Rad18 is phosphorylated in a checkpoint kinase 1-dependent manner in genotoxin-treated cells. Recombinant Rad18 was phosphorylated specifically at S409 by c-Jun N-terminal kinase (JNK) in vitro. In UV-treated cells, Rad18 S409 phosphorylation was inhibited by a pharmacological JNK inhibitor. Conversely, ectopic expression of JNK and its upstream kinase mitogen-activated protein kinase kinase 4 led to DNA damage-independent Rad18 S409 phosphorylation. These results identify Rad18 as a novel JNK substrate. A Rad18 mutant harboring a Ser -> Ala substitution at S409 was compromised for Pol. association and did not redistribute Pol eta to nuclear foci or promote Pol eta-PCNA interaction efficiently relative to wild-type Rad18. Rad18 S409A also failed to fully complement the UV sensitivity of Rad18-depleted cells. Taken together, these results show that Rad18 phosphorylation by JNK represents a novel mechanism for promoting TLS and DNA damage tolerance.
C1 [Palle, Komaraiah; Durando, Michael; Vaziri, Cyrus] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Barkley, Laura R.] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Galway, Ireland.
   [Day, Tovah A.] Dana Farber Canc Inst, Boston, MA 02215 USA.
   [Gurkar, Aditi] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
   [Gurkar, Aditi] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Kakusho, Naoko; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Setagaya Ku, Tokyo 1568506, Japan.
   [Li, Jianying] Duke Univ, Ctr Human Genome Variat, Durham, NC 27708 USA.
RP Vaziri, C (reprint author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
EM cyrus_vaziri@med.unc.edu
FU National Institute of Environmental Health Sciences [ES09558, ES016280]
FX This work was supported by National Institute of Environmental Health
   Sciences Grants ES09558 and ES016280 to C. V. We thank Satoshi Tateishi
   and Jean Cook for numerous helpful discussions during the course of this
   work. We thank Bonnie Gunn for advice with statistical analysis.
NR 67
TC 9
Z9 9
U1 0
U2 1
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD MAY 15
PY 2012
VL 23
IS 10
BP 1943
EP 1954
DI 10.1091/mbc.E11-10-0829
PG 12
WC Cell Biology
SC Cell Biology
GA 971ZE
UT WOS:000306245500012
PM 22456510
ER

PT J
AU Alef, MJ
   Tzeng, E
   Zuckerbraun, BS
AF Alef, Matthew J.
   Tzeng, Edith
   Zuckerbraun, Brian S.
TI Nitric oxide and nitrite-based therapeutic opportunities in intimal
   hyperplasia
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Review
DE Xanthine oxidoreductase; Nitric oxide; Arginase; Nitrate; Vascular
   injury
ID SMOOTH-MUSCLE-CELLS; MEDIATED GENE-TRANSFER; PERIPHERAL
   ARTERIAL-DISEASE; CYCLIC GUANOSINE-MONOPHOSPHATE; INHIBITS NEOINTIMAL
   FORMATION; L-ARGININE SUPPLEMENTATION; VIVO ISCHEMIA-REPERFUSION;
   REVERSED VEIN GRAFTS; RAT CAROTID ARTERIES; IN-STENT RESTENOSIS
AB Vascular intimal hyperplasia (IH) limits the long term efficacy of current surgical and percutaneous therapies for atherosclerotic disease. There are extensive changes in gene expression and cell signaling in response to vascular therapies, including changes in nitric oxide (NO) signaling. NO is well recognized for its vasoregulatory properties and has been investigated as a therapeutic treatment for its vasoprotective abilities. The circulating molecules nitrite (NO2-) and nitrate (NO3-), once thought to be stable products of NO metabolism, are now recognized as important circulating reservoirs of NO and represent a complementary source of NO in contrast to the classic L-arginine-NO-synthase pathway. Here we review the background of IH, its relationship with the NO and nitrite/nitrate pathways, and current and future therapeutic opportunities for these molecules. Published by Elsevier Inc.
C1 [Alef, Matthew J.; Tzeng, Edith; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
   [Tzeng, Edith; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), F1200 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
FU BLRD VA [I01 BX000635]
NR 163
TC 9
Z9 9
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD MAY 15
PY 2012
VL 26
IS 4
SI SI
BP 285
EP 294
DI 10.1016/j.niox.2012.03.014
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 958UJ
UT WOS:000305265900013
PM 22504069
ER

PT J
AU Chuang, ML
   Gona, P
   Salton, CJ
   Yeon, SB
   Kissinger, KV
   Blease, SJ
   Levy, D
   O'Donnell, CJ
   Manning, WJ
AF Chuang, Michael L.
   Gona, Philimon
   Salton, Carol J.
   Yeon, Susan B.
   Kissinger, Kraig V.
   Blease, Susan J.
   Levy, Daniel
   O'Donnell, Christopher J.
   Manning, Warren J.
TI Usefulness of the Left Ventricular Myocardial Contraction Fraction in
   Healthy Men and Women to Predict Cardiovascular Morbidity and Mortality
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID PRESERVED EJECTION FRACTION; CORONARY-HEART-DISEASE; HYPERTENSION;
   GEOMETRY; FAILURE; MASS; PREVALENCE; MECHANICS; COHORT; RISK
AB We sought to determine whether depressed myocardial contraction fraction (MCF; ratio of left ventricular [LV] stroke volume to myocardial volume) predicts cardiovascular disease (CVD) events in initially healthy adults. A subset (n = 318, 60 9 years old, 158 men) of the Framingham Heart Study Offspring cohort free of clinical CVD underwent volumetric cardiovascular magnetic resonance imaging in 1998 through 1999. LV ejection fraction (EF), mass, and MCF were determined. "Hard" CVD events consisted of cardiovascular death, myocardial infarction, stroke, or new heart failure. A Cox proportional hazards model adjusting for Framingham Coronary Risk Score was used to estimate hazard ratios for incident hard CVD events for gender-specific quartiles of MCF, LV mass, and LVEF. The lowest quartile of LV mass and highest quartiles of MCF and EF served as referents. Kaplan-Meier survival plots and log-rank test were used to compare event-free survival. MCF was greater in women (0.58 +/- 0.13) than in men (0.52 +/- 0.11, p <0.01). Nearly all participants (99%) had EF >= 0.55. During an up to 9-year follow-up (median 5.2), 31 participants (10%) developed an incident hard CVD event. Lowest-quartile MCF was 7 times more likely to develop a hard CVD (hazard ratio 7.11, p = 0.010) compared to the remaining quartiles, and increased hazards persisted even after adjustment for LV mass (hazard ratio 6.09, p = 0.020). The highest-quartile LV mass/height 2.7 had a nearly fivefold risk (hazard ratio 4.68, p = 0.016). Event-free survival was shorter in lowest-quartile MCF (p = 0.0006) but not in lowest-quartile LVEF. In conclusion, in a cohort of adults initially without clinical CVD, lowest-quartile MCF conferred an increased hazard for hard CVD events after adjustment for traditional CVD risk factors and LV mass. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:1454-1458)
C1 [Chuang, Michael L.; Salton, Carol J.; Yeon, Susan B.; Kissinger, Kraig V.; Manning, Warren J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA.
   [Manning, Warren J.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
   [Chuang, Michael L.; Gona, Philimon; Blease, Susan J.; Levy, Daniel; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
   [Gona, Philimon] Boston Univ, Dept Math & Stat, Stat Consulting Unit, Boston, MA 02215 USA.
   [O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
   [O'Donnell, Christopher J.; Manning, Warren J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manning, WJ (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA.
EM wmanning@bidmc.harvard.edu
FU National Institutes of Health, Bethesda, Maryland [ROI AG17509,
   N01-HC-38038]
FX This work was supported in part by Grant ROI AG17509 and Subcontract
   N01-HC-38038 from the National Institutes of Health, Bethesda, Maryland.
NR 17
TC 5
Z9 5
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAY 15
PY 2012
VL 109
IS 10
BP 1454
EP 1458
DI 10.1016/j.amjcard.2012.01.357
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 948KO
UT WOS:000304502300011
PM 22381161
ER

PT J
AU VanderWeele, TJ
   Asomaning, K
   Tchetgen, EJT
   Han, YH
   Spitz, MR
   Shete, S
   Wu, XF
   Gaborieau, V
   Wang, Y
   McLaughlin, J
   Hung, RJ
   Brennan, P
   Amos, CI
   Christiani, DC
   Lin, XH
AF VanderWeele, Tyler J.
   Asomaning, Kofi
   Tchetgen, Eric J. Tchetgen
   Han, Younghun
   Spitz, Margaret R.
   Shete, Sanjay
   Wu, Xifeng
   Gaborieau, Valerie
   Wang, Ying
   McLaughlin, John
   Hung, Rayjean J.
   Brennan, Paul
   Amos, Christopher I.
   Christiani, David C.
   Lin, Xihong
TI Genetic Variants on 15q25.1, Smoking, and Lung Cancer: An Assessment of
   Mediation and Interaction
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE gene-environment interaction; lung neoplasms; mediation; pathway
   analysis; smoking
ID GENOME-WIDE ASSOCIATION; NICOTINE DEPENDENCE; SUSCEPTIBILITY LOCUS;
   LOGISTIC-REGRESSION; MULTIPLE ROLES; HEAVY SMOKING; RISK; PROLIFERATION;
   INHIBITION; CIGARETTES
AB Genome-wide association studies have identified variants on chromosome 15q25.1 that increase the risks of both lung cancer and nicotine dependence and associated smoking behavior. However, there remains debate as to whether the association with lung cancer is direct or is mediated by pathways related to smoking behavior. Here, the authors apply a novel method for mediation analysis, allowing for gene-environment interaction, to a lung cancer case-control study (1992-2004) conducted at Massachusetts General Hospital using 2 single nucleotide polymorphisms, rs8034191 and rs1051730, on 15q25.1. The results are validated using data from 3 other lung cancer studies. Tests for additive interaction (P = 2 x 10(-10) and P = 1 x 10(-9)) and multiplicative interaction (P = 0.01 and P = 0.01) were significant. Pooled analyses yielded a direct-effect odds ratio of 1.26 (95% confidence interval (CI): 1.19, 1.33; P = 2 x 10(-15)) for rs8034191 and an indirect-effect odds ratio of 1.01 (95% CI: 1.00, 1.01; P = 0.09); the proportion of increased risk mediated by smoking was 3.2%. For rs1051730, direct- and indirect-effect odds ratios were 1.26 (95% CI: 1.19, 1.33; P = 1 x 10(-15)) and 1.00 (95% CI: 0.99, 1.01; P = 0.22), respectively, with a proportion mediated of 2.3%. Adjustment for measurement error in smoking behavior allowing up to 75% measurement error increased the proportions mediated to 12.5% and 9.2%, respectively. These analyses indicate that the association of the variants with lung cancer operates primarily through other pathways.
C1 [VanderWeele, Tyler J.; Tchetgen, Eric J. Tchetgen; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [VanderWeele, Tyler J.; Tchetgen, Eric J. Tchetgen; Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Asomaning, Kofi; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Han, Younghun; Spitz, Margaret R.; Shete, Sanjay; Wu, Xifeng; Amos, Christopher I.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Gaborieau, Valerie; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France.
   [Wang, Ying; Hung, Rayjean J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   [McLaughlin, John] Canc Care Ontario, Toronto, ON, Canada.
   [Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP VanderWeele, TJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
EM tvanderw@hsph.harvard.edu
RI Hung, Rayjean/A-7439-2013; McLaughlin, John/E-4577-2013
FU US National Institutes of Health [ES017876, HD060696, CA076404,
   CA134294, CA074386, CA092824, P50CA70907-05, CA121197, CPRIT RP10043,
   U19 CA148127, R01CA133996]; Canadian Cancer Society Research Institute
   [020214]
FX The authors acknowledge funding from the US National Institutes of
   Health (grants ES017876, HD060696, CA076404, CA134294, CA074386,
   CA092824, P50CA70907-05, CA121197, CPRIT RP10043, U19 CA148127, and
   R01CA133996) and the Canadian Cancer Society Research Institute (grant
   020214).
NR 35
TC 59
Z9 61
U1 13
U2 24
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2012
VL 175
IS 10
BP 1013
EP 1020
DI 10.1093/aje/kwr467
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 944KC
UT WOS:000304199000006
PM 22306564
ER

PT J
AU Mai, XM
   Chen, Y
   Camargo, CA
   Langhammer, A
AF Mai, Xiao-Mei
   Chen, Yue
   Camargo, Carlos A., Jr.
   Langhammer, Arnulf
TI Cross-Sectional and Prospective Cohort Study of Serum 25-Hydroxyvitamin
   D Level and Obesity in Adults
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE body mass index; cross-sectional studies; 25-hydroxyvitamin D; obesity;
   prospective studies; vitamin D; waist circumference
ID VITAMIN-D STATUS; BODY-MASS INDEX; D DEFICIENCY; SECONDARY
   HYPERPARATHYROIDISM; INSULIN-SENSITIVITY; AFRICAN-AMERICANS; ABDOMINAL
   OBESITY; D SUPPLEMENTATION; ALL-CAUSE; WOMEN
AB Experimental studies suggest that vitamin D modulates the activity of adipocytes. The authors examined baseline serum 25-hydroxyvitamin D (25(OH)D) level in relation to prevalent and cumulative incident obesity in Norway. A cohort of 25,616 adults aged 19-55 years participated in both the second and third surveys of the Nord-Tr circle divide ndelag Health Study (HUNT 2 (1995-1997) and HUNT 3 (2006-2008)). Serum 25(OH)D levels measured at baseline and anthropometric measurements taken at both baseline and follow-up were available for a random sample of 2,460 subjects. Overall, 40% of the 2,460 subjects had a serum 25(OH)D level less than 50.0 nmol/L, and 37% had a level of 50.0-74.9 nmol/L. The prevalence and cumulative incidence of obesity, defined as body mass index (weight (kg)/height (m)(2)) >= 30, were 12% and 15%, respectively. Lower serum 25(OH)D level was associated with a higher prevalence of obesity. In the 2,165 subjects with baseline BMI less than 30, a serum 25(OH)D level less than 50.0 nmol/L was associated with a significantly increased odds ratio for incident obesity during follow-up (adjusted odds ratio = 1.73, 95% confidence interval: 1.24, 2.41). When prevalent and incident obesity were classified according to waist circumference (>= 88 cm for women, >= 102 cm for men), similar results were obtained. In addition to prevalent obesity, a serum 25(OH)D level less than 50.0 nmol/L was significantly associated with new-onset obesity in adults.
C1 [Mai, Xiao-Mei; Langhammer, Arnulf] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, Fac Med, N-7491 Trondheim, Norway.
   [Chen, Yue] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
   [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Mai, XM (reprint author), Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, Fac Med, N-7491 Trondheim, Norway.
EM xiao-mei.mai@ntnu.no
FU Research Council of Norway [201895/V50]
FX This study was supported by the Research Council of Norway (project
   201895/V50).
NR 39
TC 50
Z9 52
U1 0
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2012
VL 175
IS 10
BP 1029
EP 1036
DI 10.1093/aje/kwr456
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 944KC
UT WOS:000304199000008
PM 22312120
ER

PT J
AU Geng, EH
   Glidden, DV
   Bangsberg, DR
   Bwana, MB
   Musinguzi, N
   Nash, D
   Metcalfe, JZ
   Yiannoutsos, CT
   Martin, JN
   Petersen, ML
AF Geng, Elvin H.
   Glidden, David V.
   Bangsberg, David R.
   Bwana, Mwebesa Bosco
   Musinguzi, Nicholas
   Nash, Denis
   Metcalfe, John Z.
   Yiannoutsos, Constantin T.
   Martin, Jeffrey N.
   Petersen, Maya L.
TI A Causal Framework for Understanding the Effect of Losses to Follow-up
   on Epidemiologic Analyses in Clinic-based Cohorts: The Case of
   HIV-infected Patients on Antiretroviral Therapy in Africa
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Africa; antiretroviral therapy; clinic-based cohorts; directed acyclic
   graphs; informative censoring; inverse probability of censoring weights;
   loss to follow-up; missing at random
ID SUB-SAHARAN AFRICA; MARGINAL STRUCTURAL MODELS; SAMPLING-BASED APPROACH;
   CD4 CELL COUNT; SOUTH-AFRICA; PATIENTS LOST; SCALE-UP; INVERSE
   PROBABILITY; TREATMENT SERVICE; EARLY MORTALITY
AB Although clinic-based cohorts are most representative of the "real world," they are susceptible to loss to follow-up. Strategies for managing the impact of loss to follow-up are therefore needed to maximize the value of studies conducted in these cohorts. The authors evaluated adult patients starting antiretroviral therapy at an HIV/AIDS clinic in Uganda, where 29% of patients were lost to follow-up after 2 years (January 1, 2004-September 30, 2007). Unweighted, inverse probability of censoring weighted (IPCW), and sampling-based approaches (using supplemental data from a sample of lost patients subsequently tracked in the community) were used to identify the predictive value of sex on mortality. Directed acyclic graphs (DAGs) were used to explore the structural basis for bias in each approach. Among 3,628 patients, unweighted and IPCW analyses found men to have higher mortality than women, whereas the sampling-based approach did not. DAGs encoding knowledge about the data-generating process, including the fact that death is a cause of being classified as lost to follow-up in this setting, revealed "collider" bias in the unweighted and IPCW approaches. In a clinic-based cohort in Africa, unweighted and IPCW approaches-which rely on the "missing at random" assumption-yielded biased estimates. A sampling-based approach can in general strengthen epidemiologic analyses conducted in many clinic-based cohorts, including those examining other diseases.
C1 [Geng, Elvin H.; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Sch Med,Div HIV AIDS & Infect Dis, San Francisco, CA 94110 USA.
   [Glidden, David V.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94110 USA.
   [Metcalfe, John Z.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, Dept Med,Sch Med, San Francisco, CA 94110 USA.
   [Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
   [Bangsberg, David R.; Bwana, Mwebesa Bosco; Musinguzi, Nicholas] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Nash, Denis] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, New York, NY USA.
   [Yiannoutsos, Constantin T.] Indiana Univ, Sch Med, Dept Med, Div Biostat, Indianapolis, IN USA.
   [Petersen, Maya L.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol & Biostat, Berkeley, CA 94720 USA.
   [Geng, Elvin H.; Glidden, David V.; Bangsberg, David R.; Bwana, Mwebesa Bosco; Musinguzi, Nicholas; Nash, Denis; Metcalfe, John Z.; Yiannoutsos, Constantin T.; Martin, Jeffrey N.; Petersen, Maya L.] E Africa Int Epidemiol Databases Evaluate AIDS Ie, Indianapolis, IN USA.
RP Geng, EH (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Sch Med,Div HIV AIDS & Infect Dis, 995 Potrero Ave,Bldg 80,Box 0874, San Francisco, CA 94110 USA.
EM genge@php.ucsf.edu
FU US National Institutes of Health [K23 AI084544, U01 AI069911, P30
   AI027763]; US President's Emergency Plan for AIDS Relief
FX This research was funded by the US National Institutes of Health (grants
   K23 AI084544, U01 AI069911, and P30 AI027763) and the US President's
   Emergency Plan for AIDS Relief.
NR 51
TC 18
Z9 18
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2012
VL 175
IS 10
BP 1080
EP 1087
DI 10.1093/aje/kwr444
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 944KC
UT WOS:000304199000014
PM 22306557
ER

PT J
AU Ignatius, MS
   Chen, E
   Elpek, NM
   Fuller, AZ
   Tenente, IM
   Clagg, R
   Liu, SL
   Blackburn, JS
   Linardic, CM
   Rosenberg, AE
   Nielsen, PG
   Mempel, TR
   Langenau, DM
AF Ignatius, Myron S.
   Chen, Eleanor
   Elpek, Natalie M.
   Fuller, Adam Z.
   Tenente, Ines M.
   Clagg, Ryan
   Liu, Sali
   Blackburn, Jessica S.
   Linardic, Corinne M.
   Rosenberg, Andrew E.
   Nielsen, Petur G.
   Mempel, Thorsten R.
   Langenau, David M.
TI In Vivo Imaging of Tumor-Propagating Cells, Regional Tumor
   Heterogeneity, and Dynamic Cell Movements in Embryonal Rhabdomyosarcoma
SO CANCER CELL
LA English
DT Article
ID SKELETAL-MUSCLE; STEM-CELLS; TRANSGENIC ZEBRAFISH; ACTIVATION;
   EXPRESSION; MYF5; REGENERATION; PROMOTER; MODELS; GROWTH
AB Embryonal rhabdomyosarcoma (ERMS) is an aggressive pediatric sarcoma of muscle. Here, we show that ERMS-propagating potential is confined to myf5+ cells and can be visualized in live, fluorescent transgenic zebrafish. During early tumor growth, myf5+ ERMS cells reside adjacent normal muscle fibers. By late-stage ERMS, myf5+ cells are reorganized into distinct regions separated from differentiated tumor cells. Time-lapse imaging of late-stage ERMS revealed that myf5+ cells populate newly formed tumor only after seeding by highly migratory myogenin+ ERMS cells. Moreover, myogenin+ ERMS cells can enter the vasculature, whereas myf5+ ERMS-propagating cells do not. Our data suggest that non-tumor-propagating cells likely have important supportive roles in cancer progression and facilitate metastasis.
C1 [Ignatius, Myron S.; Chen, Eleanor; Fuller, Adam Z.; Tenente, Ines M.; Clagg, Ryan; Liu, Sali; Blackburn, Jessica S.; Rosenberg, Andrew E.; Nielsen, Petur G.; Langenau, David M.] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA.
   [Ignatius, Myron S.; Chen, Eleanor; Fuller, Adam Z.; Tenente, Ines M.; Clagg, Ryan; Liu, Sali; Blackburn, Jessica S.; Rosenberg, Andrew E.; Nielsen, Petur G.; Langenau, David M.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
   [Elpek, Natalie M.; Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA.
   [Ignatius, Myron S.; Chen, Eleanor; Fuller, Adam Z.; Tenente, Ines M.; Clagg, Ryan; Liu, Sali; Blackburn, Jessica S.; Langenau, David M.] Harvard Stem Cell Inst, Boston, MA 02114 USA.
   [Chen, Eleanor] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Tenente, Ines M.] Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal.
   [Linardic, Corinne M.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
   [Linardic, Corinne M.] Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA.
   [Linardic, Corinne M.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA.
RP Langenau, DM (reprint author), Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA.
EM dlangenau@partners.org
FU National Institutes of Health (NIH) [T32 HL007627, 5T32CA09216-26, K01
   AR055619, 1RO1CA154923, 1R21CA156056]; Alex's Lemonade Stand Foundation;
   Sarcoma Foundation of America; American Cancer Society; Harvard Stern
   Cell Institute; Fundacao para a Ciencia e Tecnologia (Portuguese
   Foundation for Science and Technology) [SFRH/BD/51288/2010];  [R01
   CA122706];  [K12 HD043494]
FX E.C. and J.S.B. are supported by the National Institutes of Health (NIH)
   Training Grants T32 HL007627 and 5T32CA09216-26, respectively. C.M.L. is
   supported by R01 CA122706 and K12 HD043494. D.M.L. is supported by NIH
   Grants K01 AR055619, 1RO1CA154923, and 1R21CA156056; the Alex's Lemonade
   Stand Foundation; the Sarcoma Foundation of America; the American Cancer
   Society; and the Harvard Stern Cell Institute. I.M.T. is supported by
   Fundacao para a Ciencia e Tecnologia (the Portuguese Foundation for
   Science and Technology) through Fellowship SFRH/BD/51288/2010. We thank
   Huai-Jen Tsai for myf5-GFP transgenic animals and Clarrisa Henry for
   critical review of our manuscript.
NR 32
TC 49
Z9 49
U1 2
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD MAY 15
PY 2012
VL 21
IS 5
BP 680
EP 693
DI 10.1016/j.ccr.2012.03.043
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 944OQ
UT WOS:000304214100011
PM 22624717
ER

PT J
AU Matthay, KK
   George, RE
   Yu, AL
AF Matthay, Katherine K.
   George, Rani E.
   Yu, Alice L.
TI Promising Therapeutic Targets in Neuroblastoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PHASE-I TRIAL; COLONY-STIMULATING FACTOR; HIGH-DOSE
   I-131-METAIODOBENZYLGUANIDINE; ANTIGANGLIOSIDE GD2 ANTIBODY;
   BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CHILDRENS
   ONCOLOGY GROUP; HIGH-RISK NEUROBLASTOMA; STAGE 4 NEUROBLASTOMA; INRG
   TASK-FORCE
AB Neuroblastoma, the most common extracranial solid tumor in children, is derived from neural crest cells. Nearly half of patients present with metastatic disease and have a 5-year event-free survival of <50%. New approaches with targeted therapy may improve efficacy without increased toxicity. In this review we evaluate 3 promising targeted therapies: (i) I-131-metaiodobenzylguanidine (MIBG), a radiopharmaceutical that is taken up by human norepinephrine transporter (hNET), which is expressed in 90% of neuroblastomas; (ii) immunotherapy with monoclonal antibodies targeting the GD2 ganglioside, which is expressed on 98% of neuroblastoma cells; and (iii) inhibitors of anaplastic lymphoma kinase (ALK), a tyrosine kinase that is mutated or amplified in similar to 10% of neuroblastomas and expressed on the surface of most neuroblastoma cells. Early-phase trials have confirmed the activity of I-131-MIBG in relapsed neuroblastoma, with response rates of similar to 30%, but the technical aspects of administering large amounts of radioactivity in young children and limited access to this agent have hindered its incorporation into treatment of newly diagnosed patients. Anti-GD2 antibodies have also shown activity in relapsed disease, and a recent phase III randomized trial showed a significant improvement in event-free survival for patients receiving chimeric anti-GD2 (ch14.18) combined with cytokines and isotretinoin after myeloablative consolidation therapy. A recently approved small-molecule inhibitor of ALK has shown promising preclinical activity for neuroblastoma and is currently in phase I and II trials. This is the first agent directed to a specific mutation in neuroblastoma, and marks a new step toward personalized therapy for neuroblastoma. Further clinical development of targeted treatments offers new hope for children with neuroblastoma. Clin Cancer Res; 18(10); 2740-53. (C)2012 AACR.
C1 [Matthay, Katherine K.] Univ Calif San Francisco, UCSF Benioff Childrens Hosp, UCSF Helen Diller Family Comprehens Canc Ctr, Dept Pediat, San Francisco, CA 94143 USA.
   [Matthay, Katherine K.] Univ Calif San Francisco, UCSF Benioff Childrens Hosp, UCSF Med Ctr, San Francisco, CA 94143 USA.
   [Yu, Alice L.] Univ Calif San Francisco, Moores Canc Ctr, San Francisco, CA 94143 USA.
   [George, Rani E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA.
   [George, Rani E.] Harvard Univ, Childrens Hosp Boston, Sch Med, Boston, MA USA.
RP Matthay, KK (reprint author), UCSF Sch Med, 505 Parnassus Ave,M647, San Francisco, CA USA.
EM matthayk@peds.ucsf.edu
FU Edwin Conner Fund; Alex's Lemonade Stand Foundation; Frank A. Campini
   Foundation; Dougherty Foundation; National Institutes of Health [PO1
   CA81403, R01 CA148688]; Sidney Kimmel Translational Scholar Award
FX Edwin Conner Fund, Alex's Lemonade Stand Foundation, Frank A. Campini
   Foundation, Dougherty Foundation, National Institutes of Health (PO1
   CA81403 and R01 CA148688), and Sidney Kimmel Translational Scholar
   Award.
NR 97
TC 68
Z9 71
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2012
VL 18
IS 10
BP 2740
EP 2753
DI 10.1158/1078-0432.CCR-11-1939
PG 14
WC Oncology
SC Oncology
GA 945CG
UT WOS:000304249800005
PM 22589483
ER

PT J
AU Banks, WA
AF Banks, William A.
TI Drug delivery to the brain in Alzheimer's disease: Consideration of the
   blood-brain barrier
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Blood-brain barrier; Alzheimer's disease; Drug delivery; Cerebrospinal
   fluid; Biologicals; Peptides; Regulatory proteins; Transport;
   Transmembrane diffusion; P-glycoprotein
ID AMYLOID-BETA-PEPTIDE; CENTRAL-NERVOUS-SYSTEM; AGED SAMP8 MICE;
   NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MICROVASCULAR ENDOTHELIAL-CELLS;
   ACTIVATING POLYPEPTIDE PACAP; SENESCENCE-ACCELERATED MICE;
   P-GLYCOPROTEIN EXPRESSION; GLUCAGON-LIKE PEPTIDES; NECROSIS-FACTOR-ALPHA
AB The successful treatment of Alzheimer's disease (AD) will require drugs that can negotiate the blood brain barrier (BBB). However, the BBB is not simply a physical barrier, but a complex interface that is in intimate communication with the rest of the central nervous system (CNS) and influenced by peripheral tissues. This review examines three aspects of the BBB in AD. First, it considers how the BBB may be contributing to the onset and progression of AD. In this regard, the BBB itself is a therapeutic target in the treatment of AD. Second, it examines how the BBB restricts drugs that might otherwise be useful in the treatment of AD and examines strategies being developed to deliver drugs to the CNS for the treatment of AD. Third, it considers how drug penetration across the AD BBB may differ from the BBB of normal aging. In this case, those differences can complicate the treatment of CNS diseases such as depression, delirium, psychoses, and pain control in the AD population. Published by Elsevier B.V.
C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Banks, WA (reprint author), Bldg 1,Rm 810A,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU VA Merit Review;  [RO1 AG029839]
FX This works was supported by VA Merit Review and RO1 AG029839.
NR 195
TC 38
Z9 39
U1 9
U2 69
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAY 15
PY 2012
VL 64
IS 7
BP 629
EP 639
DI 10.1016/j.addr.2011.12.005
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 943OA
UT WOS:000304132500006
PM 22202501
ER

PT J
AU Qin, B
   Zhou, M
   Ge, Y
   Taing, L
   Liu, T
   Wang, Q
   Wang, S
   Chen, JS
   Shen, LL
   Duan, XK
   Hu, SE
   Li, W
   Long, H
   Zhang, Y
   Liu, XS
AF Qin, Bo
   Zhou, Meng
   Ge, Ying
   Taing, Len
   Liu, Tao
   Wang, Qian
   Wang, Su
   Chen, Junsheng
   Shen, Lingling
   Duan, Xikun
   Hu, Sheng'en
   Li, Wei
   Long, Henry
   Zhang, Yong
   Liu, X. Shirley
TI CistromeMap: a knowledgebase and web server for ChIP-Seq and DNase-Seq
   studies in mouse and human
SO BIOINFORMATICS
LA English
DT Article
AB Transcription and chromatin regulators, and histone modifications play essential roles in gene expression regulation. We have created CistromeMap as a web server to provide a comprehensive knowledgebase of all of the publicly available ChIPSeq and DNase-Seq data in mouse and human. We have also manually curated metadata to ensure annotation consistency, and developed a user-friendly display matrix for quick navigation and retrieval of data for specific factors, cells and papers. Finally, we provide users with summary statistics of ChIP-Seq and DNase-Seq studies.
C1 [Qin, Bo; Ge, Ying; Wang, Qian; Wang, Su; Chen, Junsheng; Duan, Xikun; Hu, Sheng'en; Zhang, Yong] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
   [Zhou, Meng] Univ So Calif, Dana & David Dornsife Coll Letters, Dept Biol Sci, Los Angeles, CA 90089 USA.
   [Taing, Len; Liu, Tao; Long, Henry; Liu, X. Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
   [Taing, Len; Liu, Tao; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Taing, Len; Liu, Tao; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Shen, Lingling] China Novartis Inst BioMed Res Co Ltd, Dept Informat Technol, Shanghai 201203, Peoples R China.
   [Li, Wei] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Houston, TX 77030 USA.
   [Li, Wei] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
RP Zhang, Y (reprint author), Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
EM yzhang@tongji.edu.cn; xsliu@jimmy.harvard.edu
RI Liu, Tao/G-3585-2010; Zhang, Yong/B-4838-2011; 
OI Liu, Tao/0000-0002-8818-8313; Zhang, Yong/0000-0001-6316-2734; Liu,
   Tao/0000-0003-0446-9001
FU National Basic Research (973) Program of China [2010CB944904]; National
   Natural Science Foundation of China [31028011]; National Institutes of
   Health [HG4069]
FX National Basic Research (973) Program of China [2010CB944904], National
   Natural Science Foundation of China [31028011] and National Institutes
   of Health [HG4069].
NR 8
TC 14
Z9 15
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
J9 BIOINFORMATICS
JI Bioinformatics
PD MAY 15
PY 2012
VL 28
IS 10
BP 1411
EP 1412
DI 10.1093/bioinformatics/bts157
PG 2
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA 942OA
UT WOS:000304053300021
PM 22495751
ER

PT J
AU McKenna, ES
   Tamayo, P
   Cho, YJ
   Tillman, EJ
   Mora-Blanco, EL
   Sansam, CG
   Koellhoffer, EC
   Pomeroy, SL
   Roberts, CWM
AF McKenna, Elizabeth S.
   Tamayo, Pablo
   Cho, Yoon-Jae
   Tillman, Erik J.
   Mora-Blanco, E. Lorena
   Sansam, Courtney G.
   Koellhoffer, Edward C.
   Pomeroy, Scott L.
   Roberts, Charles W. M.
TI Epigenetic inactivation of the tumor suppressor BIN1 drives
   proliferation of SNF5-deficient tumors
SO CELL CYCLE
LA English
DT Article
DE SNF5; SMARCB1; INI1; BAF47; BIN1; rhabdoid tumor
ID MALIGNANT RHABDOID TUMORS; CANCER CELL-LINES; C-MYC; LUNG-CANCER;
   ONCOGENIC TRANSFORMATION; GENOMIC INSTABILITY; SWI/SNF COMPLEX; CYCLE
   ARREST; SNF5 LEADS; GENE
AB Emerging evidence demonstrates that subunits of the SWI/SNF chromatin remodeling complex are specifically mutated at high frequency in a variety of human cancer types. SNF5 (SMARCB1/INI1/BAF47), a core subunit of the SWI/SNF complex, is inactivated in the vast majority of rhabdoid tumors (RT), an aggressive type of pediatric cancer. SNF5-deficient cancers are diploid and genomically stable, suggesting that epigenetically based changes in transcription are key drivers of tumor formation caused by SNF5 loss. However, there is limited understanding of the target genes that drive cancer formation following SNF5 loss. Here we performed comparative expression analyses upon three independent SNF5-deficient cancer data sets from both human and mouse and identify downregulation of the BIN1 tumor suppressor gene as a conserved event in primary SNF5-deficient cancers. We show that SNF5 recruits the SWI/SNF complex to the BIN1 promoter, and that the marked reduction of BIN1 expression in RT correlates with decreased SWI/SNF occupancy. Functionally, we demonstrate that re-expression of BIN1 specifically compromises the proliferation of SNF5-deficient RT cell lines. Identification of BIN1 as a SNF5 target gene reveals a novel tumor suppressive regulatory mechanism whose disruption can drive cancer formation.
C1 [McKenna, Elizabeth S.; Tillman, Erik J.; Mora-Blanco, E. Lorena; Sansam, Courtney G.; Koellhoffer, Edward C.; Roberts, Charles W. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Childrens Hosp Boston, Dept Pediat Oncol,Div Hematol Oncol,Dept Pediat, Boston, MA 02115 USA.
   [Tamayo, Pablo] Harvard Univ, MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02139 USA.
   [Cho, Yoon-Jae; Pomeroy, Scott L.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA.
RP Roberts, CWM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst,Childrens Hosp Boston, Dept Pediat Oncol,Div Hematol Oncol,Dept Pediat, 44 Binney St, Boston, MA 02115 USA.
EM charles_roberts@dfci.harvard.edu
OI Koellhoffer, Edward/0000-0002-7260-9507; Tillman,
   Erik/0000-0003-3599-0297
FU NCI PHS [R01CA113794]; Stand Up 2 Cancer Innovative Research Grant
FX The authors would like to thank George Prendergast for providing the
   BIN1 constructs, David James for providing the BT16 cell line, and
   Jonathan Jesneck and Madeleine Lemieux for helpful discussions about
   cross-platform analysis. This work was supported in part by NCI PHS
   award R01CA113794 (C.W.M. Roberts). C.W.M. Roberts is a recipient of a
   Stand Up 2 Cancer Innovative Research Grant. The Garrett B. Smith
   Foundation provided additional support.
NR 58
TC 10
Z9 11
U1 1
U2 6
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 15
PY 2012
VL 11
IS 10
BP 1956
EP 1965
DI 10.4161/cc.20280
PG 10
WC Cell Biology
SC Cell Biology
GA 942JJ
UT WOS:000304039900021
PM 22544318
ER

PT J
AU Walensky, RP
   Park, JE
   Wood, R
   Freedberg, KA
   Scott, CA
   Bekker, LG
   Losina, E
   Mayer, KH
   Seage, GR
   Paltiel, AD
AF Walensky, Rochelle P.
   Park, Ji-Eun
   Wood, Robin
   Freedberg, Kenneth A.
   Scott, Callie A.
   Bekker, Linda-Gail
   Losina, Elena
   Mayer, Kenneth H.
   Seage, George R., III
   Paltiel, A. David
TI The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in
   South African Women
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID TENOFOVIR DISOPROXIL FUMARATE; RESOURCE-LIMITED SETTINGS;
   PLACEBO-CONTROLLED TRIAL; ANTIRETROVIRAL THERAPY; VACCINE TRIAL; RISK
   BEHAVIOR; DOUBLE-BLIND; PREVENTION; EFFICACY; IMPACT
AB Background. Recent trials report the short-term efficacy of tenofovir-based pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus (HIV) infection. PrEP's long-term impact on patient outcomes, population-level transmission, and cost-effectiveness remains unknown.
   Methods. We linked data from recent trials to a computer model of HIV acquisition, screening, and care to project lifetime HIV risk, life expectancy (LE), costs, and cost-effectiveness, using 2 PrEP-related strategies among heterosexual South African women: (1) women receiving no PrEP and (2) women not receiving PrEP (a tenofovir-based vaginal microbicide). We used a South African clinical cohort and published data to estimate population demographic characteristics, age-adjusted incidence of HIV infection, and HIV natural history and treatment parameters. Baseline PrEP efficacy (percentage reduction in HIV transmission) was 39% at a monthly cost of $5 per woman. Alternative parameter values were examined in sensitivity analyses.
   Results. Among South African women, PrEP reduced mean lifetime HIV risk from 40% to 27% and increased population discounted (undiscounted) LE from 22.51 (41.66) to 23.48 (44.48) years. Lifetime costs of care increased from $7280 to $9890 per woman, resulting in an incremental cost-effectiveness ratio of $2700/year of life saved, and may, under optimistic assumptions, achieve cost savings. Under baseline HIV infection incidence assumptions, PrEP was not cost saving, even assuming an efficacy >60% and a cost, <$1. At an HIV infection incidence of 9.1%/year, PrEP achieved cost savings at efficacies >= 50%.
   Conclusions. PrEP in South African women is very cost-effective by South African standards, conferring excellent value under virtually all plausible data scenarios. Although optimistic assumptions would be required to achieve cost savings, these represent important benchmarks for future PrEP study design.
C1 [Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
   [Walensky, Rochelle P.; Park, Ji-Eun; Freedberg, Kenneth A.; Scott, Callie A.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
   [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
   [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Walensky, Rochelle P.; Freedberg, Kenneth A.; Losina, Elena] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
   [Wood, Robin; Bekker, Linda-Gail] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa.
   [Wood, Robin; Bekker, Linda-Gail] Univ Cape Town, Dept Med, ZA-7700 Rondebosch, South Africa.
   [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Cambridge, MA 02138 USA.
   [Seage, George R., III] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
   [Seage, George R., III] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res GRS, Cambridge, MA 02138 USA.
   [Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
   [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
   [Mayer, Kenneth H.] Harvard Univ, Sch Med, Fenway Inst, Fenway Hlth, Boston, MA USA.
   [Mayer, Kenneth H.] Harvard Univ, Sch Med, Div Infect Dis, Boston, MA USA.
   [Mayer, Kenneth H.] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Hosp, Boston, MA USA.
   [Paltiel, A. David] Yale Univ, Sch Med, New Haven, CT USA.
RP Walensky, RP (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, 50 Staniford St,9th Fl, Boston, MA 02114 USA.
EM rwalensky@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious Diseases [R01 AI058736, P30
   AI060354]; National Institute of Mental Health [R01 MH065869, R01
   MH087328]; Gilead Sciences; Merck Pharmaceuticals
FX This work was funded by the National Institute of Allergy and Infectious
   Diseases (R01 AI058736, P30 AI060354) and the National Institute of
   Mental Health (R01 MH065869 and R01 MH087328). The funding sources had
   no role in the design, analysis, or interpretation of the study or in
   the decision to submit the manuscript for publication. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy and
   Infectious Diseases, the National Institute of Mental Health, or the
   National Institutes of Health. R. P. W. had access to all of the data in
   the study and takes responsibility for the integrity of the data and
   accuracy of the data analysis.; K. H. M. has unrestricted educational
   and research grants from Gilead Sciences and Merck Pharmaceuticals. All
   other authors report no conflicts of interest.
NR 58
TC 55
Z9 55
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2012
VL 54
IS 10
BP 1504
EP 1513
DI 10.1093/cid/cis225
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 942MW
UT WOS:000304049300024
PM 22474224
ER

PT J
AU Chan, JP
   Hu, ZT
   Sieburth, D
AF Chan, Jason P.
   Hu, Zhitao
   Sieburth, Derek
TI Recruitment of sphingosine kinase to presynaptic terminals by a
   conserved muscarinic signaling pathway promotes neurotransmitter release
SO GENES & DEVELOPMENT
LA English
DT Article
DE sphingosine kinase; mAChR; heterotrimeric G protein; Trio RhoGEF;
   synapse; C. elegans
ID ELEGANS NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE EXOCYTOSIS; NUCLEOTIDE
   EXCHANGE FACTOR; PROTEIN-COUPLED RECEPTORS; C-ELEGANS;
   CAENORHABDITIS-ELEGANS; PLASMA-MEMBRANE; NERVOUS-SYSTEM; MOTOR-NEURONS;
   BINDING SITE
AB Sphingolipids are potent lipid second messengers that regulate cell differentiation, migration, survival, and secretion, and alterations in sphingolipid signaling have been implicated in a variety of diseases. However, how sphingolipid levels are regulated, particularly in the nervous system, remains poorly understood. Here, we show that the generation of sphingosine-1-phosphate by sphingosine kinase (SphK) promotes neurotransmitter release. Electrophysiological, imaging, and behavioral analyses of Caenorhabditis elegans mutants lacking sphingosine kinase sphk-1 indicate that neuronal development is normal, but there is a significant defect in neurotransmitter release from neuromuscular junctions. SPHK-1 localizes to discrete, nonvesicular regions within presynaptic terminals, and this localization is critical for synaptic function. Muscarinic agonists cause a rapid increase in presynaptic SPHK-1 abundance, whereas reduction of endogenous acetylcholine production results in a rapid decrease in presynaptic SPHK-1 abundance. Muscarinic regulation of presynaptic SPHK-1 abundance is mediated by a conserved presynaptic signaling pathway composed of the muscarinic acetylcholine receptor GAR-3, the heterotrimeric G protein G alpha q, and its effector, Trio RhoGEF. SPHK-1 activity is required for the effects of muscarinic signaling on synaptic transmission. This study shows that SPHK-1 promotes neurotransmitter release in vivo and identifies a novel muscarinic pathway that regulates SphK abundance at presynaptic terminals.
C1 [Chan, Jason P.; Sieburth, Derek] Univ So Calif, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA.
   [Hu, Zhitao] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Sieburth, D (reprint author), Univ So Calif, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA.
EM sieburth@usc.edu
FU American Heart Association; NIH NINDS [NS071085-02]
FX We thank the following individuals for contributions and advice: J.
   Kaplan, Q. Ch'ng, J. Chen, T. Staab, H. Wang, and M. Olahova for
   critical reading of the manuscript; B. Ramos for laboratory reagents; S.
   Gorda for technical assistance; and Q. Ch'ng and J. Dittman for
   fluorescence analysis software. This work was funded by grants from the
   American Heart Association and NIH NINDS (NS071085-02). The
   Caenorhabditis Genetics Center provided the strains used in this study.
NR 85
TC 20
Z9 41
U1 1
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD MAY 15
PY 2012
VL 26
IS 10
BP 1070
EP 1085
DI 10.1101/gad.188003.112
PG 16
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 942LV
UT WOS:000304046400007
PM 22588719
ER

PT J
AU Wheeler, C
   Nabors, LB
   Barnum, S
   Yang, XH
   Hu, XZ
   Schoeb, TR
   Chen, DQ
   Ardelt, AA
   King, PH
AF Wheeler, Crystal
   Nabors, L. Burt
   Barnum, Scott
   Yang, Xiuhua
   Hu, Xianzhen
   Schoeb, Trenton R.
   Chen, Dongquan
   Ardelt, Agnieszka A.
   King, Peter H.
TI Sex hormone-dependent attenuation of EAE in a transgenic mouse with
   astrocytic expression of the RNA regulator HuR
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE RNA binding protein; Posttranscriptional gene regulation; RNA stability;
   AU-rich element; Estrogen
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; MEDIATED
   TRANSLATION; STABILITY; PROTEINS; ESTROGEN; REGION; MICE
AB In experimental autoimmune encephalomyelitis (EAE) and other neurodegenerative diseases, astrocytes play an important role in promoting or attenuating the inflammatory response through induction of different cytokines and growth factors. HuR plays a major role in regulating many of these factors by modulating RNA stability and translational efficiency. Here, we engineered transgenic mice to express HuR in astrocytes using the human glial fibrillary acidic protein promoter and found that female transgenic mice had significantly less clinical disability and histopathological changes in the spinal cord. Ovariectomy prior to EAE induction abrogated the protective effect. Our findings support a role for the astrocyte and posttranscriptional regulation in hormonally-mediated attenuation of EAE. Published by Elsevier B.V.
C1 [Wheeler, Crystal; Nabors, L. Burt] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA.
   [Nabors, L. Burt; Yang, Xiuhua; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
   [Barnum, Scott; Hu, Xianzhen] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
   [Schoeb, Trenton R.; King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
   [Chen, Dongquan] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA.
   [Ardelt, Agnieszka A.] Univ Chicago, Dept Neurol, Med Ctr, Chicago, IL 60637 USA.
   [King, Peter H.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
   [King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP King, PH (reprint author), Sparks Ctr, Suite 260,1720-7th Ave S, Birmingham, AL 35233 USA.
EM pking@uab.edu
FU VA Merit Review; NIH [R01 NS064133, R01 CA112397, R01 NS46032]; UAB
   Transgenic and Microarray Facilities [P30 CA013148-39]; UAB Neuroscience
   Blueprint Core [NS57098]
FX This work was supported by a VA Merit Review, and NIH R01 NS064133
   (PHK), R01 CA112397 (LBN), R01 NS46032 (SRB), the UAB Transgenic and
   Microarray Facilities (P30 CA013148-39), and the UAB Neuroscience
   Blueprint Core (NS57098). Histology services were provided by the UAB
   Comparative Pathology Laboratory.
NR 19
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD MAY 15
PY 2012
VL 246
IS 1-2
BP 34
EP 37
DI 10.1016/j.jneuroim.2012.02.014
PG 4
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 942FA
UT WOS:000304026900005
PM 22445740
ER

PT J
AU Doud, MB
   Koksal, AC
   Mi, LZ
   Song, GJ
   Lu, CF
   Springer, TA
AF Doud, Michael B.
   Koksal, Adem C.
   Mi, Li-Zhi
   Song, Gaojie
   Lu, Chafen
   Springer, Timothy A.
TI Unexpected fold in the circumsporozoite protein target of malaria
   vaccines
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID B SURFACE-ANTIGEN; HEPARAN-SULFATE; BIOLOGICAL MACROMOLECULES; SOLUTION
   SCATTERING; CONSERVED EPITOPE; TYPE-1 REPEATS; BINDING-SITE; LAYERED
   FOLD; PLASMODIUM; SPOROZOITES
AB Circumsporozoite (CS) protein is the major surface component of Plasmodium falciparum sporozoites and is essential for host cell invasion. A vaccine containing tandem repeats, region III, and thrombospondin type-I repeat (TSR) of CS is efficacious in phase III trials but gives only a 35% reduction in severe malaria in the first year postimmunization. We solved crystal structures showing that region III and TSR fold into a single unit, an "alpha TSR" domain. The alpha TSR domain possesses a hydrophobic pocket and core, missing in TSR domains. CS binds heparin, but aTSR does not. Interestingly, polymorphic T-cell epitopes map to specialized aTSR regions. The N and C termini are unexpectedly close, providing clues for sporozoite sheath organization. Elucidation of a unique structure of a domain within CS enables rational design of next-generation subunit vaccines and functional and medicinal chemical investigation of the conserved hydrophobic pocket.
C1 [Springer, Timothy A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Immune Dis Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Springer, TA (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Immune Dis Inst, Boston, MA 02115 USA.
EM springer@idi.harvard.edu
RI Mi, Li-Zhi/B-1371-2016; 
OI Mi, Li-Zhi/0000-0001-9907-5245; Koksal, Adem/0000-0002-3163-7421; Doud,
   Michael/0000-0002-8172-6342
FU National Institutes of Health [A1095686]
FX We thank beamlines X9 at National Synchotron Light Source and 24ID at
   Advanced Photon Source and David King (Howard Hughes Medical Institute,
   Department of Molecular and Cell Biology, University of California at
   Berkeley) for mass spectrometry. This work was supported by National
   Institutes of Health Grant A1095686.
NR 46
TC 31
Z9 31
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 15
PY 2012
VL 109
IS 20
BP 7817
EP 7822
DI 10.1073/pnas.1205737109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 946QW
UT WOS:000304369800055
PM 22547819
ER

PT J
AU Taniguchi, RT
   DeVoss, JJ
   Moon, JJ
   Sidney, J
   Sette, A
   Jenkins, MK
   Anderson, MS
AF Taniguchi, Ruth T.
   DeVoss, Jason J.
   Moon, James J.
   Sidney, John
   Sette, Alessandro
   Jenkins, Marc K.
   Anderson, Mark S.
TI Detection of an autoreactive T-cell population within the polyclonal
   repertoire that undergoes distinct autoimmune regulator (Aire)-mediated
   selection
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE autoimmunity; uveitis
ID THYMIC EPITHELIAL-CELLS; POSITIVELY SELECTED THYMOCYTES; NEGATIVE
   SELECTION; CENTRAL TOLERANCE; ANTIGEN; PROTEIN; EXPRESSION; EPITOPES;
   BINDING; MICE
AB The autoimmune regulator (Aire) plays a critical role in central tolerance by promoting the display of tissue-specific antigens in the thymus. To study the influence of Aire on thymic selection in a physiological setting, we used tetramer reagents to detect auto-reactive T cells specific for the Aire-dependent tissue-specific antigen interphotoreceptor retinoid-binding protein (IRBP), in the polyclonal repertoire. Two class II tetramer reagents were designed to identify T cells specific for two different peptide epitopes of IRBP. Analyses of the polyclonal T-cell repertoire showed a high frequency of activated T cells specific for both IRBP tetramers in Aire(-/-) mice, but not in Aire(+/+) mice. Surprisingly, although one tetramer-binding T-cell population was efficiently deleted in the thymus in an Aire-dependent manner, the second tetramer-binding population was not deleted and could be detected in both the Aire(-/-) and Aire(+/+) T-cell repertoires. We found that Aire-dependent thymic deletion of IRBP-specific T cells relies on intercellular transfer of IRBP between thymic stroma and bone marrow-derived antigen-presenting cells. Furthermore, our data suggest that Aire-mediated deletion relies not only on thymic expression of IRBP, but also on proper antigen processing and presentation of IRBP by thymic antigen-presenting cells.
C1 [Taniguchi, Ruth T.; DeVoss, Jason J.; Anderson, Mark S.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
   [Moon, James J.; Jenkins, Marc K.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.
   [Moon, James J.; Jenkins, Marc K.] Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA.
   [Moon, James J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Moon, James J.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
   [Moon, James J.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Ctr Infect Dis Allergy & Asthma Res, La Jolla, CA 92037 USA.
RP Anderson, MS (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
EM manderson@diabetes.ucsf.edu
RI Jenkins, Marc/G-1063-2012
OI Jenkins, Marc/0000-0001-8009-7655
FU National Institutes of Health [EY16408, DK063720]
FX We thank Navdeep Grewal for technical assistance and Rachel Caspi for
   helpful discussions and her generous gift of bovine IRBP for our
   experiments. We also thank Adam Savage, Todd Metzger, Mickie Cheng, and
   Mike Waterfield for helpful comments on the manuscript. This work was
   supported by National Institutes of Health Grants EY16408 and DK063720.
NR 38
TC 45
Z9 45
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 15
PY 2012
VL 109
IS 20
BP 7847
EP 7852
DI 10.1073/pnas.1120607109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 946QW
UT WOS:000304369800060
PM 22552229
ER

PT J
AU Goel, S
   Fukumura, D
   Jain, RK
AF Goel, Shom
   Fukumura, Dai
   Jain, Rakesh K.
TI Normalization of the tumor vasculature through oncogenic inhibition: An
   emerging paradigm in tumor biology
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Letter
ID ANGIOGENESIS; CANCER
C1 [Goel, Shom; Fukumura, Dai; Jain, Rakesh K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Tumor Biol,Dept Radiat Oncol, Boston, MA 02114 USA.
RP Jain, RK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Tumor Biol,Dept Radiat Oncol, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
FU NCI NIH HHS [P01 CA080124, R01 CA096915]
NR 5
TC 13
Z9 14
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 15
PY 2012
VL 109
IS 20
BP E1214
EP E1214
DI 10.1073/pnas.1203794109
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 946QW
UT WOS:000304369800005
PM 22550180
ER

PT J
AU Andrews, JR
   Lawn, SD
   Rusu, C
   Wood, R
   Noubary, F
   Bender, MA
   Horsburgh, CR
   Losina, E
   Freedberg, KA
   Walensky, RP
AF Andrews, Jason R.
   Lawn, Stephen D.
   Rusu, Corina
   Wood, Robin
   Noubary, Farzad
   Bender, Melissa A.
   Horsburgh, C. Robert
   Losina, Elena
   Freedberg, Kenneth A.
   Walensky, Rochelle P.
TI The cost-effectiveness of routine tuberculosis screening with Xpert
   MTB/RIF prior to initiation of antiretroviral therapy: a model-based
   analysis
SO AIDS
LA English
DT Article
DE antiretroviral therapy; cost-effectiveness; diagnostics; HIV;
   tuberculosis
ID HIV-INFECTED PATIENTS; SOUTH-AFRICA; RESISTANCE; IMPLEMENTATION;
   DIAGNOSIS; SETTINGS; ASSAY
AB Background: In settings with high tuberculosis (TB) prevalence, 15-30% of HIV-infected individuals initiating antiretroviral therapy (ART) have undiagnosed TB. Such patients are usually screened by symptoms and sputum smear, which have poor sensitivity.
   Objective: To project the clinical and economic outcomes of using Xpert MTB/RIF(Xpert), a rapid TB/rifampicin-resistance diagnostic, to screen individuals initiating ART.
   Design: We used a microsimulation model to evaluate the clinical impact and cost-effectiveness of alternative TB screening modalities - in all patients or only symptomatic patients - for hypothetical cohorts of individuals initiating ART in South Africa (mean CD4 cell count = 171 cells/mu l; TB prevalence 22%). We simulated no active screening and four diagnostic strategies, smear microscopy (sensitivity 23%); smear and culture (sensitivity, 100%); one Xpert sample (sensitivity in smear-negative TB: 43%); two Xpert samples (sensitivity in smear-negative TB: 62%). Outcomes included projected life expectancy, lifetime costs (2010 US$), and incremental cost-effectiveness ratios (ICERs). Strategies with ICERs less than $7100 (South African gross domestic product per capita) were considered very cost-effective.
   Results: Compared with no screening, life expectancy in TB-infected patients increased by 1.6 months using smear in symptomatic patients and by 6.6 months with two Xpert samples in all patients. At 22% TB prevalence, the ICER of smear for all patients was $2800 per year of life saved (YLS), and of Xpert (two samples) for all patients was $5100/YLS. Strategies involving one Xpert sample or symptom screening were less efficient.
   Conclusion: Model-based analysis suggests that screening all individuals initiating ART in South Africa with two Xpert samples is very cost-effective. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Andrews, Jason R.; Rusu, Corina; Noubary, Farzad; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
   [Andrews, Jason R.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Andrews, Jason R.; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Boston, MA USA.
   [Andrews, Jason R.; Noubary, Farzad; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Ctr AIDS Res, Boston, MA USA.
   [Lawn, Stephen D.; Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Lawn, Stephen D.] London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, London WC1, England.
   [Bender, Melissa A.] NYU, Sch Med, Div Infect Dis, New York, NY USA.
   [Horsburgh, C. Robert; Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP Andrews, JR (reprint author), Massachusetts Gen Hosp, Div Gen Med, Med Practice Evaluat Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM jasonandr@gmail.com
OI Andrews, Jason/0000-0002-5967-251X
FU National Institute of General Medical Sciences [U54 GM088558]; National
   Institute of Allergy and Infectious Diseases [R01 AI058736, K01
   AI074495]; AIDS Clinical Trials Group [U01 AI068636]; Harvard Global
   Health Institute; Wellcome Trust [088590/Z/09]; Doris Duke Charitable
   Foundation
FX This work was supported by the National Institute of General Medical
   Sciences (U54 GM088558), the National Institute of Allergy and
   Infectious Diseases (R01 AI058736 and K01 AI074495), the AIDS Clinical
   Trials Group (U01 AI068636), the Harvard Global Health Institute, the
   Wellcome Trust (SDL; #088590/Z/09) and the Doris Duke Charitable
   Foundation (Clinical Scientist Development and ORACTA Awards).
NR 38
TC 39
Z9 40
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2012
VL 26
IS 8
BP 987
EP 995
DI 10.1097/QAD.0b013e3283522d47
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 937JY
UT WOS:000303656000010
PM 22333751
ER

PT J
AU Sigel, K
   Wisnivesky, J
   Gordon, K
   Dubrow, R
   Justice, A
   Brown, ST
   Goulet, J
   Butt, AA
   Crystal, S
   Rimland, D
   Rodriguez-Barradas, M
   Gibert, C
   Park, LS
   Crothers, K
AF Sigel, Keith
   Wisnivesky, Juan
   Gordon, Kirsha
   Dubrow, Robert
   Justice, Amy
   Brown, Sheldon T.
   Goulet, Joseph
   Butt, Adeel A.
   Crystal, Stephen
   Rimland, David
   Rodriguez-Barradas, Maria
   Gibert, Cynthia
   Park, Lesley S.
   Crothers, Kristina
TI HIV as an independent risk factor for incident lung cancer
SO AIDS
LA English
DT Article
DE HIV; immunosuppression; incidence; lung cancer; non-AIDS-defining
   malignancy; smoking
ID ACTIVE ANTIRETROVIRAL THERAPY; WOMENS INTERAGENCY HIV; INJECTION-DRUG
   USERS; DEFINING MALIGNANCIES; CIGARETTE-SMOKING; INFECTED PATIENTS;
   UNITED-STATES; AIDS; IMMUNODEFICIENCY; MORTALITY
AB Background: It is unclear whether the elevated rate of lung cancer among HIV-infected persons is due to biological effects of HIV, surveillance bias, or excess smoking. We compared the incidence of lung cancer between HIV-infected and demographically similar HIV-uninfected patients, accounting for smoking and stage of lung cancer at diagnosis.
   Design: Data from the Veterans Aging Cohort Study Virtual Cohort were linked to data from the Veterans Affairs Central Cancer Registry, resulting in an analytic cohort of 37 294 HIV-infected patients and 75 750 uninfected patients.
   Methods: We calculated incidence rates of pathologically confirmed lung cancer by dividing numbers of cases by numbers of person-years at risk. We used Poisson regression to determine incidence rate ratios (IRRs), adjusting for age, sex, race/ethnicity, smoking prevalence, previous bacterial pneumonia, and chronic obstructive pulmonary disease.
   Results: The incidence rate of lung cancer in HIV-infected patients was 204 cases per 100 000 person-years [95% confidence interval (CI) 167-249] and among uninfected patients was 119 cases per 100 000 person-years (95% CI 110-129). The IRR of lung cancer associated with HIV infection remained significant after multivariable adjustment (IRR 1.7; 95% CI 1.5-1.9). Lung cancer stage at presentation did not differ between HIV-infected and uninfected patients.
   Conclusion: In our cohort of demographically similar HIV-infected and uninfected patients, HIV infection was an independent risk factor for lung cancer after controlling for potential confounders including smoking. The similar stage distribution between the two groups indicated that surveillance bias was an unlikely explanation for this finding. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Sigel, Keith; Wisnivesky, Juan; Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
   [Gordon, Kirsha; Dubrow, Robert; Justice, Amy; Goulet, Joseph] Yale Univ, Sch Med, Vet Affairs VA Connecticut Healthcare Syst, New Haven, CT USA.
   [Gordon, Kirsha; Dubrow, Robert; Justice, Amy; Goulet, Joseph] Yale Univ, Sch Publ Hlth, Vet Affairs VA Connecticut Healthcare Syst, New Haven, CT USA.
   [Brown, Sheldon T.] James J Peters Vet Affairs VA Med Ctr, Bronx, NY USA.
   [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
   [Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ 08903 USA.
   [Rimland, David] Emory Univ, Sch Med, Atlanta Vet Affairs VA Med Ctr, Decatur, GA 30033 USA.
   [Rodriguez-Barradas, Maria] Michael E DeBakey Vet Affairs VA Med Ctr, Houston, TX USA.
   [Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA.
   [Gibert, Cynthia] George Washington Univ, Sch Med, Washington DC Vet Affairs Med Ctr, Washington, DC USA.
   [Crothers, Kristina] Univ Washington, Dept Internal Med, Div Pulm & Crit Care Med, Sch Med, Seattle, WA USA.
RP Sigel, K (reprint author), 17 E 102nd St,6th Floor, New York, NY 10029 USA.
EM keith.sigel@mssm.edu
OI Goulet, Joseph/0000-0002-0842-804X; Sigel, Keith/0000-0002-4051-4861;
   Crothers, Kristina/0000-0001-9702-0371
FU National Center for Research Resources [KL2RR029885]; National Institute
   on Alcohol and Alcohol Abuse [3U01 AA 13566]; National Institute of
   Aging [K23 AG00826]; Robert Wood Johnson Generalist Faculty Scholar
   Award; National Institute on Aging, National Institute of Mental Health;
   Veterans Health Administration; Veterans Health Administration Office of
   Research and Development and Public Health Strategic Healthcare Group;
   National Heart, Lung, and Blood Institute [NIH/NHLBI R01 HL090342];
   Novartis Pharmaceuticals; GlaxoSmithKline
FX This study was supported by the National Center for Research Resources
   (KL2RR029885 to K. S.), National Institute on Alcohol and Alcohol Abuse
   (3U01 AA 13566), National Institute of Aging (K23 AG00826), Robert Wood
   Johnson Generalist Faculty Scholar Award, an interagency agreement
   between National Institute on Aging, National Institute of Mental Health
   and the Veterans Health Administration, and the Veterans Health
   Administration Office of Research and Development and Public Health
   Strategic Healthcare Group (to A.C.J.), and National Heart, Lung, and
   Blood Institute (NIH/NHLBI R01 HL090342 to K. C.).; J.P.W. reports
   receiving lecture honorarium from Novartis Pharmaceuticals, and a
   research grant from GlaxoSmithKline.
NR 34
TC 75
Z9 75
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2012
VL 26
IS 8
BP 1017
EP 1025
DI 10.1097/QAD.0b013e328352d1ad
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 937JY
UT WOS:000303656000013
PM 22382152
ER

PT J
AU Fan, VS
   Gaziano, JM
   Lew, R
   Bourbeau, J
   Adams, SG
   Leatherman, S
   Thwin, SS
   Huang, GD
   Robbins, R
   Sriram, PS
   Sharafkhaneh, A
   Mador, MJ
   Sarosi, G
   Panos, RJ
   Rastogi, P
   Wagner, TH
   Mazzuca, SA
   Shannon, C
   Colling, C
   Liang, MH
   Stoller, JK
   Fiore, L
   Niewoehner, DE
AF Fan, Vincent S.
   Gaziano, J. Michael
   Lew, Robert
   Bourbeau, Jean
   Adams, Sandra G.
   Leatherman, Sarah
   Thwin, Soe Soe
   Huang, Grant D.
   Robbins, Richard
   Sriram, Peruvemba S.
   Sharafkhaneh, Amir
   Mador, M. Jeffery
   Sarosi, George
   Panos, Ralph J.
   Rastogi, Padmashri
   Wagner, Todd H.
   Mazzuca, Steven A.
   Shannon, Colleen
   Colling, Cindy
   Liang, Matthew H.
   Stoller, James K.
   Fiore, Louis
   Niewoehner, Dennis E.
TI A Comprehensive Care Management Program to Prevent Chronic Obstructive
   Pulmonary Disease Hospitalizations A Randomized, Controlled Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SELF-MANAGEMENT; ACUTE EXACERBATIONS; ACTION PLAN; COPD; HEALTH;
   METAANALYSIS; MORTALITY; DIAGNOSIS; EDUCATION; RECOVERY
AB Background: Improving a patient's ability to self-monitor and manage changes in chronic obstructive pulmonary disease (COPD) symptoms may improve outcomes.
   Objective: To determine the efficacy of a comprehensive care management program (CCMP) in reducing the risk for COPD hospitalization.
   Design: A randomized, controlled trial comparing CCMP with guideline-based usual care. (ClinicalTrials.gov registration number: NCT00395083)
   Setting: 20 Veterans Affairs hospital-based outpatient clinics.
   Participants: Patients hospitalized for COPD in the past year.
   Intervention: The CCMP included COPD education during 4 individual sessions and 1 group session, an action plan for identification and treatment of exacerbations, and scheduled proactive telephone calls for case management. Patients in both the intervention and usual care groups received a COPD informational booklet; their primary care providers received a copy of COPD guidelines and were advised to manage their patients according to these guidelines. Patients were randomly assigned, stratifying by site based on random, permuted blocks of variable size.
   Measurements: The primary outcome was time to first COPD hospitalization. Staff blinded to study group performed telephone-based assessment of COPD exacerbations and hospitalizations, and all hospitalizations were blindly adjudicated. Secondary outcomes included non-COPD health care use, all-cause mortality, health-related quality of life, patient satisfaction, disease knowledge, and self-efficacy.
   Results: Of the eligible patients, 209 were randomly assigned to the intervention group and 217 to the usual care group. Citing serious safety concerns, the data monitoring committee terminated the intervention before the trial's planned completion after 426 (44%) of the planned total of 960 patients were enrolled. Mean follow-up was 250 days. When the study was stopped, the 1-year cumulative incidence of COPD-related hospitalization was 27% in the intervention group and 24% in the usual care group (hazard ratio, 1.13 [95% CI, 0.70 to 1.80]; P = 0.62). There were 28 deaths from all causes in the intervention group versus 10 in the usual care group (hazard ratio, 3.00 [CI, 1.46 to 6.17]; P = 0.003). Cause could be assigned in 27 (71%) deaths. Deaths due to COPD accounted for the largest difference: 10 in the intervention group versus 3 in the usual care group (hazard ratio, 3.60 [CI, 0.99 to 13.08]; P = 0.053).
   Limitations: Available data could not fully explain the excess mortality in the intervention group. Ability to assess the quality of the educational sessions provided by the case managers was limited.
   Conclusion: A CCMP in patients with severe COPD had not decreased COPD-related hospitalizations when the trial was stopped prematurely. The CCMP was associated with unanticipated excess mortality, results that differ markedly from similar previous trials. A data monitoring committee should be considered in the design of clinical trials involving behavioral interventions.
C1 [Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA.
   Vet Affairs Boston Healthcare Syst, Boston, MA USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
   Montreal Chest Inst, Montreal, PQ, Canada.
   S Texas Vet Hlth Care Syst, San Antonio, TX USA.
   Dept Vet Affairs Cooperat Studies Program, Washington, DC USA.
   Phoenix Vet Affairs Med Ctr, Phoenix, AZ USA.
   N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.
   Michael E DeBakey VA Med Ctr, Houston, TX USA.
   Vet Affairs Western New York Healthcare Syst, Buffalo, NY USA.
   Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
   Dallas Vet Affairs Med Ctr, Dallas, TX USA.
   Vet Affairs Palo Alto Healthcare Syst, Menlo Pk, CA USA.
   Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
   Indiana Univ Sch Med, Indianapolis, IN USA.
   Vet Affairs Cooperat Studies Program Clin Res Pha, Albuquerque, NM USA.
   Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN USA.
   Cleveland Clin, Cleveland, OH 44106 USA.
RP Fan, VS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1600 S Columbian Way, Seattle, WA 98108 USA.
EM vincent.fan@va.gov
OI Sriram, P.S/0000-0002-6103-3573
FU Veterans Affairs Cooperative Study Program; Veterans Affairs Office of
   Research and Development [560]
FX Veterans Affairs Cooperative Study Program.; By the Cooperative Studies
   Program (CSP #560), Veterans Affairs Office of Research and Development.
NR 43
TC 132
Z9 132
U1 3
U2 22
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 15
PY 2012
VL 156
IS 10
BP 673
EP U46
DI 10.7326/0003-4819-156-10-201205150-00003
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 944IQ
UT WOS:000304193400013
PM 22586006
ER

PT J
AU Zalis, ME
   Blake, MA
   Cai, WL
   Hahn, PF
   Halpern, EF
   Kazam, IG
   Keroack, M
   Magee, C
   Nappi, JJ
   Perez-Johnston, R
   Saltzman, JR
   Vij, A
   Yee, J
   Yoshida, H
AF Zalis, Michael E.
   Blake, Michael A.
   Cai, Wenli
   Hahn, Peter F.
   Halpern, Elkan F.
   Kazam, Imrana G.
   Keroack, Myles
   Magee, Cordula
   Naeppi, Janne J.
   Perez-Johnston, Rocio
   Saltzman, John R.
   Vij, Abhinav
   Yee, Judy
   Yoshida, Hiroyuki
TI Diagnostic Accuracy of Laxative-Free Computed Tomographic Colonography
   for Detection of Adenomatous Polyps in Asymptomatic Adults A Prospective
   Evaluation
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID NONCATHARTIC CT COLONOGRAPHY; FECAL OCCULT BLOOD; COLORECTAL-CANCER;
   VIRTUAL COLONOSCOPY; CATHARTIC PREPARATION; SCREENING POPULATION;
   ADVANCED NEOPLASIA; BOWEL PREPARATION; FALSE-POSITIVES; AIDED DETECTION
AB Background: Colon screening by optical colonoscopy (OC) or computed tomographic colonography (CTC) requires a laxative bowel preparation, which inhibits screening participation.
   Objective: To assess the performance of detecting adenomas 6 mm or larger and patient experience of laxative-free, computer-aided CTC.
   Design: Prospective test comparison of laxative-free CTC and OC. The CTC included electronic cleansing and computer-aided detection. Optical colonoscopy examinations were initially blinded to CTC results, which were subsequently revealed during colonoscope withdrawal; this method permitted reexamination to resolve discrepant findings. Unblinded OC served as a reference standard. (ClinicalTrials.gov registration number: NCT01200303)
   Setting: Multicenter ambulatory imaging and endoscopy centers.
   Participants: 605 adults aged 50 to 85 years at average to moderate risk for colon cancer.
   Measurements: Per-patient sensitivity and specificity of CTC and first-pass OC for detecting adenomas at thresholds of 10 mm or greater, 8 mm or greater, and 6 mm or greater; per-lesion sensitivity and survey data describing patient experience with preparations and examinations.
   Results: For adenomas 10 mm or larger, per-patient sensitivity of CTC was 0.91 (95% CI, 0.71 to 0.99) and specificity was 0.85 (CI, 0.82 to 0.88); sensitivity of OC was 0.95 (CI, 0.77 to 1.00) and specificity was 0.89 (CI, 0.86 to 0.91). Sensitivity of CTC was 0.70 (CI, 0.53 to 0.83) for adenomas 8 mm or larger and 0.59 (CI, 0.47 to 0.70) for those 6 mm or larger; sensitivity of OC for adenomas 8 mm or larger was 0.88 (CI, 0.73 to 0.96) and 0.76 (CI, 0.64 to 0.85) for those 6 mm or larger. The specificity of OC at the threshold of 8 mm or larger was 0.91 and at 6 mm or larger was 0.94. Specificity for OC was greater than that for CTC, which was 0.86 at the threshold of 8 mm or larger and 0.88 at 6 mm or larger (P = 0.02). Reported participant experience for comfort and difficulty of examination preparation was better with CTC than OC.
   Limitations: There were 3 CTC readers. The survey instrument was not independently validated.
   Conclusion: Computed tomographic colonography was accurate in detecting adenomas 10 mm or larger but less so for smaller lesions. Patient experience was better with laxative-free CTC. These results suggest a possible role for laxative-free CTC as an alternate screening method.
C1 [Zalis, Michael E.] Massachusetts Gen Hosp, Dept Imaging, Brigham & Womens Hosp, Boston, MA 02114 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Zalis, ME (reprint author), Massachusetts Gen Hosp, Dept Imaging, Brigham & Womens Hosp, Suite 400A,25 New Chardon St, Boston, MA 02114 USA.
EM mzalis@mgh.harvard.edu
FU GE Healthcare [03-OPQ-001]; American Cancer Society [RSG-08-221-01-CCE,
   RSG-05-088-01-CCE]; National Institutes of Health [1K22CA098422, 1 RO1
   CA095279]
FX Dr. Zalis is supported by GE Healthcare (03-OPQ-001), the American
   Cancer Society (RSG-08-221-01-CCE), and the National Institutes of
   Health (1K22CA098422). Drs. Zalis, Cai, Nappi, and Yoshida are supported
   by the National Institutes of Health (1 RO1 CA095279). Dr. Yoshida is
   supported by the American Cancer Society (RSG-05-088-01-CCE).
NR 39
TC 50
Z9 51
U1 1
U2 6
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 15
PY 2012
VL 156
IS 10
BP 692
EP U71
DI 10.7326/0003-4819-156-10-201205150-00005
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 944IQ
UT WOS:000304193400015
PM 22586008
ER

PT J
AU Meissner, TB
   Liu, YJ
   Lee, KH
   Li, A
   Biswas, A
   van Eggermond, MCJA
   van den Elsen, PJ
   Kobayashi, KS
AF Meissner, Torsten B.
   Liu, Yuen-Joyce
   Lee, Kyoung-Hee
   Li, Amy
   Biswas, Amlan
   van Eggermond, Marja C. J. A.
   van den Elsen, Peter J.
   Kobayashi, Koichi S.
TI NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC
   Class I Gene Expression
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID BARE LYMPHOCYTE SYNDROME; NUCLEAR FACTOR-Y; REGULATORY FACTOR; MICE
   LACKING; TRANSACTIVATOR CIITA; ANTIGEN PRESENTATION; BINDING DOMAIN;
   DEFICIENCY; PROMOTER; MUTATION
AB Tight regulation of MHC class I gene expression is critical for CD8 T cell activation and host adaptive-immune responses. The promoters of MHC class I genes contain a well-conserved core module, the W/S-X-Y motif, which assembles a nucleoprotein complex termed MHC enhanceosome. A member of the nucleotide-binding domain, leucine-rich repeat (NLR) protein family, NLRC5, is a newly identified transcriptional regulator of MHC class I genes. NLRC5 associates with and transactivates the proximal promoters of MHC class I genes, although the molecular mechanism of transactivation has not been understood. In this article, we show that NLRC5-mediated MHC class I gene induction requires the W/S and X1, X2 cis-regulatory elements. The transcription factors RFX5, RFXAP, and RFXANK/B, which compose the RFX protein complex and associate with the X1 box, cooperate with NLRC5 for MHC class I expression. Coimmunoprecipitation experiments revealed that NLRC5 specifically interacts with the RFX subunit RFXANK/B via its ankyrin repeats. In addition, we show that NLRC5 can cooperate with ATF1 and the transcriptional coactivators CBP/p300 and general control nonderepressible 5, which display histone acetyltransferase activity. Taken together, our data suggest that NLRC5 participates in an MHC class I-specific enhanceosome, which assembles on the conserved W/S-X-Y core module of the MHC class I proximal promoters, including the RFX factor components and CREB/ATF1 family transcription factors, to promote MHC class I gene expression. The Journal of Immunology, 2012,188: 4951-4958.
C1 [Meissner, Torsten B.; Liu, Yuen-Joyce; Lee, Kyoung-Hee; Li, Amy; Biswas, Amlan; Kobayashi, Koichi S.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
   [Meissner, Torsten B.; Lee, Kyoung-Hee; Biswas, Amlan; Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Div Immunol, Boston, MA 02215 USA.
   [van Eggermond, Marja C. J. A.; van den Elsen, Peter J.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands.
   [van den Elsen, Peter J.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands.
RP Kobayashi, KS (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Dana 1420A,450 Brookline Ave, Boston, MA 02215 USA.
EM Koichi_Kobayashi@dfci.harvard.edu
OI Van den Elsen, Peter/0000-0002-5196-0082
FU National Institutes of Health; Crohn's and Colitis Foundation of
   America; Cancer Research Institute; Claudia Adams Barr Award; European
   Molecular Biology Organization
FX This work was supported by grants from the National Institutes of Health
   and the Crohn's and Colitis Foundation of America. K.S.K. is a recipient
   of the Investigator Award from the Cancer Research Institute and the
   Claudia Adams Barr Award. T.B.M. has been a recipient of the European
   Molecular Biology Organization Long Term fellowship, and A.B. is a
   recipient of a Crohn's and Colitis Foundation of America fellowship.
NR 52
TC 39
Z9 39
U1 2
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2012
VL 188
IS 10
BP 4951
EP 4958
DI 10.4049/jimmunol.1103160
PG 8
WC Immunology
SC Immunology
GA 937BP
UT WOS:000303634300028
PM 22490869
ER

PT J
AU Fang, YHD
   El Fakhri, G
   Becker, JA
   Alpert, NM
AF Fang, Yu-Hua Dean
   El Fakhri, Georges
   Becker, John A.
   Alpert, Nathaniel M.
TI Parametric imaging with Bayesian priors: A validation study with
   C-11-Altropane PET
SO NEUROIMAGE
LA English
DT Article
DE Parametric image; Bayesian estimation; Kinetic modeling; Variance
   reduction
ID DYNAMIC PET; EXAMINING PHARMACOKINETICS; RIDGE-REGRESSION;
   METABOLIC-RATE; IMAGES; NOISE; METHYLPHENIDATE; RECONSTRUCTION;
   TOMOGRAPHY; GENERATION
AB It has been suggested that Bayesian estimation methods may be used to improve the signal-to-noise ratio of parametric images. However, there is little experience with the method and some of the underlying assumptions and performance properties of Bayesian estimation remain to be investigated. We used a sample population of 54 subjects, studied previously with C-11-Altropane, to empirically evaluate the assumptions, performance and some practical issues in forming parametric images. By using normality tests, we showed that the underpinning normality assumptions of data and parametric distribution apply to more than 80% of voxels. The standard deviation of the binding potential can be reduced 30-50% using Bayesian estimation, without introducing substantial bias. The sample size required to form the a priori information was found to be modest: as little as ten subjects may be sufficient and the choice of specific subjects has little effect on Bayesian estimation. A realistic simulation study showed that detection of localized differences in parametric images, e.g. by statistical parametric mapping (SPM), could be made more reliable and/or conducted with smaller sample size using Bayesian estimation. In conclusion, Bayesian estimation can improve the SNR of parametric images and better detect localized changes in cohorts of subjects. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Fang, Yu-Hua Dean; El Fakhri, Georges; Becker, John A.; Alpert, Nathaniel M.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
   [Fang, Yu-Hua Dean] Chang Gung Mem Hosp, Mol Imaging Ctr, Linkou, Taiwan.
RP Alpert, NM (reprint author), Dept Radiol, White 427,55 Fruit St, Boston, MA 02114 USA.
NR 32
TC 3
Z9 3
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2012
VL 61
IS 1
BP 131
EP 138
DI 10.1016/j.neuroimage.2012.03.003
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 941HP
UT WOS:000303954600014
PM 22425668
ER

PT J
AU Wood, KC
   Konieczkowski, DJ
   Johannessen, CM
   Boehm, JS
   Tamayo, P
   Botvinnik, OB
   Mesirov, JP
   Hahn, WC
   Root, DE
   Garraway, LA
   Sabatini, DM
AF Wood, Kris C.
   Konieczkowski, David J.
   Johannessen, Cory M.
   Boehm, Jesse S.
   Tamayo, Pablo
   Botvinnik, Olga B.
   Mesirov, Jill P.
   Hahn, William C.
   Root, David E.
   Garraway, Levi A.
   Sabatini, David M.
TI MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response
   in Melanoma
SO SCIENCE SIGNALING
LA English
DT Article
ID LENTIVIRAL RNAI LIBRARY; NECROSIS-FACTOR-ALPHA; METASTATIC MELANOMA;
   ACQUIRED-RESISTANCE; CELL MICROARRAYS; MAMMALIAN-CELLS; RAF INHIBITION;
   KINASE; IDENTIFICATION; PATHWAY
AB Cell microarrays are a promising tool for performing large-scale functional genomic screening in mammalian cells at reasonable cost, but owing to technical limitations they have been restricted for use with a narrow range of cell lines and short-term assays. Here, we describe MicroSCALE (Microarrays of Spatially Confined Adhesive Lentiviral Features), a cell microarray-based platform that enables application of this technology to a wide range of cell types and longer-term assays. We used MicroSCALE to uncover kinases that when overexpressed partially desensitized B-RAF(V600E)-mutant melanoma cells to inhibitors of the mitogen-activated protein kinase kinase kinase (MAPKKK) RAF, the MAPKKs MEK1 and 2 (MEK1/2, mitogen-activated protein kinase kinase 1 and 2), mTOR (mammalian target of rapamycin), or PI3K (phosphatidylinositol 3-kinase). These screens indicated that cells treated with inhibitors acting through common mechanisms were affected by a similar profile of overexpressed proteins. In contrast, screens involving inhibitors acting through distinct mechanisms yielded unique profiles, a finding that has potential relevance for small-molecule target identification and combination drugging studies. Further, by integrating large-scale functional screening results with cancer cell line gene expression and pharmacological sensitivity data, we validated the nuclear factor kappa B pathway as a potential mediator of resistance to MAPK pathway inhibitors. The MicroSCALE platform described here may enable new classes of large-scale, resource-efficient screens that were not previously feasible, including those involving combinations of cell lines, perturbations, and assay outputs or those involving limited numbers of cells and limited or expensive reagents.
C1 [Wood, Kris C.; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   [Wood, Kris C.; Konieczkowski, David J.; Johannessen, Cory M.; Boehm, Jesse S.; Tamayo, Pablo; Botvinnik, Olga B.; Mesirov, Jill P.; Hahn, William C.; Root, David E.; Garraway, Levi A.; Sabatini, David M.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA.
   [Konieczkowski, David J.; Johannessen, Cory M.; Hahn, William C.; Garraway, Levi A.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, Boston, MA 02215 USA.
   [Sabatini, David M.] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
RP Wood, KC (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM kcwood@alum.mit.edu; sabatini@wi.mit.edu
OI Boehm, Jesse/0000-0002-6795-6336
FU Scientific Planning and Allocation of Resources Committee from Broad
   Institute; NIH [5R01-CA129105]; Novartis Institutes for Biomedical
   Research; Koch Institute for Integrative Cancer Research at the
   Massachusetts Institute of Technology
FX Funding: This work was supported by a Scientific Planning and Allocation
   of Resources Committee grant from the Broad Institute (D.M.S.), NIH
   grant 5R01-CA129105 (D.M.S.), and a grant from the Novartis Institutes
   for Biomedical Research (L.A.G.). K.C.W. is the recipient of an NIH Ruth
   L. Kirschstein National Research Service Award and a Misrock Fund
   Postdoctoral Fellowship through the Koch Institute for Integrative
   Cancer Research at the Massachusetts Institute of Technology. D.M.S. is
   an investigator of the Howard Hughes Medical Institute.
NR 74
TC 20
Z9 20
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAY 15
PY 2012
VL 5
IS 224
AR rs4
DI 10.1126/scisignal.2002612
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 942NH
UT WOS:000304050600002
PM 22589389
ER

PT J
AU Hayden, SJ
   Albert, TJ
   Watkins, TR
   Swenson, ER
AF Hayden, Shailaja J.
   Albert, Tyler J.
   Watkins, Timothy R.
   Swenson, Erik R.
TI Anemia in Critical Illness Insights into Etiology, Consequences, and
   Management
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE anemia; red blood cell; transfusion; erythropoietin; critical illness
ID BLOOD-CELL TRANSFUSION; RANDOMIZED CONTROLLED-TRIAL; ACUTE LUNG INJURY;
   RESPIRATORY-DISTRESS-SYNDROME; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ACUTE
   MYOCARDIAL-INFARCTION; SEVERE ISOVOLEMIC ANEMIA; PLACEBO-CONTROLLED
   TRIAL; CHRONIC KIDNEY-DISEASE; INTENSIVE-CARE UNITS
AB Anemia is common in the intensive care unit, and may be associated with adverse consequences. However, current options for correcting anemia are not without problems and presently lack convincing efficacy for improving survival in critically ill patients. In this article we review normal red blood cell physiology; etiologies of anemia in the intensive care unit; its association with adverse outcomes; and the risks, benefits, and efficacy of various management strategies, including blood transfusion, erythropoietin, blood substitutes, iron therapy, and minimization of diagnostic phlebotomy.
C1 [Hayden, Shailaja J.; Albert, Tyler J.; Watkins, Timothy R.; Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
   [Watkins, Timothy R.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
   [Albert, Tyler J.; Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA.
RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Box S-111-PULM,1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
FU National Institutes of Health, National Institute of General Medical
   Sciences [K23GM086729]; Department of Veterans Affairs
FX Supported by a grant from the National Institutes of Health, National
   Institute of General Medical Sciences (K23GM086729; T.R.W.); supported
   by a Merit Review grant from the Department of Veterans Affairs
   (E.R.S.). No source of support was used in the creation of this
   manuscript. None of the authors has a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript.
NR 117
TC 32
Z9 33
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 15
PY 2012
VL 185
IS 10
BP 1049
EP 1057
DI 10.1164/rccm.201110-1915CI
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 936WJ
UT WOS:000303620400008
PM 22281832
ER

PT J
AU Williams, SB
   Salami, S
   Regan, MM
   Ankerst, DP
   Wei, JT
   Rubin, MA
   Thompson, IM
   Sanda, MG
AF Williams, Stephen B.
   Salami, Simpa
   Regan, Meredith M.
   Ankerst, Donna P.
   Wei, John T.
   Rubin, Mark A.
   Thompson, Ian M.
   Sanda, Martin G.
TI Selective detection of histologically aggressive prostate cancer An
   Early Detection Research Network Prediction Model to Reduce Unnecessary
   Prostate Biopsies With Validation in the Prostate Cancer Prevention
   Trial
SO CANCER
LA English
DT Article
DE prostate cancer; biopsy; clinically significant; indolent
ID ANTIGEN DENSITY; MANAGEMENT; RISK; MEN; PROPHYLAXIS; MORTALITY;
   CARCINOMA; NOMOGRAM; THERAPY; TRENDS
AB BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P < .001). The Early Detection Research Network model outperformed PSA alone in predicting aggressive cancer (area under the curve [AUC] = 0.81 vs 0.71, P < .01). Model validation in the Prostate Cancer Prevention Trial cohort accurately identified men at low (<10%) risk of aggressive cancer for whom biopsy could be averted (AUC = 0.78; 95% confidence interval, 0.75-0.80). Under criteria from the Early Detection Research Network model, prostate biopsy can be restricted to men with PSAD >0.1 ng/mL/cc or abnormal DRE. When PSAD is <0.1 ng/mL/cc, family history or obesity can identify biopsy candidates. CONCLUSIONS: A predictive model incorporating age, family history, obesity, PSAD, and DRE elucidates criteria whereby 1/4 of prostate biopsies can be averted while retaining high sensitivity in detecting aggressive prostate cancer. Cancer 2011. (c) 2011 American Cancer Society.
C1 [Williams, Stephen B.; Salami, Simpa; Sanda, Martin G.] BIDMC, Div Urol, Boston, MA 02115 USA.
   [Williams, Stephen B.] Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA.
   [Williams, Stephen B.; Regan, Meredith M.; Sanda, Martin G.] Harvard Univ, Sch Med, Boston, MA USA.
   [Regan, Meredith M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Ankerst, Donna P.; Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Wei, John T.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
   [Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
RP Sanda, MG (reprint author), BIDMC, Div Urol, 330 Brookline Ave,Rabb 440, Boston, MA 02115 USA.
EM msanda@bidmc.harvard.edu
RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015; Wei,
   John/E-8967-2012; 
OI Rubin, Mark/0000-0002-8321-9950
FU National Cancer Institute-Early Detection Research Network, National
   Institutes of Health [U01 113913]
FX Supported by the National Cancer Institute-Early Detection Research
   Network, National Institutes of Health grant U01 113913.
NR 33
TC 11
Z9 13
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2012
VL 118
IS 10
BP 2651
EP 2658
DI 10.1002/cncr.26396
PG 8
WC Oncology
SC Oncology
GA 935DG
UT WOS:000303498500011
PM 22006057
ER

PT J
AU Xu, T
   Chen, MX
   Zhou, QH
   Xue, Y
   Wang, L
   De Arce, VJB
   Zhang, XL
   Jiang, W
AF Xu, Tao
   Chen, Moxi
   Zhou, Quanhong
   Xue, Ying
   Wang, Li
   De Arce, Vida J. Bil
   Zhang, Xiaoli
   Jiang, Wei
TI Antisense oligonucleotide knockdown of mGlu(5) receptor attenuates the
   antinociceptive tolerance and up-regulated expression of spinal protein
   kinase C associated with chronic morphine treatment
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Morphine; Tolerance; Metabotropic glutamate receptor 5 (mGlu(5)
   receptor); Protein kinase C (PKC); Intrathecal administration
ID LOCUS-COERULEUS NEURONS; DOWN-REGULATION; METABOTROPIC
   GLUTAMATE-RECEPTOR-5; CONDITIONED REWARD; ANTAGONISTS; MPEP; MICE; RAT;
   DESENSITIZATION; MGLUR5
AB Spinal metabotropic glutamate receptor 5 (mGlu(5) receptor) is known to influence the development of intrathecal morphine antinociceptive tolerance. However, the signaling mechanisms remain unknown. We carried out intrathecal administration of an antisense oligodeoxynucleotide (ODN), which results in reduced expression of spinal mGlu5 receptor, to determine its effects on morphine tolerance and spinal protein kinase C (PKC) expression. Rats were treated intrathecally with saline, morphine, mGlu5 receptor antisense ODN or mGlu5 receptor mismatched ODN. Behavioral tests were used to test the thermal and mechanical pain thresholds. Eight days later, rats were sacrificed and spinal cords were harvested to assess the expression of spinal PKC (alpha, gamma and epsilon) by Western blotting and real-time polymerase chain reaction (PCR). Compared to control, intrathecal mGlu(5) receptor antisense ODN resulted in a similar to 53.9% reduction of spinal mGlu(5) receptor after 8 days treatment. The mGlu5 receptor antisense ODN prevented the development of morphine tolerance. Expression of spinal PKC (alpha, gamma and epsilon) was up-regulated at the mRNA and protein levels during the development of tolerance. Meanwhile, antisense ODN but not mismatched ODN reduced the spinal dorsal horn levels of PKC (alpha, gamma and epsilon) which had been up-regulated after morphine exposure. We conclude that mGlu(5) receptor participates in the development of morphine tolerance. Expression of spinal PKC (alpha, gamma and epsilon) at the mRNA and protein levels increased during morphine tolerance. Antisense ODN of mGlu(5) receptor prevented the tolerance and inhibited the altered expression of spinal PKC (alpha, beta and epsilon) during the development of tolerance. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Xu, Tao; Chen, Moxi; Zhou, Quanhong; Xue, Ying; Wang, Li; Zhang, Xiaoli; Jiang, Wei] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Anesthesiol, Shanghai 200233, Peoples R China.
   [De Arce, Vida J. Bil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Jiang, W (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Anesthesiol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM Jiangw@sjtu.edu.cn
FU National Natural Science Foundation of China [30972850]; Ph.D. Programs
   Foundation of the Ministry of Education of China [200802480074];
   Shanghai Health Bureau [2009Y040]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30972850), the Ph.D. Programs Foundation of the
   Ministry of Education of China (200802480074), and a Youth Fund project
   to T. Xu from Shanghai Health Bureau (2009Y040).
NR 30
TC 2
Z9 4
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 15
PY 2012
VL 683
IS 1-3
BP 78
EP 85
DI 10.1016/j.ejphar.2012.02.046
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 934HY
UT WOS:000303436200010
PM 22429573
ER

PT J
AU Sandoval, KE
   Farr, SA
   Banks, WA
   Crider, AM
   Morley, JE
   Witt, KA
AF Sandoval, Karin E.
   Farr, Susan A.
   Banks, William A.
   Crider, Albert M.
   Morley, John E.
   Witt, Ken A.
TI Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases
   extracellular and intracellular A beta(1-42) trimers
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE NNC 26-9100; Somatostatin receptor subtype-4; Neprilysin; Amyloid-beta
   oligomers
ID AMYLOID PRECURSOR PROTEIN; A-BETA LEVELS; ALZHEIMERS-DISEASE; SAMP8
   MICE; SYNAPTIC PLASTICITY; OBJECT RECOGNITION; COGNITIVE DEFICITS;
   PLAQUE-FORMATION; TRANSGENIC MICE; MEMORY
AB Soluble amyloid beta-protein (A beta) oligomers are primary mediators of synaptic dysfunction associated with the progression of Alzheimer's disease. Such A beta oligomers exist dependent on their rates of aggregation and metabolism. Use of selective somatostatin receptor-subtype agonists have been identified as a potential means to mitigate A beta accumulation in the brain, via regulation of the enzyme neprilysin. Herein, we first evaluated the impact of the somatostatin receptor subtype-4 agonist 1-[3-[N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea (NNC 26-9100) on learning and memory in 12-month SAMP8 mice (i.c.v. injection). NNC 26-9100 (0.2 mu g-dose) was shown to enhance both learning (T-maze) and memory (object recognition) compared to vehicle controls. Cortical and hippocampal tissues were evaluated subsequent to NNC 26-9100 (0.2 mu g) or vehicle administration for changes in neprilysin activity, along with protein expression of amyloid-precursor protein (APP), neprilysin, and A beta(1-42) oligomers within respective cellular fractions (extracellular, intracellular and membrane). NNC 26-9100 increased neprilysin activity in cortical tissue, with an associated protein expression increase in the extracellular fraction and decreased in the intracellular fraction. A decrease in intracellular APP expression was found with treatment in both cortical and hippocampal tissues. NNC 26-9100 also significantly decreased expression of A beta(1-42) trimers within both the extracellular and intracellular cortical fractions. No expression changes were found in membrane fractions for any protein. These finding suggest the potential use of selective SSTR4 agonists to mitigate toxic oligomeric forms of A beta(1-42) in critical regions of the brain identified with learning and memory decline. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Sandoval, Karin E.; Crider, Albert M.; Witt, Ken A.] So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA.
   [Farr, Susan A.; Morley, John E.] Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO USA.
   [Farr, Susan A.; Morley, John E.] St Louis Univ, Sch Med, Div Geriatr, Dept Internal Med, St Louis, MO 63103 USA.
   [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
   [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Witt, KA (reprint author), So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Campus Box 2000, Edwardsville, IL 62026 USA.
EM kwitt@siue.edu
FU Alzheimer's Drug Discovery Foundation [261105.01]; VA Merit Review;
   National Institutes of Health National Institute on Aging [R21AG029318]
FX This work was supported by the Alzheimer's Drug Discovery Foundation
   (Grant: 261105.01), VA Merit Review, and the National Institutes of
   Health National Institute on Aging (Grant: R21AG029318).
NR 42
TC 6
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 15
PY 2012
VL 683
IS 1-3
BP 116
EP 124
DI 10.1016/j.ejphar.2012.03.020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 934HY
UT WOS:000303436200015
PM 22449380
ER

PT J
AU Keenan, BT
   Shulman, JM
   Chibnik, LB
   Raj, T
   Tran, D
   Sabuncu, MR
   Allen, AN
   Corneveaux, JJ
   Hardy, JA
   Huentelman, MJ
   Lemere, CA
   Myers, AJ
   Nicholson-Weller, A
   Reiman, EM
   Evans, DA
   Bennett, DA
   De Jager, PL
AF Keenan, Brendan T.
   Shulman, Joshua M.
   Chibnik, Lori B.
   Raj, Towfique
   Tran, Dong
   Sabuncu, Mert R.
   Allen, April N.
   Corneveaux, Jason J.
   Hardy, John A.
   Huentelman, Matthew J.
   Lemere, Cynthia A.
   Myers, Amanda J.
   Nicholson-Weller, Anne
   Reiman, Eric M.
   Evans, Denis A.
   Bennett, David A.
   De Jager, Philip L.
CA Alzheimers Dis Neuroimaging
TI A coding variant in CR1 interacts with APOE-?4 to influence cognitive
   decline
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ALZHEIMER-DISEASE PATHOLOGY; MANNAN-BINDING
   LECTIN; OLDER PERSONS; COMPLEMENT RECEPTOR-TYPE-1; CEREBRAL INFARCTIONS;
   IDENTIFIES VARIANTS; AMYLOID DEPOSITION; COMMON VARIANTS; MOUSE MODELS
AB Complement receptor 1 (CR1) is an Alzheimers disease (AD) susceptibility locus that also influences AD-related traits such as episodic memory decline and neuritic amyloid plaque deposition. We implemented a functional fine-mapping approach, leveraging intermediate phenotypes to identify functional variant(s) within the CR1 locus. Using 1709 subjects (697 deceased) from the Religious Orders Study and the Rush Memory and Aging Project, we tested 41 single-nucleotide polymorphisms (SNPs) within the linkage disequilibrium block containing the published CR1 AD SNP (rs6656401) for associations with episodic memory decline, and then examined the functional consequences of the top result. We report that a coding variant in the LHR-D (long homologous repeat D) region of the CR1 gene, rs4844609 (Ser1610Thr, minor allele frequency 0.02), is associated with episodic memory decline and accounts for the known effect of the index SNP rs6656401 (D 1, r(2) 0.084) on this trait. Further, we demonstrate that the coding variants effect is largely dependent on an interaction with APOE-?4 and mediated by an increased burden of AD-related neuropathology. Finally, in our data, this coding variant is also associated with AD susceptibility (joint odds ratio 1.4). Taken together, our analyses identify a CR1 coding variant that influences episodic memory decline; it is a variant known to alter the conformation of CR1 and points to LHR-D as the functional domain within the CR1 protein that mediates the effect on memory decline. We thus implicate C1q and MBL, which bind to LHR-D, as likely targets of the variants effect and suggest that CR1 may be an important intermediate in the clearance of A42 particles by C1q.
C1 [Keenan, Brendan T.; Shulman, Joshua M.; Chibnik, Lori B.; Raj, Towfique; Tran, Dong; De Jager, Philip L.] Brigham & Womens Hosp, Dept Neurol, Program Translat NeuroPsychiat Genom, Boston, MA 02115 USA.
   [Keenan, Brendan T.; Shulman, Joshua M.; Chibnik, Lori B.; Raj, Towfique; Tran, Dong; De Jager, Philip L.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   [Shulman, Joshua M.; Chibnik, Lori B.; Raj, Towfique; Lemere, Cynthia A.; Nicholson-Weller, Anne; De Jager, Philip L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Sabuncu, Mert R.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
   [Sabuncu, Mert R.] MIT, CSAIL, Cambridge, MA 02139 USA.
   [Sabuncu, Mert R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Allen, April N.; Corneveaux, Jason J.; Huentelman, Matthew J.; Reiman, Eric M.] Translat Genom Res Inst, Neurogen Div, Phoenix, AZ 85004 USA.
   [Allen, April N.; Corneveaux, Jason J.; Huentelman, Matthew J.; Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ 85004 USA.
   [Hardy, John A.] NIA, Neurogenet Lab, Porter Neurosci Res Ctr, Bethesda, MD 20892 USA.
   [Hardy, John A.] Inst Neurol, Dept Mol Neurosci, Reta Lila Weston Labs, London WC1N 3BG, England.
   [Lemere, Cynthia A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.
   [Myers, Amanda J.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
   [Myers, Amanda J.] Johnnie B Byrd Sr Alzheimers Ctr & Res Inst, Tampa, FL 33136 USA.
   [Nicholson-Weller, Anne] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Reiman, Eric M.] Univ Arizona, Banner Alzheimers Inst, Phoenix, AZ 85006 USA.
   [Reiman, Eric M.] Univ Arizona, Dept Psychiat, Phoenix, AZ 85006 USA.
   [Evans, Denis A.] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA.
   [Evans, Denis A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
   [Evans, Denis A.; Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
RP De Jager, PL (reprint author), Brigham & Womens Hosp, Dept Neurol, Program Translat NeuroPsychiat Genom, 77 Ave Louis Pasteur,NRB168, Boston, MA 02115 USA.
EM pdejager@rics.bwh.harvard.edu
RI Hardy, John/C-2451-2009; Myers, Amanda/B-1796-2010
OI Myers, Amanda/0000-0002-3100-9396
FU National Institutes of Health (NIH) [R01 AG30146, R01 AG179917, R01
   AG15819, K08 AG034290, P30 AG10161, R01 AG11101, R01NS059873, P50
   AG16573, R01 AG034504, K01AG024079, U01 AG024904, P30 AG010129, K01
   AG030514]; Illinois Department of Public Health; Burroughs Wellcome
   Fund; Beth Israel Deaconess Medical Center-Harvard/MIT Health Sciences
   and Technology; Pfizer, Inc.; Merck Co.; Arizona Alzheimer's Disease
   Center [P30 AG19610, RO1 AG023193]; Mayo Clinic Alzheimer's Disease
   Center [P50 AG16574]; Kronos Life Sciences Laboratories, the National
   Alzheimer's Coordinating Center [U01 AG016976]; NIH Neuroscience
   Blueprint [U24NS051872]; ENDGAME Consortium [UO1HL084744]; state of
   Arizona; National Institute of Biomedical Imaging and Bioengineering;
   Northern California Institute for Research and Education; Dana
   Foundation
FX This work is supported by the National Institutes of Health (NIH) (R01
   AG30146, R01 AG179917, R01 AG15819, K08 AG034290, P30 AG10161 and R01
   AG11101) and the Illinois Department of Public Health. J.M.S. was
   additionally supported by the Burroughs Wellcome Fund and the Clinical
   Investigator Training Program (Beth Israel Deaconess Medical
   Center-Harvard/MIT Health Sciences and Technology in collaboration with
   Pfizer, Inc. and Merck & Co.). M.J.H., J.J.C. and E. M. R. are supported
   by grants from the NIH (R01NS059873), Arizona Alzheimer's Disease Center
   P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer's Disease Center P50
   AG16574 and Intramural Research Program, Kronos Life Sciences
   Laboratories, the National Alzheimer's Coordinating Center (U01
   AG016976), the NIH Neuroscience Blueprint (U24NS051872), the ENDGAME
   Consortium (UO1HL084744), NIH grants to Carl Cotman (University of
   California, Irvine, P50 AG16573) and K01AG024079, and the state of
   Arizona. A.J.M. is supported by the NIH grant R01 AG034504 and the
   Johnnie B. Byrd Institute. J.A.H. would like to thank the Verum
   Foundation. Data collection and sharing for ADNI was funded by the NIH
   Grant U01 AG024904. ADNI is funded by the NIH, the National Institute of
   Biomedical Imaging and Bioengineering, through generous contributions
   from Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers
   Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech,
   GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli
   Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer,
   Inc., F. Hoffman-La Roche, Schering-Plough, Synarc, Inc. and non-profit
   partners the Alzheimer's Association and Alzheimer's Drug Discovery
   Foundation, with participation from the US Food and Drug Administration.
   Private sector contributions are facilitated by the Foundation for the
   NIH (www.fnih.org). The grantee organization is the Northern California
   Institute for Research and Education, and the study is coordinated by
   the Alzheimer's Disease Cooperative Study at the University of
   California, San Diego. ADNI data are disseminated by the Laboratory for
   Neuro Imaging at the University of California, Los Angeles. This
   research was also supported by NIH grants P30 AG010129, K01 AG030514,
   and the Dana Foundation. The funders had no role in study design, data
   collection, and analysis, decision to publish, or preparation of the
   manuscript.
NR 50
TC 37
Z9 37
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2012
VL 21
IS 10
BP 2377
EP 2388
DI 10.1093/hmg/dds054
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 933BH
UT WOS:000303333700020
PM 22343410
ER

PT J
AU Angin, M
   Kwon, DS
   Streeck, H
   Wen, F
   King, M
   Rezai, A
   Law, K
   Hongo, TC
   Pyo, A
   Piechocka-Trocha, A
   Toth, I
   Pereyra, F
   Ghebremichael, M
   Rodig, SJ
   Milner, DA
   Richter, JM
   Altfeld, M
   Kaufmann, DE
   Walker, BD
   Addo, MM
AF Angin, Mathieu
   Kwon, Douglas S.
   Streeck, Hendrik
   Wen, Fang
   King, Melanie
   Rezai, Ashley
   Law, Kenneth
   Hongo, Tomoyuki C.
   Pyo, Augustine
   Piechocka-Trocha, Alicja
   Toth, Ildiko
   Pereyra, Florencia
   Ghebremichael, Musie
   Rodig, Scott J.
   Milner, Danny A., Jr.
   Richter, James M.
   Altfeld, Marcus
   Kaufmann, Daniel E.
   Walker, Bruce D.
   Addo, Marylyn M.
TI Preserved Function of Regulatory T Cells in Chronic HIV-1 Infection
   Despite Decreased Numbers in Blood and Tissue
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ACTIVATION; SUPPRESSION
AB Regulatory T cells (Tregs) are potent immune modulators, but their role in human immunodeficiency virus type 1 (HIV-1) pathogenesis remains poorly understood. We performed a detailed analysis of the frequency and function of Tregs in a large cohort of HIV-1-infected individuals and HIV-1 negative controls. While HIV "elite controllers" and uninfected individuals had similar Treg numbers and frequencies, the absolute numbers of Tregs declined in blood and gut-associated lymphoid tissue in patients with chronic progressive HIV-1 infection. Despite quantitative changes in Tregs, HIV-1 infection was not associated with an impairment of ex vivo suppressive function of flow-sorted Tregs in both HIV controllers and untreated chronic progressors.
C1 [Angin, Mathieu; Kwon, Douglas S.; Streeck, Hendrik; Wen, Fang; King, Melanie; Rezai, Ashley; Law, Kenneth; Hongo, Tomoyuki C.; Pyo, Augustine; Piechocka-Trocha, Alicja; Toth, Ildiko; Pereyra, Florencia; Ghebremichael, Musie; Altfeld, Marcus; Kaufmann, Daniel E.; Walker, Bruce D.; Addo, Marylyn M.] Ragon Inst MGH MIT & Harvard, Charlestown, MA 02129 USA.
   [Kwon, Douglas S.; Kaufmann, Daniel E.; Addo, Marylyn M.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Richter, James M.] Massachusetts Gen Hosp, MIT & Harvard, Boston, MA 02114 USA.
   [Rodig, Scott J.; Milner, Danny A., Jr.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Addo, MM (reprint author), Ragon Inst MGH MIT & Harvard, 149 13th St,6th Floor,Ste 6620, Charlestown, MA 02129 USA.
EM maddo@partners.org
OI Angin, Mathieu/0000-0002-6867-4680
FU US National Institutes of Health (NIH) (NIAID [National Institute of
   Allergy and Infectious Diseases]) [KO8 AI074405, AI074405-03S1, 1K08
   AI084546-01]; Elisabeth Glaser Pediatric AIDS Foundation
   [MV-00-9-900-1429-0-00]; MGH/ECOR (Massachusetts General
   Hospital/Executive Committee on Research); Doris Duke Charitable
   Foundation; NIH [P30 AI060354]
FX This study was funded with federal funds from the US National Institutes
   of Health (NIH) (grants NIAID [National Institute of Allergy and
   Infectious Diseases] KO8 AI074405 and AI074405-03S1 to M. M. A. and 1K08
   AI084546-01 to D. K.). The work also received funding from the Elisabeth
   Glaser Pediatric AIDS Foundation (Pediatric HIV Vaccine Program award
   MV-00-9-900-1429-0-00 to M. M. A.), MGH/ECOR (Massachusetts General
   Hospital/Executive Committee on Research) (Physician Scientist
   Development Award to M. M. A.), and the Doris Duke Charitable Foundation
   (M. A.). The work was in part made possible with help from the Harvard
   University Center for AIDS Research, an NIH-funded program (P30
   AI060354) supported by the following NIH cofunding and participating
   institutes and centers: NIAID, NCI (National Cancer Institute), NICHD
   (National Institute of Child Health and Human Development), NHLBI
   (National Heart, Lung, and Blood Institute), NIDA (National Institute on
   Drug Abuse), NIMH (National Institute of Mental Health), NIA (National
   Institute on Aging), NCCAM (National Center for Complementary and
   Alternative Medicine), FIC (Fogarty International Center), and OAR
   (Office of AIDS Research).
NR 16
TC 37
Z9 37
U1 3
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2012
VL 205
IS 10
BP 1495
EP 1500
DI 10.1093/infdis/jis236
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 932ZO
UT WOS:000303329200004
PM 22427677
ER

PT J
AU Xu, GG
   McMahan, CA
   Hildreth, K
   Garcia, RA
   Herbert, DC
   Walter, CA
AF Xu, Guogang
   McMahan, C. Alex
   Hildreth, Kim
   Garcia, Rebecca A.
   Herbert, Damon C.
   Walter, Christi A.
TI Ionizing radiation-induced mutant frequencies increase transiently in
   male germ cells of older mice
SO MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
LA English
DT Article
DE Ionizing radiation; Age; Mutagenesis; Spermatogenic cells; lacI mouse
ID MOUSE MUTATION ASSAY; PARENTAL AGE; PATERNAL-AGE; SPERMATOGENIC CELLS;
   HETEROZYGOUS MICE; TRANSGENIC MICE; EXCISION-REPAIR; APERT-SYNDROME;
   TIME COURSES; RISK
AB Spontaneous mutant frequency in the male germline increases with age, thereby increasing the risk of siring offspring with genetic disorders. In the present study we investigated the effect of age on ionizing radiation-induced male germline mutagenesis. lad transgenic mice were treated with ionizing radiation at 4-, 15- and 26-month-old, and mutant frequencies were determined for pachytene spermatocytes and round spermatids at 15 days or 49 days after ionizing radiation treatment. Cells collected 15 days after treatment were derivatives of irradiated differentiating spermatogenic cells while cells collected 49 days later were derivatives of spermatogonial stem cells. The results showed that (1) spontaneous mutant frequency increased in spermatogenic cells recovered from nonirradiated old mice (26-months-old), particularly in the round spermatids; (2) mutant frequencies were significantly increased in round spermatids obtained from middle-aged mice (15-months-old) and old age mice (26-months-old) at 15 and 49 days after irradiation compared to the sham-treated old mice; and (3) pachytene spermatocytes obtained from 15- or 26-month-old mice displayed a significantly increased mutant frequency at 15 days post irradiation. This study indicates that age modulates the mutagenic response to ionizing radiation in the male germline. Published by Elsevier B.V.
C1 [Xu, Guogang; Hildreth, Kim; Garcia, Rebecca A.; Herbert, Damon C.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
   [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Walter, Christi A.] Audie Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU NIH [AG24364, AG21163]
FX This work was supported by NIH grants AG24364 and AG21163 to Dr. C.A.
   Walter. The contents are solely the responsibility of the authors, and
   do not necessarily represent the official views of the NIH or VHCS.
NR 41
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1383-5718
J9 MUTAT RES-GEN TOX EN
JI Mutat. Res. Genet. Toxicol. Environ. Mutagen.
PD MAY 15
PY 2012
VL 744
IS 2
BP 135
EP 139
DI 10.1016/j.mrgentox.2012.01.003
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 932NO
UT WOS:000303298000003
PM 22314132
ER

PT J
AU Smith, PD
   Puskas, F
   Meng, XZ
   Cho, D
   Cleveland, JC
   Weyant, MJ
   Watkins, MT
   Fullerton, DA
   Reece, TB
AF Smith, Philip D.
   Puskas, Ferenc
   Meng, Xianzhong
   Cho, Doug
   Cleveland, Joseph C., Jr.
   Weyant, Michael J.
   Watkins, Michael T.
   Fullerton, David A.
   Reece, T. Brett
TI Ischemic Dose-Response in the Spinal Cord: Both Immediate and Delayed
   Paraplegia
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE spinal cord; ischemia reperfusion; mouse; aortic surgery;
   thoracoabdominal aneurysm; paraparesis; paraplegia
ID THORACIC AORTIC DISEASE; ANEURYSM REPAIR; BLOOD-FLOW; MODEL;
   COMPLICATIONS; METAANALYSIS; HYPOTHERMIA; SURGERY; INJURY; MOUSE
AB Background. Paraplegia remains a significant complication of thoracoabdominal aortic surgery. The study of this spinal cord ischemia and reperfusion injury (SCIR) has been stifled by the constraints of current models. Large animal models are costly and restricting with regard to mechanisms of both injury and protection. While few studies of a murine model of SCIR have been published, the dose-response curve of the ischemic injury has not yet been published. We hypothesized that a viable dose-response curve of the neurological injury relative to the ischemic time could be developed.
   Materials and Methods. Through a cervicothoracic approach, the aortic arches of C57bl/6 mice were exposed to the origins of the left common carotid and the left subclavian arteries. The aorta was clamped between these two vessels with additional occlusion of the left subclavian artery. Ischemic times ranged from 3 to 12 min. Hindlimb motor function was observed for 48 h. Survival and motor function were evaluated. Spinal cord tissue was preserved for histologic analysis.
   Results. Survival curves showed increasing mortality with increasing spinal cord ischemia. This model reproduced spinal cord injury ranging from immediate paraplegia to progressive paraparesis depending on the ischemic time. Spinal cord histology mirrored the extent of functional deficits.
   Conclusions. Reproducible spinal cord ischemic injury is possible in a murine model and is directly translatable to thoracoabdominal surgery. The dose-response curve demonstrates that different degrees of injury can be studied from dense paraplegia to delayed onset injury depending on the ischemic insult. Published by Elsevier Inc.
C1 [Smith, Philip D.; Meng, Xianzhong; Cho, Doug; Cleveland, Joseph C., Jr.; Weyant, Michael J.; Fullerton, David A.; Reece, T. Brett] Univ Colorado, Dept Cardiothorac Surg, Aurora, CO 80045 USA.
   [Watkins, Michael T.] Massachusetts Gen Hosp, Dept Vasc Surg, Boston, MA 02114 USA.
   [Puskas, Ferenc] Univ Colorado, Dept Anesthesia, Aurora, CO 80045 USA.
RP Smith, PD (reprint author), Univ Colorado, Dept Cardiothorac Surg, Mail Stop C310,12631 E 17th Ave,Room 6601, Aurora, CO 80045 USA.
EM phillip.smith@ucdenver.edu
NR 19
TC 5
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAY 15
PY 2012
VL 174
IS 2
BP 238
EP 244
DI 10.1016/j.jss.2010.12.025
PG 7
WC Surgery
SC Surgery
GA 925RA
UT WOS:000302777500017
PM 21543089
ER

PT J
AU Garces, A
   McClure, EM
   Chomba, E
   Patel, A
   Pasha, O
   Tshefu, A
   Esamai, F
   Goudar, S
   Lokangaka, A
   Hambidge, KM
   Wright, LL
   Koso-Thomas, M
   Bose, C
   Carlo, WA
   Liechty, EA
   Hibberd, PL
   Bucher, S
   Whitworth, R
   Goldenberg, RL
AF Garces, Ana
   McClure, Elizabeth M.
   Chomba, Elwyn
   Patel, Archana
   Pasha, Omrana
   Tshefu, Antoinette
   Esamai, Fabian
   Goudar, Shivaprasad
   Lokangaka, Adrien
   Hambidge, K. Michael
   Wright, Linda L.
   Koso-Thomas, Marion
   Bose, Carl
   Carlo, Waldemar A.
   Liechty, Edward A.
   Hibberd, Patricia L.
   Bucher, Sherri
   Whitworth, Ryan
   Goldenberg, Robert L.
TI Home birth attendants in low income countries: who are they and what do
   they do?
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Home births; Traditional birth attendants; Perinatal mortality
ID NEWBORN-CARE; BANGLADESH; PREGNANCY; GUATEMALA; COMMUNITY; MORTALITY;
   DEATHS
AB Background: Nearly half the world's babies are born at home. We sought to evaluate the training, knowledge, skills, and access to medical equipment and testing for home birth attendants across 7 international sites.
   Methods: Face-to-face interviews were done by trained interviewers to assess level of training, knowledge and practices regarding care during the antenatal, intrapartum and postpartum periods. The survey was administered to a sample of birth attendants conducting home or out-of-facility deliveries in 7 sites in 6 countries (India, Pakistan, Guatemala, Democratic Republic of the Congo, Kenya and Zambia).
   Results: A total of 1226 home birth attendants were surveyed. Less than half the birth attendants were literate. Eighty percent had one month or less of formal training. Most home birth attendants did not have basic equipment (e. g., blood pressure apparatus, stethoscope, infant bag and mask manual resuscitator). Reporting of births and maternal and neonatal deaths to government agencies was low. Indian auxilliary nurse midwives, who perform some home but mainly clinic births, were far better trained and differed in many characteristics from the birth attendants who only performed deliveries at home.
   Conclusions: Home birth attendants in low-income countries were often illiterate, could not read numbers and had little formal training. Most had few of the skills or access to tests, medications and equipment that are necessary to reduce maternal, fetal or neonatal mortality.
C1 [Goldenberg, Robert L.] Columbia Univ, Dept Obstet & Gynecol, New York, NY 10027 USA.
   [Garces, Ana] IMSALUD, Guatemala City, Guatemala.
   [McClure, Elizabeth M.; Whitworth, Ryan] Res Triangle Inst, Durham, NC USA.
   [Chomba, Elwyn] Univ Teaching Hosp, Dept Pediat, Lusaka, Zambia.
   [Patel, Archana] Indira Ghandi Coll Med, Nagpur, Maharashtra, India.
   [Pasha, Omrana] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.
   [Tshefu, Antoinette; Lokangaka, Adrien] Kinshasa Sch Publ Hlth, Kinshasa, Zaire.
   [Esamai, Fabian] Moi Univ, Dept Pediat, Eldoret, Kenya.
   [Goudar, Shivaprasad] Jawaharlal Nehru Med Coll, Dept Med Educ, Belgaum, India.
   [Hambidge, K. Michael] Univ Denver, Sch Publ Hlth, Dept Pediat Nutr, Denver, CO USA.
   [Wright, Linda L.; Koso-Thomas, Marion] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Ctr Res Mothers & Children, Bethesda, MD USA.
   [Bose, Carl] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA.
   [Carlo, Waldemar A.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Liechty, Edward A.; Bucher, Sherri] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA.
   [Hibberd, Patricia L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Goldenberg, RL (reprint author), Columbia Univ, Dept Obstet & Gynecol, New York, NY 10027 USA.
OI GOUDAR, SHIVAPRASAD/0000-0002-8680-7053
FU Bill & Melinda Gates Foundation; Eunice Kennedy Shriver National
   Institute of Child Health and Human Development
FX The study was funded by the Bill & Melinda Gates Foundation and the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development. The investigators were solely responsible for the design
   and implementation of the study, without influence by the funding
   agencies (uoi HD040636).
NR 18
TC 17
Z9 17
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD MAY 14
PY 2012
VL 12
AR 34
DI 10.1186/1471-2393-12-34
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 038ZJ
UT WOS:000311212300001
PM 22583622
ER

PT J
AU Khanna, A
   Bush, AL
   Swint, JM
   Peskin, MF
   Street, RL
   Naik, AD
AF Khanna, Abhinav
   Bush, Amber L.
   Swint, J. Michael
   Peskin, Melissa Fleschler
   Street, Richard L., Jr.
   Naik, Aanand D.
TI Hemoglobin A(1c) improvements and better diabetes-specific quality of
   life among participants completing diabetes self-management programs: A
   nested cohort study
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Diabetes-specific quality of life; Diabetes; Quality of life;
   Diabetes-39; Self-management; Hemoglobin A(1c)
ID REPORTED HEALTH; CANCER-PATIENTS; OUTCOMES; SURVIVAL; PEOPLE; SCALE;
   CARE; CHEMOTHERAPY; COMORBIDITY; VALIDATION
AB Background: Numerous primary care innovations emphasize patient-centered processes of care. Within the context of these innovations, greater understanding is needed of the relationship between improvements in clinical endpoints and patient-centered outcomes. To address this gap, we evaluated the association between glycosylated hemoglobin (HbA(1c)) and diabetes-specific quality of life among patients completing diabetes self-management programs.
   Methods: We conducted a retrospective cohort study nested within a randomized comparative effectiveness trial of diabetes self-management interventions in 75 diabetic patients. Multiple linear regression models were developed to examine the relationship between change in HbA(1c) from baseline to one-year follow-up and Diabetes-39 (a diabetes-specific quality of life measure) at one year.
   Results: HbA(1c) levels improved for the overall cohort from baseline to one-year follow-up (t (74) = 3.09, p =.0029). One-year follow up HbA(1c) was correlated with worse overall quality of life (r = 0.33, p = 0.004). Improvements in HbA(1c) from baseline to one-year follow-up were associated with greater D-39 diabetes control (beta = 0.23, p = .04) and D-39 sexual functioning (beta = 0.25, p = .03) quality of life subscales.
   Conclusions: Improvements in HbA(1c) among participants completing a diabetes self-management program were associated with better diabetes-specific quality of life. Innovations in primary care that engage patients in self-management and improve clinical biomarkers, such as HbA(1c), may also be associated with better quality of life, a key outcome from the patient perspective.
C1 [Khanna, Abhinav; Bush, Amber L.; Street, Richard L., Jr.; Naik, Aanand D.] Baylor Coll Med, Houston, TX 77030 USA.
   [Bush, Amber L.; Street, Richard L., Jr.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr 152, Houston Hlth Serv Res & Dev, Ctr Excellence, Houston, TX 77030 USA.
   [Swint, J. Michael; Peskin, Melissa Fleschler] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA.
   [Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA.
RP Naik, AD (reprint author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.
EM anaik@bcm.edu
FU Agency for Healthcare Research and Quality, Centers for Research and
   Education on Therapeutics [U18HS016093]; Clinical Scientist Development
   Award from the Doris Duke Charitable Foundation; National Institute of
   Aging [K23AG027144]; Houston Health Services Research and Development
   Center of Excellence at the Michael E. DeBakey Veterans Affairs Medical
   Center [HFP90-020]
FX The EPIC study was supported by a grant from the Agency for Healthcare
   Research and Quality, Centers for Research and Education on Therapeutics
   (U18HS016093; principalinvestigator, Dr Suarez-Almazor). Additional
   support for the EPIC Study was provided by a Clinical Scientist
   Development Award from the Doris Duke Charitable Foundation (principal
   investigator, Dr Naik). Dr Naik received additional support from the
   National Institute of Aging (K23AG027144) and the Houston Health
   Services Research and Development Center of Excellence (HFP90-020) at
   the Michael E. DeBakey Veterans Affairs Medical Center.
NR 44
TC 12
Z9 13
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD MAY 14
PY 2012
VL 10
AR 48
DI 10.1186/1477-7525-10-48
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 986YZ
UT WOS:000307384900001
PM 22583609
ER

PT J
AU Cipriani, S
   Desjardins, CA
   Burdett, TC
   Xu, YH
   Xu, K
   Schwarzschild, MA
AF Cipriani, Sara
   Desjardins, Cody A.
   Burdett, Thomas C.
   Xu, Yuehang
   Xu, Kui
   Schwarzschild, Michael A.
TI Urate and Its Transgenic Depletion Modulate Neuronal Vulnerability in a
   Cellular Model of Parkinson's Disease
SO PLOS ONE
LA English
DT Article
ID 1-METHYL-4-PHENYLPYRIDINIUM ION MPP+; URIC-ACID LEVELS; EVOLUTIONARY
   IMPLICATIONS; MEMBRANE-PERMEABILITY; DOPAMINERGIC-NEURONS; GLUTAMATE
   TOXICITY; LIPID-PEROXIDATION; MOUSE ASTROCYTES; PC12 CELLS; OXIDASE
AB Urate is a major antioxidant as well as the enzymatic end product of purine metabolism in humans. Higher levels correlate with a reduced risk of developing Parkinson's disease (PD) and with a slower rate of PD progression. In this study we investigated the effects of modulating intracellular urate concentration on 1-methyl-4-phenyl-pyridinium (MPP+)-induced degeneration of dopaminergic neurons in cultures of mouse ventral mesencephalon prepared to contain low (neuron-enriched cultures) or high (neuron-glial cultures) percentage of astrocytes. Urate, added to the cultures 24 hours before and during treatment with MPP+, attenuated the loss of dopaminergic neurons in neuron-enriched cultures and fully prevented their loss and atrophy in neuron-astrocyte cultures. Exogenous urate was found to increase intracellular urate content in cortical neuronal cultures. To assess the effect of reducing cellular urate content on MPP+-induced toxicity, mesencephalic neurons were prepared from mice over-expressing urate oxidase (UOx). Transgenic UOx expression decreased endogenous urate content both in neurons and astrocytes. Dopaminergic neurons expressing UOx were more susceptible to MPP+ in mesencephalic neuron-enriched cultures and to a greater extent in mesencephalic neuron-astrocyte cultures. Our findings correlate intracellular urate content in dopaminergic neurons with their toxin resistance in a cellular model of PD and suggest a facilitative role for astrocytes in the neuroprotective effect of urate.
C1 [Cipriani, Sara; Desjardins, Cody A.; Burdett, Thomas C.; Xu, Yuehang; Xu, Kui; Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
RP Cipriani, S (reprint author), Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
EM scipriani@partners.org
FU United States National Institutes of Health [R21NS058324, K24NS060991];
   US Department of Defense [W81XWH-11-1-0150]; American Parkinson Disease
   Association
FX Funding came from the United States National Institutes of Health
   http://www.nih.gov/(R21NS058324 and K24NS060991), US Department of
   Defense http://www.defense.gov/(W81XWH-11-1-0150), and the American
   Parkinson Disease Association
   http://www.apdaparkinson.org/userND/index.asp. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 56
TC 22
Z9 23
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2012
VL 7
IS 5
AR e37331
DI 10.1371/journal.pone.0037331
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UF
UT WOS:000305339400080
PM 22606360
ER

PT J
AU Trautner, BW
   Gupta, K
AF Trautner, Barbara W.
   Gupta, Kalpana
TI The Advantages of Second Best Preventing Recurrent Cystitis While
   Sparing the Microbiome
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID INFECTIOUS-DISEASES; WOMEN
C1 [Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, HSR&D Ctr Excellence 152, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
   [Trautner, Barbara W.] Baylor Coll Med, Hlth Serv Res & Dev HSR&D Ctr Excellence, Houston, TX 77030 USA.
   [Gupta, Kalpana] VA Boston Healthcare Syst, Dept Med, Boston, MA USA.
   [Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Gupta, Kalpana] Natl Ctr Occupat Hlth & Infect Control, Off Pub Hlth & Environm Hazards, Vet Hlth Adm, Gainesville, FL USA.
RP Trautner, BW (reprint author), Michael E DeBakey VA Med Ctr, HSR&D Ctr Excellence 152, Dept Med, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM trautner@bcm.edu
FU HSRD VA [I01 HX000139]; NICHD NIH HHS [R21 HD058985]; NIDDK NIH HHS [R21
   DK092293]
NR 8
TC 4
Z9 4
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 14
PY 2012
VL 172
IS 9
BP 712
EP 714
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 941ZF
UT WOS:000304007800007
PM 22782200
ER

PT J
AU Smith, JG
   Newton-Cheh, C
   Almgren, P
   Melander, O
   Platonov, PG
AF Smith, J. Gustav
   Newton-Cheh, Christopher
   Almgren, Peter
   Melander, Olle
   Platonov, Pyotr G.
TI Genetic Polymorphisms for Estimating Risk of Atrial Fibrillation in the
   General Population: A Prospective Study
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID VARIANTS; COHORT; SCORE
C1 [Smith, J. Gustav; Platonov, Pyotr G.] Lund Univ, Dept Cardiol, SE-22185 Lund, Sweden.
   [Smith, J. Gustav; Almgren, Peter; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden.
   [Smith, J. Gustav; Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
   [Newton-Cheh, Christopher] Ctr Human Genet Res, Boston, MA USA.
   [Newton-Cheh, Christopher] Harvard Univ, Sch Med, Cardiovasc Res Ctr, Boston, MA USA.
   [Newton-Cheh, Christopher] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Smith, JG (reprint author), Lund Univ, Skane Univ Hosp, Dept Cardiol, Fac Med, SE-22185 Lund, Sweden.
EM gustav.smith@med.lu.se
FU European Research Council [282255]; NHLBI NIH HHS [HL098283, K23
   HL080025, R01 HL098283, HL080025]
NR 7
TC 14
Z9 14
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 14
PY 2012
VL 172
IS 9
BP 742
EP 744
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 941ZF
UT WOS:000304007800015
PM 22782207
ER

PT J
AU Smith, MR
   Saad, F
   Coleman, R
   Ye, ZS
   Goessl, C
AF Smith, Matthew R.
   Saad, Fred
   Coleman, Robert
   Ye, Zhishen
   Goessl, Carsten
TI Denosumab in castration-resistant prostate cancer Reply
SO LANCET
LA English
DT Letter
C1 [Smith, Matthew R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
   [Saad, Fred] Univ Montreal, Ctr Hosp, CRCHUM, Montreal, PQ, Canada.
   [Coleman, Robert] Weston Pk Hosp, Sheffield, S Yorkshire, England.
   [Ye, Zhishen; Goessl, Carsten] Amgen Inc, Thousand Oaks, CA USA.
RP Smith, MR (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM smith.matthew@mgh.harvard.edu
NR 2
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 12
PY 2012
VL 379
IS 9828
BP E50
EP E51
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 941BR
UT WOS:000303937700002
ER

PT J
AU Koulmanda, M
   Bhasin, M
   Awdeh, Z
   Qipo, AD
   Fan, ZG
   Hanidziar, D
   Putheti, P
   Shi, H
   Csizuadia, E
   Libermann, TA
   Strom, TB
AF Koulmanda, Maria
   Bhasin, Manoj
   Awdeh, Zuheir
   Qipo, Andi
   Fan, Zhigang
   Hanidziar, Dusan
   Putheti, Prabhakar
   Shi, Hang
   Csizuadia, Eva
   Libermann, Towia A.
   Strom, Terry B.
TI The Role of TNF-alpha in Mice with Type 1-and 2-Diabetes
SO PLOS ONE
LA English
DT Article
ID NONOBESE DIABETIC MICE; NECROSIS-FACTOR-ALPHA; NOD MICE; BIOCONDUCTOR
   PACKAGE; T-CELLS; THERAPY; MOUSE; AUTOIMMUNITY; PROGRESSION; TOLERANCE
AB Background: Previously, we have demonstrated that short-term treatment of new onset diabetic Non-obese diabetic (NOD) mice, mice that are afflicted with both type 1 (T1D) and type 2 (T2D) diabetes with either Power Mix (PM) regimen or alpha1 antitrypsin (AAT) permanently restores euglycemia, immune tolerance to self-islets and normal insulin signaling.
   Methodology and Principal Findings: To search for relevant therapeutic targets, we have applied genome wide transcriptional profiling and systems biology oriented bioinformatics analysis to examine the impact of the PM and AAT regimens upon pancreatic lymph node (PLN) and fat, a crucial tissue for insulin dependent glucose disposal, in new onset diabetic non-obese diabetic (NOD) mice. Systems biology analysis identified tumor necrosis factor alpha (TNF-alpha) as the top focus gene hub, as determined by the highest degree of connectivity, in both tissues. In PLNs and fat, TNF-alpha interacted with 53% and 32% of genes, respectively, associated with reversal of diabetes by previous treatments and was thereby selected as a therapeutic target. Short-term anti-TNF-alpha treatment ablated a T cell-rich islet-invasive and beta cell-destructive process, thereby enhancing beta cell viability. Indeed anti-TNF-alpha treatment induces immune tolerance selective to syngeneic beta cells. In addition to these curative effects on T1D anti-TNF-alpha treatment restored in vivo insulin signaling resulting in restoration of insulin sensitivity.
   Conclusions: In short, our molecular analysis suggested that PM and AAT both may act in part by quenching a detrimental TNF-alpha dependent effect in both fat and PLNs. Indeed, short-term anti-TNF-alpha mAb treatment restored enduring euglycemia, self-tolerance, and normal insulin signaling.
C1 [Koulmanda, Maria; Qipo, Andi; Fan, Zhigang; Hanidziar, Dusan; Putheti, Prabhakar; Csizuadia, Eva; Strom, Terry B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg,Transplant Inst, Boston, MA 02215 USA.
   [Koulmanda, Maria; Qipo, Andi; Fan, Zhigang; Hanidziar, Dusan; Putheti, Prabhakar; Csizuadia, Eva; Strom, Terry B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Transplant Inst, Boston, MA 02215 USA.
   [Bhasin, Manoj; Libermann, Towia A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, BIDMC Genom & Prote Ctr,Med Sch, Boston, MA 02215 USA.
   [Awdeh, Zuheir] Pulsar Clin Technol Inc, Cambridge, MA USA.
   [Shi, Hang] Wake Forest Hlth Sci, Dept Internal Med, Winston Salem, NC USA.
RP Koulmanda, M (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg,Transplant Inst, Boston, MA 02215 USA.
EM mkoulman@bidmc.harvard.edu; tstrom@bidmc.harvard.edu
OI Libermann, Towia/0000-0002-4006-8179
FU Juvenile Diabetes Research Foundation; National Institutes of Health
   (NIH) [JDRF 402004-368 NIH, NIH RO1 AI54976, NIH RO1 DK067632, NIH PO1
   AI041521, NIH NIH R37 DK 28082, NIH DK44523, DK 66056]
FX This work was funded both by the Juvenile Diabetes Research Foundation
   and National Institutes of Health (NIH). Juvenile Diabetes Research
   Foundation: TS, MK, ZF: JDRF 402004-368 NIH: MK, BH, AQ: NIH RO1
   AI54976; MK, TS: NIH RO1 DK067632: TS, PP: NIH PO1 AI041521; JSF, HS:
   NIH NIH R37 DK 28082: SBW: NIH DK44523 and DK 66056. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
NR 27
TC 12
Z9 13
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2012
VL 7
IS 5
AR e33254
DI 10.1371/journal.pone.0033254
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TW
UT WOS:000305338200002
PM 22606220
ER

PT J
AU Wang, ZY
   Feng, Y
   Bardessy, N
   Wong, KK
   Liu, XY
   Ji, HB
AF Wang, Zuoyun
   Feng, Yan
   Bardessy, Nabeel
   Wong, Kwok-Kin
   Liu, Xin-Yuan
   Ji, Hongbin
TI Temporal Dissection of K-ras(G12D) Mutant In Vitro and In Vivo Using a
   Regulatable K-ras(G12D) Mouse Allele
SO PLOS ONE
LA English
DT Article
ID LUNG-CANCER PROGRESSION; K-RAS; INDUCED APOPTOSIS; P53 RESTORATION;
   ACTIVATION; CELLS; MICE; MYC; INHIBITORS; EXPRESSION
AB Animal models which allow the temporal regulation of gene activities are valuable for dissecting gene function in tumorigenesis. Here we have constructed a conditional inducible estrogen receptor-K-ras(G12D) (ER-K-ras(G12D)) knock-in mice allele that allows us to temporally switch on or off the activity of K-ras oncogenic mutant through tamoxifen administration. In vitro studies using mice embryonic fibroblast (MEF) showed that a dose of tamoxifen at 0.05 mu M works optimally for activation of ER-K-ras(G12D) independent of the gender status. Furthermore, tamoxifen-inducible activation of K-ras(G12D) promotes cell proliferation, anchor-independent growth, transformation as well as invasion, potentially via activation of downstream MAPK pathway and cell cycle progression. Continuous activation of K-ras(G12D) in vivo by tamoxifen treatment is sufficient to drive the neoplastic transformation of normal lung epithelial cells in mice. Tamoxifen withdrawal after the tumor formation results in apoptosis and tumor regression in mouse lungs. Taken together, these data have convincingly demonstrated that K-ras mutant is essential for neoplastic transformation and this animal model may provide an ideal platform for further detailed characterization of the role of K-ras oncogenic mutant during different stages of lung tumorigenesis.
C1 [Wang, Zuoyun; Feng, Yan; Liu, Xin-Yuan; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai, Peoples R China.
   [Bardessy, Nabeel] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Wong, Kwok-Kin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Wang, ZY (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai, Peoples R China.
EM kwong1@partners.org; xyliu@sibs.ac.cn; hbji@sibs.ac.cn
OI wong, kwok kin/0000-0001-6323-235X
FU National Basic Research Program of China [2012CB910800, 2010CB912102];
   National Natural Science Foundation of China [30971461]
FX This work was supported by the National Basic Research Program of China
   (2012CB910800 and 2010CB912102), the National Natural Science Foundation
   of China (30971461). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 46
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2012
VL 7
IS 5
AR e37308
DI 10.1371/journal.pone.0037308
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TW
UT WOS:000305338200070
PM 22606359
ER

PT J
AU Eck, MJ
   Hahn, WC
AF Eck, Michael J.
   Hahn, William C.
TI EGFR in Limbo
SO CELL
LA English
DT Editorial Material
ID GROWTH-FACTOR RECEPTOR; KINASE DOMAIN; LUNG-CANCER; ACTIVATION;
   INHIBITOR; CONTRIBUTES; MUTATIONS; MECHANISM
AB The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization. Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic mutations counteract this intrinsic structural instability to promote dimerization and aberrant activation.
C1 [Eck, Michael J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Eck, Michael J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Hahn, William C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Hahn, William C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
RP Eck, MJ (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02215 USA.
EM eck@red.dfci.harvard.edu; william_hahn@dfci.harvard.edu
FU NCI NIH HHS [R01 CA116020]
NR 10
TC 0
Z9 1
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 11
PY 2012
VL 149
IS 4
BP 735
EP 737
DI 10.1016/j.cell.2012.04.015
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 941AR
UT WOS:000303934700007
PM 22579278
ER

PT J
AU Kessl, JJ
   Jena, N
   Koh, Y
   Taskent-Sezgin, H
   Slaughter, A
   Feng, L
   de Silva, S
   Wu, L
   Le Grice, SFJ
   Engelman, A
   Fuchs, JR
   Kvaratskhelia, M
AF Kessl, Jacques J.
   Jena, Nivedita
   Koh, Yasuhiro
   Taskent-Sezgin, Humeyra
   Slaughter, Alison
   Feng, Lei
   de Silva, Suresh
   Wu, Li
   Le Grice, Stuart F. J.
   Engelman, Alan
   Fuchs, James R.
   Kvaratskhelia, Mamuka
TI Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase
   Inhibitors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; CATALYTIC DOMAIN; STRUCTURAL
   BASIS; COACTIVATOR P75; DNA INTEGRATION; BINDING DOMAIN; LEDGF/P75;
   PROTEIN; IDENTIFICATION
AB The multifunctional HIV-1 enzyme integrase interacts with viral DNA and its key cellular cofactor LEDGF to effectively integrate the reverse transcript into a host cell chromosome. These interactions are crucial for HIV-1 replication and present attractive targets for antiviral therapy. Recently, 2-(quinolin-3-yl) acetic acid derivatives were reported to selectively inhibit the integrase-LEDGF interaction in vitro and impair HIV-1 replication in infected cells. Here, we show that this class of compounds impairs both integrase-LEDGF binding and LEDGF-independent integrase catalytic activities with similar IC50 values, defining them as bona fide allosteric inhibitors of integrase function. Furthermore, we show that 2-(quinolin-3-yl) acetic acid derivatives block the formation of the stable synaptic complex between integrase and viral DNA by allosterically stabilizing an inactive multimeric form of integrase. In addition, these compounds inhibit LEDGF binding to the stable synaptic complex. This multimode mechanism of action concordantly results in cooperative inhibition of the concerted integration of viral DNA ends in vitro and HIV-1 replication in cell culture. Our findings, coupled with the fact that high cooperativity of antiviral inhibitors correlates with their increased instantaneous inhibitory potential, an important clinical parameter, argue strongly that improved 2-(quinolin-3-yl) acetic acid derivatives could exhibit desirable clinical properties.
C1 [Kessl, Jacques J.; Slaughter, Alison; Feng, Lei; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, Columbus, OH 43210 USA.
   [Kessl, Jacques J.; Slaughter, Alison; Feng, Lei; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Jena, Nivedita; Fuchs, James R.] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA.
   [Koh, Yasuhiro; Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
   [Koh, Yasuhiro; Engelman, Alan] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
   [de Silva, Suresh; Wu, Li] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
   [Taskent-Sezgin, Humeyra; Le Grice, Stuart F. J.] Ohio State Univ, Dept Vet Biosci, Ctr Retrovirus Res, Columbus, OH 43210 USA.
RP Kvaratskhelia, M (reprint author), Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, 500 W 12Th Ave, Columbus, OH 43210 USA.
EM kvaratskhelia.1@osu.edu
RI Jena, Nivedita/F-4945-2012; Fuchs, James/B-4625-2012; Wu,
   Li/E-4330-2011; Kessl, Jacques/J-6073-2015
OI Wu, Li/0000-0002-5468-2487; 
FU National Institutes of Health [AI081581, AI062520, CA100730, AI097044,
   AI039394]; NCI, National Institutes of Health, Department of Health and
   Human Services
FX This work was supported by National Institutes of Health Grants
   AI081581, AI062520, and CA100730 (to M. K.), AI097044 (to J. J. K. and
   J. R. F.), AI039394 (to A. E.); the Intramural Research Program of the
   NCI, National Institutes of Health, Department of Health and Human
   Services (to H. T. S. and S. F. J. L. G.).
NR 40
TC 76
Z9 77
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 11
PY 2012
VL 287
IS 20
BP 16801
EP 16811
DI 10.1074/jbc.M112.354373
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 942GB
UT WOS:000304030900067
PM 22437836
ER

PT J
AU Black, JC
   Whetstine, JR
AF Black, Joshua C.
   Whetstine, Johnathan R.
TI LOX Out, Histones: A New Enzyme Is Nipping at Your Tails
SO MOLECULAR CELL
LA English
DT Editorial Material
ID LYSYL OXIDASE
C1 [Black, Joshua C.; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
   [Black, Joshua C.; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA.
RP Whetstine, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 13th St, Charlestown, MA 02129 USA.
EM jwhetstine@hms.harvard.edu
RI Black, Joshua/Q-2484-2015
NR 8
TC 4
Z9 4
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 11
PY 2012
VL 46
IS 3
BP 243
EP 244
DI 10.1016/j.molcel.2012.04.023
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 942SZ
UT WOS:000304071100003
PM 22578539
ER

PT J
AU Johnson, K
   Zhu, ST
   Tremblay, MS
   Payette, JN
   Wang, JN
   Bouchez, LC
   Meeusen, S
   Althage, A
   Cho, CY
   Wu, X
   Schultz, PG
AF Johnson, Kristen
   Zhu, Shoutian
   Tremblay, Matthew S.
   Payette, Joshua N.
   Wang, Jianing
   Bouchez, Laure C.
   Meeusen, Shelly
   Althage, Alana
   Cho, Charles Y.
   Wu, Xu
   Schultz, Peter G.
TI A Stem Cell-Based Approach to Cartilage Repair
SO SCIENCE
LA English
DT Article
ID ARTICULAR-CARTILAGE; CHONDROCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR;
   OSTEOARTHRITIS; BONE; PATHOGENESIS; FILAMIN; GENE; CHONDROGENESIS;
   EXPRESSION
AB Osteoarthritis (OA) is a degenerative joint disease that involves the destruction of articular cartilage and eventually leads to disability. Molecules that promote the selective differentiation of multipotent mesenchymal stem cells (MSCs) into chondrocytes may stimulate the repair of damaged cartilage. Using an image-based high-throughput screen, we identified the small molecule kartogenin, which promotes chondrocyte differentiation (median effective concentration = 100 nM), shows chondroprotective effects in vitro, and is efficacious in two OA animal models. Kartogenin binds filamin A, disrupts its interaction with the transcription factor core-binding factor beta subunit (CBF beta), and induces chondrogenesis by regulating the CBF beta-RUNX1 transcriptional program. This work provides new insights into the control of chondrogenesis that may ultimately lead to a stem cell-based therapy for osteoarthritis.
C1 [Johnson, Kristen; Tremblay, Matthew S.; Meeusen, Shelly; Althage, Alana; Cho, Charles Y.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
   [Zhu, Shoutian; Tremblay, Matthew S.; Payette, Joshua N.; Wang, Jianing; Bouchez, Laure C.; Schultz, Peter G.] Scripps Res Inst, La Jolla, CA 92037 USA.
   [Wu, Xu] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
RP Johnson, K (reprint author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
EM kjohnson@gnf.org; schultz@scripps.edu
OI Johnson, Kristen/0000-0003-0788-7217
FU California Institute for Regenerative Medicine [TR2-01829]
FX This work was funded by grants from the California Institute for
   Regenerative Medicine (TR2-01829 to P.G.S.). We are grateful to J.
   Walker for help in gene expression analysis. Microarray data have been
   deposited in the National Center for Biotechnology Information's Gene
   Expression Omnibus with accession number GSE35546. A patent application
   has been submitted by the authors on the use of kartogenin for
   chondrogenesis.
NR 35
TC 142
Z9 149
U1 18
U2 160
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 11
PY 2012
VL 336
IS 6082
BP 717
EP 721
DI 10.1126/science.1215157
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 940EH
UT WOS:000303872300049
PM 22491093
ER

PT J
AU Kumar, S
   Flinn, I
   Richardson, PG
   Hari, P
   Callander, N
   Noga, SJ
   Stewart, AK
   Turturro, F
   Rifkin, R
   Wolf, J
   Estevam, J
   Mulligan, G
   Shi, HL
   Webb, IJ
   Rajkumar, SV
AF Kumar, Shaji
   Flinn, Ian
   Richardson, Paul G.
   Hari, Parameswaran
   Callander, Natalie
   Noga, Stephen J.
   Stewart, A. Keith
   Turturro, Francesco
   Rifkin, Robert
   Wolf, Jeffrey
   Estevam, Jose
   Mulligan, George
   Shi, Hongliang
   Webb, Iain J.
   Rajkumar, S. Vincent
TI Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of
   bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in
   previously untreated multiple myeloma
SO BLOOD
LA English
DT Article
ID THALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; INDUCTION
   THERAPY; CLINICAL-TRIAL; ONCOLOGY-GROUP; STRATIFICATION; PREDNISONE;
   MELPHALAN; SURVIVAL; EFFICACY
AB Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized phase 2 trial evaluated VDC, VDR, and VDCR in previously untreated multiple myeloma (MM). Patients received V 1.3 mg/m(2) (days 1, 4, 8, 11) and D 40 mg (days 1, 8, 15), with either C 500 mg/m(2) (days 1, 8) and R 15 mg (days 1-14; VDCR), R 25 mg (days 1-14; VDR), C 500 mg/m(2) (days 1, 8; VDC) or C 500 mg/m(2) (days 1, 8, 15; VDC-mod) in 3-week cycles (maximum 8 cycles), followed by maintenance with V 1.3 mg/m(2) (days 1, 8, 15, 22) for four 6-week cycles (all arms) >= very good partial response was seen in 58%, 51%, 41%, and 53% (complete response rate of 25%, 24%, 22%, and 47%) of patients (VDCR, VDR, VCD, and VCD-mod, respectively); the corresponding 1-year progression-free survival was 86%, 83%, 93%, and 100%, respectively. Common adverse events included hematologic toxicities, peripheral neuropathy, fatigue, and gastrointestinal disturbances. All regimens were highly active and well tolerated in previously untreated MM, and, based on this trial, VDR and VCD-mod are preferred for clinical practice and further comparative testing. No substantial advantage was noted with VDCR over the 3-drug combinations. This trial is registered at www.clinicaltrials.gov (NCT00507442). (Blood. 2012;119(19):4375-4382)
C1 [Kumar, Shaji; Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN 55905 USA.
   [Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA.
   [Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA.
   [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
   [Callander, Natalie] Univ Wisconsin, Bone Marrow Hematol Clin, Ctr Comprehens Canc, Madison, WI USA.
   [Noga, Stephen J.] Sinai Hosp, Baltimore, MD 21215 USA.
   [Stewart, A. Keith] Mayo Clin Arizona, Div Hematol & Oncol, Scottsdale, AZ USA.
   [Turturro, Francesco] Louisiana State Univ, Dept Med, Feist Weiller Canc Ctr, Hlth Sci Ctr, Shreveport, LA 71105 USA.
   [Rifkin, Robert] Rocky Mt Canc Ctr, Denver, CO USA.
   [Wolf, Jeffrey] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Estevam, Jose; Mulligan, George; Shi, Hongliang; Webb, Iain J.] Millennium Pharmaceut Inc, Cambridge, MA USA.
RP Kumar, S (reprint author), Mayo Clin, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA.
EM kumar.shaji@mayo.edu
RI Kumar, Shaji/A-9853-2008; 
OI Kumar, Shaji/0000-0001-5392-9284; Rajkumar, S.
   Vincent/0000-0002-5862-1833; Hari, Parameswaran/0000-0002-8800-297X
FU Millennium Pharmaceuticals Inc.; Janssen Global Services; Celgene;
   Novartis; Genzyme; Bayer; Millennium Takeda; Cephalon; Amgen
FX The authors thank Dr Jonathan Glass for his involvement in the study.
   They also gratefully acknowledge all the patients who participated in
   the study, all the investigators, nursing staff, and research support
   staff involved in the study, and the research team at Millennium
   Pharmaceuticals Inc. The authors wrote the initial draft of the
   manuscript and all material content. The acknowledge Emma Brougham and
   editing assistance from Catherine Crookes of FireKite during the
   development of this publication, which was funded by Millennium
   Pharmaceuticals Inc.; This work was supported by research funding from
   Janssen Global Services and Millennium Pharmaceuticals Inc.; S.K. has
   acted as a consultant/advisor for Merck, and has received research
   funding from Millennium Pharmaceuticals Inc, Celgene, Novartis, Genzyme
   and Bayer. I.F. and N.C. have received research funding from Millennium
   Pharmaceuticals Inc. P.G.R. has held consultant/advisory roles for
   Millennium Pharmaceuticals Inc, Celgene, and Johnson & Johnson. S.J.N.
   has received research funding and honoraria from, and has acted as an
   advisor for, Amgen, Millennium Takeda, Celgene, and Cephalon, and has
   also received honoraria from, and has acted as an advisor for,
   Ortho-Centicor. A.K.S. has held consultant/advisory roles for, and
   received honoraria from, Onyx, Celgene, and Millennium Pharmaceuticals
   Inc, and has received research funding from Millennium Pharmaceuticals
   Inc. R.R. has held consultant/advisory roles for Onyx, Celgene, and
   Millennium Pharmaceuticals Inc, and has received honoraria from
   Millennium Pharmaceuticals Inc. J.W. has been a consultant for
   Millennium Pharmaceuticals Inc, has received honoraria for participation
   in speakers' bureaus for Celgene, Novartis, OrthoBiotech and Millennium
   Pharmaceuticals Inc, and has participated in advisory boards for
   Genentech and Multiple Myeloma Research Consortium. J.E., G.M., H.S.,
   and I.J.W. are all employees of Millennium Pharmaceuticals Inc. The
   remaining authors declare no competing financial interests.
NR 29
TC 169
Z9 177
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 10
PY 2012
VL 119
IS 19
BP 4375
EP 4382
DI 10.1182/blood-2011-11-395749
PG 8
WC Hematology
SC Hematology
GA 959CC
UT WOS:000305286900010
PM 22422823
ER

PT J
AU Krop, I
AF Krop, Ian
TI Doubling Down on Human Epidermal Growth Factor Receptor 2
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID METASTATIC BREAST-CANCER; TRASTUZUMAB; PLUS; CHEMOTHERAPY; PERTUZUMAB;
   LAPATINIB; THERAPY
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Krop, I (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 14
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1574
EP 1576
DI 10.1200/JCO.2011.40.1463
PG 3
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800003
PM 22393081
ER

PT J
AU Zhang, MF
   Qureshi, AA
   Geller, AC
   Frazier, L
   Hunter, DJ
   Han, JL
AF Zhang, Mingfeng
   Qureshi, Abrar A.
   Geller, Alan C.
   Frazier, Lindsay
   Hunter, David J.
   Han, Jiali
TI Use of Tanning Beds and Incidence of Skin Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CUTANEOUS MALIGNANT-MELANOMA; SUN EXPOSURE; RISK-FACTORS; UV-RADIATION;
   BASAL-CELL; REPRODUCIBILITY; QUESTIONNAIRE; SUNBEDS; HEALTH; WOMEN
AB Purpose
   We sought to evaluate the risk effect of tanning bed use on skin cancers among teenage and young adults. We also expected to determine whether a dose-response relationship was evident.
   Patients and Methods
   We observed 73,494 female nurses for 20 years (from 1989 to 2009) in a large and well-characterized cohort in the United States and investigated whether frequency of tanning bed use during high school/college and at ages 25 to 35 years were associated with a risk of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. We used Cox proportional hazards models and carefully adjusted for host risk factors, ultraviolet index of residence, and sun exposure behaviors at a young age.
   Results
   During follow-up, 5,506 nurses were diagnosed with BCC, 403 with SCC, and 349 with melanoma. The multivariable-adjusted hazard ratio (HR) of skin cancer for an incremental increase in use of tanning beds of four times per year during both periods was 1.15 (95% CI, 1.11 to 1.19; P < .001) for BCC, 1.15 (95% CI, 1.01 to 1.31; P = .03) for SCC, and 1.11 (95% CI, 0.97 to 1.27; P = .13) for melanoma. Compared with tanning bed use at ages 25 to 35 years, we found a significantly higher risk of BCC for use during high school/college (multivariable-adjusted HR for use more than six times per year compared with no use was 1.73 during high school/college v 1.28 at ages 25 to 35 years; P for heterogeneity < .001).
   Conclusion
   Our data provide evidence for a dose-response relationship between tanning bed use and the risk of skin cancers, especially BCC, and the association is stronger for patients with a younger age at exposure.
C1 [Zhang, Mingfeng; Qureshi, Abrar A.; Frazier, Lindsay; Hunter, David J.; Han, Jiali] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Frazier, Lindsay] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Geller, Alan C.; Hunter, David J.; Han, Jiali] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Zhang, Mingfeng] Nanjing Med Univ, Ctr Canc, Nanjing, Jiangsu, Peoples R China.
RP Han, JL (reprint author), 181 Longwood Ave, Boston, MA 02115 USA.
EM jiali.han@channing.harvard.edu
FU National Institutes of Health [CA50385]
FX The Nurses' Health Study II cohort is supported by National Institutes
   of Health Grant No. CA50385.
NR 46
TC 83
Z9 84
U1 0
U2 27
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1588
EP 1593
DI 10.1200/JCO.2011.39.3652
PG 6
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800008
PM 22370316
ER

PT J
AU Cortes, J
   Fumoleau, P
   Bianchi, GV
   Petrella, TM
   Gelmon, K
   Pivot, X
   Verma, S
   Albanell, J
   Conte, P
   Lluch, A
   Salvagni, S
   Servent, V
   Gianni, L
   Scaltriti, M
   Ross, GA
   Dixon, J
   Szado, T
   Baselga, J
AF Cortes, Javier
   Fumoleau, Pierre
   Bianchi, Giulia Valeria
   Petrella, Teresa M.
   Gelmon, Karen
   Pivot, Xavier
   Verma, Shailendra
   Albanell, Joan
   Conte, Pierfranco
   Lluch, Ana
   Salvagni, Stefania
   Servent, Veronique
   Gianni, Luca
   Scaltriti, Maurizio
   Ross, Graham A.
   Dixon, Joanna
   Szado, Tania
   Baselga, Jose
TI Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent
   Reintroduction of Trastuzumab: Activity and Tolerability in Patients
   With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast
   Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; ADJUVANT
   CHEMOTHERAPY; AMPLIFICATION; COMBINATION; ONCOGENE; SURVIVAL; EFFICACY;
   TARGETS
AB Purpose
   The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.
   Patients and Methods
   Twenty-nine patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity. Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).
   Results
   All 29 patients enrolled for pertuzumab monotherapy experienced disease progression. The objective response rate (ORR) and CBR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy. With the addition of trastuzumab, the ORR and CBR were 17.6% and 41.2%, respectively. Progression-free survival was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively). Treatment was well tolerated with minimal cardiac dysfunction.
   Conclusion
   Although pertuzumab has some activity in patients with HER2-positive breast cancer that progressed during therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than monotherapy.
C1 [Scaltriti, Maurizio; Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
   [Cortes, Javier] Vall dHebron Univ Hosp, Barcelona, Spain.
   [Albanell, Joan] Hosp del Mar, Barcelona, Spain.
   [Lluch, Ana] Hosp Clin Univ, Valencia, Spain.
   [Fumoleau, Pierre] Ctr Georges Francois Leclerc, Dijon, France.
   [Pivot, Xavier] Ctr Hosp Univ Jean Minjoz, Besancon, France.
   [Servent, Veronique] Ctr Oscar Lambret, F-59020 Lille, France.
   [Bianchi, Giulia Valeria] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy.
   [Gianni, Luca] Ist Nazl, Milan, Italy.
   [Conte, Pierfranco] Univ Hosp, Modena, Italy.
   [Salvagni, Stefania] Osped Reg Parma, Parma, Italy.
   [Petrella, Teresa M.] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
   [Verma, Shailendra] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada.
   [Gelmon, Karen] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
   [Ross, Graham A.; Dixon, Joanna; Szado, Tania] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England.
RP Baselga, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA.
EM jbaselga@partners.org
RI Conte, PierFranco/F-7418-2014; Bianchi, Giulia /C-4553-2017; 
OI Conte, PierFranco/0000-0002-5210-5344; Bianchi, Giulia
   /0000-0003-3630-4527; Cortes, Javier/0000-0001-7623-1583
FU F. Hoffmann-La Roche, Basel, Switzerland; Roche; GlaxoSmithKline
FX Supported by F. Hoffmann-La Roche, Basel, Switzerland.; Research
   Funding: Karen Gelmon, Roche; Pierfranco Conte, GlaxoSmithKline
NR 31
TC 106
Z9 109
U1 0
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1594
EP 1600
DI 10.1200/JCO.2011.37.4207
PG 7
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800009
PM 22393084
ER

PT J
AU McArthur, GA
   Puzanov, I
   Amaravadi, R
   Ribas, A
   Chapman, P
   Kim, KB
   Sosman, JA
   Lee, RJ
   Nolop, K
   Flaherty, KT
   Callahan, J
   Hicks, RJ
AF McArthur, Grant A.
   Puzanov, Igor
   Amaravadi, Ravi
   Ribas, Antoni
   Chapman, Paul
   Kim, Kevin B.
   Sosman, Jeffrey A.
   Lee, Richard J.
   Nolop, Keith
   Flaherty, Keith T.
   Callahan, Jason
   Hicks, Rodney J.
TI Marked, Homogeneous, and Early [F-18]Fluorodeoxyglucose-Positron
   Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced
   Melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMORS; CELL LUNG-CANCER; IMATINIB MESYLATE;
   METASTATIC MELANOMA; EARLY PREDICTION; KIT; INHIBITOR; MUTATIONS;
   PLX4032; GROWTH
AB Purpose
   Imaging with [F-18]fluorodeoxyglucose (FDG)-positron emission tomography (PET) allows early recognition of a response to agents that target key driver mutations in human cancer. We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma.
   Patients and Methods
   Baseline and day 15 FDG-PET was evaluated in 31 patients with advanced melanoma treated in a phase I study of dose escalation of vemurafenib (PLX06-02), which included four patients treated at subtherapeutic doses and 24 patients treated at 960 mg twice a day, which is the maximum-tolerated dose of vemurafenib.
   Results
   All 27 patients treated at potentially therapeutic levels had at least a partial metabolic response, and three patients achieved a complete metabolic response. In the 27 patients, there was an 80% +/- 3% reduction in the maximum standardized uptake value (SUVmax) of target lesions and an 87% +/- 3% decrease in the percentage of injected dose (%ID) in all identified disease sites. There was a positive correlation between % ID in all identified disease and target-lesion SUVmax (r(2) = 0.66; P < .001) that indicated a significant homogeneity of the response between lesions in individual patients. Although no relationship was found between the reduction in target lesion SUVmax and best response according to RECIST (Response Evaluation Criteria in Solid Tumors), there was a trend for patients with greater reductions in uptake of FDG to have longer progression-free survival.
   Conclusion
   FDG-PET is a useful marker of an early biologic response to vemurafenib. Little variability in PET response was found between lesions in individual patients, which suggested minimal intrapatient molecular heterogeneity. FDG-PET is a useful tool for the evaluation of the biologic impact of inhibiting mutant BRAF and may allow for the more effective development of novel agents.
C1 [McArthur, Grant A.; Callahan, Jason; Hicks, Rodney J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [McArthur, Grant A.] Univ Melbourne, Parkville, Vic 3052, Australia.
   [McArthur, Grant A.; Hicks, Rodney J.] Univ Melbourne, St Vincents Hosp, Fitzroy, Vic 3065, Australia.
   [Puzanov, Igor; Sosman, Jeffrey A.] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA.
   [Amaravadi, Ravi] Univ Penn, Philadelphia, PA 19104 USA.
   [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
   [Chapman, Paul] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Nolop, Keith] Plexxikon, Berkeley, CA USA.
   [Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Lee, Richard J.] Hoffmann La Roche AG, Basel, Switzerland.
   [Flaherty, Keith T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP McArthur, GA (reprint author), Peter MacCallum Canc Ctr, Div Canc Med & Res, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.
EM grant.mcarthur@petermac.org
FU Plexxikon; Hoffman-La Roche; Victorian Cancer Agency [EOI09_27];
   National Health and Medical Research Council [APP1002655]; Cancer
   Council of Victoria; Pfizer; Hoffman-La Roche/Genentech; Roche;
   Bristol-Myers Squibb; GlaxoSmithKline
FX Supported by Plexxikon and Hoffman-La Roche and in part by Grants No.
   EOI09_27 from the Victorian Cancer Agency and APP1002655 from the
   National Health and Medical Research Council and by the Cancer Council
   of Victoria and the Sir Edward Weary Dunlop Clinical Research Fellowship
   from the Cancer Council of Victoria.; Research Funding: Grant A.
   McArthur, Pfizer; Paul Chapman, Hoffman-La Roche/Genentech; Kevin B.
   Kim, Roche; Jeffrey A. Sosman, Bristol-Myers Squibb, GlaxoSmithKline
NR 23
TC 62
Z9 63
U1 2
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1628
EP 1634
DI 10.1200/JCO.2011.39.1938
PG 7
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800014
PM 22454415
ER

PT J
AU Nosov, DA
   Esteves, B
   Lipatov, ON
   Lyulko, AA
   Anischenko, AA
   Chacko, RT
   Doval, DC
   Strahs, A
   Slichenmyer, WJ
   Bhargava, P
AF Nosov, Dmitry A.
   Esteves, Brooke
   Lipatov, Oleg N.
   Lyulko, Alexei A.
   Anischenko, A. A.
   Chacko, Raju T.
   Doval, Dinesh C.
   Strahs, Andrew
   Slichenmyer, William J.
   Bhargava, Pankaj
TI Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II
   Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID FACTOR-TARGETED THERAPY; INTERFERON-ALPHA; SUNITINIB; EFFICACY;
   HYPERTENSION; SORAFENIB; PAZOPANIB; AGENTS
AB Purpose
   The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC).
   Patients and Methods
   In this phase II, randomized discontinuation trial, 272 patients received open-label tivozanib 1.5 mg/d (one cycle equaled three treatment weeks followed by a 1-week break) orally for 16 weeks. Thereafter, 78 patients who demonstrated >= 25% tumor shrinkage continued to take tivozanib, and 118 patients with less than 25% tumor change were randomly assigned to receive tivozanib or a placebo in a double-blind manner; patients with >= 25% tumor growth were discontinued. Primary end points included safety, the objective response rate (ORR) at 16 weeks, and the percentage of randomly assigned patients who remained progression free after 12 weeks of double-blind treatment; secondary end points included progression-free survival (PFS).
   Results
   Of 272 patients enrolled onto the study, 83% of patients had clear-cell histology, 73% of patients had undergone nephrectomy, and 54% of patients were treatment naive. The ORR after 16 weeks of tivozanib treatment was 18% (95% CI, 14% to 23%). Of the 118 randomized patients, significantly more patients who were randomly assigned to receive double-blind tivozanib remained progression free after 12 weeks versus patients who received the placebo (49% v 21%; P = .001). Throughout the study, the ORR was 24% (95% CI, 19% to 30%), and the median PFS was 11.7 months (95% CI, 8.3 to 14.3 months) in the overall study population. The most common grade 3 and 4 treatment-related adverse event was hypertension (12%).
   Conclusion
   Tivozanib was active and well tolerated in patients with advanced RCC. These data support additional development of tivozanib in advanced RCC.
C1 [Nosov, Dmitry A.] Blokhin Oncol Res Ctr, Moscow 115478, Russia.
   [Lipatov, Oleg N.] Bashkortostan Clin Oncol Ctr, Ufa, Russia.
   [Esteves, Brooke; Strahs, Andrew; Slichenmyer, William J.; Bhargava, Pankaj] AVEO Pharmaceut, Cambridge, England.
   [Bhargava, Pankaj] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Lyulko, Alexei A.] Zaporizhya Med Acad Postgrad Educ, Zaporizhya, England.
   [Anischenko, A. A.] Donetsk Reg Antitumor Ctr, Donetsk, Ukraine.
   [Chacko, Raju T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
   [Doval, Dinesh C.] Rajiv Gandhi Canc Inst, New Delhi, India.
RP Nosov, DA (reprint author), Blokhin Oncol Res Ctr, 24 Kashirskoye Sosse, Moscow 115478, Russia.
EM nosov@mail.ru
FU AVEO Pharmaceuticals
FX Supported by AVEO Pharmaceuticals.
NR 28
TC 58
Z9 61
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1678
EP 1685
DI 10.1200/JCO.2011.35.3524
PG 8
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800021
PM 22493422
ER

PT J
AU Slatore, CG
   Cecere, LM
   LeTourneau, JL
   O'Neil, ME
   Duckart, JP
   Wiener, RS
   Farjah, F
   Cooke, CR
AF Slatore, Christopher G.
   Cecere, Laura M.
   LeTourneau, Jennifer L.
   O'Neil, Maya E.
   Duckart, Jonathan P.
   Wiener, Renda Soylemez
   Farjah, Farhood
   Cooke, Colin R.
TI Intensive Care Unit Outcomes Among Patients With Lung Cancer in the
   Surveillance, Epidemiology, and End Results-Medicare Registry
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CODE STATUS; LIFE; TRENDS; STATES; AGGRESSIVENESS; ADMISSION;
   MULTICENTER; POPULATION; MORTALITY; CARCINOMA
AB Purpose
   Lung cancer is the leading cause of cancer-related mortality. Intensive care unit (ICU) use among patients with cancer is increasing, but data regarding ICU outcomes for patients with lung cancer are limited.
   Patients and Methods
   We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare registry (1992 to 2007) to conduct a retrospective cohort study of patients with lung cancer who were admitted to an ICU for reasons other than surgical resection of their tumor. We used logistic and Cox regression to evaluate associations of patient characteristics and hospital mortality and 6-month mortality, respectively. We calculated adjusted associations for mechanical ventilation receipt with hospital and 6-month mortality.
   Results
   Of the 49,373 patients with lung cancer admitted to an ICU for reasons other than surgical resection, 76% of patients survived the hospitalization, and 35% of patients were alive 6 months after discharge. Receipt of mechanical ventilation was associated with increased hospital mortality (adjusted odds ratio, 6.95; 95% CI, 6.89 to 7.01; P < .001), and only 15% of these patients were alive 6 months after discharge. Of all ICU patients with lung cancer, the percentage of patients who survived 6 months from discharge was 36% for patients diagnosed in 1992 and 32% for patients diagnosed in 2005, whereas it was 16% and 11% for patients who received mechanical ventilation, respectively.
   Conclusion
   Most patients with lung cancer enrolled in Medicare who are admitted to an ICU die within 6 months of admission. To improve patient-centered care, these results should guide shared decision making between patients with lung cancer and their clinicians before an ICU admission.
C1 [Slatore, Christopher G.; LeTourneau, Jennifer L.; O'Neil, Maya E.; Duckart, Jonathan P.] Portland Vet Affairs VA Med Ctr, Portland, Dorset, England.
   [Slatore, Christopher G.; LeTourneau, Jennifer L.; O'Neil, Maya E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Cecere, Laura M.] Univ Washington, Sch Med, Seattle, WA USA.
   [Cecere, Laura M.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
   [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Bedford, England.
   [Wiener, Renda Soylemez] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Farjah, Farhood] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Cooke, Colin R.] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Slatore, CG (reprint author), 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM christopher.slatore@va.gov
OI Wiener, Renda/0000-0001-7712-2135; Slatore,
   Christopher/0000-0003-0958-8122; Cooke, Colin/0000-0001-9713-5371
FU University of Washington Division of Pulmonary and Critical Care
   Medicine; Veterans Affairs (VA) Health Services [10-025, TPM 61-037];
   National Cancer Institute [K07 CA 138772]; Robert Wood Johnson
   Foundation
FX Supported by a University of Washington Division of Pulmonary and
   Critical Care Medicine Endowment Grant (C. G. S), a Veterans Affairs
   (VA) Health Services Research and Development Career Development Award
   (Grant No. 10-025, C. G. S.), a VA Health Services Research and
   Development Fellowship (Grant. No. TPM 61-037; L. M. C.), a career
   development award from the National Cancer Institute (K07 CA 138772; R.
   S. W.), and the Robert Wood Johnson Foundation Clinical Scholars Program
   (C.R.C).
NR 39
TC 27
Z9 28
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1686
EP 1691
DI 10.1200/JCO.2011.40.0846
PG 6
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800022
PM 22473159
ER

PT J
AU Flygare, JA
   Beresini, M
   Budha, N
   Chan, H
   Chan, IT
   Cheeti, S
   Cohen, F
   Deshayes, K
   Doerner, K
   Eckhardt, SG
   Elliott, LO
   Feng, BN
   Franklin, MC
   Reisner, SF
   Gazzard, L
   Halladay, J
   Hymowitz, SG
   La, H
   LoRusso, P
   Maurer, B
   Murray, L
   Plise, E
   Quan, C
   Stephan, JP
   Young, SG
   Tom, J
   Tsui, V
   Um, J
   Varfolomeev, E
   Vucic, D
   Wagner, AJ
   Wallweber, HJA
   Wang, L
   Ware, J
   Wen, ZY
   Wong, H
   Wong, JM
   Wong, M
   Wong, S
   Yu, R
   Zobel, K
   Fairbrother, WJ
AF Flygare, John A.
   Beresini, Maureen
   Budha, Nageshwar
   Chan, Helen
   Chan, Iris T.
   Cheeti, Sravanthi
   Cohen, Frederick
   Deshayes, Kurt
   Doerner, Karl
   Eckhardt, S. Gail
   Elliott, Linda O.
   Feng, Bainian
   Franklin, Matthew C.
   Reisner, Stacy Frankovitz
   Gazzard, Lewis
   Halladay, Jason
   Hymowitz, Sarah G.
   La, Hank
   LoRusso, Patricia
   Maurer, Brigitte
   Murray, Lesley
   Plise, Emile
   Quan, Clifford
   Stephan, Jean-Philippe
   Young, Shin G.
   Tom, Jeffrey
   Tsui, Vickie
   Um, Joanne
   Varfolomeev, Eugene
   Vucic, Domagoj
   Wagner, Andrew J.
   Wallweber, Heidi J. A.
   Wang, Lan
   Ware, Joseph
   Wen, Zhaoyang
   Wong, Harvey
   Wong, Jonathan M.
   Wong, Melisa
   Wong, Susan
   Yu, Ron
   Zobel, Kerry
   Fairbrother, Wayne J.
TI Discovery of a Potent Small-Molecule Antagonist of Inhibitor of
   Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of
   Cancer (GDC-0152)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; STRUCTURAL BASIS; CELL-DEATH; BIR DOMAIN; ML-IAP; CASPASE
   INHIBITION; MELANOMA INHIBITOR; LINKED INHIBITOR; XIAP PROTEINS; C-IAPS
AB A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K-l values of 28, 14, 17, and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 +/- 3 mL/min/kg, and the volume of distribution was 0.6 +/- 0.2 L/kg.
C1 [Flygare, John A.; Cohen, Frederick; Feng, Bainian; Gazzard, Lewis; Tsui, Vickie; Um, Joanne; Wang, Lan; Wen, Zhaoyang; Wong, Jonathan M.; Wong, Melisa] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA.
   [Beresini, Maureen; Elliott, Linda O.; Reisner, Stacy Frankovitz; Stephan, Jean-Philippe] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA.
   [Budha, Nageshwar; Cheeti, Sravanthi; Ware, Joseph] Genentech Inc, Dept Clin Pharmacol, San Francisco, CA 94080 USA.
   [Chan, Helen; Halladay, Jason; La, Hank; Plise, Emile; Young, Shin G.; Wong, Harvey; Wong, Susan] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA.
   [Chan, Iris T.] Genentech Inc, Dept Oncol Exploratory Clin Dev, San Francisco, CA 94080 USA.
   [Deshayes, Kurt; Franklin, Matthew C.; Quan, Clifford; Tom, Jeffrey; Varfolomeev, Eugene; Vucic, Domagoj; Zobel, Kerry; Fairbrother, Wayne J.] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
   [Doerner, Karl; Murray, Lesley] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
   [Hymowitz, Sarah G.; Maurer, Brigitte; Wallweber, Heidi J. A.] Genentech Inc, Dept Biol Struct, San Francisco, CA 94080 USA.
   [Yu, Ron] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA.
   [Eckhardt, S. Gail] Univ Colorado Denver, Div Med Oncol, Aurora, CO 80045 USA.
   [LoRusso, Patricia] Wayne State Univ, Dept Oncol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   [Wagner, Andrew J.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
RP Flygare, JA (reprint author), Genentech Inc, Dept Discovery Chem, 1 DNA Way, San Francisco, CA 94080 USA.
EM jflygare@gene.com; fairbro@gene.com
FU Office of Science, Office of Basic Energy Sciences, of the U.S.
   Department of Energy [DE-AC02-05CH11231]; DOE Office of Biological and
   Environmental Research; National Institutes of Health, National Center
   for Research Resources, Biomedical Technology [P41RR001209]
FX We thank members of the DMPK and Purification groups within Genentech
   Small Molecule Drug Discovery for analytical support. We also thank the
   staff at the Advanced Light Source and Stanford Synchrotron Radiation
   Lightsource for their assistance with sample handling and data
   collection. The Advanced Light Source is supported by the Director,
   Office of Science, Office of Basic Energy Sciences, of the U.S.
   Department of Energy under Contract No. DE-AC02-05CH11231. The Stanford
   Synchrotron Radiation Lightsource is a Directorate of SLAC National
   Accelerator Laboratory and an Office of Science User Facility operated
   for the U.S. Department of Energy Office of Science by Stanford
   University. The SSRL Structural Molecular Biology Program is supported
   by the DOE Office of Biological and Environmental Research and by the
   National Institutes of Health, National Center for Research Resources,
   Biomedical Technology Program (P41RR001209).
NR 63
TC 75
Z9 81
U1 3
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 10
PY 2012
VL 55
IS 9
BP 4101
EP 4113
DI 10.1021/jm300060k
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 939CY
UT WOS:000303785900004
PM 22413863
ER

PT J
AU Wang, M
   Huang, LY
   Sharma, SK
   Jeon, S
   Thota, S
   Sperandio, FF
   Nayka, S
   Chang, JL
   Hamblin, MR
   Chiang, LY
AF Wang, Min
   Huang, Liyi
   Sharma, Sulbha K.
   Jeon, Seaho
   Thota, Sammaiah
   Sperandio, Felipe F.
   Nayka, Suhasini
   Chang, Julie
   Hamblin, Michael R.
   Chiang, Long Y.
TI Synthesis and Photodynamic Effect of New Highly Photostable
   Decacationically Armed [60]- and [70]Fullerene Decaiodide Monoadducts To
   Target Pathogenic Bacteria and Cancer Cells
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID GRAM-POSITIVE BACTERIA; SINGLET OXYGEN; NEGATIVE BACTERIA;
   SURFACE-PROTEINS; THERAPY; FULLERENE; INFECTIONS; MECHANISMS; C-60;
   DERIVATIVES
AB Novel water-soluble decacationically armed C-60 and C-70 decaiodide monoadducts, C-60- and C-70[>M(C3N6+C3)(2)], were synthesized, characterized, and applied as photosensitizers and potential nano-PDT agents against pathogenic bacteria and cancer cells. A high number of cationic charges per fullerene cage and H-bonding moieties were designed for rapid binding to the anionic residues displayed on the outer parts of bacterial cell walls. In the presence of a high number of electron-donating iodide anions as parts of quaternary ammonium salts in the arm region, we found that C-70[>M(C3N6+C3)(2)] produced more HO center dot than C-60[>M(C3N6+C3)(2)], in addition to O-1(2). This finding offers an explanation of the preferential killing of Gram-positive and Gram-negative bacteria by C-60[>M(C3N6+C3)(2)] and C-70[>M(C3N6+C3)(2)], respectively. The hypothesis is that O-1(2) can diffuse more easily into porous cell walls of Gram-positive bacteria to reach sensitive sites, while the less permeable Gram-negative bacterial cell wall needs the more reactive HO center dot to cause real damage.
C1 [Huang, Liyi; Sharma, Sulbha K.; Sperandio, Felipe F.; Nayka, Suhasini; Chang, Julie; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Wang, Min; Jeon, Seaho; Thota, Sammaiah; Chiang, Long Y.] Univ Massachusetts, Inst Nanosci & Engn Technol, Dept Chem, Lowell, MA 01854 USA.
   [Huang, Liyi; Sperandio, Felipe F.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
   [Sperandio, Felipe F.] Univ Sao Paulo, Sch Dent, BR-05508000 Sao Paulo, Brazil.
   [Sperandio, Felipe F.] Minist Educ Brazil, CAPES Fdn, BR-70040020 Brasilia, DF, Brazil.
   [Chang, Julie] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA.
   [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Chiang, Long Y.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu; Long_Chiang@uml.edu
RI Sperandio, Felipe/I-4369-2012; 
OI Sperandio, Felipe/0000-0001-5589-2585; Hamblin,
   Michael/0000-0001-6431-4605
FU National Institutes of Health (NIH) [1R01CA137108]
FX We thank the financial support of National Institutes of Health (NIH)
   under Grant 1R01CA137108.
NR 38
TC 23
Z9 25
U1 6
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 10
PY 2012
VL 55
IS 9
BP 4274
EP 4285
DI 10.1021/jm3000664
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 939CY
UT WOS:000303785900017
PM 22512669
ER

PT J
AU LaLonde, JM
   Kwon, YD
   Jones, DM
   Sun, AW
   Courter, JR
   Soeta, T
   Kobayashi, T
   Princiotto, AM
   Wu, XL
   Schon, A
   Freire, E
   Kwong, PD
   Mascola, JR
   Sodroski, J
   Madani, N
   Smith, AB
AF LaLonde, Judith M.
   Kwon, Young Do
   Jones, David M.
   Sun, Alexander W.
   Courter, Joel R.
   Soeta, Takahiro
   Kobayashi, Toyoharu
   Princiotto, Amy M.
   Wu, Xueling
   Schoen, Arne
   Freire, Ernesto
   Kwong, Peter D.
   Mascola, John R.
   Sodroski, Joseph
   Madani, Navid
   Smith, Amos B., III
TI Structure-Based Design, Synthesis, and Characterization of Dual Hotspot
   Small-Molecule HIV-1 Entry Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-PROTEIN INTERACTIONS; MULTIPLE
   SEQUENCE ALIGNMENT; GP120 ENVELOPE GLYCOPROTEIN; NEUTRALIZING
   ANTIBODIES; DRUG DISCOVERY; STRUCTURE VALIDATION; CD4-BOUND STATE; ATOM
   CONTACTS; BINDING-SITE
AB Cellular infection by HIV-1 is initiated with a binding event between the viral envelope glycoprotein gp120 and the cellular receptor protein CD4. The CD4-gp120 interface is dominated by two hotspots: a hydrophobic gp120 cavity capped by Phe43(CD4) and an electrostatic interaction between residues Arg59(CD4) and Asp368(gp120). The CD4 mimetic small-molecule NBD-556 (1) binds within the gp120 cavity; however, 1 and related congeners demonstrate limited viral neutralization breadth. Herein, we report the design, synthesis, characterization, and X-ray structures of gp120 in complex with small molecules that simultaneously engage both binding hotspots. The compounds specifically inhibit viral infection of 42 tier 2 clades B and C viruses and are shown to be antagonists of entry into CD4-negative cells. Dual hotspot design thus provides both a means to enhance neutralization potency of HIV-1 entry inhibitors and a novel structural paradigm for inhibiting the CD4-gp120 protein-protein interaction.
C1 [LaLonde, Judith M.] Bryn Mawr Coll, Dept Chem, Rosemont, PA 19010 USA.
   [Kwon, Young Do; Wu, Xueling; Kwong, Peter D.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Jones, David M.; Sun, Alexander W.; Courter, Joel R.; Soeta, Takahiro; Kobayashi, Toyoharu; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
   [Princiotto, Amy M.; Sodroski, Joseph; Madani, Navid] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   [Sodroski, Joseph] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
   [Sodroski, Joseph] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Sodroski, Joseph] Ragon Inst MGH MIT & Harvard, Boston, MA 02115 USA.
RP LaLonde, JM (reprint author), Bryn Mawr Coll, Dept Chem, Rosemont, PA 19010 USA.
EM jlalonde@brynmawr.edu; smithab@sas.upenn.edu
RI Kwon, Young Do/A-6957-2010; SOETA, Takahiro/E-7060-2015
OI SOETA, Takahiro/0000-0001-9883-4772
FU NIH [GM 56550]; NIH Intramural IATAP; NIAID; Pittsburgh Supercomputing
   Center [MCB090108]
FX We thank Irwin Chaiken and Wayne Hendrickson and all the members of the
   PO1 Consortium "Structure-Based Antagonism of HIV-1 Envelope Function in
   Cell Entry". We also thank Jonathan Stuckey for assistance with figures,
   and members of the Structural Biology Section, Vaccine Research Center,
   NIAID for comments on the manuscript. Funding was provided by NIH Grant
   GM 56550 to J.M.L., E.F., A.B.S., by NIH Intramural IATAP and NIAID
   programs to Y.D.K., P.D.K., J.R.M., and J.S. J.M.L. thanks the
   Pittsburgh Supercomputing Center for an allocation for computing
   resources, Grant MCB090108.
NR 94
TC 51
Z9 51
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 10
PY 2012
VL 55
IS 9
BP 4382
EP 4396
DI 10.1021/jm300265j
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 939CY
UT WOS:000303785900026
PM 22497421
ER

PT J
AU Neale, BM
   Kou, Y
   Liu, L
   Ma'ayan, A
   Samocha, KE
   Sabo, A
   Lin, CF
   Stevens, C
   Wang, LS
   Makarov, V
   Polak, P
   Yoon, S
   Maguire, J
   Crawford, EL
   Campbell, NG
   Geller, ET
   Valladares, O
   Schafer, C
   Liu, H
   Zhao, T
   Cai, GQ
   Lihm, J
   Dannenfelser, R
   Jabado, O
   Peralta, Z
   Nagaswamy, U
   Muzny, D
   Reid, JG
   Newsham, I
   Wu, YQ
   Lewis, L
   Han, Y
   Voight, BF
   Lim, E
   Rossin, E
   Kirby, A
   Flannick, J
   Fromer, M
   Shakir, K
   Fennell, T
   Garimella, K
   Banks, E
   Poplin, R
   Gabriel, S
   DePristo, M
   Wimbish, JR
   Boone, BE
   Levy, SE
   Betancur, C
   Sunyaev, S
   Boerwinkle, E
   Buxbaum, JD
   Cook, EH
   Devlin, B
   Gibbs, RA
   Roeder, K
   Schellenberg, GD
   Sutcliffe, JS
   Daly, MJ
AF Neale, Benjamin M.
   Kou, Yan
   Liu, Li
   Ma'ayan, Avi
   Samocha, Kaitlin E.
   Sabo, Aniko
   Lin, Chiao-Feng
   Stevens, Christine
   Wang, Li-San
   Makarov, Vladimir
   Polak, Paz
   Yoon, Seungtai
   Maguire, Jared
   Crawford, Emily L.
   Campbell, Nicholas G.
   Geller, Evan T.
   Valladares, Otto
   Schafer, Chad
   Liu, Han
   Zhao, Tuo
   Cai, Guiqing
   Lihm, Jayon
   Dannenfelser, Ruth
   Jabado, Omar
   Peralta, Zuleyma
   Nagaswamy, Uma
   Muzny, Donna
   Reid, Jeffrey G.
   Newsham, Irene
   Wu, Yuanqing
   Lewis, Lora
   Han, Yi
   Voight, Benjamin F.
   Lim, Elaine
   Rossin, Elizabeth
   Kirby, Andrew
   Flannick, Jason
   Fromer, Menachem
   Shakir, Khalid
   Fennell, Tim
   Garimella, Kiran
   Banks, Eric
   Poplin, Ryan
   Gabriel, Stacey
   DePristo, Mark
   Wimbish, Jack R.
   Boone, Braden E.
   Levy, Shawn E.
   Betancur, Catalina
   Sunyaev, Shamil
   Boerwinkle, Eric
   Buxbaum, Joseph D.
   Cook, Edwin H., Jr.
   Devlin, Bernie
   Gibbs, Richard A.
   Roeder, Kathryn
   Schellenberg, Gerard D.
   Sutcliffe, James S.
   Daly, Mark J.
TI Patterns and rates of exonic de novo mutations in autism spectrum
   disorders
SO NATURE
LA English
DT Article
ID DNA-SEQUENCING DATA; ASSOCIATION; FRAMEWORK; DISEASE
AB Autism spectrum disorders (ASD) are believed to have genetic and environmental origins, yet in only a modest fraction of individuals can specific causes be identified(1,2). To identify further genetic risk factors, here we assess the role of de novo mutations in ASD by sequencing the exomes of ASD cases and their parents (n = 175 trios). Fewer than half of the cases (46.3%) carry a missense or nonsense de novo variant, and the overall rate of mutation is only modestly higher than the expected rate. In contrast, the proteins encoded by genes that harboured de novo missense or nonsense mutations showed a higher degree of connectivityamong themselves and to previous ASD genes(3) as indexed by protein-protein interaction screens. The small increase in the rate of de novo events, when taken together with the protein interaction results, are consistent with an important but limited role for de novo point mutations in ASD, similar to that documented for de novo copy number variants. Genetic models incorporating these data indicate that most of the observed de novo events are unconnected to ASD; those that do confer risk are distributed across many genes and are incompletely penetrant (that is, not necessarily sufficient for disease). Our results support polygenic models in which spontaneous coding mutations in any of a large number of genes increases risk by 5- to 20-fold. Despite the challenge posed by such models, results from de novo events and a large parallel case-control study provide strong evidence in favour of CHD8 and KATNAL2 as genuine autism risk factors.
C1 [Neale, Benjamin M.; Samocha, Kaitlin E.; Lim, Elaine; Rossin, Elizabeth; Kirby, Andrew; Fromer, Menachem; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Neale, Benjamin M.; Samocha, Kaitlin E.; Lim, Elaine; Rossin, Elizabeth; Kirby, Andrew; Fromer, Menachem; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Neale, Benjamin M.; Samocha, Kaitlin E.; Stevens, Christine; Polak, Paz; Maguire, Jared; Voight, Benjamin F.; Lim, Elaine; Rossin, Elizabeth; Kirby, Andrew; Flannick, Jason; Fromer, Menachem; Shakir, Khalid; Fennell, Tim; Garimella, Kiran; Banks, Eric; Poplin, Ryan; Gabriel, Stacey; DePristo, Mark; Sunyaev, Shamil; Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   [Kou, Yan; Ma'ayan, Avi; Dannenfelser, Ruth] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
   [Kou, Yan; Makarov, Vladimir; Yoon, Seungtai; Cai, Guiqing; Lihm, Jayon; Buxbaum, Joseph D.] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
   [Liu, Li; Schafer, Chad; Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15232 USA.
   [Sabo, Aniko; Nagaswamy, Uma; Muzny, Donna; Reid, Jeffrey G.; Newsham, Irene; Wu, Yuanqing; Lewis, Lora; Han, Yi; Boerwinkle, Eric; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
   [Makarov, Vladimir; Yoon, Seungtai; Cai, Guiqing; Lihm, Jayon; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
   [Polak, Paz; Sunyaev, Shamil] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
   [Polak, Paz; Sunyaev, Shamil] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Crawford, Emily L.; Campbell, Nicholas G.; Sutcliffe, James S.] Vanderbilt Univ, Vanderbilt Brain Inst, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   [Crawford, Emily L.; Campbell, Nicholas G.; Sutcliffe, James S.] Vanderbilt Univ, Vanderbilt Brain Inst, Dept Psychiat, Nashville, TN 37232 USA.
   [Liu, Han; Zhao, Tuo] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
   [Liu, Han; Zhao, Tuo] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21205 USA.
   [Jabado, Omar; Peralta, Zuleyma; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Voight, Benjamin F.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
   [Wimbish, Jack R.; Boone, Braden E.; Levy, Shawn E.] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.
   [Betancur, Catalina] INSERM, U952, F-75005 Paris, France.
   [Betancur, Catalina] CNRS, UMR 7224, F-75005 Paris, France.
   [Betancur, Catalina] Univ Paris 06, F-75005 Paris, France.
   [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Houston, TX 77030 USA.
   [Buxbaum, Joseph D.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY 10029 USA.
   [Cook, Edwin H., Jr.] Univ Illinois, Dept Psychiat, Chicago, IL 60608 USA.
   [Devlin, Bernie] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
RP Daly, MJ (reprint author), Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
EM joseph.buxbaum@mssm.edu; kathryn.roeder@gmail.com;
   mjdaly@atgu.mgh.harvard.edu
RI Fromer, Menachem/G-2116-2012; Sutcliffe, James/C-1348-2012; Liu,
   Li/G-1897-2015; 
OI Fromer, Menachem/0000-0003-3749-4342; Sutcliffe,
   James/0000-0001-5200-6007; Valladares, Otto/0000-0001-8055-2187;
   Buxbaum, Joseph/0000-0001-8898-8313; Geller, Evan/0000-0002-8035-8736;
   Betancur, Catalina/0000-0002-3327-4804
FU NIH [R01MH089208, R01 MH089025, R01 MH089004, R01MH089175, R01 MH089482,
   P50 HD055751, RO1 MH057881, R01 MH061009]; Seaver Foundation; NIH NCRR
   [UL1 RR024975]; Vanderbilt Kennedy Center for Research on Human
   Development [P30 HD015052];  [R01MH084676];  [U54 HG003273];  [U54
   HG003067]
FX This work was directly supported by NIH grants R01MH089208 (M.J.D.), R01
   MH089025 (J.D.B.), R01 MH089004 (G. D. S.), R01MH089175 (R. A. G.) and
   R01 MH089482 (J.S.S.), and supported in part by NIH grants P50 HD055751
   (E. H. C.), RO1 MH057881 (B. D.) and R01 MH061009 (J.S.S.). Y.K., G. C.
   and S.Y. are Seaver Fellows, supported by the Seaver Foundation. We
   thank T. Lehner, A. Felsenfeld and P. Bender for their support and
   contribution to the project. We thank S. Sanders and M. State for
   discussions on the interpretation of de novo events. We thank D. Reich
   for comments on the abstract and message of the manuscript. We thank E.
   Lander and D. Altshuler for comments on the manuscript. We acknowledge
   the assistance of M. Potter, A. McGrew and G. Crockett without whom
   these studies would not be possible, and Center for Human Genetics
   Research resources: Computational Genomics Core, Genetic Studies
   Ascertainment Core and DNA Resources core, supported in part by NIH NCRR
   grant UL1 RR024975, and the Vanderbilt Kennedy Center for Research on
   Human Development (P30 HD015052). This work was supported in part by
   R01MH084676 (S. S.). We acknowledge the clinicians and organizations
   that contributed to samples used in this study and the particular
   support of the Mount Sinai School of Medicine, University of
   Illinois-Chicago, Vanderbilt University, the Autism Genetics Resource
   Exchange and the institutions of the Boston Autism Consortium. We
   acknowledge A. Estes and G. Dawson for patient
   collection/characterization. We acknowledge partial support from U54
   HG003273 (R. A. G.) and U54 HG003067 (E. Lander). J.D.B., B. D., M.J.D.,
   R. A. G., A. S., G. D. S. and J.S.S. are lead investigators in the
   Autism Sequencing Consortium (ASC). The ASC is comprised of groups
   sharing massively parallel sequencing data in autism. Finally, we are
   grateful to the many families, without whose participation this project
   would not have been possible.
NR 18
TC 684
Z9 705
U1 7
U2 95
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 10
PY 2012
VL 485
IS 7397
BP 242
EP U129
DI 10.1038/nature11011
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 939HJ
UT WOS:000303799800042
PM 22495311
ER

PT J
AU Goldfine, AB
AF Goldfine, Allison B.
TI Statins: Is It Really Time to Reassess Benefits and Risks?
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID METAANALYSIS; THERAPY
C1 [Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Goldfine, Allison B.] Joslin Diabet Ctr, Sect Clin Behav & Outcomes Res, Boston, MA 02215 USA.
RP Goldfine, AB (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 5
TC 44
Z9 44
U1 0
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 10
PY 2012
VL 366
IS 19
BP 1752
EP 1755
DI 10.1056/NEJMp1203020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 939NB
UT WOS:000303817000002
PM 22533536
ER

PT J
AU McCarthy, PL
   Owzar, K
   Hofmeister, CC
   Hurd, DD
   Hassoun, H
   Richardson, PG
   Giralt, S
   Stadtmauer, EA
   Weisdorf, DJ
   Vij, R
   Moreb, JS
   Callander, NS
   Van Besien, K
   Gentile, T
   Isola, L
   Maziarz, RT
   Gabriel, DA
   Bashey, A
   Landau, H
   Martin, T
   Qazilbash, MH
   Levitan, D
   McClune, B
   Schlossman, R
   Hars, V
   Postiglione, J
   Jiang, C
   Bennett, E
   Barry, S
   Bressler, L
   Kelly, M
   Seiler, M
   Rosenbaum, C
   Hari, P
   Pasquini, MC
   Horowitz, MM
   Shea, TC
   Devine, SM
   Anderson, KC
   Linker, C
AF McCarthy, Philip L.
   Owzar, Kouros
   Hofmeister, Craig C.
   Hurd, David D.
   Hassoun, Hani
   Richardson, Paul G.
   Giralt, Sergio
   Stadtmauer, Edward A.
   Weisdorf, Daniel J.
   Vij, Ravi
   Moreb, Jan S.
   Callander, Natalie Scott
   Van Besien, Koen
   Gentile, Teresa
   Isola, Luis
   Maziarz, Richard T.
   Gabriel, Don A.
   Bashey, Asad
   Landau, Heather
   Martin, Thomas
   Qazilbash, Muzaffar H.
   Levitan, Denise
   McClune, Brian
   Schlossman, Robert
   Hars, Vera
   Postiglione, John
   Jiang, Chen
   Bennett, Elizabeth
   Barry, Susan
   Bressler, Linda
   Kelly, Michael
   Seiler, Michele
   Rosenbaum, Cara
   Hari, Parameswaran
   Pasquini, Marcelo C.
   Horowitz, Mary M.
   Shea, Thomas C.
   Devine, Steven M.
   Anderson, Kenneth C.
   Linker, Charles
TI Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID INTERGROUPE FRANCOPHONE; CONSOLIDATION THERAPY; RANDOMIZED PHASE-3;
   RESPONSE CRITERIA; IMPROVES SURVIVAL; ONCOLOGY-GROUP; THALIDOMIDE;
   MAINTENANCE; BORTEZOMIB; DEXAMETHASONE
AB Background
   Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma.
   Methods
   Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15).
   Results
   The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 non-hematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%).
   Conclusions
   Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
C1 [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA.
   [Gentile, Teresa] SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA.
   [Hassoun, Hani; Giralt, Sergio; Landau, Heather] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Isola, Luis] Mt Sinai Med Ctr, BMT, New York, NY 10029 USA.
   [Owzar, Kouros] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
   [Owzar, Kouros; Hars, Vera; Postiglione, John; Jiang, Chen; Bennett, Elizabeth; Barry, Susan] Duke Univ, Canc & Leukemia Grp B CALGB, Ctr Stat, Durham, NC USA.
   [Hurd, David D.; Levitan, Denise] Wake Forest Univ, Winston Salem, NC 27109 USA.
   [Gabriel, Don A.; Shea, Thomas C.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Hofmeister, Craig C.; Devine, Steven M.] Ohio State Univ, Div Hematol, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Richardson, Paul G.; Schlossman, Robert; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   [Stadtmauer, Edward A.] Univ Penn, Myeloma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Weisdorf, Daniel J.; McClune, Brian] Univ Minnesota, Med Ctr, Dept Hematol & Oncol, Minneapolis, MN 55455 USA.
   [Vij, Ravi] Washington Univ, Div Oncol, Sch Med, St Louis, MO 63130 USA.
   [Moreb, Jan S.] Univ Florida, Bone Marrow Transplant Program, Gainesville, FL USA.
   [Callander, Natalie Scott] Univ Wisconsin, Dept Hematol, Madison, WI 53706 USA.
   [Hari, Parameswaran; Pasquini, Marcelo C.; Horowitz, Mary M.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
   [Van Besien, Koen; Rosenbaum, Cara] Univ Chicago Hosp, Dept Med, Chicago, IL 60637 USA.
   [Bressler, Linda; Kelly, Michael; Seiler, Michele] Univ Chicago, CALGB, Chicago, IL 60637 USA.
   [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Bashey, Asad] BMT Grp Georgia, Atlanta, GA USA.
   [Martin, Thomas; Linker, Charles] Univ Calif San Francisco, Dept Hematol & Oncol, San Francisco, CA 94143 USA.
   [Qazilbash, Muzaffar H.] Univ Texas MD Anderson Canc Ctr, Unit 423, Houston, TX 77030 USA.
RP McCarthy, PL (reprint author), Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA.
EM philip.mccarthy@roswellpark.org
RI van Besien, Koen/G-4221-2012; Hofmeister, Craig/E-3256-2011; 
OI van Besien, Koen/0000-0002-8164-6211; Hofmeister,
   Craig/0000-0003-4816-1607; Hari, Parameswaran/0000-0002-8800-297X
FU National Cancer Institute
FX Funded by the National Cancer Institute; ClinicalTrials.gov number,
   NCT00114101.; Supported by the National Cancer Institute.
NR 43
TC 420
Z9 430
U1 6
U2 32
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 10
PY 2012
VL 366
IS 19
BP 1770
EP 1781
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 939NB
UT WOS:000303817000006
PM 22571201
ER

PT J
AU Shahian, DM
   Meyer, GS
   Yeh, RW
   Fifer, MA
   Torchiana, DF
AF Shahian, David M.
   Meyer, Gregg S.
   Yeh, Robert W.
   Fifer, Michael A.
   Torchiana, David F.
TI Percutaneous Coronary Interventions without On-Site Cardiac Surgical
   Backup
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID ACUTE-MYOCARDIAL-INFARCTION; BYPASS GRAFT-SURGERY; IN-HOSPITAL
   MORTALITY; INTRAVENOUS THROMBOLYTIC THERAPY; TO-BALLOON TIME; PRIMARY
   ANGIOPLASTY; ST-SEGMENT; UNITED-STATES; STENT ERA; COMMUNITY HOSPITALS
C1 [Shahian, David M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Shahian, DM (reprint author), Massachusetts Gen Hosp, Ctr Qual & Safety, 55 Fruit St, Boston, MA 02114 USA.
EM dshahian@partners.org
FU RAND; Institute for Clinical Effectiveness and Health Policy, Buenos
   Aires; CRICO/RM; Kaiser Permanente Division of Research; Harvard
   Clinical Research Institute; Schering-Plough
FX Dr. Fifer reports serving as an expert witness in malpractice and
   workers' compensation cases regarding diagnosis and management of
   cardiac disease and complications of cardiac catheterization and holding
   a patent (number 12/277,740) for a blood test for early diagnosis of
   myocardial infarction; Dr. Meyer reports holding unpaid board
   memberships in CRICO/RMF and the National Patient Safety Foundation,
   receiving consulting fees from RAND and lecture fees from the Institute
   for Clinical Effectiveness and Health Policy, Buenos Aires, and
   receiving expert-testimony fees regarding serious reportable events from
   CRICO/RM on behalf of his institution; Dr. Yeh reports receiving
   consulting fees from Kaiser Permanente Division of Research, consulting
   fees from Harvard Clinical Research Institute on behalf of his
   institution, and grant support from Schering-Plough on behalf of his
   former institution. No other potential conflict of interest relevant to
   this article was reported.
NR 110
TC 9
Z9 9
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 10
PY 2012
VL 366
IS 19
BP 1814
EP 1823
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 939NB
UT WOS:000303817000010
PM 22571203
ER

PT J
AU Mackool, BT
   Goverman, J
   Nazarian, RM
AF Mackool, Bonnie T.
   Goverman, Jeremy
   Nazarian, Rosalynn M.
TI Case 14-2012: A 43-Year-Old Woman with Fever and a Generalized Rash
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID KAPOSIS VARICELLIFORM ERUPTION; POTENTIALLY FATAL DISEASE; INNATE IMMUNE
   DEFECTS; ECZEMA-HERPETICUM; ATOPIC-DERMATITIS; PATIENT; SMALLPOX;
   INFECTIONS; MANAGEMENT; CONTACT
C1 [Mackool, Bonnie T.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
   [Goverman, Jeremy] Massachusetts Gen Hosp, Dept Surg, Div Burns, Boston, MA 02114 USA.
   [Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Mackool, Bonnie T.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
   [Goverman, Jeremy] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
   [Nazarian, Rosalynn M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Mackool, BT (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
OI Nazarian, Rosalynn/0000-0003-4003-7193
NR 38
TC 3
Z9 3
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 10
PY 2012
VL 366
IS 19
BP 1825
EP 1834
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 939NB
UT WOS:000303817000013
PM 22571205
ER

PT J
AU Haberer, JE
   Kiwanuka, J
   Nansera, D
   Ragland, K
   Mellins, C
   Bangsberg, DR
AF Haberer, Jessica E.
   Kiwanuka, Julius
   Nansera, Denis
   Ragland, Kathleen
   Mellins, Claude
   Bangsberg, David R.
TI Multiple Measures Reveal Antiretroviral Adherence Successes and
   Challenges in HIV-Infected Ugandan Children
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; THERAPY ADHERENCE; VIRAL SUPPRESSION; SOUTH-AFRICA;
   SELF-REPORT; OUTCOMES; PARENTS; PREDICTORS; MANAGEMENT; REGIMENS
AB Background: Adherence to HIV antiretroviral therapy (ART) among children in developing settings is poorly understood.
   Methodology/Principal Findings: To understand the level, distribution, and correlates of ART adherence behavior, we prospectively determined monthly ART adherence through multiple measures and six-monthly HIV RNA levels among 121 Ugandan children aged 2-10 years for one year. Median adherence levels were 100% by three-day recall, 97.4% by 30-day visual analog scale, 97.3% by unannounced pill count/liquid formulation weights, and 96.3% by medication event monitors (MEMS). Interruptions in MEMS adherence of >= 48 hours were seen in 57.0% of children; 36.3% had detectable HIV RNA at one year. Only MEMS correlated significantly with HIV RNA levels (r = -0.25, p = 0.04). Multivariable regression found the following to be associated with <90% MEMS adherence: hospitalization of child (adjusted odds ratio [AOR] 3.0, 95% confidence interval [CI] 1.6-5.5; p = 0.001), liquid formulation use (AOR 1.4, 95% CI 1.0-2.0; p = 0.04), and caregiver's alcohol use (AOR 3.1, 95% CI 1.8-5.2; p < 0.0001). Child's use of co-trimoxazole (AOR 0.5, 95% CI 0.4-0.9; p = 0.009), caregiver's use of ART (AOR 0.6, 95% CI 0.4-0.9; p = 0.03), possible caregiver depression (AOR 0.6, 95% CI 0.4-0.8; p = 0.001), and caregiver feeling ashamed of child's HIV status (AOR 0.5, 95% CI 0.3-0.6; p < 0.0001) were protective against <90% MEMS adherence. Change in drug manufacturer (AOR 4.1, 95% CI 1.5-11.5; p = 0.009) and caregiver's alcohol use (AOR 5.5, 95% CI 2.8-10.7; p < 0.0001) were associated with >= 48-hour interruptions by MEMS, while second-line ART (AOR 0.3, 95% CI 0.1-0.99; p = 0.049) and increasing assets (AOR 0.7, 95% CI 0.6-0.9; p = 0.0007) were protective against these interruptions.
   Conclusions/Significance: Adherence success depends on a well-established medication taking routine, including caregiver support and adequate education on medication changes. Caregiver-reported depression and shame may reflect fear of poor outcomes, functioning as motivation for the child to adhere. Further research is needed to better understand and build on these key influential factors for adherence intervention development.
C1 [Haberer, Jessica E.; Ragland, Kathleen; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
   [Haberer, Jessica E.; Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA.
   [Kiwanuka, Julius; Nansera, Denis] Mbarara Univ Sci & Technol, Dept Paediat, Mbarara, Uganda.
   [Mellins, Claude] Columbia Univ, Dept Psychiat, New York, NY USA.
   [Mellins, Claude] Columbia Univ, Dept Sociomed Sci, New York, NY USA.
RP Haberer, JE (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
EM jhaberer@partners.org
FU National Institute of Mental Health [R21MH 083306, K23MH087228,
   K24MH87227]
FX JEH and DRB received support from the National Institute of Mental
   Health (R21MH 083306 and K23MH087228; K24MH87227, respectively). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 46
TC 17
Z9 17
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2012
VL 7
IS 5
AR e36737
DI 10.1371/journal.pone.0036737
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TK
UT WOS:000305336100057
PM 22590600
ER

PT J
AU Roberts, NJ
   Vogelstein, JT
   Parmigiani, G
   Kinzler, KW
   Vogelstein, B
   Velculescu, VE
AF Roberts, Nicholas J.
   Vogelstein, Joshua T.
   Parmigiani, Giovanni
   Kinzler, Kenneth W.
   Vogelstein, Bert
   Velculescu, Victor E.
TI The Predictive Capacity of Personal Genome Sequencing
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID POPULATION-BASED COHORT; WIDE ASSOCIATION; FOLLOW-UP;
   ALZHEIMERS-DISEASE; GENETIC INFLUENCE; SWEDISH TWINS; DANISH TWINS;
   HERITABILITY; CANCER; RISK
AB New DNA sequencing methods will soon make it possible to identify all germline variants in any individual at a reasonable cost. However, the ability of whole-genome sequencing to predict predisposition to common diseases in the general population is unknown. To estimate this predictive capacity, we use the concept of a "genometype." A specific genometype represents the genomes in the population conferring a specific level of genetic risk for a specified disease. Using this concept, we estimated the maximum capacity of whole-genome sequencing to identify individuals at clinically significant risk for 24 different diseases. Our estimates were derived from the analysis of large numbers of monozygotic twin pairs; twins of a pair share the same genometype and therefore identical genetic risk factors. Our analyses indicate that (i) for 23 of the 24 diseases, most of the individuals will receive negative test results; (ii) these negative test results will, in general, not be very informative, because the risk of developing 19 of the 24 diseases in those who test negative will still be, at minimum, 50 to 80% of that in the general population; and (iii) on the positive side, in the best-case scenario, more than 90% of tested individuals might be alerted to a clinically significant predisposition to at least one disease. These results have important implications for the valuation of genetic testing by industry, health insurance companies, public policy-makers, and consumers.
C1 [Roberts, Nicholas J.; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.
   [Roberts, Nicholas J.; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA.
   [Vogelstein, Joshua T.] Johns Hopkins Univ, Dept Appl Math & Stat, Baltimore, MD 21218 USA.
   [Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Vogelstein, B (reprint author), Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.
EM vogelbe@jhmi.edu; velculescu@jhmi.edu
FU NIH [CA121113]; Virginia & D. K. Ludwig Fund for Cancer Research;
   American Association for Cancer Research Stand Up To Cancer-Dream Team
FX The project was supported by NIH grant CA121113, the Virginia & D. K.
   Ludwig Fund for Cancer Research, and American Association for Cancer
   Research Stand Up To Cancer-Dream Team Translational Cancer Research
   Grant.
NR 41
TC 82
Z9 83
U1 0
U2 32
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 9
PY 2012
VL 4
IS 133
AR 133ra58
DI 10.1126/scitranslmed.3003380
PG 9
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 939QG
UT WOS:000303827500005
PM 22472521
ER

PT J
AU Hempel, S
   Newberry, SJ
   Maher, AR
   Wang, Z
   Miles, JNV
   Shanman, R
   Johnsen, B
   Shekelle, PG
AF Hempel, Susanne
   Newberry, Sydne J.
   Maher, Alicia R.
   Wang, Zhen
   Miles, Jeremy N. V.
   Shanman, Roberta
   Johnsen, Breanne
   Shekelle, Paul G.
TI Probiotics for the Prevention and Treatment of Antibiotic-Associated
   Diarrhea A Systematic Review and Meta-analysis
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID HELICOBACTER-PYLORI ERADICATION; PLACEBO-CONTROLLED TRIAL;
   LACTOBACILLUS-ACIDOPHILUS CL1285; CLOSTRIDIUM-DIFFICILE DIARRHEA;
   SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; TRIPLE THERAPY; CLINICAL-TRIAL;
   BIFIDOBACTERIUM-LACTIS; CONTAINING YOGURT
AB Context Probiotics are live microorganisms intended to confer a health benefit when consumed. One condition for which probiotics have been advocated is the diarrhea that is a common adverse effect of antibiotic use.
   Objective To evaluate the evidence for probiotic use in the prevention and treatment of antibiotic-associated diarrhea (AAD).
   Data Sources Twelve electronic databases were searched (DARE, Cochrane Library of Systematic Reviews, CENTRAL, PubMed, EMBASE, CINAHL, AMED, MANTIS, TOXLINE, ToxFILE, NTIS, and AGRICOLA) and references of included studies and reviews were screened from database inception to February 2012, without language restriction.
   Study Selection Two independent reviewers identified parallel randomized controlled trials (RCTs) of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and/or Bacillus) for the prevention or treatment of AAD.
   Data Extraction Two independent reviewers extracted the data and assessed trial quality.
   Results A total of 82 RCTs met inclusion criteria. The majority used Lactobacillus-based interventions alone or in combination with other genera; strains were poorly documented. The pooled relative risk in a DerSimonian-Laird random-effects meta-analysis of 63 RCTs, which included 11 811 participants, indicated a statistically significant association of probiotic administration with reduction in AAD (relative risk, 0.58; 95% CI, 0.50 to 0.68; P<.001; I-2, 54%; [risk difference, -0.07; 95% CI, -0.10 to -0.05], [number needed to treat, 13; 95% CI, 10.3 to 19.1]) in trials reporting on the number of patients with AAD. This result was relatively insensitive to numerous subgroup analyses. However, there exists significant heterogeneity in pooled results and the evidence is insufficient to determine whether this association varies systematically by population, antibiotic characteristic, or probiotic preparation.
   Conclusions The pooled evidence suggests that probiotics are associated with a reduction in AAD. More research is needed to determine which probiotics are associated with the greatest efficacy and for which patients receiving which specific antibiotics. JAMA. 2012;307(18):1959-1969 www.jama.com
C1 [Hempel, Susanne; Newberry, Sydne J.; Shanman, Roberta; Johnsen, Breanne; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA.
   [Maher, Alicia R.; Wang, Zhen; Miles, Jeremy N. V.] RAND Corp, Santa Monica, CA USA.
   [Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
   [Maher, Alicia R.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
RP Hempel, S (reprint author), RAND Hlth, So Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA.
EM susanne_hempel@rand.org
RI Wang, Zhen/D-5991-2013
OI Wang, Zhen/0000-0002-9368-6149
FU HHSA [290-2007-10062-I]; National Institutes of Health (NIH) Office of
   Dietary Supplements; NIH National Center for Complementary and
   Alternative Medicine; US Food and Drug Administration (USFDA) Center for
   Food Safety and Applied Nutrition; Department of Veterans Affairs; RAND
   Corporation
FX The RAND Corporation internally funded this review, building on the
   literature database established for contract HHSA 290-2007-10062-I, an
   evidence report on the safety of probiotics commissioned by the Agency
   for Healthcare Research and Quality and funded jointly by the National
   Institutes of Health (NIH) Office of Dietary Supplements, the NIH
   National Center for Complementary and Alternative Medicine, and the US
   Food and Drug Administration (USFDA) Center for Food Safety and Applied
   Nutrition. Dr Shekelle reports support from the Department of Veterans
   Affairs.
NR 96
TC 206
Z9 235
U1 12
U2 108
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 9
PY 2012
VL 307
IS 18
BP 1959
EP 1969
DI 10.1001/jama.2012.3507
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 938OD
UT WOS:000303741900030
PM 22570464
ER

PT J
AU Chao, LL
   Lenoci, M
   Neylan, TC
AF Chao, Linda L.
   Lenoci, Maryann
   Neylan, Thomas C.
TI Effects of post-traumatic stress disorder on occipital lobe function and
   structure
SO NEUROREPORT
LA English
DT Article
DE functional magnetic resonance imaging; lateral occipital complex;
   occipital cortex; post-traumatic stress disorder
ID SCRIPT-DRIVEN IMAGERY; POSITRON-EMISSION-TOMOGRAPHY; CHILDHOOD
   SEXUAL-ABUSE; SYMPTOM PROVOCATION; PTSD; CORTEX; RESPONSES; AMYGDALA
AB Although there is evidence for strong connectivity between the amygdala and the visual cortex and some evidence for reduced occipital lobe gray matter volume in patients with post-traumatic stress disorder (PTSD), few studies have directly examined the effects of PTSD on occipital function. The current study used functional and structural MRI to examine occipital cortex function and structure in male combat veterans with and without PTSD. Left occipital gray matter volume was reduced in PTSD patients relative to the controls and correlated negatively with the severity of PTSD symptoms. Functional activity in the lateral occipital complex to aversive and nonaversive pictures presented in novel and repeated presentations was not altered by PTSD. These findings suggest that PTSD adversely affects occipital lobe volume but not the reactivity of the lateral occipital complex to generally aversive, trauma nonspecific stimuli. NeuroReport 23:412-419 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Chao, Linda L.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
   [Chao, Linda L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
   [Chao, Linda L.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Lenoci, Maryann; Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
RP Chao, LL (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU Department of Defense [W81XWH-05-2-0094]; Mental Illness Research and
   Education Clinical Center of the US Veterans Health Administration;
   Veterans Administration Medical Center, San Francisco, California
FX This work was supported by a grant from the Department of Defense
   (W81XWH-05-2-0094) to Linda L. Chao. The authors thank Dr Charles Marmar
   for helpful discussions about the study design, Jacqueline Thao Mai for
   technical assistance, and the research participants. This work was also
   supported by the Mental Illness Research and Education Clinical Center
   of the US Veterans Health Administration and the resources and
   facilities at the Veterans Administration Medical Center, San Francisco,
   California.
NR 25
TC 18
Z9 18
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 9
PY 2012
VL 23
IS 7
BP 412
EP 419
DI 10.1097/WNR.0b013e328352025e
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 927ZF
UT WOS:000302948500002
PM 22453299
ER

PT J
AU Hegarty, CE
   Foland-Ross, LC
   Narr, KL
   Townsend, JD
   Bookheimer, SY
   Thompson, PM
   Altshuler, LL
AF Hegarty, Catherine E.
   Foland-Ross, Lara C.
   Narr, Katherine L.
   Townsend, Jennifer D.
   Bookheimer, Susan Y.
   Thompson, Paul M.
   Altshuler, Lori L.
TI Anterior cingulate activation relates to local cortical thickness
SO NEUROREPORT
LA English
DT Article
DE anterior cingulate cortex; cortical thickness; functional magnetic
   resonance imaging; response inhibition
ID RESPONSE-INHIBITION; BRAIN; SCHIZOPHRENIA; CHILDREN; CORTEX; ROBUST;
   MODEL; FMRI
AB Few studies have examined the relationship between local anatomic thickness of the cortex and the activation signals arising from it. Using structural and functional MRI, we examined whether a relationship exists between cortical thickness and brain activation. Twenty-eight participants were asked to perform the Go/NoGo response inhibition task known to activate the anterior cingulate and the prefrontal cortex. Structural data of the same regions were simultaneously collected. We hypothesized that cortical thickness in these brain regions would positively correlate with brain activation. Data from the structural MRI were aligned with those of functional MRI activation. There was a positive linear correlation between cortical thickness and activation during response inhibition in the right anterior cingulate cortex (Brodmann's Area 24). No significant thickness-activation correlations were found in the prefrontal cortex. Correlations between cortical thickness and activation may occur only in certain brain regions. NeuroReport 23:420-424 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Foland-Ross, Lara C.] Stanford Univ, Dept Psychol, Mood & Anxiety Disorders Lab, Stanford, CA 94305 USA.
   [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), UCLA Neuropsychiat Inst & Hosp, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
OI Hegarty, Catherine/0000-0003-4976-774X
FU National Institute of Mental Health [5R21 MH075944, K24 MH001848, R01
   MH084955, 5F31MH078556]; Abbott Laboratories; Forest Laboratories
FX For their financial support of this study, the authors gratefully
   acknowledge the National Institute of Mental Health [5R21 MH075944 (LA),
   K24 MH001848 (LA), R01 MH084955 (LA), and 5F31MH078556 (LF)].; Dr
   Altshuler has received past (and potential future) funding from Abbott
   Laboratories (research support and consulting honoraria); Forest
   Laboratories (consulting and speakers bureau honoraria); GlaxoSmithKline
   (speakers bureau honoraria); and no past, but potential future honoraria
   from Astra-Zeneca (speakers bureau) and Merck and Co. (consulting). Drs
   Bookheimer, Foland-Ross, Narr and Thompson, Hegarty, and Townsend report
   no financial relationships with commercial interests.
NR 23
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 9
PY 2012
VL 23
IS 7
BP 420
EP 424
DI 10.1097/WNR.0b013e3283525a95
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 927ZF
UT WOS:000302948500003
PM 22440976
ER

PT J
AU Cheng, SS
   Rhee, EP
   Larson, MG
   Lewis, GD
   McCabe, EL
   Shen, DX
   Palma, MJ
   Roberts, LD
   Dejam, A
   Souza, AL
   Deik, AA
   Magnusson, M
   Fox, CS
   O'Donnell, CJ
   Vasan, RS
   Melander, O
   Clish, CB
   Gerszten, RE
   Wang, TJ
AF Cheng, Susan
   Rhee, Eugene P.
   Larson, Martin G.
   Lewis, Gregory D.
   McCabe, Elizabeth L.
   Shen, Dongxiao
   Palma, Melinda J.
   Roberts, Lee D.
   Dejam, Andre
   Souza, Amanda L.
   Deik, Amy A.
   Magnusson, Martin
   Fox, Caroline S.
   O'Donnell, Christopher J.
   Vasan, Ramachandran S.
   Melander, Olle
   Clish, Clary B.
   Gerszten, Robert E.
   Wang, Thomas J.
TI Metabolite Profiling Identifies Pathways Associated With Metabolic Risk
   in Humans
SO CIRCULATION
LA English
DT Article
DE epidemiology; metabolic syndrome; metabolomics; risk factors
ID CORONARY-HEART-DISEASE; GLUCOSE-TOLERANCE TEST; AMINO-ACID;
   INSULIN-RESISTANCE; GLUTAMINE SUPPLEMENTATION; BLOOD-PRESSURE;
   SENSITIVITY; HOMEOSTASIS; EXPRESSION; SECRETION
AB Background-Although metabolic risk factors are known to cluster in individuals who are prone to developing diabetes mellitus and cardiovascular disease, the underlying biological mechanisms remain poorly understood.
   Methods and Results-To identify pathways associated with cardiometabolic risk, we used liquid chromatography/mass spectrometry to determine the plasma concentrations of 45 distinct metabolites and to examine their relation to cardiometabolic risk in the Framingham Heart Study (FHS; n=1015) and the Malmo Diet and Cancer Study (MDC; n=746). We then interrogated significant findings in experimental models of cardiovascular and metabolic disease. We observed that metabolic risk factors (obesity, insulin resistance, high blood pressure, and dyslipidemia) were associated with multiple metabolites, including branched-chain amino acids, other hydrophobic amino acids, tryptophan breakdown products, and nucleotide metabolites. We observed strong associations of insulin resistance traits with glutamine (standardized regression coefficients, -0.04 to -0.22 per 1-SD change in log-glutamine; P<0.001), glutamate (0.05 to 0.14; P<0.001), and the glutamine-toglutamate ratio (-0.05 to -0.20; P<0.001) in the discovery sample (FHS); similar associations were observed in the replication sample (MDC). High glutamine-to-glutamate ratio was associated with lower risk of incident diabetes mellitus in FHS (odds ratio, 0.79; adjusted P=0.03) but not in MDC. In experimental models, administration of glutamine in mice led to both increased glucose tolerance (P=0.01) and decreased blood pressure (P=0.05).
   Conclusions-Biochemical profiling identified circulating metabolites not previously associated with metabolic traits. Experimentally interrogating one of these pathways demonstrated that excess glutamine relative to glutamate, resulting from exogenous administration, is associated with reduced metabolic risk in mice. (Circulation. 2012;125:2222-2231.)
C1 [Cheng, Susan; Lewis, Gregory D.; McCabe, Elizabeth L.; Shen, Dongxiao; Palma, Melinda J.; Roberts, Lee D.; Dejam, Andre; O'Donnell, Christopher J.; Gerszten, Robert E.; Wang, Thomas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
   [Rhee, Eugene P.; Lewis, Gregory D.; Gerszten, Robert E.; Wang, Thomas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
   [Rhee, Eugene P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Renal, Boston, MA 02114 USA.
   [Cheng, Susan; Larson, Martin G.; McCabe, Elizabeth L.; Fox, Caroline S.; O'Donnell, Christopher J.; Vasan, Ramachandran S.; Wang, Thomas J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
   [Cheng, Susan; Larson, Martin G.; McCabe, Elizabeth L.; Fox, Caroline S.; O'Donnell, Christopher J.; Vasan, Ramachandran S.; Wang, Thomas J.] Boston Univ, Sch Med, Framingham, MA USA.
   [Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
   [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA.
   [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
   [Larson, Martin G.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
   [Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
   [Rhee, Eugene P.; Lewis, Gregory D.; Souza, Amanda L.; Deik, Amy A.; Clish, Clary B.; Gerszten, Robert E.] Broad Inst MIT & Harvard Univ, Cambridge, MA USA.
   [Magnusson, Martin; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden.
RP Wang, TJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, GRB 800,55 Fruit St, Boston, MA 02114 USA.
EM rgerszten@partners.org; tjwang@partners.org
OI Larson, Martin/0000-0002-9631-1254; Magnusson,
   Martin/0000-0003-1710-5936; Ramachandran, Vasan/0000-0001-7357-5970;
   Roberts, Lee/0000-0002-1455-5248
FU National Institutes of Health [N01-HC-25195, R01-DK-HL081572]; Donald W.
   Reynolds Foundation; Leducq Foundation; Ellison Foundation; American
   Heart Association grant [10CRP2660009]; American Heart Association
   Established Investigator Award
FX This work was supported by National Institutes of Health contracts
   N01-HC-25195 and R01-DK-HL081572, the Donald W. Reynolds Foundation, and
   the Leducq Foundation. Dr Cheng is supported by the Ellison Foundation.
   Dr Dejam is supported by American Heart Association grant 10CRP2660009.
   Dr Gerszten is supported by an American Heart Association Established
   Investigator Award.
NR 46
TC 131
Z9 135
U1 6
U2 51
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 8
PY 2012
VL 125
IS 18
BP 2222
EP U132
DI 10.1161/CIRCULATIONAHA.111.067827
PG 24
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981JI
UT WOS:000306962600015
PM 22496159
ER

PT J
AU Emmert-Streib, F
   Dehmer, M
AF Emmert-Streib, Frank
   Dehmer, Matthias
TI Exploring Statistical and Population Aspects of Network Complexity
SO PLOS ONE
LA English
DT Article
ID SELF-GENERATED COMPLEXITY; SMALL-WORLD NETWORKS; INFORMATION CONTENT;
   FINANCIAL NETWORKS; GRAPHS; ENTROPY; INDEX; ORGANIZATION; EMERGENCE;
   MECHANICS
AB The characterization and the definition of the complexity of objects is an important but very difficult problem that attracted much interest in many different fields. In this paper we introduce a new measure, called network diversity score (NDS), which allows us to quantify structural properties of networks. We demonstrate numerically that our diversity score is capable of distinguishing ordered, random and complex networks from each other and, hence, allowing us to categorize networks with respect to their structural complexity. We study 16 additional network complexity measures and find that none of these measures has similar good categorization capabilities. In contrast to many other measures suggested so far aiming for a characterization of the structural complexity of networks, our score is different for a variety of reasons. First, our score is multiplicatively composed of four individual scores, each assessing different structural properties of a network. That means our composite score reflects the structural diversity of a network. Second, our score is defined for a population of networks instead of individual networks. We will show that this removes an unwanted ambiguity, inherently present in measures that are based on single networks. In order to apply our measure practically, we provide a statistical estimator for the diversity score, which is based on a finite number of samples.
C1 [Emmert-Streib, Frank] Queens Univ Belfast, Computat Biol & Machine Learning Lab, Ctr Canc Res & Cell Biol, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Emmert-Streib, Frank] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Dehmer, Matthias] UMIT, Inst Bioinformat & Translat Res, Hall In Tirol, Austria.
RP Emmert-Streib, F (reprint author), Queens Univ Belfast, Computat Biol & Machine Learning Lab, Ctr Canc Res & Cell Biol, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
EM v@bio-complexity.com
RI Emmert-Streib, Frank/G-8099-2011
OI Emmert-Streib, Frank/0000-0003-0745-5641
FU School of Medicine, Dentistry and Biomedical Sciences of the Queen's
   University Belfast; Austrian Science Funds [P22029-N13]
FX Frank Emmert-Streib is supported by the School of Medicine, Dentistry
   and Biomedical Sciences of the Queen's University Belfast. Matthias
   Dehmer is supported by the Austrian Science Funds for supporting this
   work (project P22029-N13). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 97
TC 11
Z9 11
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2012
VL 7
IS 5
AR e34523
DI 10.1371/journal.pone.0034523
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TF
UT WOS:000305335500002
PM 22590495
ER

PT J
AU Patil, S
   Figlin, RA
   Hutson, TE
   Michaelson, MD
   Negrier, S
   Kim, ST
   Huang, X
   Motzer, RJ
AF Patil, S.
   Figlin, R. A.
   Hutson, T. E.
   Michaelson, M. D.
   Negrier, S.
   Kim, S. T.
   Huang, X.
   Motzer, R. J.
TI Q-TWiST analysis to estimate overall benefit for patients with
   metastatic renal cell carcinoma treated in a phase III trial of
   sunitinib vs interferon-alpha
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE sunitinib; metastatic renal cell carcinoma; TWiST; Q-TWiST;
   progression-free survival; quality-adjusted survival
ID QUALITY-OF-LIFE; OPERABLE BREAST-CANCER; ADJUVANT THERAPY; SURVIVAL
AB BACKGROUND: In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in progression-free survival (PFS) compared with interferon (IFN)-alpha. We assessed between-treatment differences in overall benefit using a quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (TWiST; Gelber and Goldhirsch, 1986) analysis.
   METHODS: In this analysis, in which only grade 3/4 treatment-related toxicities were included, overall survival was partitioned into three health states: toxicity (time with toxicity after randomisation and before progression), time without symptoms of disease progression or toxicity, and time from progression until death. Between-treatment differences in the mean duration of each state were calculated. A threshold utility analysis was used to assess quality-adjusted TWiST (Q-TWiST) outcomes.
   RESULTS: Q-TWiST scores showed that quality-adjusted survival time was greater with sunitinib than with IFN-alpha, even though certain grade 3/4 toxicities occurred more frequently with sunitinib. For both treatments, the mean number of days with toxicity was small compared with PFS. This effect was more pronounced with sunitinib in which time spent without progression or toxicity was 151 days greater than with IFN-alpha.
   CONCLUSION: Patients randomised to sunitinib had longer clinical benefit, defined as Q-TWiST scores, than patients randomised to IFN-alpha. British Journal of Cancer (2012) 106, 1587-1590. doi:10.1038/bjc.2012.149 www.bjcancer.com (C) 2012 Cancer Research UK
C1 [Patil, S.; Motzer, R. J.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
   [Figlin, R. A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
   [Hutson, T. E.] Baylor Sammons Canc Ctr, Dallas, TX 75246 USA.
   [Michaelson, M. D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Negrier, S.] Ctr Leon Berard, F-69008 Lyon, France.
   [Kim, S. T.; Huang, X.] Pfizer La Jolla, San Diego, CA 92121 USA.
RP Patil, S (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM patils@mskcc.org
OI Michaelson, Dror/0000-0001-9249-6338
FU Pfizer, Inc.
FX This study was sponsored by Pfizer, Inc. Medical writing support was
   provided by Jean Scott and Felicity Leigh at ACUMED (Tytherington, UK)
   with funding from Pfizer, Inc.
NR 16
TC 7
Z9 7
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 8
PY 2012
VL 106
IS 10
BP 1587
EP 1590
DI 10.1038/bjc.2012.149
PG 4
WC Oncology
SC Oncology
GA 939PB
UT WOS:000303823400003
PM 22568998
ER

PT J
AU Ribi, K
   Aldridge, J
   Phillips, KA
   Thompson, A
   Harvey, V
   Thurlimann, B
   Cardoso, F
   Pagani, O
   Coates, AS
   Goldhirsch, A
   Price, KN
   Gelber, RD
   Bernhard, J
AF Ribi, K.
   Aldridge, J.
   Phillips, K-A
   Thompson, A.
   Harvey, V.
   Thuerlimann, B.
   Cardoso, F.
   Pagani, O.
   Coates, A. S.
   Goldhirsch, A.
   Price, K. N.
   Gelber, R. D.
   Bernhard, J.
CA Big I-98 Collaborative Grp
   IBCSG
TI Subjective cognitive complaints one year after ceasing adjuvant
   endocrine treatment for early-stage breast cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE subjective cognitive function; quality of life; breast cancer; aromatase
   inhibitor; tamoxifen; letrozole
ID GENERAL HEALTH QUESTIONNAIRE; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN;
   AROMATASE INHIBITORS; CHEMOTHERAPY; THERAPY; TAMOXIFEN; IMPAIRMENT;
   FATIGUE; MULTICENTER
AB BACKGROUND: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF).
   METHODS: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored.
   RESULTS: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P = 0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R = 0.80). Correlations between SCF and the other patient-reported outcomes were generally low.
   CONCLUSION: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute. British Journal of Cancer (2012) 106, 1618-1625. doi:10.1038/bjc.2012.156 www.bjcancer.com Published online 24 April 2012 (C) 2012 Cancer Research UK
C1 [Ribi, K.; Coates, A. S.; Bernhard, J.] IBCSG Coordinating Ctr, CH-3008 Bern, Switzerland.
   [Aldridge, J.; Price, K. N.; Gelber, R. D.] Dana Farber Canc Inst, IBCSG Stat Ctr, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
   [Phillips, K-A] Univ Melbourne, Melbourne, Vic 8006, Australia.
   [Phillips, K-A] Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia.
   [Thompson, A.] Univ Dundee, Dundee Canc Ctr, Dundee, Scotland.
   [Harvey, V.] Auckland City Hosp, Auckland 1, New Zealand.
   [Harvey, V.] Australian New Zealand Breast Canc Trials Grp, Hrmc, NSW 2310, Australia.
   [Thuerlimann, B.] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland.
   [Thuerlimann, B.; Pagani, O.] Swiss Grp Clin Canc Res SAKK, CH-3008 Bern, Switzerland.
   [Cardoso, F.] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium.
   [Pagani, O.] Osped Italiano, Oncol Inst So Switzerland, Lugano, Switzerland.
   [Coates, A. S.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Goldhirsch, A.] European Inst Oncol, Dept Med, I-20141 Milan, Italy.
   [Goldhirsch, A.] Swiss Ctr Breast Hlth, St Anna Clin, CH-6924 Lugano, Switzerland.
   [Price, K. N.; Gelber, R. D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA 02215 USA.
   [Gelber, R. D.] Harvard Univ, Sch Med, Harvard Sch Publ Heath, Boston, MA 02215 USA.
   [Bernhard, J.] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland.
RP Bernhard, J (reprint author), IBCSG Coordinating Ctr, Effingerstr 40, CH-3008 Bern, Switzerland.
EM juerg.bernhard@ibcsg.org
RI friedlander, michael/G-3490-2013; Wardley, ANdrew/N-8135-2015; 
OI friedlander, michael/0000-0002-6488-0604; Wardley,
   ANdrew/0000-0002-9639-0888; Phillips, Kelly-Anne/0000-0002-0475-1771;
   Cardoso, Fatima/0000-0002-6692-2249
FU Novartis;  [CA-75362]
FX We thank the women who participated in this trial, collaborators, and
   funding sources. Acknowledgement for involved individuals is given in
   the Appendix. This work was supported by Novartis and coordinated by
   IBCSG. Support for the IBCSG: Swedish Cancer Society; The Cancer Council
   Australia; Australian New Zealand Breast Cancer Trials Group; Frontier
   Science and Technology Research Foundation; Swiss Group for Clinical
   Cancer Research (SAKK); National Cancer Institute at the National
   Institutes of Health (Grant number CA-75362); Cancer Research
   Switzerland/Oncosuisse; and the Foundation for Clinical Cancer Research
   of Eastern Switzerland (OSKK); The Cancer Council Victoria, Dr John
   Colebatch Clinical Research Fellowship (to KAP). The substudy was funded
   by Novartis.
NR 49
TC 8
Z9 8
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 8
PY 2012
VL 106
IS 10
BP 1618
EP 1625
DI 10.1038/bjc.2012.156
PG 8
WC Oncology
SC Oncology
GA 939PB
UT WOS:000303823400008
PM 22531635
ER

PT J
AU van Ham, TJ
   Kokel, D
   Peterson, RT
AF van Ham, Tjakko J.
   Kokel, David
   Peterson, Randall T.
TI Apoptotic Cells Are Cleared by Directional Migration and elmo1-Dependent
   Macrophage Engulfment
SO CURRENT BIOLOGY
LA English
DT Article
ID IN-VIVO; DROSOPHILA EMBRYOGENESIS; ZEBRAFISH; CLEARANCE; DEATH; PU.1;
   REQUIREMENT; MECHANISM; ABLATION; RECEPTOR
AB Apoptotic cell death is essential for development and tissue homeostasis [1, 2]. Failure to clear apoptotic cells can ultimately cause inflammation and autoimmunity [3, 4]. Apoptosis has primarily been studied by staining of fixed tissue sections, and a clear understanding of the behavior of apoptotic cells in living tissue has been elusive. Here, we use a newly developed technique [5] to track apoptotic cells in real time as they emerge and are cleared from the zebrafish brain. We find that apoptotic cells are remarkably motile, frequently migrating several cell diameters to the periphery of living tissues. F-actin remodeling occurs in surrounding cells, but also within the apoptotic cells themselves, suggesting a cell-autonomous component of motility. During the first 2 days of development, engulfment is rare, and most apoptotic cells lyse at the brain periphery. By 3 days postfertilization, most cell corpses are rapidly engulfed by macrophages. This engulfment requires the guanine nucleotide exchange factor elmo1. In elmo1-deficient macrophages, engulfment is rare and may occur through macropinocytosis rather than directed engulfment. These findings suggest that clearance of apoptotic cells in living vertebrates is accomplished by the combined actions of apoptotic cell migration and eimo1-dependent macrophage engulfment.
C1 [van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Dept Med, Charlestown, MA 02129 USA.
   [van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Broad Inst, Cambridge, MA 02142 USA.
   [van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
RP van Ham, TJ (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9700 RB Groningen, Netherlands.
EM t.j.van.ham@umcg.nl; peterson@cvrc.mgh.harvard.edu
RI van Ham, Tjakko/I-2382-2013; van Ham, Tjakko/A-1989-2015; 
OI van Ham, Tjakko/0000-0002-2175-8713; kokel, david/0000-0002-1981-1511
FU National Institutes of Health [NS063733, MH086867, K01MH091449]; Charles
   and Ann Sanders MGH Research Scholar Award
FX We thank the members of the Peterson laboratory for helpful discussion
   and Kristin White and lain Drummond for helpful discussion and critical
   reading of the manuscript. We thank John Kanki, Marnie Halpern,
   Francesca Peri, Chetana Sachidanandan, and Reinhard Koster for
   transgenic zebrafish and Erez Raz and Roland Wedlich-Soldner for
   providing Lifeact reagents. This work was supported by National
   Institutes of Health grants NS063733 (R.T.P.), MH086867 (R.T.P.) and
   K01MH091449 (D.K.) and by the Charles and Ann Sanders MGH Research
   Scholar Award.
NR 38
TC 22
Z9 23
U1 1
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
J9 CURR BIOL
JI Curr. Biol.
PD MAY 8
PY 2012
VL 22
IS 9
BP 830
EP 836
DI 10.1016/j.cub.2012.03.027
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 941MP
UT WOS:000303967600034
PM 22503503
ER

PT J
AU Stephen, TL
   Wilson, BS
   Laufer, TM
AF Stephen, Tom Li
   Wilson, Bridget S.
   Laufer, Terri M.
TI Subcellular distribution of Lck during CD4 T-cell maturation in the
   thymic medulla regulates the T-cell activation threshold
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE autoreactivity; thymic selection; T cell receptor signaling
ID PROTEIN-TYROSINE-PHOSPHATASE; SRC-FAMILY KINASES; CLASS-II MHC; ANTIGEN
   RECEPTOR; POSITIVE SELECTION; THYMOCYTE SENSITIVITY;
   ELECTRON-MICROSCOPY; CENTRAL TOLERANCE; EXPRESSION; SIGNALS
AB Mature peripheral T cells respond to foreign but not to self-antigens. During development in the thymus, deletion of high-affinity self-reactive immature thymocytes contributes to tolerance of mature T cells. However, double-positive thymocytes are positively selected to survive if they respond to self-peptide-MHC complexes; thus, there must be mechanisms to prevent overt reactivity to those same complexes in the periphery. "Developmental tuning" is the active process through which T-cell receptor (TCR)-associated signaling pathways of single-positive (SP) thymocytes are attenuated to respond appropriately to self-peptide-MHC complexes in the periphery. We previously showed that MHC class II expression in the thymic medulla was necessary to tune CD4(+) SP (CD4 SP) thymocytes. CD4 SP thymocytes from mice lacking medullary MHC class II expression had inappropriately enhanced proximal TCR signaling to low-affinity self-ligands that was associated with altered cellular distribution of the tyrosine kinase Lck. Now, we report that activation of both tuned and untuned CD4 SP thymocytes is Lck-dependent. Untuned CD4 SP cells contain a pool of Lck with increased basal phosphorylation that is not associated with the CD4 coreceptor. Phosphorylation of this pool of Lck decreases with tuning. Immunogold transmission electron microscopy of membrane sheets permitted direct visualization of Lck. In the absence of tuning, a significant proportion of Lck and the TCR subunit CD3 zeta are expressed on the same protein island; this close association of Lck and the TCR probably explains the enhanced activation of untuned CD4 SP cells. Thus, changes in membrane topography during thymic maturation determine the set point for TCR responsiveness.
C1 [Stephen, Tom Li; Laufer, Terri M.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Wilson, Bridget S.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
   [Wilson, Bridget S.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
   [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
RP Laufer, TM (reprint author), Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
EM tlaufer@mail.med.upenn.edu
FU National Institutes of Health [R01 AI068819]; Arthritis Foundation
FX We thank Mary Ann Raymond-Stintz at the University of New Mexico for
   assistance with plasma membrane sheet preparations and TEM analysis.
   This work was supported by National Institutes of Health Grant R01
   AI068819 (to T. M. L.) and an Arthritis Foundation postdoctoral
   fellowship (to T. L. S.).
NR 53
TC 7
Z9 7
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 8
PY 2012
VL 109
IS 19
BP 7415
EP 7420
DI 10.1073/pnas.1119272109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 942ZQ
UT WOS:000304090600061
PM 22529380
ER

PT J
AU Hanyu, R
   Wehbi, VL
   Hayata, T
   Moriya, S
   Feinstein, TN
   Ezura, Y
   Nagao, M
   Saita, Y
   Hemmi, H
   Notomi, T
   Nakamoto, T
   Schipani, E
   Takeda, S
   Kaneko, K
   Kurosawa, H
   Karsenty, G
   Kronenberg, HM
   Vilardaga, JP
   Noda, M
AF Hanyu, Ryo
   Wehbi, Vanessa L.
   Hayata, Tadayoshi
   Moriya, Shuichi
   Feinstein, Timothy N.
   Ezura, Yoichi
   Nagao, Masashi
   Saita, Yoshitomo
   Hemmi, Hiroaki
   Notomi, Takuya
   Nakamoto, Tetsuya
   Schipani, Ernestina
   Takeda, Shu
   Kaneko, Kazuo
   Kurosawa, Hisashi
   Karsenty, Gerard
   Kronenberg, Henry M.
   Vilardaga, Jean-Pierre
   Noda, Masaki
TI Anabolic action of parathyroid hormone regulated by the
   beta(2)-adrenergic receptor
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone anabolism; bone cells
ID SYMPATHETIC-NERVOUS-SYSTEM; ELEMENT-BINDING PROTEIN; BONE-MINERAL
   DENSITY; POSTMENOPAUSAL WOMEN; IN-VIVO; OSTEOPOROSIS; EXPRESSION;
   THERAPY; OSTEOPROTEGERIN; TERIPARATIDE
AB Parathyroid hormone (PTH), the major calcium-regulating hormone, and norepinephrine (NE), the principal neurotransmitter of sympathetic nerves, regulate bone remodeling by activating distinct cell-surface G protein-coupled receptors in osteoblasts: the parathyroid hormone type 1 receptor (PTHR) and the beta(2)-adrenergic receptor (beta(2)AR), respectively. These receptors activate a common cAMP/PKA signal transduction pathway mediated through the stimulatory heterotrimeric G protein. Activation of beta(2)AR via the sympathetic nervous system decreases bone formation and increases bone resorption. Conversely, daily injection of PTH (1-34), a regimen known as intermittent (i) PTH treatment, increases bone mass through the stimulation of trabecular and cortical bone formation and decreases fracture incidences in severe cases of osteoporosis. Here, we show that iPTH has no osteoanabolic activity in mice lacking the beta(2)AR. beta(2)AR deficiency suppressed both iPTH-induced increase in bone formation and resorption. We showed that the lack of beta(2)AR blocks expression of iPTH-target genes involved in bone formation and resorption that are regulated by the cAMP/PKA pathway. These data implicate an unexpected functional interaction between PTHR and beta(2)AR, two G protein-coupled receptors from distinct families, which control bone formation and PTH anabolism.
C1 [Wehbi, Vanessa L.; Feinstein, Timothy N.; Vilardaga, Jean-Pierre] Univ Pittsburgh, Lab Prot Coupled Receptor Biol G, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
   [Hanyu, Ryo; Hayata, Tadayoshi; Moriya, Shuichi; Ezura, Yoichi; Nagao, Masashi; Saita, Yoshitomo; Hemmi, Hiroaki; Notomi, Takuya; Nakamoto, Tetsuya; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Tokyo 1138510, Japan.
   [Hanyu, Ryo; Hayata, Tadayoshi; Ezura, Yoichi; Hemmi, Hiroaki; Notomi, Takuya; Nakamoto, Tetsuya; Takeda, Shu; Noda, Masaki] Tokyo Med & Dent Univ, Global Ctr Excellence Program, Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo 1138510, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Adv Bone Joint Sci Ctr, Tokyo 1138510, Japan.
   [Hanyu, Ryo; Moriya, Shuichi; Nagao, Masashi; Saita, Yoshitomo; Kaneko, Kazuo; Kurosawa, Hisashi] Juntendo Univ, Sch Med, Dept Orthoped, Tokyo 1138421, Japan.
   [Hemmi, Hiroaki; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Tokyo 1010062, Japan.
   [Schipani, Ernestina; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Schipani, Ernestina; Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Karsenty, Gerard] Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10027 USA.
RP Vilardaga, JP (reprint author), Univ Pittsburgh, Lab Prot Coupled Receptor Biol G, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
EM jpv@pitt.edu; noda.mph@tmd.ac.jp
RI Ezura, Yoichi/L-9485-2016
FU Japanese Ministry of Education [18109011, 18659438, 18123456, 20013014,
   23659868]; Japan Space Forum; National Institutes of Health
   [R01DK087688]
FX This work was supported by the Japanese Ministry of Education [Global
   Center of Excellence (COE) Program, International Research Center for
   Molecular Science in Tooth and Bone Diseases Grants-in-Aid 18109011,
   18659438, 18123456, 20013014, and 23659868), grants from the Japan Space
   Forum (to M. Noda), and National Institutes of Health Grant R01DK087688
   (to J.-P.V).
NR 21
TC 24
Z9 26
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 8
PY 2012
VL 109
IS 19
BP 7433
EP 7438
DI 10.1073/pnas.1109036109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 942ZQ
UT WOS:000304090600064
PM 22538810
ER

PT J
AU Hayakawa, K
   Pham, LDD
   Katusic, ZS
   Arai, K
   Lo, EH
AF Hayakawa, Kazuhide
   Pham, Loc-Duyen D.
   Katusic, Zvonimir S.
   Arai, Ken
   Lo, Eng H.
TI Astrocytic high-mobility group box 1 promotes endothelial progenitor
   cell-mediated neurovascular remodeling during stroke recovery
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE reactive glia; vascular repair; brain remodeling
ID END-PRODUCTS RAGE; TRAUMATIC BRAIN-INJURY; NEURITE OUTGROWTH;
   ISCHEMIC-STROKE; NEUROGENESIS; ANGIOGENESIS; RECEPTOR; HMGB1;
   MECHANISMS; INFLAMMATION
AB Crosstalk between the brain and systemic responses in blood is increasingly suspected of playing critical roles in stroke. However, how this communication takes place remains to be fully understood. Here, we show that reactive astrocytes can release a damage-associated molecular-pattern molecule called high-mobilitygroup-box-1 (HMGB1) that promotes endothelial progenitor cell (EPC)-mediated neurovascular remodeling during stroke recovery. Conditioned media from reactive astrocytes increase EPC proliferation in vitro. siRNA suppression of HMGB1 in astrocytes or blockade of the HMGB1 receptor for advanced glycation end-products in EPCs prevents this effect. In a mouse model of focal cerebral ischemia, reactive astrocytes in the peri-infarct cortex upregulate HMGB1 at 14 d poststroke, along with an accumulation of endogenous EPCs. In vivo siRNA suppression of HMGB1 blocks this EPC response, reduces peri-infact angiogenesis, and worsens neurological deficits. Taken together, these molecular and in vivo findings support a previously undescribed mechanism of crosstalk between reactive astrocytes and EPCs wherein HMGB1 promotes neurovascular remodeling and functional recovery after stroke and brain injury.
C1 [Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.
   [Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
   [Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Katusic, Zvonimir S.] Mayo Clin, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA.
RP Lo, EH (reprint author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.
EM Lo@helix.mgh.harvard.edu
FU Deane Foundation; American Heart Association; National Institutes of
   Health
FX This work was supported in part by the Deane Foundation, the American
   Heart Association, and the National Institutes of Health.
NR 36
TC 60
Z9 64
U1 1
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 8
PY 2012
VL 109
IS 19
BP 7505
EP 7510
DI 10.1073/pnas.1121146109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 942ZQ
UT WOS:000304090600076
PM 22529378
ER

PT J
AU Li, YH
   Siegel, DL
   Scholler, N
   Kaplan, DE
AF Li, Yonghai
   Siegel, Donald L.
   Scholler, Nathalie
   Kaplan, David E.
TI Validation of glypican-3-specific scFv isolated from paired
   display/secretory yeast display library
SO BMC BIOTECHNOLOGY
LA English
DT Article
ID HUMAN HEPATOCELLULAR-CARCINOMA; PHASE-II; IN-VITRO; MARKER; EXPRESSION;
   ANTIBODY; CELLS; GENERATION; PROTEIN; GROWTH
AB Background: Glypican-3 (GPC3) is a heparan-sulfate proteoglycan frequently expressed on the cell membrane of malignant hepatocytes in hepatocellular carcinoma. The capacity for screening potential antibodies in vitro using human hepatocellular lines is critical to ensure binding to this highly post-translationally modified glycophosphatidylinositiol linked protein. We hypothesized that we could utilize a recently described paired display/secretory yeast library to isolate human-derived scFv against glypican-3 for potential diagnostic and/or therapeutic application.
   Results: Using two different biotinylated antigen targets, a synthesized 29mer fragment GPC3(550-558) and a truncated GPC3(368-548) fused with glutathione S-transferase (GST) we enriched the yeast display library to greater than 30% target-specific yeast with both positive selection and depletion of streptavidin-and GST-specific clones. After cloning of scFv cDNA from the enriched sub-library, scFv specificity was validated by ELISA for binding to recombinant protein from prokaryotic and eukaryotic sources and ultimately naturally presented human protein on the cell membrane of human hepatocellular cell lines. Specificity was confirmed using non-expressing cell lines and shRNA knockdown. Ultimately, five unique scFv with affinity EC50 ranging from 5.0-110.9nM were identified.
   Conclusions: Using a paired display/secretory yeast library, five novel and unique scFvs for potential humoral or chimeric therapeutic development in human hepatocellular carcinoma were isolated and characterized.
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA.
   [Li, Yonghai; Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Siegel, Donald L.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Scholler, Nathalie] Univ Penn, Dept Obstet & Gynecol, Ctr Res Reprod & Womens Hlth, Penn Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA.
EM dakaplan@mail.med.upenn.edu
RI Scholler, Nathalie/O-9003-2014; 
OI Kaplan, David E./0000-0002-3839-336X
FU McCabe Family Research Foundation [R21 CA149908]; Veterans Health
   Administration; University of Pennsylvania
FX This work was supported by R21 CA149908 (DEK), McCabe Family Research
   Foundation, and Research Career Development Award from the Veterans
   Health Administration (DEK), academic development funds from the
   University of Pennsylvania (DEK). The authors would like to thank Aizhi
   Zhao for his technical assistance. The content of this article does not
   reflect the views of the VA or of the US Government.
NR 32
TC 3
Z9 4
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6750
J9 BMC BIOTECHNOL
JI BMC Biotechnol.
PD MAY 7
PY 2012
VL 12
AR 23
DI 10.1186/1472-6750-12-23
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 992EH
UT WOS:000307757900001
PM 22564378
ER

PT J
AU Baeza, JC
   Jagannathan, JP
   Krajewski, K
   O'Regan, K
   Zukotynski, K
   Kulke, M
   Ramaiya, NH
AF Baeza, Juan C.
   Jagannathan, Jyothi P.
   Krajewski, Katherine
   O'Regan, Kevin
   Zukotynski, Katherine
   Kulke, Matthew
   Ramaiya, Nikhil H.
TI Pheochromocytoma and paraganglioma: imaging characteristics
SO CANCER IMAGING
LA English
DT Review
DE Pheochromocytoma; paraganglioma; multiple endocrine neoplasia
ID CT; SCINTIGRAPHY
AB The accurate diagnosis of adult pheochromocytoma and paraganglioma necessitates a multidisciplinary approach that includes clinical history, biochemical testing, and multimodality imaging such as computed tomography, magnetic resonance imaging, and nuclear medicine studies. This review illustrates the different imaging characteristics of primary adult pheochromocytomas as well as both sympathetic and parasympathetic paragangliomas. The review also describes known genetic associations and shows common metastatic patterns. Knowledge of the diverse appearance of pheochromocytomas and paragangliomas can result in early initial diagnosis or detection of disease recurrence thereby affecting patient management and prognosis.
C1 [Baeza, Juan C.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
   [Jagannathan, Jyothi P.; Krajewski, Katherine; O'Regan, Kevin; Zukotynski, Katherine; Kulke, Matthew; Ramaiya, Nikhil H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
RP Baeza, JC (reprint author), 75 Francis St, Boston, MA 02115 USA.
EM jcbaez@gmail.com
NR 16
TC 6
Z9 11
U1 0
U2 5
PU E-MED
PI LONDON
PA PO BOX 29761, LONDON, NW3 7ZS, ENGLAND
SN 1470-7330
J9 CANCER IMAGING
JI Cancer Imaging
PD MAY 7
PY 2012
VL 12
IS 1
BP 153
EP 162
DI 10.1102/1470-7330.2012.0016
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 961ZP
UT WOS:000305509000003
PM 22571874
ER

PT J
AU Bunschoten, A
   Buckle, T
   Visser, NL
   Kuil, J
   Yuan, HS
   Josephson, L
   Vahrmeijer, AL
   van Leeuwen, FWB
AF Bunschoten, Anton
   Buckle, Tessa
   Visser, Nils L.
   Kuil, Joeri
   Yuan, Hushan
   Josephson, Lee
   Vahrmeijer, Alexander L.
   van Leeuwen, Fijs W. B.
TI Multimodal Interventional Molecular Imaging of Tumor Margins and Distant
   Metastases by Targeting alpha v beta 3 Integrin
SO CHEMBIOCHEM
LA English
DT Article
DE angiogenesis; fluorescence; imaging agents; multimodal imaging; surgical
   guidance
ID NEAR-INFRARED FLUORESCENCE; BREAST-CANCER; IN-VIVO; PEPTIDE; EXPRESSION;
   PROBE; RADIONUCLIDE; CONJUGATION; DENDRIMERS; SURGERY
AB av beta 3 Integrin is involved in (tumor-induced) angiogenesis and is a promising candidate for the specific visualization of both primary tumors and of their distant metastases. Combination of radioactive and fluorescent imaging labels in a single multimodal, or rather hybrid, RGD-based imaging agent enables integration of pre-, intra-, and postoperative angiogenesis imaging. A hybrid imaging agent targeting the av beta 3 integrin111In-MSAP-RGD (MSAP=multifunctional single-attachment-point reagent), which contains a targeting moiety, a pentetic acid (DTPA) chelate, and a cyanine dyewas evaluated for its potential value in combined lesion detection and interventional molecular imaging in a 4T1 mouse breast cancer model. SPECT/CT and fluorescence imaging were used to visualize the tumor in vivo. Tracer distribution was evaluated ex vivo down to the microscopic level. The properties of 111In-MSAP-RGD were compared with those of 111In-DTPA-RGD. Biodistribution studies revealed a prolonged retention and increased tumor accumulation of 111In-MSAP-RGD relative to 111In-DTPA-RGD. With 111In-MSAP-RGD, identical features could be visualized preoperatively (SPECT/CT) and intraoperatively (fluorescence imaging). As well as the primary tumor, 111In-MSAP-RGD also enabled detection and accurate excision of distant metastases in the head and neck region of the mice. Therefore, the hybrid RGD derivative 111In-MSAP-RGD shows potential in preoperative planning and fluorescence-based surgical intervention.
C1 [Bunschoten, Anton; Buckle, Tessa; Kuil, Joeri; van Leeuwen, Fijs W. B.] Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands.
   [Bunschoten, Anton; Buckle, Tessa; Kuil, Joeri; van Leeuwen, Fijs W. B.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Diagnost Oncol, NL-1066 CX Amsterdam, Netherlands.
   [Visser, Nils L.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands.
   [Yuan, Hushan; Josephson, Lee] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Translat Nucl Med & Mol Imaging, Boston, MA 02129 USA.
   [Vahrmeijer, Alexander L.] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands.
RP van Leeuwen, FWB (reprint author), Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands.
EM f.w.b.van_leeuwen@lumc.nl
OI van leeuwen, Fijs/0000-0002-6844-4025; Buckle, Tessa/0000-0003-2980-6895
FU Koningin Wilhelmina Fonds (KWF) [PGF 2009-4344]; NWO [STW BGT 11271];
   NIH [R01 EB009 691, EB011996]
FX This research was supported by a Koningin Wilhelmina Fonds (KWF)
   translational research award (Grant No. PGF 2009-4344; F. v. L.), an NWO
   VIDI-Grant (STW BGT 11271; F. v. L.), and by the NIH grants R01 EB009
   691 and EB011996 (L.J.). This research was performed within the
   framework of the Centre for Translational Molecular Medicine
   (http://www.ctmm.nl) project MUSIS (A. B.), and the FP7-project hyper
   image (T.B.).
NR 43
TC 20
Z9 20
U1 1
U2 25
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1439-4227
J9 CHEMBIOCHEM
JI ChemBioChem
PD MAY 7
PY 2012
VL 13
IS 7
BP 1039
EP 1045
DI 10.1002/cbic.201200034
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 931CL
UT WOS:000303191900016
PM 22505018
ER

PT J
AU Ngwa, W
   Tsiamas, P
   Zygmanski, P
   Makrigiorgos, GM
   Berbeco, RI
AF Ngwa, Wilfred
   Tsiamas, Panagiotis
   Zygmanski, Piotr
   Makrigiorgos, G. Mike
   Berbeco, Ross I.
TI A multipurpose quality assurance phantom for the small animal radiation
   research platform (SARRP)
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID STEREOTACTIC RADIOSURGERY; DOSE CALCULATIONS; MOSFET DETECTORS;
   RADIOTHERAPY; SYSTEM; GUIDANCE; QA
AB In this work, the suitability and performance of a mouse-size MOSFET (Mousefet) phantom is investigated for routine quality assurance (QA) of the small animal radiation research platform (SARRP). This Mousefet phantom is a simple construction consisting of five micro-MOSFETS custom integrated in a quincunx pattern within a tissue-equivalent phantom, allowing repeat/multiple QA tasks to be quickly performed in one experimental set-up. The Mousefet phantom is particularly evaluated for facilitating SARRP QA tasks which may warrant daily evaluation, including output constancy, isocenter congruency test and cone beam computed tomography (CBCT) image geometric accuracy. Results for the output constancy measurements showed a maximum daily variation of less than 2.6% for all MOSFETS, in consonance with observations from concurrent ion chamber measurements. It is also shown that the design of the Mousefet phantom allows the output check data to be used for prompt verification of beam energy and cone profile constancy. For the isocenter congruency test, it is demonstrated that the Mousefet phantom can detect 0.3 mm deviations of the CBCT isocenter from the radiation isocenter. Meanwhile, results for CBCT image geometric accuracy were consistently found to be within 2% of the expected value. Other CBCT image quality parameters could also be assessed in terms of image intensity constancy, noise and image uniformity. Overall, the results establish the Mousefet phantom as a simple and time-efficient multipurpose tool that could be employed effectively for routine QA of the SARRP.
C1 [Ngwa, Wilfred; Tsiamas, Panagiotis; Zygmanski, Piotr; Makrigiorgos, G. Mike; Berbeco, Ross I.] Brigham & Womens Hosp, Dept Radiat Oncol, Div Med Phys & Biophys, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Ngwa, Wilfred; Tsiamas, Panagiotis; Zygmanski, Piotr; Makrigiorgos, G. Mike; Berbeco, Ross I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Tsiamas, Panagiotis] Univ Thessaly, Dept Med Phys, Sch Med, Larisa 4100, Greece.
RP Ngwa, W (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Div Med Phys & Biophys, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM wngwa@lroc.harvard.edu
NR 29
TC 4
Z9 4
U1 0
U2 1
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 7
PY 2012
VL 57
IS 9
DI 10.1088/0031-9155/57/9/2575
PG 12
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 929FH
UT WOS:000303046200013
PM 22491061
ER

PT J
AU Ren, Q
   Nishioka, S
   Shirato, H
   Berbeco, R
AF Ren, Qing
   Nishioka, Seiko
   Shirato, Hiroki
   Berbeco, Ross
TI Adaptive external gating based on the updating method of
   internal/external correlation and gating window before each beam
   delivery
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID LUNG-CANCER RADIOTHERAPY; TUMOR TRACKING; RESPIRATORY SURROGATES; GATED
   RADIOTHERAPY; MARKERS; MOTION; SIMULATION; ALGORITHM
AB The purpose of this study is to evaluate the performance of an adaptive gating method, which is designed to accommodate the beam-to-beam and day-today variation of the internal/external correlation, as well as the real tumor position during respiratory-gated fractionated radiotherapy. We define a two-step procedure: (1) before each treatment, target positions are detected and synchronized with an external surrogate for establishing the internal/external correlation model and determining the position of the gating window, and then (2) during the delivery of the treatment beam, the gating is triggered by an external signal based on the updated internal/external correlation and window position. This correlation is described by a linear-quadratic model including a time shift between the internal and external signals. To simulate the proposed method, data of tumor motion in the superior-inferior direction synchronized with an external surrogate during hypo-fractionated radiotherapy from five lung patients are analyzed retrospectively. Duty cycle (DC), target coverage (TC) and the average distance (AD) between the internal target position and the edge of the gating window for all false positives are calculated as evaluative criteria. Under a 5 mm gating window, the average TC is 88.9%, with a DC around 45% and a mean AD of 0.7 mm. A daily update is also simulated for comparison, and it is found that beam-to-beam updating is superior. In conclusion, the combined updating of internal/external correlation and the gating window for each beam can improve the accuracy and reliability of respiratory-gated radiotherapy.
C1 [Ren, Qing] Varian Med Syst China Co Ltd, Beijing, Peoples R China.
   [Nishioka, Seiko] NTT Hosp, Dept Radiol, Sapporo, Hokkaido, Japan.
   [Shirato, Hiroki] Hokkaido Univ, Sch Med, Dept Radiat Med, Sapporo, Hokkaido 060, Japan.
   [Berbeco, Ross] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Berbeco, Ross] Harvard Univ, Sch Med, Boston, MA USA.
RP Ren, Q (reprint author), Varian Med Syst China Co Ltd, Beijing, Peoples R China.
EM qing.ren@varian.com
RI Shirato, Hiroki/A-7068-2010
NR 18
TC 2
Z9 2
U1 0
U2 3
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 7
PY 2012
VL 57
IS 9
DI 10.1088/0031-9155/57/9/N145
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 929FH
UT WOS:000303046200004
PM 22507921
ER

PT J
AU Verburg, JM
   Seco, J
AF Verburg, Joost M.
   Seco, Joao
TI CT metal artifact reduction method correcting for beam hardening and
   missing projections
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID COMPUTED-TOMOGRAPHY; RECONSTRUCTION; SUPPRESSION; ALGORITHM; IMPLANTS
AB We present and validate a computed tomography (CT) metal artifact reduction method that is effective for a wide spectrum of clinical implant materials. Projections through low-Z implants such as titanium were corrected using a novel physics correction algorithm that reduces beam hardening errors. In the case of high-Z implants (dental fillings, gold, platinum), projections through the implant were considered missing and regularized iterative reconstruction was performed. Both algorithms were combined if multiple implant materials were present. For comparison, a conventional projection interpolation method was implemented. In a blinded and randomized evaluation, ten radiation oncologists ranked the quality of patient scans on which the different methods were applied. For scans that included low-Z implants, the proposed method was ranked as the best method in 90% of the reviews. It was ranked superior to the original reconstruction (p = 0.0008), conventional projection interpolation (p < 0.0001) and regularized limited data reconstruction (p = 0.0002). All reviewers ranked the method first for scans with high-Z implants, and better as compared to the original reconstruction (p < 0.0001) and projection interpolation (p = 0.004). We conclude that effective reduction of CT metal artifacts can be achieved by combining algorithms tailored to specific types of implant materials.
C1 [Verburg, Joost M.; Seco, Joao] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Verburg, Joost M.; Seco, Joao] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
   [Verburg, Joost M.] Eindhoven Univ Technol, Sch Med Phys & Engn, NL-5600 MB Eindhoven, Netherlands.
RP Verburg, JM (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM jverburg@fas.harvard.edu
RI Seco, Joao/J-4451-2012
FU Federal Share of program [C06-CA059267]
FX The authors would like to thank Mukta Joshi for her assistance with the
   acquisition of the projection data from the scanner, and Maria Francesca
   Spadea, PhD, for the helpful discussions. This work was supported by the
   Federal Share of program income earned by Massachusetts General Hospital
   on C06-CA059267, Proton Therapy Research and Treatment Center.
NR 22
TC 40
Z9 41
U1 4
U2 19
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 7
PY 2012
VL 57
IS 9
DI 10.1088/0031-9155/57/9/2803
PG 16
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 929FH
UT WOS:000303046200027
PM 22510753
ER

PT J
AU Nunez, AL
   Jhala, NC
   Carroll, AJ
   Mikhail, FM
   Reddy, VVB
   Xian, RR
   Jhala, DN
AF Nunez, Amberly L.
   Jhala, Nirag C.
   Carroll, Andrew J.
   Mikhail, Fady M.
   Reddy, Vishnu V. B.
   Xian, Rena R.
   Jhala, Darshana N.
TI Endoscopic ultrasound and endobronchial ultrasound-guided fine-needle
   aspiration of deep-seated lymphadenopathy: Analysis of 1338 cases
SO CYTOJOURNAL
LA English
DT Article
DE Endoscopic ultrasound; endobronchial ulatrsound; fine-needle aspiration;
   mediastinum; flow cytometry; fluorescence in situ hybridization; lymph
   node; lymphoma
ID B-CELL LYMPHOMA; FLOW-CYTOMETRY; CENTER EXPERIENCE; RECURRENT LYMPHOMA;
   DIAGNOSIS; BIOPSY; SUBCLASSIFICATION; CYTOMORPHOLOGY; CLASSIFICATION;
   ACCURATE
AB Background: We retrospectively studied 1338 samples of lymph nodes obtained by endoscopic and endobronchial ultrasound-guided fine needle aspiration biopsy (EUS and EBUS-FNAB) with an objective of characterizing the utility of this diagnostic modality in the assessment of deep-seated lymphadenopathy. The secondary aims were to establish the utility in the diagnosis of lymphoma and to determine the number of passes required to obtain adequate cellularity for flow cytometric analysis. Materials and Methods: On-site assessment was performed by a cytopathologist using Diff-Quik (American Scientific Products, McGraw Park, IL) stain. In addition, Papanicolaou and immunohistochemical stains were performed and additional samples were sent for flow cytometric analyses (n = 145). The final cytologic diagnosis was correlated with surgical pathology diagnosis and/or clinical follow-up. In select cases, fluorescence in situ hybridization analysis with specific probes was performed on Diff-Quik smears. Results: Both morphology as well as ancillary studies (flow cytometry or immunohistochemical stain and/or fluorescence in situ hybridization) show that EUS and EBUS-FNA are effective techniques to detect and stage intrathoracic and intra-abdominal tumors. Operating characteristics show that these are highly sensitive (89) and specific (100) techniques for the diagnosis of lymphoma. At least two passes provided an average of 5.66 million cells (range, 0.12-62.32 million) for lymphoma cases. Conclusions: EUS and EBUS-FNA are powerful modalities to stage malignancies and at least two passes can provide adequate cells for flow cytometric analysis. We also demonstrate that fluorescence in situ hybridization analysis can be performed on Diff-Quik-stained and mounted smears.
C1 [Nunez, Amberly L.; Reddy, Vishnu V. B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Carroll, Andrew J.; Mikhail, Fady M.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
   [Jhala, Nirag C.; Xian, Rena R.; Jhala, Darshana N.] Univ Penn, Philadelphia, PA 19104 USA.
   [Jhala, Nirag C.; Reddy, Vishnu V. B.; Xian, Rena R.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Nunez, AL (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM alinda@uab.edu; nirag.jhala@uphs.upenn.edu; acarroll@uab.edu;
   fmikhail@uab.edu; vreddy@uab.edu; rena.xian@uphs.upenn.edu;
   darshana.jhala@uphs.upenn.edu
OI Reddy, Vishnu/0000-0001-5474-3289
NR 28
TC 11
Z9 11
U1 0
U2 3
PU MEDKNOW PUBLICATIONS
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0974-5963
J9 CYTOJOURNAL
JI CytoJournal
PD MAY 5
PY 2012
VL 9
AR 14
DI 10.4103/1742-6413.95845
PG 10
WC Pathology
SC Pathology
GA 976CF
UT WOS:000306557400002
PM 22615712
ER

PT J
AU Zhang, ZL
   Wu, XM
   Duan, J
   Hinrichs, D
   Wegmann, K
   Zhang, GL
   Hall, M
   Rosenbaum, JT
AF Zhang, Zili
   Wu, Xiumei
   Duan, Jie
   Hinrichs, David
   Wegmann, Keith
   Zhang, Gary L.
   Hall, Mark
   Rosenbaum, James T.
TI Low Dose Rapamycin Exacerbates Autoimmune Experimental Uveitis
SO PLOS ONE
LA English
DT Article
ID INDUCED CELL-DEATH; OF-THE-LITERATURE; MAMMALIAN TARGET; T-CELLS;
   METABOLIC-REGULATION; CYCLOSPORINE-A; MTOR; SIROLIMUS; MICE; ACTIVATION
AB Background: Rapamycin, a potent immune modulator, is used to treat transplant rejection and some autoimmune diseases. Uveitis is a potentially severe inflammatory eye disease, and 2 clinical trials of treating uveitis with rapamycin are under way. Unexpectedly, recent research has demonstrated that low dose rapamycin enhances the memory T cell population and function. However, it is unclear how low dose rapamycin influences the immune response in the setting of uveitis.
   Design and Methods: B10.RIII mice were immunized to induce experimental autoimmune uveitis (EAU). Ocular inflammation of control and rapamycin-treated mice was compared based on histological change. ELISPOT and T cell proliferation assays were performed to assess splenocyte response to ocular antigen. In addition, we examined the effect of rapamycin on activation-induced cell death (AICD) using the MitoCapture assay and Annexin V staining.
   Results: Administration of low dose rapamycin exacerbated EAU, whereas treating mice with high dose rapamycin attenuated ocular inflammation. The progression of EAU by low dose rapamycin coincided with the increased frequency of antigen-reactive lymphocytes. Lastly, fewer rapamycin-treated T cells underwent AICD, which might contribute to exaggerated ocular inflammation and the uveitogenic immune response.
   Conclusion: These data reveal a paradoxical role for rapamycin in uveitis in a dose-dependent manner. This study has a potentially important clinical implication as rapamycin might cause unwanted consequences dependent on dosing and pharmacokinetics. Thus, more research is needed to further define the mechanism by which low dose rapamycin augments the immune response.
C1 [Zhang, Zili; Wu, Xiumei; Duan, Jie; Zhang, Gary L.; Hall, Mark] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
   [Hinrichs, David; Wegmann, Keith] Portland VA Med Ctr, Portland, OR USA.
   [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
   [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
RP Zhang, ZL (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM zhangzi@ohsu.edu; rosenbaj@ohsu.edu
FU National Institutes of Health [EY016788, EY013093, EY006484]; Stan and
   Madelle Rosenfeld Family Trust; William and Mary Bauman Foundation;
   Research to Prevent Blindness; William C. Kuzell Foundation
FX This work was supported by National Institutes of Health Grants EY016788
   (ZZ), EY013093 (JTR), and EY006484 (JTR). Funds from the Stan and
   Madelle Rosenfeld Family Trust, the William and Mary Bauman Foundation,
   Research to Prevent Blindness and William C. Kuzell Foundation also
   supported this work. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 56
TC 14
Z9 15
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2012
VL 7
IS 5
AR e36589
DI 10.1371/journal.pone.0036589
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WV
UT WOS:000305349800085
PM 22574188
ER

PT J
AU Alonso, JL
   Goldmann, WH
AF Alonso, Jose Luis
   Goldmann, Wolfgang H.
TI Influence of divalent cations on the cytoskeletal dynamics of K562 cells
   determined by nano-scale bead tracking
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE K562 cells; Divalent cations; Integrins; Actin cytoskeleton; Spontaneous
   bead motion
ID INTEGRIN ALPHA-V-BETA-3; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT;
   ADHESION; ALPHA(5)BETA(1); VINCULIN; DOMAIN; ALPHA(V)BETA(3); LIGAND
AB Cytoskeletal reorganization processes can be analyzed by studying the nanometer-scale spontaneous motion of beads bound to the cytoskeleton. The bead motion is determined by force fluctuations within the cytoskeletal network that originates from myosin motor activity and dynamic restructuring of cytoskeletal filaments. We investigated to what extend the spontaneous bead motion is influenced by the dynamics of the link between the bead and the cytoskeleton in the presence of divalent cations. Our data show that, when K562 cells expressing constitutively (alpha 5 beta 1) integrin and when stably transfected with (alpha v beta 3) integrin, spontaneous bead motion is dramatically affected by the presence of 1 mM Mn2+ (integrin, activate state) compared to 1 mM Ca2+/Mg2+ ions (integrin, inactive state). The directionality of the bead motion, which is influenced by the overall stability of the cytoskeletal network and by actomyosin-generated forces, is markedly different, whilst the persistence remained similar due to the specific binding of either Mn2+ or Mg2+/Ca2+ ions. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Goldmann, Wolfgang H.] Univ Erlangen Nurnberg, Biophys Grp, Ctr Med Phys & Technol, D-91052 Erlangen, Germany.
   [Alonso, Jose Luis] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
RP Goldmann, WH (reprint author), Univ Erlangen Nurnberg, Biophys Grp, Ctr Med Phys & Technol, Henkestr 91, D-91052 Erlangen, Germany.
EM wgoldmann@biomed.uni-erlangen.de
RI Alonso, Jose Luis/G-7961-2012; Goldmann, Wolfgang/H-5572-2013
FU Bayerische Forschungsallianz; Deutscher Akademischer Austausch Dienst;
   Deutsche Forschungsgemeinschaft
FX We thank Drs. Ben Fabry and Claus Metzner for helpful discussions and
   Ms. Astrid Mainka for technical assistance. This work was supported by
   grants from Bayerische Forschungsallianz, Deutscher Akademischer
   Austausch Dienst, and Deutsche Forschungsgemeinschaft.
NR 21
TC 3
Z9 3
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 4
PY 2012
VL 421
IS 2
BP 245
EP 248
DI 10.1016/j.bbrc.2012.03.145
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 944QZ
UT WOS:000304220200015
PM 22497890
ER

PT J
AU Zuo, KQ
   Li, D
   Pulli, B
   Yu, F
   Cai, HD
   Yuan, XY
   Zhang, XP
   Lv, ZW
AF Zuo, Keqiang
   Li, Dan
   Pulli, Benjamin
   Yu, Fei
   Cai, Haidong
   Yuan, Xueyu
   Zhang, Xiaoping
   Lv, Zhongwei
TI Short-hairpin RNA-mediated Heat shock protein 90 gene silencing inhibits
   human breast cancer cell growth in vitro and in vivo
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Heat shock protein 90; Short hairpin RNA; Breast cancer; MCF-7 cell
ID HSP90 MOLECULAR CHAPERONE; SURVIVAL; ACTIVATION; APOPTOSIS; COMPLEX;
   BINDING; TARGET; DEATH; HSP27; CDC37
AB Hsp90 interacts with proteins that mediate signaling pathways involved in the regulation of essential processes such as proliferation, cell cycle control, angiogenesis and apoptosis. Hsp90 inhibition is therefore an attractive strategy for blocking abnormal pathways that are crucial for cancer cell growth. In the present study, the role of Hsp90 in human breast cancer MCF-7 cells was examined by stably silencing Hsp90 gene expression with an Hsp90-silencing vector (Hsp90-5hRNA). RT-PCR and Western blot analyses showed that Hsp90-shRNA specifically and markedly down-regulated Hsp90 mRNA and protein expression. NF-kB and Akt protein levels were down-regulated in Hsp90-shRNA transfected cells, indicating that Hsp90 knockout caused a reduction of survival factors and induced apoptosis. Treatment with Hsp90-shRNA significantly increased apoptotic cell death and caused cell cycle arrest in the G1/S phase in MCF-7 cells, as shown by flow cytometry. Silencing of Hsp90 also reduced cell viability, as determined by MTT assay. In vivo experiments showed that MCF-7 cells stably transfected with Hsp90-5hRNA grew slowly in nude mice as compared with control groups. In summary, the Hsp90-shRNA specifically silenced the Hsp90 gene, and inhibited MCF-7 cell growth in vitro and in vivo. Possible molecular mechanisms underlying the effects of Hsp90-5hRNA include the degradation of Hsp90 breast cancer-related client proteins, the inhibition of survival signals and the upregulation of apoptotic pathways. shRNA-mediated interference may have potential therapeutic utility in human breast cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Dan; Yu, Fei; Cai, Haidong; Yuan, Xueyu; Zhang, Xiaoping; Lv, Zhongwei] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China.
   [Zuo, Keqiang] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Gen Surg, Shanghai 200072, Peoples R China.
   [Pulli, Benjamin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
RP Zhang, XP (reprint author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nucl Med, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
EM zxpsibs@163.com; heyixue163@163.com
FU National Natural Science Foundation of China [30901770]; International
   (Regional) Cooperation and Exchange Program [81150110493]; Shanghai
   Municipal Science and Technology Commission [10JC1412700]
FX The present study was funded by National Natural Science Foundation of
   China (No. 30901770), the International (Regional) Cooperation and
   Exchange Program (No. 81150110493), Shanghai Municipal Science and
   Technology Commission (No. 10JC1412700).
NR 33
TC 2
Z9 2
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 4
PY 2012
VL 421
IS 2
BP 396
EP 402
DI 10.1016/j.bbrc.2012.04.032
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 944QZ
UT WOS:000304220200041
PM 22521890
ER

PT J
AU Wu, H
   Zhang, Y
AF Wu, Hao
   Zhang, Yi
TI Early Embryos Reprogram DNA Methylation in Two Steps
SO CELL STEM CELL
LA English
DT Editorial Material
ID PREIMPLANTATION EMBRYOS; 5-HYDROXYMETHYLCYTOSINE; OOCYTES; GENOME
C1 [Wu, Hao; Zhang, Yi] Univ N Carolina, Lineberger Comprehens Canc Ctr, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.
   [Wu, Hao; Zhang, Yi] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.
   [Wu, Hao] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
   [Wu, Hao] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
RP Zhang, Y (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.
EM yi_zhang@med.unc.edu
RI Wu, Hao/G-4145-2013; Waha, Andreas/J-2950-2014
OI Wu, Hao/0000-0002-1256-6891; 
NR 10
TC 8
Z9 8
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 4
PY 2012
VL 10
IS 5
BP 487
EP 489
DI 10.1016/j.stem.2012.04.012
PG 3
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 944WN
UT WOS:000304234600005
PM 22560071
ER

PT J
AU Brack, AS
   Rando, TA
AF Brack, Andrew S.
   Rando, Thomas A.
TI Tissue-Specific Stem Cells: Lessons from the Skeletal Muscle Satellite
   Cell
SO CELL STEM CELL
LA English
DT Review
ID TEMPLATE DNA STRANDS; SELF-RENEWAL; PROGENITOR CELLS; ADULT MUSCLE;
   CORTICAL NEUROGENESIS; UP-REGULATION; GROWING RATS; REGENERATION; MOUSE;
   MYOGENESIS
AB In 1961, the satellite cell was first identified when electron microscopic examination of skeletal muscle demonstrated a cell wedged between the plasma membrane of the muscle fiber and the basement membrane. In recent years it has been conclusively demonstrated that the satellite cell is the primary cellular source for muscle regeneration and is equipped with the potential to self renew, thus functioning as a bona fide skeletal muscle stem cell (MuSC). As we move past the 50th anniversary of the satellite cell, we take this opportunity to discuss the current state of the art and dissect the unknowns in the MuSC field.
C1 [Brack, Andrew S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
   [Brack, Andrew S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Brack, Andrew S.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Rando, Thomas A.] Stanford Univ, Sch Med, Paul F Glenn Labs Biol Aging, Stanford, CA 94305 USA.
   [Rando, Thomas A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
   [Rando, Thomas A.] Vet Affairs Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA.
   [Rando, Thomas A.] Vet Affairs Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr Excellence, Palo Alto, CA 94304 USA.
RP Brack, AS (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM abrack@partners.org
FU NIH [R01 AIR060868, P01 AG036695, R37 AG23806, RO1 AR056849]
FX This work was supported by grants from the NIH (R01 AIR060868 to A.S.B.
   and P01 AG036695, R37 AG23806, [MERIT Award], and RO1 AR056849 to
   T.A.R.). We thank Jenna Norton for artwork and Josef Christensen for
   critical reading of the manuscript.
NR 106
TC 113
Z9 120
U1 4
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 4
PY 2012
VL 10
IS 5
BP 504
EP 514
DI 10.1016/j.stem.2012.04.001
PG 11
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 944WN
UT WOS:000304234600009
PM 22560074
ER

PT J
AU Cerletti, M
   Jang, YC
   Finley, LWS
   Haigis, MC
   Wagers, AJ
AF Cerletti, Massimiliano
   Jang, Young C.
   Finley, Lydia W. S.
   Haigis, Marcia C.
   Wagers, Amy J.
TI Short-Term Calorie Restriction Enhances Skeletal Muscle Stem Cell
   Function
SO CELL STEM CELL
LA English
DT Article
ID SATELLITE CELLS; PROGENITOR CELLS; SELF-RENEWAL; REGENERATION;
   MYOGENESIS; CANCER; MOUSE; FAT
AB Calorie restriction (CR) extends life span and ameliorates age-related pathologies in most species studied, yet the mechanisms underlying these effects remain unclear. Using mouse skeletal muscle as a model, we show that CR acts in part by enhancing the function of tissue-specific stem cells. Even short-term CR significantly enhanced stem cell availability and activity in the muscle of young and old animals, in concert with an increase in mitochondrial abundance and induction of conserved metabolic and longevity regulators. Moreover, CR enhanced endogenous muscle repair and CR initiated in either donor or recipient animals improved the contribution of donor cells to regenerating muscle after transplant. These studies indicate that metabolic factors play a critical role in regulating stem cell function and that this regulation can influence the efficacy of recovery from injury and the engraftment of transplanted cells.
C1 [Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
   [Cerletti, Massimiliano; Jang, Young C.; Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
   [Cerletti, Massimiliano; Jang, Young C.; Wagers, Amy J.] Joslin Diabet Ctr, Boston, MA 02215 USA.
   [Finley, Lydia W. S.; Haigis, Marcia C.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
RP Wagers, AJ (reprint author), Harvard Univ, Harvard Stem Cell Inst, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.
EM amy_wagers@harvard.edu
FU NIH [P30DK036836, 1R01 AG033053, 1P30 AG031679]; Harvard Stem Cell
   Institute; Glenn Foundation; NIA [AG032375]; Ellison Medical Foundation;
   NSF
FX The authors gratefully acknowledge Joslin's HSCl/DERC Flow Cytometry
   Core (NIH award number P30DK036836) and the HSCRB Flow Cytometry Core at
   Harvard for excellent flow cytometry support. This work was funded in
   part by grants from the Harvard Stem Cell Institute, NIH (1R01 AG033053
   and 1P30 AG031679), and Glenn Foundation to A.J.W.; grants from the NIA
   (AG032375), Glenn Foundation, Ellison Medical Foundation, and MDA to
   M.N.; and an NSF graduate research fellowship to L.F. All experiments
   involving animals were approved by appropriate Institutional Animal Care
   and Use Committees. Content is solely the responsibility of the authors
   and does not necessarily represent the official views of the NIH or
   other funding agencies.
NR 34
TC 92
Z9 95
U1 4
U2 24
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 4
PY 2012
VL 10
IS 5
BP 515
EP 519
DI 10.1016/j.stem.2012.04.002
PG 5
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 944WN
UT WOS:000304234600010
PM 22560075
ER

PT J
AU Perez, B
   Paquette, N
   Paidassi, H
   Zhai, B
   White, K
   Skvirsky, R
   Lacy-Hulbert, A
   Stuart, LM
AF Perez, Beatriz
   Paquette, Nicholas
   Paidassi, Helena
   Zhai, Bo
   White, Kristin
   Skvirsky, Rachel
   Lacy-Hulbert, Adam
   Stuart, Lynda M.
TI Apoptotic Cells Can Deliver Chemotherapeutics to Engulfing Macrophages
   and Suppress Inflammatory Cytokine Production
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CALRETICULIN EXPOSURE; CLEARANCE;
   IMMUNOGENICITY; PHAGOCYTOSIS; NEUTROPHILS; CANCER; BETA
AB Immunosuppression via cell-cell contact with apoptotic cells is a well studied immunological phenomenon. Although the original studies of immune repression used primary cells, which undergo spontaneous cell death or apoptosis in response to irradiation, more recent studies have relied on chemotherapeutic agents to induce apoptosis in cell lines. In this work, we demonstrate that Jurkat cells induced to die with actinomycin D suppressed inflammatory cytokine production by macrophages, whereas cells treated with etoposide did not. This immune repression mediated by actinomycin D-treated cells did not require phagocytosis or cell-cell contact and thus occurs through a different mechanism from that seen with primary apoptotic neutrophils. Moreover, cells induced to die with etoposide and then treated for a short time with actinomycin D also suppressed macrophage responses, indicating that suppression was mediated by actinomycin D independent of the mechanism of cell death. Finally, phagocytosis of actinomycin D-treated cells caused apoptosis in macrophages, and suppression could be blocked by inhibition of caspase activity in the target macrophage. Together, these data indicate that apoptotic cells act as "Trojan horses," delivering actinomycin D to engulfing macrophages. Suppression of cytokine production by macrophages is therefore due to exposure to actinomycin D from apoptotic cells and is not the result of cell-receptor interactions. These data suggest that drug-induced death may not be an appropriate surrogate for the immunosuppressive activity of apoptotic cells. Furthermore, these effects of cytotoxic drugs on infiltrating immune phagocytes may have clinical ramifications for their use as antitumor therapies.
C1 [Perez, Beatriz; Paquette, Nicholas; Paidassi, Helena; Lacy-Hulbert, Adam; Stuart, Lynda M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Dev Immunol, Boston, MA 02114 USA.
   [Zhai, Bo; White, Kristin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
   [Perez, Beatriz; Skvirsky, Rachel] Univ Massachusetts Boston, Dept Biol, Boston, MA 02125 USA.
   [Paidassi, Helena] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland.
RP Stuart, LM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Dev Immunol, Jackson 14,55 Fruit St, Boston, MA 02114 USA.
EM lstuart@partners.org
RI Paidassi, Helena/M-5739-2014; 
OI Lacy-Hulbert, Adam/0000-0003-2162-0156; Paidassi,
   Helena/0000-0001-9915-4365
FU National Institutes of Health [RO1AI79198, U24A1082660, NIH R25GM076321,
   5RO1 GM069541]; National Science Foundation [EHR0412390]; NIH/NERCE
   [U54AI057159]; UK Medical Research Council [G0802069]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants RO1AI79198 and U24A1082660 (to L. M. S.), NIH R25GM076321
   (to R. S.), and 5RO1 GM069541 (to K. W.) and a National Science
   Foundation Grant EHR0412390 (to R. S.). Additionally, N. P. was
   supported by NIH/NERCE Grant U54AI057159, and H. P. was supported by UK
   Medical Research Council Grant G0802069.
NR 19
TC 3
Z9 3
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 4
PY 2012
VL 287
IS 19
BP 16029
EP 16036
DI 10.1074/jbc.M112.340489
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 941YS
UT WOS:000304006300080
PM 22433861
ER

PT J
AU Ameur, A
   Enroth, S
   Johansson, A
   Zaboli, G
   Igl, W
   Johansson, ACV
   Rivas, MA
   Daly, MJ
   Schmitz, G
   Hicks, AA
   Meitinger, T
   Feuk, L
   van Duijn, C
   Oostra, B
   Pramstaller, PP
   Rudan, I
   Wright, AF
   Wilson, JF
   Campbell, H
   Gyllensten, U
AF Ameur, Adam
   Enroth, Stefan
   Johansson, Asa
   Zaboli, Ghazal
   Igl, Wilmar
   Johansson, Anna C. V.
   Rivas, Manuel A.
   Daly, Mark J.
   Schmitz, Gerd
   Hicks, Andrew A.
   Meitinger, Thomas
   Feuk, Lars
   van Duijn, Cornelia
   Oostra, Ben
   Pramstaller, Peter P.
   Rudan, Igor
   Wright, Alan F.
   Wilson, James F.
   Campbell, Harry
   Gyllensten, Ulf
TI Genetic Adaptation of Fatty-Acid Metabolism: A Human-Specific Haplotype
   Increasing the Biosynthesis of Long-Chain Omega-3 and Omega-6 Fatty
   Acids
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID WIDE ASSOCIATION ANALYSIS; DOCOSAHEXAENOIC ACID; HUMAN-POPULATIONS;
   HUMAN GENOME; POSITIVE SELECTION; AFRICAN-AMERICANS; ARACHIDONIC-ACID;
   COMMON VARIANTS; CLUSTER; SEQUENCE
AB Omega-3 and omega-6 long-chain polyunsaturated fatty acids (LC-PUFAs) are essential for the development and function of the human brain. They can be obtained directly from food, e.g., fish, or synthesized from precursor molecules found in vegetable oils. To determine the importance of genetic variability to fatty-acid biosynthesis, we studied FADS1 and FADS2, which encode rate-limiting enzymes for fatty-acid conversion. We performed genome-wide genotyping (n = 5,652 individuals) and targeted resequencing (n = 960 individuals) of the FADS region in five European population cohorts. We also analyzed available genomic data from human populations, archaic hominins, and more distant primates. Our results show that present-day humans have two common FADS haplotypes-defined by 28 closely linked SNPs across 38.9 kb-that differ dramatically in their ability to generate LC-PUFAs. No independent effects on FADS activity were seen for rare SNPs detected by targeted resequencing. The more efficient, evolutionarily derived haplotype appeared after the lineage split leading to modern humans and Neanderthals and shows evidence of positive selection. This human-specific haplotype increases the efficiency of synthesizing essential long-chain fatty acids from precursors and thereby might have provided an advantage in environments with limited access to dietary LC-PUFAs. In the modern world, this haplotype has been associated with lifestyle-related diseases, such as coronary artery disease.
C1 [Ameur, Adam; Enroth, Stefan; Johansson, Asa; Zaboli, Ghazal; Igl, Wilmar; Johansson, Anna C. V.; Feuk, Lars; Gyllensten, Ulf] Uppsala Univ, Rudbeck Lab, SciLifeLab Uppsala, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
   [Rivas, Manuel A.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Rivas, Manuel A.; Daly, Mark J.] Broad Inst MIT & Harvard, Boston, MA 02114 USA.
   [Schmitz, Gerd] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany.
   [van Duijn, Cornelia] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3015 GE Rotterdam, Netherlands.
   [Oostra, Ben] Erasmus Univ, Med Ctr, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands.
   [Hicks, Andrew A.; Pramstaller, Peter P.] European Acad Bozen Bolzano, Ctr Biomed, I-39100 Bolzano, Italy.
   [Hicks, Andrew A.; Pramstaller, Peter P.] Univ Lubeck, Affiliated Inst, D-23562 Lubeck, Germany.
   [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, I-39100 Bolzano, Italy.
   [Pramstaller, Peter P.] Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany.
   [Meitinger, Thomas] Helmholtz Zentrum Munchen, D-85764 Neuherberg, Germany.
   [Rudan, Igor] Univ Split, Fac Med, Croatian Ctr Global Hlth, Split 21000, Croatia.
   [Rudan, Igor; Wilson, James F.; Campbell, Harry] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Wright, Alan F.] Univ Edinburgh, Med Res Council Inst Genet & Mol Med, Med Res Council Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
RP Gyllensten, U (reprint author), Uppsala Univ, Rudbeck Lab, SciLifeLab Uppsala, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
EM ulf.gyllensten@igp.uu.se
RI Enroth, Stefan/C-7396-2009; Rudan, Igor/I-1467-2012; Pramstaller,
   Peter/C-2357-2008; Johansson, Asa/G-5270-2011; Wilson, James
   F/A-5704-2009; Meitinger, Thomas/O-1318-2015; Hicks, Andrew/E-9518-2017;
   
OI Enroth, Stefan/0000-0002-5056-9137; Rudan, Igor/0000-0001-6993-6884;
   Johansson, Asa/0000-0002-2915-4498; Wilson, James F/0000-0001-5751-9178;
   Hicks, Andrew/0000-0001-6320-0411; Ameur, Adam/0000-0001-6085-6749
FU Knut and Alice Wallenberg foundation (CMS); Swedish Research Council
   (SNISS); Science for Life Laboratory Uppsala; Swedish Research Council
FX The SOLiD DNA sequencing and Taqman genotyping were performed by the
   Uppsala Genome Center, funded by the Knut and Alice Wallenberg
   foundation (CMS), The Swedish Research Council (SNISS), and Science for
   Life Laboratory Uppsala. The study was supported by grants from the
   Swedish Research Council.
NR 66
TC 40
Z9 40
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY 4
PY 2012
VL 90
IS 5
BP 809
EP 820
DI 10.1016/j.ajhg.2012.03.014
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 940QG
UT WOS:000303907500005
PM 22503634
ER

PT J
AU Rieder, MJ
   Green, GE
   Park, SS
   Stamper, BD
   Gordon, CT
   Johnson, JM
   Cunniff, CM
   Smith, JD
   Emery, SB
   Lyonnet, S
   Amiel, J
   Holder, M
   Heggie, AA
   Bamshad, MJ
   Nickerson, DA
   Cox, TC
   Hing, AV
   Horst, JA
   Cunningham, ML
AF Rieder, Mark J.
   Green, Glenn E.
   Park, Sarah S.
   Stamper, Brendan D.
   Gordon, Christopher T.
   Johnson, Jason M.
   Cunniff, Christopher M.
   Smith, Joshua D.
   Emery, Sarah B.
   Lyonnet, Stanislas
   Amiel, Jeanne
   Holder, Muriel
   Heggie, Andrew A.
   Bamshad, Michael J.
   Nickerson, Deborah A.
   Cox, Timothy C.
   Hing, Anne V.
   Horst, Jeremy A.
   Cunningham, Michael L.
TI A Human Homeotic Transformation Resulting from Mutations in PLCB4 and
   GNAI3 Causes Auriculocondylar Syndrome
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID QUESTION MARK EARS; CONDYLAR SYNDROME; PHOSPHOLIPASE-C; MICE;
   ENDOTHELIN-1; ZEBRAFISH; JAW; MORPHOGENESIS; PROTEINS; EXPRESSION
AB Auriculocondylar syndrome (ACS) is a rare, autosomal-dominant craniofacial malformation syndrome characterized by variable micrognathia, temporomandibular joint ankylosis, cleft palate, and a characteristic "question-mark" ear malformation. Careful phenotypic characterization of severely affected probands in our cohort suggested the presence of a mandibular patterning defect resulting in a maxillary phenotype (i.e., homeotic transformation). We used exome sequencing of five probands and identified two novel (exclusive to the patient and/or family studied) missense mutations in PLCB4 and a shared mutation in GNAI3 in two unrelated probands. In confirmatory studies, three additional novel PLCB4 mutations were found in multigenerational ACS pedigrees. All mutations were confirmed by Sanger sequencing, were not present in more than 10,000 control chromosomes, and resulted in amino-acid substitutions located in highly conserved protein domains. Additionally, protein-structure modeling demonstrated that all ACS substitutions disrupt the catalytic sites of PLCB4 and GNAI3. We suggest that PLCB4 and GNAI3 are core signaling molecules of the endothelin-1-distal-less homeobox 5 and 6 (EDN1-DLX5/DLX6) pathway. Functional studies demonstrated a significant reduction in downstream DLX5 and DLX6 expression in ACS cases in assays using cultured osteoblasts from probands and controls. These results support the role of the previously implicated EDN1-DLX5/6 pathway in regulating mandibular specification in other species, which, when disrupted, results in a maxillary phenotype. This work defines the molecular basis of ACS as a homeotic transformation (mandible to maxilla) in humans.
C1 [Rieder, Mark J.; Smith, Joshua D.; Bamshad, Michael J.; Nickerson, Deborah A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Green, Glenn E.; Emery, Sarah B.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA.
   [Park, Sarah S.; Stamper, Brendan D.; Cox, Timothy C.; Hing, Anne V.; Cunningham, Michael L.] Seattle Childrens Res Inst, Ctr Tissue & Cell Sci, Seattle, WA 98101 USA.
   [Gordon, Christopher T.; Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, INSERM, U781, F-75743 Paris, France.
   [Gordon, Christopher T.; Lyonnet, Stanislas; Amiel, Jeanne] Univ Paris Descartes Sorbonne Paris Cite, Inst Imagine, F-75743 Paris, France.
   [Johnson, Jason M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Neuroradiol, Boston, MA 02114 USA.
   [Cunniff, Christopher M.] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA.
   [Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, AP HP, Dept Genet, F-75743 Paris, France.
   [Holder, Muriel] CHRU, Hop Jeanne de Flandre, Serv Genet Clin, F-59037 Lille, France.
   [Heggie, Andrew A.] Royal Childrens Hosp, Dept Plast & Maxillofacial Surg, Melbourne, Vic 3052, Australia.
   [Bamshad, Michael J.; Cox, Timothy C.; Hing, Anne V.; Cunningham, Michael L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Cox, Timothy C.; Hing, Anne V.; Cunningham, Michael L.] Seattle Childrens Res Inst, Craniofacial Ctr, Seattle, WA 98105 USA.
   [Cox, Timothy C.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic 3800, Australia.
   [Horst, Jeremy A.] UCSF, Dept Orofacial Sci, Div Pediat Dent, San Francisco, CA 94143 USA.
RP Rieder, MJ (reprint author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
EM acs_rieder_cunningham@uw.edu
RI Gordon, Christopher/F-1267-2017
OI Gordon, Christopher/0000-0002-9300-8399
FU NIH-NHGRI Next Generation Mendelian Genetics [HG005608]; Jean Renny
   Endowment for Craniofacial Medicine; Laurel Foundation Center for
   Craniofacial Research; NIH-NIDCD [P30-DC05188]; E-Rare CRANIRARE
FX This study was supported by grants from the NIH-NHGRI Next Generation
   Mendelian Genetics (HG005608, M.J.R., D.A.N., M.J.B.), the Jean Renny
   Endowment for Craniofacial Medicine, the Laurel Foundation Center for
   Craniofacial Research (M.L.C.), NIH-NIDCD (P30-DC05188, G.E.G.), and the
   E-Rare CRANIRARE project (S.L.).
NR 45
TC 29
Z9 32
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY 4
PY 2012
VL 90
IS 5
BP 907
EP 914
DI 10.1016/j.ajhg.2012.04.002
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 940QG
UT WOS:000303907500016
PM 22560091
ER

PT J
AU Karsai, M
   Kaski, K
   Barabasi, AL
   Kertesz, J
AF Karsai, Marton
   Kaski, Kimmo
   Barabasi, Albert-Laszlo
   Kertesz, Janos
TI Universal features of correlated bursty behaviour
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN DYNAMICS; FIELD-THEORY; HEAVY TAILS; COMMUNICATION; EARTHQUAKES;
   AVALANCHES; MEMORY; LAW
AB Inhomogeneous temporal processes, like those appearing in human communications, neuron spike trains, and seismic signals, consist of high-activity bursty intervals alternating with long low-activity periods. In recent studies such bursty behavior has been characterized by a fat-tailed inter-event time distribution, while temporal correlations were measured by the autocorrelation function. However, these characteristic functions are not capable to fully characterize temporally correlated heterogenous behavior. Here we show that the distribution of the number of events in a bursty period serves as a good indicator of the dependencies, leading to the universal observation of power-law distribution for a broad class of phenomena. We find that the correlations in these quite different systems can be commonly interpreted by memory effects and described by a simple phenomenological model, which displays temporal behavior qualitatively similar to that in real systems.
C1 [Karsai, Marton; Kaski, Kimmo; Kertesz, Janos] Aalto Univ, BECS, Sch Sci, FI-00076 Helsinki, Finland.
   [Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA.
   [Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
   [Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Barabasi, Albert-Laszlo; Kertesz, Janos] Budapest Univ Technol & Econ, Inst Phys, H-1111 Budapest, Hungary.
RP Kertesz, J (reprint author), Aalto Univ, BECS, Sch Sci, POB 12200, FI-00076 Helsinki, Finland.
EM kertesz@phy.bme.hu
RI Kaski, Kimmo/G-8067-2012; Karsai, Marton/G-3391-2011
OI Karsai, Marton/0000-0001-5752-556X
FU EU [238597]; TEKES (FiDiPro)
FX We thank J. Saramaki, H-H. Jo, M. Kivela, C. Song, D. Wang, L. de
   Arcangelis and I. Kovacs for comments and useful discussions. Financial
   support from EUs FP7 FET-Open to ICTeCollective Project No. 238597 and
   TEKES (FiDiPro) are acknowledged.
NR 52
TC 78
Z9 78
U1 2
U2 42
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 4
PY 2012
VL 2
AR 397
DI 10.1038/srep00397
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 939JO
UT WOS:000303806100003
PM 22563526
ER

PT J
AU Savoia, E
   Testa, MA
   Viswanath, K
AF Savoia, Elena
   Testa, Marcia A.
   Viswanath, Kasisomayajula
TI Predictors of knowledge of H1N1 infection and transmission in the U.S.
   population
SO BMC PUBLIC HEALTH
LA English
DT Article
DE H1N1; Communication; Socioeconomic position; Neighborhood cohesion; USA;
   Race; Knowledge gaps; Survey
ID HOUSING TENURE; UNITED-STATES; HEALTH; TELEVISION; RISK
AB Background: The strength of a society's response to a public health emergency depends partly on meeting the needs of all segments of the population, especially those who are most vulnerable and subject to greatest adversity. Since the early stages of the H1N1 pandemic, public communication of H1N1 information has been recognized as a challenging issue. Public communication is considered a critical public health task to mitigating adverse population health outcomes before, during, and after public health emergencies. To investigate knowledge and knowledge gaps in the general population regarding the H1N1 pandemic, and to identify the social determinants associated with those gaps, we conducted a survey in March 2010 using a representative random sample of U.S. households.
   Methods: Data were gathered from 1,569 respondents (66.3% response rate) and analyzed using ordered logistic regression to study the impact of socioeconomic factors and demographic characteristics on the individual's knowledge concerning H1N1 infection and transmission.
   Results: Results suggest that level of education and home ownership, reliable indicators of socioeconomic position (SEP), were associated with knowledge of H1N1. Level of education was found to be directly associated with level of knowledge about virus transmission [OR = 1.35, 95% C.I. 1.12-1.63]. Home ownership versus renting was also positively associated with knowledge on the signs and symptoms of H1N1 infection in particular [OR = 2.89, 95% C.I. 1.26-6.66].
   Conclusions: Policymakers and public health practitioners should take specific SEP factors into consideration when implementing educational and preventive interventions promoting the health and preparedness of the population, and when designing communication campaigns during a public health emergency.
C1 [Savoia, Elena; Testa, Marcia A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Savoia, Elena; Testa, Marcia A.] Harvard Univ, Sch Publ Hlth, Div Policy Translat & Leadership Dev, Boston, MA 02115 USA.
   [Viswanath, Kasisomayajula] Harvard Univ, Sch Publ Hlth, Dept Soc Hlth & Human Dev, Boston, MA 02115 USA.
   [Viswanath, Kasisomayajula] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Savoia, E (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA.
EM esavoia@hsph.harvard.edu
FU U.S. Centers for Disease Control and Prevention (CDC) [5PO1TP000307-03]
FX We acknowledge funding support from the U.S. Centers for Disease Control
   and Prevention (CDC) grant number 5PO1TP000307-03. The content of this
   publication as well as the views and discussions expressed in this paper
   are solely those of the authors and do not necessarily represent the
   views of any partner organizations, the CDC, or the U.S. Department of
   Health and Human Services, nor does mention of trade names, commercial
   practices, or organizations imply endorsement by the U.S. Government.
NR 26
TC 5
Z9 6
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD MAY 3
PY 2012
VL 12
AR 328
DI 10.1186/1471-2458-12-328
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 002LT
UT WOS:000308534300001
PM 22554124
ER

PT J
AU Horwitz, SM
   Kim, YH
   Foss, F
   Zain, JM
   Myskowski, PL
   Lechowicz, MJ
   Fisher, DC
   Shustov, AR
   Bartlett, NL
   Delioukina, ML
   Koutsoukos, T
   Saunders, ME
   O'Connor, OA
   Duvic, M
AF Horwitz, Steven M.
   Kim, Youn H.
   Foss, Francine
   Zain, Jasmine M.
   Myskowski, Patricia L.
   Lechowicz, Mary Jo
   Fisher, David C.
   Shustov, Andrei R.
   Bartlett, Nancy L.
   Delioukina, Maria L.
   Koutsoukos, Tony
   Saunders, Michael E.
   O'Connor, Owen A.
   Duvic, Madeleine
TI Identification of an active, well-tolerated dose of pralatrexate in
   patients with relapsed or refractory cutaneous T-cell lymphoma
SO BLOOD
LA English
DT Article
ID ADVANCED SOLID TUMORS; PHASE-II TRIAL; MYCOSIS-FUNGOIDES; DENILEUKIN
   DIFTITOX; SEZARY-SYNDROME; LUNG-CANCER;
   10-PROPARGYL-10-DEAZAAMINOPTERIN; MULTICENTER; COMBINATION; ANTIFOLATE
AB Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with high affinity for reduced folate carrier-1. A dose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstrated high activity, good rates of disease control, and an acceptable toxicity profile for continuous long-term dosing. Eligibility included mycosis fungoides, Sezary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression after >= 1 prior systemic therapy. The starting dose and schedule was 30 mg/m(2)/wk intravenously for 3 of 4 (3/4) weeks. Subsequent starting doses were 20, 15, and 10 mg/m(2)/wk for 3/4 or 2 of 3 (2/3) weeks. Response was evaluated by the modified severity-weighted adjustment tool. Fifty-four patients were treated. The recommended regimen was identified as 15 mg/m(2)/wk for 3/4 weeks and was explored in the expansion cohort. In 29 patients treated overall with the recommended dosing regimen, the median number of prior systemic therapies was 4. Pralatrexate was administered for a median of 4 cycles; response rate was 45%. The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high activity with acceptable toxicity in patients with relapsed/refractory CTCL. (Blood.2012;119(18):4115-4122)
C1 [Horwitz, Steven M.; Myskowski, Patricia L.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
   [Kim, Youn H.] Stanford Univ, Stanford Canc Ctr, Stanford, CA 94305 USA.
   [Foss, Francine] Yale Canc Ctr, New Haven, CT USA.
   [Zain, Jasmine M.] NYU, Langone Med Ctr, New York, NY USA.
   [Lechowicz, Mary Jo] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
   [Fisher, David C.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
   [Shustov, Andrei R.] Univ Washington, Sch Med, Seattle, WA USA.
   [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA.
   [Delioukina, Maria L.] Cedars Sinai Samuel Oschin Canc Ctr, Blood & Marrow Transplant Program, Los Angeles, CA USA.
   [Koutsoukos, Tony; Saunders, Michael E.] Allos Therapeut Inc, Princeton, NJ USA.
   [O'Connor, Owen A.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Irving Canc Res Ctr, New York, NY USA.
   [Duvic, Madeleine] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Dept Dermatol, Houston, TX 77030 USA.
RP Horwitz, SM (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.
EM horwitzs@mskcc.org
FU Allos Therapeutics Inc
FX Monica Ramchandani, PhD, and Lindsey Lozano of Allos Therapeutics Inc
   provided medical writing support with direction and guidance from
   authors. Adrienne Schreiber of inScience Communications provided editing
   support, which was funded by Allos Therapeutics Inc. This study was
   sponsored by Allos Therapeutics Inc.The opinions expressed are those of
   the authors, who received no honoraria for manuscript development.
NR 35
TC 45
Z9 47
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 3
PY 2012
VL 119
IS 18
BP 4115
EP 4122
DI 10.1182/blood-2011-11-390211
PG 8
WC Hematology
SC Hematology
GA 959BL
UT WOS:000305284600007
PM 22394596
ER

PT J
AU Xu, GS
   Liu, K
   Anderson, J
   Patrene, K
   Lentzsch, S
   Roodman, GD
   Ouyang, HJ
AF Xu, Guoshuang
   Liu, Kai
   Anderson, Judy
   Patrene, Kenneth
   Lentzsch, Suzanne
   Roodman, G. David
   Ouyang, Hongjiao
TI Expression of XBP1s in bone marrow stromal cells is critical for myeloma
   cell growth and osteoclast formation
SO BLOOD
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR XBP-1; MULTIPLE-MYELOMA;
   DIFFERENTIATION; MICROENVIRONMENT; DISEASE; STRESS; IDENTIFICATION;
   PATHOGENESIS; IRE1-ALPHA
AB BM stromal cells (BMSCs) are key players in the microenvironmental support of multiple myeloma (MM) cell growth and bone destruction. A spliced form of the X-boxbinding protein-1 (XBP1s), a major proximal effector of unfolded protein response signaling, is highly expressed in MM cells and plays an indispensable role in MM pathogenesis. In the present study, we found that XBP1s is induced in the BMSCs of the MM microenvironment. XBP1s overexpression in healthy human BMSCs enhanced gene and/or protein expression of VCAM-1, IL-6, and receptor activator of NF-kappa B ligand (RANKL), enhancing BMSC support of MM cell growth and osteoclast formation in vitro and in vivo. Conversely, deficiency of XBP1 in healthy donor BMSCs displayed a range of effects on BMSCs that were opposite to those cells with overexpression of XBP1s. Knock-down of XBP1 in MM patient BM-SCs greatly compromised their increased VCAM-1 protein expression and IL-6 and RANKL secretion in response to TNF alpha and reversed their enhanced support of MM-cell growth and osteoclast formation. Our results demonstrate that XBP1s is a pathogenic factor underlying BMSC support of MM cell growth and osteoclast formation and therefore represents a therapeutic target for MM bone disease. (Blood. 2012;119(18):4205-4214)
C1 [Xu, Guoshuang; Liu, Kai; Anderson, Judy; Patrene, Kenneth; Lentzsch, Suzanne; Roodman, G. David; Ouyang, Hongjiao] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol & Oncol, Pittsburgh, PA USA.
   [Xu, Guoshuang] Fourth Mil Med Univ PLA, Xijing Hosp, Dept Nephrol, Xian, Peoples R China.
   [Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Roodman, G. David] VA Med Ctr, Pittsburgh, PA USA.
   [Ouyang, Hongjiao] Univ Pittsburgh, Sch Dent Med, Dept Comprehens Care Restorat Dent & Endodont, Pittsburgh, PA USA.
RP Ouyang, HJ (reprint author), VA Pittsburgh Healthcare Syst, R&D 151-U,2W-143 Univ Dr C, Pittsburgh, PA 15240 USA.
EM hoo1@pitt.edu
FU Multiple Myeloma Research Foundation; National Institutes of
   Health/National Institute of Dental and Craniofacial Research
   [DE017439]; VA Merit Review
FX This work was supported by the Multiple Myeloma Research Foundation (to
   H.O.), a National Institutes of Health/National Institute of Dental and
   Craniofacial Research grant (DE017439 to H.O.), and by a Multiple
   Myeloma Research Foundation and VA Merit Review Grant (to G.D.R).
NR 34
TC 23
Z9 24
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 3
PY 2012
VL 119
IS 18
BP 4205
EP 4214
DI 10.1182/blood-2011-05-353300
PG 10
WC Hematology
SC Hematology
GA 959BL
UT WOS:000305284600017
PM 22427205
ER

PT J
AU Nieborowska-Skorska, M
   Kopinski, PK
   Ray, R
   Hoser, G
   Ngaba, D
   Flis, S
   Cramer, K
   Reddy, MM
   Koptyra, M
   Penserga, T
   Glodkowska-Mrowka, E
   Bolton, E
   Holyoake, TL
   Eaves, CJ
   Cerny-Reiterer, S
   Valent, P
   Hochhaus, A
   Hughes, TP
   van der Kuip, H
   Sattler, M
   Wiktor-Jedrzejczak, W
   Richardson, C
   Dorrance, A
   Stoklosa, T
   Williams, DA
   Skorski, T
AF Nieborowska-Skorska, Margaret
   Kopinski, Piotr K.
   Ray, Regina
   Hoser, Grazyna
   Ngaba, Danielle
   Flis, Sylwia
   Cramer, Kimberly
   Reddy, Mamatha M.
   Koptyra, Mateusz
   Penserga, Tyrone
   Glodkowska-Mrowka, Eliza
   Bolton, Elisabeth
   Holyoake, Tessa L.
   Eaves, Connie J.
   Cerny-Reiterer, Sabine
   Valent, Peter
   Hochhaus, Andreas
   Hughes, Timothy P.
   van der Kuip, Heiko
   Sattler, Martin
   Wiktor-Jedrzejczak, Wieslaw
   Richardson, Christine
   Dorrance, Adrienne
   Stoklosa, Tomasz
   Williams, David A.
   Skorski, Tomasz
TI Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid
   leukemia stem cells and primitive progenitors
SO BLOOD
LA English
DT Article
ID CHRONIC MYELOGENOUS LEUKEMIA; SMALL-MOLECULE INHIBITOR; DNA-DAMAGE;
   COMPLEX-III; MITOCHONDRIA; RAC; ACTIVATION; GTPASES; IMATINIB; CANCER
AB Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII-generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor-resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondria targeted catalase, or addition of ROS scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML. (Blood. 2012;119(18):4253-4263)
C1 [Nieborowska-Skorska, Margaret; Kopinski, Piotr K.; Ray, Regina; Ngaba, Danielle; Flis, Sylwia; Cramer, Kimberly; Koptyra, Mateusz; Penserga, Tyrone; Bolton, Elisabeth; Skorski, Tomasz] Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA.
   [Hoser, Grazyna] Med Ctr Postgrad Educ, Dept Clin Cytol, Warsaw, Poland.
   [Reddy, Mamatha M.; Sattler, Martin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Glodkowska-Mrowka, Eliza; Stoklosa, Tomasz] Med Univ Warsaw, Dept Immunol, Warsaw, Poland.
   [Holyoake, Tessa L.] Univ Glasgow, Paul OGorman Leukemia Res Ctr, Glasgow, Lanark, Scotland.
   [Eaves, Connie J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada.
   [Cerny-Reiterer, Sabine; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria.
   [Cerny-Reiterer, Sabine; Valent, Peter] Ludwig Boltzmann Oncol Cluster, Vienna, Austria.
   [Hochhaus, Andreas] Jena Univ Hosp, Dept Hematol Oncol, Jena, Germany.
   [Hughes, Timothy P.] Univ Adelaide, Sch Med, Dept Hematol, Adelaide, SA, Australia.
   [Hughes, Timothy P.] Univ Adelaide, Sch Med, Ctr Canc Biol, Adelaide, SA, Australia.
   [van der Kuip, Heiko] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany.
   [van der Kuip, Heiko] Univ Tubingen, Stuttgart, Germany.
   [Wiktor-Jedrzejczak, Wieslaw] Med Univ Warsaw, Dept Hematol Oncol & Internal Dis, Warsaw, Poland.
   [Richardson, Christine] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA.
   [Richardson, Christine] Univ N Carolina, Ctr Bioinformat, Charlotte, NC 28223 USA.
   [Dorrance, Adrienne; Williams, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Harvard Stem Cell Inst, Div Hematol Oncol,Childrens Hosp Boston, Boston, MA 02115 USA.
RP Skorski, T (reprint author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St,MRB 548, Philadelphia, PA 19140 USA.
EM tskorski@temple.edu
RI Flis, Sylwia/N-6795-2013; Holyoake, Tessa/M-3668-2015; 
OI Holyoake, Tessa/0000-0002-0608-6066; Hoser, Grazyna/0000-0002-0917-5611;
   Stoklosa, Tomasz/0000-0001-6918-5056; Hochhaus,
   Andreas/0000-0003-0626-0834
FU National Institutes of Health [CA123014, CA134458, CA133646, CA134660,
   T32 HL07574-29, DK62757]; American Society of Hematology Research
   Trainee Award; Polish Ministry of Education and Science [N401 039037];
   Medical University of Warsaw [1M19/NK1W/2009]; Polish National Science
   Center [N N402 676540]; Canadian Cancer Research Institute; Canadian
   Cancer Society; Cancer Research UK [C1174/A11008]; Leukaemia & Lymphoma
   Research; Glasgow Experimental Cancer Medicine Centre (ECMC); Chief
   Scientist Office, Scotland
FX This work was supported in part by the National Institutes of Health
   (grants CA123014, CA134458, and CA133646 to T. Skorski; CA134660 to
   M.S.; T32 HL07574-29 to A.D.; and DK62757 to D.A.W.); by an American
   Society of Hematology Research Trainee Award (to P.K.K.); by the Polish
   Ministry of Education and Science (N401 039037 to G.H.); by the Medical
   University of Warsaw (1M19/NK1W/2009) and the Polish National Science
   Center (N N402 676540 to T. Stoklosa); by a grant from the Canadian
   Cancer Research Institute supported by the Canadian Cancer Society (to
   C.E.); and by grants from Cancer Research UK C1174/A11008, Leukaemia &
   Lymphoma Research, and the Glasgow Experimental Cancer Medicine Centre
   (ECMC), which is funded by Cancer Research UK and by the Chief Scientist
   Office, Scotland (to T.L.H.). Dr Ivan de Curtis (San Raffaele Scientific
   Institute, Milan, Italy) provided Rac3<SUP>-/-</SUP> mice. Dr Jose A.
   Enriquez (Universidad de Zagaroza, Zagaroza, Spain) provided MRC-cI and
   MRC-cIII-depleted cell lines. Drs Ilona Seferynska (Institute of
   Hematology and Blood Transfusion, Warsaw, Poland), Joanna
   Niesiobedzka-Kretzel (Medical University of Warsaw, Warsaw, Poland), and
   Deborah White (University of Adelaide, Adelaide, Australia) provided CML
   samples. Drs Magdalena Ambrozek (Medical Center for Postgraduate
   Education, Warsaw, Poland) and Artur Slupianek (Temple University,
   Philadelphia, PA) assisted with the retroviral transfections.
NR 50
TC 60
Z9 63
U1 3
U2 18
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 3
PY 2012
VL 119
IS 18
BP 4253
EP 4263
DI 10.1182/blood-2011-10-385658
PG 11
WC Hematology
SC Hematology
GA 959BL
UT WOS:000305284600022
PM 22411871
ER

PT J
AU Gerszten, RE
   Tager, AM
AF Gerszten, Robert E.
   Tager, Andrew M.
TI The Monocyte in Atherosclerosis-Should I Stay or Should I Go Now?
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID DEFICIENT MICE; REGRESSION; PROMOTES; PLAQUES; CELLS
C1 [Gerszten, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Gerszten, RE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU NHLBI NIH HHS [R01 HL108975]
NR 6
TC 20
Z9 22
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 3
PY 2012
VL 366
IS 18
BP 1734
EP 1736
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 934HH
UT WOS:000303434300016
PM 22551134
ER

PT J
AU Baselga, J
AF Baselga, Jose
TI Everolimus in HR-Positive Advanced Breast Cancer REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID PHASE-II TRIAL; EXEMESTANE
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Baselga, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM jbaselga@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 3
PY 2012
VL 366
IS 18
BP 1739
EP 1740
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 934HH
UT WOS:000303434300022
ER

PT J
AU Thoreen, CC
   Chantranupong, L
   Keys, HR
   Wang, T
   Gray, NS
   Sabatini, DM
AF Thoreen, Carson C.
   Chantranupong, Lynne
   Keys, Heather R.
   Wang, Tim
   Gray, Nathanael S.
   Sabatini, David M.
TI A unifying model for mTORC1-mediated regulation of mRNA translation
SO NATURE
LA English
DT Article
ID RIBOSOME ENTRY SITES; LARGE GENE LISTS; CELL-PROLIFERATION; INDEPENDENT
   MANNER; MAMMALIAN TARGET; MTOR PATHWAY; AKT ACTIVITY; CYCLIN D1;
   RAPAMYCIN; INHIBITION
AB The mTOR complex 1 (mTORC1) kinase nucleates a pathway that promotes cell growth and proliferation and is the target of rapamycin, a drug with many clinical uses(1). mTORC1 regulates messenger RNA translation, but the overall translational program is poorly defined and no unifying model exists to explain how mTORC1 differentially controls the translation of specific mRNAs. Here we use high-resolution transcriptome-scale ribosome profiling to monitor translation in mouse cells acutely treated with the mTOR inhibitor Torin 1, which, unlike rapamycin, fully inhibits mTORC1 (ref. 2). Our data reveal a surprisingly simple model of the mRNA features and mechanisms that confer mTORC1-dependent translation control. The subset of mRNAs that are specifically regulated by mTORC1 consists almost entirely of transcripts with established 5' terminal oligopyrimidine (TOP) motifs, or, like Hsp90ab1 and Ybx1, with previously unrecognized TOP or related TOP-like motifs that we identified. We find no evidence to support proposals that mTORC1 preferentially regulates mRNAs with increased 5' untranslated region length or complexity(3). mTORC1 phosphorylates a myriad of translational regulators, but how it controls TOP mRNA translation is unknown(4). Remarkably, loss of just the 4E-BP family of translational repressors, arguably the best characterized mTORC1 substrates, is sufficient to render TOP and TOP-like mRNA translation resistant to Torin 1. The 4E-BPs inhibit translation initiation by interfering with the interaction between the cap-binding protein eIF4E and eIF4G1. Loss of this interaction diminishes the capacity of eIF4E to bind TOP and TOP-like mRNAs much more than other mRNAs, explaining why mTOR inhibition selectively suppresses their translation. Our results clarify the translational program controlled by mTORC1 and identify 4E-BPs and eIF4G1 as its master effectors.
C1 [Thoreen, Carson C.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Thoreen, Carson C.; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Thoreen, Carson C.; Chantranupong, Lynne; Keys, Heather R.; Wang, Tim; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   [Chantranupong, Lynne; Keys, Heather R.; Wang, Tim; Sabatini, David M.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
   [Chantranupong, Lynne; Keys, Heather R.; Wang, Tim; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02139 USA.
   [Chantranupong, Lynne; Keys, Heather R.; Sabatini, David M.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 250 Longwood Ave, Boston, MA 02115 USA.
EM nathanael_gray@dfci.harvard.edu; sabatini@wi.mit.edu
FU National Institutes of Health [CA103866, CA129105]; Department of
   Defense [W81XWH-07-0448]; W.M. Keck Foundation; LAM Foundation; Dana
   Farber Cancer Institute; American Cancer Society; National Science
   Foundation
FX We thank members of the Gray and Sabatini laboratories for helpful
   discussions, H. Guo, S. Hawthorne, G. Brar, J. Damon, C. Miller and W.
   Gilbert for advice and N. Sonenberg for providing 4EBP1/2 wild-type and
   double-knockout MEFs. This work was supported by the National Institutes
   of Health (CA103866 and CA129105 to D. M. S.), Department of Defense
   (W81XWH-07-0448 to D. M. S.), the W.M. Keck Foundation (D. M. S.), LAM
   Foundation (D. M. S.), Dana Farber Cancer Institute (N. S. G., C. C.
   T.), and fellowship support from the American Cancer Society (C. C. T.),
   and the National Science Foundation (L. C. and T. W.). D. M. S. is an
   investigator of the Howard Hughes Medical Institute.
NR 39
TC 396
Z9 406
U1 11
U2 70
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 3
PY 2012
VL 485
IS 7396
BP 109
EP U142
DI 10.1038/nature11083
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 934NV
UT WOS:000303451900044
PM 22552098
ER

PT J
AU Ascierto, PA
   Grimaldi, AM
   Curti, B
   Faries, MB
   Ferrone, S
   Flaherty, K
   Fox, BA
   Gajewski, TF
   Gershenwald, JE
   Gogas, H
   Grossmann, K
   Hauschild, A
   Hodi, FS
   Kefford, R
   Kirkwood, JM
   Leachmann, S
   Maio, M
   Marais, R
   Palmieri, G
   Morton, DL
   Ribas, A
   Stroncek, DF
   Stewart, R
   Wang, E
   Mozzillo, N
   Marincola, FM
AF Ascierto, Paolo A.
   Grimaldi, Antonio M.
   Curti, Brendan
   Faries, Mark B.
   Ferrone, Soldano
   Flaherty, Keith
   Fox, Bernard A.
   Gajewski, Thomas F.
   Gershenwald, Jeffrey E.
   Gogas, Helen
   Grossmann, Kenneth
   Hauschild, Axel
   Hodi, F. Stephen
   Kefford, Richard
   Kirkwood, John M.
   Leachmann, Sancy
   Maio, Michele
   Marais, Richard
   Palmieri, Giuseppe
   Morton, Donald L.
   Ribas, Antoni
   Stroncek, David F.
   Stewart, Rodney
   Wang, Ena
   Mozzillo, Nicola
   Marincola, Franco M.
TI FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the
   "Melanoma Research: a bridge from Naples to the World. Napoli, December
   5th-6th 2011"
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID TUMOR-INFILTRATING LYMPHOCYTES; ZEBRAFISH NEURAL CREST; HIGH-RISK
   MELANOMA; STAGE-IV MELANOMA; METASTATIC MELANOMA;
   PROGNOSTIC-SIGNIFICANCE; CUTANEOUS MELANOMA; INTERFERON-ALPHA; ADJUVANT
   THERAPY; FOXD3
AB After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization. After the first congress in December 2010, the second edition of "Melanoma Research: a bridge from Naples to the World" meeting, organized by Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) took place in Naples, on 5-6 December 2011. We have identified four new topics of discussion: Innovative Approaches in Prevention, Diagnosis and Surgical Treatment, New Pathways and Targets in Melanoma: An Update about Immunotherapy, and Combination Strategies.
   This international congress gathered more than 30 international faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive atmosphere which stimulated discussion of new approaches and strategies in the field of melanoma.
C1 [Ascierto, Paolo A.; Grimaldi, Antonio M.; Mozzillo, Nicola] Fdn Pascale, Ist Nazl Tumori, Dept Melanoma Sarcoma & Head & Neck Dis, Naples, Italy.
   [Curti, Brendan] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA.
   [Faries, Mark B.; Morton, Donald L.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Melanoma Res, Santa Monica, CA USA.
   [Ferrone, Soldano] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Flaherty, Keith] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Fox, Bernard A.] Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, Lab Mol & Tumor Immunol, Portland, OR USA.
   [Fox, Bernard A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
   [Gajewski, Thomas F.] Univ Chicago, Chicago, IL 60637 USA.
   [Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Gogas, Helen] Univ Athens, Athens Med Sch, Dept Med 1, Athens, Greece.
   [Grossmann, Kenneth; Leachmann, Sancy; Stewart, Rodney] Univ Utah, Melanoma & Cutaneous Oncol Program, Huntsman Canc Inst, Salt Lake City, UT USA.
   [Hauschild, Axel] Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany.
   [Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Kefford, Richard] Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia.
   [Kefford, Richard] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
   [Kirkwood, John M.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA.
   [Kirkwood, John M.] Univ Pittsburgh, Sch Med, Dept Dermatol, Div Hematol Oncol, Pittsburgh, PA 15261 USA.
   [Kirkwood, John M.] Univ Pittsburgh, Sch Med, Dept Translat Sci, Div Hematol Oncol, Pittsburgh, PA USA.
   [Kirkwood, John M.] Pittsburgh Canc Inst, Melanoma Program, Pittsburgh, PA 15213 USA.
   [Maio, Michele] Univ Hosp Siena, Ist Toscano Tumori, Dept Oncol, Siena, Italy.
   [Marais, Richard] Paterson Inst Canc Res, Mol Oncol Grp, Manchester M20 4BX, Lancs, England.
   [Palmieri, Giuseppe] CNR, Inst Biomol Chem, Unit Canc Genet, Sassari, Italy.
   [Ribas, Antoni] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA.
   [Stroncek, David F.] NIH, Cell Proc Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
   [Wang, Ena; Marincola, Franco M.] NIH, IDIS, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
   [Wang, Ena; Marincola, Franco M.] NIH, CHI, Bethesda, MD 20892 USA.
   [Ascierto, Paolo A.; Grimaldi, Antonio M.] Fdn G Pascale, Ist Nazl Studio & Cura Tumori, Unit Med Oncol & Innovat Therapy, I-80131 Naples, Italy.
RP Ascierto, PA (reprint author), Fdn Pascale, Ist Nazl Tumori, Dept Melanoma Sarcoma & Head & Neck Dis, Naples, Italy.
EM paolo.ascierto@gmail.com
OI Marais, Richard/0000-0001-7484-4183
FU Fondazione Melanoma Onlus; Society of ImmunoTherapy of Cancer (SITC);
   Collage Congressi of Napoli; BC Prometheus Pharmaceuticals; BMS;
   Boehringer Ingelheim; Celgene; Eisai; GSK; IGEA; MSD; Novartis;
   Roche-Genentech
FX The meeting was supported by Fondazione Melanoma Onlus and the Society
   of ImmunoTherapy of Cancer (SITC). A special thanks to Collage Congressi
   of Napoli for their support and cooperation in organizing the meeting
   and to Michael Hoetzel for providing us the group picture from the
   meeting.; PAA participated to Advisory Board from Bristol Myers Squibb,
   MSD, Roche-Genentech, GSK, Celgene, Amgen, Medimmune, and Novartis and
   received honoraria from Brystol Myers Squibb, MSD and Roche-Genentech.
   AMG has no competing interest. BC Prometheus Pharmaceuticals: grant
   support and speakers bureau. MBF has no competing interests. SF has no
   competing interests. KF Consultant: Roche/Genentech, GlaxoSmithKline.
   BAF has no competing interests. TG consultant for GSK-Bio, Incyte, BMS,
   Roche-Genentech, and Eisai. JEG has no competing interest. HG has an
   Advisor role in MSD compensated. KG has participated on Advisory Board
   for BMS, and has received honoraria from BMS. AH consultancies, paid
   presentations or financial trial support from: BMS, Boehringer
   Ingelheim, Celgene, Eisai, GSK, IGEA, MSD, Novartis, Roche-Genentech. SH
   has served as a nonpaid consultant to BMS and Genentech, and received
   clinical trial support from BMS and Genentech. RK Institutional
   reimbursement for Advisory Boards and conference travel from GSK and
   Roche. JMK is a consultant to GSKbio, and has participated in advisory
   boards for Novartis, Merck, and GSK. SL serves on an Advisory Board for
   Myriad Genetics Laboratories. MM Advisory Boards from BMS, Roche and
   GSK. RM receives research support from Novartis, and has consulted for
   Roche. He is eligible to income from drugs that are commercialized by
   the Institute of Cancer Research through the "Rewards to Inventors
   Scheme". DLM has no competing interest. GP has no competing interest. AR
   participated to Advisory Board from Amgen, Bristol Myers Squibb,
   Celgene, Roche-Genentech, GSK, Merck, Millennium, Novartis and
   Prometheus and received honoraria from these companies. DFS is a
   co-inventor on a patent related to the growth of TIL in gas permeable
   flasks. RS has no competing interest. EW has no competing interest. NM
   has no competing interest. FMM has no competing interest.
NR 40
TC 6
Z9 7
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAY 2
PY 2012
VL 10
AR 83
DI 10.1186/1479-5876-10-83
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 968IR
UT WOS:000305972700001
PM 22551296
ER

PT J
AU Singh, JA
AF Singh, Jasvinder A.
TI Stem cells and other innovative intra-articular therapies for
   osteoarthritis: what does the future hold?
SO BMC MEDICINE
LA English
DT Editorial Material
DE osteoarthritis; intra-articular; novel; treatment; gene therapy; stem
   cell
ID CRUCIATE LIGAMENT TRANSECTION; FIBROBLAST GROWTH FACTOR-18; RANDOMIZED
   CONTROLLED-TRIAL; PLATELET-RICH PLASMA; BOTULINUM-TOXIN-A;
   QUALITY-OF-LIFE; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; IN-VIVO;
   OARSI RECOMMENDATIONS
AB Osteoarthritis (OA), the most common type of arthritis in the world, is associated with suffering due to pain, productivity loss, decreased mobility and quality of life. Systemic therapies available for OA are mostly symptom modifying and have potential gastrointestinal, renal, hepatic, and cardiac side effects. BMC Musculoskeletal Disorders recently published a study showing evidence of reparative effects demonstrated by homing of intra-articularly injected autologous bone marrow stem cells in damaged cartilage in an animal model of OA, along with clinical and radiographic benefit. This finding adds to the growing literature showing the potential benefit of intra-articular (IA) bone marrow stem cells. Other emerging potential IA therapies include IL-1 receptor antagonists, conditioned autologous serum, botulinum toxin, and bone morphogenetic protein-7. For each of these therapies, trial data in humans have been published, but more studies are needed to establish that they are safe and effective. Several additional promising new OA treatments are on the horizon, but challenges remain to finding safe and effective local and systemic therapies for OA. Please see related article: http://www.biomedcentral.com/1471-2474/12/259
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
NR 59
TC 5
Z9 5
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD MAY 2
PY 2012
VL 10
AR 44
DI 10.1186/1741-7015-10-44
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 951HV
UT WOS:000304712400001
PM 22551396
ER

PT J
AU Robida-Stubbs, S
   Glover-Cutter, K
   Lamming, DW
   Mizunuma, M
   Narasimhan, SD
   Neumann-Haefelin, E
   Sabatini, DM
   Blackwell, TK
AF Robida-Stubbs, Stacey
   Glover-Cutter, Kira
   Lamming, Dudley W.
   Mizunuma, Masaki
   Narasimhan, Sri Devi
   Neumann-Haefelin, Elke
   Sabatini, David M.
   Blackwell, T. Keith
TI TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf
   and DAF-16/FoxO
SO CELL METABOLISM
LA English
DT Article
ID LIFE-SPAN EXTENSION; RESTRICTION-INDUCED LONGEVITY; RNA PROCESSING
   FACTORS; CAENORHABDITIS-ELEGANS; C-ELEGANS; STRESS-RESPONSE; INHIBITION;
   GENES; METABOLISM; GROWTH
AB The TOR kinase, which is present in the functionally distinct complexes TORC1 and TORC2, is essential for growth but associated with disease and aging. Elucidation of how TOR influences life span will identify mechanisms of fundamental importance in aging and TOR functions. Here we show that when TORC1 is inhibited genetically in C. elegans, SKN-1/Nrf, and DAF-16/FoxO activate protective genes, and increase stress resistance and longevity. SKN-1 also upregulates TORC1 pathway gene expression in a feedback loop. Rapamycin triggers a similar protective response in C. elegans and mice, but increases worm life span dependent upon SKN-1 and not DAF-16, apparently by interfering with TORC2 along with TORC1. TORC1, TORC2, and insulin/IGF-1-like signaling regulate SKN-1 activity through different mechanisms. We conclude that modulation of SKN-1/Nrf and DAF-16/FoxO may be generally important in the effects of TOR signaling in vivo and that these transcription factors mediate an opposing relationship between growth signals and longevity.
C1 [Robida-Stubbs, Stacey; Glover-Cutter, Kira; Mizunuma, Masaki; Narasimhan, Sri Devi; Neumann-Haefelin, Elke; Blackwell, T. Keith] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Joslin Diabet Ctr, Boston, MA 02215 USA.
   [Robida-Stubbs, Stacey; Glover-Cutter, Kira; Mizunuma, Masaki; Narasimhan, Sri Devi; Neumann-Haefelin, Elke; Blackwell, T. Keith] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA.
   [Lamming, Dudley W.; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   [Lamming, Dudley W.; Sabatini, David M.] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.
   [Lamming, Dudley W.; Sabatini, David M.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Lamming, Dudley W.; Sabatini, David M.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
   [Mizunuma, Masaki] Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan.
   [Neumann-Haefelin, Elke] Univ Hosp Freiburg, Renal Div, D-79106 Freiburg, Germany.
RP Blackwell, TK (reprint author), Harvard Univ, Sch Med, Harvard Stem Cell Inst, Joslin Diabet Ctr, Boston, MA 02215 USA.
EM keith.blackwell@joslin.harvard.edu
OI Glover-Cutter, Kira/0000-0002-7321-8604
FU NIH [GM62891, CA129105]; Ellison Medical Foundation; American Federation
   for Aging Research; Starr Foundation; Koch Institute; DRC from NIDDK;
   NIDDK [T32]; ADA [F32 NRSA]; JSPS
FX We thank Javier Apfeld, Eric Greer, Marcia Haigis, and the Blackwell lab
   for helpful discussions, and David Bentley, Bruce Bowerman, and Heidi
   Tissenbaum for reagents. This work was supported by grants from the NIH
   (GM62891 to T.K.B and CA129105 to D.M.S.), the Ellison Medical
   Foundation (to T.K.B and to D.M.S.), the American Federation for Aging
   Research, Starr Foundation, and Koch Institute Frontier Research Program
   (to D.M.S.), and a DRC grant from the NIDDK. KG-C. was supported by an
   NIDDK T32 and an F32 NRSA, D.W.L. by an F32 NRSA and a Mentor-Based
   Fellowship from the ADA, and M.M. by the JSPS Excellent Young
   Researchers Overseas Visit Program. T.K.B. planned the project, T.K.B.
   and D.M.S. oversaw the work, all authors designed, carried out, and/or
   interpreted the experiments, and T.K.B., S.R.-S., K.G.-C., and D.W.L.
   wrote the paper.
NR 55
TC 153
Z9 162
U1 3
U2 48
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD MAY 2
PY 2012
VL 15
IS 5
BP 713
EP 724
DI 10.1016/j.cmet.2012.04.007
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 937WL
UT WOS:000303694100019
PM 22560223
ER

PT J
AU Da Cruz, S
   Parone, PA
   Lopes, VS
   Lillo, C
   McAlonis-Downes, M
   Lee, SK
   Vetto, AP
   Petrosyan, S
   Marsala, M
   Murphy, AN
   Williams, DS
   Spiegelman, BM
   Cleveland, DW
AF Da Cruz, Sandrine
   Parone, Philippe A.
   Lopes, Vanda S.
   Lillo, Concepcion
   McAlonis-Downes, Melissa
   Lee, Sandra K.
   Vetto, Anne P.
   Petrosyan, Susanna
   Marsala, Martin
   Murphy, Anne N.
   Williams, David S.
   Spiegelman, Bruce M.
   Cleveland, Don W.
TI Elevated PGC-1 alpha Activity Sustains Mitochondrial Biogenesis and
   Muscle Function without Extending Survival in a Mouse Model of Inherited
   ALS
SO CELL METABOLISM
LA English
DT Article
ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; AMYOTROPHIC-LATERAL-SCLEROSIS;
   SKELETAL-MUSCLE; PRIMARY TARGET; SOD1; TOXICITY; ATROPHY; FIBERS; ONSET;
   MICE
AB The transcriptional coactivator PGC-1 alpha induced multiple effects on muscle, including increased mitochondrial mass and activity. Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, adult-onset neurodegenerative disorder characterized by selective loss of motor neurons and skeletal muscle degeneration. An early event is thought to be denervation-induced muscle atrophy accompanied by alterations in mitochondrial activity and morphology within muscle. We now report that elevation of PGC-1 alpha levels in muscles of mice that develop fatal paralysis from an ALS-causing SOD1 mutant elevates PGC-1 alpha-dependent pathways throughout disease course. Mitochondrial biogenesis and activity are maintained through end-stage disease, accompanied by retention of muscle function, delayed muscle atrophy, and significantly improved muscle endurance even at late disease stages. However, survival was not extended. Therefore, muscle is not a primary target of mutant SOD1-mediated toxicity, but drugs increasing PGC-1 alpha activity in muscle represent an attractive therapy for maintaining muscle function during progression of ALS.
C1 [Da Cruz, Sandrine; Parone, Philippe A.; McAlonis-Downes, Melissa; Lee, Sandra K.; Vetto, Anne P.; Cleveland, Don W.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.
   [Da Cruz, Sandrine; Parone, Philippe A.; McAlonis-Downes, Melissa; Lee, Sandra K.; Vetto, Anne P.; Cleveland, Don W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Petrosyan, Susanna; Murphy, Anne N.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Lopes, Vanda S.; Williams, David S.] Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Lopes, Vanda S.; Williams, David S.] Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Marsala, Martin] Univ Calif San Diego, Dept Anesthesiol, Anesthesiol Res Lab, La Jolla, CA 92093 USA.
   [Lillo, Concepcion] Inst Neurociencias Castilla & Leon, Salamanca 37007, Spain.
   [Marsala, Martin] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia.
   [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
   [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Cleveland, DW (reprint author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.
EM dcleveland@ucsd.edu
RI Lillo, Concepcion/A-6321-2009
OI Lillo, Concepcion/0000-0001-5814-9826
FU Muscular Dystrophy Association; NIH; ALS Association; Ludwig Institute
   for Cancer Research; RPB
FX We are very grateful to Prof. Randal Johnson for the use his treadmill
   apparatus. This work has been supported by grants from the Muscular
   Dystrophy Association and the NIH to D.W.C. S.D.C. was supported by a
   postdoctoral fellowship from the ALS Association. Salary support for
   D.W.C. is provided by the Ludwig Institute for Cancer Research. Support
   from the NIH and an RPB Jules and Doris Stein Professorship was also
   provided to D.S.W.
NR 23
TC 65
Z9 65
U1 0
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD MAY 2
PY 2012
VL 15
IS 5
BP 778
EP 786
DI 10.1016/j.cmet.2012.03.019
PG 9
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 937WL
UT WOS:000303694100024
PM 22560226
ER

PT J
AU Pletcher, MJ
   Kertesz, SG
AF Pletcher, Mark J.
   Kertesz, Stefan G.
TI Long-term Marijuana Use and Pulmonary Function Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID RECRUITMENT; CARDIA
C1 [Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Pletcher, MJ (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
EM mpletcher@epi.ucsf.edu
NR 2
TC 0
Z9 0
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 2
PY 2012
VL 307
IS 17
BP 1796
EP 1797
DI 10.1001/jama.2012.3607
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 933TV
UT WOS:000303386800011
ER

PT J
AU Pae, CU
   Bodkin, JA
   Portland, KB
   Thase, ME
   Patkar, AA
AF Pae, Chi-Un
   Bodkin, J. Alexander
   Portland, Kimberly Blanchard
   Thase, Michael E.
   Patkar, Ashwin A.
TI Safety of Selegiline Transdermal System in Clinical Practice: Analysis
   of Adverse Events From Postmarketing Exposures
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; MONOAMINE-OXIDASE INHIBITORS; DOUBLE-BLIND;
   PARALLEL-GROUP; DRUG SAFETY; TRIAL; SURVEILLANCE; PRODUCT; FDA
AB Objective: The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs).
   Method: Deidentified data were obtained on AEs, regardless of causality, as collected and compiled in the pharmaceutical company's adverse event collection systems/databases after the launch of STS in the United States. All reports of hypertensive crisis, suicide attempts, and STS overdoses were carefully examined to independently determine relation of the AE to STS.
   Results: From April 2006 to October 2010, a total of 3,155 AEs in 1,516 patients were reported (5.2% of the total exposures; N = 29,141), regardless of causality. The most frequently reported categories of AEs were general disorders (no. of AEs = 1,037, 3.6%) and central nervous system (CNS) disorders (no. of AEs = 574, 2.0%). A total of 266 reports (0.9%) were classified as serious AEs; CNS disorders (no. of AEs = 71, 26.7%) and cardiac and vascular disorders (no. of AEs = 44, 16.5%) were most common. There were 13 self-reports of possible hypertensive events or hypertension, although objective clinical data were not submitted in any of these cases. Thirteen drug-drug interactions (0.04%) were reported, and 5 were classified as serious.
   Conclusions: The most commonly reported AEs were application site reactions and insomnia. Very few patients reported a hypertensive event, and there were no objectively confirmed reports of hypertensive crisis with food at any STS dose. Therapeutic doses of STS appear to have a safety profile in clinical practice that is consistent with that observed in clinical trials. However, given the relatively modest exposure numbers, continued safety monitoring is recommended. J Clin Psychiatry 2012;73(5):661-668 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 [Pae, Chi-Un; Patkar, Ashwin A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27705 USA.
   [Pae, Chi-Un] Catholic Univ Korea, Coll Med, Seoul, South Korea.
   [Bodkin, J. Alexander] McLean Hosp, Clin Psychopharmacol Res Program, Belmont, MA 02178 USA.
   [Portland, Kimberly Blanchard] Mylan Specialty LP, Basking Ridge, NJ USA.
   [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Patkar, AA (reprint author), Duke Univ, Med Ctr, Dept Psychiat, 2218 Elder St,Suite B-2, Durham, NC 27705 USA.
EM pae@catholic.ac.kr; ashwin.patkar@duke.edu
FU GlaxoSmithKline Korea; GlaxoSmithKline; AstraZeneca Korea; Janssen
   Pharmaceuticals Korea; Eli Lilly Korea; KHIDI; Otsuka Korea; Wyeth
   Korea; Ministry of Health and Welfare; Korea Research Foundation; Korean
   Institute of Science and Technology Evaluation and Planning; Pfizer;
   Shire; Merck; Bristol Myers Squibb; Otsuka; CeNeRx; Eli Lilly; National
   Institute of Mental Health; Agency for Healthcare Research and Quality;
   Sepracor; National Institutes of Health (National Institute on Drug
   Abuse/National Institute on Alcohol Abuse and Alcoholism); Duke
   Endowment; AstraZeneca; Forest; Cephalon; Janssen; Jazz; McNeil;
   Organon; Orphan; Lundbeck; Titan; Sunovion; Mylan Specialty LP, Basking
   Ridge, New Jersey
FX Dr Pae has received research grants from GlaxoSmithKline Korea,
   GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli
   Lilly Korea, KHIDI, Otsuka Korea, Wyeth Korea, Ministry of Health and
   Welfare, Korea Research Foundation, and Korean Institute of Science and
   Technology Evaluation and Planning; has received honoraria from and is
   on the speakers bureaus of GlaxoSmithKline Korea, Pfizer Korea, Lundbeck
   Korea, Sandoz Korea, AstraZeneca Korea, Jeil Pharmaceuticals, Eisai
   Korea, Janssen Korea, Eli Lilly Korea, and Otsuka Korea; and has stock
   holdings in Dongwha Pharmaceuticals. Dr Bodkin has received
   grant/research support from Pfizer, Shire, Merck, Bristol Myers Squibb,
   Otsuka, and CeNeRx; has been on the speakers bureau of Bristol-Myers
   Squibb; and has been a consultant to Bristol-Myers Squibb, Alkermes, and
   Mylan. Dr Portland is an employee of Mylan. Dr Thase has provided
   scientific consultation to AstraZeneca, Bristol-Myers Squibb, Mylan, Eli
   Lilly, Forest, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global,
   H. Lundbeck A/S, MedAvante, Merck, Neuronetics, Novartis, Otsuka,
   Ortho-McNeil, PamLab, Pfizer (formerly Wyeth-Ayerst Laboratories),
   Schering-Plough (formerly Organon), Shire US, Supernus, Takeda
   (Lundbeck), and Transcept; has been on the speakers bureaus of
   AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer
   (formerly Wyeth-Ayerst Laboratories); receives grant funding from Eli
   Lilly, GlaxoSmithKline, National Institute of Mental Health, Agency for
   Healthcare Research and Quality, and Sepracor; has equity holdings in
   MedAvante; and receives royalty income from American Psychiatric
   Foundation, Guilford Publications, Herald House, Oxford University
   Press, and W W Norton & Co. His wife is employed as the Group Scientific
   Director for Embryon-formerly Advogent. Dr Patkar has received research
   support from National Institutes of Health (National Institute on Drug
   Abuse/National Institute on Alcohol Abuse and Alcoholism), Duke
   Endowment, AstraZeneca, Forest, Cephalon, Janssen, Jazz, McNeil,
   Organon, Orphan, Merck, Lundbeck, Pfizer, Titan, Shire, and Sunovion;
   has been a consultant to/advisory board member for Forest, Gilead,
   Mylan, Titan, and Reckitt Benckiser; and has been on the speakers
   bureaus of Alkermes, Bristol-Myers Squibb, Mylan, Pfizer, and Sunovion.;
   Sponsored by Mylan Specialty LP, Basking Ridge, New Jersey.
NR 25
TC 16
Z9 17
U1 1
U2 5
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2012
VL 73
IS 5
BP 661
EP 668
DI 10.4088/JCP.12m07648
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SI
UT WOS:000314999900009
PM 22697192
ER

PT J
AU Iovieno, N
   Papakostas, GI
AF Iovieno, Nadia
   Papakostas, George I.
TI Does the Presence of an Open-Label Antidepressant Treatment Period
   Influence Study Outcome in Clinical Trials Examining
   Augmentation/Combination Strategies in Treatment Partial
   Responders/Nonresponders With Major Depressive Disorder?
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; TREATMENT-RESISTANT DEPRESSION; SEROTONIN
   REUPTAKE INHIBITORS; TREATMENT-REFRACTORY DEPRESSION; EXTENDED-RELEASE
   QUETIAPINE; PRELIMINARY DOUBLE-BLIND; OLANZAPINE/FLUOXETINE COMBINATION;
   LITHIUM AUGMENTATION; ADJUNCTIVE THERAPY; TESTOSTERONE GEL
AB Objective:The authors sought to determine study design factors that may influence clinical trial outcome in augmentation/combination trials for antidepressant partial responders/nonresponders with major depressive disorder (MDD) and to examine whether the use of a prospective treatment phase (lead-in) to assess antidepressant nonresponse may result in a better chance to detect a drug-placebo separation in such trials.
   Data Sources: MEDLINE/PubMed publication databases were searched for randomized, double-blind, placebo-controlled trials of adjunctive pharmacologic strategies for antidepressant partial responders/nonresponders with MDD. The search term depression was successively cross-referenced with the terms augmentation, adjunct, and adjunctive to identify pertinent trials. (The search was limited to articles published between January 1980 and October 2010.)
   Study Selection:Thirty-five articles involving 40 adjunctive drug versus placebo comparisons were pooled (n = 4,676). Final inclusion of articles was determined by consensus between the authors.
   Data Extraction: Data extracted included whether there was a lead-in phase and, if so, the drugs, the doses, and the total duration of the lead-in phase. Additional data extracted included the number of patients enrolled, patient characteristics, methods used to define treatment resistance, drug dosages, duration of the adjunctive trial, response and remission rates, and rates of discontinuation for any reason and for adverse events.
   Results:The risk ratio of responding to the adjunctive drug versus placebo was not influenced by any of the study design factors analyzed (probability of receiving placebo, year of publication, severity of depression at baseline). Meta-regression analysis yielded no significant difference in the risk ratio of responding and remitting to the adjunctive drug versus placebo between studies that did versus did not include an antidepressant lead-in phase. However, pooled response/remission rates for adjunctive drug and placebo were statistically significantly lower in trials that did versus did not include a lead-in phase (response rates: for adjunctive drug, 42.6% vs 47.4%, respectively, P = .014; for adjunctive placebo, 29.7% vs 36.2%, respectively, P = .002; remission rates: for adjunctive drug, 31.0% vs 37.3%, respectively, P = .003; and adjunctive placebo, 18.1% vs 24.7%, respectively, P = .001).
   Conclusions:These results suggest that the choice to use historical data only to define treatment resistance prior to patient enrollment and randomization rather than requiring patients to first undergo a prospective lead-in phase can be a reasonable and evidence-supported approach to design effective clinical trials on augmentation/combination strategies for partial responders/nonresponders with MDD. J Clin Psychiatry 2012;73(5):676-683 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 [Iovieno, Nadia; Papakostas, George I.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Treatment Resistant Depress, Boston, MA 02114 USA.
   [Iovieno, Nadia; Papakostas, George I.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Iovieno, Nadia] Univ Pisa, Dept Psychiat Pharmacol Neurobiol & Biotechnol, I-56100 Pisa, Italy.
RP Iovieno, N (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, 1 Bowdoin Sq, Boston, MA 02114 USA.
EM niovieno@partners.org
RI Papakostas, George/I-6905-2013
OI Papakostas, George/0000-0002-2465-5103
FU Bristol-Myers Squibb; Forest; National Institute of Mental Health;
   Pamlab; Pamlab, Pfizer; Ridge Diagnostics
FX Dr Papakostas has served as a consultant for Abbott, AstraZeneca,
   Brainsway, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline,
   Evotec, Inflabloc, Jazz, Otsuka, Pamlab, Pfizer, Pierre Fabre, Ridge
   Diagnostics, Shire, and Wyeth; has received honoraria from Abbott, Astra
   Zeneca, Bristol-Myers Squibb, Brainsway, Cephalon, Eli Lilly, Evotec,
   GlaxoSmithKline, Inflabloc, Jazz, Lundbeck, Otsuka, Pamlab, Pfizer,
   Pierre Fabre, Ridge Diagnostics, Shire, and Wyeth; has received
   grant/research support from Bristol-Myers Squibb, Forest, the National
   Institute of Mental Health, Pamlab, Pfizer, and Ridge Diagnostics; and
   has served (in the past but not currently) on the speakers bureaus for
   Bristol-Myers Squibb and Pfizer. Dr Iovieno reports no competing
   interests.
NR 76
TC 10
Z9 10
U1 0
U2 3
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2012
VL 73
IS 5
BP 676
EP 683
DI 10.4088/JCP.11r06978
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SI
UT WOS:000314999900011
PM 22569112
ER

PT J
AU Keating, NL
   Landrum, MB
   Lamont, EB
   Bozeman, SR
   McNeil, BJ
AF Keating, Nancy L.
   Landrum, Mary Beth
   Lamont, Elizabeth B.
   Bozeman, Samuel R.
   McNeil, Barbara J.
TI Area-Level Variations in Cancer Care and Outcomes
SO MEDICAL CARE
LA English
DT Article
DE variation; cancer care; Medicare spending
ID QUALITY-OF-CARE; CELL LUNG-CANCER; REGIONAL-VARIATIONS;
   GEOGRAPHIC-VARIATION; COLORECTAL-CANCER; PROSTATE-CANCER; MEDICARE;
   BENEFICIARIES; CHEMOTHERAPY; SERVICES
AB Background: Substantial regional variations in health-care spending exist across the United States; yet, care and outcomes are not better in higher-spending areas. Most studies have focused on care in fee-for-service Medicare; whether spillover effects exist in settings without financial incentives for more care is unknown.
   Objective: We studied care for cancer patients in fee-for-service Medicare and the Veterans Health Administration (VA) to understand whether processes and outcomes of care vary with area-level Medicare spending.
   Design: An observational study using logistic regression to assess care by area-level measures of Medicare spending.
   Subjects: Patients with lung, colorectal, or prostate cancers diagnosed during 2001-2004 in Surveillance, Epidemiology, and End Results (SEER) areas or the VA. The SEER cohort included fee-for-service Medicare patients aged older than 65 years.
   Measures: Recommended and preference-sensitive cancer care and mortality.
   Results: In fee-for-service Medicare, higher-spending areas had higher rates of recommended care (curative surgery and adjuvant chemotherapy for early-stage non-small-cell lung cancer and chemotherapy for stage III colon cancer) and preference-sensitive care (chemotherapy for stage IV lung and colon cancer and primary treatment of local/regional prostate cancer) and had lower lung cancer mortality. In the VA, we observed minimal variation in care by area-level Medicare spending.
   Discussion: Our findings suggest that intensity of care for Medicare beneficiaries is not driving variations in VA care, despite some overlap in physician networks. Although the Dartmouth Atlas work has been of unprecedented importance in demonstrating variations in Medicare spending, new measures may be needed to better understand variations in other populations.
C1 [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
   [Keating, Nancy L.; Landrum, Mary Beth; Lamont, Elizabeth B.; McNeil, Barbara J.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
   [Lamont, Elizabeth B.] Massachusetts Gen Hosp, Div Adult Oncol, Boston, MA 02114 USA.
   [Bozeman, Samuel R.] ABT Associates Inc, Cambridge, MA 02138 USA.
   [McNeil, Barbara J.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM keating@hcp.med.harvard.edu
FU Department of Veterans Affairs through the Office of Policy and Planning
FX Supported by the Department of Veterans Affairs through the Office of
   Policy and Planning.
NR 29
TC 19
Z9 19
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAY
PY 2012
VL 50
IS 5
BP 366
EP 373
DI 10.1097/MLR.0b013e31824d74c0
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 083IH
UT WOS:000314456400002
PM 22437623
ER

PT J
AU Steinman, MA
   Lee, SJ
   Peterson, CA
   Fung, KZ
   Goldstein, MK
AF Steinman, Michael A.
   Lee, Sei J.
   Peterson, Carolyn A.
   Fung, Kathy Z.
   Goldstein, Mary K.
TI A Clinically Guided Approach for Improving Performance Measurement for
   Hypertension
SO MEDICAL CARE
LA English
DT Article
DE quality of health care; quality indicators; health care; hypertension;
   physician's prescribing practices
ID QUALITY-OF-CARE; ELECTRONIC HEALTH RECORDS; CORONARY-ARTERY-DISEASE;
   TREATMENT INTENSIFICATION; BLOOD-PRESSURE; MEDICATION; GUIDELINES;
   ADHERENCE; OUTCOMES; PAY
AB Background: Performance measures often fail to account for legitimate reasons why patients do not achieve recommended treatment targets.
   Methods: We tested a novel performance measurement system for blood pressure (BP) control that was designed to mimic clinical reasoning. This clinically guided approach focuses on (1) exempting patients for whom tight BP control may not be appropriate or feasible and (2) assessing BP over time. Trained abstractors conducted structured chart reviews of 201 adults with hypertension in 2 VA health care systems. Results were compared with traditional methods of performance measurement.
   Results: Among 201 veterans, 183 (91%) were male, and the mean age was 71 +/- 11 years. Using the clinically guided approach, 61 patients (30%) were exempted from performance measurement. The most common reasons for exemption were inadequate opportunity to manage BP (35 patients, 17%) and the use of 4 or more anti-hypertensive medications (19 patients, 9%). Among patients eligible for performance measurement, there was little agreement on the presence of controlled versus uncontrolled BP when comparing the most recent BP (the traditional approach) with an integrated assessment of BP control (kappa 0.14). After accounting for clinically guided exemptions and methods of BP assessment, only 15 of 72 patients (21%) whose last BP was >= 140/90 mm Hg were classified as problematic by the clinically guided approach.
   Conclusions: Many patients have legitimate reasons for not achieving tight BP control, and the methods used for BP assessment have marked effects on whether a patient is classified as having adequate or inadequate BP control.
C1 [Steinman, Michael A.; Lee, Sei J.; Peterson, Carolyn A.; Fung, Kathy Z.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA.
   [Steinman, Michael A.; Lee, Sei J.; Peterson, Carolyn A.; Fung, Kathy Z.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
   [Goldstein, Mary K.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA.
   [Goldstein, Mary K.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU Department of Veterans Affairs (VA) Health Services Research &
   Development Service [CDTA 01-013, IAF 06-080-02, CPI 99-275, IMV
   04-062]; National Institutes on Aging; American Federation for Aging
   Research [K23 AG030999]; San Francisco Veterans Affairs Medical Center
   Health Services Research and Development Research Enhancement Award
   Program; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]
FX Supported by the Department of Veterans Affairs (VA) Health Services
   Research & Development Service (CDTA 01-013 and related to IAF
   06-080-02, CPI 99-275, and IMV 04-062) and by the National Institutes on
   Aging and the American Federation for Aging Research (K23 AG030999), and
   further supported with resources of the San Francisco Veterans Affairs
   Medical Center Health Services Research and Development Research
   Enhancement Award Program. Dr Lee was supported by NIH/NCRR/OD UCSF-CTSI
   Grant number KL2 RR024130.
NR 30
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2012
VL 50
IS 5
BP 399
EP 405
DI 10.1097/MLR.0b013e318245a147
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 083IH
UT WOS:000314456400007
PM 22627680
ER

PT J
AU Kulkarni, VT
   Shah, SJ
   Bernheim, SM
   Wang, YF
   Normand, SLT
   Han, LF
   Rapp, MT
   Drye, EE
   Krumholz, HM
AF Kulkarni, Vivek T.
   Shah, Sachin J.
   Bernheim, Susannah M.
   Wang, Yongfei
   Normand, Sharon-Lise T.
   Han, Lein F.
   Rapp, Michael T.
   Drye, Elizabeth E.
   Krumholz, Harlan M.
TI Regional Associations Between Medicare Advantage Penetration and
   Administrative Claims-based Measures of Hospital Outcomes
SO MEDICAL CARE
LA English
DT Article
DE acute MI; heart failure; Medicare; mortality; outcomes assessment;
   pneumonia; readmissions; risk adjustment
ID ACUTE MYOCARDIAL-INFARCTION; CAUSE READMISSION RATES; 30-DAY
   MORTALITY-RATES; HEART-FAILURE; PERFORMANCE
AB Background: Risk-standardized measures of hospital outcomes reported by the Centers for Medicare and Medicaid Services include Medicare fee-for-service (FFS) patients and exclude Medicare Advantage (MA) patients due to data availability. MA penetration varies greatly nationwide and seems to be associated with increased FFS population risk. Whether variation in MA penetration affects the performance on the Centers for Medicare and Medicaid Service measures is unknown.
   Objective: To determine whether the MA penetration rate is associated with outcomes measures based on FFS patients.
   Research Design: In this retrospective study, 2008 MA penetration was estimated at the Hospital Referral Region (HRR) level. Risk-standardized mortality rates and risk-standardized readmission rates for heart failure, acute myocardial infarction, and pneumonia from 2006 to 2008 were estimated among HRRs, along with several markers of FFS population risk. Weighted linear regression was used to test the association between each of these variables and MA penetration among HRRs.
   Results: Among 304 HRRs, MA penetration varied greatly (median, 17.0%; range, 2.1%-56.6%). Although MA penetration was significantly (P < 0.05) associated with 5 of the 6 markers of FFS population risk, MA penetration was insignificantly (P >= 0.05) associated with 5 of 6 hospital outcome measures.
   Conclusion: Risk-standardized mortality rates and risk-standardized readmission rates for heart failure, acute myocardial infarction, and pneumonia do not seem to differ systematically with MA penetration, lending support to the widespread use of these measures even in areas of high MA penetration.
C1 [Kulkarni, Vivek T.] Yale Univ, Sch Med, New Haven, CT USA.
   [Shah, Sachin J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Bernheim, Susannah M.; Wang, Yongfei; Drye, Elizabeth E.; Krumholz, Harlan M.] Yale New Haven Hosp Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Wang, Yongfei; Drye, Elizabeth E.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
   [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
   [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Han, Lein F.; Rapp, Michael T.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA.
   [Rapp, Michael T.] George Washington Univ, Sch Med & Hlth Sci, Dept Emergency Med, Washington, DC 20052 USA.
   [Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
RP Bernheim, SM (reprint author), Yale YNHH Ctr Outcomes Res & Evaluat CORE, 1 Church St,Suite 200, New Haven, CT 06510 USA.
EM susannah.bernheim@yale.edu
FU Ruth L. Kirchstein National Research Service Award from the National
   Institutes of Health [5T35 HL07649-24]; (Center for Cardiovascular
   Outcomes Research at Yale University) from the National Heart, Lung, and
   Blood Institute [U01 HL 105270-01]
FX V.T.K. was supported by a Ruth L. Kirchstein National Research Service
   Award (5T35 HL07649-24) from the National Institutes of Health. H. M. K.
   is supported by grant U01 HL 105270-01 (Center for Cardiovascular
   Outcomes Research at Yale University) from the National Heart, Lung, and
   Blood Institute. Each of the other authors reports no support received
   for this work.
NR 16
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2012
VL 50
IS 5
BP 406
EP 409
DI 10.1097/MLR.0b013e318245a0f9
PG 4
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 083IH
UT WOS:000314456400008
PM 22456113
ER

PT J
AU Karr, S
   Kelley, KW
   McBane, S
   Thomas, T
AF Karr, Samantha
   Kelley, Kristi W.
   McBane, Sarah
   Thomas, Tyan
TI Overcoming practice site challenges in clinical faculty positions
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
ID PHARMACY; PRACTITIONERS
C1 [Karr, Samantha] Midwestern Univ, Coll Pharm Glendale, Glendale, AZ 85308 USA.
   [Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
   [Kelley, Kristi W.] Baptist Hlth Syst Inc, Trinity Med Ctr, Continu Clin, Birmingham, AL USA.
   [McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
   [Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA.
   [Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Karr, S (reprint author), Midwestern Univ, Coll Pharm Glendale, 19555 N 59th Ave, Glendale, AZ 85308 USA.
EM skarrx@midwestern.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2012
VL 69
IS 9
BP 738
EP +
DI 10.2146/ajhp110289
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VA
UT WOS:000313770000005
PM 22517019
ER

PT J
AU Toma, M
   McAlister, FA
   Coglianese, EE
   Vidi, V
   Vasaiwala, S
   Bakal, JA
   Armstrong, PW
   Ezekowitz, JA
AF Toma, Mustafa
   McAlister, Finlay A.
   Coglianese, Erin E.
   Vidi, Venkatesan
   Vasaiwala, Samip
   Bakal, Jeffrey A.
   Armstrong, Paul W.
   Ezekowitz, Justin A.
TI Testosterone Supplementation in Heart Failure A Meta-Analysis
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE heart failure; testosterone; androgens; meta-analysis
ID RANDOMIZED CONTROLLED-TRIAL; PROSTATE-SPECIFIC ANTIGEN; DOUBLE-BLIND;
   OLDER MEN; SERUM TESTOSTERONE; INSULIN-RESISTANCE; BODY-COMPOSITION;
   SKELETAL-MUSCLE; CARDIAC RESYNCHRONIZATION; PHYSICAL PERFORMANCE
AB Background-Low testosterone is an independent predictor of reduced exercise capacity and poor clinical outcomes in patients with heart failure (HF). We sought to determine whether testosterone therapy improves exercise capacity in patients with stable chronic HF.
   Methods and Results-We searched Medline, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (1980-2010). Eligible studies included randomized controlled trials (RCTs) reporting the effects of testosterone on exercise capacity in patients with HF. Reviewers determined the methodological quality of studies and collected descriptive, quality, and outcome data. Four trials (n = 198; men, 84%; mean age, 67 years) were identified that reported the 6-minute walk test (2 RCTs), incremental shuttle walk test (2 RCTs), or peak oxygen consumption (2 RCTs) to assess exercise capacity after up to 52 weeks of treatment. Testosterone therapy was associated with a significant improvement in exercise capacity compared with placebo. The mean increase in the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption between the testosterone and placebo groups was 54.0 m (95% CI, 43.0-65.0 m), 46.7 m (95% CI, 12.6-80.9 m), and 2.70 mL/kg per min (95% CI, 2.68-2.72 mL/kg per min), respectively. Testosterone therapy was associated with a significant increase in exercise capacity as measured by units of pooled SDs (net effect, 0.52 SD; 95% CI, 0.10-0.94 SD). No significant adverse cardiovascular events were noted.
   Conclusions-Given the unmet clinical needs, testosterone appears to be a promising therapy to improve functional capacity in patients with HF. Adequately powered RCTs are required to assess the benefits of testosterone in this high-risk population with regard to quality of life, clinical events, and safety. (Circ Heart Fail. 2012;5:315-321.)
C1 [Toma, Mustafa] Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada.
   [McAlister, Finlay A.; Bakal, Jeffrey A.; Armstrong, Paul W.; Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB T6G 2B7, Canada.
   [McAlister, Finlay A.; Bakal, Jeffrey A.; Armstrong, Paul W.; Ezekowitz, Justin A.] Mazankowski Alberta Heart Inst, Edmonton, AB T6G 2B7, Canada.
   [Coglianese, Erin E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
   [Vidi, Venkatesan; Vasaiwala, Samip] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
RP Ezekowitz, JA (reprint author), Univ Alberta, 8440 112 St, Edmonton, AB T6G 2B7, Canada.
EM jae2@ualberta.ca
RI McAlister, Finlay/C-4151-2013; Ezekowitz, Justin/C-4579-2013
OI Ezekowitz, Justin/0000-0002-2724-4086
FU Alberta Innovates-Health Solutions; Canadian Institutes of Health
   Research
FX Dr McAlister is funded as a Senior Health Scholar of Alberta
   Innovates-Health Solutions. Dr Ezekowitz is funded as a New Investigator
   by the Canadian Institutes of Health Research and Alberta
   Innovates-Health Solutions.
NR 46
TC 63
Z9 64
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAY
PY 2012
VL 5
IS 3
BP 315
EP 321
DI 10.1161/CIRCHEARTFAILURE.111.965632
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 071GC
UT WOS:000313577100006
PM 22511747
ER

PT J
AU David, SP
   Hamidovic, A
   Chen, GK
   Bergen, AW
   Wessel, J
   Kasberger, JL
   Brown, WM
   Petruzella, S
   Thacker, EL
   Kim, Y
   Nalls, MA
   Tranah, GJ
   Sung, YJ
   Ambrosone, CB
   Arnett, D
   Bandera, EV
   Becker, DM
   Becker, L
   Berndt, SI
   Bernstein, L
   Blot, WJ
   Broeckel, U
   Buxbaum, SG
   Caporaso, N
   Casey, G
   Chanock, SJ
   Deming, SL
   Diver, WR
   Eaton, CB
   Evans, DS
   Evans, MK
   Fornage, M
   Franceschini, N
   Harris, TB
   Henderson, BE
   Hernandez, DG
   Hitsman, B
   Hu, JJ
   Hunt, SC
   Ingles, SA
   John, EM
   Kittles, R
   Kolb, S
   Kolonel, LN
   Le Marchand, L
   Liu, Y
   Lohman, KK
   McKnight, B
   Millikan, RC
   Murphy, A
   Neslund-Dudas, C
   Nyante, S
   Press, M
   Psaty, BM
   Rao, DC
   Redline, S
   Rodriguez-Gil, JL
   Rybicki, BA
   Signorello, LB
   Singleton, AB
   Smoller, J
   Snively, B
   Spring, B
   Stanford, JL
   Strom, SS
   Swan, GE
   Taylor, KD
   Thun, MJ
   Wilson, AF
   Witte, JS
   Yamamura, Y
   Yanek, LR
   Yu, K
   Zheng, W
   Ziegler, RG
   Zonderman, AB
   Jorgenson, E
   Haiman, CA
   Furberg, H
AF David, S. P.
   Hamidovic, A.
   Chen, G. K.
   Bergen, A. W.
   Wessel, J.
   Kasberger, J. L.
   Brown, W. M.
   Petruzella, S.
   Thacker, E. L.
   Kim, Y.
   Nalls, M. A.
   Tranah, G. J.
   Sung, Y. J.
   Ambrosone, C. B.
   Arnett, D.
   Bandera, E. V.
   Becker, D. M.
   Becker, L.
   Berndt, S. I.
   Bernstein, L.
   Blot, W. J.
   Broeckel, U.
   Buxbaum, S. G.
   Caporaso, N.
   Casey, G.
   Chanock, S. J.
   Deming, S. L.
   Diver, W. R.
   Eaton, C. B.
   Evans, D. S.
   Evans, M. K.
   Fornage, M.
   Franceschini, N.
   Harris, T. B.
   Henderson, B. E.
   Hernandez, D. G.
   Hitsman, B.
   Hu, J. J.
   Hunt, S. C.
   Ingles, S. A.
   John, E. M.
   Kittles, R.
   Kolb, S.
   Kolonel, L. N.
   Le Marchand, L.
   Liu, Y.
   Lohman, K. K.
   McKnight, B.
   Millikan, R. C.
   Murphy, A.
   Neslund-Dudas, C.
   Nyante, S.
   Press, M.
   Psaty, B. M.
   Rao, D. C.
   Redline, S.
   Rodriguez-Gil, J. L.
   Rybicki, B. A.
   Signorello, L. B.
   Singleton, A. B.
   Smoller, J.
   Snively, B.
   Spring, B.
   Stanford, J. L.
   Strom, S. S.
   Swan, G. E.
   Taylor, K. D.
   Thun, M. J.
   Wilson, A. F.
   Witte, J. S.
   Yamamura, Y.
   Yanek, L. R.
   Yu, K.
   Zheng, W.
   Ziegler, R. G.
   Zonderman, A. B.
   Jorgenson, E.
   Haiman, C. A.
   Furberg, H.
TI Genome-wide meta-analyses of smoking behaviors in African Americans
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Article
DE African American; genome-wide association; health disparities; nicotine;
   smoking; tobacco
ID HAPLOTYPE-PHASE INFERENCE; NICOTINE DEPENDENCE; LUNG-CANCER; GENOTYPE
   IMPUTATION; BRONCHOPULMONARY DYSPLASIA; SUSCEPTIBILITY LOCUS;
   EUROPEAN-AMERICANS; RACIAL-DIFFERENCES; CIGARETTE-SMOKING; TWIN REGISTRY
AB The identification and exploration of genetic loci that influence smoking behaviors have been conducted primarily in populations of the European ancestry. Here we report results of the first genome-wide association study meta-analysis of smoking behavior in African Americans in the Study of Tobacco in Minority Populations Genetics Consortium (n = 32 389). We identified one non-coding single-nucleotide polymorphism (SNP; rs2036527[A]) on chromosome 15q25.1 associated with smoking quantity (cigarettes per day), which exceeded genome-wide significance (beta = 0.040, s.e. = 0.007, P = 1.84 x 10(-)8). This variant is present in the 5'-distal enhancer region of the CHRNA5 gene and defines the primary index signal reported in studies of the European ancestry. No other SNP reached genome-wide significance for smoking initiation (SI, ever vs never smoking), age of SI, or smoking cessation (SC, former vs current smoking). Informative associations that approached genome-wide significance included three modestly correlated variants, at 15q25.1 within PSMA4, CHRNA5 and CHRNA3 for smoking quantity, which are associated with a second signal previously reported in studies in European ancestry populations, and a signal represented by three SNPs in the SPOCK2 gene on chr10q22.1. The association at 15q25.1 confirms this region as an important susceptibility locus for smoking quantity in men and women of African ancestry. Larger studies will be needed to validate the suggestive loci that did not reach genome-wide significance and further elucidate the contribution of genetic variation to disparities in cigarette consumption, SC and smoking-attributable disease between African Americans and European Americans. Translational Psychiatry (2012) 2, e119; doi:10.1038/tp.2012.41; published online 22 May 2012
C1 [David, S. P.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Ctr Educ & Res Family & Community Med, Stanford, CA 93405 USA.
   [David, S. P.; Bergen, A. W.; Wessel, J.; Swan, G. E.] SRI Int, Policy Div, Ctr Hlth Sci, Menlo Pk, CA 94025 USA.
   [David, S. P.; Eaton, C. B.] Brown Alpert Med Sch, Ctr Primary Care & Prevent, Dept Family Med, Pawtucket, RI USA.
   [Hamidovic, A.; Hitsman, B.; Spring, B.] Northwestern Univ, Dept Preventat Med, Chicago, IL 60611 USA.
   [Chen, G. K.; Casey, G.; Henderson, B. E.; Ingles, S. A.; Press, M.; Haiman, C. A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Wessel, J.] Indiana Univ Sch Med, Div Epidemiol & Environm Hlth, Dept Publ Hlth, Indianapolis, IN USA.
   [Wessel, J.] Indiana Univ Sch Med, Div Cardiol, Dept Med, Indianapolis, IN USA.
   [Kasberger, J. L.; Jorgenson, E.] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94143 USA.
   [Brown, W. M.; Lohman, K. K.; Snively, B.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
   [Petruzella, S.; Furberg, H.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Thacker, E. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Kim, Y.; Wilson, A. F.] NHGRI, Genometr Sect, NIH, Baltimore, MD USA.
   [Nalls, M. A.; Hernandez, D. G.; Singleton, A. B.] NIA, Neurogenet Lab, NIH, Baltimore, MD 21224 USA.
   [Tranah, G. J.; Evans, D. S.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Sung, Y. J.; Rao, D. C.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
   [Ambrosone, C. B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Arnett, D.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
   [Bandera, E. V.] Canc Inst New Jersey, New Brunswick, NJ USA.
   [Becker, D. M.; Becker, L.; Yanek, L. R.] Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins GeneSTAR Res Program, Baltimore, MD 21205 USA.
   [Berndt, S. I.; Caporaso, N.; Chanock, S. J.; Yu, K.; Ziegler, R. G.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
   [Bernstein, L.] City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Etiol, Dept Populat Sci, Duarte, CA 91010 USA.
   [Blot, W. J.; Signorello, L. B.] Int Epidemiol Inst, Rockville, MD USA.
   [Blot, W. J.; Deming, S. L.; Zheng, W.] Vanderbilt Univ, Dept Med, Div Epidemiol, Vanderbilt Epidemiol Ctr, Nashville, TN USA.
   [Blot, W. J.; Deming, S. L.; Zheng, W.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   [Broeckel, U.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
   [Buxbaum, S. G.] Jackson State Univ, Jackson Heart Study, Jackson, MS USA.
   [Diver, W. R.; Thun, M. J.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
   [Evans, M. K.] NIA, Hlth Dispar Res Sect, Clin Res Branch, NIH, Baltimore, MD 21224 USA.
   [Fornage, M.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Brown Fdn Inst Mol Med, Div Epidemiol, Houston, TX USA.
   [Franceschini, N.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Harris, T. B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
   [Hu, J. J.; Rodriguez-Gil, J. L.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Hunt, S. C.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [John, E. M.] Canc Prevent Inst Calif, Fremont, CA USA.
   [John, E. M.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA USA.
   [Kittles, R.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Dept Med, Chicago, IL USA.
   [Kolb, S.; Stanford, J. L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   [Kolonel, L. N.; Le Marchand, L.] Univ Hawaii, Canc Res Ctr, Program Epidemiol, Honolulu, HI 96813 USA.
   [Liu, Y.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
   [McKnight, B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Millikan, R. C.; Nyante, S.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Murphy, A.] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA.
   [Neslund-Dudas, C.; Rybicki, B. A.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA.
   [Psaty, B. M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Psaty, B. M.] Univ Washington, Dept Med, Seattle, WA USA.
   [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Psaty, B. M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
   [Redline, S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Redline, S.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA.
   [Smoller, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Ctr Human Genet Res, Boston, MA USA.
   [Strom, S. S.; Yamamura, Y.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Taylor, K. D.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
   [Witte, J. S.] Univ Calif San Francisco, Inst Human Genet, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Witte, J. S.] Univ Calif San Francisco, Inst Human Genet, Dept Urol, San Francisco, CA 94143 USA.
   [Zonderman, A. B.] NIA, Lab Personal & Cognit, NIH, Baltimore, MD 21224 USA.
RP David, SP (reprint author), Stanford Univ, Sch Med, Div Gen Med Disciplines, Ctr Educ & Res Family & Community Med, 1215 Welch Rd, Stanford, CA 93405 USA.
EM spdavid@stanford.edu; ejorgenson@gallo.ucsf.edu; haiman@usc.edu
RI Bandera, Elisa/M-4169-2014; Singleton, Andrew/C-3010-2009; Buxbaum,
   Sarah/E-1970-2013; 
OI Bandera, Elisa/0000-0002-8789-2755; Thacker, Evan/0000-0002-3813-0885;
   David, Sean/0000-0002-4922-2603; Buxbaum, Sarah/0000-0002-4886-3564;
   Bergen, Andrew/0000-0002-1237-7644; Wessel,
   Jennifer/0000-0002-7031-0085; Zonderman, Alan B/0000-0002-6523-4778
FU NCATS NIH HHS [UL1 TR000124, UL1 TR000150]; NCI NIH HHS [P30 CA015704,
   P50 CA058223, R01 CA092447]; NCRR NIH HHS [UL1 RR025741]; NHLBI NIH HHS
   [R01 HL105756]; NIDA NIH HHS [R21 DA027331, U01 DA020830]; NIEHS NIH HHS
   [P30 ES010126]; NIMHD NIH HHS [P20 MD006899]; WHI NIH HHS [N01 WH032108,
   N01 WH022110, N01 WH032105, N01 WH032109, N01 WH032111, N01 WH32115]
NR 60
TC 35
Z9 36
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD MAY
PY 2012
VL 2
AR e119
DI 10.1038/tp.2012.41
PG 8
WC Psychiatry
SC Psychiatry
GA 062CC
UT WOS:000312895700012
PM 22832964
ER

PT J
AU Kamboh, MI
   Demirci, FY
   Wang, X
   Minster, RL
   Carrasquillo, MM
   Pankratz, VS
   Younkin, SG
   Saykin, AJ
   Jun, G
   Baldwin, C
   Logue, MW
   Buros, J
   Farrer, L
   Pericak-Vance, MA
   Haines, JL
   Sweet, RA
   Ganguli, M
   Feingold, E
   DeKosky, ST
   Lopez, OL
   Barmada, MM
AF Kamboh, M. I.
   Demirci, F. Y.
   Wang, X.
   Minster, R. L.
   Carrasquillo, M. M.
   Pankratz, V. S.
   Younkin, S. G.
   Saykin, A. J.
   Jun, G.
   Baldwin, C.
   Logue, M. W.
   Buros, J.
   Farrer, L.
   Pericak-Vance, M. A.
   Haines, J. L.
   Sweet, R. A.
   Ganguli, M.
   Feingold, E.
   DeKosky, S. T.
   Lopez, O. L.
   Barmada, M. M.
CA Alzheimers Dis Neuroimaging Initia
TI Genome-wide association study of Alzheimer's disease
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Article
DE Alzheimer's disease; genome-wide association study; meta-analysis;
   PPP1R3B; PTK2B; single-nucleotide polymorphisms
ID IDENTIFIES VARIANTS; COMMON VARIANTS; APOE; SUSCEPTIBILITY; POPULATION;
   RISK; LOCI; CLU; POLYMORPHISM; PROGRESS
AB In addition to apolipoprotein E (APOE), recent large genome-wide association studies (GWASs) have identified nine other genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7) for late-onset Alzheimer's disease (LOAD). However, the genetic effect attributable to known loci is about 50%, indicating that additional risk genes for LOAD remain to be identified. In this study, we have used a new GWAS data set from the University of Pittsburgh (1291 cases and 938 controls) to examine in detail the recently implicated nine new regions with Alzheimer's disease (AD) risk, and also performed a meta-analysis utilizing the top 1% GWAS single-nucleotide polymorphisms (SNPs) with P < 0.01 along with four independent data sets (2727 cases and 3336 controls) for these SNPs in an effort to identify new AD loci. The new GWAS data were generated on the Illumina Omni1-Quad chip and imputed at similar to 2.5 million markers. As expected, several markers in the APOE regions showed genome-wide significant associations in the Pittsburg sample. While we observed nominal significant associations (P < 0.05) either within or adjacent to five genes (PICALM, BIN1, ABCA7, MS4A4/MS4A6E and EPHA1), significant signals were observed 69-180 kb outside of the remaining four genes (CD33, CLU, CD2AP and CR1). Meta-analysis on the top 1% SNPs revealed a suggestive novel association in the PPP1R3B gene (top SNP rs3848140 with P = 3.05E-07). The association of this SNP with AD risk was consistent in all five samples with a meta-analysis odds ratio of 2.43. This is a potential candidate gene for AD as this is expressed in the brain and is involved in lipid metabolism. These findings need to be confirmed in additional samples. Translational Psychiatry (2012) 2, e117; doi:10.1038/tp.2012.45; published online 15 May 2012
C1 [Kamboh, M. I.; Demirci, F. Y.; Wang, X.; Minster, R. L.; Feingold, E.; Barmada, M. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Kamboh, M. I.; Lopez, O. L.] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA.
   [Kamboh, M. I.; Sweet, R. A.; Ganguli, M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
   [Carrasquillo, M. M.; Pankratz, V. S.; Younkin, S. G.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA.
   [Saykin, A. J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN USA.
   [Saykin, A. J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA.
   [Jun, G.; Baldwin, C.; Logue, M. W.; Buros, J.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Genet Program, Boston, MA 02215 USA.
   [Jun, G.; Logue, M. W.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
   [Jun, G.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Opthalmol, Boston, MA 02215 USA.
   [Baldwin, C.] Boston Univ, Sch Med & Publ Hlth, Ctr Human Genet, Boston, MA 02215 USA.
   [Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Neurol, Boston, MA 02215 USA.
   [Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
   [Pericak-Vance, M. A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
   [Haines, J. L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   [Sweet, R. A.; Lopez, O. L.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
   [Sweet, R. A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
   [DeKosky, S. T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA.
   [DeKosky, S. T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
RP Kamboh, MI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
EM kamboh@pitt.edu
RI Haines, Jonathan/C-3374-2012; Saykin, Andrew/A-1318-2007; MORAN,
   CATHERINE/C-9539-2015; 
OI Feingold, Eleanor/0000-0003-2898-6484; Saykin,
   Andrew/0000-0002-1376-8532; Logue, Mark/0000-0001-9347-7892; Farrer,
   Lindsay/0000-0001-5533-4225; Buros, Jacqueline/0000-0001-9588-4889;
   Demirci, F. Yesim/0000-0001-6907-9843; Kamboh, M.
   Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460
FU National Institute on Aging [AG030653, AG005133, AG027224, AG07562,
   AG023651, AG18023]; Alzheimer's Disease Neuroimaging Initiative (ADNI)
   (National Institutes of Health Grant) [U01 AG024904, RC2 AG036535];
   National Institute of Biomedical Imaging and Bioengineering; Canadian
   Institutes of Health Research; NIH [P30 AG010129, K01 AG030514]; Dana
   Foundation; NIA National Cell Repository for Alzheimer's Disease (NCRAD)
   [U24 AG021886];  [R01 AG19771];  [P30 AG10133]
FX This study was supported by the National Institute on Aging grants
   AG030653 (MIK), AG005133 (ADRC), AG027224 (RAS), AG07562 and AG023651
   (MG) and AG18023 (SGY). We thank Drs Peter Gregersen and Annette Lee of
   the Feinstein Institute of Medical Research where the genotyping of the
   discovery sample was performed. We acknowledge Drs Neill R
   Graff-Radford, Dennis W Dickson and Ronald C Petersen for their key
   contribution in collecting the Mayo replication sample. One of the
   replication data sets was funded by the Alzheimer's Disease Neuroimaging
   Initiative (ADNI) (National Institutes of Health Grant U01 AG024904; RC2
   AG036535). ADNI is funded by the National Institute on Aging, the
   National Institute of Biomedical Imaging and Bioengineering, and through
   generous contributions from the following: Abbott; Alzheimer's
   Association; Alzheimer's Drug Discovery Foundation; Amorfix Life
   Sciences; AstraZeneca; Bayer HealthCare; BioClinica; Biogen Idec;
   Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly and
   Company; F Hoffmann-La Roche and its affiliated company Genentech; GE
   Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research
   & Development, LLC.; Johnson & Johnson Pharmaceutical Research &
   Development LLC.; Medpace; Merck & Co.; Meso Scale Diagnostics, LLC.;
   Novartis Pharmaceuticals Corporation; Pfizer; Servier; Synarc; and
   Takeda Pharmaceutical Company. The Canadian Institutes of Health
   Research is providing funds to support ADNI clinical sites in Canada.
   Private sector contributions are facilitated by the Foundation for the
   National Institutes of Health (http://www.fnih.org). The grantee
   organization is the Northern California Institute for Research and
   Education, and the study is coordinated by the Alzheimer's Disease
   Cooperative Study at the University of California, San Diego. ADNI data
   are disseminated by the Laboratory for Neuro Imaging at the University
   of California, Los Angeles. This research was also supported by NIH
   grants P30 AG010129, K01 AG030514 and the Dana Foundation. Some sample
   collection was supported by the NIA National Cell Repository for
   Alzheimer's Disease (NCRAD; U24 AG021886) and additional support for
   data analysis was provided by R01 AG19771 and P30 AG10133.. We thank the
   following people for their contributions to the ADNI genotyping project:
   Tatiana Foroud, Kelley Faber, Li Shen, Steven G Potkin, Matthew J
   Huentelman, David W Craig, Sungeun Kim, Kwangsik Nho and Bryan M
   DeChairo.
NR 30
TC 72
Z9 73
U1 7
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD MAY
PY 2012
VL 2
AR e117
DI 10.1038/tp.2012.45
PG 7
WC Psychiatry
SC Psychiatry
GA 062CC
UT WOS:000312895700010
PM 22832961
ER

PT J
AU Roh, S
   Evins, AE
AF Roh, Sungwon
   Evins, A. Eden
TI Possible role of nicotine for the treatment of mild cognitive impairment
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE continuous performance test; mild cognitive impairment; nicotine;
   randomized controlled trial
ID ALZHEIMERS-DISEASE; DOUBLE-BLIND; VITAMIN-E; PERFORMANCE; DONEPEZIL;
   DISORDER; ADULTS; MCI
AB Expert Rev. Neurother. 12(5), 531-533 (2012) There have been several drug trials in recent years investigating the efficacy of commonly used Alzheimer's disease therapies for symptoms of mild cognitive impairment (MCI). However, there are no US FDA-approved pharmacological treatments for MCI. As the incidence rates of MCI are considerable, it is clear that better treatments for MCI need to be developed. The reviewed paper presents new data on a pilot clinical trial which shows that transdermal nicotine treatment for 6 months improved cognitive performance in subjects with amnestic MCI. Further studies will possibly bring us wider usage of nicotine for individuals with cognitive dysfunction.
C1 [Roh, Sungwon; Evins, A. Eden] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Ctr Addict Med, Boston, MA 02114 USA.
RP Evins, AE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Ctr Addict Med, Boston, MA 02114 USA.
EM a_eden_evins@hms.harvard.edu
NR 22
TC 0
Z9 0
U1 0
U2 7
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD MAY
PY 2012
VL 12
IS 5
BP 531
EP 533
DI 10.1586/ERN.12.36
PG 3
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 056FP
UT WOS:000312474100010
PM 22550981
ER

PT J
AU Rice, TR
   Sher, L
AF Rice, Timothy R.
   Sher, Leo
TI Suicidal behavior in war veterans
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE OEF/OIF; Operation Enduring Freedom/Operation Iraqi Freedom;
   post-traumatic mood disorder; suicidal behavior; suicidal ideation;
   suicide; suicide risk factors; traumatic brain injury; veteran
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; RANDOMIZED
   CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; VIETNAM THEATER VETERANS;
   MENTAL-HEALTH PROBLEMS; PERSIAN-GULF-WAR; TERM-FOLLOW-UP; US-AIR-FORCE;
   RISK-FACTORS
AB Expert Rev. Neurother. 12(5), 611-624 (2012) Military veterans represent a unique, heterogeneous population with suicide prevalence rates, risk factors and preventative management needs that differ from those of the rest of community. Veterans worldwide receive high proportions of their healthcare from community providers, and sensitivity to these distinct needs is required for optimized care. An overview of the recent prevalence-study literature, with a focus upon statistical design, is presented in order to provide a critical orientation within this field with high levels of popular media attention. Attention to psychiatric comorbidity, subthreshold symptomology, select signature disorders of contemporary conflicts (namely, post-traumatic stress disorder and traumatic brain injury), and veteran life narratives before, within and beyond military service will guide our review of risk factor assessment and management strategies. This critical review of the literature provides an overview of this active field of neuropsychiatric research with a select focus upon these topics of special interest.
C1 [Rice, Timothy R.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
   [Rice, Timothy R.; Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA.
EM timothy.rice@mssm.edu
NR 164
TC 7
Z9 7
U1 14
U2 27
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD MAY
PY 2012
VL 12
IS 5
BP 611
EP 624
DI 10.1586/ERN.12.31
PG 14
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 056FP
UT WOS:000312474100018
PM 22550989
ER

PT J
AU Thliveris, AT
   Clipson, L
   Sommer, LL
   Schoenike, BA
   Hasenstein, JR
   Schlamp, CL
   Alexander, CM
   Newton, MA
   Dove, WF
   Amos-Landgraf, JM
AF Thliveris, Andrew T.
   Clipson, Linda
   Sommer, Lacy L.
   Schoenike, Barry A.
   Hasenstein, Jason R.
   Schlamp, Cassandra L.
   Alexander, Caroline M.
   Newton, Michael A.
   Dove, William F.
   Amos-Landgraf, James M.
TI Regulated Expression of Chromobox Homolog 5 Revealed in Tumors of
   Apc(Min/+) ROSA11 Gene Trap Mice
SO G3-GENES GENOMES GENETICS
LA English
DT Article
DE WNT signaling; cancer progenitor; lacZ reporter; Cre drivers
ID UCSC GENOME BROWSER; SEQUENCE DATABASE; STEM-CELLS; MOUSE;
   HETEROCHROMATIN; TRANSCRIPTS; HP1; EUKARYOTES; NEOPLASIA; ADENOMAS
AB The gene-trap lacZ reporter insertion, ROSA11, in the Cbx5 mouse gene illuminates the regulatory complexity of this locus in Apc(Min/+) mice. The insertion site of the beta-Geo gene-trap element lies in the 24-kb intron proximal to the coding region of Cbx5. Transcript analysis indicates that two promoters for Cbx5 flank this insertion site. Heterozygotes for the insertion express lacZ widely in fetal tissues but show limited expression in adult tissues. In the intestine, strong expression is limited to proliferative zones of crypts and tumors. Homozygotes for ROSA11, found at a lower than Mendelian frequency, express reduced levels of the coding region transcript in normal tissues, using a downstream promoter. Analysis via real-time polymerase chain reaction indicates that the upstream promoter is the dominant promoter in normal epithelium and tumors. Bioinformatic analysis of the Cbx5 locus indicates that WNT and its target transcription factor MYC can establish a feedback loop that may play a role in regulating the self-renewal of the normal intestinal epithelium and its tumors.
C1 [Clipson, Linda; Hasenstein, Jason R.; Alexander, Caroline M.; Dove, William F.; Amos-Landgraf, James M.] Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.
   [Thliveris, Andrew T.; Sommer, Lacy L.; Schlamp, Cassandra L.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Schoenike, Barry A.] Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA.
   [Newton, Michael A.] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA.
   [Newton, Michael A.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA.
   [Dove, William F.] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.
   [Thliveris, Andrew T.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI 53705 USA.
RP Dove, WF (reprint author), Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.
EM dove@oncology.wisc.edu
RI Amos-Landgraf, James/K-9288-2013
OI Amos-Landgraf, James/0000-0003-2535-7746
FU National Cancer Institute [R37 CA63677, U01 CA84227]; Helmerich Chair
   from the Retina Research Foundation
FX We thank Phil Soriano for his generous gift of the R11 strain; Karen
   Gould for the initial discovery of the R11 intestinal expression
   pattern; Alexandra Shedlovsky for making the congenic strain; Ryan Burch
   and Dawn Albrecht for assistance with experiments; and Jane Weeks,
   Harlene Edwards, and other members of the Histotechology Facility for
   expert support. This study was supported by National Cancer Institute
   grants R37 CA63677 and U01 CA84227 to WFD and the Helmerich Chair from
   the Retina Research Foundation to A.T.T. This is publication 3649 from
   the Laboratory of Genetics, University of Wisconsin-Madison.
NR 41
TC 3
Z9 3
U1 0
U2 3
PU GENETICS SOC AM
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 2160-1836
J9 G3-GENES GENOM GENET
JI G3-Genes Genomes Genet.
PD MAY 1
PY 2012
VL 2
IS 5
BP 569
EP 578
DI 10.1534/g3.112.002436
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 055YH
UT WOS:000312453500006
PM 22670227
ER

PT J
AU Udeshi, ND
   Mani, DR
   Eisenhaure, T
   Mertins, P
   Jaffe, JD
   Clauser, KR
   Hacohen, N
   Carr, SA
AF Udeshi, Namrata D.
   Mani, D. R.
   Eisenhaure, Thomas
   Mertins, Philipp
   Jaffe, Jacob D.
   Clauser, Karl R.
   Hacohen, Nir
   Carr, Steven A.
TI Methods for Quantification of in vivo Changes in Protein Ubiquitination
   following Proteasome and Deubiquitinase Inhibition
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MASS-SPECTROMETRY; DRUG TARGETS; DEGRADATION; PHOSPHORYLATION;
   IDENTIFICATION; PROTEOMICS; EXPRESSION; ENRICHMENT; PEPTIDES; HISTONES
AB Ubiquitination plays a key role in protein degradation and signal transduction. Ubiquitin is a small protein modifier that is adducted to lysine residues by the combined function of E1, E2, and E3 enzymes and is removed by deubiquitinating enzymes. Characterization of ubiquitination sites is important for understanding the role of this modification in cellular processes and disease. However, until recently, large-scale characterization of endogenous ubiquitination sites has been hampered by the lack of efficient enrichment techniques. The introduction of antibodies that specifically recognize peptides with lysine residues that harbor a di-glycine remnant (K-epsilon-GG) following tryptic digestion has dramatically improved the ability to enrich and identify ubiquitination sites from cellular lysates. We used this enrichment technique to study the effects of proteasome inhibition by MG-132 and deubiquitinase inhibition by PR-619 on ubiquitination sites in human Jurkat cells by quantitative high performance mass spectrometry. Minimal fractionation of digested lysates prior to immunoaffinity enrichment increased the yield of K-epsilon-GG peptides three-to fourfold resulting in detection of up to similar to 3300 distinct K-GG peptides in SILAC triple encoded experiments starting from 5 mg of protein per label state. In total, we identify 5533 distinct K-epsilon-GG peptides of which 4907 were quantified in this study, demonstrating that the strategy presented is a practical approach to perturbational studies in cell systems. We found that proteasome inhibition by MG-132 and deubiquitinase inhibition by PR-619 induces significant changes to the ubiquitin landscape, but that not all ubiquitination sites regulated by MG-132 and PR-619 are likely substrates for the ubiquitin-proteasome system. Additionally, we find that the proteasome and deubiquitinase inhibitors studied induced only minor changes in protein expression levels regardless of the extent of regulation induced at the ubiquitin site level. We attribute this finding to the low stoichiometry of the majority ubiquitination sites identified in this study. Molecular & Cellular Proteomics 11: 10.1074/mcp.M111.016857, 148-159, 2012.
C1 [Udeshi, Namrata D.; Mani, D. R.; Eisenhaure, Thomas; Mertins, Philipp; Jaffe, Jacob D.; Clauser, Karl R.; Hacohen, Nir; Carr, Steven A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Eisenhaure, Thomas; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA.
RP Carr, SA (reprint author), Broad Inst MIT & Harvard, 7 Cambridge Ctr, Cambridge, MA 02142 USA.
EM scarr@broad.mit.edu
FU Broad Institute of MIT and Harvard; National Cancer Institute
   [U24CA160034]; National Heart Lung and Blood Institute
   [HHSN268201000033C, R01HL096738]
FX Support for this work was provided in part by the Broad Institute of MIT
   and Harvard and by grants from the National Cancer Institute
   (U24CA160034) and National Heart Lung and Blood Institute
   (HHSN268201000033C and R01HL096738) to SAC. We would like to acknowledge
   James Strickler of LifeSensors Inc. for helpful discussions.
NR 42
TC 66
Z9 67
U1 2
U2 27
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAY
PY 2012
VL 11
IS 5
BP 148
EP 159
DI 10.1074/mcp.M111.016857
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 974BS
UT WOS:000306405400013
PM 22505724
ER

PT J
AU Schilling, B
   Rardin, MJ
   MacLean, BX
   Zawadzka, AM
   Frewen, BE
   Cusack, MP
   Sorensen, DJ
   Bereman, MS
   Jing, EX
   Wu, CC
   Verdin, E
   Kahn, CR
   MacCoss, MJ
   Gibson, BW
AF Schilling, Birgit
   Rardin, Matthew J.
   MacLean, Brendan X.
   Zawadzka, Anna M.
   Frewen, Barbara E.
   Cusack, Michael P.
   Sorensen, Dylan J.
   Bereman, Michael S.
   Jing, Enxuan
   Wu, Christine C.
   Verdin, Eric
   Kahn, C. Ronald
   MacCoss, Michael J.
   Gibson, Bradford W.
TI Platform-independent and Label-free Quantitation of Proteomic Data Using
   MS1 Extracted Ion Chromatograms in Skyline APPLICATION TO PROTEIN
   ACETYLATION AND PHOSPHORYLATION
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MASS-SPECTROMETRY; BREAST-CANCER; TARGETED PROTEOMICS; PEPTIDES;
   SOFTWARE; EXPRESSION; SIRT3; REPRODUCIBILITY; QUANTIFICATION;
   IDENTIFICATION
AB Despite advances in metabolic and postmetabolic labeling methods for quantitative proteomics, there remains a need for improved label-free approaches. This need is particularly pressing for workflows that incorporate affinity enrichment at the peptide level, where isobaric chemical labels such as isobaric tags for relative and absolute quantitation and tandem mass tags may prove problematic or where stable isotope labeling with amino acids in cell culture labeling cannot be readily applied. Skyline is a freely available, open source software tool for quantitative data processing and proteomic analysis. We expanded the capabilities of Skyline to process ion intensity chromatograms of peptide analytes from full scan mass spectral data (MS1) acquired during HPLC MS/MS proteomic experiments. Moreover, unlike existing programs, Skyline MS1 filtering can be used with mass spectrometers from four major vendors, which allows results to be compared directly across laboratories. The new quantitative and graphical tools now available in Skyline specifically support interrogation of multiple acquisitions for MS1 filtering, including visual inspection of peak picking and both automated and manual integration, key features often lacking in existing software. In addition, Skyline MS1 filtering displays retention time indicators from underlying MS/MS data contained within the spectral library to ensure proper peak selection. The modular structure of Skyline also provides well defined, customizable data reports and thus allows users to directly connect to existing statistical programs for post hoc data analysis. To demonstrate the utility of the MS1 filtering approach, we have carried out experiments on several MS platforms and have specifically examined the performance of this method to quantify two important post-translational modifications: acetylation and phosphorylation, in peptidecentric affinity workflows of increasing complexity using mouse and human models. Molecular & Cellular Proteomics 11: 10.1074/mcp.M112.017707, 202-214, 2012.
C1 [MacLean, Brendan X.; Frewen, Barbara E.; Bereman, Michael S.; MacCoss, Michael J.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA.
   [Jing, Enxuan; Kahn, C. Ronald] Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
   [Wu, Christine C.] Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA 15261 USA.
   [Verdin, Eric] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
   [Schilling, Birgit; Rardin, Matthew J.; Zawadzka, Anna M.; Cusack, Michael P.; Sorensen, Dylan J.; Gibson, Bradford W.] Buck Inst Res Aging, Novato, CA 94945 USA.
RP MacCoss, MJ (reprint author), Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA.
EM maccoss@uw.edu; bgibson@buckinstitute.org
OI Verdin, Eric/0000-0003-3703-3183
FU National Institutes of Health [PL1 AG032118, R24 DK085610, T32AG000266,
   R01 RR032708, P41 RR011823]; National Cancer Institute which is part of
   the National Cancer Institute Clinical Proteomic Technologies for Cancer
   initiative [U24 CA126477]; NCRR [S10 RR024615]; AB SCIEX
FX This work was supported by National Institutes of Health Grants PL1
   AG032118 (to B. W. G.), R24 DK085610 (to E. V.), T32AG000266 (to M. J.
   R.), R01 RR032708 (to M. J. M.), and P41 RR011823 (to M. J. M.) and by
   National Cancer Institute Grant U24 CA126477 (to B. W. G., subcontract
   to UCSF), which is part of the National Cancer Institute Clinical
   Proteomic Technologies for Cancer initiative. This work was also
   supported in part by NCRR Shared Instrumentation Grant S10 RR024615 (to
   B. W. G.) and by funds from AB SCIEX for evaluation of the TripleTOF
   5600 at the Buck Institute. The costs of publication of this article
   were defrayed in part by the payment of page charges. This article must
   therefore be hereby marked "advertisement" in accordance with 18 U.S.C.
   Section 1734 solely to indicate this fact.
NR 45
TC 136
Z9 138
U1 8
U2 46
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAY
PY 2012
VL 11
IS 5
BP 202
EP 214
DI 10.1074/mcp.M112.017707
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 974BS
UT WOS:000306405400017
PM 22454539
ER

PT J
AU Kalim, S
   Tamez, H
   Wenger, J
   Ankers, E
   Berg, A
   Karumanchi, A
   Thadhani, R
AF Kalim, Sahir
   Tamez, Hector
   Wenger, Julia
   Ankers, Elizabeth
   Berg, Anders
   Karumanchi, Ananth
   Thadhani, Ravi
TI PROTEIN CARBAMYLATION AND ERYTHROPOIETIN RESISTANCE IN END STAGE KIDNEY
   DISEASE
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Meeting Abstract
CT 49th Congress of the
   European-Renal-Association/European-Dialysis-and-Transplant-Association
   (ERA-EDTA)
CY MAY 24-27, 2012
CL Paris, FRANCE
SP European Renal Assoc (ERA), European Dialysis & Transplant Assoc (EDTA)
C1 [Kalim, Sahir; Tamez, Hector; Wenger, Julia; Ankers, Elizabeth; Thadhani, Ravi] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Berg, Anders; Karumanchi, Ananth] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAY
PY 2012
VL 27
SU 2
BP 28
EP 28
PG 1
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 042TU
UT WOS:000311494700061
ER

PT J
AU Emmons, RR
   Cirnigliaro, CM
   Jensen, AM
   Kirshblum, SC
   Bauman, WA
AF Emmons, Racine R.
   Cirnigliaro, Christopher M.
   Jensen, A. Marley
   Kirshblum, Steven C.
   Bauman, William A.
TI Association of Apolipoprotein B with Postprandial Lipemic Responses in
   Persons with Chronic Spinal Cord Injury
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
C1 [Emmons, Racine R.] William Paterson Univ, Wayne, NJ USA.
   [Cirnigliaro, Christopher M.; Jensen, A. Marley; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
   [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2012
VL 44
SU 2
BP 261
EP 261
PG 1
WC Sport Sciences
SC Sport Sciences
GA 027OT
UT WOS:000310363301381
ER

PT J
AU Allsup, K
   Zavin, A
   Arena, R
   Daniels, K
   Davis, S
   Joseph, J
   Lecker, S
   Lazzari, A
   Forman, DE
AF Allsup, Kelly
   Zavin, Alexandra
   Arena, Ross
   Daniels, Karla
   Davis, Samuel
   Joseph, Jacob
   Lecker, Stewart
   Lazzari, Antonio
   Forman, Daniel E.
TI Relationship Between Body Composition and Oxygen Uptake Efficiency Slope
   in Heart Failure Patients
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
C1 [Allsup, Kelly; Zavin, Alexandra; Daniels, Karla; Davis, Samuel; Joseph, Jacob; Lazzari, Antonio; Forman, Daniel E.] VA Boston Healthcare Syst, Boston, MA USA.
   [Arena, Ross] Univ New Mexico, Albuquerque, NM 87131 USA.
   [Lecker, Stewart] Harvard Univ, Sch Med, Boston, MA USA.
RI Arena, Ross/A-3141-2008
OI Arena, Ross/0000-0002-6675-1996
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2012
VL 44
SU 2
BP 501
EP 502
PG 2
WC Sport Sciences
SC Sport Sciences
GA 027OT
UT WOS:000310363303015
ER

PT J
AU Lee, AM
   Engel, LC
   Shah, B
   Liew, G
   Sidhu, MS
   Kalra, M
   Abbara, S
   Brady, TJ
   Hoffmann, U
   Ghoshhajra, BB
AF Lee, Ashley M.
   Engel, Leif-Christopher
   Shah, Baiju
   Liew, Gary
   Sidhu, Manavjot S.
   Kalra, Mannudeep
   Abbara, Suhny
   Brady, Thomas J.
   Hoffmann, Udo
   Ghoshhajra, Brian B.
TI Coronary computed tomography angiography during arrhythmia: Radiation
   dose reduction with prospectively ECG-triggered axial and
   retrospectively ECG-gated helical 128-slice dual-source CT
SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY
LA English
DT Article
DE Coronary computed tomography angiography; Arrhythmia; Radiation dose
   reduction
ID ATRIAL-FIBRILLATION; ARTERY-DISEASE; ACCURACY
AB BACKGROUND: Arrhythmia during coronary computed tomography angiography (coronary CTA) acquisition increases the risk of nondiagnostic segments and high radiation exposure. An advanced arrhythmia rejection algorithm for prospectively electrocardiogram (ECG)-triggered axial scans using dual-source CT (DSCT) examinations has recently been reported.
   OBJECTIVE: We compared image quality and effective dose at DSCT examinations using prospectively ECG-triggered axial scanning with advanced arrhythmia rejection software (PT-AAR) versus retrospectively ECG-gated helical scanning with tube-current modulation (RG-TCM) during arrhythmia.
   METHODS: This was a retrospective case-control study of 90 patients (43 PT-AAR, 47 RG-TCM) with arrhythmia (defined as heart rate variability [HRV] > 10 beats/min during data acquisition) referred for physician-supervised coronary CTA between April 2010 and September 2011. A subset of 22 cases matched for body mass index, HR, HRV, and other scan parameters was identified. Subjective image quality (4-point scale) and effective dose (dose length product method) were compared.
   RESULTS: PT-AAR was associated with lower effective close than RG-TCM (4.1 vs 12.6 mSv entire cohort and 4.3 vs 9.1 mSv matched controls; both P < 0.01). Image quality scores were excellent in both groups (3.9 PT-AAR vs 3.6 RG-TCM) and nondiagnostic segment rates were low (0.1% vs 0.6%). Significantly higher image quality scores were found with PT-AAR in the entire cohort (P < 0.05), and in matched controls with high HRV > 28 beats/min (P < 0.05).
   CONCLUSIONS: In patients with variable heart rates, prospectively ECG-triggered axial DSCT with arrhythmia rejection algorithm is feasible and can decrease radiation exposure by similar to 50% versus retrospectively ECG-gated helical DSCT, with preserved image quality. (C) 2012 Society of Cardiovascular Computed Tomography. All rights reserved.
C1 [Lee, Ashley M.] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Div Cardiol, Boston, MA 02114 USA.
RP Lee, AM (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, 165 Cambridge St,Ste 400, Boston, MA 02114 USA.
EM amlee@partners.org
NR 23
TC 16
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-5925
J9 J CARDIOVASC COMPUT
JI J. Cardiovasc. Comput. Tomogr.
PD MAY-JUN
PY 2012
VL 6
IS 3
BP 172
EP 183
DI 10.1016/j.jcct.2012.04.003
PG 12
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 035HM
UT WOS:000310934000005
PM 22542280
ER

PT J
AU Habener, JF
   Stanojevic, V
AF Habener, Joel F.
   Stanojevic, Violeta
TI alpha-cell role in beta-cell generation and regeneration
SO ISLETS
LA English
DT Review
DE islet progenitor cells; pro-alpha-cells; de-differentiation;
   trans-differentiation; beta-cell regeneration
ID GLUCAGON-LIKE PEPTIDE-1; RECEPTOR KNOCKOUT MICE; EMBRYONIC STEM-CELLS;
   PROHORMONE CONVERTASE 1/3; HUMAN PANCREATIC-ISLETS; INSULIN-PRODUCING
   CELLS; ADULT-MOUSE PANCREAS; ENDOCRINE PANCREAS; TRANSCRIPTION FACTOR;
   GLUCOSE-TOLERANCE
AB This review considers the role of alpha-cells in beta-cell generation and regeneration. We present recent evidence obtained from lineage-tracing studies showing that alpha-cells can serve as progenitors of beta-cells and present a hypothetical model how injured beta-cells might activate alpha-cells in adult islets to promote beta-cell regeneration. beta-cells appear to arise by way of their trans-differentiation from undifferentiated a progenitor cells, pro-alpha-cells, both during embryonic development of the islets and in the adult pancreas in response to beta-cell injuries. Plasticity of alpha-cells is endowed by the expression of the gene encoding proglucagon, a prohormone that can give rise to glucagon and glucagon-like peptides (GLPs). The production of glucagon from proglucagon is characteristic of fully-differentiated alpha-cells whereas GLP-1 becomes a product of undifferentiated alpha-cells. GLP-1, a cell growth and survival factor, is proposed to promote the expansion of undifferentiated pro-alpha-cells during development. beta-cells arise from pro-alpha-cells by a change in the relative amounts of the transcription factors Arx and Pax4, master regulators of the alpha- and beta-cell lineages, respectively. A paracrine/autocrine model is proposed whereby injuries of beta-cells in adult islets induce the production and release of factors, such as stromal cell-derived factor-1, that cause the dedifferentiation of adjacent alpha-cells into pro-alpha-cells. Pro-alpha-cells produce GLP-1 and its receptor that renders them competent to trans-differentiate into beta-cells. The trans-differentiation of pro-alpha-cells into beta-cells provides a potentially exploitable mechanism for the regeneration of beta-cells in individuals with type 1 diabetes.
C1 [Habener, Joel F.; Stanojevic, Violeta] Massachusetts Gen Hosp, Lab Mol Endocrinol, Boston, MA 02114 USA.
RP Habener, JF (reprint author), Massachusetts Gen Hosp, Lab Mol Endocrinol, Boston, MA 02114 USA.
EM jhabener@partners.org
FU Juvenile Diabetes Research Foundation; American Diabetes Association;
   Novo Nordisk
FX We thank Vishal Saxena for careful reading and suggestions for the
   manuscript. The concepts and studies described were supported in part by
   grants from the Juvenile Diabetes Research Foundation, the American
   Diabetes Association and Novo Nordisk.
NR 133
TC 23
Z9 25
U1 0
U2 12
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1938-2014
J9 ISLETS
JI Islets
PD MAY-JUN
PY 2012
VL 4
IS 3
BP 188
EP 198
DI 10.4161/isl.20500
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 983LD
UT WOS:000307119900002
PM 22847495
ER

PT J
AU Hula, WD
   Fergadiotis, G
   Martin, N
AF Hula, William D.
   Fergadiotis, Gerasimos
   Martin, Nadine
TI Model Choice and Sample Size in Item Response Theory Analysis of Aphasia
   Tests
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Article
DE aphasia; psychometrics; assessment
ID CONFIRMATORY FACTOR-ANALYSIS; RASCH MODEL; MONTE-CARLO; ABILITY;
   REHABILITATION; VALIDITY; OUTCOMES; CURVES; LIKERT
AB Purpose: The purpose of this study was to identify the most appropriate item response theory (IRT) measurement model for aphasia tests requiring 2-choice responses and to determine whether small samples are adequate for estimating such models.
   Method: Pyramids and Palm Trees (Howard & Patterson, 1992) test data that had been collected from individuals with aphasia were analyzed, and the resulting item and person estimates were used to develop simulated test data for 3 sample size conditions. The simulated data were analyzed using a standard 1-parameter logistic (1-PL) model and 3 models that accounted for the influence of guessing: augmented 1-PL and 2-PL models and a 3-PL model. The model estimates obtained from the simulated data were compared to their known true values.
   Results: With small and medium sample sizes, an augmented 1-PL model was the most accurate at recovering the known item and person parameters; however, no model performed well at any sample size. Follow-up simulations confirmed that the large influence of guessing and the extreme easiness of the items contributed substantially to the poor estimation of item difficulty and person ability.
   Conclusion: Incorporating the assumption of guessing into IRT models improves parameter estimation accuracy, even for small samples. However, caution should be exercised in interpreting scores obtained from easy 2-choice tests, regardless of whether IRT modeling or percentage correct scoring is used.
C1 [Hula, William D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
   [Fergadiotis, Gerasimos] Arizona State Univ, Tempe, AZ USA.
   [Martin, Nadine] Temple Univ, Philadelphia, PA 19122 USA.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM william.hula@va.gov
FU Veterans Affairs Rehabilitation Research & Development Career
   Development Award [C7476W]; VA Pittsburgh Healthcare System Geriatric
   Research Education and Clinical Center; National Institutes of Health
   (National Institute on Deafness and Other Communication Disorders)
   [DC01924-15]
FX This research was supported by Veterans Affairs Rehabilitation Research
   & Development Career Development Award C7476W, the VA Pittsburgh
   Healthcare System Geriatric Research Education and Clinical Center, and
   Grant DC01924-15 from the National Institutes of Health (National
   Institute on Deafness and Other Communication Disorders) to Temple
   University (PI N. Martin). The authors also gratefully acknowledge the
   support and assistance of Heather Harris Wright and Michelene
   Kalinyak-Fliszar. The contents of this paper do not represent the views
   of the Department of Veterans Affairs or the U.S. Government.
NR 52
TC 1
Z9 1
U1 0
U2 5
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY 1
PY 2012
VL 21
IS 2
BP S38
EP S50
DI 10.1044/1058-0360(2011/11-0090)
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 019SZ
UT WOS:000309760900003
PM 22230175
ER

PT J
AU Kiran, S
   Caplan, D
   Sandberg, C
   Levy, J
   Berardino, A
   Ascenso, E
   Villard, S
   Tripodis, Y
AF Kiran, Swathi
   Caplan, David
   Sandberg, Chaleece
   Levy, Joshua
   Berardino, Alex
   Ascenso, Elsa
   Villard, Sarah
   Tripodis, Yorghos
TI Development of a Theoretically Based Treatment for Sentence
   Comprehension Deficits in Individuals With Aphasia
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Article
DE rehabilitation; aphasia; sentence comprehension; treatment
ID AGRAMMATIC APHASIA; SYNTACTIC COMPREHENSION; PROCESSING DEFICITS;
   MOVEMENT STRUCTURES; COMPLEXITY; DISORDERS; LANGUAGE; THERAPY;
   DETERMINANTS; ASSIGNMENT
AB Purpose: Two new treatments, 1 based on sentence to picture matching (SPM) and the other on object manipulation (OM), that train participants on the thematic roles of sentences using pictures or by manipulating objects were piloted.
   Method: Using a single-subject multiple-baseline design, sentence comprehension was trained on the affected sentence type in 1 task-related protocol in 15 participants with aphasia. The 2 tasks were SPM and OM; the treatment stimuli were object relatives, object clefts, passives, and unaccusatives, as well as two control structures-object relatives with a complex noun phrase (NP) and active sentences with three NPs.
   Results: The criteria for efficacious treatment was an increase in the level of performance from the pretreatment probes to the posttreatment probes for the treated structure such that accuracy rose from at or below chance to above chance and either (a) accuracy rose by 33% or (b) the effect size was 2.6. Based on these criteria, the success rate for training the target structure was 2/6 participants in the SPM condition and 4/7 participants in the OM condition.
   Conclusion: The outcome of this study illustrates the utility of this theoretically motivated and efficacious treatment for sentence comprehension deficits in individuals with aphasia.
C1 [Kiran, Swathi; Caplan, David; Sandberg, Chaleece; Levy, Joshua; Berardino, Alex; Ascenso, Elsa; Villard, Sarah; Tripodis, Yorghos] Boston Univ, Boston, MA 02215 USA.
   [Caplan, David; Levy, Joshua] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kiran, S (reprint author), Boston Univ, Boston, MA 02215 USA.
EM kirans@bu.edu
RI Kiran, S/B-1892-2013; 
OI Tripodis, Yorghos/0000-0003-2190-7608
FU National Institute on Deafness and Other Communication Disorders
   [1R21DC010461-01]
FX This project was funded by Grant 1R21DC010461-01 from the National
   Institute on Deafness and Other Communication Disorders. The authors
   thank Marissa Simms, Rebecca Hufford, and Balaji Rangarathnam for their
   assistance in data collection and Jennifer Richardson for her assistance
   in data analysis.
NR 45
TC 3
Z9 3
U1 0
U2 16
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY 1
PY 2012
VL 21
IS 2
BP S88
EP S102
DI 10.1044/1058-0360(2012/11-0106)
PG 15
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 019SZ
UT WOS:000309760900006
PM 22411773
ER

PT J
AU Levy, J
   Hoover, E
   Waters, G
   Kiran, S
   Caplan, D
   Berardino, A
   Sandberg, C
AF Levy, Joshua
   Hoover, Elizabeth
   Waters, Gloria
   Kiran, Swathi
   Caplan, David
   Berardino, Alex
   Sandberg, Chaleece
TI Effects of Syntactic Complexity, Semantic Reversibility, and
   Explicitness on Discourse Comprehension in Persons With Aphasia and in
   Healthy Controls
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Article
DE aphasia; discourse analysis; syntax; functional communication assessment
ID LANGUAGE
AB Purpose: Prior studies of discourse comprehension have concluded that the deficits of persons with aphasia (PWA) in syntactically based comprehension of sentences in isolation are not predictive of deficits in comprehension of sentences in discourse (Brookshire & Nicholas, 1984; Caplan & Evans, 1990). However, these studies used semantically constrained sentences in discourse, which do not require syntactic analysis to be understood. A discourse task was developed to assess the effect of syntactic complexity, among other factors, on discourse comprehension in PWA.
   Method: Thirty-eight PWA and 30 neurologically healthy control participants were presented with passages that contained 2-3 semantically reversible sentences that were either syntactically simple or syntactically complex. The passages were presented auditorily, and comprehension was assessed with the auditory and written presentation of 4 multiple-choice questions immediately following each passage.
   Results: Passages with syntactically simple sentences were better understood than passages with syntactically complex sentences. Moreover, semantically constrained sentences were more likely to be accurately interpreted than semantically reversible sentences. Comprehension accuracy on our test correlated positively with comprehension accuracy on an existing test.
   Conclusion: The presence of semantically reversible, syntactically complex sentences in a passage affects comprehension of the passage in both PWA and neurologically healthy individuals.
C1 [Levy, Joshua; Hoover, Elizabeth; Waters, Gloria; Kiran, Swathi; Caplan, David; Berardino, Alex; Sandberg, Chaleece] Boston Univ, Boston, MA 02215 USA.
   [Levy, Joshua] Univ Massachusetts Amherst, Amherst, MA USA.
   [Levy, Joshua; Caplan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Caplan, D (reprint author), Boston Univ, Boston, MA 02215 USA.
EM dcaplan@partners.org
RI Kiran, S/B-1892-2013
FU National Institute on Deafness and Other Communication Disorders
   [DC010461]
FX This research was supported by National Institute on Deafness and Other
   Communication Disorders Grant DC010461. The authors thank Elsa Ascenco,
   Rebecca Hufford, Balaji Rangarathnam, Daisy Sapolsky, and Marissa Simms
   for their assistance in data collection.
NR 26
TC 5
Z9 5
U1 0
U2 14
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY 1
PY 2012
VL 21
IS 2
BP S154
EP S165
DI 10.1044/1058-0360(2012/11-0104)
PG 12
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 019SZ
UT WOS:000309760900011
PM 22355004
ER

PT J
AU Greenup, R
   Camp, M
   Taghian, A
   Buckley, J
   Coopey, S
   Gadd, M
   Hughes, K
   Specht, M
   Smith, B
AF Greenup, Rachel
   Camp, Melissa
   Taghian, Alphonse
   Buckley, Julliette
   Coopey, Suzanne
   Gadd, Michele
   Hughes, Kevin
   Specht, Michelle
   Smith, Barbara
TI Cost Comparison of Radiation Treatment Options After Lumpectomy for
   Breast Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 13th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 02-06, 2012
CL Phoenix, AZ
SP Amer Soc Breast Surg
C1 [Greenup, Rachel; Camp, Melissa; Taghian, Alphonse; Buckley, Julliette; Coopey, Suzanne; Gadd, Michele; Hughes, Kevin; Specht, Michelle; Smith, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2012
VL 19
SU 2
BP 15
EP 15
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 025PH
UT WOS:000310203200018
ER

PT J
AU Buckley, J
   Fernandez, L
   Brachtel, E
   Aftreth, O
   Tang, R
   Michaelson, J
   Coopey, S
   Gadd, M
   Specht, M
   Hughes, K
   Koerner, F
   Smith, B
AF Buckley, Julliette
   Fernandez, Leopoldo
   Brachtel, Elena
   Aftreth, Owen
   Tang, Rong
   Michaelson, James
   Coopey, Suzanne
   Gadd, Michele
   Specht, Michelle
   Hughes, Kevin
   Koerner, Frederick
   Smith, Barbara
TI The Predictive Value of Micro-Computed Tomography for Margin Assessment
   in Breast Cancer Lumpectomy Specimens
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 13th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 02-06, 2012
CL Phoenix, AZ
SP Amer Soc Breast Surg
C1 [Buckley, Julliette; Fernandez, Leopoldo; Brachtel, Elena; Aftreth, Owen; Tang, Rong; Michaelson, James; Coopey, Suzanne; Gadd, Michele; Specht, Michelle; Hughes, Kevin; Koerner, Frederick; Smith, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2012
VL 19
SU 2
BP 30
EP 30
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 025PH
UT WOS:000310203200040
ER

PT J
AU Camp, M
   Greenup, R
   Taghian, A
   Coopey, S
   Specht, M
   Gadd, M
   Hughes, K
   Smith, B
AF Camp, Melissa
   Greenup, Rachel
   Taghian, Alphonse
   Coopey, Suzanne
   Specht, Michelle
   Gadd, Michele
   Hughes, Kevin
   Smith, Barbara
TI Is Application of the Z0011 Criteria a Cost-Effective Strategy?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 13th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 02-06, 2012
CL Phoenix, AZ
SP Amer Soc Breast Surg
C1 [Camp, Melissa; Greenup, Rachel; Taghian, Alphonse; Coopey, Suzanne; Specht, Michelle; Gadd, Michele; Hughes, Kevin; Smith, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2012
VL 19
SU 2
BP 30
EP 31
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 025PH
UT WOS:000310203200041
ER

PT J
AU Coopey, S
   Specht, M
   Warren, L
   Smith, B
   Winograd, J
   Fleischmann, K
AF Coopey, Suzanne
   Specht, Michelle
   Warren, Lisa
   Smith, Barbara
   Winograd, Jonathan
   Fleischmann, Katharine
TI Use of Preoperative Paravertebral Block Decreases Length of Stay in
   Patients Undergoing Mastectomy Plus Immediate Reconstruction
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 13th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 02-06, 2012
CL Phoenix, AZ
SP Amer Soc Breast Surg
C1 [Coopey, Suzanne; Specht, Michelle; Warren, Lisa; Smith, Barbara; Winograd, Jonathan; Fleischmann, Katharine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2012
VL 19
SU 2
BP 37
EP 38
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 025PH
UT WOS:000310203200050
ER

PT J
AU Miller, C
   Skolny, M
   Jammallo, L
   Horick, N
   O'Toole, J
   Hughes, K
   Gadd, M
   Smith, B
   Taghian, A
   Specht, M
AF Miller, Cynthia
   Skolny, Melissa
   Jammallo, Lauren
   Horick, Nora
   O'Toole, Jean
   Hughes, Kevin
   Gadd, Michele
   Smith, Barbara
   Taghian, Alphonse
   Specht, Michelle
TI Risk of Lymphedema After Prophylactic Mastectomy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 13th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 02-06, 2012
CL Phoenix, AZ
SP Amer Soc Breast Surg
C1 [Miller, Cynthia; Skolny, Melissa; Jammallo, Lauren; Horick, Nora; O'Toole, Jean; Hughes, Kevin; Gadd, Michele; Smith, Barbara; Taghian, Alphonse; Specht, Michelle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2012
VL 19
SU 2
BP 85
EP 86
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 025PH
UT WOS:000310203200120
ER

PT J
AU Pikula, A
   Beiser, AS
   DeCarli, C
   Himali, JJ
   Debette, S
   Au, R
   Selhub, J
   Toffler, GH
   Wang, TJ
   Meigs, JB
   Kelly-Hayes, M
   Kase, CS
   Wolf, PA
   Vasan, RS
   Seshadri, S
AF Pikula, Aleksandra
   Beiser, Alexa S.
   DeCarli, Charles
   Himali, Jayandra J.
   Debette, Stephanie
   Au, Rhoda
   Selhub, Jacob
   Toffler, Geoffrey H.
   Wang, Thomas J.
   Meigs, James B.
   Kelly-Hayes, Margaret
   Kase, Carlos S.
   Wolf, Philip A.
   Vasan, Ramachandran S.
   Seshadri, Sudha
TI Multiple Biomarkers and Risk of Clinical and Subclinical Vascular Brain
   Injury The Framingham Offspring Study
SO CIRCULATION
LA English
DT Article
DE biological markers; epidemiology; magnetic resonance imaging; primary
   prevention; risk assessment; stroke
ID TOTAL HOMOCYSTEINE LEVELS; CORONARY-HEART-DISEASE; SMALL-VESSEL DISEASE;
   C-REACTIVE PROTEIN; CARDIOVASCULAR EVENTS; NATRIURETIC PEPTIDE; STROKE
   RISK; ISCHEMIC-STROKE; FOLLOW-UP; PLASMA
AB Background-Several biomarkers have been individually associated with vascular brain injury, but no prior study has explored the simultaneous association of a biologically plausible panel of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclinical brain injury.
   Methods and Results-In 3127 stroke-free Framingham offspring (age, 59 +/- 10 years; 54% female), we related a panel of 8 biomarkers assessing inflammation (C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptides), and endothelial function (homocysteine and urinary albumin/creatinine ratio) measured at the sixth examination (1995-1998) to risk of incident stroke/transient ischemic attack. In a subset of 1901 participants with available brain magnetic resonance imaging (1999-2005), we further related these biomarkers to total cerebral brain volume, covert brain infarcts, and large white-matter hyperintensity volume. During a median follow-up of 9.2 years, 130 participants experienced incident stroke/transient ischemic attack. In multivariable analyses adjusted for stroke risk factors, the biomarker panel was associated with incident stroke/transient ischemic attack and with total cerebral brain volume (P < 0.05 for both) but not with covert brain infarcts or white-matter hyperintensity volume (P > 0.05). In backward elimination analyses, higher log-B-type natriuretic peptide (hazard ratio, 1.39 per 1-SD increment; P = 0.002) and log-urinary albumin/creatinine ratio (hazard ratio, 1.31 per 1-SD increment; P = 0.004) were associated with increased risk of stroke/transient ischemic attack and improved risk prediction compared with the Framingham Stroke Risk Profile alone; when the <5%, 5% to 15%, or >15% 10-year risk category was used, the net reclassification index was 0.109 (P = 0.037). Higher C-reactive protein (beta = -0.21 per 1-SD increment; P = 0.008), D-dimer (beta = -0.18 per 1-SD increment; P = 0.041), total homocysteine (beta = -0.21 per 1-SD increment; P = 0.005), and urinary albumin/creatinine ratio (beta = -0.15 per 1-SD increment; P = 0.042) were associated with lower total cerebral brain volume.
   Conclusion-In a middle-aged community sample, we identified multiple biomarkers that were associated with clinical and subclinical vascular brain injury and could improve risk stratification. (Circulation. 2012;125:2100-2107.)
C1 [Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Pikula, Aleksandra; Beiser, Alexa S.; Himali, Jayandra J.; Debette, Stephanie; Au, Rhoda; Kelly-Hayes, Margaret; Kase, Carlos S.; Wolf, Philip A.; Vasan, Ramachandran S.; Seshadri, Sudha] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
   [Pikula, Aleksandra; Beiser, Alexa S.; Debette, Stephanie; Au, Rhoda; Wang, Thomas J.; Kelly-Hayes, Margaret; Kase, Carlos S.; Wolf, Philip A.; Vasan, Ramachandran S.; Seshadri, Sudha] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
   [DeCarli, Charles] Univ Calif Davis, Sacramento, CA 95817 USA.
   [Selhub, Jacob] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer US Dept Agr, Boston, MA 02111 USA.
   [Toffler, Geoffrey H.] Royal N Shore Hosp, Sydney, NSW, Australia.
   [Wang, Thomas J.; Meigs, James B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Seshadri, S (reprint author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,B-602, Boston, MA 02118 USA.
EM suseshad@bu.edu
OI Seshadri, Sudha/0000-0001-6135-2622; Pikula,
   Aleksandra/0000-0002-8378-5522; Au, Rhoda/0000-0001-7742-4491;
   Ramachandran, Vasan/0000-0001-7357-5970; Beiser,
   Alexa/0000-0001-8551-7778; /0000-0003-1391-9481
FU National Institutes of Health (NIH)/National Heart, Lung, and Blood
   Institute (NHLBI) [N01-HC-25195]; National Institute on Aging (NIA) [R01
   AG16495, AG08122, AG033193, 031287, 033040, P30AG013846, P30 AG 10129];
   National Institute of Neurological Disorders and Stroke (NINDS) [R01
   NS17950]; National Institute of Diabetes and Digestive and Kidney
   Diseases [K24 DK080140]; American Diabetes Association;
   Bettencourt-Schueller Foundation
FX This work was supported by the National Institutes of Health
   (NIH)/National Heart, Lung, and Blood Institute (NHLBI) contract
   N01-HC-25195, the National Institute on Aging (NIA; R01 AG16495;
   AG08122; AG033193, 031287, 033040, P30AG013846, P30 AG 10129), the
   National Institute of Neurological Disorders and Stroke (NINDS; R01
   NS17950), and the National Institute of Diabetes and Digestive and
   Kidney Diseases (K24 DK080140); by a clinical research grant from the
   American Diabetes Association; and by Roche Diagnostics, which donated
   assay reagents for measurement of urinary albumin and creatinine. Dr
   Debette was partially supported by an award grant from the
   Bettencourt-Schueller Foundation. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NINDS, NHLBI, NIA, or NIH.
NR 43
TC 31
Z9 33
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 1
PY 2012
VL 125
IS 17
BP 2100
EP 2107
DI 10.1161/CIRCULATIONAHA.110.989145
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981IC
UT WOS:000306959200019
PM 22456473
ER

PT J
AU Vigen, R
   Shetterly, S
   Magid, DJ
   O'Connor, PJ
   Margolis, KL
   Schmittdiel, J
   Ho, PM
AF Vigen, Rebecca
   Shetterly, Susan
   Magid, David J.
   O'Connor, Patrick J.
   Margolis, Karen L.
   Schmittdiel, Julie
   Ho, P. Michael
TI A Comparison Between Antihypertensive Medication Adherence and Treatment
   Intensification as Potential Clinical Performance Measures
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE hypertension; performance measures; medication adherence; treatment
   intensification; quality of care
ID BLOOD-PRESSURE CONTROL; CORONARY-ARTERY-DISEASE; ASSOCIATION TASK-FORCE;
   COLLEGE-OF-CARDIOLOGY; AMERICAN-COLLEGE; DIABETES-MELLITUS;
   HYPERTENSION; CARE; QUALITY; THERAPY
AB Background-Medication adherence and treatment intensification have been advocated as performance measures to assess the quality of care provided. Whereas previous studies have shown that adherence and treatment intensification (TI) of antihypertensive medications is associated with blood pressure (BP) control at the patient level, less is known about whether adherence and TI is associated with BP control at the clinic level.
   Methods and Results-We included 162 879 patients among 89 clinics in the Cardiovascular Research Network Hypertension Registry with incident hypertension who were started on antihypertensive medications. Adherence was measured by the proportion of days covered (PDC). TI was defined by the standard based method with scores ranging between -1 to 1 and categorized as: -1 indicated no TI occurred when BP was elevated; 0 indicated TI occurred when BP was elevated; and 1 indicated that TI was made at all visits, even when BP was not elevated. Logistic regression models assessed the association between adherence and TI with blood pressure control (BP <= 140/90 at the clinic visit closest to 12 months after study entry) at the patient and clinic levels. Mean adherence was 0.77 +/- 0.28 (PDC +/- SD) at the patient level and 0.78 +/- 0.05 at the clinic level. Mean TI was 0.026 +/- 0.23 at the patient level and 0.01 +/- 0.04 at the clinic level. At the patient level, for each 0.25 increase in adherence and TI, the odds (OR) of achieving blood pressure control increased by 28% and 55%, respectively [OR for adherence, 1.28 (1.26-1.29), and for TI, 1.55 (1.53-1.57)]. At the clinic level, each 0.04 increment increase in treatment intensification was associated with a 25% increased odds of achieving blood pressure control (OR, 1.24; 95% CI, 1.21-1.27). In contrast, there was an inverse association between increasing adherence and BP control (OR, 0.93; 95% confidence interval, 0.90-0.95).
   Conclusions-Patient adherence to antihypertensive medications is not associated with BP control at the clinic level and may not be suitable as a performance measure. TI is associated with BP control, but its use as a performance measure may be constrained by challenges in measuring it and by concerns about unintended consequences of aggressive hypertension treatment in some subgroups of patients. (Circ Cardiovasc Qual Outcomes. 2012; 5: 276-282.)
C1 [Vigen, Rebecca; Ho, P. Michael] Univ Colorado, Denver, CO 80202 USA.
   [Shetterly, Susan; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
   [O'Connor, Patrick J.; Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA.
   [Schmittdiel, Julie] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA.
   [Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
RP Vigen, R (reprint author), Denver VAMC, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA.
EM Rebecca.vigen@ucdenver.edu
FU Cardiovascular Outcomes Research Fellowship through a Department of
   Veterans Affairs Graduate Medical Education Enhancement Grant; Berman
   Center [HHSN268201100027C]; Assessing Accuracy of Blood Pressure
   Measurement in HealthPartners Usual Clinical Care [A12-046];  [HL
   089471];  [HL 093345];  [DK 079861];  [HL 102144]; 
   [NIH/R01HL093345-01];  [KPNC/U19 HL091179];  [NHLBI/1R01HL089451-01A1]; 
   [NHLBI/R01 HL090965-01];  [NHLBI/N01-WH-3-2101];  [NIA/U01AG029824]; 
   [NHLBI/1R01HL102144-01]
FX Dr Vigen was supported by a Cardiovascular Outcomes Research Fellowship
   through a Department of Veterans Affairs Graduate Medical Education
   Enhancement Grant.; Dr O'Connor was supported by Research Grants HL
   089471, HL 093345, DK 079861, and HL 102144. Dr Margolis was supported
   by Research Grants NIH/R01HL093345-01; Berman Center/HHSN268201100027C;
   KPNC/U19 HL091179; NHLBI/1R01HL089451-01A1; NHLBI/R01 HL090965-01;
   NHLBI/N01-WH-3-2101; NIA/U01AG029824; NHLBI/1R01HL102144-01; A12-046
   Assessing Accuracy of Blood Pressure Measurement in HealthPartners Usual
   Clinical Care.
NR 16
TC 7
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2012
VL 5
IS 3
BP 276
EP 282
DI 10.1161/CIRCOUTCOMES.112.965665
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002NO
UT WOS:000308539100009
PM 22576846
ER

PT J
AU Rost, NS
   Smith, EE
   Pervez, MA
   Mello, P
   Dreyer, P
   Schwamm, LH
AF Rost, Natalia S.
   Smith, Eric E.
   Pervez, Muhammad A.
   Mello, Philip
   Dreyer, Paul
   Schwamm, Lee H.
TI Predictors of Increased Intravenous Tissue Plasminogen Activator Use
   Among Hospitals Participating in the Massachusetts Primary Stroke
   Service Program
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE acute stroke; quality improvement; stroke management; thrombolysis
ID ACUTE ISCHEMIC-STROKE; QUALITY-OF-CARE; GUIDELINES-STROKE;
   PERFORMANCE-MEASURES; THROMBOLYSIS; OUTCOMES; IMPLEMENTATION;
   ASSOCIATION; IMPROVEMENT; ALTEPLASE
AB Background-We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute ischemic stroke increased in Massachusetts in association with the Primary Stroke Service program, a statewide stroke center designation and quality improvement initiative.
   Methods and Results-We analyzed prospectively acquired data from the Massachusetts Department of Public Health between October 2004 and June 2008, including 10 045 consecutive emergency department-based acute ischemic stroke encounters arriving <= 3 hours after stroke onset at 69 participating Massachusetts PSS hospitals. The overall rate of IV tPA use was 854 of 3866 (22.1%) of patients arriving <= 2 hours of symptom onset. IV tPA use increased steadily from 2005 (the first full year of the program) to 2008 (18.4%, 21.9%, 22.6%, 25.5%; P=0.001). Patients treated with IV tPA were more likely to be younger (72.3 +/- 14.1 versus 74.7 +/- 14.0 years, P<0.005) and to have presented after emergency medical services rerouting in July 2005 (96% versus 94%, P=0.009). Patients who arrived at hospitals with a performance achievement award from the Get With The Guidelines-Stroke program were more likely to receive IV tPA after versus before award recognition (28.1% versus 22.3%, P<0.001).
   Conclusions-In this nearly complete capture of statewide data, rates of IV tPA improved significantly in Massachusetts from 2005 to 2008 in association with a state Primary Stroke Service designation program. Further studies are needed to confirm that treatment disparities exist for older acute ischemic stroke patients and that the rates of thrombolysis have increased above and beyond secular trends. (Circ Cardiovasc Qual Outcomes. 2012; 5: 314-320.)
C1 [Rost, Natalia S.; Smith, Eric E.; Pervez, Muhammad A.; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA.
   [Mello, Philip; Dreyer, Paul] Dept Publ Hlth, Boston, MA USA.
RP Rost, NS (reprint author), Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM nrost@partners.org
OI Schwamm, Lee/0000-0003-0592-9145; Smith, Eric/0000-0003-3956-1668
FU NINDS NIH HHS [K23 NS064052]
NR 31
TC 16
Z9 16
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2012
VL 5
IS 3
BP 314
EP 320
DI 10.1161/CIRCOUTCOMES.111.962829
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002NO
UT WOS:000308539100014
PM 22534407
ER

PT J
AU Messe, SR
   Fonarow, GC
   Smith, EE
   Kaltenbach, L
   Olson, DM
   Kasner, SE
   Schwamm, LH
AF Messe, Steven R.
   Fonarow, Gregg C.
   Smith, Eric E.
   Kaltenbach, Lisa
   Olson, DaiWai M.
   Kasner, Scott E.
   Schwamm, Lee H.
TI Use of Tissue-Type Plasminogen Activator Before and After Publication of
   the European Cooperative Acute Stroke Study III in Get With The
   Guidelines-Stroke
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE stroke; therapeutic thrombolysis; outcome assessment (health care)
ID ACUTE ISCHEMIC-STROKE; THROMBOLYSIS; ASSOCIATION; REGISTRY; PROGRAM
AB Background-The European Cooperative Acute Stroke Study (ECASS) III demonstrated benefit to expanding the intravenous tissue-type plasminogen activator (tPA) window from 3 to 4.5 hours for patients with acute ischemic stroke (AIS). We investigated how this trial influenced use of tPA in clinical practice.
   Methods and Results-Using the Get With The Guidelines-Stroke data set, we identified 217 692 patients who presented to the hospital within 4.5 hours of AIS from April 2003 to March 2011, 106 113 before and 111 579 after the publication of ECASS III in September 2008. The proportion of patients with AIS who presented within 4.5 hours and were treated with tPA in the 3- to 4.5-hour window increased from 1.2% before ECASS III to 3.5% after (P<0.0001). The proportion of eligible patients with AIS presenting within 3.5 hours and treated within 4.5 hours increased from 19% (18 484/96 208) to 35% (26 888/77 309) (P<0.0001). ECASS III appeared to have no adverse affect on the treatment of patients who presented early because the proportion of eligible patients with AIS presenting within 2 hours and treated within 3 hours increased after ECASS III from 57% to 75% (P<0.0001), whereas median door-to-needle times in patients treated within 3 hours decreased from 79 to 74 minutes (P<0.0001).
   Conclusions-Following publication of ECASS III, there has been a significant increase in the use of tPA between 3 and 4.5 hours without adversely affecting treatment of patients in the <3-hour window. However, there remains substantial opportunity to further improve treatment rates in the later time window. (Circ Cardiovasc Qual Outcomes. 2012; 5:321-326.)
C1 [Messe, Steven R.; Kasner, Scott E.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
   [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
   [Smith, Eric E.] Univ Calgary, Dept Neurol, Calgary, AB, Canada.
   [Kaltenbach, Lisa; Olson, DaiWai M.] Duke Clin Res Ctr, Durham, NC USA.
   [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Messe, SR (reprint author), Hosp Univ Penn, Dept Neurol, 3 W Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM messe@mail.med.upenn.edu
OI Schwamm, Lee/0000-0003-0592-9145; Smith, Eric/0000-0003-3956-1668
FU Janssen Pharmaceutical Companies of Johnson Johnson; Boehringer
   Ingelheim; Merck; Bristol-Myers Squibb/Sanofi Pharmaceutical
   partnership; AHA Pharmaceutical Roundtable; Council on Clinical
   Cardiology; National Institutes of Health; W.L. Gore Associates
FX The GWTG-Stroke program is provided by the AHA/ASA and currently
   supported in part by a charitable contribution from Janssen
   Pharmaceutical Companies of Johnson & Johnson. GWTG-Stroke has been
   funded in the past through support from Boehringer Ingelheim, Merck, a
   Bristol-Myers Squibb/Sanofi Pharmaceutical partnership, and the AHA
   Pharmaceutical Roundtable. A Young Investigator Database Research Seed
   Grant was sponsored by the Council on Clinical Cardiology.; Dr Messe has
   served on the speaker's bureau for Boehringer Ingelheim (modest),
   receives research support from the National Institutes of Health
   (significant) and from W.L. Gore & Associates (modest). Dr Fonarow
   serves as a member of the GWTG Steering Committee; receives research
   support from the National Institutes of Health (significant); served as
   a consultant to Pfizer (modest); and is an employee of the University of
   California, which holds a patent on retriever devices for stroke
   (significant). Dr Smith serves as a member of the GWTG Steering
   Committee and has served on an advisory board for Genentech (modest). Ms
   Kaltenbach and Dr Olson are members of the Duke Clinical Research
   Institute, which serves as the GWTG data coordinating center. Dr Kasner
   serves as a member of the GWTG Steering Committee and the AHA Stroke
   Scientific Statement Oversight Committee and receives research support
   from the National Institutes of Health (significant) and W. L. Gore &
   Associates (significant). Dr Schwamm serves as chair of the GWTG
   Steering Committee, serves as a consultant to the Research Triangle
   Institute and Massachusetts Department of Public Health, and serves on
   the steering committee for Lundbeck's DIAS4 clinical trial.
NR 13
TC 17
Z9 18
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2012
VL 5
IS 3
BP 321
EP 326
DI 10.1161/CIRCOUTCOMES.111.964064
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002NO
UT WOS:000308539100015
PM 22550132
ER

PT J
AU Rahilly-Tierney, C
   Sesso, HD
   Gaziano, JM
   Djousse, L
AF Rahilly-Tierney, Catherine
   Sesso, Howard D.
   Gaziano, J. Michael
   Djousse, Luc
TI High-Density Lipoprotein and Mortality Before Age 90 in Male Physicians
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE aging; lipoproteins; epidemiology; prevention
ID CORONARY-HEART-DISEASE; LINE RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   MYOCARDIAL-INFARCTION; EXCEPTIONAL LONGEVITY; CHOLESTEROL; MEN; TRIAL;
   WOMEN; TRIGLYCERIDES
AB Background-In cross-sectional and some cohort studies with shorter follow-up, high-density lipoprotein cholesterol (HDL-C) has been associated with longer life. We sought to examine the relationship between HDL-C and death before age 90 in the Physicians' Health Study (PHS).
   Methods and Results-Of PHS enrollees who had blood collected at PHS II baseline (approximately 1997), we selected 1351 men old enough to reach age 90 by March 4, 2009, and with complete data on HDL-C and total cholesterol, lifestyle factors, and comorbidities. We used Cox proportional hazards to determine the hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD), and non-CVD mortality before age 90, adjusting for potential confounders.
   After a mean (SD) follow-up of 6.8 (3.2) years, 44.1% of men in the lowest baseline HDL-C quartile (<32.8 mg/dL) compared with 32.9% (11.2% absolute risk reduction) in the highest HDL-C quartile (>= 54.1 mg/dL) died before age 90. In multivariable adjusted analyses, men in the highest HDL-C quartile had a 28% lower risk (HR, 0.72; 95% CI, 0.55 to 0.94) of death before age 90 compared with men in the lowest HDL-C quartile. In age-adjusted analyses, increasing baseline HDL-C was significantly associated with a lower risk of CVD death. No association was found between HDL-C and non-CVD mortality.
   Conclusion-In male physicians, higher baseline HDL-C levels were associated with a lower risk of all-cause and CVD mortality before age 90. (Circ Cardiovasc Qual Outcomes. 2012; 5: 381-386.)
C1 [Rahilly-Tierney, Catherine; Gaziano, J. Michael; Djousse, Luc] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol & Res Informat Ctr MA, Boston, MA USA.
   [Gaziano, J. Michael; Djousse, Luc] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
   [Rahilly-Tierney, Catherine; Sesso, Howard D.; Gaziano, J. Michael; Djousse, Luc] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
   [Sesso, Howard D.; Gaziano, J. Michael] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
RP Rahilly-Tierney, C (reprint author), MAVERIC, MPH, 13th Floor,150 S Huntington Ave, Jamaica Plain, MA 02130 USA.
EM crahilly-tierney@partners.org
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
FU National Cancer Institute [CA-34933, CA-40360, CA-097193]; National
   Heart, Lung, and Blood Institute [HL-26490, HL-34595]
FX The PHS is supported by the National Cancer Institute (CA-34933,
   CA-40360, and CA-097193) and the National Heart, Lung, and Blood
   Institute (HL-26490 and HL-34595). The sponsor had no role in the design
   and conduct of the study; collection, management, analysis, and
   interpretation of the data; and preparation, review, or approval of the
   manuscript. All authors had full access to all of the data in the study
   and take responsibility for the integrity of the data and the accuracy
   of the data analysis.
NR 32
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2012
VL 5
IS 3
BP 381
EP 386
DI 10.1161/CIRCOUTCOMES.111.963850
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002NO
UT WOS:000308539100023
PM 22474245
ER

PT J
AU Ghazani, AA
   Castro, CM
   Gorbatov, R
   Lee, H
   Weissleder, R
AF Ghazani, Arezou A.
   Castro, Cesar M.
   Gorbatov, Rostic
   Lee, Hakho
   Weissleder, Ralph
TI Sensitive and Direct Detection of Circulating Tumor Cells by Multimarker
   mu-Nuclear Magnetic Resonance
SO NEOPLASIA
LA English
DT Article
ID METASTATIC BREAST-CANCER; PROGRESSION-FREE SURVIVAL; LUNG-CANCER;
   BIOMARKERS; EXPRESSION; PROSTATE; OVARIAN
AB Identifying circulating tumor cells (CTCs) with greater sensitivity could facilitate early detection of cancer and rapid assessment of treatment response. Most current technologies use EpCAM expression as a CTC identifier. However, given that a significant fraction of cancer patients have low or even absent EpCAM levels, there is a need for better detection methods. Here, we hypothesize that a multimarker strategy combined with direct sensing of CTC in whole blood would increase the detection of CTC in patients. Accordingly, molecular profiling of biopsies from a patient cohort revealed a four-marker set (EpCAM, HER-2, EGFR, and MUC-1) capable of effectively differentiating cancer cells from normal host cells. Using a point-of-care micro-nuclear magnetic resonance (mu NMR) system, we consequently show that this multimarker combination readily detects individual CTC directly in whole blood without the need for primary purification. We also confirm these results in a comparative trial of patients with ovarian cancer. This platform could potentially benefit a broad range of applications in clinical oncology. Neoplasia (2012) 14, 388-395
C1 [Ghazani, Arezou A.; Castro, Cesar M.; Gorbatov, Rostic; Lee, Hakho; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
   [Castro, Cesar M.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
RP Weissleder, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU National Institutes of Health [U54CA151884, R01EB010011, R01EB004626,
   P50CA86355, K12CA087723-09, UO1EB012493]
FX This work was supported in part by the following National Institutes of
   Health grants: U54CA151884, R01EB010011, R01EB004626, P50CA86355,
   K12CA087723-09, and UO1EB012493.
NR 24
TC 26
Z9 27
U1 5
U2 51
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD MAY
PY 2012
VL 14
IS 5
BP 388
EP +
DI 10.1596/neo.12696
PG 9
WC Oncology
SC Oncology
GA 001VC
UT WOS:000308487200004
PM 22745585
ER

PT J
AU Hou, JG
   Wu, LJ
   Moore, S
   Ward, C
   York, M
   Atassi, F
   Fincher, L
   Nelson, N
   Sarwar, A
   Lai, EC
AF Hou, Jyhgong Gabriel
   Wu, Laura J.
   Moore, Suzanne
   Ward, Constance
   York, Michele
   Atassi, Farah
   Fincher, Linda
   Nelson, Naomi
   Sarwar, Aliya
   Lai, Eugene C.
TI Assessment of appropriate medication administration for hospitalized
   patients with Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; Hospitalization; Medication administration;
   Medication schedule
ID EXCESS LENGTH; COMPLICATIONS; ADMISSIONS; MANAGEMENT; FREQUENCY;
   ADHERENCE; EVENTS; STAY; CARE
AB Background: For Parkinson's disease (PD) patients, adherence to a regular PD medication schedule is important in achieving optimal symptom control. There are few published studies quantifying PD medication administrations in hospitalized PD patients.
   Methods: Hospitalization records for 100 veterans with idiopathic PD and admitted to our center were reviewed to determine the on time rate and contraindicated medication doses. A barcode based computerized medication administration system within the electronic medical record provided information of the exact time the medication was given to a patient.
   Results: Eighty-nine idiopathic PD patients met study inclusion criteria. Among them, 87 were on levodopa monotherapy or in combination with other PD medications. Two patients were on dopamine agonists only. A total of 3873 doses of PD medications were prescribed during hospitalization. Among 675 incorrect medication administrations, 322 doses were omitted, 300 doses late by >= 30 min, and 53 doses given early by >= 30 min. Contraindicated medications were prescribed for 19 patients. The correct administration percentage was lower during the first 2 days post-admission compared to subsequent days (mean 74.6% vs. 82.8%) and higher for patients who had neurological consultations (mean 85.5% vs. 76.5%). Correct administration rates were better for patient-based medication schedules (85.6%) than with hospital-based schedules (77.5%), but did not achieve statistical significance.
   Conclusion: Adherence to regular PD medication dosing schedules during hospitalization is problematic, but improves with specialist consultation. Staff involved in the admission process for PD patients should work to safeguard against disruption of the prescribed home dosing schedule. Published by Elsevier Ltd.
C1 [Hou, Jyhgong Gabriel; Wu, Laura J.; Moore, Suzanne; Ward, Constance; York, Michele; Atassi, Farah; Fincher, Linda; Nelson, Naomi; Sarwar, Aliya] Baylor Coll Med, Dept Neurol, Parkinsons Dis Res Educ & Clin Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
   [Wu, Laura J.] SUNY Stony Brook, Dept Neurol, Med Ctr, Stony Brook, NY 11794 USA.
   [Atassi, Farah; Lai, Eugene C.] Methodist Neurol Inst, Dept Neurol, Houston, TX 77030 USA.
RP Hou, JG (reprint author), Baylor Coll Med, Dept Neurol, Parkinsons Dis Res Educ & Clin Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM jhou@bcm.edu
FU Department of Veterans Affairs
FX This study is sponsored by the Department of Veterans Affairs.
NR 29
TC 14
Z9 14
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD MAY
PY 2012
VL 18
IS 4
BP 377
EP 381
DI 10.1016/j.parkreldis.2011.12.007
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 991CK
UT WOS:000307678900014
PM 22236581
ER

PT J
AU Brown-Endres, L
   Schoenfeld, D
   Tian, F
   Kim, HG
   Namba, T
   Munoz-Fontela, C
   Mandinova, A
   Aaronson, SA
   Lee, SW
AF Brown-Endres, Lauren
   Schoenfeld, David
   Tian, Fang
   Kim, Hyung-Gu
   Namba, Takushi
   Munoz-Fontela, Cesar
   Mandinova, Anna
   Aaronson, Stuart A.
   Lee, Sam W.
TI Expression of the p53 Target CDIP Correlates with Sensitivity to TNF
   alpha-Induced Apoptosis in Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; MEDIATED
   APOPTOSIS; JNK ACTIVATION; DEATH; INDUCTION; GENE; ANTAGONISM; COMPLEXES
AB TNF alpha is a pleiotropic cytokine that signals for both survival and apoptotic cell fates. It is still unclear that the dual role of TNF alpha can be regulated in cancer cells. We previously described an apoptotic pathway involving p53 -> CDIP -> TNF alpha that was activated in response to genotoxic stress. This pathway operated in the presence of JNK activation; therefore, we postulated that CDIP itself could sensitize cells to a TNF alpha apoptotic cell fate, survival, or death. We show that CDIP mediates sensitivity to TNF alpha-induced apoptosis and that cancer cells with endogenous CDIP expression are inherently sensitive to the growth-suppressive effects of TNF alpha in vitro and in vivo. Thus, CDIP expression correlates with sensitivity of cancer cells with TNF alpha, and CDIP seems to be a regulator of the p53-mediated death versus survival response of cells to TNF alpha. This CDIP-mediated sensitivity to TNF alpha-induced apoptosis favors pro- over antiapoptotic program in cancer cells, and CDIP may serve as a predictive biomarker for such sensitivity. Cancer Res; 72(9); 2373-82. (C) 2012 AACR.
C1 [Brown-Endres, Lauren; Schoenfeld, David; Tian, Fang; Kim, Hyung-Gu; Namba, Takushi; Mandinova, Anna; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
   [Brown-Endres, Lauren; Schoenfeld, David; Tian, Fang; Kim, Hyung-Gu; Namba, Takushi; Mandinova, Anna; Lee, Sam W.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Mandinova, Anna; Lee, Sam W.] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Munoz-Fontela, Cesar; Aaronson, Stuart A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA.
RP Lee, SW (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
EM swlee@partners.org
FU NIH [CA085681, CA142805, CA80058]; MGH ECOR Fund for Medical Research
   Fellowship
FX This work was supported by NIH grants CA085681, CA142805, and CA80058.
   L. Brown-Endres is supported by an MGH ECOR Fund for Medical Research
   Fellowship.
NR 24
TC 3
Z9 3
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2012
VL 72
IS 9
BP 2373
EP 2382
DI 10.1158/0008-5472.CAN-11-3369
PG 10
WC Oncology
SC Oncology
GA 986MI
UT WOS:000307345300023
PM 22549949
ER

PT J
AU Lin, HY
AF Lin, Herbert Y.
TI Transforming Growth Factor-beta and the Kidney Revisited: Introduction
SO SEMINARS IN NEPHROLOGY
LA English
DT Editorial Material
ID TGF-BETA; DIABETIC-NEPHROPATHY; RENAL DEVELOPMENT; EXPRESSION
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lin, HY (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 17
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0270-9295
J9 SEMIN NEPHROL
JI Semin. Nephrol.
PD MAY
PY 2012
VL 32
IS 3
BP 225
EP 227
DI 10.1016/j.semnephrol.2012.04.010
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 986DS
UT WOS:000307321800001
PM 22835452
ER

PT J
AU Gradus, JL
   Qin, P
   Lincoln, AK
   Miller, M
   Lawler, E
   Sorensen, HT
   Lash, TL
AF Gradus, Jaimie L.
   Qin, Ping
   Lincoln, Alisa K.
   Miller, Matthew
   Lawler, Elizabeth
   Sorensen, Henrik Toft
   Lash, Timothy L.
TI Sexual Victimization and Completed Suicide Among Danish Female Adults
SO VIOLENCE AGAINST WOMEN
LA English
DT Article
DE crime; case-control studies; sex offense; suicide
ID ASSAULT; WOMEN; COMMUNITY; ASSOCIATION; PREVALENCE; REGISTER; BEHAVIOR;
   DENMARK; SAMPLE; RISK
AB Although sexual victimization has been associated with suicidal behaviors, its association with completed suicide has not been examined. We investigated this association among Danish women using longitudinal data and a conservative definition of victimization. This population-based case-control study included 476 suicide cases and 12,010 matched controls. Seven cases (1.5%) and 5 controls (0.04%) experienced sexual victimization that was reported to the police and resulted in a conviction. Sexual victimization was associated with a 14-fold increased rate of suicide, controlling for confounders and matching (95% CI: [3.4, 59]). Completed suicide is an important potential outcome of sexual victimization, warranting further examination.
C1 [Gradus, Jaimie L.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
   [Qin, Ping] Aarhus Univ, DK-8000 Aarhus C, Denmark.
   [Lincoln, Alisa K.] Northeastern Univ, Boston, MA 02115 USA.
   [Miller, Matthew] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Lawler, Elizabeth] Harvard Univ, Cambridge, MA 02138 USA.
   [Lash, Timothy L.] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark.
RP Gradus, JL (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave,116B-3, Boston, MA 02130 USA.
EM jaimie.gradus@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327
NR 22
TC 6
Z9 6
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-8012
J9 VIOLENCE AGAINST WOM
JI Violence Against Women
PD MAY
PY 2012
VL 18
IS 5
BP 552
EP 561
DI 10.1177/1077801212453141
PG 10
WC Women's Studies
SC Women's Studies
GA 989SC
UT WOS:000307579600003
PM 22790557
ER

PT J
AU Tegos, GP
   Haynes, MK
   Schweizer, HP
AF Tegos, George P.
   Haynes, Mark K.
   Schweizer, Herbert P.
TI Dissecting novel virulent determinants in the Burkholderia cepacia
   complex
SO VIRULENCE
LA English
DT Editorial Material
DE Burkholderia cepacia complex; toxins; hemolysis; non-ribosomal peptide
   synthetase; virulence factors; non-vertebrate hosts
ID GALLERIA-MELLONELLA LARVAE; CYSTIC-FIBROSIS PATIENTS; C-DI-GMP;
   CENOCEPACIA; PATHOGEN; PSEUDOMALLEI; STRAINS; BIOSYNTHESIS;
   EPIDEMIOLOGY; MULTIVORANS
AB Prevention and control of infectious diseases remains a major public health challenge and a number of highly virulent pathogens are emerging both in and beyond the hospital setting. Despite beneficial aspects such as use in biocontrol and bioremediation exhibited by members of the Burkholderia cepacia complex (Bcc) some members of this group have recently gained attention as significant bacterial pathogens due to their high levels of intrinsic antibiotic resistance, transmissibility in nosocomial settings, persistence in the presence of antimicrobials and intracellular survival capabilities. The Bcc are opportunistic pathogens and their arsenal of virulence factors includes proteases, lipases and other secreted exoproducts, including secretion system-associated effectors. Deciphering the function of virulence factors and assessment of novel therapeutic strategies has been facilitated by use of diverse non-vertebrate hosts (the fly Drosophila melanogaster, the microscopic nematode Caenorhabditis elegans, the zebrafish and the greater Galleria mellonella wax moth caterpillar larvae). Researchers are now employing sophisticated approaches to dissect the virulence determinants of Bcc with the ultimate goal being the development of novel anti-infective countermeasures. This editorial will highlight selected recent research endeavors aimed at dissecting adaptive responses and the virulence factor portfolio of Burkholderia species.
C1 [Tegos, George P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
   [Tegos, George P.; Haynes, Mark K.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
   [Tegos, George P.; Haynes, Mark K.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
   [Schweizer, Herbert P.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Tegos, GP (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM gtegos@salud.unm.edu
NR 40
TC 5
Z9 5
U1 0
U2 15
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2150-5594
J9 VIRULENCE
JI Virulence
PD MAY-JUN
PY 2012
VL 3
IS 3
BP 234
EP 237
DI 10.4161/viru.19844
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 995JI
UT WOS:000308003900002
PM 22546904
ER

PT J
AU Muhammed, M
   Feldmesser, M
   Shubitz, LF
   Lionakis, MS
   Sil, A
   Wang, Y
   Glavis-Bloom, J
   Lewis, RE
   Galgiani, JN
   Casadevall, A
   Kontoyiannis, DP
   Mylonakis, E
AF Muhammed, Maged
   Feldmesser, Marta
   Shubitz, Lisa F.
   Lionakis, Michail S.
   Sil, Anita
   Wang, Yan
   Glavis-Bloom, Justin
   Lewis, Russell E.
   Galgiani, John N.
   Casadevall, Arturo
   Kontoyiannis, Dimitrios P.
   Mylonakis, Eleftherios
TI Mouse models for the study of fungal pneumonia A collection of detailed
   experimental protocols for the study of Coccidioides, Cryptococcus,
   Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus
SO VIRULENCE
LA English
DT Article
DE animal models; Aspergillus; Coccidioides; Cryptococcus; fungal
   infection; Fusarium; Histoplasma; pulmonary infection; Rhizopus
ID IMMUNODEFICIENCY-VIRUS-INFECTION; MURINE PULMONARY INFECTION;
   HEMATOLOGIC MALIGNANCIES; IMMITIS INFECTION; IMMUNE-RESPONSES;
   QUANTITATIVE PCR; MICE; NEOFORMANS; CAPSULATUM; FUMIGATUS
C1 [Muhammed, Maged; Wang, Yan; Glavis-Bloom, Justin; Mylonakis, Eleftherios] Harvard Univ, Sch Med, Div Infect Dis, Boston, MA 02115 USA.
   [Muhammed, Maged; Wang, Yan; Glavis-Bloom, Justin; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Feldmesser, Marta; Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
   [Feldmesser, Marta; Casadevall, Arturo] Albert Einstein Coll Med, Div Infect Dis, Bronx, NY 10467 USA.
   [Shubitz, Lisa F.; Galgiani, John N.] Univ Arizona, Valley Fever Ctr Excellence, Tucson, AZ USA.
   [Shubitz, Lisa F.; Galgiani, John N.] Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ USA.
   [Lionakis, Michail S.] NIAID, Clin Mycol Unit, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
   [Sil, Anita] Univ Calif San Francisco, Dept Microbiol & Immunol, Howard Hughes Med Inst, San Francisco, CA 94143 USA.
   [Wang, Yan] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
   [Lewis, Russell E.; Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Lewis, Russell E.; Kontoyiannis, Dimitrios P.] Univ Houston, Coll Pharm, Houston, TX 77030 USA.
RP Mylonakis, E (reprint author), Harvard Univ, Sch Med, Div Infect Dis, Boston, MA 02115 USA.
EM emylonakis@partners.org
OI Glavis-Bloom, Justin/0000-0002-4879-1572; Lewis,
   Russell/0000-0002-2002-4339
FU National Institute of Allergy and Infectious Diseases [U54AI065359]
FX J.N.G. was supported in part by Award Number U54AI065359 from the
   National Institute of Allergy and Infectious Diseases.
NR 47
TC 8
Z9 8
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2150-5594
EI 2150-5608
J9 VIRULENCE
JI Virulence
PD MAY-JUN
PY 2012
VL 3
IS 3
BP 329
EP 338
DI 10.4161/viru.20142
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 995JI
UT WOS:000308003900015
PM 22546902
ER

PT J
AU Leung, DT
   Rahman, MA
   Mohasin, M
   Patel, SM
   Aktar, A
   Khanam, F
   Uddin, T
   Riyadh, MA
   Saha, A
   Alam, MM
   Chowdhury, F
   Khan, AI
   Charles, R
   LaRocque, R
   Harris, JB
   Calderwood, SB
   Qadri, F
   Ryan, ET
AF Leung, Daniel T.
   Rahman, Mohammad Arif
   Mohasin, M.
   Patel, Sweta M.
   Aktar, Amena
   Khanam, Farhana
   Uddin, Taher
   Riyadh, M. Asrafuzzaman
   Saha, Amit
   Alam, Mohammad Murshid
   Chowdhury, Fahima
   Khan, Ashraful Islam
   Charles, Richelle
   LaRocque, Regina
   Harris, Jason B.
   Calderwood, Stephen B.
   Qadri, Firdausi
   Ryan, Edward T.
TI Memory B Cell and Other Immune Responses in Children Receiving Two Doses
   of an Oral Killed Cholera Vaccine Compared to Responses following
   Natural Cholera Infection in Bangladesh
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; VIBRIOCIDAL ANTIBODY-RESPONSE;
   FIELD-TRIAL; WHOLE-CELL; CVD 103-HGR; O1; IMMUNOGENICITY; EPIDEMIOLOGY;
   PROTECTION; ZINC
AB Current oral cholera vaccines induce lower protective efficacy and shorter duration of protection against cholera than wild-type infection provides, and this difference is most pronounced in young children. Despite this, there are limited data comparing immune responses in children following wild-type disease versus vaccination, especially with regard to memory responses associated with long-term immunity. Here, we report a comparison of immune responses in young children (2 to 5 years of age; n = 20) and older children (6 to 17 years of age; n = 20) given two doses of an oral killed cholera vaccine containing recombinant cholera toxin B subunit (CtxB) 14 days apart and compare these responses to those induced in similarly aged children recovering from infection with Vibrio cholerae O1 Ogawa in Bangladesh. We found that the two vaccine groups had comparable vibriocidal and lipopolysaccharide (LPS)-specific plasma antibody responses. Vaccinees developed lower levels of IgG memory B cell (MBC) responses against CtxB but no significant MBC responses against LPS. In contrast, children recovering from natural cholera infection developed prominent LPS IgG and IgA MBC responses, as well as CtxB IgG MBC responses. Plasma LPS IgG, IgA, and IgM responses, as well as vibriocidal responses, were also significantly higher in children following disease than after vaccination. Our findings suggest that acute and memory immune responses following oral cholera vaccination in children are significantly lower than those observed following wild-type disease, especially responses targeting LPS. These findings may explain, in part, the lower efficacy of oral cholera vaccination in children.
C1 [Leung, Daniel T.; Rahman, Mohammad Arif; Mohasin, M.; Patel, Sweta M.; Aktar, Amena; Khanam, Farhana; Uddin, Taher; Riyadh, M. Asrafuzzaman; Saha, Amit; Alam, Mohammad Murshid; Chowdhury, Fahima; Khan, Ashraful Islam; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Dhaka 1000, Bangladesh.
   [Leung, Daniel T.; Patel, Sweta M.; Charles, Richelle; LaRocque, Regina; Harris, Jason B.; Calderwood, Stephen B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Leung, Daniel T.; Charles, Richelle; LaRocque, Regina; Calderwood, Stephen B.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.
   [Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Leung, DT (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh.
EM dleung@partners.org
OI leung, daniel/0000-0001-8401-0801
FU National Institutes of Health; National Institute of Allergy and
   Infectious Diseases [U01 AI058935, R03 AI063079, U01 AI077883]; Fogarty
   International Center [TW005572, TW05572, K01 TW07409, TW07144, K08
   AI089721, R24 TW007988]; Swedish Agency for International Development
   and Cooperation; Howard Hughes Medical Institute; American Society for
   Tropical Medicine; Hygiene-Burroughs Wellcome Fund; Harvard Initiative
   for Global Health Postdoctoral Fellowship in Global Infectious Diseases
FX This work was supported by the ICDDR,B, grants from the National
   Institutes of Health, including the National Institute of Allergy and
   Infectious Diseases (U01 AI058935 to S. B. C. and E. T. R., R03 AI063079
   to F. Q., U01 AI077883 to E. T. R.), Training Grant in Vaccine
   Development and Public Health (TW005572 to M. M. A. and F. Q.), an
   American Recovery and Reinvestment Act Postdoctoral Fellowship in Global
   Infectious Diseases (TW05572 to D. T. L.), a Career Development Award
   (K01 TW07409 to J.B.H., TW07144 to R. C. L., and K08 AI089721 to R. C.
   C.), and a Clinical Research Scholars award (R24 TW007988 to S. M. P.
   and F. K.) from the Fogarty International Center, the Swedish Agency for
   International Development and Cooperation (to F. Q. and A. S.), a
   Physician Scientist Early Career Award from the Howard Hughes Medical
   Institute (to R. C. L.), a Postdoctoral Fellowship in Tropical
   Infectious Diseases from the American Society for Tropical Medicine and
   Hygiene-Burroughs Wellcome Fund (to D. T. L.), and the Harvard
   Initiative for Global Health Postdoctoral Fellowship in Global
   Infectious Diseases (to D. T. L.).
NR 43
TC 19
Z9 19
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAY
PY 2012
VL 19
IS 5
BP 690
EP 698
DI 10.1128/CVI.05615-11
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 983GU
UT WOS:000307108600009
PM 22441386
ER

PT J
AU Kaczorowski, DJ
   Scott, MJ
   Pibris, JP
   Afrazi, A
   Nakao, A
   Edmonds, RD
   Kim, S
   Kwak, JH
   Liu, YJ
   Fan, J
   Billiar, TR
AF Kaczorowski, David J.
   Scott, Melanie J.
   Pibris, John P.
   Afrazi, Amin
   Nakao, Atsunori
   Edmonds, Rebecca D.
   Kim, Sodam
   Kwak, Joon H.
   Liu, Yujian
   Fan, Jie
   Billiar, Timothy R.
TI Mammalian DNA Is an Endogenous Danger Signal That Stimulates Local
   Synthesis and Release of Complement Factor B
SO MOLECULAR MEDICINE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; PLASMACYTOID DENDRITIC CELLS;
   COLLAGEN-INDUCED ARTHRITIS; INNATE IMMUNE-RESPONSES; TOLL-LIKE
   RECEPTOR-4; ACUTE-RENAL-FAILURE; TNF-ALPHA; INFLAMMATORY RESPONSES;
   ENDOTHELIAL-CELLS; CYTOPLASMIC DNA
AB Complement factor B plays a critical role in ischemic tissue injury and autoimmunity. Factor B is dynamically synthesized and released by cells outside of the liver, but the molecules that trigger local factor B synthesis and release during endogenous tissue injury nave not been identified. We determined that factor B is upregulated early after cold ischemia-eperfusion in mice, using a heterotopic heart transplant model. These data suggested upregulation of factor B by damage-associated molecular patterns (DAMPs), but multiple common DAMPs did not induce factor B in RAW264.7 mouse macrophages. However, exogenous DNA induced factor B mRNA and protein expression in RAW cells in vitro, as well as in peritoneal and alveolar macrophages in vivo. To determine the cellular mechanisms involved in DNA-induced factor B upregulation we then investigated the role of multiple known DNA receptors or binding partners. We stimulated peritoneal macrophages from wild-type (WT), toll-like receptor 9 (TLR9)-deficient, receptor for advanced glycation end products (RAGE)(-/-) and myeloid differentiation factor 88 (MyD88)(-/-) mice, or mouse macrophages deficient in high-mobility group box proteins (HMGBs). DNA-dependent activator of interferon-regulatory factors (DAI) or absent in melanoma 2 (AIM2), with DNA in the presence or absence of lipofection reagent. Reverse transcription-polymerase chain reaction, Western blotting and immunocytochemical analysis were employed for analysis. Synthesis of factor B was independent of TLR9, RAGE, DAI and AIM2, but was dependent on HMGBs, MyD88, p38 and NF-kappa B. Our data therefore show that mammalian DNA is an endogenous molecule that stimulates factor B synthesis and release from macrophages via HMGBs, MyD88, p38 and NF-kappa B signaling. This activation of the immune system likely contributes to damage following sterile injury such as hemorrhagic shock and ischemia-reperfusion. Online address: http://www.molmed.org doi: 10.2119/molmed.2012.00011
C1 [Scott, Melanie J.; Pibris, John P.; Afrazi, Amin; Nakao, Atsunori; Edmonds, Rebecca D.; Kim, Sodam; Kwak, Joon H.; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
   [Kaczorowski, David J.] Univ Penn, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
   [Liu, Yujian; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA USA.
RP Billiar, TR (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, Presbyterian Univ Hosp, F1281,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM billiartr@upmc.edu
FU National Institutes of Health [P50-GM-53789]; American College of
   Surgeons Resident Research Scholarships
FX This work was supported by National Institutes of Health grant
   P50-GM-53789 (TR Billiar). DJ Kaczorowski and RD Edmonds are each
   recipients of American College of Surgeons Resident Research
   Scholarships. We thank M Bo, H Liao and D Reiser for technical
   assistance.
NR 52
TC 10
Z9 10
U1 0
U2 2
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076-1551
J9 MOL MED
JI Mol. Med.
PD MAY
PY 2012
VL 18
IS 5
BP 851
EP 860
DI 10.2119/molmed.2012.00011
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 983TY
UT WOS:000307142800014
PM 22526919
ER

PT J
AU Tanaka, M
   Fernandez-del Castillo, C
   Adsay, V
   Chari, S
   Falconi, M
   Jang, JY
   Kimura, W
   Levy, P
   Pitman, MB
   Schmidt, CM
   Shimizu, M
   Wolfgang, CL
   Yamaguchi, K
   Yamao, K
AF Tanaka, Masao
   Fernandez-del Castillo, Carlos
   Adsay, Volkan
   Chari, Suresh
   Falconi, Massimo
   Jang, Jin-Young
   Kimura, Wataru
   Levy, Philippe
   Pitman, Martha Bishop
   Schmidt, C. Max
   Shimizu, Michio
   Wolfgang, Christopher L.
   Yamaguchi, Koji
   Yamao, Kenji
TI International consensus guidelines 2012 for the management of IPMN and
   MCN of the pancreas
SO PANCREATOLOGY
LA English
DT Review
DE International guidelines; Intraductal papillary mucinous neoplasm;
   Mucinous cystic neoplasm
ID PAPILLARY-MUCINOUS NEOPLASMS; FINE-NEEDLE-ASPIRATION; TERM-FOLLOW-UP;
   FLUID CARCINOEMBRYONIC ANTIGEN; MELANOMA FAMMM SYNDROME;
   INTRADUCTAL-PAPILLARY; BRANCH-DUCT; CLINICOPATHOLOGICAL FEATURES; CYSTIC
   NEOPLASMS; DISTAL PANCREATECTOMY
AB The international consensus guidelines for management of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm of the pancreas established in 2006 have increased awareness and improved the management of these entities. During the subsequent 5 years, a considerable amount of information has been added to the literature. Based on a consensus symposium held during the 14th meeting of the International Association of Pancreatology in Fukuoka, Japan, in 2010, the working group has generated new guidelines. Since the levels of evidence for all items addressed in these guidelines are low, being 4 or 5, we still have to designate them "consensus", rather than "evidence-based", guidelines. To simplify the entire guidelines, we have adopted a statement format that differs from the 2006 guidelines, although the headings are similar to the previous guidelines, i.e., classification, investigation, indications for and methods of resection and other treatments, histological aspects, and methods of follow-up. The present guidelines include recent information and recommendations based on our current understanding, and highlight issues that remain controversial and areas where further research is required. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt, Ltd. All rights reserved.
C1 [Tanaka, Masao] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan.
   [Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pancreas & Biliary Surg Program, Boston, MA USA.
   [Adsay, Volkan] Emory Univ Hosp, Dept Anat Pathol, Atlanta, GA 30322 USA.
   [Chari, Suresh] Mayo Clin, Div Gastroenterol & Hepatol, Pancreas Interest Grp, Rochester, MN USA.
   [Falconi, Massimo] Policlin GB Rossi, Dipartimento Chirurg, UO Chirurg B, Verona, Italy.
   [Jang, Jin-Young] Seoul Natl Univ, Coll Med, Dept Surg, Div Hepatobiliary Pancreat Surg, Seoul, South Korea.
   [Kimura, Wataru] Yamagata Univ, Dept Surg 1, Yamagata 990, Japan.
   [Levy, Philippe] Hop Beaujon, Serv Gastroenterol Pancreatol, Clichy, France.
   [Pitman, Martha Bishop] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Schmidt, C. Max] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA.
   [Shimizu, Michio] Saitama Med Univ, Int Med Ctr, Dept Pathol, Saitama, Japan.
   [Wolfgang, Christopher L.] Johns Hopkins Univ, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA.
   [Wolfgang, Christopher L.] Johns Hopkins Univ, Cameron Div Surg Oncol, Baltimore, MD USA.
   [Yamaguchi, Koji] Univ Occupat & Environm Hlth, Dept Surg 1, Fukuoka, Japan.
RP Tanaka, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan.
EM masaotan@med.kyushu-u.ac.jp
RI Jang, Jin-Young/J-2787-2012; U-ID, Kyushu/C-5291-2016; 
OI Falconi, Massimo/0000-0001-9654-7243
NR 206
TC 642
Z9 668
U1 5
U2 55
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1424-3903
J9 PANCREATOLOGY
JI Pancreatology
PD MAY-JUN
PY 2012
VL 12
IS 3
BP 183
EP 197
DI 10.1016/j.pan.2012.04.004
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 983NX
UT WOS:000307127100003
PM 22687371
ER

PT J
AU Chitsaz, S
   Gundiah, N
   Blackshear, C
   Tegegn, N
   Yan, KS
   Azadani, AN
   Hope, M
   Tseng, EE
AF Chitsaz, Sam
   Gundiah, Namrata
   Blackshear, Charlie
   Tegegn, Nebiyu
   Yan, Kimberly S.
   Azadani, Ali N.
   Hope, Michael
   Tseng, Elaine E.
TI Correlation of Calcification on Excised Aortic Valves by Micro-Computed
   Tomography with Severity of Aortic Stenosis
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID ELECTRON-BEAM TOMOGRAPHY; MULTIDETECTOR ROW CT; CALCIUM;
   ECHOCARDIOGRAPHY; QUANTIFICATION; MARKER; AREA
AB Background and aim of the study: The quantification of incidentally found aortic valve calcification on computed tomography (CT) is not performed routinely, as data relating to the accuracy of aortic valve calcium for estimating the severity of aortic stenosis (AS) is neither consistent nor validated. As aortic valve calcium quantification by CT is confounded by wall and coronary ostial calcification, as well as motion artifact, the ex-vivo micro-computed tomography (micro-CT) of stenotic aortic valves allows a precise measurement of the amounts of calcium present. The study aim, using excised aortic valves from patients with confirmed AS, was to determine if the amount of calcium on micro-CT correlated with the severity of AS.
   Methods: Each of 35 aortic valves that had been excised from patients during surgical valve replacement were examined using micro-CT imaging. The amount of calcium present was determined by absolute and proportional values of calcium volume in the specimen. Subsequently, the correlation between calcium volume and preoperative mean aortic valve gradient (MAVG), peak transaortic velocity (V-max), and aortic valve area (AVA) on echocardiography, was evaluated.
   Results: The mean calcium volume across all valves was 603.2 +/- 398.5 mm(3), and the mean ratio of calcium volume to total valve volume was 0.36 +/- 0.16. The mean aortic valve gradient correlated positively with both calcium volume and ratio (r = 0.72, p <0.001). V-max also correlated positively with the calcium volume and ratio (r = 0.69 and 0.76 respectively; p <0.001). A logarithmic curvilinear model proved to be the best fit to the correlation. A calcium volume of 480 mm(3) showed sensitivity and specificity of 0.76 and 0.83, respectively, for a diagnosis of severe AS, while a calcium ratio of 0.37 yielded sensitivity and specificity of 0.82 and 0.94, respectively.
   Conclusion: A radiological estimation of calcium amount by volume, and its proportion to the total valve volume, were shown to serve as good predictive parameters for severe AS. An estimation of the calcium volume may serve as a complementary measure for determining the severity of AS when aortic valve calcification is identified on CT imaging. The Journal of Heart Valve Disease 2012;21:320-327
C1 [Chitsaz, Sam; Gundiah, Namrata; Blackshear, Charlie; Tegegn, Nebiyu; Yan, Kimberly S.; Azadani, Ali N.; Tseng, Elaine E.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Chitsaz, Sam; Gundiah, Namrata; Blackshear, Charlie; Tegegn, Nebiyu; Yan, Kimberly S.; Azadani, Ali N.; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Gundiah, Namrata] Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Karnataka, India.
   [Hope, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
RP Tseng, EE (reprint author), UCSF Med Ctr, 500 Parnassus Ave,Suite W405,Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
RI Chitsaz, Sam/C-4586-2008
NR 21
TC 4
Z9 4
U1 0
U2 3
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET,
   ENGLAND
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAY
PY 2012
VL 21
IS 3
BP 320
EP 327
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977OY
UT WOS:000306675500008
PM 22808832
ER

PT J
AU Littman, AJ
   Boyko, EJ
   McDonell, MB
   Fihn, SD
AF Littman, Alyson J.
   Boyko, Edward J.
   McDonell, Mary B.
   Fihn, Stephan D.
TI Evaluation of a Weight Management Program for Veterans
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID OBESITY; INTERVENTIONS; PREVALENCE; FACILITIES; ADULTS
AB Introduction
   To improve the health of overweight and obese veterans, the Department of Veterans Affairs (VA) developed the MOVE! Weight Management Program for Veterans. The aim of this evaluation was to assess its reach and effectiveness.
   Methods
   We extracted data on program involvement, demographics, medical conditions, and outcomes from VA administrative databases in 4 Western states. Eligibility criteria for MOVE! were being younger than 7 0 years and having a body mass index (BMI, in kg/m(2)) of at least 30.0, or 25.0 to 29.9 with an obesity-related condition. To evaluate reach, we estimated the percentage of eligible veterans who participated in the program and their representativeness. To evaluate effectiveness, we estimated changes in weight and BMI using multivariable linear regression.
   Results
   Less than 5% of eligible veterans participated, of whom half had only a single encounter. Likelihood of participation was greater in women, those with a higher BMI, and those with more primary care visits, sleep apnea, or a mental health condition. Likelihood of participation was lower among those who were younger than 5 5 (vs 55-64), widowed, current smokers, and residing farther from the medical center (>= 3 0 vs <30 miles). At 6- and 12-month follow-up, participants lost an average of 1.3 lb (95% confidence interval [CI], -2.6 to -0.02 lb) and 0.9 lb (95% CI, -2.0 to 0.1 lb) more than nonparticipants, after covariate adjustment. More intensive treatment (>= 6 encounters) was associated with greater weight loss at 12 months (-3.7 lb; 95% CI, -5.1 to -2.3 lb).
   Conclusion
   Few eligible patients participated in the program during the study period, and overall estimates of effectiveness were low.
C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
   [McDonell, Mary B.] Off Analyt & Business Intelligence, VHA Off Informat & Analyt, Seattle, WA USA.
   [Boyko, Edward J.; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA.
   [Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Littman, AJ (reprint author), VA Puget Sound Hlth Care Syst 152E, Seattle Epidemiol Res & Informat Ctr, 1100 Ol Way,Ste 1400, Seattle, WA 98101 USA.
EM alyson@u.washington.edu
FU Quality Enhancement Research Initiative [RRP-07-279]; Cooperative
   Studies Program; VA Puget Sound Health Care System, Department of
   Veterans Affairs; VA Rehabilitation Research and Development Career
   Development Award [6982]
FX This study was supported in part by the Quality Enhancement Research
   Initiative (RRP-07-279), the Cooperative Studies Program, and VA Puget
   Sound Health Care System, Department of Veterans Affairs. Dr Littman was
   supported by a VA Rehabilitation Research and Development Career
   Development Award (#6982). Dr Leila Kahwati provided valuable feedback
   on program components, study analysis, and interpretation.
NR 19
TC 7
Z9 8
U1 0
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAY
PY 2012
VL 9
AR 110267
DI 10.5888/pcd9.110267
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 977HU
UT WOS:000306648100007
ER

PT J
AU Santos, ICT
   Gazelle, GS
   Rocha, LA
   Tavares, JMRS
AF Santos, Isa C. T.
   Gazelle, G. Scott
   Rocha, Luis A.
   Tavares, Joao Manuel R. S.
TI Medical device specificities: opportunities for a dedicated product
   development methodology
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Review
DE Europe; Global Harmonization Task Force; medical device characteristics;
   product regulatory approval; regulations; standards; USA
ID USERS
AB The medical sector, similarly to other industries such as the aviation industry, has to comply with multiple regulations, guidelines and standards. In addition, there are multiple definitions for the expression 'medical device', and before entering the market, manufacturers must demonstrate their product's safety and effectiveness. In such a complex and demanding environment, it is crucial to know the particularities surrounding the product being developed in order to minimize the chances of a commercial flop. Thus, in this paper, medical device specificities are identified, and the most relevant legislation is reviewed providing the foundations for a dedicated product development methodology.
C1 [Tavares, Joao Manuel R. S.] Univ Porto, Fac Engn, Inst Engn Mecan & Gestao Ind, Dept Engn Mecan, P-4100 Oporto, Portugal.
   [Gazelle, G. Scott] Harvard Univ, Sch Med, Dept Radiol, Inst Technol Assessment,Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Rocha, Luis A.] Univ Minho, Inst Polymers & Composites, Guimaraes, Portugal.
RP Tavares, JMRS (reprint author), Univ Porto, Fac Engn, Inst Engn Mecan & Gestao Ind, Dept Engn Mecan, Rua Campo Alegre 823, P-4100 Oporto, Portugal.
EM tavares@fe.up.pt
RI Rocha, Luis/A-6676-2013; Tavares, Joao/M-5305-2013; 
OI Rocha, Luis/0000-0001-8184-8801; Tavares, Joao/0000-0001-7603-6526;
   Santos, Isa/0000-0003-1862-4877
FU Fundacao para a Ciencia e Tecnologia (FCT), Portugal
   [SFRH/BD/42967/2008]; project SenseCardioHealth
   [MIT-Pt/EDAM-EMD/0007/2008]; FEDER through COMPETE; FCT
FX This work was supported by the PhD grant SFRH/BD/42967/2008 from
   Fundacao para a Ciencia e Tecnologia (FCT), Portugal, and was partially
   supported by the project SenseCardioHealth: new technological solutions
   for smart cardiovascular medical devices - MIT-Pt/EDAM-EMD/0007/2008,
   sponsored by FEDER through COMPETE and national funds through FCT. The
   authors wish to thank A Torres (www.tdetangerina.com) for the
   illustrations. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
NR 22
TC 11
Z9 11
U1 1
U2 10
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1743-4440
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD MAY
PY 2012
VL 9
IS 3
BP 299
EP 311
DI 10.1586/ERD.12.3
PG 13
WC Engineering, Biomedical
SC Engineering
GA 975WP
UT WOS:000306542500018
PM 22702261
ER

PT J
AU Helm, S
   Deer, TR
   Manchikanti, L
   Datta, S
   Chopra, P
   Singh, V
   Hirsch, JA
AF Helm, Standiford, II
   Deer, Timothy R.
   Manchikanti, Laxmaiah
   Datta, Sukdeb
   Chopra, Pradeep
   Singh, Vijay
   Hirsch, Joshua A.
TI Effectiveness of Thermal Annular Procedures in Treating Discogenic Low
   Back Pain
SO PAIN PHYSICIAN
LA English
DT Review
DE Spinal pain; chronic low back pain; discogenic pain; thermal procedures;
   annular procedures; IDET; biaculoplasty; disctrode
ID INTRADISCAL ELECTROTHERMAL THERAPY; CLINICAL-PRACTICE GUIDELINE; UPDATED
   METHOD GUIDELINES; INTERNAL DISC DISRUPTION; LUMBAR DISKOGENIC PAIN;
   CAUDA-EQUINA SYNDROME; 12-MONTH FOLLOW-UP; CONTROLLED-TRIAL; SYSTEMATIC
   REVIEWS; IDET
AB Background: Persistent low back pain refractory to conservative treatment is a common problem that leads to widespread impairment, resulting in significant costs to society. The intervertebral disc is a major source of persistent low back pain. Technologies developed to treat this problem, including various surgical instrumentation and fusion techniques, have not reliably provided satisfactory results in terms of either pain relief or increased function.
   Thermal annular procedures (TAPs) were first developed in the late 1990s in an attempt to treat discogenic pain. The hope was that they would provide greater value than fusion in terms of efficacy, morbidity, and cost. Three technologies have been developed to apply heat to the annulus: intradiscal electrothermal therapy (IDET), discTRODE, and biacuplasty. Since nerve ingrowth and tissue regeneration in the annulus is felt to be the source of pain in discogenic low back pain, when describing the 3 above techniques we use the term "thermal annular procedures" rather than "thermal intradiscal procedures." We have specifically excluded studies treating the nucleus. TAPs have been the subject of significant controversy. Multiple reviews have been conducted resulting in varying conclusions.
   Study Design: A systematic review of TAPs for the treatment of discogenic low back pain.
   Objective: To evaluate the effectiveness of TAPs in treating discogenic low back pain and to assess complications associated with those procedures.
   Methods: The available literature on TAPs in treating discogenic low back pain was reviewed. The quality assessment and clinical relevance criteria utilized were the Cochrane Musculoskeletal Review Group criteria for interventional techniques for randomized trials, and the criteria developed by the Newcastle-Ottawa Scale criteria for observational studies. The level of evidence was classified as good, fair, or limited (or poor) based on the quality of evidence developed by the U.S. Preventive Services Task Force. Data sources included relevant literature identified through searches of PubMed and EMBASE from 1966 through December 2011, and manual searches of the bibliographies of known primary and review articles.
   Outcome Measures: The primary outcome measure was pain relief of at least 6 months. Secondary outcome measures were improvements in functional status.
   Results: For this systematic review, 43 studies were identified. Of these, 3 randomized controlled trials and one observational study met the inclusion criteria.
   Using current criteria for successful outcomes, the evidence is fair for IDET and limited (or poor) for discTRODE and biacuplasty procedures regarding whether they are effective in relieving discogenic low back pain. Since 2 randomized controlled trials are in progress on that procedure, assessment of biacuplasty may change upon publication of those studies.
   Limitations: The limitations of this systematic review include the paucity of literature and non-availability of 2 randomized trials which are in progress for biacuplasty.
   Conclusion: In summary, the evidence is fair for IDET and limited (or poor) for discTRODE and biacuplasty is being evaluated in 2 ongoing randomized controlled trials.
C1 [Helm, Standiford, II] Helm Ctr Pain Management, Laguna Hills, CA USA.
   [Deer, Timothy R.] W Virginia Univ, Sch Med, Ctr Pain Relief, Charleston, WV 25304 USA.
   [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
   [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
   [Datta, Sukdeb] Laser Spine & Pain Inst, New York, NY USA.
   [Chopra, Pradeep] Brown Alpert Med Sch, Providence, RI USA.
   [Chopra, Pradeep] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Chopra, Pradeep] Intervent Pain Ctr, Pawtucket, RI USA.
   [Singh, Vijay] Pain Diagnost Associates, Niagara, WI USA.
   [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Helm, S (reprint author), 24902 Moulton Pkwy,Suite 200, Laguna Hills, CA 92637 USA.
EM drhelm@thehelmcenter.com
FU Sucampo Pharmaceuticals
FX Dr. Deer, MD, is a consultant and research advisor for Bioness,
   Medtronic, St. Jude, Spinal Modulation, and Vertos. Dr. Hirsch, MD, is a
   consultant for CareFusion and receives royalties for products related to
   vertebral augmentation. He also participated in an Aetrium focus group
   and received compensation. Dr. Datta, MD, receives research support from
   Sucampo Pharmaceuticals and an honorarium from Smith and Nephew.
NR 122
TC 15
Z9 15
U1 1
U2 7
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAY-JUN
PY 2012
VL 15
IS 3
BP E279
EP E304
PG 26
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA 977VJ
UT WOS:000306692600004
PM 22622914
ER

PT J
AU Wu, H
   Tao, JF
   Sun, YE
AF Wu, Hao
   Tao, Jifang
   Sun, Yi Eve
TI Regulation and function of mammalian DNA methylation patterns: a genomic
   perspective
SO BRIEFINGS IN FUNCTIONAL GENOMICS
LA English
DT Article
DE DNA methylation; DNA methyltransferases; Tet DNA hydroxylases; Polycomb
   repression; promoter and non-promoter DNA methylation; epigenomics;
   methylome
ID EMBRYONIC STEM-CELLS; CPG-BINDING PROTEIN; ACTIVITY-INDUCED GADD45B;
   DE-NOVO METHYLATION; METHYLTRANSFERASE DNMT3A; GENE-EXPRESSION; WIDE
   ANALYSIS; HISTONE H3; EPIGENETIC INHERITANCE; ADULT NEUROGENESIS
AB Mammalian DNA methyltransferases (DNMTs) establish and maintain genomic DNA methylation patterns that are required for proper epigenetic regulation of gene expression and maintenance of genome stability during normal development. Aberrant DNA methylation patterns are implicated in a variety of pathological conditions including cancer and neurological disorders. Rapid advances in genomic technologies have allowed the generation of high resolution whole-genome views of DNA methylation and DNA methyltransferase occupancy in pluripotent stem cells and differentiated somatic cells. Furthermore, recent identification of oxidation derivatives of cytosine methylation in mammalian DNA raises the possibility that DNA methylation patterns are more dynamic than previously anticipated. Here, we review the recent progress in our understanding of the genomic function and regulatory mechanisms of mammalian DNA methylation.
C1 [Wu, Hao] Harvard Univ, Massachusetts Gen Hosp, Labs Drs Kenneth Chien, Cambridge, MA 02138 USA.
   [Tao, Jifang] MIT, HHMI, Dr Mark Bears Lab, Cambridge, MA 02139 USA.
   [Sun, Yi Eve] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
RP Wu, H (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Sherman Fairchild Biochem Bldg,7 Divin Ave, Cambridge, MA 02138 USA.
EM haowu7@gmail.com
RI Wu, Hao/G-4145-2013
OI Wu, Hao/0000-0002-1256-6891
FU Jane Coffin Childs postdoctoral fellowship; Rett Syndrome Trust
   postdoctoral fellowship
FX H.W. is supported by a Jane Coffin Childs postdoctoral fellowship. J.T.
   is supported by a Rett Syndrome Trust postdoctoral fellowship.
NR 133
TC 13
Z9 14
U1 3
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2041-2649
J9 BRIEF FUNCT GENOMICS
JI Brief. Funct. Genomics
PD MAY
PY 2012
VL 11
IS 3
SI SI
BP 240
EP 250
DI 10.1093/bfgp/els011
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 970MV
UT WOS:000306135700006
PM 22402507
ER

PT J
AU Ni, J
   Liu, QS
   Xie, SZ
   Carlson, C
   Von, T
   Vogel, K
   Riddle, S
   Benes, C
   Eck, M
   Roberts, T
   Gray, N
   Zhao, J
AF Ni, Jing
   Liu, Qingsong
   Xie, Shaozhen
   Carlson, Coby
   Thanh Von
   Vogel, Kurt
   Riddle, Steve
   Benes, Cyril
   Eck, Michael
   Roberts, Thomas
   Gray, Nathanael
   Zhao, Jean
TI Functional Characterization of an Isoform-Selective Inhibitor of
   PI3K-p110 beta as a Potential Anticancer Agent
SO CANCER DISCOVERY
LA English
DT Article
ID PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; CATALYTIC
   SUBUNIT; BREAST-CANCER; CELL; P110-ALPHA; ACTIVATION; PATHWAY; PI3K;
   SENSITIVITY
AB Genetic approaches have shown that the p110 beta isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110 beta-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collection of compounds possessing activities against kinases in the PI3K superfamily and identified a potent and selective p110 beta inhibitor: KIN-193. We show that KIN-193 is efficacious specifically in blocking AKT signaling and tumor growth that are dependent on p110 beta activation or PTEN loss. Broad profiling across a panel of 422 human tumor cell lines shows that the PTEN mutation status of cancer cells strongly correlates with their response to KIN-193. Together, our data provide the first pharmacologic evidence that PTEN-deficient tumors are dependent on p110 beta in animals and suggest that KIN-193 can be pursued as a drug to treat tumors that are dependent on p110 beta while sparing other PI3K isoforms.
   SIGNIFICANCE: We report the first functional characterization of a p110 beta-selective inhibitor, KIN-193, that is efficacious as an antitumor agent in mice. We show that this class of inhibitor holds great promise as a pharmacologic agent that could be used to address the potential therapeutic benefit of treating p110 beta-dependent PTEN-deficient human tumors. Cancer Discov; 2(5); 425-33. (c) 2012 AACR.
C1 [Ni, Jing; Liu, Qingsong; Xie, Shaozhen; Thanh Von; Eck, Michael; Gray, Nathanael; Zhao, Jean] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Ni, Jing; Liu, Qingsong; Xie, Shaozhen; Thanh Von; Eck, Michael; Roberts, Thomas; Gray, Nathanael; Zhao, Jean] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA.
   [Benes, Cyril] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
   [Carlson, Coby; Vogel, Kurt; Riddle, Steve] Life Technol Corp, Madison, WI USA.
RP Zhao, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02215 USA.
EM nathanael_gray@dfci.harvard.edu; jean_zhao@dfci.harvard.edu
FU NIH [CA030002, P01 CA089021, CA134502, P50 CA089393-08S1, P01 CA142536,
   CA148164-01, 1U54HG006097-01]; Stand Up To Cancer Dream Team
   Translational Research Grant; Program of the Entertainment Industry
   Foundation [SU2C-AACR-DT0209]; AstraZeneca
FX This work was supported by NIH grants CA030002 and P01 CA089021 (T.
   Roberts); CA134502, P50 CA089393-08S1, and P01 CA142536 (J. Zhao);
   CA148164-01 (J. Zhao, N. Gray, M. Eck, and T. Roberts); and
   1U54HG006097-01 (C. Benes). T. Roberts and J. Zhao are supported by a
   Stand Up To Cancer Dream Team Translational Research Grant, a Program of
   the Entertainment Industry Foundation (SU2C-AACR-DT0209). C. Benes
   received a research grant from AstraZeneca.
NR 24
TC 65
Z9 69
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD MAY
PY 2012
VL 2
IS 5
BP 425
EP 433
DI 10.1158/2159-8290.CD-12-0003
PG 9
WC Oncology
SC Oncology
GA 973BZ
UT WOS:000306328600036
PM 22588880
ER

PT J
AU Vivanco, I
   Robins, HI
   Rohle, D
   Campos, C
   Grommes, C
   Nghiemphu, PL
   Kubek, S
   Oldrini, B
   Chheda, MG
   Yannuzzi, N
   Tao, H
   Zhu, SJ
   Iwanami, A
   Kuga, D
   Dang, JL
   Pedraza, A
   Brennan, CW
   Heguy, A
   Liau, LM
   Lieberman, F
   Yung, WKA
   Gilbert, MR
   Reardon, DA
   Drappatz, J
   Wen, PY
   Lamborn, KR
   Chang, SM
   Prados, MD
   Fine, HA
   Horvath, S
   Wu, N
   Lassman, AB
   DeAngelis, LM
   Yong, WH
   Kuhn, JG
   Mischel, PS
   Mehta, MP
   Cloughesy, TF
   Mellinghoff, IK
AF Vivanco, Igor
   Robins, H. Ian
   Rohle, Daniel
   Campos, Carl
   Grommes, Christian
   Nghiemphu, Phioanh Leia
   Kubek, Sara
   Oldrini, Barbara
   Chheda, Milan G.
   Yannuzzi, Nicolas
   Tao, Hui
   Zhu, Shaojun
   Iwanami, Akio
   Kuga, Daisuke
   Dang, Julie
   Pedraza, Alicia
   Brennan, Cameron W.
   Heguy, Adriana
   Liau, Linda M.
   Lieberman, Frank
   Yung, W. K. Alfred
   Gilbert, Mark R.
   Reardon, David A.
   Drappatz, Jan
   Wen, Patrick Y.
   Lamborn, Kathleen R.
   Chang, Susan M.
   Prados, Michael D.
   Fine, Howard A.
   Horvath, Steve
   Wu, Nian
   Lassman, Andrew B.
   DeAngelis, Lisa M.
   Yong, William H.
   Kuhn, John G.
   Mischel, Paul S.
   Mehta, Minesh P.
   Cloughesy, Timothy F.
   Mellinghoff, Ingo K.
TI Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR
   Mutations to EGFR Kinase Inhibitors
SO CANCER DISCOVERY
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR INHIBITORS; TYROSINE KINASE;
   MALIGNANT GLIOMAS; TUMOR-CELLS; 3T3 CELLS; THERAPY; GLIOBLASTOMA;
   GEFITINIB; LAPATINIB
AB Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer, glioma-specific EGFR EC mutants are poorly inhibited by EGFR inhibitors that target the active kinase conformation (e.g., erlotinib). Inhibitors that bind to the inactive EGFR conformation, however, potently inhibit EGFR EC mutants and induce cell death in EGFR-mutant GBM cells. Our results provide first evidence for single kinase addiction in GBM and suggest that the disappointing clinical activity of first-generation EGFR inhibitors in GBM versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these 2 cancer types.
   SIGNIFICANCE: Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain. Cancer Discov; 2(5); 458-71. (c) 2012 AACR.
C1 [Mehta, Minesh P.] Northwestern Univ, Chicago, IL 60611 USA.
   [Fine, Howard A.] NCI, NeuroOncol Branch, Bethesda, MD 20892 USA.
   [Lamborn, Kathleen R.; Chang, Susan M.; Prados, Michael D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Reardon, David A.; Drappatz, Jan; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Reardon, David A.; Kuhn, John G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Yung, W. K. Alfred; Gilbert, Mark R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Lieberman, Frank] Univ Pittsburgh, Pittsburgh, PA USA.
   [Robins, H. Ian] Univ Wisconsin, Madison, WI USA.
   [Nghiemphu, Phioanh Leia; Cloughesy, Timothy F.] David Geffen UCLA Sch Med, Dept Neurol, Los Angeles, CA USA.
   [Liau, Linda M.] David Geffen UCLA Sch Med, Dept Neurosurg, Los Angeles, CA USA.
   [Zhu, Shaojun; Iwanami, Akio; Kuga, Daisuke; Dang, Julie; Yong, William H.; Mischel, Paul S.] David Geffen UCLA Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA.
   [Horvath, Steve] David Geffen UCLA Sch Med, Dept Human Genet & Biostat, Los Angeles, CA USA.
   [Mischel, Paul S.] David Geffen UCLA Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
   [Rohle, Daniel; Kubek, Sara; Mellinghoff, Ingo K.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA.
   [Vivanco, Igor; Campos, Carl; Oldrini, Barbara; Chheda, Milan G.; Yannuzzi, Nicolas; Brennan, Cameron W.; Heguy, Adriana; Mellinghoff, Ingo K.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Grommes, Christian; Lassman, Andrew B.; DeAngelis, Lisa M.; Mellinghoff, Ingo K.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA.
   [Tao, Hui; Wu, Nian] Mem Sloan Kettering Canc Ctr, Analyt Pharmacol Core, New York, NY 10021 USA.
   [Pedraza, Alicia; Brennan, Cameron W.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10021 USA.
RP Cloughesy, TF (reprint author), Geffen UCLA Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
EM tcloughesy@mednet.ucla.edu; mellingi@mskcc.org
RI Gilbert, Mark/J-7494-2016; 
OI Gilbert, Mark/0000-0003-2556-9722; Vivanco, Igor/0000-0001-6347-9416;
   Brennan, Cameron/0000-0003-4064-8891; Campos, Carl/0000-0002-7616-8518;
   mehta, minesh/0000-0002-4812-5713
FU National Cancer Institute [U54CA143798, U01 CA141502]; Leon Levy
   foundation; Sontag Foundation; Doris Duke Charitable Foundation;
   Advanced Clinical Research Award from the American Society of Clinical
   Oncology; American Brain Tumor Association Basic Research Fellowship
   Award; American Italian Cancer Foundation [NIH5K08NS062907]; Memorial
   Sloan-Kettering Cancer Center (MSKCC) Brain Tumor Center grant; American
   Brain Tumor Association Medical Student Summer Fellowship; NABTC
   [CA62399, CA62422]; GCRC grant [M01-RR00079, CA62426, CA62412, CA16672,
   U01CA62407-08, U01CA62421-08, M01-RR03186, U01CA62405, M01-RR00056,
   U01CA62399, M01-RR0865]; MSKCC Experimental Therapeutics Center; 
   [5-U01CA62399-09]
FX This work was supported through U54CA143798 (I.K. Mellinghoff) and U01
   CA141502 from the National Cancer Institute. Further funding support was
   provided by the Leon Levy foundation, the Sontag Foundation, the Doris
   Duke Charitable Foundation, and an Advanced Clinical Research Award from
   the American Society of Clinical Oncology (I.K. Mellinghoff). C. Grommes
   was supported through an American Brain Tumor Association Basic Research
   Fellowship Award, M.G. Chheda was supported through NIH5K08NS062907, B.
   Oldrini was supported through grants from the American Italian Cancer
   Foundation and a Memorial Sloan-Kettering Cancer Center (MSKCC) Brain
   Tumor Center grant, and N. Yannuzzi was the recipient of an American
   Brain Tumor Association Medical Student Summer Fellowship. Investigators
   of the NABTC-04-01 Clinical Trial were supported through the following
   funding sources: 5-U01CA62399-09 (A.B. Lassman and L.M. DeAngelis);
   NABTC number CA62399 and member number CA62422, GCRC grant number
   M01-RR00079 (S.M. Chang, K.R. Lamborn, and M.D. Prados); CA62426 (J.G.
   Kuhn); CA62412, GCRC grant number CA16672 (W.K.A. Yung and M. R.
   Gilbert); U01CA62407-08 (P.Y. Wen); U01CA62421-08, GCRC grant number
   M01-RR03186 (M.P. Mehta and H.I. Robins); U01CA62405, GCRC grant number
   M01-RR00056 (F. Lieberman); and U01CA62399, GCRC grant number M01-RR0865
   (T.F. Cloughesy). This work was supported in part by the MSKCC
   Experimental Therapeutics Center.
NR 50
TC 98
Z9 99
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD MAY
PY 2012
VL 2
IS 5
BP 458
EP 471
DI 10.1158/2159-8290.CD-11-0284
PG 14
WC Oncology
SC Oncology
GA 973BZ
UT WOS:000306328600039
PM 22588883
ER

PT J
AU Hubert, J
   Kopecky, J
   Perotti, MA
   Nesvorna, M
   Braig, HR
   Sagova-Mareckova, M
   Macovei, L
   Zurek, L
AF Hubert, Jan
   Kopecky, Jan
   Perotti, M. Alejandra
   Nesvorna, Marta
   Braig, Henk R.
   Sagova-Mareckova, Marketa
   Macovei, Lilia
   Zurek, Ludek
TI Detection and Identification of Species-Specific Bacteria Associated
   with Synanthropic Mites
SO MICROBIAL ECOLOGY
LA English
DT Article
ID CALCITRANS L. DIPTERA; DERMATOPHAGOIDES-PTERONYSSINUS;
   TYROPHAGUS-PUTRESCENTIAE; ENTEROBACTER-SAKAZAKII; STOMOXYS-CALCITRANS;
   PROTEOLYTIC ACTIVITIES; CARDINIUM SYMBIONTS; VECTOR COMPETENCE; ACARIDID
   MITES; STABLE FLIES
AB Internal bacterial communities of synanthropic mites Acarus siro, Dermatophagoides farinae, Lepidoglyphus destructor, and Tyrophagus putrescentiae (Acari: Astigmata) were analyzed by culturing and culture-independent approaches from specimens obtained from laboratory colonies. Homogenates of surface-sterilized mites were used for cultivation on non-selective agar and DNA extraction. Isolated bacteria were identified by sequencing of the 16S rRNA gene. PCR amplified 16S rRNA genes were analyzed by terminal restriction fragment length polymorphism analysis (T-RFLP) and cloning sequencing. Fluorescence in situ hybridization using universal bacterial probes was used for direct bacterial localization. T-RFLP analysis of 16S rRNA gene revealed distinct species-specific bacterial communities. The results were further confirmed by cloning and sequencing (284 clones). L. destructor and D. farinae showed more diverse communities then A. siro and T. putrescentiae. In the cultivated part of the community, the mean CFUs from four mite species ranged from 5.2 x 10(2) to 1.4 x 10(3) per mite. D. farinae had significantly higher CFUs than the other species. Bacteria were located in the digestive and reproductive tract, parenchymatical tissue, and in bacteriocytes. Among the clones, Bartonella-like bacteria occurring in A. siro and T. putresecentiae represented a distinct group related to Bartonellaceae and to Bartonella-like symbionts of ants. The clones of high similarity to Xenorhabdus cabanillasii were found in L. destructor and D. farinae, and one clone related to Photorhabdus temperata in A. siro. Members of Sphingobacteriales cloned from D. farinae and A. siro clustered with the sequences of "Candidatus Cardinium hertigii" and as a separate novel cluster.
C1 [Hubert, Jan; Kopecky, Jan; Nesvorna, Marta; Sagova-Mareckova, Marketa] Res Inst Crop Prod, CR-16106 Prague 6, Ruzyne, Czech Republic.
   [Hubert, Jan] Med Ctr Prague, Prague 14300 4, Czech Republic.
   [Perotti, M. Alejandra] Univ Reading, Sch Biol Sci, Reading RG6 6AS, Berks, England.
   [Braig, Henk R.] Bangor Univ, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.
   [Macovei, Lilia] Forsyth Inst, Boston, MA 02142 USA.
   [Zurek, Ludek] Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA.
   [Zurek, Ludek] Kansas State Univ, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
RP Hubert, J (reprint author), Res Inst Crop Prod, Drnovska 507, CR-16106 Prague 6, Ruzyne, Czech Republic.
EM hubert@vurv.cz
RI Hubert, Jan/K-5489-2012; Kopecky, Jan/C-7400-2013; Braig,
   Henk/I-5477-2013; Mareckova, Marketa/D-9898-2017
OI Hubert, Jan/0000-0003-0740-166X; Kopecky, Jan/0000-0002-3437-257X;
   Braig, Henk/0000-0001-9592-1141; Mareckova, Marketa/0000-0002-0331-8570
FU Czech Science Foundation [GA525/09/1872]; Ministry of Education, Youth
   and Sports of the Czech Republic [ME09013]; OECD [AGR/PROG-JA00038773];
   Royal Society, UK
FX This work was supported by the Czech Science Foundation (grant no.
   GA525/09/1872); the Ministry of Education, Youth and Sports of the Czech
   Republic (grant no. ME09013); and by the OECD (project
   AGR/PROG-JA00038773). M. A. P. is supported by the Royal Society, UK.
NR 69
TC 26
Z9 30
U1 0
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0095-3628
EI 1432-184X
J9 MICROB ECOL
JI Microb. Ecol.
PD MAY
PY 2012
VL 63
IS 4
BP 919
EP 928
DI 10.1007/s00248-011-9969-6
PG 10
WC Ecology; Marine & Freshwater Biology; Microbiology
SC Environmental Sciences & Ecology; Marine & Freshwater Biology;
   Microbiology
GA 970KM
UT WOS:000306127300020
PM 22057398
ER

PT J
AU Fox, AN
   Vagefi, PA
   Stock, PG
AF Fox, Alyson N.
   Vagefi, Parsia A.
   Stock, Peter G.
TI Liver Transplantation in HIV Patients
SO SEMINARS IN LIVER DISEASE
LA English
DT Review
DE liver transplantation; HIV; viral hepatitis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; ACTIVE ANTIRETROVIRAL
   THERAPY; INFECTED PATIENTS; NATURAL-HISTORY; UNITED-STATES; B-VIRUS;
   HEPATOCELLULAR-CARCINOMA; COINFECTED PATIENTS; PROSPECTIVE COHORT
AB In the last three decades, the management of human immunodeficiency virus (HIV) has improved dramatically. The use of combination antiretroviral therapy (ART) has been successful at preventing death and the myriad infectious, malignant, and immune-mediated complications of HIV. Once considered to be a fatal disease, HIV is now considered by many to be a chronic disease; those affected may now live to experience complications of other coexistent diseases. Liver disease has been increasingly recognized as a leading cause of non-HIV/acquired immunodeficiency syndrome- (AIDS-) related morbidity and mortality in this population.(1-3) Although liver transplantation offers the opportunity to prolong life, the transplant community has been slow to recognize the chronicity of HIV and potential for transplantation within this population. The experience with liver transplantation in HIV-positive patients is evolving and successful outcomes have been observed when specific criteria are used to select candidates.
C1 [Stock, Peter G.] Univ Calif San Francisco, Dept Surg, Div Transplant Surg, San Francisco, CA 94143 USA.
   [Fox, Alyson N.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Ctr Liver Dis & Transplantat, New York, NY USA.
   [Vagefi, Parsia A.] Massachusetts Gen Hosp, Div Transplant Surg, Boston, MA 02114 USA.
RP Stock, PG (reprint author), Univ Calif San Francisco, Dept Surg, Div Transplant Surg, 505 Parnassus Ave,Box 0780, San Francisco, CA 94143 USA.
EM Peter.Stock@ucsfmedctr.org
NR 45
TC 17
Z9 17
U1 0
U2 1
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0272-8087
J9 SEMIN LIVER DIS
JI Semin. Liver Dis.
PD MAY
PY 2012
VL 32
IS 2
BP 177
EP 185
DI 10.1055/s-0032-1316474
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 969UL
UT WOS:000306084800010
PM 22760657
ER

PT J
AU Yiu, G
   Lessell, S
AF Yiu, Glenn
   Lessell, Simmons
TI Dorsal Midbrain Syndrome from a Ring-Enhancing Lesion
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Parinaud syndrome; Melanoma
ID OCULOMOTOR NERVE PALSY; METASTASIS; HYDROCEPHALUS
AB A ring-enhancing lesion is an uncommon cause of a dorsal midbrain syndrome. Here, we describe the case of a 60-year-old man with eye movement and pupillary findings consistent with dorsal midbrain syndrome, and in whom neuroimaging showed a single ring-enhancing lesion in the right midbrain and thalamus. Further investigation revealed a longstanding right groin mass which proved to be a malignant melanoma. His intracranial lesion was presumed to be a metastatic lesion, and treated with stereotactic radiosurgery. We report the patient's clinical course, and discuss the diagnosis and management of the solitary midbrain lesion.
C1 [Yiu, Glenn; Lessell, Simmons] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
RP Yiu, G (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM glenn_yiu@meei.harvard.edu
NR 15
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY-JUL
PY 2012
VL 27
IS 3-4
BP 65
EP 68
DI 10.3109/08820538.2012.680645
PG 4
WC Ophthalmology
SC Ophthalmology
GA 972MT
UT WOS:000306281900008
PM 22784268
ER

PT J
AU Morgenroth, DC
   Gellhorn, AC
   Suri, P
AF Morgenroth, David C.
   Gellhorn, Alfred C.
   Suri, Pradeep
TI Osteoarthritis in the Disabled Population: A Mechanical Perspective
SO PM&R
LA English
DT Article
ID COMPARTMENT KNEE OSTEOARTHRITIS; TRANS-TIBIAL AMPUTATION; BONE-MINERAL
   DENSITY; TO-STEP TRANSITIONS; REACTION FORCE DATA; SPINAL-CORD-INJURY;
   LOW-BACK-PAIN; HUMAN WALKING; PROSTHETIC FEET; AMPUTEE GAIT
AB Primary disabling conditions, such as amputation, not only limit mobility, but also predispose individuals to secondary musculoskeletal impairments, such as osteoarthritis (OA) of the intact limb joints, that can result in additive disability. Altered gait biomechanics that cause increased loading of the intact limb have been suggested as a cause of the increased prevalence of intact limb knee and hip osteoarthritis in this population. Optimizing socket fit and prosthetic alignment, as well as developing and prescribing prosthetic feet with improved push-off characteristics, can lead to reduced asymmetric loading of the intact limb and therefore are potential strategies to prevent and treat osteoarthritis in the amputee population. Research on disabled populations associated with altered biomechanics offers an opportunity to focus on the mechanical risk factors associated with this condition. Continued research into the causes of secondary disability and the development of preventive strategies are critical to enable optimal rehabilitation practices to maximize function and quality of life in patients with disabilities. PM R 2012;4:S20-S27
C1 [Morgenroth, David C.] Vet Affairs Puget Sound Healthcare Syst, RR&D Res Ctr, Seattle, WA USA.
   [Morgenroth, David C.; Gellhorn, Alfred C.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Suri, Pradeep] Vet Affairs Boston Healthcare Syst, Div Phys Med & Rehabil, Boston, MA USA.
   [Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
   [Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA.
   [Suri, Pradeep] New England Baptist Hosp, Boston, MA USA.
RP Morgenroth, DC (reprint author), RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dmorgen@uw.edu
FU NIH [K12 HD001097]
FX 8B, NIH (grant #K12 HD001097)
NR 94
TC 32
Z9 34
U1 4
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2012
VL 4
IS 5
SU 1
BP S20
EP S27
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 966YJ
UT WOS:000305873000004
PM 22632698
ER

PT J
AU Suri, P
   Morgenroth, DC
   Hunter, DJ
AF Suri, Pradeep
   Morgenroth, David C.
   Hunter, David J.
TI Epidemiology of Osteoarthritis and Associated Comorbidities
SO PM&R
LA English
DT Article
ID BONE-MINERAL DENSITY; SYMPTOMATIC KNEE OSTEOARTHRITIS; LIMB LENGTH
   INEQUALITY; ANTERIOR CRUCIATE LIGAMENT; POPULATION-BASED COHORT;
   VITAMIN-D STATUS; BODY-MASS INDEX; LOW-BACK-PAIN; HIP OSTEOARTHRITIS;
   OLDER-ADULTS
AB Osteoarthritis (OA) is the most common cause of walking-related disability among older adults in the United States, and the prevalence and incidence of OA are increasing rapidly. Systemic and local risk factors for knee OA have been identified, and obesity and joint injury appear to be the strongest risk factors that are both modifiable and have the potential for substantial impact on a population level. The risk factors for functional decline and disability in persons with symptomatic OA have been examined in relatively few studies. The course of functional decline in persons with symptomatic OA on a population level is generally one of stable to slowly deteriorating function, but on an individual level, many patients maintain function or improve during the first 3 years of follow-up. Obesity stands out as one of few modifiable risk factors of OA that also is a potentially modifiable predictor of functional decline. Physical activity also appears to have a substantial protective impact on future OA-related disability. Further epidemiologic studies and randomized controlled trials are needed to prioritize prevention through targeting these modifiable risk factors for OA and related disability. PM R 2012;4:S10-S19
C1 [Suri, Pradeep] VA Boston Healthcare Syst, Div PM&R, Boston, MA 02130 USA.
   [Suri, Pradeep] Harvard Univ, Sch Med, Dept PM&R, Cambridge, MA 02138 USA.
   [Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA.
   [Suri, Pradeep] New England Baptist Hosp, Boston, MA USA.
   [Morgenroth, David C.] VA Puget Sound Healthcare Syst, RR&D Res Ctr, Seattle, WA USA.
   [Morgenroth, David C.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Hunter, David J.] Univ Sydney, No Clin Sch, Sydney, NSW 2006, Australia.
RP Suri, P (reprint author), VA Boston Healthcare Syst, Div PM&R, JP Campus,150 S Huntington Ave, Boston, MA 02130 USA.
EM pradeep.suri@va.gov
RI Hunter, David/A-4622-2010; 
OI Hunter, David/0000-0003-3197-752X; Morgenroth, David/0000-0002-0226-7775
FU NIH [K12 HD001097]
FX 8B, NIH (grant #K12 HD001097)
NR 120
TC 55
Z9 59
U1 3
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2012
VL 4
IS 5
SU 1
BP S10
EP S19
DI 10.1016/j.pmrj.2012.01.007
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 966YJ
UT WOS:000305873000003
PM 22632687
ER

PT J
AU Balon, R
   Coverdale, JH
   Beresin, EV
   Louie, AK
   Roberts, LW
AF Balon, Richard
   Coverdale, John H.
   Beresin, Eugene V.
   Louie, Alan K.
   Roberts, Laura Weiss
TI Richness and Creativity in Medical Student Education in Psychiatry
SO ACADEMIC PSYCHIATRY
LA English
DT Editorial Material
C1 [Balon, Richard] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA.
   [Balon, Richard] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA.
   [Coverdale, John H.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
   [Coverdale, John H.] Baylor Coll Med, Ctr Eth, Houston, TX 77030 USA.
   [Beresin, Eugene V.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
   [Beresin, Eugene V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Louie, Alan K.] UCSF, Dept Psychiat, San Francisco, CA USA.
   [Roberts, Laura Weiss] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
RP Balon, R (reprint author), UPC Jefferson, 2751 E Jefferson 200, Detroit, MI USA.
EM rbalon@wayne.edu
NR 23
TC 1
Z9 1
U1 0
U2 3
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1042-9670
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD MAY-JUN
PY 2012
VL 36
IS 3
BP 159
EP 162
PG 4
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA 964DJ
UT WOS:000305673600001
PM 22751812
ER

PT J
AU Sidhu, SS
   Chandra, RM
   Wang, L
   Gollan, JK
   Rasminsky, S
   Brar, SK
   Anzia, JM
AF Sidhu, Shawn S.
   Chandra, Rohit M.
   Wang, Lei
   Gollan, Jacqueline K.
   Rasminsky, Sonya
   Brar, Simerjeet K.
   Anzia, Joan M.
TI The Effect of an End-of-Clerkship Review Session on NBME Psychiatry
   Subject Exam Scores
SO ACADEMIC PSYCHIATRY
LA English
DT Review
ID STUDENT PERFORMANCE
AB Objective: The NBME Psychiatry Subject Examination (PSE) is used throughout North America to test MS-III end-of-clerkship knowledge; yet, literature on PSE preparatory methods remains sparse. This study assesses the effect of a curriculum intervention on NBME PSE scores.
   Method: An optional 1.5-hour review session and accompanying fill-in-the-blank handout was offered to 62 MS-III students 3 days before their exam. Students who did not attend the session were e-mailed the handout with completed answers. The primary outcome measure was a change in scores, with students in the previous year serving as the control group.
   Results: The average raw PSE score of students offered the review session was 84.53, versus 77.15 for matched controls (p < 0.0001). The effect size for the intervention was 0.89.
   Conclusion: This study may suggest that offering a comprehensive review session to third-year medical students 3 days before their NBME PSE significantly improves their scores.
C1 [Sidhu, Shawn S.; Wang, Lei; Gollan, Jacqueline K.; Rasminsky, Sonya; Brar, Simerjeet K.; Anzia, Joan M.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA.
   [Chandra, Rohit M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Child & Adolescent Psychiat, Cambridge, MA 02138 USA.
RP Sidhu, SS (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA.
EM shawnsidhu@yahoo.com
OI Wang, Lei/0000-0003-3870-3388
NR 9
TC 3
Z9 3
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1042-9670
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD MAY-JUN
PY 2012
VL 36
IS 3
BP 226
EP 228
PG 3
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA 964DJ
UT WOS:000305673600016
PM 22751827
ER

PT J
AU Schlozman, SC
AF Schlozman, Steven C.
TI A Unique Tool for Teaching Development: A Review of Dr. Geri Fox's 20
   Years of Family Video Material Created to Teach Human Development
SO ACADEMIC PSYCHIATRY
LA English
DT Editorial Material
C1 [Schlozman, Steven C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
   [Schlozman, Steven C.] McLean Hosp, Massachusetts Gen Hosp, Dept Child & Adolescent Psychiat, Boston, MA USA.
RP Schlozman, SC (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
EM sschlozman@partners.org
NR 6
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD MAY-JUN
PY 2012
VL 36
IS 3
BP 256
EP 257
PG 2
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA 964DJ
UT WOS:000305673600025
PM 22751836
ER

PT J
AU Hadlock, T
AF Hadlock, Tessa
TI Evaluation and Management of the Patient With Postoperative Facial
   Paralysis
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Review
ID FACE
AB Postoperative facial paralysis comprises a spectrum of injuries ranging from mild, temporary weakness to severe, permanent paralysis, affecting as little as one muscle group to as much as the full hemiface. Herein is presented an introductory review of iatrogenic facial paralysis, from initial evaluation and decision making to the full range of conservative and operative management. Arch Otolaryngol Head Neck Surg. 2012; 138(5): 505-508
C1 Massachusetts Eye & Ear Infirm, Dept Facial Plast & Reconstruct Surg, Boston, MA 02114 USA.
RP Hadlock, T (reprint author), Massachusetts Eye & Ear Infirm, Dept Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA.
EM tessa_hadlock@meei.harvard.edu
NR 9
TC 1
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0886-4470
EI 1538-361X
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD MAY
PY 2012
VL 138
IS 5
BP 505
EP 508
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 960TZ
UT WOS:000305415100011
PM 22652950
ER

PT J
AU Lee, CP
   Hoffmann, U
   Bamberg, F
   Brown, DF
   Chang, YC
   Swap, C
   Parry, BA
   Nagurney, JT
AF Lee, Chuen Peng
   Hoffmann, Udo
   Bamberg, Fabian
   Brown, David F.
   Chang, Yuchaio
   Swap, Clifford
   Parry, Blair A.
   Nagurney, John T.
TI Emergency physician estimates of the probability of acute coronary
   syndrome in a cohort of patients enrolled in a study of coronary
   computed tomographic angiography
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CHEST-PAIN; ACUTE CARDIAC ISCHEMIA;
   ST-SEGMENT ELEVATION; TIMI RISK SCORE; UNSTABLE ANGINA; CLINICAL
   CHARACTERISTICS; TRIAGE DECISIONS; EARLY-DIAGNOSIS; ELECTROCARDIOGRAMS
AB Introduction:
   Little information exists regarding how accurately emergency physicians (EPs) predict the probability of acute coronary syndrome (ACS). Our objective was to determine if EPs can accurately predict ACS in a prospectively identified cohort of emergency department (ED) patients who met enrolment criteria for a study of coronary computed tomographic angiography (CCTA) and were admitted for a "rule out ACS" protocol.
   Methods:
   A prospective observational pilot study in an academic medical centre was carried out. EPs caring for patients with chest pain provided whole-number estimates of the probability of ACS after clinical review. This substudy was part of the now published Rule Out Myocardial Infarction/Ischemia Using Computer Assisted Tomography (ROMICAT) study, a study of CCTA and admission of patients for a rule out ACS protocol after a nondiagnostic evaluation. Predictions were grouped into probability groups based on the validated Goldman criteria. ACS was determined by an adjudication committee using American Heart Association/American College of Cardiology/European Society of Cardiology guidelines.
   Results:
   A total of 334 predictions were obtained for a study population with a mean age of 54 (SD 12) years, 63% of whom were male. There were 35 ACS events. EPs predicted ACS better than by chance, and increasingly higher estimates were associated with a higher incidence of ACS (p = 0.0004). The percentage of patients with ACS was 0%, 6%, 7%, and 17%, respectively, for very low, low, intermediate, and high probability groups. EPs' estimates had a sensitivity of 63% using a > 20% probability of ACS to define a positive test. Lowering this threshold to > 7% to define a test as positive increased the sensitivity of physician estimates to 89% but lowered specificity from 65% to 24%.
   Conclusion:
   Our data suggest that for a selected ED cohort meeting eligibility criteria for a study of CCTA, EPs predict ACS better than by chance, with an increasing proportion of patients proving to have ACS with increasing probability estimates. Lowering the estimate threshold does not result in an overall sensitivity level that is sufficient to send patients home from the ED and is associated with a poor specificity.
C1 [Brown, David F.; Swap, Clifford; Parry, Blair A.; Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
   [Lee, Chuen Peng] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore.
   [Hoffmann, Udo; Bamberg, Fabian] Massachusetts Gen Hosp, Dept Cardiac Imaging, Boston, MA 02114 USA.
   [Chang, Yuchaio] Massachusetts Gen Hosp, Dept Gen Internal Med, Boston, MA 02114 USA.
RP Nagurney, JT (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.
EM nagurney.john@mgh.harvard.edu
NR 45
TC 0
Z9 0
U1 0
U2 5
PU DECKER PUBL INC
PI HAMILTON
PA 69 JOHN ST S, STE 310, HAMILTON, ONTARIO L8N 2B9, CANADA
SN 1481-8035
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD MAY
PY 2012
VL 14
IS 3
BP 147
EP U79
PG 14
WC Emergency Medicine
SC Emergency Medicine
GA 963FQ
UT WOS:000305605900003
PM 22575295
ER

PT J
AU Bautista, PA
   Yagi, Y
AF Bautista, Pinky A.
   Yagi, Yukako
TI Digital simulation of staining in histopathology multispectral images:
   enhancement and linear transformation of spectral transmittance
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE hyperspectral imaging; image analysis; image processing; image
   understanding; multispectral enhancement; digital staining
ID QUANTIFICATION; CLASSIFICATION; TECHNOLOGY
AB Hematoxylin and eosin (H&E) stain is currently the most popular for routine histopathology staining. Special and/or immuno-histochemical (IHC) staining is often requested to further corroborate the initial diagnosis on H&E stained tissue sections. Digital simulation of staining (or digital staining) can be a very valuable tool to produce the desired stained images from the H&E stained tissue sections instantaneously. We present an approach to digital staining of histopathology multispectral images by combining the effects of spectral enhancement and spectral transformation. Spectral enhancement is accomplished by shifting the N-band original spectrum of the multispectral pixel with the weighted difference between the pixel's original and estimated spectrum; the spectrum is estimated using M < N principal component (PC) vectors. The pixel's enhanced spectrum is transformed to the spectral configuration associated to its reaction to a specific stain by utilizing an N x N transformation matrix, which is derived through application of least mean squares method to the enhanced and target spectral transmittance samples of the different tissue components found in the image. Results of our experiments on the digital conversion of an H&E stained multispectral image to its Masson's trichrome stained equivalent show the viability of the method. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.5.056013]
C1 [Bautista, Pinky A.; Yagi, Yukako] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
RP Bautista, PA (reprint author), Pathol Imaging & Commun Technol PICT Ctr, 101 Merrimac St,Suite 820, Boston, MA 02114 USA.
EM pbautista@partners.org
FU Olympus Inc., Japan
FX This work is supported in part by Olympus Inc., Japan.
NR 27
TC 7
Z9 7
U1 0
U2 11
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY
PY 2012
VL 17
IS 5
AR 056013
DI 10.1117/1.JBO.17.5.056013
PG 10
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 962WU
UT WOS:000305579600021
PM 22612136
ER

PT J
AU Goergen, CJ
   Chen, HH
   Bogdanov, A
   Sosnovik, DE
   Kumar, ATN
AF Goergen, Craig J.
   Chen, Howard H.
   Bogdanov, Alexei, Jr.
   Sosnovik, David E.
   Kumar, Anand T. N.
TI In vivo fluorescence lifetime detection of an activatable probe in
   infarcted myocardium
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE near-infrared fluorescence; lifetime; myocardium; protease
ID PROTEASE ACTIVITY; MOLECULAR PROBES; CONTRAST; FLUOROPHORES; TOMOGRAPHY;
   RESOLUTION; PROTEINS; SYSTEM; MODEL; CELL
AB Activatable fluorescent molecular probes are predominantly nonfluorescent in their inactivated state due to intramolecular quenching, but increase fluorescence yield significantly after enzyme-mediated hydrolysis of peptides. Continuous wave in vivo detection of these protease-activatable fluorophores in the heart, however, is limited by the inability to differentiate between activated and nonactivated fractions of the probe and is frequently complicated by large background signal from probe accumulation in the liver. Using a cathepsin-activatable near-infrared probe (PGC-800), we demonstrate here that fluorescence lifetime (FL) significantly increases in infarcted murine myocardial tissue (0.67 ns) when compared with healthy myocardium (0.59 ns) after 24 h. Furthermore, we show that lifetime contrast can be used to distinguish in vivo cardiac fluorescence from background nonspecific liver signal. The results of this study show that lifetime contrast is a helpful addition to preclinical imaging of activatable fluorophores in the myocardium by reporting molecular activity in vivo due to changes in intramolecular quenching. This characterization of FL from activatable molecular probes will be helpful for advancing in vivo imaging of enzyme activity. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI:10.1117/1.JBO.17.5.056001]
C1 [Goergen, Craig J.; Kumar, Anand T. N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
   [Chen, Howard H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
   [Bogdanov, Alexei, Jr.] Univ Massachusetts, Sch Med, Lab Mol Imaging Probes, Dept Radiol, Worcester, MA 01605 USA.
   [Sosnovik, David E.] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
   [Sosnovik, David E.] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
RP Kumar, ATN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM ankumar@nmr.mgh.harvard.edu
OI Goergen, Craig/0000-0001-8883-7953
FU NIH [R01 HL093038, R01 AG026240, R01 EB015325, T32 HL076136]
FX This study was supported by NIH Grants R01 HL093038, R01 AG026240, R01
   EB015325, and T32 HL076136. We also gratefully acknowledge Soeun Ngoy
   for his surgical help and Thomas J. Brady, MD, for his support.
NR 31
TC 11
Z9 11
U1 0
U2 10
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY
PY 2012
VL 17
IS 5
AR 056001
DI 10.1117/1.JBO.17.5.056001
PG 6
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 962WU
UT WOS:000305579600009
PM 22612124
ER

PT J
AU Islam, MS
   Oliveira, MC
   Wang, Y
   Henry, FP
   Randolph, MA
   Park, BH
   de Boer, JF
AF Islam, M. Shahidul
   Oliveira, Michael C.
   Wang, Yan
   Henry, Francis P.
   Randolph, Mark A.
   Park, B. Hyle
   de Boer, Johannes F.
TI Extracting structural features of rat sciatic nerve using
   polarization-sensitive spectral domain optical coherence tomography
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE sciatic nerve; optical coherence tomography; bands of Fontana; myelin;
   epineurium; birefringence
ID BIOLOGICAL TISSUE; BIREFRINGENCE CHARACTERIZATION; PERIPHERAL-NERVES;
   INJURY; BIOPSY; TECHNOLOGY; FONTANA; FIBERS; REPAIR; BANDS
AB We present spectral domain polarization-sensitive optical coherence tomography (SD PS-OCT) imaging of peripheral nerves. Structural and polarization-sensitive OCT imaging of uninjured rat sciatic nerves was evaluated both qualitatively and quantitatively. OCT and its functional extension, PS-OCT, were used to image sciatic nerve structure with clear delineation of the nerve boundaries to muscle and adipose tissues. A long-known optical effect, bands of Fontana, was also observed. Postprocessing analysis of these images provided significant quantitative information, such as epineurium thickness, estimates of extinction coefficient and birefringence of nerve and muscle tissue, frequency of bands of Fontana at different stretch levels of nerve, and change in average birefringence of nerve under stretched condition. We demonstrate that PS-OCT combined with regular-intensity OCT (compared with OCT alone) allows for a clearer determination of the inner and outer boundaries of the epineurium and distinction of nerve and muscle based on their birefringence pattern. PS-OCT measurements on normal nerves show that the technique is promising for studies on peripheral nerve injury. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.5.056012]
C1 [Islam, M. Shahidul; Oliveira, Michael C.; Wang, Yan; Park, B. Hyle] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Randolph, Mark A.] Massachusetts Gen Hosp, Plast Surg Res Lab, Boston, MA 02114 USA.
   [de Boer, Johannes F.] Vrije Univ Amsterdam, Dept Phys, Amsterdam, Netherlands.
RP Park, BH (reprint author), Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
EM hylepark@engr.ucr.edu
RI de Boer, Johannes/B-7590-2012; 
OI de Boer, Johannes/0000-0003-1253-4950; Henry, Francis
   P./0000-0003-4170-7806; Wang, Yan/0000-0002-6401-7464
FU National Institutes of Health [R00EB007241]; Department of
   Bioengineering at University of California Riverside; Center for
   Bioengineering Research; Wellman Center for Photomedicine at
   Massachusetts General Hospital
FX This research was supported in part by a research grant from the
   National Institutes of Health (R00EB007241). Support from the Department
   of Bioengineering at University of California Riverside, the Center for
   Bioengineering Research, and the Wellman Center for Photomedicine at
   Massachusetts General Hospital are also gratefully acknowledged. The
   authors thank Xorge E. Alanis for his contribution in data processing.
NR 41
TC 6
Z9 7
U1 2
U2 9
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY
PY 2012
VL 17
IS 5
AR 056012
DI 10.1117/1.JBO.17.5.056012
PG 9
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 962WU
UT WOS:000305579600020
PM 22612135
ER

PT J
AU Mutluoglu, M
   Uzun, G
   Turhan, V
   Gorenek, L
   Ay, H
   Lipsky, BA
AF Mutluoglu, Mesut
   Uzun, Gunalp
   Turhan, Vedat
   Gorenek, Levent
   Ay, Hakan
   Lipsky, Benjamin A.
TI How reliable are cultures of specimens from superficial swabs compared
   with those of deep tissue in patients with diabetic foot ulcers?
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetic foot ulcer; Swab culture; Tissue biopsy; Wound microbiology
ID RESISTANT STAPHYLOCOCCUS-AUREUS; INFECTION; MICROBIOLOGY; MANAGEMENT;
   CONSENSUS; ISCHEMIA; DISEASE; WOUNDS; BURDEN; BIOPSY
AB Purpose: To assess the reliability of cultures of superficial swabs (SS) by comparing them with cultures of concomitantly obtained deep tissue (DT) specimens in patients with diabetic foot ulcers.
   Methods: We reviewed clinical and microbiological data from patients with diabetes who presented during a two-year period to our hyperbaric medicine center with a foot ulcer. We identified patients who had at least one concomitantly collected SS and DT pair of specimens sent for culture.
   Results: A total of 89 culture pairs were available from 54 eligible patients, 33 (61.1%) of whom were hospitalized. Wounds were infected in 47 (87.0%) of the patients and 28 (51.9%) patients had received antibiotic therapy within the previous month. Overall, 65(73%) of the SS and DT pairs had identical culture results, but in 11(16.9%) cases the cultures were sterile; thus, only 54 (69.2%) of the 78 culture-positive pairs had identical results. Compared with DT, SS cultures yielded >= 1 extra organism in 10 (11.2%) cases, missed at least one organism in 8 (9.0%), and were completely different in 6 (6.7%). When compared to DT culture results, SS cultures had a positive predictive value of 84.4%, negative predictive value of 44.0%, and overall accuracy of 73.0%.
   Conclusions: In patients with diabetic foot ulcers, results of specimens for culture taken by SS did not correlate well with those obtained by DT. This suggests that SS specimens may be less reliable for guiding antimicrobial therapy than DT specimens. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Mutluoglu, Mesut; Uzun, Gunalp; Ay, Hakan] GATA Haydarpasa Teaching Hosp, Dept Underwater & Hyperbar Med, TR-34668 Istanbul, Turkey.
   [Turhan, Vedat; Gorenek, Levent] GATA Haydarpasa Teaching Hosp, Dept Infect Dis & Clin Microbiol, TR-34668 Istanbul, Turkey.
   [Lipsky, Benjamin A.] Univ Washington, Primary Care Clin, VA Puget Sound, Seattle, WA 98108 USA.
RP Mutluoglu, M (reprint author), Haydarpasa Teaching Hosp, Gulhane Mil Med Acad, Dept Underwater & Hyperbar Med, TR-34668 Istanbul, Turkey.
EM drmutluoglu@gmail.com; balipsky@uw.edu
RI mutluoglu, mesut/B-4451-2009; 
OI Lipsky, Benjamin A./0000-0001-9886-5114; Mutluoglu,
   Mesut/0000-0002-1112-5779; Uzun, Gunalp/0000-0002-8717-6230
NR 25
TC 14
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAY-JUN
PY 2012
VL 26
IS 3
BP 225
EP 229
DI 10.1016/j.jdiacomp.2012.03.015
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 960BH
UT WOS:000305362500013
PM 22520404
ER

PT J
AU Itri, JN
   Krishnaraj, A
AF Itri, Jason N.
   Krishnaraj, Arun
TI Do We Need a National Incident Reporting System for Medical Imaging?
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Incident reporting; quality improvement; error; registry; GRID
ID PATIENT SAFETY; AIMS-ICU; EXPERIENCE; LESSONS; ERRORS; CARE
AB The essential role of an incident reporting system as a tool to improve safety and reliability has been described in high-risk industries such as aviation and nuclear power, with anesthesia being the first medical specialty to successfully integrate incident reporting into a comprehensive quality improvement strategy. Establishing an incident reporting system for medical imaging that effectively captures system errors and drives improvement in the delivery of imaging services is a key component of developing and evaluating national quality improvement initiatives in radiology. Such a national incident reporting system would be most effective if implemented as one piece of a comprehensive quality improvement strategy designed to enhance knowledge about safety, identify and learn from errors, raise standards and expectations for improvement, and create safer systems through implementation of safe practices. The potential benefits of a national incident reporting system for medical imaging include reduced morbidity and mortality, improved patient and referring physician satisfaction, reduced health care expenses and medical liability costs, and improved radiologist satisfaction. The purposes of this article are to highlight the positive impact of external reporting systems, discuss how similar advancements in quality and safety can be achieved with an incident reporting system for medical imaging in the United States, and describe current efforts within the imaging community toward achieving this goal.
C1 [Itri, Jason N.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
   [Krishnaraj, Arun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
RP Itri, JN (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM jason.itri@uphs.upenn.edu
NR 35
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2012
VL 9
IS 5
BP 329
EP 335
DI 10.1016/j.jacr.2011.11.015
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 961FN
UT WOS:000305449700009
PM 22554630
ER

PT J
AU Scheinfeld, MH
   Campe, C
   Avery, LL
AF Scheinfeld, Meir H.
   Campe, Carson
   Avery, Laura L.
TI Radiology Goes Back to School: Presenting the Face of Radiology to
   School Children
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Scheinfeld, Meir H.] Montefiore Med Ctr, Dept Radiol, Div Emergency Radiol, Bronx, NY 10467 USA.
   [Campe, Carson; Avery, Laura L.] Massachusetts Gen Hosp, Dept Radiol, Div Emergency Radiol, Boston, MA 02114 USA.
RP Scheinfeld, MH (reprint author), Montefiore Med Ctr, Dept Radiol, Div Emergency Radiol, 111 E 210th St, Bronx, NY 10467 USA.
EM mscheinf@montefiore.org
OI Scheinfeld, Meir H/0000-0001-8880-4318
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2012
VL 9
IS 5
BP 363
EP 365
DI 10.1016/j.jacr.2011.12.012
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 961FN
UT WOS:000305449700015
PM 22554636
ER

PT J
AU Narayanavari, SA
   Sritharan, M
   Haake, DA
   Matsunaga, J
AF Narayanavari, Suneel A.
   Sritharan, Manjula
   Haake, David A.
   Matsunaga, James
TI Multiple leptospiral sphingomyelinases (or are there?)
SO MICROBIOLOGY-SGM
LA English
DT Review
ID BACILLUS-CEREUS SPHINGOMYELINASE; INTERROGANS SEROVAR HARDJO;
   STAPHYLOCOCCUS-AUREUS; BETA-TOXIN; NEUTRAL SPHINGOMYELINASE; BINDING
   PROTEIN; HEMOLYSIN; LAI; EXPRESSION; MATRIX
AB Culture supernatants of leptospiral pathogens have long been known to haemolyse erythrocytes. This property is due, at least in part, to sphingomyelinase activity. Indeed, genome sequencing reveals that pathogenic Leptospira species are richly endowed with sphingomyelinase homologues: five genes have been annotated to encode sphingomyelinases in Leptospira interrogans. Such redundancy suggests that this class of genes is likely to benefit leptospiral pathogens in their interactions with the mammalian host. Surprisingly, sequence comparison with bacterial sphingomyelinases for which the crystal structures are known reveals that only one of the leptospiral homologues has the active site amino acid residues required for enzymic activity. Based on studies of other bacterial toxins, we propose that leptospiral sphingomyelinase homologues, irrespective of their catalytic activity, may possess additional molecular functions that benefit the spirochaete. Potential secretion pathways and roles in pathogenesis are discussed, including nutrient acquisition, dissemination, haemorrhage and immune evasion. Although leptospiral sphingomyelinase-like proteins are best known for their cytolytic properties, we believe that a better understanding of their biological role requires the examination of their sublytic properties as well.
C1 [Narayanavari, Suneel A.; Sritharan, Manjula] Univ Hyderabad, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India.
   [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
   [Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
   [Haake, David A.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
   [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA USA.
   [Matsunaga, James] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
RP Narayanavari, SA (reprint author), Univ Hyderabad, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India.
EM leptolysin@gmail.com
FU Public Health Service National Institute of Allergy and Infectious
   Diseases [AI-034431]; VA Medical Research Funds; United States India
   Educational Foundation (USIEF)
FX S. A. N. would like to acknowledge the United States India Educational
   Foundation (USIEF) for financial support in the form of Fulbright Nehru
   Doctoral and Professional Research Fellowship. This study was supported
   by Public Health Service National Institute of Allergy and Infectious
   Diseases grant AI-034431 (to D. A. H.) and VA Medical Research Funds (to
   J. M. and D. A. H.). We thank Ben Adler (Monash University) for
   providing the sphingomyelinase sequences of Lept. interrogans serovars
   Manilae and Pomona.
NR 60
TC 9
Z9 9
U1 0
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD MAY
PY 2012
VL 158
BP 1137
EP 1146
DI 10.1099/mic.0.057737-0
PN 5
PG 10
WC Microbiology
SC Microbiology
GA 960GL
UT WOS:000305375900001
PM 22422753
ER

PT J
AU Ritch, JJ
   Valencia, A
   Alexander, J
   Sapp, E
   Gatune, L
   Sangrey, GR
   Sinha, S
   Scherber, CM
   Zeitlin, S
   Sadri-Vakili, G
   Irimia, D
   DiFiglia, M
   Kegel, KB
AF Ritch, James J.
   Valencia, Antonio
   Alexander, Jonathan
   Sapp, Ellen
   Gatune, Leah
   Sangrey, Gavin R.
   Sinha, Saurabh
   Scherber, Cally M.
   Zeitlin, Scott
   Sadri-Vakili, Ghazaleh
   Irimia, Daniel
   DiFiglia, Marian
   Kegel, Kimberly B.
TI Multiple phenotypes in Huntington disease mouse neural stem cells
SO MOLECULAR AND CELLULAR NEUROSCIENCE
LA English
DT Article
DE Embryonic stem cell; Mutant huntingtin; Neural stem; Cholesterol;
   Reactive oxygen species (ROS); Reactive oxygen intermediates (ROI);
   Motility; Actin; GFAP; Astrocytes
ID KNOCK-IN MICE; NEURODEGENERATIVE DISEASE; NEURONAL DIFFERENTIATION;
   NUCLEAR-LOCALIZATION; MUTANT HUNTINGTIN; OXIDATIVE STRESS; CAG REPEATS;
   GENE; EXPRESSION; PROTEIN
AB Neural stem (NS) cells are a limitless resource, and thus superior to primary neurons for drug discovery provided they exhibit appropriate disease phenotypes. Here we established NS cells for cellular studies of Huntington's disease (HD). HD is a heritable neurodegenerative disease caused by a mutation resulting in an increased number of glutamines (Q) within a polyglutamine tract in Huntingtin (Htt). NS cells were isolated from embryonic wild-type (Htt(7Q/7Q)) and "knock-in" HD (Htt(140Q/140Q)) mice expressing full-length endogenous normal or mutant Htt. NS cells were also developed from mouse embryonic stem cells that were devoid of Htt (Htt(-/-)), or knock-in cells containing human exon1 with an N-terminal FLAG epitope tag and with 7Q or 140Q inserted into one of the mouse alleles (Htt(F7Q/7Q) and Htt(F140Q/7Q)). Compared to Htt(7Q/7Q) NS cells, HD Htt(140Q/140Q) NS cells showed significantly reduced levels of cholesterol, increased levels of reactive oxygen species (ROS), and impaired motility. The heterozygous Htt(F140Q/7Q) NS cells had increased ROS and decreased motility compared to Htt(F7Q/7Q). These phenotypes of HD NS cells replicate those seen in HD patients or in primary cell or in vivo models of HD. Huntingtin "knock-out" NS cells (Htt(-/-)) also had impaired motility, but in contrast to HD cells had increased cholesterol. In addition, Htt(140Q/140Q) NS cells had higher phospho-AKT/AKT ratios than Htt(7Q/7Q) NS cells in resting conditions and after BDNF stimulation, suggesting mutant htt affects AKT dependent growth factor signaling. Upon differentiation, the Htt(7Q/7Q) and Htt(140Q/140Q) generated numerous Beta(III)-Tubulin- and GABA-positive neurons; however, after 15 days the cellular architecture of the differentiated Htt(140Q/140Q) cultures changed compared to Htt(7Q/7Q) cultures and included a marked increase of GFAP-positive cells. Our findings suggest that NS cells expressing endogenous mutant Htt will be useful for study of mechanisms of HD and drug discovery. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Ritch, James J.; Valencia, Antonio; Alexander, Jonathan; Sapp, Ellen; Gatune, Leah; Sangrey, Gavin R.; Sinha, Saurabh; Sadri-Vakili, Ghazaleh; DiFiglia, Marian; Kegel, Kimberly B.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis MIND, Charlestown, MA 02129 USA.
   [Zeitlin, Scott] Univ Virginia, Dept Neurosci, Charlottesville, VA 22908 USA.
   [Scherber, Cally M.; Irimia, Daniel] Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Charlestown, MA 02129 USA.
RP Kegel, KB (reprint author), Massachusetts Gen Hosp E, Dept Neurol, 114 16th St,Room 2150, Charlestown, MA 02129 USA.
EM kkegel@partners.org
OI Irimia, Daniel/0000-0001-7347-2082
FU NICHD; Hereditary Disease Foundation; CHDI;  [CA135601]
FX The Rip monoclonal antibody developed by S. Hockfield, the RC2 antibody
   developed by E.J. de la Rosa and the 3CB2 antibody developed by M.
   Yamamoto were obtained from the Developmental Studies Hybridoma Bank
   developed under the auspices of the NICHD and maintained by The
   University of Iowa, Department of Biology, Iowa City, IA 52242. This
   work was funded by a grant from the Hereditary Disease Foundation to KBK
   and a grant from CHDI to KBK and a grant to DI for the cell migration
   assays (CA135601).
NR 57
TC 19
Z9 19
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1044-7431
J9 MOL CELL NEUROSCI
JI Mol. Cell. Neurosci.
PD MAY
PY 2012
VL 50
IS 1
BP 70
EP 81
DI 10.1016/j.mcn.2012.03.011
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 962LX
UT WOS:000305547700007
PM 22508027
ER

PT J
AU Furmaga, H
   Carreno, FR
   Frazer, A
AF Furmaga, Havan
   Carreno, Flavia Regina
   Frazer, Alan
TI Vagal Nerve Stimulation Rapidly Activates Brain-Derived Neurotrophic
   Factor Receptor TrkB in Rat Brain
SO PLOS ONE
LA English
DT Article
ID TREATMENT-RESISTANT DEPRESSION; HIPPOCAMPAL-NEURONS; GROWTH-FACTOR;
   SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR BDNF; SEROTONIN
   TRANSPORTER; ANTIDEPRESSANT ACTION; TRUNCATED RECEPTORS; GENE-EXPRESSION
AB Background: Vagal nerve stimulation (VNS) has been approved for treatment-resistant depression. Many antidepressants increase expression of brain-derived neurotrophic factor (BDNF) in brain or activate, via phosphorylation, its receptor, TrkB. There have been no studies yet of whether VNS would also cause phosphorylation of TrkB.
   Methods: Western blot analysis was used to evaluate the phosphorylation status of TrkB in the hippocampus of rats administered VNS either acutely or chronically. Acute effects of VNS were compared with those caused by fluoxetine or desipramine (DMI) whereas its chronic effects were compared with those of sertraline or DMI.
   Results: All treatments, given either acutely or chronically, significantly elevated phosphorylation of tyrosines 705 and 816 on TrkB in the hippocampus. However, only VNS increased the phosphorylation of tyrosine 515, with both acute and chronic administration causing this effect. Pretreatment with K252a, a nonspecific tyrosine kinase inhibitor, blocked the phosphorylation caused by acute VNS at all three tyrosines. Downstream effectors of Y515, namely Akt and ERK, were also phosphorylated after acute treatment with VNS, whereas DMI did not cause this effect.
   Conclusion: VNS rapidly activates TrkB phosphorylation and this effect persists over time. VNS-induced phosphorylation of tyrosine 515 is distinct from the effect of standard antidepressant drugs.
C1 [Furmaga, Havan; Carreno, Flavia Regina; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
   [Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Furmaga, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
EM frazer@uthscsa.edu
FU National Institute of Mental Health grant [R01 MH082933]; Cyberonics,
   Inc.
FX This work was supported by National Institute of Mental Health grant R01
   MH082933 (Alan Frazer). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; Drs. Furmaga and Carreno have no competing interests to
   declare. Previously, Dr. Frazer received financial compensation as a
   consultant for Cyberonics, Inc. and had also obtained grant support from
   them for a preclinical study. This does not alter the authors' adherence
   to all the PLoS ONE policies on sharing data and materials.
NR 66
TC 28
Z9 29
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2012
VL 7
IS 5
AR e34844
DI 10.1371/journal.pone.0034844
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UN
UT WOS:000305340700007
PM 22563458
ER

PT J
AU Peterson, AJ
   Jensen, PA
   Shimell, M
   Stefancsik, R
   Wijayatonge, R
   Herder, R
   Raftery, LA
   O'Connor, MB
AF Peterson, Aidan J.
   Jensen, Philip A.
   Shimell, MaryJane
   Stefancsik, Ray
   Wijayatonge, Ranjula
   Herder, Rachel
   Raftery, Laurel A.
   O'Connor, Michael B.
TI R-Smad Competition Controls Activin Receptor Output in Drosophila
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; BMP; SIGNALS; PHOSPHORYLATION; PROTEIN; EMBRYO;
   PROLIFERATION; ACTIVATION; MECHANISMS; COMPLEXES
AB Animals use TGF-beta superfamily signal transduction pathways during development and tissue maintenance. The superfamily has traditionally been divided into TGF-beta/Activin and BMP branches based on relationships between ligands, receptors, and R-Smads. Several previous reports have shown that, in cell culture systems, "BMP-specific" Smads can be phosphorylated in response to TGF-beta/Activin pathway activation. Using Drosophila cell culture as well as in vivo assays, we find that Baboon, the Drosophila TGF-beta/Activin-specific Type I receptor, can phosphorylate Mad, the BMP-specific R-Smad, in addition to its normal substrate, dSmad2. The Baboon-Mad activation appears direct because it occurs in the absence of canonical BMP Type I receptors. Wing phenotypes generated by Baboon gain-of-function require Mad, and are partially suppressed by over-expression of dSmad2. In the larval wing disc, activated Baboon cell-autonomously causes C-terminal Mad phosphorylation, but only when endogenous dSmad2 protein is depleted. The Baboon-Mad relationship is thus controlled by dSmad2 levels. Elevated P-Mad is seen in several tissues of dSmad2 protein-null mutant larvae, and these levels are normalized in dSmad2; baboon double mutants, indicating that the cross-talk reaction and Smad competition occur with endogenous levels of signaling components in vivo. In addition, we find that high levels of Activin signaling cause substantial turnover in dSmad2 protein, providing a potential cross-pathway signal-switching mechanism. We propose that the dual activity of TGF-beta/Activin receptors is an ancient feature, and we discuss several ways this activity can modulate TGF-beta signaling output.
C1 [Peterson, Aidan J.; Jensen, Philip A.; Shimell, MaryJane; Herder, Rachel; O'Connor, Michael B.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Stefancsik, Ray; Wijayatonge, Ranjula; Raftery, Laurel A.] Harvard Univ, Sch Med, Cutaneous Biol Res Ctr, Massachusetts Gen Hosp, Charlestown, MA USA.
   [Raftery, Laurel A.] Univ Nevada, Sch Life Sci, Las Vegas, NV 89154 USA.
RP Peterson, AJ (reprint author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM moconnor@umn.edu
RI Raftery, Laurel/H-1406-2012; 
OI Raftery, Laurel/0000-0003-4797-4163; Stefancsik,
   Raymund/0000-0001-8314-2140
FU National Institutes of Health [R01 GM95746, R01 GM060501, T32
   HD007430-11A1]
FX This work was supported by National Institutes of Health grants to MBO
   (R01 GM95746) and LAR (R01 GM060501). PAJ was supported in part by a
   National Institutes of Health Institutional Training Grant (T32
   HD007430-11A1). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
NR 30
TC 12
Z9 13
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2012
VL 7
IS 5
AR e36548
DI 10.1371/journal.pone.0036548
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UN
UT WOS:000305340700056
PM 22563507
ER

PT J
AU Ray, S
   Pyne, S
AF Ray, Surajit
   Pyne, Saumyadipta
TI A Computational Framework to Emulate the Human Perspective in Flow
   Cytometric Data Analysis
SO PLOS ONE
LA English
DT Article
ID MAXIMUM-LIKELIHOOD; TRANSFORMATIONS; DISPLAY
AB Background: In recent years, intense research efforts have focused on developing methods for automated flow cytometric data analysis. However, while designing such applications, little or no attention has been paid to the human perspective that is absolutely central to the manual gating process of identifying and characterizing cell populations. In particular, the assumption of many common techniques that cell populations could be modeled reliably with pre-specified distributions may not hold true in real-life samples, which can have populations of arbitrary shapes and considerable inter-sample variation.
   Results: To address this, we developed a new framework flowScape for emulating certain key aspects of the human perspective in analyzing flow data, which we implemented in multiple steps. First, flowScape begins with creating a mathematically rigorous map of the high-dimensional flow data landscape based on dense and sparse regions defined by relative concentrations of events around modes. In the second step, these modal clusters are connected with a global hierarchical structure. This representation allows flowScape to perform ridgeline analysis for both traversing the landscape and isolating cell populations at different levels of resolution. Finally, we extended manual gating with a new capacity for constructing templates that can identify target populations in terms of their relative parameters, as opposed to the more commonly used absolute or physical parameters. This allows flowScape to apply such templates in batch mode for detecting the corresponding populations in a flexible, sample-specific manner. We also demonstrated different applications of our framework to flow data analysis and show its superiority over other analytical methods.
   Conclusions: The human perspective, built on top of intuition and experience, is a very important component of flow cytometric data analysis. By emulating some of its approaches and extending these with automation and rigor, flowScape provides a flexible and robust framework for computational cytomics.
C1 [Ray, Surajit] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
   [Pyne, Saumyadipta] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Pyne, Saumyadipta] MIT, Broad Inst, Cambridge, MA 02139 USA.
   [Pyne, Saumyadipta] Harvard Univ, Cambridge, MA 02138 USA.
RP Ray, S (reprint author), Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
EM sray@math.bu.edu; spyne@broad.mit.edu
NR 44
TC 3
Z9 3
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2012
VL 7
IS 5
AR e35693
DI 10.1371/journal.pone.0035693
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UN
UT WOS:000305340700015
PM 22563466
ER

PT J
AU Chan, ST
   Fung, PK
   Ng, NY
   Ngan, TL
   Chong, MY
   Tang, CN
   He, JF
   Zheng, YP
AF Chan, Suk-Tak
   Fung, Po-Kwan
   Ng, Nim-Yu
   Ngan, Tsz-Lung
   Chong, Man-Yan
   Tang, Chi-Ngong
   He, Jun-Feng
   Zheng, Yong-Ping
TI Dynamic changes of elasticity, cross-sectional area, and fat
   infiltration of multifidus at different postures in men with chronic low
   back pain
SO SPINE JOURNAL
LA English
DT Article
DE Multifidus; Chronic low back pain; Elasticity; Cross-sectional area; Fat
   infiltration; Biomechanics
ID IN-VIVO ASSESSMENT; LUMBAR SPINE; MUSCLE; ULTRASOUND; MRI; CONTRACTION;
   DISABILITY; TISSUES; SYSTEM; SIZE
AB BACKGROUND CONTEXT: Multifidus cross-sectional area was often measured in chronic low back pain (LBP) patients to estimate the muscle activity for spinal stability. However, such estimation may be inadequate as the contribution of muscle elasticity in muscle activity is ignored. In vivo quantitative data on multifidus elasticity is therefore important for the study of muscle contractile function in response to motor control for spinal stability in chronic LBP patients.
   PURPOSE: The purpose of this study was to quantify the elasticity, cross-sectional area, and fat area of the multifidus for the contractile function and the distribution of deformable muscle tissue and nondeformable fat tissue at different postures in patients with and without chronic LBP.
   STUDY DESIGN/SETTING: This is a prospective study. Force-deformation data of the multifidus were acquired using ultrasound elastography. The anatomical changes of the multifidus were measured on the cross-sectional images of the multifidus acquired using B-mode ultrasound imaging.
   PATIENT SAMPLE: The sample comprised 12 adult male patients with chronic LBP and 12 asymptomatic male controls.
   OUTCOME MEASURES: The outcome measure was the elasticity of the multifidus at the L4 level for the assessment of muscle contractile function when patients were in the prone, upright, and 25 degrees and 45 degrees forward stooping positions. The cross-sectional area and fat area were also measured on the B-mode ultrasound images of the multifidus acquired at the same vertebral level and the postures.
   METHODS: With the patients in each of the prone, upright, and 25 degrees and 45 degrees forward stooping positions, ultrasound elastography and B-mode ultrasound imaging were performed on the left and right multifidus at the L4 level. The elasticity of multifidus indicated by the effective Young's modulus was derived from the force-deformation data acquired using ultrasound elastography. The cross-sectional area and fat area were assessed on the B-mode ultrasound images. The effective Young's modulus, cross-sectional area, and fat area were analyzed with multivariate general linear model analysis to investigate the possible effects of LBP and posture.
   RESULTS: There was an increasing stiffness of multifidus demonstrated by increasing effective Young's modulus from the prone to upright position and 25 degrees and 45 degrees forward stooping positions. Differences in multifidus stiffness between chronic LBP patients and asymptomatic controls were shown in the upright and 25 degrees and 45 degrees forward stooping positions but not in the prone position. The cross-sectional area of the multifidus increased from the prone position to the greatest value in the upright position and decreased in 25 degrees and 45 degrees forward stooping positions. Smaller multifidus cross-sectional area was demonstrated in chronic LBP patients than that in controls at all postures. No effect of posture on fat area within the multifidus was shown although the fat area within the multifidus was larger in chronic LBP patients.
   CONCLUSIONS: Different, changing patterns of elasticity and cross-sectional area were identified in the multifidus in relation to posture. Increased stiffness of multifidus in response to the physiologic range of static loads and smaller cross-sectional area was characterized in the chronic LBP condition for spinal stability. Ultrasound elastography offers in vivo assessment of muscle contractile function of deep trunk muscles, which benefits the future investigation of the neuromuscular regulating mechanism in LBP. It can also be applied to refine the palpatory skill for the physical assessment in sports training and physical therapy. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Chan, Suk-Tak] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
   [Fung, Po-Kwan; Ng, Nim-Yu; Ngan, Tsz-Lung; Chong, Man-Yan; Tang, Chi-Ngong; He, Jun-Feng; Zheng, Yong-Ping] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China.
RP Chan, ST (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St,Mailcode 149-2301, Charlestown, MA 02129 USA.
EM phoebe@nmr.mgh.harvard.edu
RI Chan, Suk-tak/G-5846-2015; 
OI Zheng, Yong-Ping/0000-0002-3407-9226
NR 33
TC 18
Z9 21
U1 2
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-9430
EI 1878-1632
J9 SPINE J
JI Spine Journal
PD MAY
PY 2012
VL 12
IS 5
BP 381
EP 388
DI 10.1016/j.spinee.2011.12.004
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 959FM
UT WOS:000305298300005
PM 22197782
ER

PT J
AU Urdaneta, RA
   Daher, S
   Leary, J
   Emanuel, KM
   Chuang, SK
AF Urdaneta, Rainier A.
   Daher, Shadi
   Leary, Joseph
   Emanuel, Kimberly M.
   Chuang, Sung-Kiang
TI The Survival of Ultrashort Locking-Taper Implants
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE dental implants; implant length; retrospective cohort study; short
   implants; single-tooth implants
ID RETAINED MANDIBULAR OVERDENTURES; MULTICENTER CLINICAL-TRIAL; DENTAL
   IMPLANTS; FOLLOW-UP; ROUGH-SURFACE; RISK-FACTORS; PROSTHESES; RATIOS;
   RESTORATIONS; EDENTULISM
AB Purpose: To evaluate the performance of 5-mm-long implants. Materials and Methods: A retrospective cohort study was conducted between January 2008 and December 2009. The sample was composed of patients who had received at least one 5-mm-wide, hydroxyapatite-coated Bicon implant. The outcome variable was implant failure. Descriptive statistics and univariate and multivariate Cox proportional hazards regression models, adjusted for multiple implants in the same patient, were utilized to identify predictors of dental implant failure. Results: Two hundred ninety-one subjects who received 410 locking-taper implants were followed for an average of 20 months. Of these, 211 were ultrashort implants (57 were 5 x 5.0 mm and 154 were 5 X 6.0 mm) and 199 were short implants (5 x 8.0 mm). Three hundred twenty-two implants (93.4%) were restored with single crowns. There was a higher proportion of ultrashort single-tooth implants (94.6%) as compared to short single-tooth implants (92.2%). Nine implants failed, for a cumulative survival rate of 97.5%. Of the failed implants, five were ultrashort (all 5 x 6.0 mm) and four were short. No failures were documented for 5- x 5.0-mm ultrashort implants. There was no statistically significant difference (P = .68) in the Kaplan-Meier survival rates of ultrashort implants (97.6%) and short implants (95.2%). After adjusting for other covariates in a multivariate model, implant length was not associated with implant failure (P = .49). Conclusions: The survival of ultrashort (5- and 6-mm) implants was comparable to that of short (8-mm) implants. INT J ORAL MAXILLOFAC IMPLANTS 2012;27:644-654.
C1 [Urdaneta, Rainier A.; Daher, Shadi; Emanuel, Kimberly M.] Implant Dent Ctr, Boston, MA USA.
   [Leary, Joseph] Private Practice Ltd Periodont, Norwood, MA USA.
   [Chuang, Sung-Kiang] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
   [Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
RP Urdaneta, RA (reprint author), 25 Prairie Ave, Auburndale, MA 02466 USA.
EM rainieru@yahoo.com
NR 37
TC 15
Z9 17
U1 0
U2 4
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882-2786
EI 1942-4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD MAY-JUN
PY 2012
VL 27
IS 3
BP 644
EP 654
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 957YP
UT WOS:000305203300019
PM 22616059
ER

PT J
AU Bae, SH
   Che, JH
   Seo, JM
   Jeong, J
   Kim, ET
   Lee, SW
   Koo, KI
   Suaning, GJ
   Lovell, NH
   Cho, DI
   Kim, SJ
   Chung, H
AF Bae, So Hyun
   Che, Jeong-Hwan
   Seo, Jong-Mo
   Jeong, Joonsoo
   Kim, Eui Tae
   Lee, Seung Woo
   Koo, Kyo-in
   Suaning, Gregg J.
   Lovell, Nigel H.
   Cho, Dong-Il 'Dan'
   Kim, Sung June
   Chung, Hum
TI In Vitro Biocompatibility of Various Polymer-Based Microelectrode Arrays
   for Retinal Prosthesis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID LONG-TERM IMPLANTATION; ELECTRODE ARRAY; MORPHOMETRIC-ANALYSIS;
   RETINITIS-PIGMENTOSA; POLYIMIDE; CYTOTOXICITY; ASSAYS; DOGS
AB PURPOSE. The purpose of our study is to evaluate the biocompatibility of various polymers used as microelectrode arrays (MEAs) in retinal prostheses through in vitro cytotoxicity testing following a standardized method.
   METHODS. Three types of polymer-based MEAs were examined: silicone-based platinum, polyimide-based gold and liquid crystal polymer (LCP)-based gold MEAs. The silicone/platinum MEAs were fabricated by a Nd:YAG laser, polyimide/gold MEAs by a semiconductor manufacturing technique, and LCP/gold MEAs by laser micromachining and thermal-bonding process. All experimental procedures followed the International Organization for Standardization (ISO) 10993-5. To obtain the extracts of specimens, 4 g of each type of MEA were eluted by culture media, MEM, for 24 hours. Then, several diluents of extracts, including the original extracts, were applied to a cultured-cell monolayer, L929 fibroblasts. The morphologic changes of cells were analyzed by microscope after 24 and 48 hours of incubation. The quantitative evaluations of cell viability were performed by MTT assay after 24 hours of incubation.
   RESULTS. The microscopic evaluations revealed that extracts from polymer-based MEAs did not induce morphologic changes or reduction of cells compared with control irrespective of concentrations of extracts. The MTT assay showed high viability values of approximately 80 to 130% regardless of diluted ratio of extracts from polymer-based MEAs. None of the polymers demonstrated a significant reduction of cell viability when compared with control.
   CONCLUSIONS. All types of polymer-based MEAs, including silicone/platinum, polyimide/gold, and LCP/gold MEAs, meet the criteria of biocompatibility guided by international standards, ISO 10993-5. (Invest Ophthalmol Vis Sci. 2012;53:2653-2657) DOI:10.1167/iovs.11-9341
C1 [Che, Jeong-Hwan] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 110744, South Korea.
   [Bae, So Hyun] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Coll Med, Seoul, South Korea.
   [Bae, So Hyun; Seo, Jong-Mo] Seoul Natl Univ, Interdisciplinary Program Bioengn, Seoul, South Korea.
   [Seo, Jong-Mo; Chung, Hum] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul 110744, South Korea.
   [Seo, Jong-Mo; Jeong, Joonsoo; Koo, Kyo-in; Cho, Dong-Il 'Dan'; Kim, Sung June] Seoul Natl Univ, Interuniv Semicond Res Ctr, Seoul, South Korea.
   [Koo, Kyo-in; Cho, Dong-Il 'Dan'] Seoul Natl Univ, Dept Elect Engn & Comp Sci, Automat & Syst Res Inst, Seoul, South Korea.
   [Kim, Eui Tae] Korean Intellectual Property Off, Convergence Technol Exam Div 2, Taejon, South Korea.
   [Lee, Seung Woo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA.
   [Suaning, Gregg J.; Lovell, Nigel H.] Univ New S Wales, Grad Sch Biomed Engn, Sydney, NSW, Australia.
RP Che, JH (reprint author), Seoul Natl Univ Hosp, Clin Res Inst, 101 Daehak Ro, Seoul 110744, South Korea.
EM casache@snu.ac.kr; callme@snu.ac.kr
RI Chung, Hum/J-5657-2012; Koo, Kyo-in/E-4611-2017
OI Koo, Kyo-in/0000-0003-4173-9218
FU MIHWAF [A050251]; MKE [10033634]; MEST [2010-0020851]
FX Supported by the Korea Health 21 R&D Project A050251 of MIHWAF,
   Technology Innovation Program 10033634 of MKE, and Public Welfare and
   Safety Program 2010-0020851 of MEST.
NR 27
TC 16
Z9 16
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 2653
EP 2657
DI 10.1167/iovs.11-9341
PG 5
WC Ophthalmology
SC Ophthalmology
GA 953JY
UT WOS:000304864600016
PM 22427592
ER

PT J
AU Zhou, XH
   Robinson, CM
   Rajaiya, J
   Dehghan, S
   Seto, D
   Jones, MS
   Dyer, DW
   Chodosh, J
AF Zhou, Xiaohong
   Robinson, Christopher M.
   Rajaiya, Jaya
   Dehghan, Shoaleh
   Seto, Donald
   Jones, Morris S.
   Dyer, David W.
   Chodosh, James
TI Analysis of Human Adenovirus Type 19 Associated with Epidemic
   Keratoconjunctivitis and its Reclassification as Adenovirus Type 64
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ACUTE RESPIRATORY-DISEASE; HUMAN CORNEAL FIBROBLASTS; BIOINFORMATICS
   ANALYSIS; COMPUTATIONAL ANALYSIS; CELLULAR RECEPTOR; GENOME SEQUENCE;
   FIBER GENES; KERATITIS; CELLS; RECOMBINATION
AB PURPOSE. Human adenovirus species D type 19 (HAdV-D19) has been associated with epidemic keratoconjunctivitis (EKC), a highly inflammatory infection of the ocular surface. Confusion exists regarding the origins of HAdV-D19. The prototype virus (HAdV-D19p) does not cause EKC, while a virus identified later with the identical serologic determinant is a significant ocular pathogen.
   METHODS. High throughput genome sequencing and bioinformatics analysis were performed on HAdV-D19p and three HAdV-D19 EKC strains, and compared to the previously sequenced clinical isolate, HAdV-D19 (C) and HAdV-D37. Corneas of C57BL/6J mice were injected with HAdV-D19p, HAdV-D19 (C), or virus-free buffer, and inflammation assessed by clinical examination, flow cytometry, and cytokine ELISA. Confocal microscopy and real-time PCR of infected corneal cell cultures were used to test viral entry.
   RESULTS. HAdV-D19 (C) and the other clinical EKC isolates showed nearly 100% sequence identity. EKC strains diverged from HAdV-D19p in the penton base, E3, and fiber transcription units. Simplot analysis showed recombination between EKC-associated HAdV-D19 with HAdV-D37, HAdV-D22, and HAdV-D19p, the latter contributing only the hexon gene, the principal serum neutralization determinant. HAdV-D19p induced stromal keratitis in the C57BL/6J mouse, but failed to infect productively human corneal epithelial cells. These data led to retyping of the clinical EKC isolates with a HAdV-D19 hexon gene as HAdV-D64.
   CONCLUSIONS. HAdV-D19 associated with EKC (HAdV-D64) originated from a recombination between HAdV-D19p, HAdV-D37, and HAdV-D22, and was mischaracterized because of a shared hexon gene. HAdV-D19p is not infectious for corneal epithelial cells, thus explaining the lack of any association with keratitis. (Invest Ophthalmol Vis Sci. 2012; 53: 2804-2811) DOI: 10.1167/iovs.12-9656
C1 [Zhou, Xiaohong; Robinson, Christopher M.; Rajaiya, Jaya; Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab, Boston, MA 02114 USA.
   [Dehghan, Shoaleh; Seto, Donald; Jones, Morris S.] George Mason Univ, Sch Syst Biol, Manassas, VA USA.
   [Dyer, David W.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
RP Chodosh, J (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab, 243 Charles St, Boston, MA 02114 USA.
EM james_chodosh@meei.harvard.edu
FU NIH [EY013124, EY021558, EY014104]; Research to Prevent Blindness, Inc.,
   New York, NY; Massachusetts Lions Eye Research Fund
FX Supported by NIH Grants EY013124, EY021558, and EY014104; a Senior
   Scientific Investigator Award grant (JC) from Research to Prevent
   Blindness, Inc., New York, NY; and the Massachusetts Lions Eye Research
   Fund.
NR 60
TC 26
Z9 28
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 2804
EP 2811
DI 10.1167/iovs.12-9656
PG 8
WC Ophthalmology
SC Ophthalmology
GA 953JY
UT WOS:000304864600034
PM 22467570
ER

PT J
AU Mendiola, J
   Meeker, JD
   Jorgensen, N
   Andersson, AM
   Liu, F
   Calafat, AM
   Redmon, JB
   Drobnis, EZ
   Sparks, AE
   Wang, C
   Hauser, R
   Swan, SH
AF Mendiola, Jaime
   Meeker, John D.
   Jorgensen, Niels
   Andersson, Anna-Maria
   Liu, Fan
   Calafat, Antonia M.
   Redmon, J. Bruce
   Drobnis, Erma Z.
   Sparks, Amy E.
   Wang, Christina
   Hauser, Russ
   Swan, Shanna H.
TI Urinary Concentrations of Di(2-ethylhexyl) Phthalate Metabolites and
   Serum Reproductive Hormones: Pooled Analysis of Fertile and Infertile
   Men
SO JOURNAL OF ANDROLOGY
LA English
DT Article
DE Anti-androgens; DEHP metabolites; endocrine disruptor; male hormones
ID FOLLICLE-STIMULATING-HORMONE; RAT GRANULOSA-CELLS; MONO-(2-ETHYLHEXYL)
   PHTHALATE; NEONATAL-RATS; SEMEN QUALITY; YOUNG MEN; DIETHYLHEXYL
   PHTHALATE; SEXUAL-DIFFERENTIATION; TEMPORAL VARIABILITY; ESTRADIOL
   PRODUCTION
AB Urinary concentrations of metabolites of the anti-androgenic xenobiotic di-(2-ethylhexyl) phthalate (DEHP) were previously shown to be weakly associated with serum levels of several hormones in 2 disparate US populations: partners of pregnant women participating in the Study for Future Families and partners in infertile couples from Massachusetts General Hospital infertility clinic. The observed associations between phthalate metabolites and reproductive hormones were robust and insensitive to the characteristics of the subpopulation or the laboratory in which the hormones were measured, despite the fact that these 2 populations span a range of fertility, urinary phthalate metabolites, and reproductive hormone levels. We therefore examined associations between urinary metabolites of DEHP and reproductive hormones follicle-stimulating hormone, luteinizing hormone, testosterone (T), inhibin B, and estradiol (E-2) and sex hormone binding globulin (SHBG) in the pooled population. The magnitude of the associations seen were similar to those reported for each population separately, but effect estimates were more precise because of the increased sample size and the greater range of phthalate metabolite concentrations and hormone levels. Urinary concentrations of 3 metabolites of DEHP [mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP)] were inversely associated with the free androgen index (FAI = T/SHBG) and calculated free testosterone. Urinary concentrations of MEHHP and MEOHP were positively associated with SHBG, and MEHP was inversely associated with E2. No other phthalate metabolites were associated with serum hormones, consistent with results in each population. Our results in this diverse population suggest that DEHP exposure is robustly associated with some male sex steroid hormones.
C1 [Mendiola, Jaime; Liu, Fan; Hauser, Russ; Swan, Shanna H.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA.
   [Meeker, John D.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
   [Jorgensen, Niels; Andersson, Anna-Maria] Univ Copenhagen, Rigshosp, Univ Dept Growth & Reprod, DK-2100 Copenhagen, Denmark.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
   [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
   [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Urol Surg, Minneapolis, MN 55455 USA.
   [Drobnis, Erma Z.] Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Columbia, MO USA.
   [Sparks, Amy E.] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.
   [Wang, Christina] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA.
   [Wang, Christina] Los Angeles Biomed Res Inst, Torrance, CA USA.
   [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Androl Lab, Vitro Fertilizat Unit, Boston, MA 02114 USA.
   [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Swan, Shanna H.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA.
RP Swan, SH (reprint author), Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, 601 Elmwood Ave,Box 668, Rochester, NY 14642 USA.
EM shanna_swan@urmc.rochester.edu
RI Jorgensen, Niels/A-8148-2012; Andersson, Anna-Maria/F-5842-2013; 
OI Jorgensen, Niels/0000-0003-4827-0838; Andersson,
   Anna-Maria/0000-0002-7300-1659; Redmon, J. Bruce/0000-0002-1883-9467;
   Drobnis, Erma Z./0000-0001-5495-3489; Meeker, John/0000-0001-8357-5085
FU Danish Agency for Science, Technology, and Innovation [271070678];
   University of Iowa Center for Health Effects of Environmental
   Contamination cooperative project grant; General Clinical Research
   Center at Harbor UCLA Medical Center [MO1 RR00425]; NIEHS [ES009718]
FX This study is supported by The Danish Agency for Science, Technology,
   and Innovation, grant 271070678 to N.J.; a University of Iowa Center for
   Health Effects of Environmental Contamination cooperative project grant
   to A.E.S.; the General Clinical Research Center at Harbor UCLA Medical
   Center (MO1 RR00425); and NIEHS grant ES009718 to R.H.
NR 52
TC 33
Z9 33
U1 2
U2 14
PU AMER SOC ANDROLOGY, INC
PI LAWRENCE
PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA
SN 0196-3635
J9 J ANDROL
JI J. Androl.
PD MAY-JUN
PY 2012
VL 33
IS 3
BP 488
EP 498
DI 10.2164/jandrol.111.013557
PG 11
WC Andrology
SC Endocrinology & Metabolism
GA 959JM
UT WOS:000305308700025
PM 21597090
ER

PT J
AU Fox, CS
   White, CC
   Lohman, K
   Heard-Costa, N
   Cohen, P
   Zhang, YY
   Johnson, AD
   Emilsson, V
   Liu, CT
   Chen, YDI
   Taylor, KD
   Allison, M
   Budoff, M
   Rotter, JI
   Carr, JJ
   Hoffmann, U
   Ding, JZ
   Cupples, LA
   Liu, YM
AF Fox, Caroline S.
   White, Charles C.
   Lohman, Kurt
   Heard-Costa, Nancy
   Cohen, Paul
   Zhang, Yingying
   Johnson, Andrew D.
   Emilsson, Valur
   Liu, Ching-Ti
   Chen, Y. -D. Ida
   Taylor, Kent D.
   Allison, Matthew
   Budoff, Matthew
   Rotter, Jerome I.
   Carr, J. Jeffrey
   Hoffmann, Udo
   Ding, Jingzhong
   Cupples, L. Adrienne
   Liu, Yongmei
CA CARDIoGRAM Consortium
TI Genome-Wide Association of Pericardial Fat Identifies a Unique Locus for
   Ectopic Fat
SO PLOS GENETICS
LA English
DT Article
ID PERIVASCULAR ADIPOSE-TISSUE; VISCERAL ABDOMINAL FAT; BODY-MASS INDEX;
   GENE-EXPRESSION; ATHEROSCLEROSIS MESA; INTRATHORACIC FAT; RISK-FACTORS;
   HIP RATIO; HEART; DISEASE
AB Pericardial fat is a localized fat depot associated with coronary artery calcium and myocardial infarction. We hypothesized that genetic loci would be associated with pericardial fat independent of other body fat depots. Pericardial fat was quantified in 5,487 individuals of European ancestry from the Framingham Heart Study (FHS) and the Multi-Ethnic Study of Atherosclerosis (MESA). Genotyping was performed using standard arrays and imputed to similar to 2.5 million Hapmap SNPs. Each study performed a genome-wide association analysis of pericardial fat adjusted for age, sex, weight, and height. A weighted z-score meta-analysis was conducted, and validation was obtained in an additional 3,602 multi-ethnic individuals from the MESA study. We identified a genome-wide significant signal in our primary meta-analysis at rs10198628 near TRIB2 (MAF 0.49, p = 2.7 x 10(-08)). This SNP was not associated with visceral fat (p = 0.17) or body mass index (p = 0.38), although we observed direction-consistent, nominal significance with visceral fat adjusted for BMI (p = 0.01) in the Framingham Heart Study. Our findings were robust among African ancestry (n = 1,442, p = 0.001), Hispanic (n = 1,399, p = 0.004), and Chinese (n = 761, p = 0.007) participants from the MESA study, with a combined p-value of 5.4E-14. We observed TRIB2 gene expression in the pericardial fat of mice. rs10198628 near TRIB2 is associated with pericardial fat but not measures of generalized or visceral adiposity, reinforcing the concept that there are unique genetic underpinnings to ectopic fat distribution.
C1 [Fox, Caroline S.; Johnson, Andrew D.] NHLBI, Ctr Populat Studies, Framingham, MA USA.
   [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
   [Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
   [White, Charles C.; Liu, Ching-Ti; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Lohman, Kurt; Liu, Yongmei] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA.
   [Heard-Costa, Nancy] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Cohen, Paul] Brigham & Womens Hosp, Dept Canc Biol, Boston, MA 02115 USA.
   [Cohen, Paul] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
   [Zhang, Yingying] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Emilsson, Valur] Iceland Heart Assoc, Hjartavernd, Iceland.
   [Chen, Y. -D. Ida; Taylor, Kent D.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
   [Allison, Matthew] Univ Calif San Diego, Dept Prevent Med, La Jolla, CA 92093 USA.
   [Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA.
   [Carr, J. Jeffrey] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol Sci, Winston Salem, NC USA.
   [Carr, J. Jeffrey] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med Cardiol, Winston Salem, NC USA.
   [Carr, J. Jeffrey] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA.
   [Hoffmann, Udo] Massachusetts Gen Hosp, CT Program, PET, Cardiac MR, Boston, MA 02114 USA.
   [Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   [Ding, Jingzhong] Wake Forest Sch Med, Dept Internal Med Geriatr, Winston Salem, NC USA.
RP Fox, CS (reprint author), NHLBI, Ctr Populat Studies, Framingham, MA USA.
EM foxca@nhlbi.nih.gov; yoliu@wfubmc.edu
RI Johnson, Andrew/G-6520-2013; Carr, John/A-1938-2012; 
OI Cupples, L. Adrienne/0000-0003-0273-7965; Allison,
   Matthew/0000-0003-0777-8272; Carr, John/0000-0002-4398-8237;
   Heard-Costa, Nancy/0000-0001-9730-0306
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-25195,
   N02-HL-6-4278]; Affymetrix for genotyping services [N02-HL-6-4278];
   Robert Dawson Evans Endowment of the Department of Medicine at Boston
   University School of Medicine; Boston Medical Center;  [R01-HL-085323]; 
   [R01-HL-071205];  [N01 HC-95159];  [N01-HC-95160];  [N01-HC-95161]; 
   [N01-HC-95162];  [N01-HC-95163];  [N01-HC-95164];  [N01-HC-95165]; 
   [N01-HC-95166];  [N01-HC-95167];  [N01-HC-95168];  [N01-HC-95169]; 
   [RR-024156]
FX Framingham Heart Study: This research was conducted in part using data
   and resources from the Framingham Heart Study of the National Heart,
   Lung, and Blood Institute of the National Institutes of Health and
   Boston University School of Medicine. The analyses reflect intellectual
   input and resource development from the Framingham Heart Study
   investigators participating in the SNP Health Association Resource
   (SHARe) project. This work was partially supported by the National
   Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No.
   N01-HC-25195) and its contract with Affymetrix for genotyping services
   (Contract No. N02-HL-6-4278). A portion of this research utilized the
   Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert
   Dawson Evans Endowment of the Department of Medicine at Boston
   University School of Medicine and Boston Medical Center. MESA Study:
   MESA and the MESA SHARe project are conducted and supported by the
   National Heart, Lung, and Blood Institute (NHLBI) in collaboration with
   MESA investigators. Support is provided by grants R01-HL-085323 and
   R01-HL-071205 and by contracts N01 HC-95159, N01-HC-95160, N01-HC-95161,
   N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
   N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156. MESA SNP Health
   Association Resource (SHARe): Funding for SHARe genotyping was provided
   by NHLBI Contract N02-HL-6-4278. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 57
TC 24
Z9 24
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2012
VL 8
IS 5
AR e1002705
DI 10.1371/journal.pgen.1002705
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 953JT
UT WOS:000304864000032
PM 22589742
ER

PT J
AU Li, JY
   Song, JS
   Bell, RJA
   Tran, TNT
   Haq, R
   Liu, HF
   Love, KT
   Langer, R
   Anderson, DG
   Larue, L
   Fisher, DE
AF Li, Juying
   Song, Jun S.
   Bell, Robert J. A.
   Tran, Thanh-Nga T.
   Haq, Rizwan
   Liu, Huifei
   Love, Kevin T.
   Langer, Robert
   Anderson, Daniel G.
   Larue, Lionel
   Fisher, David E.
TI YY1 Regulates Melanocyte Development and Function by Cooperating with
   MITF
SO PLOS GENETICS
LA English
DT Article
ID TRANSCRIPTION FACTOR YIN-YANG-1; WAARDENBURG SYNDROME; MASTER REGULATOR;
   KIT; PROTOONCOGENE; PIEBALDISM; MUTATIONS; LINEAGE; UPDATE; GENE
AB Studies of coat color mutants have greatly contributed to the discovery of genes that regulate melanocyte development and function. Here, we generated Yy1 conditional knockout mice in the melanocyte-lineage and observed profound melanocyte deficiency and premature gray hair, similar to the loss of melanocytes in human piebaldism and Waardenburg syndrome. Although YY1 is a ubiquitous transcription factor, YY1 interacts with M-MITF, the Waardenburg Syndrome IIA gene and a master transcriptional regulator of melanocytes. YY1 cooperates with M-MITF in regulating the expression of piebaldism gene KIT and multiple additional pigmentation genes. Moreover, ChIP-seq identified genome-wide YY1 targets in the melanocyte lineage. These studies mechanistically link genes implicated in human conditions of melanocyte deficiency and reveal how a ubiquitous factor (YY1) gains lineage-specific functions by co-regulating gene expression with a lineage-restricted factor (M-MITF)-a general mechanism which may confer tissue-specific gene expression in multiple lineages.
C1 [Li, Juying; Tran, Thanh-Nga T.; Haq, Rizwan; Fisher, David E.] Harvard Univ, Sch Med, Dept Dermatol, Cutaneous Biol Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Song, Jun S.; Bell, Robert J. A.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
   [Song, Jun S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Dept Bioengn & Therapeut Sci, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
   [Haq, Rizwan] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA.
   [Liu, Huifei] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
   [Love, Kevin T.; Langer, Robert; Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Langer, Robert; Anderson, Daniel G.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Larue, Lionel] CNRS, Inst Curie, INSERM, U1021,UMR 3347, F-91405 Orsay, France.
RP Li, JY (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Cutaneous Biol Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM songj@humgen.ucsf.edu; dfisher3@partners.org
RI Larue, Lionel/F-7355-2013; Larue, Lionel/I-6532-2016
FU MGH; NIH [2T32AR007098-37, RO1 EB000244]; PhRMA Foundation; National
   Cancer Institute [R01CA163336]; Doris Duke Medical Foundation; National
   Institutes of Health (NIAMS); Dr. Miriam and Sheldon Adelson Medical
   Research Foundation; Melanoma Research Alliance; U.S.-Israel Binational
   Science Foundation
FX JL acknowledges support from MGH Tosteson Postdoctoral Fellowship and
   NIH Dermatology Training Grant (2T32AR007098-37). JSS was partially
   supported by the PhRMA Foundation and the National Cancer Institute
   (R01CA163336). DEF gratefully acknowledges grant support from the Doris
   Duke Medical Foundation, National Institutes of Health (NIAMS), Dr.
   Miriam and Sheldon Adelson Medical Research Foundation, Melanoma
   Research Alliance, and U.S.-Israel Binational Science Foundation. DGA
   was partially supported by NIH RO1 EB000244. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 34
TC 16
Z9 19
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2012
VL 8
IS 5
AR e1002688
DI 10.1371/journal.pgen.1002688
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 953JT
UT WOS:000304864000019
PM 22570637
ER

PT J
AU Perry, JRB
   Voight, BF
   Yengo, L
   Amin, N
   Dupuis, J
   Ganser, M
   Grallert, H
   Navarro, P
   Li, M
   Qi, L
   Steinthorsdottir, V
   Scott, RA
   Almgren, P
   Arking, DE
   Aulchenko, Y
   Balkau, B
   Benediktsson, R
   Bergman, RN
   Boerwinkle, E
   Bonnycastle, L
   Burtt, NP
   Campbell, H
   Charpentier, G
   Collins, FS
   Gieger, C
   Green, T
   Hadjadj, S
   Hattersley, AT
   Herder, C
   Hofman, A
   Johnson, AD
   Kottgen, A
   Kraft, P
   Labrune, Y
   Langenberg, C
   Manning, AK
   Mohlke, KL
   Morris, AP
   Oostra, B
   Pankow, J
   Petersen, AK
   Pramstaller, PP
   Prokopenko, I
   Rathmann, W
   Rayner, W
   Roden, M
   Rudan, I
   Rybin, D
   Scott, LJ
   Sigurdsson, G
   Sladek, R
   Thorleifsson, G
   Thorsteinsdottir, U
   Tuomilehto, J
   Uitterlinden, AG
   Vivequin, S
   Weedon, MN
   Wright, AF
   Hu, FB
   Illig, T
   Kao, L
   Meigs, JB
   Wilson, JF
   Stefansson, K
   van Duijn, C
   Altschuler, D
   Morris, AD
   Boehnke, M
   McCarthy, MI
   Froguel, P
   Palmer, CNA
   Wareham, NJ
   Groop, L
   Frayling, TM
   Cauchi, S
AF Perry, John R. B.
   Voight, Benjamin F.
   Yengo, Loic
   Amin, Najaf
   Dupuis, Josee
   Ganser, Martha
   Grallert, Harald
   Navarro, Pau
   Li, Man
   Qi, Lu
   Steinthorsdottir, Valgerdur
   Scott, Robert A.
   Almgren, Peter
   Arking, Dan E.
   Aulchenko, Yurii
   Balkau, Beverley
   Benediktsson, Rafn
   Bergman, Richard N.
   Boerwinkle, Eric
   Bonnycastle, Lori
   Burtt, Noel P.
   Campbell, Harry
   Charpentier, Guillaume
   Collins, Francis S.
   Gieger, Christian
   Green, Todd
   Hadjadj, Samy
   Hattersley, Andrew T.
   Herder, Christian
   Hofman, Albert
   Johnson, Andrew D.
   Kottgen, Anna
   Kraft, Peter
   Labrune, Yann
   Langenberg, Claudia
   Manning, Alisa K.
   Mohlke, Karen L.
   Morris, Andrew P.
   Oostra, Ben
   Pankow, James
   Petersen, Ann-Kristin
   Pramstaller, Peter P.
   Prokopenko, Inga
   Rathmann, Wolfgang
   Rayner, William
   Roden, Michael
   Rudan, Igor
   Rybin, Denis
   Scott, Laura J.
   Sigurdsson, Gunnar
   Sladek, Rob
   Thorleifsson, Gudmar
   Thorsteinsdottir, Unnur
   Tuomilehto, Jaakko
   Uitterlinden, Andre G.
   Vivequin, Sidonie
   Weedon, Michael N.
   Wright, Alan F.
   Hu, Frank B.
   Illig, Thomas
   Kao, Linda
   Meigs, James B.
   Wilson, James F.
   Stefansson, Kari
   van Duijn, Cornelia
   Altschuler, David
   Morris, Andrew D.
   Boehnke, Michael
   McCarthy, Mark I.
   Froguel, Philippe
   Palmer, Colin N. A.
   Wareham, Nicholas J.
   Groop, Leif
   Frayling, Timothy M.
   Cauchi, Stephane
CA MAGIC
   DIAGRAM Consortium
   GIANT Consortium
TI Stratifying Type 2 Diabetes Cases by BMI Identifies Genetic Risk
   Variants in LAMA1 and Enrichment for Risk Variants in Lean Compared to
   Obese Cases
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; EXPRESSION; CELLS;
   DIFFERENTIATION; INSULIN; DISEASE; GLUCOSE; MOUSE; PROTEIN
AB Common diseases such as type 2 diabetes are phenotypically heterogeneous. Obesity is a major risk factor for type 2 diabetes, but patients vary appreciably in body mass index. We hypothesized that the genetic predisposition to the disease may be different in lean (BMI<25 Kg/m(2)) compared to obese cases (BMI >= 30 Kg/m(2)). We performed two case-control genome-wide studies using two accepted cut-offs for defining individuals as overweight or obese. We used 2,112 lean type 2 diabetes cases (BMI<25 kg/m(2)) or 4,123 obese cases (BMI >= 30 kg/m(2)), and 54,412 un-stratified controls. Replication was performed in 2,881 lean cases or 8,702 obese cases, and 18,957 un-stratified controls. To assess the effects of known signals, we tested the individual and combined effects of SNPs representing 36 type 2 diabetes loci. After combining data from discovery and replication datasets, we identified two signals not previously reported in Europeans. A variant (rs8090011) in the LAMA1 gene was associated with type 2 diabetes in lean cases (P = 8.4610 29, OR = 1.13 [95% CI 1.09-1.18]), and this association was stronger than that in obese cases (P = 0.04, OR = 1.03 [95% CI 1.00-1.06]). A variant in HMG20A-previously identified in South Asians but not Europeans-was associated with type 2 diabetes in obese cases (P = 1.3 x 10(-8), OR= 1.11 [95% CI 1.07-1.15]), although this association was not significantly stronger than that in lean cases (P = 0.02, OR = 1.09 [95% CI 1.02-1.17]). For 36 known type 2 diabetes loci, 29 had a larger odds ratio in the lean compared to obese (binomial P = 0.0002). In the lean analysis, we observed a weighted per-risk allele OR = 1.13 [95% CI 1.10-1.17], P = 3.2 x 10(-14). This was larger than the same model fitted in the obese analysis where the OR = 1.06 [95% CI 1.05-1.08], P = 2.2 x 10(-16). This study provides evidence that stratification of type 2 diabetes cases by BMI may help identify additional risk variants and that lean cases may have a stronger genetic predisposition to type 2 diabetes.
C1 [Perry, John R. B.; Hattersley, Andrew T.; Weedon, Michael N.; Frayling, Timothy M.] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
   [Perry, John R. B.; Morris, Andrew P.; Prokopenko, Inga; Rayner, William; McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Perry, John R. B.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
   [Voight, Benjamin F.; Burtt, Noel P.; Green, Todd; Altschuler, David] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
   [Yengo, Loic; Labrune, Yann; Vivequin, Sidonie; Froguel, Philippe; Cauchi, Stephane] CNRS UMR 8199, Lille, France.
   [Amin, Najaf; Aulchenko, Yurii; Hofman, Albert; van Duijn, Cornelia] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Dupuis, Josee; Johnson, Andrew D.] NHLBI, Framingham Heart Study, Framingham, MA USA.
   [Ganser, Martha; Scott, Laura J.; Boehnke, Michael] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Ganser, Martha; Scott, Laura J.; Boehnke, Michael] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Grallert, Harald; Illig, Thomas] Helmholtz Zentrum Muenchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
   [Navarro, Pau; Wright, Alan F.] Univ Edinburgh, Inst Genet & Mol Med, MRC, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Li, Man; Kottgen, Anna; Kao, Linda] Johns Hopkins Bloomberg Sch Publ Hlth & Epidemiol, Baltimore, MD USA.
   [Qi, Lu; Kraft, Peter; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Qi, Lu; Kraft, Peter; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Steinthorsdottir, Valgerdur; Thorleifsson, Gudmar; Thorsteinsdottir, Unnur; Stefansson, Kari] DeCODE Genet, Reykjavik, Iceland.
   [Scott, Robert A.; Langenberg, Claudia; Wareham, Nicholas J.] MRC, MRC Epidemiol Unit, Cambridge, England.
   [Almgren, Peter; Groop, Leif] Lund Univ, Dept Clin Sci, Diabet & Endocrinol Res Unit, Malmo, Sweden.
   [Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
   [Balkau, Beverley] INSERM CESP U1018, Villejuif, France.
   [Benediktsson, Rafn; Sigurdsson, Gunnar] Landspitali Univ Hosp, Reykjavik, Iceland.
   [Benediktsson, Rafn; Sigurdsson, Gunnar] Iceland Heart Assoc, Kopavogur, Iceland.
   [Bergman, Richard N.] Cedars Sinai Med Ctr, Diabet & Obes Res Inst, Los Angeles, CA 90048 USA.
   [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
   [Bonnycastle, Lori; Collins, Francis S.] NHGRI, NIH, Bethesda, MD 20892 USA.
   [Campbell, Harry; Wilson, James F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Charpentier, Guillaume] Corbeil Essonnes Hosp, Dept Endocrinol Diabetol, Corbeil Essonnes, France.
   [Gieger, Christian; Petersen, Ann-Kristin] Helmholtz Zentrum Muenchen, Inst Genet Epidemiol, Neuherberg, Germany.
   [Hadjadj, Samy] Univ Med & Pharmaceut Sci, INSERM U927, CIC INSERM 0801, CHU Poitiers,Dept Endocrinol Diabetol, Poitiers, France.
   [Herder, Christian; Roden, Michael] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany.
   [Kottgen, Anna] Freiburg Univ Clin, Div Renal, Freiburg, Germany.
   [Manning, Alisa K.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
   [Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Oostra, Ben] Erasmus Univ, Sch Med, Rotterdam, Netherlands.
   [Pankow, James] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN USA.
   [Pramstaller, Peter P.] European Acad Bozen Bolzano EURAC, Ctr Biomed, Bolzano, Italy.
   [Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany.
   [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Bolzano, Italy.
   [Prokopenko, Inga; McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
   [Rathmann, Wolfgang] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Biometr & Epidemiol, D-40225 Dusseldorf, Germany.
   [Roden, Michael] Univ Hosp Dusseldorf, Dept Metab Dis, Dusseldorf, Germany.
   [Rudan, Igor] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Rybin, Denis] Boston Univ, Data Coordinating Ctr, Boston, MA 02215 USA.
   [Sladek, Rob] McGill Univ, Fac Med, Dept Human Genet, Montreal, PQ, Canada.
   [Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland.
   [Tuomilehto, Jaakko] S Ostrobothnia Cent Hosp, Seinajoki, Finland.
   [Tuomilehto, Jaakko] Hosp Univ La Paz, Red RECAVA Grp RD06 0014 0015, Madrid, Spain.
   [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, D-3000 Hannover, Germany.
   [Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
   [Morris, Andrew D.; Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Inst, Dundee DD1 9SY, Scotland.
   [McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
   [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Genom Common Dis, London, England.
RP Perry, JRB (reprint author), Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
EM tim.frayling@pms.ac.uk; Stephane.Cauchi@good.ibl.fr
RI Palmer, Colin/C-7053-2008; Rudan, Igor/I-1467-2012; Grallert,
   Harald/B-3424-2013; Johnson, Andrew/G-6520-2013; Aulchenko,
   Yurii/M-8270-2013; Pramstaller, Peter/C-2357-2008; Wilson, James
   F/A-5704-2009; Prokopenko, Inga/H-3241-2014; Study, GoDARTS/K-9448-2016;
   Yengo, Loic/D-2692-2017
OI Rybin, Denis/0000-0002-3657-4829; Dupuis, Josee/0000-0003-2871-3603;
   Gieger, Christian/0000-0001-6986-9554; Pankow,
   James/0000-0001-7076-483X; Sladek, Robert/0000-0002-2730-1204; Navarro,
   Pau/0000-0001-5576-8584; Palmer, Colin/0000-0002-6415-6560; Rudan,
   Igor/0000-0001-6993-6884; Aulchenko, Yurii/0000-0002-7899-1575; Wilson,
   James F/0000-0001-5751-9178; Prokopenko, Inga/0000-0003-1624-7457;
   Yengo, Loic/0000-0002-4272-9305
FU Wellcome Trust [092447/Z/10/Z, 083270/Z/07/Z]; MRC [G0601261]; National
   Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
   R01HL59367, R01HL086694]; National Human Genome Research Institute
   [U01HG004402]; National Institutes of Health [HHSN268200625226C,
   DK062370, DK072193, UL1RR025005, NIDCR: U01DE018993, U01DE018903, NIAAA:
   U10AA008401, NIDA: P01CA089392, R01DA013423, NCI: CA63464, CA54281,
   CA136792, Z01CP010200]; NIH Roadmap for Medical Research; Swedish
   Research Council; NHS Research and Development; National Heart, Lung,
   and Blood Institute's Framingham Heart Study [N01-HC-25195,
   N02-HL-6-4278]; Robert Dawson Evans Endowment of the Department of
   Medicine at Boston University School of Medicine; Boston Medical Center;
   National Institute for Diabetes and Digestive and Kidney Diseases
   (NIDDK) [R01 DK078616, K24 DK080140]; European Community
   [HEALTH-F4-2007-201413]; French Government (Agence Nationale de la
   Recherche); French Region of Nord Pas De Calais (Contrat de Projets
   Etat-Region); French Ministry of Health; Association Francaise des
   Diabetiques; Programme National de Recherche sur le Diabete; Association
   de Langue Francaise pour l'Etude du Diabete et des Maladies
   Metaboliques; Association Diabete Risque Vasculaire (Paris, France);
   Groupe d'Etude des Maladies Metaboliques et Systemiques; European Union
   of European Community [LSHM-CT-2006-518153]; Caisse Nationale
   d'Assurance Maladie des Travailleurs Salaries; Lilly; Novartis Pharma;
   Sanofi-Aventis; Institut National de la Sante et de la Recherche
   Medicale (INSERM) (Reseaux en Sante Publique, Interactions entre les
   determinants de la sante, Cohortes Sante TGIR); Association Diabete
   Risque Vasculaire; Federation Francaise de Cardiologie; Fondation de
   France; Office National Interprofessionnel des Vins; Ardix Medical;
   Bayer Diagnostics; Becton Dickinson; Cardionics; Merck Sante; Novo
   Nordisk; Pierre Fabre; Roche and Topcon; NIH Genes, Environment and
   Health Initiative (GEI) [U01HG004402, U01HG004399, U01HG004738,
   U01HG004422, U01HG004729, U01HG004726, U01HG004735, U01HG004415,
   U01HG004436, U01HG004423, U01HG004728, RFAHG006033]; European Union
   [LSHG-CT-2006-018947]; NWO; Erasmus MC; Centre for Medical Systems
   Biology (CMSB); Ministry of Health and Department of Educational
   Assistance, University and Research of the Autonomous Province of
   Bolzano; South Tyrolean Sparkasse Foundation; Ministry of Science,
   Education and Sport of the Republic of Croatia [108-1080315-0302];
   Medical Research Council UK; German Center for Diabetes Research (DZD);
   Helmholtz Zentrum Munchen, Neuherberg, Germany; German Federal Ministry
   of Education and Research the Federal Ministry of Health; Ministry of
   Innovation, Science, Research, and Technology of the state North
   Rhine-Westphalia; German National Genome Research Network (NGFN); Munich
   Center of Health Sciences (MC Health) as part of LMUinnovativ
FX JRB Perry is supported by the Wellcome Trust as a Sir Henry Wellcome
   Postdoctoral Research Fellow (092447/Z/10/Z). This work was partially
   funded by grants from the Wellcome Trust 083270/Z/07/Z and MRC G0601261.
   The Atherosclerosis Risk in Communities Study is carried out as a
   collaborative study supported by National Heart, Lung, and Blood
   Institute contracts (HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C),
   R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research
   Institute contract U01HG004402; National Institutes of Health contract
   HHSN268200625226C; and grants DK062370 and DK072193. ARIC:
   Infrastructure was partly supported by Grant Number UL1RR025005, a
   component of the National Institutes of Health and NIH Roadmap for
   Medical Research. Work at Lund University diabetes centre was funded by
   several grants from the Swedish Research Council (LG prject grant,
   Linne, Exodiab). Norfolk Diabetes Case-Control and ADDITION-Ely Studies:
   The work on Ely, ADDITION, and EPIC-Norfolk studies was funded by
   support from the Wellcome Trust and MRC. The Norfolk Diabetes study is
   funded by the MRC with support from NHS Research and Development and the
   Wellcome Trust. This research was conducted in part using data and
   resources from the Framingham Heart Study of the National Heart, Lung,
   and Blood Institute of the National Institutes of Health and Boston
   University School of Medicine. The analyses reflect intellectual input
   and resource development from the Framingham Heart Study investigators
   participating in the SNP Health Association Resource (SHARe) project.
   This work was partially supported by the National Heart, Lung, and Blood
   Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its
   contract with Affymetrix for genotyping services (Contract No.
   N02-HL-6-4278). A portion of this research utilized the Linux Cluster
   for Genetic Analysis (LinGA-II), funded by the Robert Dawson Evans
   Endowment of the Department of Medicine at Boston University School of
   Medicine and Boston Medical Center. Also supported by National Institute
   for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to
   JB Meigs and J Dupuis, and NIDDK K24 DK080140 to JB Meigs. The research
   performed at deCODE Genetics was part funded through the European
   Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project,
   grant agreement HEALTH-F4-2007-201413. The DGDG study was supported by
   the French Government (Agence Nationale de la Recherche), the French
   Region of Nord Pas De Calais (Contrat de Projets Etat-Region), Programme
   Hospitalier de Recherche Clinique (French Ministry of Health), and the
   following charities: Association Francaise des Diabetiques, Programme
   National de Recherche sur le Diabete, Association de Langue Francaise
   pour l'Etude du Diabete et des Maladies Metaboliques, Association
   Diabete Risque Vasculaire (Paris, France), and Groupe d'Etude des
   Maladies Metaboliques et Systemiques. This study was also supported in
   part by a grant from the European Union (Integrated Project EuroDia
   LSHM-CT-2006-518153 in the Framework Programme 6 [FP6] of the European
   Community). The D. E. S. I. R.; study was supported by the Caisse
   Nationale d'Assurance Maladie des Travailleurs Salaries, Lilly, Novartis
   Pharma and Sanofi-Aventis, Institut National de la Sante et de la
   Recherche Medicale (INSERM) (Reseaux en Sante Publique, Interactions
   entre les determinants de la sante, Cohortes Sante TGIR 2008),
   Association Diabete Risque Vasculaire, Federation Francaise de
   Cardiologie, Fondation de France, Association de Langue Francaise pour
   l'Etude du Diabete et des Maladies Metaboliques, Office National
   Interprofessionnel des Vins, Ardix Medical, Bayer Diagnostics, Becton
   Dickinson, Cardionics, Merck Sante, Novo Nordisk, Pierre Fabre, Roche
   and Topcon. The D. E. S. I. R. Study Group: INSERM 1018: B Balkau, P
   Ducimetiere, E Eschwege; INSERM U367: F Alhenc-Gelas; Centre Hospitalier
   Universitaire D'Angers: Y Gallois, A Girault; Bichat Hospital: F
   Fumeron, M Marre, R Roussel; CHU de Rennes: F Bonnet; CNRS UMR8199,
   Lille: P Froguel; Medical Examination Services: Alencon, Angers, Blois,
   Caen, Chartres, Chateauroux, Cholet, Le Mans, Orleans and Tours;
   Research Institute for General Medicine: J Cogneau; General
   practitioners of the region; Cross-Regional Institute for Health: C
   Born, E Caces, M Cailleau, JG Moreau, F Rakotozafy, J Tichet, S. Vol. We
   are grateful to all patients for participation in the genetic study. We
   also thank Marianne Deweirder, Frederic Allegaert (UMR CNRS 8199,
   Genomic and Metabolic Disease, Lille, France) for their technical
   assistance and their precious management of DNA samples. This work was
   partially funded by grants from the Wellcome Trust 083270/Z/07/Z and MRC
   G0601261. This work was presented as a poster at the American Diabetes
   Association's scientific sessions June 2011. The NHS/HPFS T2D GWA study
   (U01HG004399) is a component of a collaborative project that includes 13
   other GWA studies funded as part of the Gene Environment-Association
   Studies (GENEVA) under the NIH Genes, Environment and Health Initiative
   (GEI) (U01HG004738, U01HG004422, U01HG004402, U01HG004729, U01HG004726,
   U01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728,
   RFAHG006033) with additional support from individual NIH (NIDCR:
   U01DE018993, U01DE018903; NIAAA: U10AA008401, NIDA: P01CA089392,
   R01DA013423; NCI: CA63464, CA54281, CA136792, Z01CP010200). EUROSPAN
   cohorts were supported by the European Union framework program 6
   EUROSPAN project (contract no. LSHG-CT-2006-018947). The ERF study was
   supported by grants from the NWO, Erasmus MC and the Centre for Medical
   Systems Biology (CMSB). We are grateful to all patients and their
   relatives, general practitioners and neurologists for their
   contributions and to P Veraart for her help in genealogy, Jeannette
   Vergeer for the supervision of the laboratory work and P Snijders for
   his help in data collection. MICROS: The MICROS study is part of the
   genomic health care program 'GenNova' and was carried out in three
   villages of the Val Venosta on the populations of Stelvio, Vallelunga
   and Martello. In South Tyrol, the study was supported by the Ministry of
   Health and Department of Educational Assistance, University and Research
   of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse
   Foundation. The VIS study in the Croatian island of Vis was supported
   through the grants from the Medical Research Council UK and Ministry of
   Science, Education and Sport of the Republic of Croatia (number
   108-1080315-0302).; The research within the KORA study was partially
   funded by the German Center for Diabetes Research (DZD), the Helmholtz
   Zentrum Munchen, Neuherberg, Germany, and supported by grants from the
   German Federal Ministry of Education and Research the Federal Ministry
   of Health, the Ministry of Innovation, Science, Research, and Technology
   of the state North Rhine-Westphalia, the German National Genome Research
   Network (NGFN), and the Munich Center of Health Sciences (MC Health) as
   part of LMUinnovativ. The research of I Prokopenko is funded in part
   through the European Community's Seventh Framework Programme
   (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007-201413.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 49
TC 75
Z9 77
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2012
VL 8
IS 5
AR e1002741
DI 10.1371/journal.pgen.1002741
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA 953JT
UT WOS:000304864000058
PM 22693455
ER

PT J
AU Ensminger, AW
   Yassin, Y
   Miron, A
   Isberg, RR
AF Ensminger, Alexander W.
   Yassin, Yosuf
   Miron, Alexander
   Isberg, Ralph R.
TI Experimental Evolution of Legionella pneumophila in Mouse Macrophages
   Leads to Strains with Altered Determinants of Environmental Survival
SO PLOS PATHOGENS
LA English
DT Article
ID SENSITIVE GEL-ELECTROPHORESIS; LONG-TERM EXPERIMENT; ESCHERICHIA-COLI;
   LEGIONNAIRES DISEASE; LYSINE BIOSYNTHESIS; BACTERIAL EVOLUTION;
   COXIELLA-BURNETII; VIRAL ADAPTATION; HOST ENVIRONMENT; FLAGELLAR NUMBER
AB The Gram-negative bacterium, Legionella pneumophila, is a protozoan parasite and accidental intracellular pathogen of humans. We propose a model in which cycling through multiple protozoan hosts in the environment holds L. pneumophila in a state of evolutionary stasis as a broad host-range pathogen. Using an experimental evolution approach, we tested this hypothesis by restricting L. pneumophila to growth within mouse macrophages for hundreds of generations. Whole-genome resequencing and high-throughput genotyping identified several parallel adaptive mutations and population dynamics that led to improved replication within macrophages. Based on these results, we provide a detailed view of the population dynamics of an experimentally evolving bacterial population, punctuated by frequent instances of transient clonal interference and selective sweeps. Non-synonymous point mutations in the flagellar regulator, fleN, resulted in increased uptake and broadly increased replication in both macrophages and amoebae. Mutations in multiple steps of the lysine biosynthesis pathway were also independently isolated, resulting in lysine auxotrophy and reduced replication in amoebae. These results demonstrate that under laboratory conditions, host restriction is sufficient to rapidly modify L. pneumophila fitness and host range. We hypothesize that, in the environment, host cycling prevents L. pneumophila host-specialization by maintaining pathways that are deleterious for growth in macrophages and other hosts.
C1 [Ensminger, Alexander W.; Isberg, Ralph R.] Howard Hughes Med Inst, Boston, MA 02115 USA.
   [Ensminger, Alexander W.; Isberg, Ralph R.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
   [Ensminger, Alexander W.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Ensminger, Alexander W.] Publ Hlth Ontario, Toronto, ON, Canada.
   [Yassin, Yosuf; Miron, Alexander] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Ensminger, AW (reprint author), Howard Hughes Med Inst, Boston, MA 02115 USA.
EM alex.ensminger@utoronto.ca; ralph.isberg@tufts.edu
FU Howard Hughes Medical Institute; National Institutes of Health
   [F32AI074193]
FX This work was supported by the Howard Hughes Medical Institute and a
   postdoctoral Ruth L. Kirschstein National Research Service Award
   F32AI074193 from the National Institutes of Health (to AWE). RRI is a
   Howard Hughes Medical Institute Investigator. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 94
TC 33
Z9 33
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2012
VL 8
IS 5
AR e1002731
DI 10.1371/journal.ppat.1002731
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 959OS
UT WOS:000305322900059
PM 22693450
ER

PT J
AU Silberbogen, AK
   Ulloa, E
   Mori, DL
   Brown, K
AF Silberbogen, Amy K.
   Ulloa, Erin
   Mori, DeAnna L.
   Brown, Kirstin
TI A Telehealth Intervention for Veterans on Antiviral Treatment for the
   Hepatitis C Virus
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE hepatitis C; interferon; telehealth; mental health; health behaviors
ID QUALITY-OF-LIFE; ADMINISTERED PSYCHOTHERAPY; PSYCHOMETRIC PROPERTIES;
   INTERFERON-ALPHA; CONTROLLED-TRIAL; BECK DEPRESSION; UNITED-STATES;
   THERAPY; HEALTH; MANAGEMENT
AB The standard treatment for chronic hepatitis C (pegylated interferon and ribavirin) causes challenging physical and psychological side effects. The current pilot study evaluated the efficacy of a brief, telephone-based, cognitive behavioral self-management intervention designed to address mood and quality of life within a sample of veterans on antiviral treatment for hepatitis C. Results from this pilot study support the feasibility of this telehealth intervention, showing that veterans were highly satisfied with the content of the intervention and compliant with the telephone calls. Findings further indicate that symptoms of depression and anxiety and mental health quality of life either remained stable or improved in those participants who received the brief telephone intervention, while those receiving usual care showed significant declines in mood and mental health quality of life. The findings from this study provide evidence that a brief, clinician-administered phone intervention may help individuals on antiviral therapy for hepatitis C to cope more effectively with the negative treatment side effects.
C1 [Silberbogen, Amy K.; Ulloa, Erin; Mori, DeAnna L.; Brown, Kirstin] Vet Affairs Boston HealthCare Syst, Psychol Serv, Boston, MA USA.
   [Silberbogen, Amy K.; Ulloa, Erin; Mori, DeAnna L.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Silberbogen, AK (reprint author), VA Boston Healthcare Syst, Psychol Serv 116B, 150 S Huntington Ave, Boston, MA 02130 USA.
EM amy.silberbogen@va.gov
NR 37
TC 2
Z9 2
U1 1
U2 3
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 163
EP 173
DI 10.1037/a0026821
PG 11
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000004
PM 22662730
ER

PT J
AU Palyo, SA
   Schopmeyer, KA
   McQuaid, JR
AF Palyo, Sarah A.
   Schopmeyer, Kathryn A.
   McQuaid, John R.
TI Tele-Pain Management: Use of Videoconferencing Technology in the
   Delivery of an Integrated Cognitive-Behavioral and Physical Therapy
   Group Intervention
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE chronic pain; pain management; telehealth; depression
AB Chronic pain has been recognized as a highly prevalent problem, and interdisciplinary treatments have been shown to be effective in the treatment of chronic pain. An integrated cognitive behavioral and physical therapy group protocol has been developed and then implemented at remote sites using videoconferencing technology to provide pain management for veterans. The treatment model is summarized and recommendations are made for addressing challenges in implementing this type of treatment via videoconferencing.
C1 [Palyo, Sarah A.; McQuaid, John R.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
   [Palyo, Sarah A.; McQuaid, John R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Schopmeyer, Kathryn A.] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA.
RP Palyo, SA (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St,116B, San Francisco, CA 94121 USA.
EM sarah.palyo@va.gov
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 200
EP 202
DI 10.1037/a0025987
PG 3
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000008
PM 22662734
ER

PT J
AU Barnwell, SVS
   Juretic, MA
   Hoerster, KD
   Van de Plasch, R
AF Barnwell, Sara V. Smucker
   Juretic, Meghan A.
   Hoerster, Katherine D.
   Van de Plasch, Richard
TI VA Puget Sound Telemental Health Service to Rural Veterans: A Growing
   Program
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE telemental health; telepsychology; telehealth; veteran
AB The VA Puget Sound Health Care System Telemental Health program connects veterans with psychologists, psychiatrists, and social workers via live clinical video teleconferencing. Providers deliver care to veterans in rural Veteran Affairs medical centers, community-based outpatient clinics and residences, and thus, increase access to specialty mental health care for rural and medically underserved veteran communities.
C1 [Van de Plasch, Richard] Dept Vet Affairs Med Ctr, VISN Pacific NW Mental Illness Res Educ & Clin Ct, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
   [Barnwell, Sara V. Smucker; Hoerster, Katherine D.; Van de Plasch, Richard] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Barnwell, SVS (reprint author), VA Puget Sound Hlth Care Syst, S-116-MHC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM ssmucker@post.harvard.edu
NR 0
TC 7
Z9 7
U1 2
U2 3
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 209
EP 211
DI 10.1037/a0025999
PG 3
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000011
PM 22662737
ER

PT J
AU Hayden, LJ
   Glynn, SM
   Hahn, TJ
   Randall, F
   Randolph, E
AF Hayden, Lisa J.
   Glynn, Shirley M.
   Hahn, Theodore J.
   Randall, Frychettya
   Randolph, Eugenia
TI The Use of Internet Technology for Psychoeducation and Support With
   Dementia Caregivers
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE internet technology; Alzheimer's disease; dementia; caregiver support;
   randomized trial
AB A large randomized trial evaluated the benefits of online education, support, and self-care promotion for caregivers of persons with dementia. Anecdotal reports from participants indicated enjoyment of the materials, convenient access from home, and support from professionals and other caregivers. A substantial number of screened caregivers experienced obstacles of access, cost, and time regarding use of technology. Telephone options are being explored, and future caregiving generations are expected to have increased exposure and willingness to use computer technology, such as the program described here.
C1 [Hayden, Lisa J.; Randolph, Eugenia] VA Greater Los Angeles Healthcare Syst W Los Angl, Res Serv, Los Angeles, CA 90073 USA.
   [Glynn, Shirley M.; Randall, Frychettya] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
   [Hahn, Theodore J.] VA Greater Los Angeles Healthcare Syst W Los Angl, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
   [Hahn, Theodore J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
RP Hayden, LJ (reprint author), VA Greater Los Angeles Healthcare Syst W Los Angl, Res Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM lisa.hayden@va.gov
RI LOPES, LAIS/F-7380-2012
NR 1
TC 9
Z9 10
U1 5
U2 23
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 215
EP 218
DI 10.1037/a0027056
PG 4
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000013
PM 22662739
ER

PT J
AU Soremekun, OA
   Biddinger, PD
   White, BA
   Sinclair, JR
   Chang, YC
   Carignan, SB
   Brown, DFM
AF Soremekun, Olanrewaju A.
   Biddinger, Paul D.
   White, Benjamin A.
   Sinclair, Julia R.
   Chang, Yuchiao
   Carignan, Sarah B.
   Brown, David F. M.
TI Operational and financial impact of physician screening in the ED
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID EMERGENCY-DEPARTMENT; TRIAGE; CARE; ANTIBIOTICS; OUTCOMES; VISITS; TIME;
   PAIN
AB Background: Physician screening is one of many front-end interventions being implemented to improve emergency department (ED) efficiency.
   Study objective: We aimed to quantify the operational and financial impact of this intervention at an urban tertiary academic center.
   Methods: We conducted a 2-year before-after analysis of a physician screening system at an urban tertiary academic center with 90 000 annual visits. Financial impact consisted of the ED and inpatient revenue generated from the incremental capacity and the reduction in left without being seen (LWBS) rates. The ED and inpatient margin contribution as well as capital expenditure were based on available published data. We summarized the financial impact using net present value of future cash flows performing sensitivity analysis on the assumptions. Operational outcome measures were ED length of stay and percentage of LWBS.
   Results: During the first year, we estimate the contribution margin of the screening system to be $2.71 million and the incremental operational cost to be $1.86 million. Estimated capital expenditure for the system was $1 200 000. The NPV of this investment was $2.82 million, and time to break even from the initial investment was 13 months. Operationally, despite a 16.7% increase in patient volume and no decrease in boarding hours, there was a 7.4% decrease in ED length of stay and a reduction in LWBS from 3.3% to 1.8%.
   Conclusions: In addition to improving operational measures, the implementation of a physician screening program in the ED allowed for an incremental increase in patient care capacity leading to an overall positive financial impact. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Soremekun, Olanrewaju A.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
   [Biddinger, Paul D.; White, Benjamin A.; Brown, David F. M.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA.
   [Biddinger, Paul D.; White, Benjamin A.; Sinclair, Julia R.; Carignan, Sarah B.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
   [Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Soremekun, OA (reprint author), Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
EM olanmd@gmail.com
NR 28
TC 6
Z9 6
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD MAY
PY 2012
VL 30
IS 4
BP 532
EP 539
DI 10.1016/j.ajem.2011.01.024
PG 8
WC Emergency Medicine
SC Emergency Medicine
GA 950RN
UT WOS:000304666500003
PM 21419587
ER

PT J
AU Hasegawa, K
   Fix, ML
   Wendell, L
   Schwab, K
   Ay, H
   Smith, EE
   Greenberg, SM
   Rosand, J
   Goldstein, JN
   Brown, DFM
AF Hasegawa, Kohei
   Fix, Megan L.
   Wendell, Lauren
   Schwab, Kristin
   Ay, Hakan
   Smith, Eric E.
   Greenberg, Steven M.
   Rosand, Jonathan
   Goldstein, Joshua N.
   Brown, David F. M.
TI Ischemic-appearing electrocardiographic changes predict myocardial
   injury in patients with intracerebral hemorrhage
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID ANEURYSMAL SUBARACHNOID HEMORRHAGE; ACUTE CORONARY SYNDROMES; ACUTE
   CEREBRAL-HEMORRHAGE; CRITICALLY-ILL PATIENTS; TROPONIN-T LEVELS; ACUTE
   STROKE; QTC DISPERSION; ECG-CHANGES; RISK-FACTOR; ABNORMALITIES
AB Objectives: Myocardial injury is common among patients with intracerebral hemorrhage (ICH). However, it is challenging for emergency physicians to recognize acute myocardial injury in this population, as electrocardiographic (ECG) abnormalities are common in this setting. Our objective is to examine whether ischemic-appearing ECG changes predict subsequent myocardial injury in the context of ICH.
   Methods: Consecutive patients with primary ICH presenting to a single academic center were prospectively enrolled. Electrocardiograms were retrospectively reviewed by 3 independent readers. Anatomical areas of ischemia were defined as I and aVL; II, III, and aVF; V-1 to V-4; and V-5 and V-6. Medical record review identified myocardial injury, defined as troponin I or T elevation (cutoff 1.5 and 0.1 ng/mL, respectively), within 30 days.
   Results: Between 1998 and 2004, 218 patients presented directly to our emergency department and did not have a do-not-resuscitate/do-not-intubate order; arrival ECGs and troponin levels were available for 206 patients. Ischemic-appearing changes were noted in 41% of patients, and myocardial injury was noted in 12% of patients. Ischemic-appearing changes were more common in patients with subsequent injury (64% vs 37%; P = .02). After multivariable analysis controlling for age and cardiac risk factors, ischemic-appearing ECG changes independently predicted myocardial injury (odds ratio, 3.2; 95% confidence interval, 1.3-8.2). In an exploratory analysis, ischemic-appearing ECG changes in leads I and aVL as well as V-5 and V-6 were more specific for myocardial injury (P = .002 and P = .03, respectively).
   Conclusion: In conclusion, although a range of ECG abnormalities can occur after ICH, the finding of ischemic-appearing changes in an anatomical distribution can help predict which patients are having true myocardial injury. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Hasegawa, Kohei; Goldstein, Joshua N.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
   [Fix, Megan L.] Univ Utah Hosp, Dept Emergency Med, Salt Lake City, UT USA.
   [Wendell, Lauren; Schwab, Kristin; Ay, Hakan; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB, Canada.
   [Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
EM dbrown2@partners.org
RI Goldstein, Joshua/H-8953-2016; 
OI Smith, Eric/0000-0003-3956-1668
FU CSL Behring; National Institute of Neurological Disorders and Stroke
   (NIH) [K23NS059774]
FX Dr Joshua N. Goldstein has received consulting fees from CSL Behring.;
   This study is funded by the National Institute of Neurological Disorders
   and Stroke (NIH K23NS059774).
NR 69
TC 7
Z9 7
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD MAY
PY 2012
VL 30
IS 4
BP 545
EP 552
DI 10.1016/j.ajem.2011.02.007
PG 8
WC Emergency Medicine
SC Emergency Medicine
GA 950RN
UT WOS:000304666500005
PM 21450435
ER

PT J
AU Martindale, JL
   Senecal, EL
AF Martindale, J. L.
   Senecal, E. L.
TI Atraumatic neck pain and rigidity: a case of calcific retropharyngeal
   tendonitis
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Editorial Material
AB Neck pain with associated rigidity is a concerning clinical presentation that emergency physicians encounter regularly. We present the case of a 58-year-old man with acute neck pain, worsened by movement and swallowing, that was found to be secondary to acute calcific retropharyngeal tendonitis. Patients with severe neck pain, neck stiffness, and odynophagia may have this condition. The diagnosis can be confirmed with imaging, and response to conservative treatment is often dramatic.
C1 [Martindale, J. L.; Senecal, E. L.] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Div Emergency Med,Med Sch, Boston, MA 02114 USA.
RP Martindale, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Div Emergency Med,Med Sch, Boston, MA 02114 USA.
EM jmartindale@partners.org
NR 7
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD MAY
PY 2012
VL 30
IS 4
AR 636.e1
DI 10.1016/j.ajem.2011.02.004
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 950RN
UT WOS:000304666500029
PM 21514765
ER

PT J
AU Wong, MH
   Chapin, OC
   Johnson, MD
AF Wong, Mandi H.
   Chapin, Olivia C.
   Johnson, Meshell D.
TI LPS-Stimulated Cytokine Production in Type I Cells Is Modulated by the
   Renin-Angiotensin System
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE cytokines; alveolar Type I cells; angiotensin Type 1 receptor;
   angiotensin-converting enzyme 2; lipopolysaccharide
ID ALVEOLAR EPITHELIAL-CELLS; INDUCED LUNG INJURY; CONVERTING
   ENZYME-INHIBITOR; NECROSIS-FACTOR-ALPHA; PRIMARY CULTURE; AT(1)
   RECEPTOR; CXC CHEMOKINES; TNF-ALPHA; RAT MODEL; LIPOPOLYSACCHARIDE
AB The alveolar epithelium serves as a barrier to the entry of potential respiratory pathogens. Alveolar Type II (TII) cells have immunomodulatory functions, but whether Type I (TI) cells, which comprise approximately 95% of the alveolar epithelium, also play a role in immunity is unknown. Because the renin-angiotensin system (RAS) is emerging as an important mediator of inflammation, and angiotensin-converting enzyme 2 (ACE2), an element of the RAS, has been implicated in lung injury, we hypothesize that TI cells canproduce cytokines in response to LPS stimulation, and that this inflammation can be modulated by the RAS. Alveolar TI cells were isolated from adult Sprague-Dawley rat lungs that had been injured with an intratracheal instillation of LPS. PCR was performed to determine whether TI cells expressed transcripts for TNF-alpha, IL-6, or IL-1 beta at baseline and after lung injury. Immunocytochemical and protein analysis detected angiotensin II (Ang II) and ACE2, as well as angiotensin Type 1 receptor (AT1R) and Type 2 receptor (AT2R), in TI cells. To separate cell-specific responses, primary TI cells were isolated, cultured, and exposed to LPS, Ang II, or specific inhibitors of AT1R or AT2R. Cytokine production was assayed by ELISA. LPS stimulated the production of all cytokines, whereas ACE2 and losartan, an AT1R inhibitor, blocked elements of the LPS-induced cytokine response. Primary TI cells produce cytokines when treated with LPS, contain important components of the RAS, and can modulate LPS-induced cytokine production via the RAS, suggesting a role for TI cells in the innate immune response of the lung.
C1 [Wong, Mandi H.; Johnson, Meshell D.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
   [Wong, Mandi H.; Johnson, Meshell D.] No Calif Inst Res & Educ, San Francisco, CA USA.
   [Chapin, Olivia C.; Johnson, Meshell D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Johnson, MD (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111-D, San Francisco, CA 94121 USA.
EM meshell.johnson@ucsf.edu
FU Department of Veterans Affairs; Northern California Institute for
   Research and Education; National Institutes of Health [HL088025]
FX This work was supported by grants from the Department of Veterans
   Affairs and the Northern California Institute for Research and
   Education, and by grant HL088025 from the National Institutes of Health
   (M.D.J).
NR 44
TC 10
Z9 12
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2012
VL 46
IS 5
BP 641
EP 650
DI 10.1165/rcmb.2011-0289OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 956CX
UT WOS:000305068500011
PM 22205632
ER

PT J
AU Holmes, LB
   Noonan, MS
   Harkins, M
   Smith, CR
   Hernandez-Dias, S
AF Holmes, L. B.
   Noonan, M. S.
   Harkins, M.
   Smith, C. R.
   Hernandez-Dias, S.
TI Topiramate: Potential Fetal Effects
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Holmes, L. B.; Noonan, M. S.; Harkins, M.; Smith, C. R.] MassGen Hosp Children, Boston, MA USA.
   [Hernandez-Dias, S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Holmes, L. B.; Noonan, M. S.; Harkins, M.; Smith, C. R.; Hernandez-Dias, S.] N Amer AED Pregnancy Registry, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2012
VL 94
IS 5
SI SI
BP 369
EP 369
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 956FF
UT WOS:000305074800146
ER

PT J
AU Noonan, M
   Smith, C
   Hernandez-Diaz, S
   Holmes, L
AF Noonan, M.
   Smith, C.
   Hernandez-Diaz, S.
   Holmes, L.
TI Oral Clefts in Anticonvulsant-Exposed Newborns
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Noonan, M.; Smith, C.; Hernandez-Diaz, S.; Holmes, L.] MassGen Hosp Children, N Amer AED Pregnancy Registry, Boston, MA USA.
   [Hernandez-Diaz, S.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2012
VL 94
IS 5
SI SI
BP 410
EP 410
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 956FF
UT WOS:000305074800196
ER

PT J
AU Pauk, M
   Grabusic, K
   Grgurevic, L
   Brkljacic, J
   Rogic, D
   Babbit, JL
   Lin, HY
   Volarevic, S
   Oppermann, H
   Vukicevic, S
AF Pauk, M.
   Grabusic, K.
   Grgurevic, L.
   Brkljacic, J.
   Rogic, D.
   Babbit, J. L.
   Lin, H. Y.
   Volarevic, S.
   Oppermann, H.
   Vukicevic, S.
TI The effect of iron on bone and plasma bone morphogenetic proteins
SO BONE
LA English
DT Meeting Abstract
CT 39th Annual Congress of the European-Calcified-Tissue-Society (ECTS)
CY MAY 19-23, 2012
CL Stockholm, SWEDEN
SP European Calcified Tissue Soc (ECTS), Amgen/GSK, Lilly, MSD, Takeda Pharmaceut Int GmbH, Alliance Better Bone Hlth (Warner Chilcott & Sanofi), Act Life Sci Inc, Alex Pharmaceut Inc, Arrow Lakemedel AB, b-cube AG, Biomedica, Ferrosan A/S - Pfizer Inc, Holog Inc, Int Bone & Mineral Soc (IBMS), Immunodiagnost Syst (IDS) Ltd, John Wiley & Sons, Medivir, OsteoMetr Inc, Pharma-Vinci A/S, Quidel Corp & TECO Med Corp, RISyst AG, Scanco Med AG, Sectra, SkyScan NV, Stratec Medizintechnik, Xradia Inc
C1 [Pauk, M.; Grgurevic, L.; Brkljacic, J.; Vukicevic, S.] Univ Zagreb, Sch Med, Lab Mineralized Tissues, Zagreb 41001, Croatia.
   [Grabusic, K.; Volarevic, S.] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia.
   [Rogic, D.] Clin Hosp Ctr Zagreb, Lab Clin Biochem, Zagreb, Croatia.
   [Oppermann, H.] Genera Res, Zagreb, Croatia.
   [Babbit, J. L.; Lin, H. Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD MAY
PY 2012
VL 50
SU 1
BP S103
EP S103
DI 10.1016/j.bone.2012.02.311
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 948LA
UT WOS:000304503500284
ER

PT J
AU Shacka, JJ
AF Shacka, John J.
TI Mouse models of neuronal ceroid lipofuscinoses: Useful pre-clinical
   tools to delineate disease pathophysiology and validate therapeutics
SO BRAIN RESEARCH BULLETIN
LA English
DT Review
DE NCL; Lysosome; Autophagy; Cathepsin D; Apoptosis; Therapeutic
ID PALMITOYL-PROTEIN THIOESTERASE-1; LYSOSOMAL STORAGE DISEASE;
   TRIPEPTIDYL-PEPTIDASE-I; CATHEPSIN-D DEFICIENCY; DEGENERATION MND MOUSE;
   CENTRAL-NERVOUS-SYSTEM; ENZYME-REPLACEMENT THERAPY; JUVENILE
   BATTEN-DISEASE; CELL-DEATH PATHWAYS; LATE INFANTILE NCL
AB The neuronal ceroid lipofuscinoses (NCL, also known as Batten disease) is a devastating neurodegenerative diseases caused by mutations in either soluble enzymes or membrane-associated structural proteins that result in lysosome dysfunction. Different forms of NCL were defined initially by age of onset, affected population and/or type of storage material but collectively represent the most prevalent pediatric hereditary neurovisceral storage disorder. Specific gene mutations are now known for each subclass of NCL in humans that now largely define the disease: cathepsin D (CTSD) for congenital (CLN10 form); palmitoyl protein thioesterase 1 (PPT1) for infantile (CLN1 form); tripeptidyl peptidase 1 (TPP1) for classic late infantile (CLN2 form); variant late infantile-CLN5, CLN6 or CLN8 for variant late infantile forms; and CLN3 for juvenile (CLN3 form). Several mouse models of NCL have been developed, or in some cases exist sporadically, that exhibit mutations producing a progressive neurodegenerative phenotype similar to that observed in human NCL The study of these mouse models of NCL has dramatically advanced our knowledge of NCL pathophysiology and in some cases has helped delineate the function of proteins mutated in human NCL In addition, NCL mutant mice have been tested for several different therapeutic approaches and as such they have become important pre-clinical models for validating treatment options. In this review we will assess the current state of mouse models of NCL with regards to their unique pathophysiology and how these mice have helped investigators achieve a better understanding of human NCL disease and therapy. This article is part of a Special Issue entitled 'Mose Models'. Published by Elsevier Inc.
C1 [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
   [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Shacka, JJ (reprint author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
EM shacka@uab.edu
RI di Ronza, Alberto/H-7674-2016
OI di Ronza, Alberto/0000-0002-9813-5143
FU VA Merit Review Award [1 I01 BX000957-01]
FX I wish to thank Rhonda Carr and Barry Bailey for expert technical
   assistance, and to Kathryn Davidson for expert technical support in
   preparation of this manuscript. I wish to also thank the UAB
   Neuroscience Molecular Detection Core (P30 NS47466; Kevin Roth, MD, PhD,
   Director; Terry Lewis, Technical Director) for their help in preparation
   of this manuscript. Dr. Shacka is supported by a VA Merit Review Award
   (1 I01 BX000957-01).
NR 171
TC 23
Z9 23
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD MAY 1
PY 2012
VL 88
IS 1
SI SI
BP 43
EP 57
DI 10.1016/j.brainresbull.2012.03.003
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 950EB
UT WOS:000304631300005
PM 22502604
ER

PT J
AU Wilson, WH
   Jung, SH
   Porcu, P
   Hurd, D
   Johnson, J
   Martin, SE
   Czuczman, M
   Lai, R
   Said, J
   Chadburn, A
   Jones, D
   Dunleavy, K
   Canellos, G
   Zelenetz, AD
   Cheson, BD
   Hsi, ED
AF Wilson, Wyndham H.
   Jung, Sin-Ho
   Porcu, Pierluigi
   Hurd, David
   Johnson, Jeffrey
   Martin, S. Eric
   Czuczman, Myron
   Lai, Raymond
   Said, Jonathan
   Chadburn, Amy
   Jones, Dan
   Dunleavy, Kieron
   Canellos, George
   Zelenetz, Andrew D.
   Cheson, Bruce D.
   Hsi, Eric D.
CA Canc Leukemia Grp B
TI A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab
   in untreated diffuse large B-cell lymphoma with analysis of outcome by
   molecular subtype
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Article
DE diffuse large B-cell lymphoma; DA-EPOCH-rituximab; untreated; outome;
   molecular
ID NON-HODGKINS-LYMPHOMAS; DOSE-ADJUSTED EPOCH; CHEMOTHERAPY PLUS
   RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; 3-WEEKLY CHOP CHEMOTHERAPY;
   GERMINAL-CENTER; ELDERLY-PATIENTS; AGGRESSIVE LYMPHOMAS; TISSUE
   MICROARRAY; DRUG-RESISTANCE
AB Background
   A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting.
   Design and Methods
   The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years of age and at least stage II. Radiaton therapy was not permitted on study. Median age was 58 years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk. Immunohistochemical biomarkers for cell of origin and proliferation were performed.
   Results
   With a median follow up of 62 months, time to progression and overall survival were 81% and 84%, respectively, and time to progression was 87%, 92% and 54% for low/low-intermediate, high-intermediate and high International Prognostic Index risk groups, respectively, at 5-years and beyond. The time to progression and event-free survival of germinal center B-cell lymphoma were 100% and 94%, respectively, and non-germinal center B-cell GCB diffuse large B-cell lymphoma were 67% and 58%, respectively, at 62 months (germinal center vs. non-germinal center B cell P=0.008). DA-EPOCH-R was tolerated without significant grade 4 non-hematologic toxicities.
   Conclusions
   These results provide the first confirmation by a multi-institutional group that DA-EPOCH-R provides high durable remissions in diffuse large B-cell lymphoma and is effective in both germinal center and non-germinal center B-cell subtypes.
C1 [Wilson, Wyndham H.] NCI, Metab Branch, Bethesda, MD 20892 USA.
   [Jung, Sin-Ho; Johnson, Jeffrey] Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC USA.
   [Porcu, Pierluigi] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
   [Hurd, David] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
   [Martin, S. Eric] Helen F Graham Canc Ctr, Newark, DE USA.
   [Czuczman, Myron] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Said, Jonathan] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Said, Jonathan] Univ Alberta, Edmonton, AB, Canada.
   [Chadburn, Amy] Northwestern Univ, Chicago, IL 60611 USA.
   [Jones, Dan] Quest Diagnost Nichols Inst, Chantilly, VA USA.
   [Canellos, George] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Cheson, Bruce D.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
   [Hsi, Eric D.] Cleveland Clin, Cleveland, OH 44106 USA.
RP Wilson, WH (reprint author), NCI, Metab Branch, Bldg 10,Room 4N-115,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM wilsonw@mail.nih.gov
RI Jones, Daniel/I-7399-2015; 
OI Zelenetz, Andrew/0000-0003-1403-6883
NR 50
TC 70
Z9 75
U1 0
U2 5
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD MAY
PY 2012
VL 97
IS 5
BP 758
EP 765
DI 10.3324/haematol.2011.056531
PG 8
WC Hematology
SC Hematology
GA 950SK
UT WOS:000304669000023
PM 22133772
ER

PT J
AU Piette, EW
   Werth, VP
AF Piette, Evan W.
   Werth, Victoria P.
TI Dapsone in the Management of Autoimmune Bullous Diseases
SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Dapsone; Autoimmune bullous disease; Review
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DERMATITIS-HERPETIFORMIS; ACQUISITA;
   PEMPHIGUS; DIAGNOSIS; ERUPTION; COLCHICINE; DERMATOSIS; THERAPY; WOMAN
AB Dapsone is used in the treatment of autoimmune bullous diseases (AIBD), a group of disorders resulting from autoimmunity directed against basement membrane and/or intercellular adhesion molecules on cutaneous and mucosal surfaces. This review summarizes the limited published data evaluating dapsone as a therapy for AIBD.
C1 [Piette, Evan W.; Werth, Victoria P.] Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA 19104 USA.
   [Werth, Victoria P.] Philadelphia VA Med Ctr, Div Dermatol, Philadelphia, PA USA.
RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU National Institutes of Health [NIH K24-AR 02207]
FX Funding: National Institutes of Health, including NIH K24-AR 02207
   (V.P.W.).
NR 41
TC 9
Z9 9
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8561
J9 IMMUNOL ALLERGY CLIN
JI Immunol. Allerg. Clin. North Am.
PD MAY
PY 2012
VL 32
IS 2
BP 317
EP +
DI 10.1016/j.iac.2012.04.011
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 955RP
UT WOS:000305038900013
PM 22560144
ER

PT J
AU Wiggs, JL
AF Wiggs, Janey L.
TI The Cell and Molecular Biology of Complex Forms of Glaucoma: Updates on
   Genetic, Environmental, and Epigenetic Risk Factors
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; NORMAL-TENSION GLAUCOMA; VARIANTS; THICKNESS;
   HISTORY; LOCI; EYE
C1 [Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Wiggs, Janey L.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Wiggs, JL (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM janey_wiggs@meei.harvard.edu
NR 33
TC 22
Z9 24
U1 2
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 5
SI SI
BP 2467
EP 2469
DI 10.1167/iovs.12-9483e
PG 3
WC Ophthalmology
SC Ophthalmology
GA 952YE
UT WOS:000304831400006
PM 22562842
ER

PT J
AU Yared, K
   Garcia-Camarero, T
   Fernandez-Friera, L
   Llano, M
   Durst, R
   Reddy, AA
   O'Neill, WW
   Picard, MH
AF Yared, Kibar
   Garcia-Camarero, Tamara
   Fernandez-Friera, Leticia
   Llano, Miguel
   Durst, Ronen
   Reddy, Anil A.
   O'Neill, William W.
   Picard, Michael H.
TI Impact of Aortic Regurgitation After Transcatheter Aortic Valve
   Implantation Results From the REVIVAL Trial
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE aortic regurgitation; echocardiography; transcatheter aortic valve
   implantation
ID NATURAL-HISTORY; PARAVALVULAR REGURGITATION; HEART-VALVE; STENOSIS;
   REPLACEMENT; PROSTHESIS; RETROGRADE; EXPERIENCE; DISEASE
AB OBJECTIVES Understanding the severity of aortic regurgitation (AR) after transcatheter aortic valve implantation, its impact on left ventricular (LV) structure and function, and the structural factors associated with worsening AR could lead to improvements in patient selection, implantation technique, and valve design.
   BACKGROUND Initial studies in patients at high risk of surgical aortic valve replacement have reported both central valvular and paravalvular AR after transcatheter aortic valve implantation.
   METHODS Transthoracic echocardiograms were quantified from 95 patients in the REVIVAL (TRanscatheter EndoVascular Implantation of VALves) trial. Transthoracic echocardiograms were obtained before implantation of the Edwards-Sapien valve (Edwards Lifesciences, Irvine, California) and thereafter at selected intervals. Measurements included LV internal diameters and volumes, ejection fraction, aortic valve area, and the degree of aortic regurgitation. Measures of degree of native leaflet mobility, thickness, and calcification, as well as left ventricular outflow tract, aortic annulus, and aortic root diameters were also made.
   RESULTS Eighty-four patients remained after 11 were excluded; 26 (29.8%) died over a period of 3 years. At 24 h post-implantation, 75% had some degree of AR, mostly paravalvular. By 1 year, the mean AR grade increased slightly, but not significantly (1.1 +/- 0.8 to 1.3 +/- 0.9), and all measures of LV structure and function improved (LV ejection fraction, 50.7 +/- 16.1% to 59.4 +/- 14.0%). Native aortic leaflet calcification and annulus diameter correlated significantly with the severity of AR at 1 year (p < 0.05).
   CONCLUSIONS AR after transcatheter aortic valve implantation is frequent but is rarely more than mild. Although AR progresses, it is not associated with a harmful impact on LV structure and function over the first year. Native valve calcification and aortic annulus diameter influence the degree of AR at 6 months. (J Am Coll Cardiol Img 2012;5:469-77) (C) 2012 by the American College of Cardiology Foundation
C1 [Yared, Kibar; Garcia-Camarero, Tamara; Fernandez-Friera, Leticia; Llano, Miguel; Durst, Ronen; Reddy, Anil A.; Picard, Michael H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
   [O'Neill, William W.] Univ Miami Hosp, Miller Sch Med, Div Cardiol, Miami, FL USA.
RP Yared, K (reprint author), Univ Toronto, Scarborough Hosp, Div Cardiol, 3050 Lawrence Ave, E Toronto, ON M1P 2V5, Canada.
EM kibaryared@yahoo.com
RI Fernandez Friera, Leticia /E-9931-2015; 
OI Fernandez Friera, Leticia /0000-0002-4237-2166; Picard,
   Michael/0000-0002-9264-3243
FU Edwards Lifesciences
FX Division of Cardiology, University of Miami Hospital, Miller School of
   Medicine, Miami, Florida. Dr. O'Neill is a consultant for Medtronic. Dr.
   Picard directs the REVIVAL Trial echocardiography core laboratory, which
   is supported by Edwards Lifesciences. All other authors have reported
   that they have no relationships relevant to the contents of this paper
   to disclose.
NR 23
TC 23
Z9 25
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD MAY
PY 2012
VL 5
IS 5
BP 469
EP 477
DI 10.1016/j.jcmg.2012.02.008
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 950UM
UT WOS:000304675600001
PM 22595154
ER

PT J
AU Holmvang, G
   Dec, GW
AF Holmvang, Godtfred
   Dec, G. William
TI CMR in Myocarditis Valuable Tool, Room for Improvement
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE cardiac magnetic resonance; delayed enhancement; endomyocardial biopsy;
   global early relative enhancement; late gadolinium enhancement;
   myocarditis; T2-weighted imaging
ID CARDIOVASCULAR MAGNETIC-RESONANCE
C1 [Holmvang, Godtfred; Dec, G. William] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
RP Holmvang, G (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Bulfinch 161,32 Fruit St, Boston, MA 02114 USA.
EM gholmvang@partners.org
NR 4
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD MAY
PY 2012
VL 5
IS 5
BP 525
EP 527
DI 10.1016/j.jcmg.2012.01.014
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 950UM
UT WOS:000304675600007
PM 22595160
ER

PT J
AU Elmariah, S
   Arzamendi, D
   Llanos, A
   Margey, RJ
   Inglessis, I
   Passeri, JJ
   Mehrotra, P
   Baker, JN
   Rosenfield, K
   Agnihotri, AK
   Vlahakes, GJ
   Palacios, IF
AF Elmariah, Sammy
   Arzamendi, Dabit
   Llanos, Alexander
   Margey, Ronan J.
   Inglessis, Ignacio
   Passeri, Jonathan J.
   Mehrotra, Praveen
   Baker, Joshua N.
   Rosenfield, Kenneth
   Agnihotri, Arvind K.
   Vlahakes, Gus J.
   Palacios, Igor F.
TI First Experience With Transcatheter Valve-In-Valve Implantation for a
   Stenotic Mitral Prosthesis Within the United States
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
C1 [Elmariah, Sammy; Arzamendi, Dabit; Llanos, Alexander; Margey, Ronan J.; Inglessis, Ignacio; Passeri, Jonathan J.; Mehrotra, Praveen; Rosenfield, Kenneth; Palacios, Igor F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Cardiol, Boston, MA 02114 USA.
   [Baker, Joshua N.; Agnihotri, Arvind K.; Vlahakes, Gus J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Cardiac Surg, Boston, MA USA.
RP Palacios, IF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Cardiol, Bigelow 800,55 Fruit St, Boston, MA 02114 USA.
EM palacios.igor@mgh.harvard.edu
NR 1
TC 5
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD MAY
PY 2012
VL 5
IS 5
BP E13
EP E14
DI 10.1016/j.jcin.2012.01.020
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 952WI
UT WOS:000304824600001
PM 22625204
ER

PT J
AU Hewitt, KJ
   Shamis, Y
   Knight, E
   Smith, A
   Maione, A
   Alt-Holland, A
   Sheridan, SD
   Haggarty, SJ
   Garlick, JA
AF Hewitt, Kyle J.
   Shamis, Yulia
   Knight, Elana
   Smith, Avi
   Maione, Anna
   Alt-Holland, Addy
   Sheridan, Steven D.
   Haggarty, Stephen J.
   Garlick, Jonathan A.
TI PDGFR beta expression and function in fibroblasts derived from
   pluripotent cells is linked to DNA demethylation
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE 3D tissues; DNA methylation; PDGFR beta; Fibroblasts; Human embryonic
   stem cells; Induced pluripotent stem cells
ID MESENCHYMAL STEM-CELLS; GROWTH-FACTOR; REGENERATIVE MEDICINE; FIBROTIC
   DISEASES; STROMAL CELLS; IN-VIVO; TISSUE; DIFFERENTIATION; METHYLATION;
   REPAIR
AB Platelet-derived growth factor receptor-beta (PDGFR beta) is required for the development of mesenchymal cell types, and plays a diverse role in the function of fibroblasts in tissue homeostasis and regeneration. In this study, we characterized the expression of PDGFR beta in fibroblasts derived from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), and showed that this expression is important for cellular functions such as migration, extracellular matrix production and assembly in 3D self-assembled tissues. To determine potential regulatory regions predictive of expression of PDGFR beta following differentiation from ESCs and iPSCs, we analyzed the DNA methylation status of a region of the PDGFRB promoter that contains multiple CpG sites, before and after differentiation. We demonstrated that this promoter region is extensively demethylated following differentiation, and represents a developmentally regulated, differentially methylated region linked to PDGFR beta expression. Understanding the epigenetic regulation of genes such as PDGFRB, and identifying sites of active DNA demethylation, is essential for future applications of iPSC-derived fibroblasts for regenerative medicine.
C1 [Hewitt, Kyle J.; Shamis, Yulia; Maione, Anna; Garlick, Jonathan A.] Tufts Univ, Sch Med, Program Cell Mol & Dev Biol, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Sheridan, Steven D.; Haggarty, Stephen J.] Harvard Univ, Sch Med, Ctr Human Genet Res, Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Knight, Elana; Smith, Avi; Garlick, Jonathan A.] Tufts Univ, Dept Oral & Maxillofacial Pathol, Boston, MA 02111 USA.
   [Alt-Holland, Addy] Tufts Univ, Dept Endodont, Sch Dent Med, Boston, MA 02111 USA.
RP Garlick, JA (reprint author), Tufts Univ, Sch Med, Program Cell Mol & Dev Biol, Sackler Sch Grad Biomed Sci, 136 Harrison Ave, Boston, MA 02111 USA.
EM jonathan.garlick@tufts.edu
OI Haggarty, Stephen J./0000-0002-7872-168X
FU National Institute of Craniofacial and Dental Research [DE017413-01A1];
   National Institute of Mental Health [R33MH087896]
FX This work was support by the National Institute of Craniofacial and
   Dental Research [grant number #DE017413-01A1 to J.A.G.] and the National
   Institute of Mental Health [grant number R33MH087896 to S. D. S. and
   S.J.H.]. Deposited in PMC for release after 12 months.
NR 48
TC 8
Z9 8
U1 1
U2 6
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD MAY 1
PY 2012
VL 125
IS 9
BP 2276
EP 2287
DI 10.1242/jcs.099192
PG 12
WC Cell Biology
SC Cell Biology
GA 955IP
UT WOS:000305011400019
PM 22344267
ER

PT J
AU Lenehan, G
AF Lenehan, Gail
TI THE EMERGENCY NURSES ASSOCIATION (ENA) "WEIGHS IN" ON PEDIATRIC
   MEDICATION SAFETY: "WEIGH CHILDREN IN KILOGRAMS ONLY!"
SO JOURNAL OF EMERGENCY NURSING
LA English
DT Editorial Material
C1 [Lenehan, Gail] Emergency Nurses Assoc, Boston, MA USA.
   [Lenehan, Gail] Massachusetts Gen Hosp, Emergency Dept, Boston, MA 02114 USA.
RP Lenehan, G (reprint author), Emergency Nurses Assoc, Boston, MA USA.
EM gail.lenehan@gmail.com
NR 10
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-1767
J9 J EMERG NURS
JI J. Emerg. Nurs.
PD MAY
PY 2012
VL 38
IS 3
BP 205
EP 206
DI 10.1016/j.jen.2012.04.010
PG 2
WC Emergency Medicine; Nursing
SC Emergency Medicine; Nursing
GA 953FN
UT WOS:000304852400001
PM 22578387
ER

PT J
AU Drager, KK
   du Sac, P
AF Drager, Kristin K.
   du Sac, Prairie
TI IMPROVING PATIENT OUTCOMES WITH COMPRESSION-ONLY CPR: WILL BYSTANDER CPR
   RATES IMPROVE?
SO JOURNAL OF EMERGENCY NURSING
LA English
DT Article
ID HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; CHEST
   COMPRESSION; SURVIVAL
C1 [Drager, Kristin K.] William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA.
   [Drager, Kristin K.] William S Middleton Mem Vet Adm Med Ctr, ACLS, Madison, WI USA.
   [Drager, Kristin K.] St Xavier Univ, Clin Nurse Leader Program, Chicago, IL USA.
RP Drager, KK (reprint author), William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA.
EM Kristin.Drager@va.gov
NR 10
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-1767
J9 J EMERG NURS
JI J. Emerg. Nurs.
PD MAY
PY 2012
VL 38
IS 3
BP 234
EP 238
DI 10.1016/j.jen.2011.02.008
PG 5
WC Emergency Medicine; Nursing
SC Emergency Medicine; Nursing
GA 953FN
UT WOS:000304852400009
PM 21514650
ER

PT J
AU Pena, A
   Estrada, CA
   Soniat, D
   Taylor, B
   Burton, M
AF Pena, Adolfo
   Estrada, Carlos A.
   Soniat, Debbie
   Taylor, Benjamin
   Burton, Michael
TI Nominal group technique: A brainstorming tool for identifying areas to
   improve pain management in hospitalized patients
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID PRODUCTIVITY LOSS; CARE
AB BACKGROUND: Pain management in hospitalized patients remains a priority area for improvement; effective strategies for consensus development are needed to prioritize interventions. OBJECTIVE: To identify challenges, barriers, and perspectives of healthcare providers in managing pain among hospitalized patients. DESIGN: Qualitative and quantitative group consensus using a brainstorming technique for quality improvementthe nominal group technique (NGT). SETTING: One medical, 1 medical-surgical, and 1 surgical hospital unit at a large academic medical center. PARTICIPANTS: Nurses, resident physicians, patient care technicians, and unit clerks. MEASUREMENTS: Responses and ranking to the NGT question: What causes uncontrolled pain in your unit? RESULTS: Twenty-seven health workers generated a total of 94 ideas. The ideas perceived contributing to a suboptimal pain control were grouped as system factors (timeliness, n = 18 ideas; communication, n = 11; pain assessment, n = 8), human factors (knowledge and experience, n = 16; provider bias, n = 8; patient factors, n = 19), and interface of system and human factors (standardization, n = 14). Knowledge, timeliness, provider bias, and patient factors were the top ranked themes. CONCLUSIONS: Knowledge and timeliness are considered main priorities to improve pain control. NGT is an efficient tool for identifying general and context-specific priority areas for quality improvement; teams of healthcare providers should consider using NGT to address their own challenges and barriers. Journal of Hospital Medicine 2012; (c) 2011 Society of Hospital Medicine
C1 [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham Vet Affair Med Ctr, Vet Affair Natl Qual Scholars Program, Birmingham, AL 35294 USA.
   [Pena, Adolfo] St Joseph Hosp, Sect Hosp Med, London, KY USA.
   [Estrada, Carlos A.; Soniat, Debbie; Taylor, Benjamin] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL USA.
   [Estrada, Carlos A.; Soniat, Debbie; Taylor, Benjamin] Univ Hosp, Birmingham, AL USA.
   [Burton, Michael] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affair Med Ctr, Vet Affair Natl Qual Scholars Program, FOT 732,510 20th St S, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
FU Veterans Affairs National Quality Scholars Program
FX Drs. Pena, Burton, and Estrada were supported by the Veterans Affairs
   National Quality Scholars Program. The opinions expressed in this
   article are those of the authors alone and do not reflect the views of
   the Department of Veterans Affairs.
NR 24
TC 11
Z9 11
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY-JUN
PY 2012
VL 7
IS 5
BP 416
EP 420
DI 10.1002/jhm.1900
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 953LA
UT WOS:000304867600010
PM 22190453
ER

PT J
AU Chester, JG
   Harrington, MB
   Rudolph, JL
AF Chester, Jennifer G.
   Harrington, Mary Beth
   Rudolph, James L.
CA VA Delirium Working Grp
TI Serial administration of a modified richmond agitation and sedation
   scale for delirium screening
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID RELIABILITY; VALIDITY
AB OBJECTIVES: Because delirium is a common yet frequently unrecognized condition, this study sought to design a brief screening tool for a core feature of mental status and to validate the instrument as a serial assessment for delirium. DESIGN: Prospective cohort study. SETTING: Tertiary VA Hospital in New England. PARTICIPANTS: A total of 95 veterans admitted to the medical service. METHODS: A consensus panel developed a modified version of the Richmond Agitation and Sedation Scale (RASS) to capture alterations in consciousness. Upon admission, and daily thereafter, patients were screened with a modified RASS (mRASS) and independently underwent a comprehensive mental status interview by a geriatric expert, who determined whether the criteria for delirium were met. The sensitivity, specificity, and positive likelihood ratio (LR) of the mRASS for delirium are reported. RESULTS: As a single assessment, the mRASS had a sensitivity of 64% and a specificity of 93% for delirium (LR, 9.4). When used to detect change, serial mRASS assessments had a sensitivity of 74% and a specificity of 92% (LR, 8.9) in both prevalent and incident delirium. When prevalent cases were excluded, any change in the mRASS had a sensitivity of 85% and a specificity of 92% for incident delirium (LR, 10.2) CONCLUSION: When administered daily, the mRASS has good sensitivity and specificity for incident delirium. Given the brevity of the instrument (<30 seconds), consideration should be given to incorporating the modified RASS as a daily screening measure for consciousness and delirium. Journal of Hospital Medicine 2012; (c) 2012 Society of Hospital Medicine
C1 [Chester, Jennifer G.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Harrington, Mary Beth; Rudolph, James L.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
   [Rudolph, James L.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
   [Rudolph, James L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rudolph, JL (reprint author), VABHS GRECC, 150 S Huntington Ave, Boston, MA 02130 USA.
EM jrudolph@partners.org
FU Einstein Research Fellowship; VA Rehabilitation Research Career
   Development Award; American Federation for Aging Research; Boston MSTAR;
   National Institutes of Health [AG 026781-05, AG 038027]
FX Funding: Jennifer G. Chester was funded by an Einstein Research
   Fellowship. James L. Rudolph is supported by a VA Rehabilitation
   Research Career Development Award. Additional support was provided by
   the American Federation for Aging Research, the Boston MSTAR, and
   National Institutes of Health grants AG 026781-05 and AG 038027. James
   L. Rudolph and Mary Beth Harrington and the VA Delirium Working Group
   Consensus Panel are VA employees. The authors have no additional
   disclosures to report.
NR 13
TC 36
Z9 36
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY-JUN
PY 2012
VL 7
IS 5
BP 450
EP 453
DI 10.1002/jhm.1003
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 953LA
UT WOS:000304867600016
PM 22173963
ER

PT J
AU Berkowitz, RS
AF Berkowitz, Ross S.
TI Gestational Trophoblastic Disease Presentations from the XVIth World
   Congress on Gestational Trophoblastic Diseases Introduction
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Editorial Material
DE chemotherapy; gestational trophoblastic neoplasms
C1 Harvard Univ, New England Trophoblast Dis Ctr,Dana Farber Canc, Donald P Goldstein MD Trophoblast Tumor Registry, Div Gynecol Oncol,Dept Obstet & Gynecol,Med Sch,B, Boston, MA 02115 USA.
RP Berkowitz, RS (reprint author), Harvard Univ, New England Trophoblast Dis Ctr,Dana Farber Canc, Donald P Goldstein MD Trophoblast Tumor Registry, Div Gynecol Oncol,Dept Obstet & Gynecol,Med Sch,B, 75 Francis St, Boston, MA 02115 USA.
EM rberkowitz@partners.org
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD MAY-JUN
PY 2012
VL 57
IS 5-6
BP 187
EP 188
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 951RX
UT WOS:000304738800002
PM 22696810
ER

PT J
AU Goldstein, DP
AF Goldstein, Donald P.
TI The Past Is Prologue to the Present: Milestones in the Modern Management
   of Molar Pregnancy and Gestational Trophoblastic Neoplasia Keynote
   Address
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE gestational trophoblastic disease; gestational trophoblastic neoplasia;
   hydatidiform mole; molar pregnancy
ID HYDATIDIFORM MOLE; DISEASE; CHEMOTHERAPY; CHORIOCARCINOMA; TUMORS;
   WOMEN; RISK; EXPERIENCE; THERAPY
C1 [Goldstein, Donald P.] Dana Farber Brigham & Womens Canc Ctr, New England Trophoblast Dis Ctr, Div Gynecol Oncol, Boston, MA USA.
RP Goldstein, DP (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM dgoldstein@partners.org
NR 40
TC 1
Z9 1
U1 0
U2 2
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD MAY-JUN
PY 2012
VL 57
IS 5-6
BP 189
EP 196
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 951RX
UT WOS:000304738800003
PM 22696811
ER

PT J
AU Braga, A
   Growdon, WB
   Bernstein, M
   Maesta, I
   Rudge, MVC
   Goldstein, DP
   Berkowitz, RS
AF Braga, Antonio
   Growdon, Whitfield B.
   Bernstein, Marilyn
   Maesta, Izildinha
   Rudge, Marilza Vieira Cunha
   Goldstein, Donald P.
   Berkowitz, Ross S.
TI Molar Pregnancy in Adolescents
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE adolescent pregnancy; adolescents; gestational trophoblastic neoplasia;
   hydatidiform mole; molar pregnancy
ID GESTATIONAL TROPHOBLASTIC DISEASE; QUALITY-OF-LIFE; PARTIAL HYDATIDIFORM
   MOLE; EPIDEMIOLOGY; AGE; NEOPLASIA; MANAGEMENT; WOMEN; RISK
AB OBJECTIVE: To describe the clinical presentation of hydatidiform molar pregnancy in women under the age of 20 years. In addition, we sought to understand if this adolescent population manifests differences in clinical factors compared to an adult population that may affect outcome.
   STUDY DESIGN: We used a database from the New England Trophoblastic Disease Center to analyze clinical data from all women followed for molar pregnancy between 1970 and 2009 with complete follow-up information. This population was stratified by age and clinical parameters including presenting signs, molar histology and development of gestational trophoblastic neoplasia (GTN). Univariable and multivariable logistic regression was employed to discern clinical factors that associated with adolescent age. The Partners Human Research Committee approved this study.
   RESULTS: We identified 1,494 women diagnosed with hydatidiform mole (HM), of which 220 (14.7%) were adolescents defined as age <20 years. The most common presenting clinical signs were vaginal bleeding and an enlarged uterus compared to dates. Median gestational age at diagnosis was 13.4 weeks, not different from that in the adult population. Similarly, no difference in presenting human chorionic gonadotropin was observed between the adult and adolescent populations. Adolescents presented with a significant overrepresentation of complete mole (86% vs. 75%, p < 0.001) compared to adults. Complete mole was associated with a heightened risk of developing GTN (OR 2.6, 95% CI 1.9-3.5), and despite the association of complete mole with young maternal age, univariable analysis showed no difference in the rate of GTN observed between adolescents and adults (24% vs. 30%, p = 0.08). Multivariable analysis controlling for molar histology demonstrated that adolescent age was associated with a decreased risk of GTN (hazard ratio 0.67, 95% CI 0.48 0.93).
   CONCLUSION: Adolescents account for a substantial proportion of the population with HM. They commonly present with vaginal bleeding. Though this population develops a complete mole with a higher frequency than adults, adolescents appear to have a significantly decreased risk of developing GTN. (J Reprod Med 2012; 57:225-230)
C1 [Berkowitz, Ross S.] Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Boston, MA 02115 USA.
   Univ Fed Fluminense, Trophoblast Dis Ctr, Univ Hosp Antonio Pedro, Niteroi, RJ, Brazil.
   UNESP Sao Paulo State Univ, Trophoblast Dis Ctr, Dept Gynecol & Obstet, Botucatu Med Sch, Botucatu, SP, Brazil.
   Massachusetts Gen Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Harvard Canc Ctr,Dana Farber Canc Inst, Boston, MA 02114 USA.
   Donald P Goldstein MD Trophoblast Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Berkowitz, RS (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.
EM rberkowitz@partners.org
RI Braga, Antonio/F-7144-2014; Rudge, Marilza /C-8338-2012
OI Braga, Antonio/0000-0002-2942-6182; Rudge, Marilza /0000-0002-9227-832X
NR 28
TC 5
Z9 5
U1 0
U2 4
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD MAY-JUN
PY 2012
VL 57
IS 5-6
BP 225
EP 230
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 951RX
UT WOS:000304738800009
PM 22696817
ER

PT J
AU Rauh-Hain, JA
   Growdon, WB
   Braga, A
   Goldstein, DP
   Berkowitz, RS
AF Rauh-Hain, J. Alejandro
   Growdon, Whitfield B.
   Braga, Antonio
   Goldstein, Donald P.
   Berkowitz, Ross S.
TI Gestational Trophoblastic Neoplasia in Adolescents
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE adolescents; female; gestational trophoblastic disease; gestational
   trophoblastic neoplasia; molar pregnancy
ID DISEASE; MANAGEMENT; RISK; CLASSIFICATION; PREGNANCY; SYSTEM
AB OBJECTIVE: To evaluate the clinical outcomes in adolescents with gestational trophoblastic neoplasia (GTN) compared to adult women.
   STUDY DESIGN: Patients with International Federation of Gynecology and Obstetrics criteria for GTN who underwent treatment between January 1, 1973, and December 31, 2010, were identified from the Donald P. Goldstein, M.D., Trophoblastic Tumor Registry of the New England Trophoblastic Disease Center. Adolescents included patients <20 years old at the time of diagnosis. Standard univariate analyses were peiformed, as were multivariate analyses with logistic regression to control for potential confounding variables.
   RESULTS: We identified 423 women with GTN; 50 (12%) patients were adolescents (<20 years old), and 373 (88%) were 20 years old. Both groups had the same rate of low-risk GTN score (98% vs. 98%, p = 0.9). In the adolescent group 47 (94%) women had stage I GTN, and 3 (6%) had stage III. In the adult group 304(81.5%) women had stage I GTN, 4 (1%) had stage II, 64 (17%) had stage III and only 1 (0.5%) had stage IV disease (p = 0.7). Adolescents at molar presentation had higher rates of anemia (30% vs. 14%, p = 0.001), vaginal bleeding (86% vs. 67%, p = 0.001), and a uterus with size greater than dates (42% vs. 24%, p = 0.007). Factors determined to significantly influence resistance to initial chemotherapeutic treatment on multivariate analysis were 0-hCG level at molar presentation >100,000 mIU/mL, /3-hCG level at persistence > 20,000 inIU/mL, the presence of metastasis, and duration of disease >4 months. Age <20 years old was not a prognostic factor of resistance to initial chemotherapeutic treatment.
   CONCLUSION: There was no difference between adolescents and adult women in the rates of low-risk GTN, stage of GTN, and the frequency of resistance to initial chemotherapeutic treatment. (J Reprod Med 2012;57: 237-242)
C1 [Berkowitz, Ross S.] Harvard Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA.
   Donald P Goldstein MD Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA.
   Univ Fed Fluminense, Antonio Pedro Univ, Trophoblast Dis Ctr, Rio De Janeiro, Brazil.
RP Berkowitz, RS (reprint author), Harvard Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Brigham & Womens Hosp,Med Sch, 75 Francis St, Boston, MA 02115 USA.
EM rberkowitz@partners.org
RI Braga, Antonio/F-7144-2014
OI Braga, Antonio/0000-0002-2942-6182
NR 14
TC 2
Z9 3
U1 0
U2 2
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD MAY-JUN
PY 2012
VL 57
IS 5-6
BP 237
EP 242
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 951RX
UT WOS:000304738800011
PM 22696819
ER

PT J
AU Elias, KM
   Shoni, M
   Bernstein, M
   Goldstein, DP
   Berkowitz, RS
AF Elias, Kevin M.
   Shoni, Melina
   Bernstein, Marilyn
   Goldstein, Donald P.
   Berkowitz, Ross S.
TI Complete Hydatidiform Mole in Women Aged 40 to 49 Years
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE gestational trophoblastic disease; gestational trophoblastic neoplasia;
   hydatidiform mole; hydatidiform mole; complete
ID GESTATIONAL TROPHOBLASTIC NEOPLASIA; DISEASE; PREGNANCY; RISK;
   MANAGEMENT; DIAGNOSIS
AB OBJECTIVE: To describe the clinical course of women aged 40 to 49 presenting with complete hydatidiform mole.
   STUDY DESIGN: All cases of complete mole diagnosed at the New England Trophoblastic Disease Center were reviewed. A total of 82 patients met the study criteria.
   RESULTS: Study patients had a mean age of 44.2 years, gravidity of 4.6 and parity of 2.6. The mean hCG on presentation was 230,484 mIU/mL. Most patients presented with abnormal vaginal bleeding (77%). Of the 82 patients, 83% underwent dilation and curettage without prophylactic chemotherapy; 53% of those patients developed gestational trophoblastic neoplasia (GTN). Patients who developed GTN were significantly more likely both before and after evacuation to have higher hCG levels than those who did not. There were no GTN cases among patients receiving either prophylactic chemotherapy or upfront hysterectomy. Aggressive upfront therapy was associated with shortened time to hCG normalization and fewer lines of surgical or chemotherapeutic therapy.
   CONCLUSION: All women in their 40s with complete mole are at high risk for GTN and might benefit from aggressive upfront therapy. Those patients with hCG levels > 175,000 mIU/mL constitute an "ultra-high-risk" group for whom prophylactic chemotherapy or hysterectomy should be especially considered. (J Reprod Med 2012;57:254-258)
C1 [Elias, Kevin M.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02115 USA.
   Donald P Goldstein MD Trophoblast Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Elias, KM (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM kelias1@partners.org
OI Elias, Kevin/0000-0003-1502-5553
NR 16
TC 10
Z9 10
U1 1
U2 3
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD MAY-JUN
PY 2012
VL 57
IS 5-6
BP 254
EP 258
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 951RX
UT WOS:000304738800014
PM 22696822
ER

PT J
AU James, MF
   Stivison, E
   Beauchamp, R
   Han, S
   Li, H
   Wallace, MR
   Gusella, JF
   Stemmer-Rachamimov, AO
   Ramesh, V
AF James, Marianne F.
   Stivison, Elizabeth
   Beauchamp, Roberta
   Han, Sangyeul
   Li, Hua
   Wallace, Margaret R.
   Gusella, James F.
   Stemmer-Rachamimov, Anat O.
   Ramesh, Vijaya
TI Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient
   Target Cell Types
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR; VESTIBULAR SCHWANNOMA; TUBEROUS SCLEROSIS; TSC1-TSC2
   COMPLEX; ACTIVATION; GROWTH; NF2; PATHWAY; MERLIN; GENE
AB Inactivating mutations in the neurofibromatosis 2 (NF2) tumor suppressor gene results in the development of schwannomas and meningiomas. Using NF2-deficient meningioma cells and tumors, together with the normal cellular counterparts that meningiomas derive, arachnoid cells, we identified merlin as a novel negative regulator of mTOR complex 1 (mTORC1). We now show that merlin positively regulates the kinase activity of mTORC2, a second functionally distinct mTOR complex, and that downstream phosphorylation of mTORC2 substrates, including Akt, is reduced upon acute merlin deficiency in cells. In response to general growth factor stimulation, Akt signaling is attenuated in merlin merlin RNA interference-suppressed human arachnoid and Schwann cells by mechanisms mediated by hyperactivem TORC1 and impaired mTORC2. Moreover, Akt signaling is impaired differentially in a cell type-dependent manner in response to distinct growth factor stimuli. However, contrary to activation of mTORC1, the attenuated mTORC2 signaling profiles exhibited by normal arachnoid and Schwann cells in response to acute merlin loss were not consistently reflected in NF2-deficient meningiomas and schwannomas, suggesting additional genetic events may have been acquired in tumors after initial merlin loss. This finding contrasts with another benign tumor disorder, tuberous sclerosis complex, which exhibits attenuated mTORC2 signaling profiles in both cells and tumors. Finally, we examined rapamycin, as well as the mTOR kinase inhibitor, Torin1, targeting both mTOR complexes to identify the most efficacious class of compounds for blocking mTOR-mediated signaling and proliferation in merlin-deficient meningioma cells. These studies may ultimately aid in the development of suitable therapeutics for NF2-associated tumors. Mol Cancer Res; 10(5); 649-59. (C) 2012 AACR.
C1 [James, Marianne F.; Stivison, Elizabeth; Beauchamp, Roberta; Han, Sangyeul; Gusella, James F.; Ramesh, Vijaya] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Stemmer-Rachamimov, Anat O.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurooncol Lab, Div Neuropathol, Boston, MA 02114 USA.
   [Li, Hua; Wallace, Margaret R.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA.
RP Ramesh, V (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Richard B Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM james@helix.mgh.harvard.edu; ramesh@helix.mgh.harvard.edu
FU NIH [NS024279]; Department of Defense (DOD); S. Sydney De Young
   Foundation, Neurofibromatosis, Inc., New England; Children's Tumor
   Foundation Drug Discovery Initiative
FX This work was supported by the NIH grants NS024279, Department of
   Defense (DOD) Neurofibromatosis Research Program, S. Sydney De Young
   Foundation, Neurofibromatosis, Inc., New England, and Children's Tumor
   Foundation Drug Discovery Initiative.
NR 50
TC 32
Z9 32
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2012
VL 10
IS 5
BP 649
EP 659
DI 10.1158/1541-7786.MCR-11-0425-T
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 956EZ
UT WOS:000305074200008
PM 22426462
ER

PT J
AU Thota, S
   Wang, M
   Jeon, S
   Maragani, S
   Hamblin, MR
   Chiang, LY
AF Thota, Sammaiah
   Wang, Min
   Jeon, Seaho
   Maragani, Satyanarayana
   Hamblin, Michael R.
   Chiang, Long Y.
TI Synthesis and Characterization of Positively Charged Pentacationic
   [60]Fullerene Monoadducts for Antimicrobial Photodynamic Inactivation
SO MOLECULES
LA English
DT Article
DE pentacationic C-60 monoadducts; decacationic C-60 monoadduct; N,N
   ',N,N,N,N-hexapropyl-hexa(aminoethyl)amine; photosensitizer
ID FULLERENE DERIVATIVES; SURFACE-PROTEINS; THERAPY; BACTERIA; C-60;
   INFECTIONS
AB We designed and synthesized two analogous pentacationic [60]fullerenyl monoadducts, C-60(> ME1N6+C3) (1) and C-60(> ME3N6+C3) (2), with variation of the methoxyethyleneglycol length. Each of these derivatives bears a well-defined number of cationic charges aimed to enhance and control their ability to target pathogenic Gram-positive and Gram-negative bacterial cells for allowing photodynamic inactivation. The synthesis was achieved by the use of a common synthon of pentacationic N,N',N,N,N,N-hexapropylhexa(aminoethyl)amine arm (C3N6+) having six attached propyl groups, instead of methyl or ethyl groups, to provide a well-balanced hydrophobicity-hydrophilicity character to pentacationic precursor intermediates and better compatibility with the highly hydrophobic C-60 cage moiety. We demonstrated two plausible synthetic routes for the preparation of 1 and 2 with the product characterization via various spectroscopic methods.
C1 [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Thota, Sammaiah; Wang, Min; Jeon, Seaho; Maragani, Satyanarayana; Chiang, Long Y.] Univ Massachusetts, Dept Chem, Inst Nanosci & Engn Technol, Lowell, MA 01854 USA.
   [Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
   [Hamblin, Michael R.] Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Chiang, Long Y.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu; Long_Chiang@uml.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU National Institute of Health (NIH) [R01CA137108]
FX We thank the financial support of National Institute of Health (NIH)
   under the grant number R01CA137108.
NR 19
TC 9
Z9 9
U1 1
U2 16
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD MAY
PY 2012
VL 17
IS 5
BP 5225
EP 5243
DI 10.3390/molecules17055225
PG 19
WC Chemistry, Organic
SC Chemistry
GA 949PH
UT WOS:000304587600038
PM 22565476
ER

PT J
AU Berruti, A
   Cook, R
   Saad, F
   Buttigliero, C
   Lipton, A
   Tampellini, M
   Lee, KA
   Coleman, RE
   Smith, MR
AF Berruti, Alfredo
   Cook, Richard
   Saad, Fred
   Buttigliero, Consuelo
   Lipton, Allan
   Tampellini, Marco
   Lee, Ker-Ai
   Coleman, Robert E.
   Smith, Matthew R.
TI Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate
   Cancer Patients Undergoing Zoledronic Acid Administration
SO ONCOLOGIST
LA English
DT Article
DE Bone metastasis; Parathyroid hormone; Prostate cancer; Zoledronic acid
ID VITAMIN-D; BREAST-CANCER; CELL-LINES; PROTEIN; BONE; INTERLEUKIN-6;
   METASTASIS; EXPRESSION; RECEPTORS; CALCIUM
AB Background. Secondary hyperparathyroidism is frequent in prostate cancer patients with bone metastases, and this condition is worsened by the administration of potent bisphosphonates. Serum parathyroid hormone (PTH) elevation can impair the efficacy of these drugs in terms of survival.
   Methods. The prognostic role of elevated serum PTH levels at baseline and after 3 months of zoledronic acid administration was assessed prospectively in 643 bone metastatic prostate cancer patients enrolled in a prospective randomized, placebo-controlled study.
   Results. On multivariate analysis, after adjusting for major prognostic factors and bone turnover markers, elevated baseline serum PTH level was negatively associated with overall survival (hazard ratio [HR], 1.448; 95% confidence interval [CI], 1.045-2.006; p < .03) in zoledronic acid-treated patients but not in placebo-treated patients. In patients with normal baseline PTH levels, there was a trend but insignificant association between zoledronic acid administration and a better survival outcome than with placebo (HR, 0.81; 95% CI, 0.65-1.01; p = .065), whereas a trend in the opposite direction was observed in patients with elevated PTH levels (HR, 1.45; 95% CI, 0.87-2.39; p = .151); interaction test, p = .040. Elevated serum PTH level after 3 months of zoledronic acid treatment was not significantly associated with survival outcome.
   Conclusions. Secondary hyperparathyroidism has a negative prognostic impact in metastatic prostate cancer patients undergoing zoledronic acid administration. Counteracting elevated PTH levels by adequate doses of vitamin D may improve the efficacy of this drug. The Oncologist 2012;17:645-652
C1 [Berruti, Alfredo; Buttigliero, Consuelo; Tampellini, Marco] Univ Turin, Azienda Osped San Luigi, Dept Clin & Biol Sci, I-10043 Orbassano, Italy.
   [Cook, Richard; Lee, Ker-Ai] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
   [Saad, Fred] CRCHUM Univ Montreal, Montreal, PQ, Canada.
   [Lipton, Allan] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Div Hematol Oncol, Hershey, PA 17033 USA.
   [Coleman, Robert E.] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
   [Smith, Matthew R.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
RP Berruti, A (reprint author), Univ Turin, Azienda Osped San Luigi, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Orbassano, Italy.
EM alfredo.berruti@gmail.com
RI Tampellini, Marco/F-9227-2013; Inov Farmaceutica, Inct/K-2313-2013
FU Novartis; Amgen; Novartis Pharmaceuticals Corporation; Italian Ministry
   of University and Research (MIUR)
FX Alfredo Berruti: Novartis (C/A, H, RF); Fred Saad: Novartis (C/A, H,
   RF); Allan Lipton: Amgen, Novartis (C/A, H, RF); Other: Expert
   testimony: Novartis; Robert E. Coleman: Novartis, Amgen (H, RF); Other:
   Expert testimony: Novartis. The other authors indicated no financial
   relationships.; Research and technical support were provided by a grant
   from Novartis Pharmaceuticals Corporation and the Italian Ministry of
   University and Research (MIUR).
NR 26
TC 7
Z9 7
U1 0
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAY
PY 2012
VL 17
IS 5
BP 645
EP 652
DI 10.1634/theoncologist.2011-0448
PG 8
WC Oncology
SC Oncology
GA 953MC
UT WOS:000304871100010
PM 22523198
ER

PT J
AU Li, XY
   DiFiglia, M
AF Li, Xueyi
   DiFiglia, Marian
TI The recycling endosome and its role in neurological disorders
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Membrane traffic; The recycling endosome; Rab11; Neurological disorders;
   Huntington's disease
ID FAMILIAL ALZHEIMERS-DISEASE; GDP DISSOCIATION INHIBITOR; CANINE
   KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MITOCHONDRIAL
   ENERGY-METABOLISM; NEURONAL GLUTAMATE TRANSPORTER;
   LOW-DENSITY-LIPOPROTEIN; LONG-TERM POTENTIATION; TRANS-GOLGI NETWORK;
   PLASMA-MEMBRANE
AB The recycling endosome (RE) is an organelle in the endocytic pathway where plasma membranes (proteins and lipids) internalized by endocytosis are processed back to the cell surface for reuse. Endocytic recycling is the primary way for the cell to maintain constituents of the plasma membrane (Griffiths et al., 1989), i.e., to maintain the abundance of receptors and transporters on cell surfaces. Membrane traffic through the RE is crucial for several key cellular processes including cytokinesis and cell migration. In polarized cells, including neurons, the RE is vital for the generation and maintenance of the polarity of the plasma membrane. Many RE dependent cargo molecules are known to be important for neuronal function and there is evidence that improper function of key proteins in RE-associated pathways may contribute to the pathogenesis of neurological disorders, including Huntington's disease. The function of the RE in neurons is poorly understood. Therefore, there is need to understand how membrane dynamics in RE-associated pathways are affected or participate in the development or progression of neurological diseases. This review summarizes advances in understanding endocytic recycling associated with the RE, challenges in elucidating molecular mechanisms underlying RE function, and evidence for RE dysfunction in neurological disorders. (C) 2011 Published by Elsevier Ltd.
C1 [DiFiglia, Marian] Massachusetts Gen Hosp, Lab Cellular Neurobiol, Charlestown, MA 02129 USA.
   Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
RP DiFiglia, M (reprint author), Massachusetts Gen Hosp, Lab Cellular Neurobiol, 114 16th St, Charlestown, MA 02129 USA.
EM difiglia@helix.mgh.harvard.edu
NR 218
TC 21
Z9 21
U1 3
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD MAY
PY 2012
VL 97
IS 2
SI SI
BP 127
EP 141
DI 10.1016/j.pneurobio.2011.10.002
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 952MH
UT WOS:000304796100006
PM 22037413
ER

PT J
AU Schoenfeld, JD
   Odejide, OO
   Wirth, LJ
   Chan, AW
AF Schoenfeld, Jonathan D.
   Odejide, Oreofe O.
   Wirth, Lori J.
   Chan, Annie W.
TI Survival of a Patient with Anaplastic Thyroid Cancer Following
   Intensity-modulated Radiotherapy and Sunitinib - A Case Report
SO ANTICANCER RESEARCH
LA English
DT Article
DE Anaplastic thyroid carcinoma; chemoradiation; intensity-modulated
   radiation therapy (IMRT); sunitinib; case report
ID PROGNOSTIC-FACTORS; TREATMENT OUTCOMES; PHASE-II; CARCINOMA; SURGERY;
   TRIAL; RADIATION
AB Background: Anaplastic: thyroid cancer has a very poor prognosis, especially in patients who have gross residual disease following resection. Case Report: We present the case of a patient with anaplastic thyroid cancer and a significant gross residual disease treated with intensity-modulated radiotherapy with concurrent chemotherapy and sunitinib who had a complete response and remains without evidence of disease more than 18 months after diagnosis. Conclusion: Chemoradiotherapy has an important role in the adjuvant treatment of anaplastic thyroid cancer in selected patients and should be considered when gross residual disease is present following resection. The combined use of radiotherapy and targeted biological agents such as sunitinib may warrant further investigation.
C1 [Schoenfeld, Jonathan D.; Chan, Annie W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
   [Odejide, Oreofe O.; Wirth, Lori J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med Oncol, Boston, MA 02114 USA.
   [Schoenfeld, Jonathan D.] Harvard Radiat Oncol Program, Boston, MA USA.
   [Odejide, Oreofe O.] Dana Farber Partners CancerCare Hematol Oncol Fel, Boston, MA USA.
RP Schoenfeld, JD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Cox Bldg,3rd Floor,100 Blossom St, Boston, MA 02114 USA.
EM jdschoenfeld@partners.org
NR 24
TC 8
Z9 9
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD MAY
PY 2012
VL 32
IS 5
BP 1743
EP 1746
PG 4
WC Oncology
SC Oncology
GA 947LQ
UT WOS:000304431900023
PM 22593455
ER

PT J
AU De la Marche, W
   Noens, I
   Luts, J
   Scholte, E
   Van Huffel, S
   Steyaert, J
AF De la Marche, Wouter
   Noens, Ilse
   Luts, Jan
   Scholte, Evert
   Van Huffel, Sabine
   Steyaert, Jean
TI Quantitative autism traits in first degree relatives: evidence for the
   broader autism phenotype in fathers, but not in mothers and siblings
SO AUTISM
LA English
DT Article
DE Quantitative autism traits; broader autism phenotype; autism spectrum
   disorders; siblings; parents
ID PERVASIVE DEVELOPMENTAL DISORDERS; FAMILIAL AGGREGATION; SPECTRUM
   DISORDERS; GENERAL-POPULATION; DIAGNOSTIC INTERVIEW; MULTIPLE-INCIDENCE;
   PARENTS; TWIN; QUOTIENT; CHILDREN
AB Autism spectrum disorder (ASD) symptoms are present in unaffected relatives and individuals from the general population. Results are inconclusive, however, on whether unaffected relatives have higher levels of quantitative autism traits (QAT) or not. This might be due to differences in research populations, because behavioral data and molecular genetic research suggest that the genetic etiology of ASD is different in multiplex and simplex families. We compared 117 unaffected siblings and 276 parents of at least one child with ASD with 280 children and 595 adults from the general population on the presence of QAT using the Social Responsiveness Scale (SRS). Mean SRS scores for siblings, control children, parents and control adults were 25.4, 26.6, 33.7 and 32.9. Fathers of children with ASD showed significantly higher levels of QAT than controls, but siblings and mothers did not. We could not detect a statistically significant difference in SRS scores between relatives from simplex and multiplex families. These results do not support the theory of differential (genetic) etiology in multiplex and simplex families and suggest that a carried genetic risk is generally not expressed phenotypically in most relatives, except in fathers.
C1 [De la Marche, Wouter; Steyaert, Jean] UPC KU Leuven, Child & Adolescent Psychiat Dept, B-3000 Louvain, Belgium.
   [De la Marche, Wouter; Steyaert, Jean] UPC KU Leuven, Leuven Autism Res, B-3000 Louvain, Belgium.
   [Steyaert, Jean] Univ Hosp Maastricht, Maastricht, Netherlands.
   [Noens, Ilse] Katholieke Univ Leuven, Parenting & Special Educ Res Grp, Louvain, Belgium.
   [Noens, Ilse; Van Huffel, Sabine] Katholieke Univ Leuven, Leuven Autism Res, Louvain, Belgium.
   [Noens, Ilse] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
   [Luts, Jan; Van Huffel, Sabine] Katholieke Univ Leuven, Res Div SCD, Dept Elect Engn ESAT, Heverlee, Belgium.
   [Scholte, Evert] Leiden Univ, Leiden, Netherlands.
RP Steyaert, J (reprint author), UPC KU Leuven, Child & Adolescent Psychiat Dept, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.
EM jean.steyaert@med.kuleuven.be
RI Steyaert, Jean/B-5326-2015
OI Steyaert, Jean/0000-0003-2512-4694
NR 30
TC 12
Z9 12
U1 5
U2 24
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1362-3613
J9 AUTISM
JI Autism
PD MAY
PY 2012
VL 16
IS 3
BP 247
EP 260
DI 10.1177/1362361311421776
PG 14
WC Psychology, Developmental
SC Psychology
GA 950QY
UT WOS:000304665000003
PM 21949002
ER

PT J
AU Huang, N
   Shah, PK
   Li, C
AF Huang, Norman
   Shah, Parantu K.
   Li, Cheng
TI Lessons from a decade of integrating cancer copy number alterations with
   gene expression profiles
SO BRIEFINGS IN BIOINFORMATICS
LA English
DT Article
DE data integration; copy number; gene expression; integrative analysis;
   cancer
ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN BREAST-CANCER; PROSTATE-CANCER;
   TARGET GENES; LUNG-CANCER; COLORECTAL TUMORIGENESIS;
   GLIOBLASTOMA-MULTIFORME; CHROMOSOMAL REGIONS; MICROARRAY ANALYSIS;
   ANALYSIS REVEALS
AB Over the last decade, multiple functional genomic datasets studying chromosomal aberrations and their downstream effects on gene expression have accumulated for several cancer types. A vast majority of them are in the form of paired gene expression profiles and somatic copy number alterations (CNA) information on the same patients identified using microarray platforms. In response, many algorithms and software packages are available for integrating these paired data. Surprisingly, there has been no serious attempt to review the currently available methodologies or the novel insights brought using them. In this work, we discuss the quantitative relationships observed between CNA and gene expression in multiple cancer types and biological milestones achieved using the available methodologies. We discuss the conceptual evolution of both, the step-wise and the joint data integration methodologies over the last decade. We conclude by providing suggestions for building efficient data integration methodologies and asking further biological questions.
C1 [Shah, Parantu K.; Li, Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst,CLS 11075, Boston, MA 02115 USA.
RP Shah, PK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst,CLS 11075, CLS 11075,3 Blackfan Circle, Boston, MA 02115 USA.
EM parantu.shah@gmail.com; cli@hsph.harvard.edu
FU NIH [T32 CA09337, 1R01GM077122, 5P50 CA100707-07]; Claudia Adams Barr
   Award for basic innovative research in cancer; DFCI/HCC Multiple Myeloma
   SPORE
FX The cancer training grant (NIH T32 CA09337 to Yi Li and N.H.); Claudia
   Adams Barr Award for basic innovative research in cancer;Multiple
   Myeloma Career Development Award that is a part of DFCI/HCC Multiple
   Myeloma SPORE (grant NIH 5P50 CA100707-07 to P. K. S.); dChip grant (NIH
   1R01GM077122 to C.L.).
NR 88
TC 22
Z9 24
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1467-5463
J9 BRIEF BIOINFORM
JI Brief. Bioinform.
PD MAY
PY 2012
VL 13
IS 3
BP 305
EP 316
DI 10.1093/bib/bbr056
PG 12
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 948XH
UT WOS:000304536200004
PM 21949216
ER

PT J
AU Dell'Italia, LJ
AF Dell'Italia, Louis J.
TI Anatomy and Physiology of the Right Ventricle
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Right ventricle; Anatomy; Physiology
ID CANINE RIGHT VENTRICLE; PRESSURE-VOLUME RELATIONSHIP; PULMONARY ARTERIAL
   SYSTEM; TIME-VARYING ELASTANCE; MYOCARDIAL BLOOD-FLOW; RIGHT ATRIAL
   PRESSURE; PULSE WAVE VELOCITY; OPEN-CHEST DOGS; OXYGEN-METABOLISM;
   POSTEXTRASYSTOLIC POTENTIATION
AB Under normal baseline conditions the unique anatomy, myocardial ultrastructure, and coronary physiology of the right ventricle (RV) reflect a high-volume low-pressure pump. Early work described the RV as a passive conduit with minimal pumping capability. It is now appreciated that through a mechanism of ventricular interdependence, RV systolic function and diastolic load are extremely important in the prognosis and treatment of congestive heart failure, cardiac transplantation, pulmonary hypertension, congenital heart disease, and left ventricle assist devices. Magnetic resonance imaging with three-dimensional analysis has shown the complex geometry of the RV and the interaction of both ventricles within the pericardium.
C1 Birmingham VA Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
EM loudell@uab.edu
NR 135
TC 23
Z9 26
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2012
VL 30
IS 2
BP 167
EP +
DI 10.1016/j.cc1.2012.03.009
PG 22
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 949JN
UT WOS:000304572600004
PM 22548810
ER

PT J
AU Sayer, GT
   Semigran, MJ
AF Sayer, Gabriel T.
   Semigran, Marc J.
TI Right Ventricular Performance in Chronic Congestive Heart Failure
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Right ventricle; Right ventricular failure; Right ventricular
   dysfunction; Ventricular interdependence; Pulmonary hypertension; Right
   heart catheterization; Phosphodiesterase-5 inhibitors
ID PULMONARY ARTERIAL-HYPERTENSION; TIME 3-DIMENSIONAL ECHOCARDIOGRAPHY;
   EJECTION FRACTION; MYOCARDIAL-INFARCTION; INDEPENDENT PREDICTOR;
   EXERCISE CAPACITY; SYSTOLIC FUNCTION; SHORT-TERM;
   CARDIOVASCULAR-DISEASE; PRESSURE-OVERLOAD
AB Right ventricular physiology is characterized by its close relationship with the pulmonary circuit. The right ventricle can accommodate significant changes in preload, but is highly sensitive to increases in afterload. Progressive dilatation and dysfunction can initiate a cycle of oxygen supply-demand mismatch that ultimately leads to right ventricular failure. Echocardiography and cardiac magnetic resonance imaging are the primary modalities used for non-invasive assessment of right ventricular function. The management of right ventricular failure centers on the optimization of preload, afterload and contractility. Few targeted therapies exist, although novel agents have shown promise in early studies.
C1 [Sayer, Gabriel T.; Semigran, Marc J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
   [Sayer, Gabriel T.; Semigran, Marc J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Semigran, MJ (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM msemigran@partners.org
NR 72
TC 3
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2012
VL 30
IS 2
BP 271
EP +
DI 10.1016/j.cc1.2012.03.011
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 949JN
UT WOS:000304572600011
PM 22548817
ER

PT J
AU Vlahakes, GJ
AF Vlahakes, Gus J.
TI Right Ventricular Failure After Cardiac Surgery
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Right ventricle; Right ventricular failure; Interventricular failure;
   Nitric oxide; Prostacyclin; Cardiac transplantation; Cardiac assist
   device
ID INHALED NITRIC-OXIDE; PULMONARY-HYPERTENSION; PROSTACYCLIN;
   DETERMINANTS; DYSFUNCTION; PRESSURE; THERAPY
AB Right ventricular (RV) failure remains a major problem in cardiac surgery, particularly in the setting of heart transplantation and following institution of left ventricular support. Experimental studies have shown that RV function is derived from 2 sources: the free wall of the RV and the interventricular septum. Management of RV failure involves not only decreasing RV afterload, but also optimizing both contributions to RV function, which is best achieved by optimizing developed systemic pressure. Techniques for managing the pulmonary circulation and strategies for optimizing RV function in various clinical settings are presented.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiac Surg, Boston, MA 02114 USA.
RP Vlahakes, GJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiac Surg, 55 Fruit St,COX630, Boston, MA 02114 USA.
EM vlahakes.gus@mgh.harvard.edu
NR 16
TC 5
Z9 5
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2012
VL 30
IS 2
BP 283
EP +
DI 10.1016/j.cc1.2012.03.010
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 949JN
UT WOS:000304572600012
PM 22548818
ER

PT J
AU Chen, WT
   Wang, SJ
   Fuh, JL
   Ko, YC
   Lee, YC
   Hamalainen, MS
   Lin, YY
AF Chen, Wei-Ta
   Wang, Shuu-Jiun
   Fuh, Jong-Ling
   Ko, Yu-Chieh
   Lee, Yi-Chung
   Haemaelaeinen, Matti S.
   Lin, Yung-Yang
TI Visual cortex excitability and plasticity associated with remission from
   chronic to episodic migraine
SO CEPHALALGIA
LA English
DT Article
DE Migraine; chronic migraine; magnetoencephalography; visual evoked
   magnetic field; visual cortical excitability; topiramate
ID CHRONIC DAILY HEADACHE; TRANSCRANIAL MAGNETIC STIMULATION; BRAIN-STEM
   ACTIVATION; CORTICAL EXCITABILITY; FOLLOW-UP; TOPIRAMATE; HABITUATION;
   DYSFUNCTION; POTENTIALS; ATTACK
AB Objective: Previous magnetoencephalographic (MEG) studies showed different P100m (where 'm' denotes the magnetic counterpart of P100 in conventional visual evoked potentials) responses between episodic migraine (EM) and chronic migraine (CM) interictally. This study investigated the changes of visual P100m in CM patients who remitted to EM from CM after treatment.
   Methods: At baseline, 25 patients with CM were studied interictally. For each patient, 30 sequential blocks of 50 P100m responses were obtained by MEG. Sub-averaged amplitudes at blocks 2, 9, 16, 23 and 30 were further compared with that at block 1 to assess response habituation or potentiation (i.e. significant decrease or increase at either block vs block 1). The same study was repeated in those patients who remitted from CM to EM after topiramate treatment.
   Results: In total, 10 CM patients remitted to EM after treatment. In the follow-up study of these patients during the interictal stage, the P100m at block 1 decreased in amplitude from 53.6 +/- 6.6 nAm before remission to 43.0 +/- 5.1 nAm (p = 0.028), and the responses at subsequent blocks switched from habituation (amplitude block 30 < block 1 before remission, p = 0.011) to potentiation (block 2 > block 1, p = 0.028).
   Conclusion: The pattern of P100m responses to consecutive stimulation changes with the transition from CM to EM. Visual cortex plasticity might be a potential biomarker reflecting clinical remission of CM.
C1 [Chen, Wei-Ta; Wang, Shuu-Jiun; Fuh, Jong-Ling; Lee, Yi-Chung; Lin, Yung-Yang] Taipei Vet Gen Hosp, Neurol Inst, Taipei 112, Taiwan.
   [Ko, Yu-Chieh] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Chen, Wei-Ta; Wang, Shuu-Jiun; Fuh, Jong-Ling; Ko, Yu-Chieh; Lee, Yi-Chung; Lin, Yung-Yang] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Chen, Wei-Ta; Haemaelaeinen, Matti S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
   [Wang, Shuu-Jiun; Lin, Yung-Yang] Natl Yang Ming Univ, Inst Brain Sci, Taipei 112, Taiwan.
   [Lin, Yung-Yang] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.
   [Wang, Shuu-Jiun] Natl Yang Ming Univ, Brain Res Ctr, Taipei 112, Taiwan.
RP Wang, SJ (reprint author), Taipei Vet Gen Hosp, Neurol Inst, 201 Shihpai Rd,Sec 2, Taipei 112, Taiwan.
EM sjwang@vghtpe.gov.tw; yylin@vghtpe.gov.tw
RI Hamalainen, Matti/C-8507-2013; 
OI Fuh, Jong-Ling/0000-0001-9135-3351; Lee, Yi-Chung/0000-0003-0102-164X
FU National Science Council of Taiwan [NSC 94-2314-B-038-014,
   NSC-96-2314-B-075-073-MY3, NSC-98-2321-B-010-007, NSC-99-2321-B-010-004,
   NSC-100-2321-B-010-004, NSC-95-2314-B-010-031-MY3NSC, NSC
   99-2911-I-008-100]; Taipei Veterans General Hospital [V98B2-004,
   V99C1-063, V97ER3-006, VGHUST97-P6-24, V97C1-034, VGH ER3-98-002,
   VGH-S4-98-018, VGH-C1-99-156, VGH-ER3-99-006]; Brain Research Center,
   National Yang-Ming University; Ministry of Education, Taipei, Taiwan
FX This study was supported by the National Science Council of Taiwan [NSC
   94-2314-B-038-014 and NSC-96-2314-B-075-073-MY3 to WT,
   NSC-98-2321-B-010-007, NSC-99-2321-B-010-004 and NSC-100-2321-B-010-004
   to YY, NSC-95-2314-B-010-031-MY3NSC and NSC 99-2911-I-008-100 (NSC
   support for the Center for Dynamical Biomarkers and Translational
   Medicine, National Central University, Taiwan) to SJ]; Taipei Veterans
   General Hospital (V98B2-004 to WT, V99C1-063 to SJ, V97ER3-006,
   VGHUST97-P6-24, V97C1-034, VGH ER3-98-002, VGH-S4-98-018, VGH-C1-99-156
   and VGH-ER3-99-006 to YY); Brain Research Center, National Yang-Ming
   University; and the Ministry of Education, Taipei, Taiwan (Aim for the
   Top University Plan to SJ).
NR 29
TC 16
Z9 17
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
J9 CEPHALALGIA
JI Cephalalgia
PD MAY
PY 2012
VL 32
IS 7
BP 537
EP 543
DI 10.1177/0333102412443337
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 951DU
UT WOS:000304701800004
PM 22529191
ER

PT J
AU Levy, D
   Moskowitz, MA
   Noseda, R
   Burstein, R
AF Levy, Dan
   Moskowitz, Michael A.
   Noseda, Rodrigo
   Burstein, Rami
TI Activation of the migraine pain pathway by cortical spreading
   depression: Do we need more evidence?
SO CEPHALALGIA
LA English
DT Letter
ID CUTANEOUS ALLODYNIA; STIMULATION; NEURONS; MEDULLARY; HEADACHE; RATS
C1 [Levy, Dan; Noseda, Rodrigo; Burstein, Rami] Beth Israel Deaconess Med Ctr, Baltimore, MD USA.
   [Moskowitz, Michael A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Levy, Dan; Moskowitz, Michael A.; Noseda, Rodrigo; Burstein, Rami] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Levy, D (reprint author), Beth Israel Deaconess Med Ctr, Baltimore, MD USA.
EM dlevy1@bidmc.harvard.edu
FU NINDS NIH HHS [R01 NS069847, R37 NS079678]
NR 13
TC 7
Z9 7
U1 1
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
J9 CEPHALALGIA
JI Cephalalgia
PD MAY
PY 2012
VL 32
IS 7
BP 581
EP 582
DI 10.1177/0333102411424621
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 951DU
UT WOS:000304701800009
PM 21996564
ER

PT J
AU Marcum, ZA
   Gellad, WF
AF Marcum, Zachary A.
   Gellad, Walid F.
TI Medication Adherence to Multidrug Regimens
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Article
DE Medication; Adherence; Polypharmacy; Elderly; Geriatric
ID PRIMARY-CARE PATIENTS; OLDER-ADULTS; PREDICTIVE-VALIDITY;
   ELDERLY-PATIENTS; BLOOD-PRESSURE; POLYPHARMACY; HEALTH; NONADHERENCE;
   PERSISTENCE; COST
AB Polypharmacy and medication adherence present a unique challenge for the older adult, their caregiver(s), and the health care team. There appears to be an association in the literature between polypharmacy and poorer medication adherence in older adults. However, the heterogeneity of how adherence is defined in the literature limits the certainty of this conclusion. Nonetheless, improving medication adherence to maximize the therapeutic benefit of pharmacotherapy remains a cornerstone of geriatric care. We discuss strategies for limiting polypharmacy and improving adherence and suggest ideas for future research focused on identifying and translating safe and effective interventions to improve adherence into routine clinical practice.
C1 [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA.
   [Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Med Geriatr, Pittsburgh, PA 15213 USA.
   [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA 15213 USA.
   [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA 15213 USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM Walid.gellad@va.gov
FU National Institute on Aging [P30AG024827]; VA Career Development Award
   [09-207]
FX Dr Marcum is supported by a National Institute on Aging grant
   (P30AG024827), and Dr Gellad is supported by a VA Career Development
   Award (09-207).
NR 44
TC 26
Z9 28
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD MAY
PY 2012
VL 28
IS 2
BP 287
EP +
DI 10.1016/j.cger.2012.01.008
PG 15
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 949JJ
UT WOS:000304572200010
PM 22500544
ER

PT J
AU Lancaster, RT
   Conrad, MF
   Patel, VI
   Cambria, RP
   LaMuraglia, GM
AF Lancaster, R. T.
   Conrad, M. F.
   Patel, V. I.
   Cambria, R. P.
   LaMuraglia, G. M.
TI Predictors of Early Graft Failure After Infrainguinal Bypass Surgery: A
   Risk-adjusted Analysis from the NSQIP
SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE Lower extremity bypass; Predictors of failure; Peripheral arterial
   occlusive disease
ID AFFAIRS SURGICAL RISK; SAPHENOUS-VEIN BYPASS; ESSENTIAL THROMBOCYTHEMIA;
   POSTOPERATIVE MORTALITY; LIMB SALVAGE; OUTCOMES; MORBIDITY; QUALITY;
   CARE; MULTICENTER
AB Introduction and objectives: Infrainguinal bypass surgery (BPG) is accompanied by significant 30-day mortality and morbidity, including early graft failure. The goal of this study is to identify patient- and procedure-specific factors which predict the rate of early graft failure in contemporary practice.
   Methods: Data was obtained from the private sector National Surgical Quality Improvement Program, a prospective, validated database collected between 2005 and 2008 from 211 hospitals, using primary and modifier Current Procedural Terminology codes for BPG. The primary endpoint was graft failure at 30 days. Procedural parameters, patient demographics and clinical variables were analyzed by univariate and multivariate methods.
   Results: There were 9217 BPG procedures (limb salvage, 49%; infrapopliteal distal anastomosis, 43%; prosthetic 32%) with patient variables: age 67 +/- 12 years, male 64%, diabetes 44%, dialysis 7.4%. Mortality was 2.4%, major morbidity was 17.3%, and graft failure rate was 6.3% at 30 days. Multivariate predictors of graft failure demonstrated correlation (p-value, OR) with female gender (p = 0.0054, 1.29), limb salvage indication (p < 0.0001, 1.60), infrapopliteal anastomosis (p < 0.0001, 2.15), composite graft (p = 0.0436, 1.82), current smoking (p = 0.0007, 1.36), impaired sensorium (p = 0.0075, 2.13), emergency procedure (p < 0.0001, 2.03), previous vascular procedure (p = 0.0005, 1.39), and platelets >400K (p = 0.0019, 1.49). High-risk composite constructs utilizing these significant predictive factors can identify cohorts of patients with up to a 98-fold increase in odds of early graft failure.
   Conclusions: These results describe common risk factors that correlate with early graft thrombosis including the unique description of its association with thrombocytosis. Additional risk factors thus identify a subset of patients who are at highest risk for early BPG failure. This data may be used to refine patient selection. (C) 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [LaMuraglia, G. M.] Massachusetts Gen Hosp, Gen Surg Serv, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP LaMuraglia, GM (reprint author), Massachusetts Gen Hosp, Gen Surg Serv, Div Vasc & Endovasc Surg, 15 Parkman St,Wang ACC 440, Boston, MA 02114 USA.
EM glamuraglia@comcast.net
NR 32
TC 19
Z9 19
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1078-5884
J9 EUR J VASC ENDOVASC
JI Eur. J. Vasc. Endovasc. Surg.
PD MAY
PY 2012
VL 43
IS 5
BP 549
EP 555
DI 10.1016/j.ejvs.2012.01.026
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 949NN
UT WOS:000304583000013
PM 22342690
ER

PT J
AU Sharff, ME
   DeMarco, TA
   Mays, D
   Peshkin, BN
   Valdimarsdottir, HB
   Garber, JE
   Schneider, KA
   Patenaude, AF
   Tercyak, KP
AF Sharff, McKane E.
   DeMarco, Tiffani A.
   Mays, Darren
   Peshkin, Beth N.
   Valdimarsdottir, Heiddis B.
   Garber, Judy E.
   Schneider, Katherine A.
   Patenaude, Andrea F.
   Tercyak, Kenneth P.
TI Parenting Through Genetic Uncertainty: Themes in the Disclosure of
   Breast Cancer Risk Information to Children
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
ID FAMILY COMMUNICATION; BRCA1/2; CARRIERS; TELL; DISEASE; MOTHERS; MINORS;
   NEEDS; WOMEN
AB Aim: Among mothers undergoing BRCA1/2 testing and their spouses/partners, this study sought to examine decision support needs and motivations for family communication of genetic risk information to asymptomatic children. Methods: This study gathered data from 213 tested mothers and 104 of their untested parenting partners 1 month after maternal receipt of genetic test results and upon making a decision about communicating genetic information to their child (ages 8-21 years). Data include parents' perceived needs for family communication decision support, decision motivations, and parent-child communication. Results: Parents reported high decision support needs (e. g., educational materials, professional counseling, peer assistance). Motivations for disclosure to children among mothers and partners focused on promoting the parent-child bond and maintaining family health (55.3% and 75%, respectively) and promoting positive child affect (44.7% and 25.5%, respectively). Motivations for nondisclosure to children among mothers and partners focused on the lack of appropriateness (69.6% and 51.3%, respectively) and relative importance of genetic test results (30.4% and 48.7%, respectively). Significant discrepancies in parental motivation for family communication were observed. Decision support needs were highest among disclosing mothers with affect-related motivations [t (129) = 2.47; p = 0.01]. Parent-child communication was poorest among nondisclosing mothers concerned about the appropriateness of genetic information for their child [t (77)= -3.29; p = .002]. Conclusions: Parents receiving information about hereditary cancer predisposition have unmet needs when making decisions about disclosing genetic risk information to their asymptomatic children. These data can guide the development of cancer risk communication decision support interventions for parents undergoing such testing.
C1 [Tercyak, Kenneth P.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Canc Control Program, Washington, DC 20007 USA.
   [Valdimarsdottir, Heiddis B.] Mt Sinai Sch Med, New York, NY USA.
   [Garber, Judy E.; Schneider, Katherine A.; Patenaude, Andrea F.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Tercyak, KP (reprint author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Canc Control Program, 3300 Whitehaven St NW,Suite 4100, Washington, DC 20007 USA.
EM tercyakk@georgetown.edu
FU National Human Genome Research Institute [R01 HG002686]
FX The authors would like to thank the genetic counselors, physicians, and
   staff at study sites for their participation, and Susan Marx for
   assistance with manuscript preparation. This work was funded by grant
   R01 HG002686 from the National Human Genome Research Institute to Dr.
   Tercyak.
NR 26
TC 13
Z9 13
U1 0
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD MAY
PY 2012
VL 16
IS 5
BP 376
EP 382
DI 10.1089/gtmb.2011.0154
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 947RU
UT WOS:000304448300013
PM 22085394
ER

PT J
AU Bot, AGJ
   Ring, DC
AF Bot, Arjan G. J.
   Ring, David C.
TI Recovery After Fracture of the Distal Radius
SO HAND CLINICS
LA English
DT Article
DE Recovery; Distal radius fracture; Coaching; Exercises
ID REGIONAL PAIN SYNDROME; RANDOMIZED CONTROLLED-TRIAL; BRIDGING EXTERNAL
   FIXATION; REDISPLACED UNSTABLE FRACTURES; VOLAR PLATE FIXATION; COLLES
   FRACTURE; EARLY MOBILIZATION; WRIST FRACTURES; OCCUPATIONAL-THERAPY;
   EXERCISE PROGRAM
AB Stretching exercises are an important part of recovery after sustaining a fracture of the distal radius. However, from the patient's perspective, painful stretching exercises can be counterintuitive after injury. Stretching exercises are straightforward and do not require a significant amount of coaching. It is ultimately the protectiveness, passivity, and sometimes a sense of futility that require coaching. The key for the provider is to empathize with the difficult and counterintuitive nature of the recovery process.
C1 [Ring, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Boston, MA 02114 USA.
RP Ring, DC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
FU Skeletal Dynamics; AO North America
FX (A.G.J.B.) Stichting Anna Fonds, VSBfonds, Prins Bernhard
   Cultuurfonds/Banning-de Jong Fonds. (D.C.R.) Study-specific grants:
   Skeletal Dynamics (pending); Consultant: Wright Medical, Skeletal
   Dynamics, Biomet; Honoraria: AO North America, AO International;
   Royalties received: Wright Medical; Royalties contracted: Biomet,
   Skeletal Dynamics; Stock options: Illuminos; Funding for Hand Surgery
   Fellowship: AO North America.
NR 81
TC 2
Z9 4
U1 0
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0712
J9 HAND CLIN
JI Hand Clin.
PD MAY
PY 2012
VL 28
IS 2
BP 235
EP +
DI 10.1016/j.hcl.2012.03.006
PG 10
WC Orthopedics
SC Orthopedics
GA 949JG
UT WOS:000304571900016
PM 22554667
ER

PT J
AU Jupiter, J
AF Jupiter, Jesse
TI Future Treatment and Research Directions in Distal Radius Fracture
SO HAND CLINICS
LA English
DT Article
DE Distal radius; Future; Fracture; Treatment; Economics
ID NONOPERATIVE TREATMENT; FIXATION; COMPLICATIONS; TRIAL; END
AB Whether or not they will have their lives dramatically extended in the next few decades, it is clear that people are living longer, healthier, and more active lives. The two peak incidences of distal radius fractures will remain within the pediatric and geriatric age groups, with the latter experiencing a substantial increase in the coming years. This article attempts to project future developments with regard to epidemiology, risk and prevention, fracture assessment, and treatment of distal radius fractures, and the ever increasing concern for the economic impact of this prevalent injury.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Jupiter, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey 2,Suite 2100, Boston, MA 02114 USA.
EM JJUPITER1@PARTNERS.ORG
NR 24
TC 5
Z9 6
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0712
J9 HAND CLIN
JI Hand Clin.
PD MAY
PY 2012
VL 28
IS 2
BP 245
EP +
DI 10.1016/j.hcl.2012.02.006
PG 5
WC Orthopedics
SC Orthopedics
GA 949JG
UT WOS:000304571900017
PM 22554668
ER

PT J
AU Greaney, ML
   Puleo, E
   Geller, AC
   Hu, SW
   Werchniak, AE
   DeCristofaro, S
   Emmons, KM
AF Greaney, Mary L.
   Puleo, Elaine
   Geller, Alan C.
   Hu, Stephanie W.
   Werchniak, Andrew E.
   DeCristofaro, Susan
   Emmons, Karen M.
TI Patient Follow-Up After Participating in a Beach-Based Skin Cancer
   Screening Program
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Recent Advances in Environmental Health
   Research
CY SEP 18-21, 2011
CL Jackson, MS
SP Jackson State Univ (JSU), Natl Inst Hlth, RCMI-Ctr Environm Hlth, U S Dept Educ, Title III Grad Educ Program, U S Environm Protect Agcy, JSU Off Acad Affairs, JSU Off Res & Fed Relat
DE cancer screening; skin cancer prevention; skin examinations; sun
   protection
ID UNITED-STATES; AMERICAN ACADEMY; MELANOMA; SATISFACTION; DERMATOLOGY;
   PREVALENCE; CAMPAIGN; BELGIUM; ADULTS
AB Many skin cancer screenings occur in non-traditional community settings, with the beach being an important setting due to beachgoers being at high risk for skin cancer. This study is a secondary analysis of data from a randomized trial of a skin cancer intervention in which participants (n = 312) had a full-body skin examination by a clinician and received a presumptive diagnosis (abnormal finding, no abnormal finding). Participants' pursuit of follow-up was assessed post-intervention (n = 283). Analyses examined: (1) participant's recall of screening results; and (2) whether cognitive and behavioral variables were associated with follow-up being as advised. Just 12% of participants (36/312) did not correctly recall the results of their skin examination. One-third (33%, 93/283) of participants' follow-up was classified as being not as advised (recommend follow-up not pursued, unadvised follow-up pursued). Among participants whose follow-up was not as advised, 71% (66/93) did not seek recommended care. None of the measured behavioral and cognitive variables were significantly associated with recall of screening examination results or whether follow-up was as advised. Research is needed to determine what factors are associated with follow-up being as advised and to develop messages that increase receipt of advised follow-up care.
C1 [Greaney, Mary L.; Emmons, Karen M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
   [Puleo, Elaine] Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA.
   [Geller, Alan C.; Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
   [Hu, Stephanie W.] NYU, Med Ctr, New York, NY 10016 USA.
   [Werchniak, Andrew E.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
RP Greaney, ML (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
EM mary_greaney@dfci.harvard.edu; epuleo@schoolph.umass.edu;
   ageller@hsph.harvard.edu; stephwhu@gmail.com; awerchniak@partners.org;
   Susan_DeCristofaro@dfci.harvard.edu; Karen_M_Emmons@dfci.harvard.edu
NR 26
TC 1
Z9 1
U1 0
U2 3
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAY
PY 2012
VL 9
IS 5
BP 1836
EP 1845
DI 10.3390/ijerph9051836
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 948ZJ
UT WOS:000304543200022
PM 22754476
ER

PT J
AU Cevasco, M
   Haime, M
AF Cevasco, Marisa
   Haime, Miguel
TI Aortic Valve Endocarditis from Staphylococcus lugdunensis
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Editorial Material
AB This is a case of aortic valve endocarditis and leaflet perforation caused by Staphylococcus lugdunensis successfully treated with aortic valve replacement and antibiotics. We believe that the patient's endocarditis may be related to the vasectomy he underwent two months prior to presentation, as S. lugdunensis is an integral component of normal skin flora of the lower abdomen and groin. We also suggest that whenever this organism is found in patients with endocarditis, early surgical treatment of the infected valve should be considered, as S. lugdunensis is an aggressive and virulent coagulase-negative staphylococcus. doi: 10.1111/j.1540-8191.2011.01267.x (J Card Surg 2012;27:299-300)
C1 [Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
   [Haime, Miguel] Harvard Univ, Sch Med, W Roxbury, MA USA.
   [Haime, Miguel] VA Boston Healthcare Syst, Dept Cardiac Surg, W Roxbury, MA USA.
RP Haime, M (reprint author), VA Boston Hlth Care Syst, Dept Cardiac Surg, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Miguel.Haime@med.va.gov
NR 4
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
J9 J CARDIAC SURG
JI J. Card. Surg.
PD MAY
PY 2012
VL 27
IS 3
BP 299
EP 300
DI 10.1111/j.1540-8191.2011.01267.x
PG 2
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA 946IF
UT WOS:000304344200005
PM 21810116
ER

PT J
AU Salhab, KF
   Said, SM
   Sundt, TM
AF Salhab, Khaled F.
   Said, Sameh M.
   Sundt, Thoralf M., III
TI Aortic Dissection and Recurrence Both Precipitated by Sexual Activity
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Editorial Material
ID RUPTURE
AB Risk factors for aortic dissection include: hypertension, connective tissue disorders, chronic obstructive pulmonary diseases, and severe physical and emotional stress. Although dissection associated with extreme physical activity has been reported, to date, there have been no reports in the literature to our knowledge of acute dissection and recurrence both occurring during sexual activity. We report a case of a 34-year-old male who underwent emergency replacement of his aortic root and hemiarch for an aortic dissection precipitated by sexual intercourse. doi: 10.1111/j.1540-8191.2012.01445. x (J Card Surg 2012;27:374375)
C1 [Salhab, Khaled F.; Said, Sameh M.] Mayo Clin, Div Cardiovasc Surg, Rochester, MN 55905 USA.
   [Sundt, Thoralf M., III] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
RP Salhab, KF (reprint author), Mayo Clin, Div Cardiovasc Surg, 200 1st St SW, Rochester, MN 55905 USA.
EM salhab.khaled@alumni.mayo.edu
NR 7
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
J9 J CARDIAC SURG
JI J. Card. Surg.
PD MAY
PY 2012
VL 27
IS 3
BP 374
EP 375
DI 10.1111/j.1540-8191.2012.01445.x
PG 2
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA 946IF
UT WOS:000304344200029
PM 22621720
ER

PT J
AU Swanson, E
   Vercler, C
   Yaremchuk, MJ
   Gordon, CR
AF Swanson, Edward
   Vercler, Christian
   Yaremchuk, Michael J.
   Gordon, Chad R.
TI Modified Gillies Approach for Zygomatic Arch Fracture Reduction in the
   Setting of Bicoronal Exposure
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Craniofacial surgery; Gillies approach; closed zygoma reduction;
   zygomatic arch; craniomaxillofacial trauma; facial reconstruction
ID FIXATION; COMPLEX; CLASSIFICATION; MANAGEMENT; CATHETER
AB Zygomatic arch fractures are common injuries, occurring in isolation in 5% of all patients with facial fractures and in 10% of patients with any fracture to the zygomaticomaxillary complex. Isolated noncomminuted depressed zygomatic arch fractures are easily treated with the minimally invasive Gillies approach, which most often provides long-term stability. However, zygomatic arch fractures often occur in conjunction with zygomaticomaxillary complex, Le Fort, calvarial, and naso-orbitoethmoid fractures. In situations requiring a bicoronal incision to address concomitant injuries, zygomatic arch fractures are frequently treated with wide dissection and rigid fixation. Using principles obtained from isolated arch fractures, we present for the first time to our knowledge the use of a modified Gillies approach to noncomminuted zygomatic arch fractures in a case requiring a bicoronal incision. With the deep temporal fascia exposed from the reflected bicoronal flap, a 1-cm horizontal incision is made within the deep temporal fascia allowing a Gillies elevator to easily reduce the arch fracture in a plane between the deep layer of the deep temporal fascia and the temporalis muscle. This technique exploits the advantages of the traditional Gillies approach, preserving fascial attachments, avoiding neurovascular injury, and obviating the need for rigid fixation. Moreover, this method saves time and money and decreases morbidity. Our modified Gillies approach to zygomatic arch fractures in the setting of a bicoronal incision can be applied to a wide range of cases because of the frequency with which arch fractures occur with concomitant craniomaxillofacial injuries requiring wide exposure.
C1 [Gordon, Chad R.] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD 21287 USA.
   [Swanson, Edward; Vercler, Christian; Yaremchuk, Michael J.; Gordon, Chad R.] Harvard Univ, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Dept Surg,Sch Med, Boston, MA USA.
RP Gordon, CR (reprint author), Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, JHOC 8152F,601 N Caroline St, Baltimore, MD 21287 USA.
EM cgordon@jhmi.edu
NR 20
TC 7
Z9 7
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1049-2275
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2012
VL 23
IS 3
BP 859
EP 862
DI 10.1097/SCS.0b013e31824dd5c3
PG 4
WC Surgery
SC Surgery
GA 948BW
UT WOS:000304479600096
PM 22565912
ER

PT J
AU Afshar, R
   Strassner, J
   Seung, E
   Medoff, B
   Luster, A
AF Afshar, Roshi
   Strassner, James
   Seung, Edward
   Medoff, Benjamin
   Luster, Andrew
TI Chemokine-mediated Treg trafficking is required to suppress allergic
   airway inflammation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Afshar, Roshi; Strassner, James; Seung, Edward; Medoff, Benjamin; Luster, Andrew] Harvard Univ, Massachusetts Gen Hosp, Ctr Immununol & Inflammatory Dis, Sch Med,Div Rheumatol Allergy & Immunol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702199
ER

PT J
AU Alexe, G
   Tamayo, P
   Mesirov, J
   Gupta, P
   Wolski, D
   Lauer, G
   Haining, W
AF Alexe, Gabriela
   Tamayo, Pablo
   Mesirov, Jill
   Gupta, Prakash
   Wolski, David
   Lauer, Georg
   Haining, William
TI Metagene projection strategies for discovering mechanisms of T cell
   differentiation in gene expression profiling data
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Alexe, Gabriela; Gupta, Prakash; Haining, William] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Alexe, Gabriela; Tamayo, Pablo; Mesirov, Jill; Haining, William] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Gupta, Prakash] Univ Oxford, Oxford, England.
   [Wolski, David; Lauer, Georg] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Haining, William] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700424
ER

PT J
AU Angin, M
   King, M
   Klarenbeek, P
   Moodley, E
   Rezai, A
   Piechocka-Trocha, A
   Toth, I
   Walker, B
   Addo, M
AF Angin, Mathieu
   King, Melanie
   Klarenbeek, Paulus
   Moodley, Eshia
   Rezai, Ashley
   Piechocka-Trocha, Alicja
   Toth, Ildiko
   Walker, Bruce
   Addo, Marylyn
TI Regulatory T cells can be expanded from HIV-1 infected individuals with
   preservation of suppressive function and TCR repertoire
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Angin, Mathieu; King, Melanie; Rezai, Ashley; Piechocka-Trocha, Alicja; Toth, Ildiko; Walker, Bruce; Addo, Marylyn] Harvard Univ, Sch Med, Ragon Inst MGH MIT & Harvard, Charlestown, MA USA.
   [Klarenbeek, Paulus] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Moodley, Eshia] Doris Duke Med Res Inst, HIV Pathogenesis Program, Durban, South Africa.
   [Moodley, Eshia] KwaZulu Natal Res Inst TB & HIV, Durban, South Africa.
   [Addo, Marylyn] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702017
ER

PT J
AU Barnett, B
   Ciocca, M
   Goenka, R
   Barnett, L
   Wu, JM
   Laufer, T
   Burkhardt, J
   Cancro, M
   Reiner, S
AF Barnett, Burton
   Ciocca, Maria
   Goenka, Radhika
   Barnett, Lisa
   Wu, Junmin
   Laufer, Terri
   Burkhardt, Janis
   Cancro, Michael
   Reiner, Steven
TI Asymmetric division of germinal center B cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Barnett, Burton; Ciocca, Maria; Barnett, Lisa; Wu, Junmin; Laufer, Terri; Burkhardt, Janis; Reiner, Steven] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Barnett, Burton; Ciocca, Maria; Wu, Junmin; Reiner, Steven] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Goenka, Radhika; Cancro, Michael] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Barnett, Burton; Ciocca, Maria; Barnett, Lisa; Wu, Junmin; Laufer, Terri; Burkhardt, Janis] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Laufer, Terri] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
   [Burkhardt, Janis] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Reiner, Steven] Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700669
ER

PT J
AU Chang, JJ
   Lindsay, R
   Doyle, E
   Vrbanac, V
   Seung, E
   Dudek, T
   Precopio, M
   Kandimalla, E
   Tager, A
   Altfeld, M
AF Chang, J. Judy
   Lindsay, Robert
   Doyle, Erin
   Vrbanac, Vladimir
   Seung, Edward
   Dudek, Timothy
   Precopio, Melissa
   Kandimalla, Ekambar
   Tager, Andrew
   Altfeld, Marcus
TI Modification of immune activation in HIV-1-infected humanized mouse
   model using TLR7/9 antagonists
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Chang, J. Judy; Lindsay, Robert; Doyle, Erin; Altfeld, Marcus] Harvard Univ, Sch Med, Ragon Inst MIT MGH & Harvard, Boston, MA USA.
   [Vrbanac, Vladimir; Seung, Edward; Dudek, Timothy; Tager, Andrew] Massachusetts Gen Hosp, Rheumatol Allergy & Immunol Div, Boston, MA 02114 USA.
   [Precopio, Melissa; Kandimalla, Ekambar] Idera Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701105
ER

PT J
AU Chatterjee, P
   Agyemang, A
   Alimzhanov, M
   Degn, S
   Herbst, R
   Tan, T
   Alicot, E
   Carroll, M
AF Chatterjee, Priyadarshini
   Agyemang, Amma
   Alimzhanov, Marat
   Degn, Soren
   Herbst, Ronald
   Tan, Tze
   Alicot, Elizabeth
   Carroll, Michael
TI Intersection of Complement C4 and Interferon Alpha pathways in B cell
   tolerance
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Chatterjee, Priyadarshini; Agyemang, Amma; Alicot, Elizabeth; Carroll, Michael] Childrens Hosp, Dept Pediat, Immune Dis Inst, Boston, MA 02115 USA.
   [Agyemang, Amma; Tan, Tze; Carroll, Michael] Harvard Univ, Sch Med, PhD Program Immunol, Boston, MA USA.
   [Alimzhanov, Marat] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Herbst, Ronald] MedImmune, Resp Inflammat & Autoimmun Res, Gaithersburg, MD USA.
   [Degn, Soren] Univ Aarhus, Dept Med Microbiol & Immunol, Aarhus, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702056
ER

PT J
AU Nguyen, D
   Goettel, J
   Wurbel, MA
   Marin, R
   Ahmed, O
   Horwitz, B
   Snapper, S
AF Deanna Nguyen
   Goettel, Jeremy
   Wurbel, Marc-Andre
   Marin, Romela
   Ahmed, Osub
   Horwitz, Bruce
   Snapper, Scott
TI Colitis in mice with WASP deficiency in innate immune cells is
   associated with impairment in IL-10 production
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Deanna Nguyen; Marin, Romela] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Deanna Nguyen; Marin, Romela] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
   [Deanna Nguyen; Snapper, Scott] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Goettel, Jeremy; Wurbel, Marc-Andre; Ahmed, Osub; Snapper, Scott] Childrens Hosp Boston, Dept Gastroenterol Nutr, Boston, MA USA.
   [Goettel, Jeremy; Wurbel, Marc-Andre] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Horwitz, Bruce] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Horwitz, Bruce] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Snapper, Scott] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700555
ER

PT J
AU Ding, YN
   Hsu, HC
   Druey, K
   Wu, Q
   Li, J
   Yang, PA
   Zajac, A
   Mountz, J
AF Ding, Yanna
   Hsu, Hui-Chen
   Druey, Kirk
   Wu, Qi
   Li, Jun
   Yang, PingAr
   Zajac, Allan
   Mountz, John
TI IL-17-induced Rgs16 expression is essential for follicular T helper cell
   localization in the germinal centers of autoimmune BXD2 mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Ding, Yanna; Hsu, Hui-Chen; Wu, Qi; Li, Jun; Yang, PingAr; Zajac, Allan; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
   [Druey, Kirk] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701305
ER

PT J
AU Dose, M
   Konstantinou, T
   Zhang, JW
   Aghajani, K
   Le Beau, M
   Rosen, S
   Georgopoulos, K
   Gounari, F
AF Dose, Marei
   Konstantinou, Tassos
   Zhang, Jiangwen
   Aghajani, Katayoun
   Le Beau, Michelle
   Rosen, Steven
   Georgopoulos, Katia
   Gounari, Fotini
TI Tcf-1 protects thymocytes from malignant transformation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Le Beau, Michelle] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA.
   [Zhang, Jiangwen] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Rosen, Steven] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Georgopoulos, Katia] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701015
ER

PT J
AU Duraiswamy, J
   Freeman, G
   Coukos, G
AF Duraiswamy, Jaikumar
   Freeman, Gordon
   Coukos, George
TI Modulation of immunostimulatory and inhibitory signals augments T cell
   function by distinct mechanisms in the ovarian cancer microenvironment
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Duraiswamy, Jaikumar; Coukos, George] Univ Penn, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
   [Freeman, Gordon] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701520
ER

PT J
AU Farley, K
   Stolley, J
   Zhao, PC
   Cooley, J
   Remold-O'Donnell, E
AF Farley, Kalamo
   Stolley, James
   Zhao, Picheng
   Cooley, Jessica
   Remold-O'Donnell, Eileen
TI SerpinB1 is essential for regulation of neutrophil extracellular trap
   (NET) generation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Farley, Kalamo; Stolley, James; Zhao, Picheng; Cooley, Jessica; Remold-O'Donnell, Eileen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
   [Farley, Kalamo; Stolley, James; Zhao, Picheng; Cooley, Jessica; Remold-O'Donnell, Eileen] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
RI ZHAO, PICHENG/G-3737-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701186
ER

PT J
AU Fletcher, A
   Malhotra, D
   Lukacs-Kornek, V
   Elpek, K
   Turley, S
AF Fletcher, Anne
   Malhotra, Deepali
   Lukacs-Kornek, Veronika
   Elpek, Kutlu
   Turley, Shannon
TI Integrin alpha-7+pericytes are a novel, immunologically relevant lymph
   node stromal subset found in mice and humans
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Fletcher, Anne; Malhotra, Deepali; Lukacs-Kornek, Veronika; Elpek, Kutlu; Turley, Shannon] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Turley, Shannon] Harvard Univ, Dept Microbiol & Immunobiol, Sch Med, Boston, MA USA.
   [Malhotra, Deepali] Harvard Univ, Div Med Sci, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700199
ER

PT J
AU Fonseca, C
   Imam, S
   Alexe, G
   Piccioni, F
   Root, D
   Haining, W
AF Fonseca, Catia
   Imam, Sabrina
   Alexe, Gabriela
   Piccioni, Federica
   Root, David
   Haining, William
TI A Kinase/Phosphatase RNAi screen to identify genes required for
   PD-1-mediated inhibition of TCR activation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Fonseca, Catia; Imam, Sabrina; Alexe, Gabriela; Haining, William] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Piccioni, Federica; Root, David] Broad Inst MIT & Harvard, RNAi Platform, Cambridge, MA USA.
   [Haining, William] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701255
ER

PT J
AU Fu, WX
   Wojtkiewicz, G
   Weissleder, R
   Benoist, C
   Mathis, D
AF Fu, Wenxian
   Wojtkiewicz, Gregory
   Weissleder, Ralph
   Benoist, Christophe
   Mathis, Diane
TI Non-invasive imaging of islet infiltration reveals an early window of
   CRIg-dependent diabetes determinism in NOD mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Fu, Wenxian; Benoist, Christophe; Mathis, Diane] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
   [Wojtkiewicz, Gregory; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702059
ER

PT J
AU Gupta, P
   Wolski, D
   Alexe, G
   Lauer, G
   Haining, W
AF Gupta, Prakash
   Wolski, David
   Alexe, Gabriela
   Lauer, Georg
   Haining, William
TI Identification of novel, biologically distinct T cell responses to
   chronic viral infection by unsupervised analysis of gene expression
   profiles of hepatitis C-specific CD8+T cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Gupta, Prakash; Alexe, Gabriela; Haining, William] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Wolski, David; Lauer, Georg] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Haining, William] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
   [Alexe, Gabriela] Broad Inst Harvard & MIT, Cambridge, MA USA.
   [Gupta, Prakash] Univ Oxford, Oxford, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700266
ER

PT J
AU Henrickson, S
   Senman, B
   Quigley, M
   Alexe, G
   Stutte, S
   Jesneck, J
   Iannacone, M
   Flynn, M
   Imam, S
   Mazo, I
   Haining, W
   von Andrian, U
AF Henrickson, Sarah
   Senman, Balimkiz
   Quigley, Michael
   Alexe, Gabriela
   Stutte, Susanne
   Jesneck, Jonathan
   Iannacone, Matteo
   Flynn, Michael
   Imam, Sabrina
   Mazo, Irina
   Haining, William
   von Andrian, Ulrich
TI Antigen availability is a critical determinant of in vivo CD8+T
   cell-dendritic cell interaction kinetics and initiates effector/memory
   fate decisions
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Henrickson, Sarah; Senman, Balimkiz; Stutte, Susanne; Iannacone, Matteo; Flynn, Michael; Mazo, Irina; von Andrian, Ulrich] Harvard Univ, Sch Med, Boston, MA USA.
   [Henrickson, Sarah; Senman, Balimkiz; Stutte, Susanne; Iannacone, Matteo; Flynn, Michael; Mazo, Irina; von Andrian, Ulrich] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Quigley, Michael; Alexe, Gabriela; Jesneck, Jonathan; Imam, Sabrina; Haining, William] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700689
ER

PT J
AU Hu, Z
   Wargo, J
   Yang, YG
AF Hu, Zheng
   Wargo, Jennifer
   Yang, Yong-Guang
TI A humanized mouse model for generation of tumor antigen specific T cells
   for preclinical research and anticancer therapy
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Hu, Zheng; Yang, Yong-Guang] Columbia Univ, New York, NY USA.
   [Wargo, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700585
ER

PT J
AU Jones, C
AF Jones, Caroline
TI Microfluidic Assay for Neutrophil Chemotaxis Towards Chemoattractant
   Gradients
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Jones, Caroline] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702158
ER

PT J
AU Kannan, A
   Sahu, N
   August, A
AF Kannan, Arun
   Sahu, Nisebeta
   August, Avery
TI Complex role for IL-2 Inducible T cell kinase (Itk) in T helper 1 and T
   helper 2 differentiation and function
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kannan, Arun; August, Avery] Cornell Univ, Ithaca, NY USA.
   [Sahu, Nisebeta] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701567
ER

PT J
AU Kanzaki, H
   Chiba, M
   Suzuki, M
   Taubman, M
AF Kanzaki, Hiroyuki
   Chiba, Mirei
   Suzuki, Maiko
   Taubman, Martin
TI TNF-alpha Converting Enzyme Degradates Interferon-Gamma.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kanzaki, Hiroyuki] Tohoku Univ Hosp, Dept Orthodont, Sendai, Miyagi, Japan.
   [Chiba, Mirei] Tohoku Univ, Grad Sch Dent, Sendai, Miyagi 980, Japan.
   [Kanzaki, Hiroyuki; Suzuki, Maiko; Taubman, Martin] Forsyth Inst, Dept Immunol, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702177
ER

PT J
AU Khan, N
   Tam, J
   Mansour, M
   Vyas, J
AF Khan, Nida
   Tam, Jenny
   Mansour, Michael
   Vyas, Jatin
TI Use of Fungal-like Particles to probe Dectin-1 Responses in Innate
   Immunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Khan, Nida; Tam, Jenny; Mansour, Michael; Vyas, Jatin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700425
ER

PT J
AU Kissick, H
   Dunn, L
   Lu, B
   Sanda, M
   Arredouani, MS
AF Kissick, Haydn
   Dunn, Laura
   Lu, Bin
   Sanda, Martin
   Arredouani, M. Simo
TI Immunogenic Peptides Derived from the Transcription Factor ERG as a
   Vaccine for Prostate Cancer
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kissick, Haydn; Dunn, Laura; Lu, Bin; Sanda, Martin; Arredouani, M. Simo] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701518
ER

PT J
AU Kissick, H
   Finke, J
   Dunn, L
   Asara, J
   Sanda, M
   Arredouani, MS
AF Kissick, Haydn
   Finke, Jorge
   Dunn, Laura
   Asara, John
   Sanda, Martin
   Arredouani, M. Simo
TI Metabolic profiling of T-cell differentiation and tolerance
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kissick, Haydn; Finke, Jorge; Dunn, Laura; Asara, John; Sanda, Martin; Arredouani, M. Simo] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701129
ER

PT J
AU Kurnick, J
   Haggerty, T
   Rose, L
   Dunn, I
   Newton, E
   Pandolfi, F
AF Kurnick, James
   Haggerty, Timothy
   Rose, Lenora
   Dunn, Ian
   Newton, Estelle
   Pandolfi, Franco
TI Enhanced MHC Class I and II expression induced following staggered
   combination treatment of human tumor cells with Hsp90 inhibitors and
   Interferons.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kurnick, James] Massachusetts Gen Hosp, Beverly, MA USA.
   [Kurnick, James; Haggerty, Timothy; Rose, Lenora; Dunn, Ian; Newton, Estelle] CytoCure LLC, Mol Biol, Beverly, MA USA.
   [Pandolfi, Franco] Catholic Univ Col Med, Rome, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701609
ER

PT J
AU Kurt-Jones, E
   Soberman, R
   Vaine, C
   Mackay, C
   Ryan, G
   Knipe, D
AF Kurt-Jones, Evelyn
   Soberman, Roy
   Vaine, Christine
   Mackay, Christopher
   Ryan, Glennice
   Knipe, David
TI Loss of the ITAM receptor CD200R1 attenuates HSV-1 infection and
   encephalitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Kurt-Jones, Evelyn; Mackay, Christopher; Ryan, Glennice] Univ Mass, Sch Med, Worcester, MA USA.
   [Soberman, Roy; Vaine, Christine] Massachusetts Gen Hosp, Charlestown, MA USA.
   [Knipe, David] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700524
ER

PT J
AU Lan, YY
   Londono, D
   Hacohen, N
AF Lan, Yuk Yuen
   Londono, Diana
   Hacohen, Nir
TI Lysosomal DNaseII degrades nuclear DNA and prevents self DNA recognition
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Lan, Yuk Yuen; Londono, Diana; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA.
   [Lan, Yuk Yuen; Londono, Diana; Hacohen, Nir] Broad Inst MIT & Harvard, RNAi Platform, Cambridge, MA USA.
   [Lan, Yuk Yuen; Hacohen, Nir] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701464
ER

PT J
AU Lee, KM
   Kim, J
   Yeh, H
   Stott, R
   Soohoo, J
   Deng, SP
   Markmann, J
AF Lee, Kang Mi
   Kim, James
   Yeh, Heidi
   Stott, Ryan
   Soohoo, Julie
   Deng, Shaoping
   Markmann, James
TI Regulatory-B cell and regulatory-T cell collaborate to promote
   transplantation tolerance
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Lee, Kang Mi; Kim, James; Yeh, Heidi; Stott, Ryan; Soohoo, Julie; Deng, Shaoping; Markmann, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701377
ER

PT J
AU LeGuern, C
   Martins, P
   Germana, S
AF LeGuern, Christian
   Martins, Paulo
   Germana, Sharon
TI Role of MHC class II in Treg-mediated tolerance to allogeneic
   transplants
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [LeGuern, Christian; Martins, Paulo; Germana, Sharon] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701386
ER

PT J
AU Li, C
   Pereyra, F
   Rychert, J
   Rosenberg, E
   Lichterfeld, M
   Yu, X
AF Li, Chun
   Pereyra, Florencia
   Rychert, Jenna
   Rosenberg, Eric
   Lichterfeld, Mathias
   Yu, Xu
TI HLA-G expressing Tregs inhibit bystander immune activation in HIV-1
   infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Chun] Harvard Univ, Cambridge, MA 02138 USA.
   [Li, Chun; Pereyra, Florencia; Yu, Xu] Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Charlestown, MA USA.
   [Rychert, Jenna; Rosenberg, Eric; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702016
ER

PT J
AU Li, H
   Hsu, HC
   Li, J
   Yang, PA
   Wu, Q
   Cua, D
   Oukka, M
   Mountz, J
AF Li, Hao
   Hsu, Hui-Chen
   Li, Jun
   Yang, PingAr
   Wu, Qi
   Cua, Daniel
   Oukka, Mohamed
   Mountz, John
TI IL-23 induces IRF5 and polarizes inflammatory M1 macrophages to promote
   inflammation in a mouse model of arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Hao; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Wu, Qi; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Cua, Daniel] Merck Res Labs, Merck Res Lab, Palo Alto, CA USA.
   [Oukka, Mohamed] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702083
ER

PT J
AU Li, H
   Hsu, HC
   Li, J
   Yang, P
   Wu, Q
   Cua, D
   Oukka, M
   Mountz, J
AF Li, Hao
   Hsu, Hui-Chen
   Li, Jun
   Yang, PingAr
   Wu, Qi
   Cua, Daniel
   Oukka, Mohamed
   Mountz, John
TI IL-23 inhibits autoimmunity by facilitating clearance of apoptotic
   bodies in the marginal zone
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Hao; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Wu, Qi; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Cua, Daniel] Merck Res Lab, Palo Alto, CA USA.
   [Oukka, Mohamed] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702062
ER

PT J
AU Li, J
   Hsu, HC
   Yang, PA
   Wu, Q
   Li, H
   Spalding, D
   Chatham, W
   Kimberly, R
   Bridges, S
   Mountz, J
AF Li, Jun
   Hsu, Hui-Chen
   Yang, PingAr
   Wu, Qi
   Li, Hao
   Spalding, David
   Chatham, W.
   Kimberly, Robert
   Bridges, S.
   Mountz, John
TI Death Receptor 5 (DR5) marks the highly pathogenic interacting GM-CSF+ T
   helper cells and IL-23(+) macrophages rendering it as an attractive
   therapeutic target of autoimmunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Li, Hao; Spalding, David; Chatham, W.; Kimberly, Robert; Bridges, S.; Mountz, John] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Hsu, Hui-Chen; Yang, PingAr; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700272
ER

PT J
AU Liao, GX
   Berger, S
   Detre, C
   Malefyt, RD
   Herzog, R
   Bhan, A
   Terhorst, C
AF Liao, Gongxian
   Berger, Scott
   Detre, Cynthia
   Malefyt, Rene de Waal
   Herzog, Roland
   Bhan, Atul
   Terhorst, Cox
TI GITR on the surface of antigen presenting cells, but not on T cells,
   regulates the pathogenesis of CD4+T cell-mediated experimental colitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Liao, Gongxian; Berger, Scott; Detre, Cynthia; Terhorst, Cox] Harvard Univ, Sch Med, BIDMC, Div Immunol, Boston, MA USA.
   [Herzog, Roland] Univ Florida, Dept Pediat, Gainesville, FL USA.
   [Malefyt, Rene de Waal] Merck Res Labs, Biol Discovery, Palo Alto, CA USA.
   [Bhan, Atul] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701216
ER

PT J
AU Liao, GX
   Song, JH
   O'Keeffe, M
   Calpe, S
   Castro, W
   Magelky, E
   Wang, NH
   Mora, R
   Reinecker, HC
   Terhorst, C
AF Liao, Gongxian
   Song, Joo-Hye
   O'Keeffe, Micahel
   Calpe, Silvia
   Castro, Wilson
   Magelky, Erica
   Wang, Ninghai
   Mora, Rodrigo
   Reinecker, Hans-Christian
   Terhorst, Cox
TI Regulation of expression of SLAMF4 on the surface of mucosal lymphocytes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Liao, Gongxian; O'Keeffe, Micahel; Calpe, Silvia; Castro, Wilson; Magelky, Erica; Wang, Ninghai; Terhorst, Cox] Harvard Univ, Sch Med, BIDMC, Div Immunol, Boston, MA USA.
   [Song, Joo-Hye; Mora, Rodrigo; Reinecker, Hans-Christian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701224
ER

PT J
AU Lin, T
   Sammy, F
   Yang, H
   Thundivalappil, S
   Tracey, KJ
   Warren, HS
AF Lin, Tian
   Sammy, Fatima
   Yang, Huan
   Thundivalappil, Sujatha
   Tracey, Kevin J.
   Warren, H. Shaw
TI Identification of hemopexin as an anti-inflammatory factor that inhibits
   hemoglobin synergy with HMGB1 in sterile and infectious inflammation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Lin, Tian; Sammy, Fatima; Warren, H. Shaw] Massachusetts Gen Hosp, Charlestown, MA USA.
   [Yang, Huan; Thundivalappil, Sujatha; Tracey, Kevin J.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702102
ER

PT J
AU Linden, J
   Lin, GN
   Neuberg, D
   Nathan, D
   Field, J
AF Linden, Joel
   Lin, Gene
   Neuberg, Donna
   Nathan, David
   Field, Joshua
TI Inhibition of iNKT cells by adenosine A2A receptor activation in
   patients with sickle cell disease
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Linden, Joel; Lin, Gene] La Jolla Inst Allergy & Immunol, Cardiovasc Res Ctr, La Jolla, CA USA.
   [Neuberg, Donna; Nathan, David] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Nathan, David] Childrens Hosp, Boston, MA 02115 USA.
   [Field, Joshua] Blood Res Inst, BloodCtr Wisconsin, Milwaukee, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700132
ER

PT J
AU Liu, CH
   Sharma, S
   Miller, H
   Upadhyaya, A
   Dahlberg, C
   Westerberg, L
   Snapper, S
   Song, WX
AF Liu, Chaohong
   Sharma, Shruti
   Miller, Heather
   Upadhyaya, Arpita
   Dahlberg, Carin
   Westerberg, Lisa
   Snapper, Scott
   Song, Wenxia
TI Pivotal roles of both Wiskott-Aldrich syndrome protein (WASP) and N-WASP
   in the activation and attenuation of the B cell receptor
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Liu, Chaohong; Miller, Heather; Song, Wenxia] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
   [Upadhyaya, Arpita] Univ Maryland, Dept Phys, College Pk, MD 20742 USA.
   [Sharma, Shruti] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA USA.
   [Dahlberg, Carin; Westerberg, Lisa] Karolinska Inst, Dept Med, Unit Clin Allergy Res, Stockholm, Sweden.
   [Snapper, Scott] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Snapper, Scott] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
   [Snapper, Scott] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RI Dahlberg, Carin/N-1625-2013
OI Dahlberg, Carin/0000-0002-8610-6302
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700052
ER

PT J
AU Ma, CY
   Wang, NH
   Detre, C
   Wang, GX
   O'Keeffe, M
   Terhorst, C
AF Ma, Chunyan
   Wang, Ninghai
   Detre, Cynthia
   Wang, Guoxing
   O'Keeffe, Michael
   Terhorst, Cox
TI SLAM is a microbial sensor which regulates bacterial phagosome functions
   in macrophages by recruiting a Vps34/beclin 1/UVRAG complex
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Ma, Chunyan; Wang, Ninghai; Detre, Cynthia; Wang, Guoxing; O'Keeffe, Michael; Terhorst, Cox] BIDMC, Div Immunol, Boston, MA USA.
RI Wang, Guoxing/G-6586-2013
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701062
ER

PT J
AU Maldonado, R
   Perdomo, LC
   Vascotto, F
   Bauquet, A
   Sharpe, A
   Kuchroo, V
   von Andrian, U
AF Maldonado, Roberto
   Perdomo, L. Carolina
   Vascotto, Fulvia
   Bauquet, Aurelie
   Sharpe, Arlene
   Kuchroo, Vijay
   von Andrian, Ulrich
TI Induced-tolerogenic Dendritic Cells promote tolerance and de novo
   differentiation of regulatory T cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Maldonado, Roberto] Selecta Biosci, Immunology, Watertown, MA USA.
   [Perdomo, L. Carolina; von Andrian, Ulrich] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
   [Bauquet, Aurelie; Kuchroo, Vijay] Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA USA.
   [Kuchroo, Vijay] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700487
ER

PT J
AU Malhotra, D
   Fletcher, A
   Astarita, J
   Lukacs-Kornek, V
   Elpek, K
   Turley, S
AF Malhotra, Deepali
   Fletcher, Anne
   Astarita, Jillian
   Lukacs-Kornek, Veronika
   Elpek, Kutlu
   Turley, Shannon
CA Immunological Genome Project Conso
TI Transcriptional profiling of steady-state and inflamed lymph node stroma
   reveals potential hematopoietic-stromal cross-talk pathways and suggests
   an active role for stroma during ongoing immune responses.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Malhotra, Deepali; Fletcher, Anne; Astarita, Jillian; Lukacs-Kornek, Veronika; Elpek, Kutlu; Turley, Shannon] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Malhotra, Deepali; Astarita, Jillian] Harvard Univ, Sch Med, Div Med Sci, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702223
ER

PT J
AU Mansour, M
   Tam, J
   Khan, N
   Puranam, S
   Vyas, J
AF Mansour, Michael
   Tam, Jenny
   Khan, Nida
   Puranam, Srav
   Vyas, Jatin
TI Dectin-1 controls maturation of fungal phagosomes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mansour, Michael; Tam, Jenny; Khan, Nida; Puranam, Srav; Vyas, Jatin] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700359
ER

PT J
AU Marangoni, F
   Murooka, T
   Manzo, T
   Elpek, N
   Mempel, T
AF Marangoni, Francesco
   Murooka, Thomas
   Manzo, Teresa
   Elpek, Natalie
   Mempel, Thorsten
TI Multiphoton intravital microscopy analysis of signaling in T cells
   reveals persistent NFAT activation during dynamic APC scanning
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Marangoni, Francesco; Murooka, Thomas; Elpek, Natalie; Mempel, Thorsten] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA.
   [Marangoni, Francesco; Murooka, Thomas; Mempel, Thorsten] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Manzo, Teresa] Ist Sci San Raffaele, Lymphocyte Activat Unit, I-20132 Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701267
ER

PT J
AU Mikucki, M
   Skitzki, J
   Fisher, D
   Luster, A
   Evans, S
AF Mikucki, Maryann
   Skitzki, Joseph
   Fisher, Daniel
   Luster, Andrew
   Evans, Sharon
TI Obligate role of CXCR3 chemokine receptor for trafficking of effector
   CD8 T cells in the tumor microenvironment
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mikucki, Maryann; Skitzki, Joseph; Fisher, Daniel; Evans, Sharon] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Luster, Andrew] Harvard Univ, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700190
ER

PT J
AU Mizoguchi, E
   Lee, IA
   Kamba, A
   Santhanam, R
AF Mizoguchi, Emiko
   Lee, In-Ah
   Kamba, Alan
   Santhanam, Radhika
TI Chitinase 3-like 1 enhances bacterial adhesion to colonic epithelial
   cells through the bacterial chitin-binding motif
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mizoguchi, Emiko; Lee, In-Ah; Kamba, Alan; Santhanam, Radhika] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Mizoguchi, Emiko] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701061
ER

PT J
AU Mountz, J
   Wang, J
   New, J
   Yang, P
   Wu, Q
   Druey, K
   Hsu, HC
AF Mountz, John
   Wang, John
   New, James
   Yang, PingAr
   Wu, Qi
   Druey, Kirk
   Hsu, Hui-Chen
TI IL-17-induced Regulator of G-protein Signaling orchestrates germinal
   center kinetics in the onset of autoimmunity in BXD2 mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mountz, John; Wang, John; New, James; Yang, PingAr; Wu, Qi; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Druey, Kirk] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701457
ER

PT J
AU Mukherjee, G
   Geliebter, A
   Sharpe, A
   Freeman, G
   DiLorenzo, T
AF Mukherjee, Gayatri
   Geliebter, Ari
   Sharpe, Arlene
   Freeman, Gordon
   DiLorenzo, Teresa
TI DEC-205-mediated antigen targeting to steady-state dendritic cells
   induces deletion of cognate CD8(+) T cells independently of the PD-1
   pathway
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mukherjee, Gayatri; Geliebter, Ari; DiLorenzo, Teresa] Albert Einstein Col Med, Microbiol & Immunol, Bronx, NY USA.
   [Sharpe, Arlene; Freeman, Gordon] Harvard Univ, Sch Med, Boston, MA USA.
   [Freeman, Gordon] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701328
ER

EF